PT J
AU Zou, J
   Dong, X
   Wang, K
   Shi, J
   Sun, N
AF Zou, Jing
   Dong, Xueyang
   Wang, Ke
   Shi, Jing
   Sun, Ning
TI Electroacupuncture Inhibits Autophagy of Neuron Cells in Postherpetic Neuralgia
SO BioMed research international
LA English
DT Journal Article
AB Postherpetic neuralgia (PHN) is a complication of herpes zoster viral infection.  Its main manifestations are continuous or intermittent burning-like and  electroshock-like pain in the affected nerves. Electroacupuncture (EA) is widely  used in clinical treatment and exerts effects in alleviating neuropathic pain. In  this study, we investigated the effect and underlying mechanism of EA on PHN.  Sprague-Dawley rats were treated with resiniferatoxin (RTX) to establish a PHN  model and subjected to EA and/or miR-223-3p overexpression (OV) or interference.  Mechanical withdrawal latency was measured as an indication of pain sensitivity.  Hematoxylin-eosin staining and transmission electron microscopy were performed to  observe neuron cell morphology and autophagic vacuoles, respectively. ELISA was  performed to detect reactive oxygen species (ROS) production and the levels of  tumor necrosis factor- (TNF-) α, inducible nitric oxide synthase (iNOS),  interleukin- (IL-) 6, and IL-10. Changes in autophagy and apoptosis-related  miRNAs were detected by immunofluorescence and qRT-PCR, respectively. In  RTX-treated rats, OV and EA reduced pain sensitivity, decreased the number of  eosinophils, and increased that of nerve cells. ROS generation and the levels of  TNF-α and iNOS were significantly reduced, while those of IL-6 and IL-10 were  increased. OV and EA induced fewer autophagic vacuoles than those in the model  group. The expression of autophagy-related protein microtubule-associated protein  1 light chain 3-II, ATG9, and Rab1 was decreased by OV and EA, whereas that of  P62 was increased. qRT-PCR revealed that miR-223-3p expression in the model group  decreased but was increased by EA. EA inhibits neuron cell autophagy in PHN by  increasing miR-223-3p expression.
C1 Department of Neurobiology, School of Basic Medicine, Tongji Medical College of Huazhong University of Science and Technology, China.
   Department of Acupuncture & Moxibustion, Wuhan Hospital of Integrated Chinese & 
   Wuhan Hospital of Integrated Chinese & Western Medicine, China.
   Acupuncture College, Hubei University of Traditional Chinese Medicine, China.
   Department of Neurobiology, School of Basic Medicine, Tongji Medical College of Huazhong University of Science and Technology, China.
   Department of Neurobiology, School of Basic Medicine, Tongji Medical College of Huazhong University of Science and Technology, China.
NR 0
TC 0
SN 2314-614
EI 2314-613
J9 Biomed Res Int
PD APR 17
PY 2021
VL 2021
IS 
BP 6637693
EP 6637693
DI 10.1155/2021/6637693
PG 0
WC Animals; Apoptosis; genetics; Autophagy; Diterpenes; Electroacupuncture; Gene Expression Regulation; Hyperalgesia; complications; Male; MicroRNAs; genetics; Neuralgia, Postherpetic; complications; Neuroglia; metabolism; Neurons; metabolism; Rats, Sprague-Dawley; rab1 GTP-Binding Proteins; metabolism; Rats
UT PubMed:33860046
PM 33860046
DA 2021-04-17
ER

PT J
AU Wu, C
   Yang, JF
   Zhang, Q
   Liu, W
   Liao, K
   Hu, B
AF Wu, Chuncheng
   Yang, Juliana F
   Zhang, Qiongying
   Liu, Wei
   Liao, Ke
   Hu, Bing
TI Successful cholangioscopic electrocoagulation for biliary papillomatosis: Report
SO Gastroenterologia y hepatologia
LA spa
DT Journal Article
DE Biliary papillomatosis; Cholangioscopic; Colangioscopia; Electrocoagulación; Electrocoagulation; Papilomatosis biliar
AB BACKGROUND: Biliary papillomatosis is a rare type of papillomatosis. Depending on  the location of the disease, radical surgical resection or liver transplants are  the treatment of choice. These radical surgical options may be unrealistic in  patients who are not surgical candidates or who are unwilling to consider  surgery. AIMS: To evaluate the effectiveness of endoscopic electrocoagulation for  the biliary papillomatosis. METHODS: In this case series, we report six patients  with unresectable biliary papillomatosis who underwent cholangioscopic  electrocoagulation using needle knife and their clinic follow up information.  RESULTS: After patients received cholangioscopy with electrocoagulation of the  residual biliary papilloma, the daily T-tube drainage volume increased to  200-400ml with improvement in the drainage content and significant relief of  clinical symptoms, such as jaundice and abdominal pain. CONCLUSION: This method  of using electrocoagulation to directly target and destroy tumor tissue is a safe  and effective alternative for those with unresectable disease, and this method  has shown to enhance T-tube drainage volume and improve patients' overall  clinical symptoms.
C1 Department of Gastroenterology, West China Hospital, Sichuan University, China.
   Department of Internal Medicine, Division of Digestive and Liver Diseases, The Vanderbilt University Medical Center, Nashville, TN, USA.
   Department of Gastroenterology, West China Hospital, Sichuan University, China.
   Department of Gastroenterology, West China Hospital, Sichuan University, China.
   Department of Gastroenterology, West China Hospital, Sichuan University, China.
   Department of Gastroenterology, West China Hospital, Sichuan University, China.
EM hubingnj@163.com
NR 0
TC 0
SN 
EI 0210-570
J9 Gastroenterol Hepatol
PD FEB 23
PY 2021
VL 44
IS 8
BP 546
EP 551
DI 10.1016/j.gastrohep.2020.12.012
PG 5
WC Abdominal Pain; etiology; Aged; Bile Duct Neoplasms; complications; Cholangitis; etiology; Drainage; instrumentation; Electrocoagulation; methods; Endoscopy, Digestive System; Female; Humans; Jaundice; etiology; Male; Middle Aged; Pancreatitis; etiology; Papilloma; complications
UT PubMed:33617929
PM 33617929
DA 2021-02-23
ER

PT J
AU Dong, B
   Lin, L
   Chen, QY
   Qi, YS
   Wang, F
   Qian, KY
   Tian, L
AF Dong, Bei
   Lin, Lu
   Chen, Qiuyun
   Qi, Yishu
   Wang, Fen
   Qian, Keyan
   Tian, Li
TI Wrist-ankle acupuncture has a positive effect on cancer pain: a meta-analysis
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Wrist-ankle acupuncture; Pain; Cancer; Meta-analysis; Randomized controlled trial
AB Background: Wrist-ankle acupuncture (WAA) as a kind of micro acupuncture therapy has been used to management cancer pain, however, the effects of WAA on cancer pain were controversial in the current studies. Therefore, the purpose of this meta-analysis was to critically evaluate the effect of wrist-ankle acupuncture (WAA) on cancer pain. Methods: Seven digital databases were searched from the inception of databases to July 2020, including CNKI, Wanfang, VIP, CBM, Cochrane Library, PubMed and Embase. Randomized controlled trials conforming to the inclusion and exclusion criteria were screened and extracted; the risk of bias was evaluated using the Cochrane Collaboration criteria. The primary outcome indicators included pain relief rate and pain score, and the secondary outcome was adverse reaction incidence. All analyses were performed with Review Manager 5.3. Results: A total of 13 studies with 1005 cancer patients (intervention group: 568, control group: 437) were included in this meta-analysis. The results demonstrated that the pain relief rate of experimental group (WAA / WAA + drug intervention) was better than that of control group (analgesic drug intervention), and the difference was statistically significant [RR = 1.31, 95%CI: 1.15 similar to 1.49, P < 0.01]. Conclusions: WAA has certain effect on cancer pain, and the effect of WAA combined with pharmacological intervention is better than that of drug therapy alone.
C1 [Dong, Bei; Chen, Qiuyun; Wang, Fen; Tian, Li] Soochow Univ, Affiliated Hosp 1, Oncol Dept, 188 Shizi Rd, Suzhou 215006, Peoples R China.
   [Lin, Lu; Qi, Yishu; Tian, Li] Soochow Univ, Sch Nursing, Med Coll, 188 Shizi Rd, Suzhou 215006, Peoples R China.
   [Qian, Keyan] Soochow Univ, Affiliated Hosp 1, Radiotherapy Dept, Suzhou, Peoples R China.
C3 Soochow University - China; Soochow University - China; Soochow University - China
RP Tian, L (corresponding author), Soochow Univ, Affiliated Hosp 1, Oncol Dept, 188 Shizi Rd, Suzhou 215006, Peoples R China.; Tian, L (corresponding author), Soochow Univ, Sch Nursing, Med Coll, 188 Shizi Rd, Suzhou 215006, Peoples R China.
EM tianlisz@suda.edu.cn
FU National Natural Science Foundation of China [81801098]; Humanity and Social Science Youth Foundation of Ministry of Education of China [18YJCZH164]
CR Chen Y, 2012, CHIN COMMUNITY DOCTO, V14, P176
   Deer TR, 2011, PAIN PHYSICIAN, V14, P0
   Dong B, 2019, BREAST CANCER RES TR, V177, P5, DOI 10.1007/s10549-019-05278-w
   [董毓敏 Dong Yumin], 2015, 介入放射学杂志 JOURNAL OF INTERVENTIONAL RADIOLOGY, V24, P914
   Filshie Jacqueline, 2006, ACUPUNCT MED, V24, P172
   刘冬雪, 2013, 中国老年学杂志 CHINESE JOURNAL OF GERONTOLOGY, V33, P6067
   Huang Y, 2005, J NURS ADMIN, V5, P11
   Jing Z, 2020, J NURS EDUC, V35, P723
   Lin L, 2017, PEOPLES MIL SURG, V60, P56
   Luan Y, 2019, YUNNAN J TRAD CHIN M, V40, P95
   Ma LS, 2017, WORLD CHIN MED, V12, P2847
   Moher D, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b2535
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Shen S-e, 2000, CHINESE ACUPUNCTURE, V2000, P15
   Shiying Y, 2012, CHIN J PAIN MED, V18, P706
   von Moos R, 2017, EUR J CANCER, V71, P80, DOI 10.1016/j.ejca.2016.10.021
   Wang Qiong, 2017, ZHONGGUO ZHEN JIU, V37, P509, DOI 10.13703/j.0255-2930.2017.05.016
   Wang X, 2019, J TRADIT CHIN MED, V60, P768
   Wu Qiu-Lan, 2019, ZHONGGUO ZHEN JIU, V39, P1051, DOI 10.13703/j.0255-2930.2019.10.005
   Xia H, 2004, CLIN STUDIES EFFICAC, V0, P0
   Xu LP, 2020, COMPLEMENT THER CLIN, V39, P0, DOI 10.1016/j.ctcp.2020.101170
   Yang X, 2018, SHANGHAI J ACUPUNCTU, V37, P1419
   Yuanyuan JIA, 2018, J CLIN NURS PRACTICA, V3, P99
   Zeng K, 2014, AM J CHINESE MED, V42, P289, DOI 10.1142/S0192415X14500190
   Zhang B, 2018, ZHEJIANG J INTEGRATE, V28, P781
   Zhang W, 2019, CLIN OBSERVATION JIA, V0, P0
   Zheng Y, 2014, J LIAONING UNIV TRADIT CHIN MED, V16, P152, DOI 10.13194/j.issn.1673-842x.2014.01.055
   Zhou Q, 2002, PRACTICAL WRIST ANKL, V0, P23
   Zhou QH, 2005, J ZHEJIANG COLL TRAD, V29, P53
   Zhou You-Long, 2007, ZHONGGUO ZHEN JIU, V27, P923
   Zimei D, 2018, NURS PRACT RES, V15, P74
NR 32
TC 18
Z9 23
U1 1
U2 40
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD JAN 7
PY 2021
VL 21
IS 1
BP 
EP 
DI 10.1186/s12906-020-03193-y
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA PW1AU
UT WOS:000610409300005
PM 33413347
DA 2026-01-16
ER

PT J
AU Ao, L
   Shi, JL
   Bai, YW
   Zhang, S
   Gan, JH
AF Ao, Li
   Shi, Jinlin
   Bai, Yaowu
   Zhang, Shan
   Gan, Jianhui
TI Effects of transcutaneous electrical acupoint stimulation on perioperative immune function and postoperative analgesia in patients undergoing radical mastectomy: A randomized controlled trial
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE transcutaneous electrical acupoint stimulation; breast cancer; radical mastectomy; postoperative analgesia; immunity
ID breast-cancer surgery; general-anesthesia; t-cells; acupuncture; electroacupuncture; pain; metastasis; parameters; expression; prognosis
AB Radical mastectomy may lead to suppression of cellular immune function in patients with malignant tumors. Transcutaneous electrical acupoint stimulation (TEAS) is widely used in clinical practice. However, there have been relatively few studies on the effects of TEAS on postoperative analgesia and immune function. The present study aimed to evaluate the effects of TAES on postoperative pain and immune function in patients undergoing radical mastectomy. A total of 65 patients were enrolled and allocated to either receive TEAS or sham TEAS. TEAS was implemented on bilateral Hegu (LI4), Neiguan (PC6) and Zusanli (ST36) acupoints simultaneously for 30 min before induction of anesthesia at 4 and 12 h post-operation. The primary outcomes included visual analogue scale (VAS) scores at 4 h (T-1), 12 h T-2), 24 h (T-3) and 48 h (T-4) post-operation, and serum levels of IL-2, IL-4, IFN-gamma and the IL-2/IL-4 ratio at 30 min before TEAS (T-0), T-1, T-2, T-3 and T-4. Secondary outcomes included the cumulative time of rescue analgesia within 48 h post-surgery, as well as the incidence of postoperative nausea and vomiting (PONV) and pruritus. Compared with the sham TEAS group, postoperative VAS scores at T-2 and T-3, the total consumption of opioids in the patient-controlled analgesia (PCA) pump, pressing times of the PCA pump and the incidences of PONV and headache were significantly lower in the TEAS group. The serum levels of IFN-gamma at T-3 and T-4, and the serum levels of IL-2 and the IL-2/IL-4 ratio at T-2, T-3 and T-4 were higher in the TEAS group compared with the sham TEAS group. By contrast, the serum levels of IL-4 were lower at T-2, T-3 and T-4 in the TEAS group compared with the sham TEAS group. The results indicated that TEAS could improve postoperative analgesia, reduce postoperative consumption of opioids and alleviate postoperative side effects. Simultaneously, TEAS was able to reverse decreased serum levels of IL-2 and IFN-gamma, reduce the level of IL-4 and restore the balance of Th1/Th2, thereby partially attenuating perioperative immune function depression in patients with breast cancer. The current trial was registered prior to participant enrollment at (Clinical Trial no. ChiCTR1800017768).
C1 [Ao, Li; Bai, Yaowu] North China Univ Sci & Technol, Dept Anesthesiol, Tangshan Matern & Child Healthcare Hosp, Tangshan 063000, Hebei, Peoples R China.
   [Shi, Jinlin; Gan, Jianhui] North China Univ Sci & Technol, Dept Anesthesiol, Tangshan Peoples Hosp, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
   [Shi, Jinlin; Gan, Jianhui] North China Univ Sci & Technol, Dept Anesthesiol, Tangshan Canc Hosp, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
   [Zhang, Shan] Hebei Med Univ, Hosp 2, Dept Anesthesiol, Shijiazhuang 050000, Hebei, Peoples R China.
C3 North China University of Science & Technology; North China University of Science & Technology; North China University of Science & Technology; Hebei Medical University
RP Gan, JH (corresponding author), North China Univ Sci & Technol, Dept Anesthesiol, Tangshan Peoples Hosp, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.; Gan, JH (corresponding author), North China Univ Sci & Technol, Dept Anesthesiol, Tangshan Canc Hosp, 65 Shengli Rd, Tangshan 063000, Hebei, Peoples R China.
EM ganjianhui666@163.com
CR Acar HV, 2016, COMPLEMENT THER MED, V29, P48, DOI 10.1016/j.ctim.2016.09.013
   Alonzo NC, 2002, INFECT DIS CLIN N AM, V16, P553, DOI 10.1016/S0891-5520(02)00018-1
   Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8
   Bobocea AC, 2012, CHIRURGIA-BUCHAREST, V107, P154
   Boland JW, 2014, BRIT J CANCER, V111, P866, DOI 10.1038/bjc.2014.384
   Bradley LM, 1996, J IMMUNOL, V157, P1350
   Buckley A, 2014, BRIT J ANAESTH, V113, P56, DOI 10.1093/bja/aeu200
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Cata JP, 2013, J CLIN ANESTH, V25, P255, DOI 10.1016/j.jclinane.2012.12.007
   Chen LY, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0175568
   Chen YQ, 2015, INT J CLIN EXP MED, V8, P5972
   Chernyak GV, 2005, ANESTHESIOLOGY, V102, P1031, DOI 10.1097/00000542-200505000-00024
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cho JS, 2017, INT J MED SCI, V14, P970, DOI 10.7150/ijms.20064
   Cooke M, 2014, BMJ OPEN, V4, P0, DOI 10.1136/bmjopen-2014-006179
   Oliveira CRD, 2017, REV BRAS ANESTESIOL, V67, P72, DOI 10.1016/j.bjan.2016.10.002
   Desmond F, 2015, ANTICANCER RES, V35, P1311
   Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x
   Enwere EK, 2017, MODERN PATHOL, V30, P577, DOI 10.1038/modpathol.2016.221
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Gavronsky S, 2012, PAIN MANAG NURS, V13, P150, DOI 10.1016/j.pmn.2009.08.001
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Grech D, 2016, J ACUPUNCT MERIDIAN, V9, P234
   Green JS, 2013, CAN J ANESTH, V60, P1248, DOI 10.1007/s12630-013-0037-1
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Han YF, 2011, WORLD J GASTROENTERO, V17, P4258, DOI 10.3748/wjg.v17.i38.4258
   Hao CJ, 2016, GENET MOL RES, V15, P0, DOI 10.4238/gmr.15027936
   Huang S, 2017, J ANESTH, V31, P58, DOI 10.1007/s00540-015-2057-1
   HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8
   International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 1996, ICH HARM TRIP GUID, V0, P0
   Kagitani F, 2005, JPN J PHYSIOL, V55, P149, DOI 10.2170/jjphysiol.R2120
   Kim SY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003602
   Kurosawa S, 2012, CURR OPIN ANESTHESIO, V25, P376, DOI 10.1097/ACO.0b013e328352b4a8
   Lai Min, 2008, ZHEN CI YAN JIU, V33, P245
   Leaver HA, 2000, EUR J CLIN INVEST, V30, P230
   Lee A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub3
   Lee S, 2013, CHIN J INTEGR MED, V19, P277, DOI 10.1007/s11655-013-1425-7
   Li GY, 2013, EXP THER MED, V6, P699, DOI 10.3892/etm.2013.1225
   Liang Y, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-018-3145-y
   Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003
   Lin LL, 2016, CELL TRANSPLANT, V25, P621, DOI 10.3727/096368916X690872
   Narahara H, 2013, J ANESTH, V27, P676, DOI 10.1007/s00540-013-1597-5
   Neeman E, 2013, BRAIN BEHAV IMMUN, V30, PS32, DOI 10.1016/j.bbi.2012.03.006
   Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6
   Pérez-González O, 2017, REGION ANESTH PAIN M, V42, P751, DOI 10.1097/AAP.0000000000000662
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Rawal N, 2016, EUR J ANAESTH, V33, P160, DOI 10.1097/EJA.0000000000000366
   Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Shen Yoshi F, 2007, PAIN PRACT, V7, P256
   Su TF, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-98
   Suzuki M, 2013, AM J HOSP PALLIAT ME, V30, P712, DOI 10.1177/1049909112469823
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Tu Q, 2018, TECHNOL CANCER RES T, V17, P0, DOI 10.1177/1533033818806477
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Wang K, 2009, ANESTH ANALG, V109, P1666, DOI 10.1213/ANE.0b013e3181b5a234
   Wei G, 2003, BIOCHEM PHARMACOL, V65, P1761, DOI 10.1016/S0006-2952(03)00085-6
   Witt CM, 2008, CEPHALALGIA, V28, P334, DOI 10.1111/j.1468-2982.2007.01504.x
   Woo JH, 2015, J KOREAN MED SCI, V30, P1503, DOI 10.3346/jkms.2015.30.10.1503
   Wu HX, 2016, EXP THER MED, V11, P495, DOI 10.3892/etm.2015.2913
   Yao YS, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/324360
   Yim YK, 2007, EVID-BASED COMPL ALT, V4, P51, DOI 10.1093/ecam/nel054
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 64
TC 28
Z9 35
U1 2
U2 35
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD MAR 15
PY 2021
VL 21
IS 3
BP 
EP 
DI 10.3892/etm.2021.9615
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA PW3BI
UT WOS:000610547700001
PM 33488793
DA 2026-01-16
ER

PT J
AU Wang, XQ
   Xiao, L
   Duan, PB
   Xu, Q
   Yang, LH
   Wang, AQ
   Wang, Y
AF Wang, Xiao-Qing
   Xiao, Lei
   Duan, Pei-Bei
   Xu, Qian
   Yang, Li-Hua
   Wang, A-Qin
   Wang, Yan
TI The feasibility and efficacy of perioperative auricular acupuncture technique via
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Auricular acupuncture; Gastric cancer; Intradermal needle; Movement-evoked pain; Randomized controlled trial
AB INTRODUCTION: Auricular acupuncture is widely used in the treatment of pain.  Recently, the most commonly used method of auricular acupuncture is to embed an  intradermal needle into the skin to enhance analgesia through continuous  stimulation. We aimed to explore the efficacy and feasibility of this form of  auricular acupuncture in the treatment of postoperative movement-evoked pain.  METHODS: This single-blind randomized controlled pilot trial was conducted  between 23/8/2019 and 10/1/2020. Forty patients were recruited and randomised to  either the control group (n = 20) or the experimental group (n = 20). Patients in  the control group received sham auricular acupuncture, while patients in the  experimental group received auricular acupuncture. A standard routine analgesia  was performed in both groups. The patients with NRS score≥4 were given rescue  analgesia. Postoperative pain, use of opioids and other analgesics, postoperative  recovery and patient's satisfaction were recorded. RESULTS: The credibility and  feasibility of auricular acupuncture for postoperative pain were high in both  groups. After auricular acupuncture, the scores of the postoperative  movement-evoked pain had a tendency to decrease, but no significant difference  was observed between two groups at any time point (P = 0.234∼0.888). The data on  postoperative pain at rest confirmed that no significant difference was observed  between two groups within 48 h of surgery (P = 0.134∼0.520), and the  postoperative pain at rest scores decreased over time; however, from the third  day, the pain at rest scores of the experimental group were decreased, and  significant differences were observed between the two groups (P = 0.039∼0.047).  As for use of rescue analgesic, total opioid consumption and the incidence of  postoperative nausea and vomiting, there were no significant differences between  the two groups (P = 0.311, P = 0.101, P = 0.661) . In terms of patients'  satisfaction, the score of the experimental group was higher than that of the  control group, and a significant difference was observed between the two groups  (P = 0.000). As for adverse events, two participants reported pain and one  patient reported discomfort at the insertion sites during the process of  auricular acupuncture intervention, but they both were minor and tolerable.  CONCLUSION: Auricular acupuncture may have a relief effect on mild postoperative  pain at rest with pain score below 3, suggesting that it may be a feasible  adjuvant method to relieve mild pain at rest. However, more multi-centre and  large-sample studies are needed to verify this result.
C1 Department of surgical oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road,Qinhuai District, Nanjing, Jiangsu 210029, China. 
   Department of Nursing, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinhuaiDistrict, Nanjing, Jiangsu 210029, China. 
   Department of Nursing, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinhuaiDistrict, Nanjing, Jiangsu 210029, China. 
   Anesthesiology and Pain Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road,Qinhuai District, Nanjing, Jiangsu 210029, China. 
   Department of Oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinhuaiDistrict, Nanjing, Jiangsu 210029, China,. 
   School of Nursing, Nanjing University of Chinese Medicine, 138 Xianlin Road, Qixia District, Nanjing, Jiangsu 210046, China. 
   Department of Nursing, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, QinhuaiDistrict, Nanjing, Jiangsu 210029, China.
EM zyyssswy@sina.com
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD OCT 14
PY 2021
VL 18
IS 1
BP 36
EP 43
DI 10.1016/j.explore.2021.09.007
PG 7
WC Acupuncture, Ear; methods; Feasibility Studies; Gastrectomy; Humans; Pain, Postoperative; therapy; Pilot Projects; Single-Blind Method
UT PubMed:34642104
PM 34642104
DA 2021-10-14
ER

PT J
AU Tender, T
   Rahangdale, RR
   Balireddy, S
   Nampoothiri, M
   Sharma, KK
   Chandrashekar, HR
AF Tender, Tenzin
   Rahangdale, Rakesh Ravishankar
   Balireddy, Sridevi
   Nampoothiri, Madhavan
   Sharma, K. Krishna
   Raghu Chandrashekar, Hariharapura
TI Melittin, a honeybee venom derived peptide for the treatment of chemotherapy-induced peripheral neuropathy
SO MEDICAL ONCOLOGY
LA English
DT Review
DE Chemotherapy; Peripheral neuropathy; Melittin; Haemolysis; alpha-Crystallin
ID quality-of-life; acupoint stimulation; arab breast; pain; prevalence; cancer; acupuncture; thalidomide; activation; paclitaxel
AB Chemotherapy-induced peripheral neuropathy (CIPN) is the most prevalent neurological complication of cancer treatment which involves sensory and motor nerve dysfunction. Severe CIPN has been reported in around 5% of patients treated with single and up to 38% of patients treated with multiple chemotherapeutic agents. Present medications available for CIPN are the use of opioids, nonsteroidal anti-inflammatory agents, and tricyclic antidepressants, which are only marginally effective in treating neuropathic symptoms. In reality, symptom reappears after these drugs are discontinued. The pathogenesis of CIPN has not been sufficiently recognized and methods for the prevention and treatment of CIPN remain vulnerable to therapeutic problems. It has witnessed that the present medicines available for the disease offer only symptomatic relief for the short term and have severe adverse side effects. There is no standard treatment protocol for preventing, reducing, and treating CIPN. Therefore, there is a need to develop curative therapy that can be used to treat this complication. Melittin is the main pharmacological active constituent of honeybee venom and has therapeutic values including in chemotherapeutic-induced peripheral neuropathy. It has been shown that melittin and whole honey bee venom are effective in treating paclitaxel and oxaliplatin-induced peripheral neuropathy. The use of melittin against peripheral neuropathy caused by chemotherapy has been limited despite having strong therapeutic efficacy against the disease. Melittin mediated haemolysis is the key reason to restrict its use. In our study, it is found that alpha-Crystallin (an eye lens protein) is capable of inhibiting melittin-induced haemolysis which gives hope of using an appropriate combination of melittin and alpha-Crystallin in the treatment of CIPN. The review summarizes the efforts made by different research groups to address the concern with melittin in the treatment of chemotherapeutic-induced neuropathy. It also focuses on the possible approaches to overcome melittin-induced haemolysis. Graphic
C1 [Tender, Tenzin; Rahangdale, Rakesh Ravishankar; Balireddy, Sridevi; Raghu Chandrashekar, Hariharapura] Manipal Acad Higher Educ, Dept Pharmaceut Biotechnol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
   [Nampoothiri, Madhavan] Manipal Acad Higher Educ, Dept Pharmacol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
   [Sharma, K. Krishna] Univ Missouri, Dept Ophthalmol & Biochem, Columbia Sch Med, Columbia, MO 65211 USA.
C3 Manipal Academy of Higher Education (MAHE); Manipal Academy of Higher Education (MAHE); University of Missouri System; University of Missouri Columbia
RP Chandrashekar, HR (corresponding author), Manipal Acad Higher Educ, Dept Pharmaceut Biotechnol, Manipal Coll Pharmaceut Sci, Manipal 576104, Karnataka, India.
EM raghu.c@manipal.edu
FU Manipal Academy of Higher Education, Manipal
CR Alhuqail A, 2018, BREAST CANCER RES TR, V168, P695, DOI 10.1007/s10549-017-4635-4
   Augusteyn Robert C, 2004, CLIN EXP OPTOM, V87, P356
   Banach M, 2017, BRAIN BEHAV, V7, P0, DOI 10.1002/brb3.558
   Barton DL, 2011, SUPPORT CARE CANCER, V19, P833, DOI 10.1007/s00520-010-0911-0
   Bhat SP, 2003, PROG DRUG RES, V60, P205
   Cheng B, 2015, J MATER CHEM B, V3, P25, DOI 10.1039/c4tb01401d
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi S, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11070396
   Cioroiu C, 2017, CURR NEUROL NEUROSCI, V17, P0, DOI 10.1007/s11910-017-0757-7
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   Fernyhough P, 2005, J NEUROSCI, V25, P1682, DOI 10.1523/JNEUROSCI.3127-04.2005
   Ghafoor M, 2003, MED J MALAYSIA, V58, P712
   Gornstein EL, 2017, EXP NEUROL, V288, P153, DOI 10.1016/j.expneurol.2016.11.015
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hilal L, 2015, CLIN GENITOURIN CANC, V13, P505, DOI 10.1016/j.clgc.2015.05.010
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Jester JV, 2008, SEMIN CELL DEV BIOL, V19, P82, DOI 10.1016/j.semcdb.2007.09.015
   Jones D, 2015, J CANCER SURVIV, V9, P1, DOI 10.1007/s11764-014-0379-x
   Jones MR, 2020, CURR CLIN PHARMACOL, V15, P38, DOI 10.2174/1574884714666190121154813
   JONES SL, 1991, PROG BRAIN RES, V88, P381
   Karakas B, 2013, CANCER BIOL THER, V14, P888, DOI 10.4161/cbt.25945
   Kim HW, 2003, J VET MED SCI, V65, P349, DOI 10.1292/jvms.65.349
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652
   Kwon YB, 2001, NEUROSCI LETT, V308, P133, DOI 10.1016/S0304-3940(01)01989-9
   Kwon YB, 2006, NEUROSCI RES, V55, P197, DOI 10.1016/j.neures.2006.03.003
   Lee JE, 2019, J PHARMACOL SCI, V140, P26, DOI 10.1016/j.jphs.2019.03.009
   Lee JS, 2006, J PHARMACOPUNCT, V9, P61
   Lopus M, 2015, CANCER CHEMOTH PHARM, V76, P1013, DOI 10.1007/s00280-015-2863-z
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   McKeage MJ, 2001, BRIT J CANCER, V85, P1219, DOI 10.1054/bjoc.2001.2024
   Mohty B, 2010, HAEMATOL-HEMATOL J, V95, P311, DOI 10.3324/haematol.2009.012674
   Pan H, 2011, WIRES NANOMED NANOBI, V3, P318, DOI 10.1002/wnan.126
   Park JW, 2012, INTEGR CANCER THER, V11, P166, DOI 10.1177/1534735411413265
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Richardson P, 2002, BIOMED PHARMACOTHER, V56, P115, DOI 10.1016/S0753-3322(02)00168-3
   Roh DH, 2004, J PAIN, V5, P297, DOI 10.1016/j.jpain.2004.05.003
   Rok KK, 2006, J PHARMACOPUNCT, V9, P79
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Sharma KK, 2000, J BIOL CHEM, V275, P3767, DOI 10.1074/jbc.275.6.3767
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   THOMSON JA, 1985, EXP EYE RES, V40, P393, DOI 10.1016/0014-4835(85)90152-6
   WALL PD, 1974, EXP NEUROL, V43, P580, DOI 10.1016/0014-4886(74)90197-6
   Wani TH, 2017, CHEM RES TOXICOL, V30, P1622, DOI 10.1021/acs.chemrestox.7b00127
   Winters-Stone KM, 2017, J CLIN ONCOL, V35, P2604, DOI 10.1200/JCO.2016.71.3552
   Wolf S, 2008, EUR J CANCER, V44, P1507, DOI 10.1016/j.ejca.2008.04.018
   Xiao WH, 2012, NEUROSCIENCE, V203, P194, DOI 10.1016/j.neuroscience.2011.12.023
   Yang EJ, 2011, J NEUROINFLAMM, V8, P0, DOI 10.1186/1742-2094-8-69
   Yoon SY, 2009, J PAIN, V10, P253, DOI 10.1016/j.jpain.2008.09.002
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
NR 52
TC 22
Z9 22
U1 2
U2 23
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD MAY 15
PY 2021
VL 38
IS 5
BP 
EP 
DI 10.1007/s12032-021-01496-9
PG 9
WC Oncology
SC Oncology
GA RH0WW
UT WOS:000635949500001
PM 33796975
DA 2026-01-16
ER

PT J
AU Chen, L
   Li, MY
   Fan, L
   Zhu, XP
   Liu, JH
   Li, H
   Xu, ZH
   Chen, JJ
   Liang, ZH
   Liu, ZY
   Feng, LM
   Chen, XY
   He, Q
   Chen, XK
   Ou, AH
   He, JS
   Ma, R
   Ning, BL
   Jiang, L
   Li, S
   Fu, WB
AF Chen, Ling
   Li, Minying
   Fan, Li
   Zhu, Xiaoping
   Liu, Jianhua
   Li, Hui
   Xu, Zhenhua
   Chen, Junjun
   Liang, Zhaohui
   Liu, Zhiyan
   Feng, Lingmei
   Chen, Xiaoyun
   He, Qing
   Chen, Xiaokai
   Ou, Aihua
   He, Jiangshan
   Ma, Rui
   Ning, Baile
   Jiang, Li
   Li, Sheng
   Fu, Wenbin
TI Optimized acupuncture treatment (acupuncture and intradermal needling) for cervical spondylosis-related neck pain: a multicenter randomized controlled trial
SO PAIN
LA English
DT Article
DE Cervical spondylosis-related neck pain; Optimized acupuncture treatment; Shallow acupuncture; Sham acupuncture
ID quality-of-life; breast-cancer; mcgill pain; task-force; joint pain; usual care; questionnaire; electroacupuncture; disability; protocol
AB Cervical spondylosis (CS)-related neck pain is difficult to treat because of its degenerative nature. The aim of this 9-center, single-blinded, randomized controlled trial was to evaluate the efficacy of optimized acupuncture for CS-related neck pain. Participants who met the inclusion criteria were randomized to optimized, shallow, and sham acupuncture groups (1:1:1). The primary outcome was the change from baseline in the Northwick Park Neck Pain Questionnaire score at week 4. Participants were followed up until week 16. Of the 896 randomized participants, 857 received >= 1 intervention session; 280, 286, and 291 received optimized, shallow, and sham acupuncture, respectively. A total of 835 (93.2%) participants completed the study. At week 4, significant differences (P < 0.001) were observed in the changes in Northwick Park Neck Pain Questionnaire scores between the optimized acupuncture group and both the shallow {7.72 (95% confidence interval [CI], 5.57-9.86)} and sham acupuncture (10.38 [95% CI, 8.25-12.52]) groups. The difference in the scores at week 16 between the optimized acupuncture group and the shallow (8.84 [95% CI, 6.34-11.34]) and sham acupuncture (10.81 [95% CI, 8.32-13.30]) groups were significant. The center effect indicated wide variability in the treatment effects (Cohen's d = 0.01-2.19). Most SF-36 scores were higher in the optimized acupuncture group than those in the other groups. These results suggest that 4-week optimized acupuncture treatment alleviates CS-related neck pain and improves the quality of life, with the effects persisting for minimum 3 months. Therefore, acupuncture can have positive effects on CS-related neck pain, although the effect size may vary widely.
C1 [Chen, Ling; Zhu, Xiaoping; Liu, Jianhua; Li, Hui; Xu, Zhenhua; Ma, Rui; Ning, Baile; Jiang, Li; Li, Sheng; Fu, Wenbin] Guangzhou Univ Chinese Med, Dept Acupuncture & Moxibust, Affiliated Hosp 2, 111 Dade Rd, Guangzhou, Guangdong, Peoples R China.
   [Chen, Ling; Li, Minying; He, Jiangshan] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China.
   [Fan, Li] Guangzhou Univ Chinese Med, Dept Tradit Therapy Ctr, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Chen, Junjun] Hunan Univ Tradit Chinese Med, Dept Acupuncture & Moxibust, Affiliated Hosp 1, Changsha, Peoples R China.
   [Liang, Zhaohui] York Univ, Toronto, ON, Canada.
   [Liu, Zhiyan] Xinjiang Uygur Autonomous Reg Hosp Tradit Chinese, Dept Acupuncture & Moxibust, Urumqi, Peoples R China.
   [Feng, Lingmei] Guizhou Univ Tradit Chinese Med, Dept Acupuncture & Massage, Guiyang, Peoples R China.
   [Chen, Xiaoyun] Hainan Gen Hosp, Dept Acupuncture & Moxibust, Haikou, Hainan, Peoples R China.
   [He, Qing] Yan Chai Hosp Cum Hong Kong Baptist Univ Yan Chai, Chinese Med Ctr Training & Res, Hong Kong, Peoples R China.
   [Chen, Xiaokai] Guangzhou Med Univ, Huizhou Peoples Hosp 3, Huizhou, Peoples R China.
   [Ou, Aihua] Guangzhou Univ Chinese Med, Dept Big Data Res Chinese Med, Affiliated Hosp 2, Guangzhou, Peoples R China.
   [Fu, Wenbin] Shenzhen Baoan Res Ctr Acupuncture & Moxibust, Shenzhen, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Hunan University of Chinese Medicine; York University - Canada; Guizhou University of Traditional Chinese Medicine; Hainan Medical University; Guangzhou Medical University; Guangzhou University of Chinese Medicine
RP Fu, WB (corresponding author), Guangzhou Univ Chinese Med, Dept Acupuncture & Moxibust, Affiliated Hosp 2, 111 Dade Rd, Guangzhou, Guangdong, Peoples R China.
EM fuwenbin@gzucm.edu.cn
FU Ministry of Science and Technology of the People's Republic of China through the Eleventh Five-Year National Science and Technology Pillar Program [2006BAI12B04-1]; Sanming Project of Medicine in Shenzhen [SZSM201806077]; China Postdoctoral Science Foundation [2019M652867]; Foundation for Basic and Applied Basic Research of Guangdong Province [2019M652867]; Scientific Research Project of Guangdong Traditional Chinese Medicine Bureau [20201118]
CR Baeumler PI, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0113731
   Baime MJ, 2016, ANN INTERN MED, V164, PJC29, DOI 10.7326/ACPJC-2016-164-6-029
   Cerezo-Téllez E, 2018, HEALTH QUAL LIFE OUT, V16, P0, DOI 10.1186/s12955-018-1032-6
   Chaffee A, 2011, J SPORT REHABIL, V20, P250, DOI 10.1123/jsr.20.2.250
   Chen L, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j1284
   Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65
   Cohen J, 1988, STAT POWER ANAL BEHA, V2nd ed, P0
   Cohen SP, 2015, MAYO CLIN PROC, V90, P284, DOI 10.1016/j.mayocp.2014.09.008
   Côté P, 2008, SPINE, V33, PS60, DOI 10.1097/BRS.0b013e3181643ee4
   Couto C, 2014, CLIN J PAIN, V30, P214, DOI 10.1097/AJP.0b013e3182934b8d
   Dziedzic K, 2005, ARTHRIT RHEUM-ARTHR, V53, P214, DOI 10.1002/art.21087
   Ebell MH, 2006, AM FAM PHYSICIAN, V74, P1126
   Fireman Z, 2001, DIGESTION, V64, P100, DOI 10.1159/000048847
   Giles LGF, 2003, SPINE, V28, P1490, DOI 10.1097/00007632-200307150-00003
   Haldeman S, 2010, J OCCUP ENVIRON MED, V52, P424, DOI 10.1097/JOM.0b013e3181d44f3b
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P2270, DOI 10.1001/jama.2018.16744
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/S0140-6736(18)32279-7
   Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301
   Kong J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081049
   Lee SH, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-026632
   Liang ZH, 2012, TRIALS, V13, P0, DOI 10.1186/1745-6215-13-107
   Liang ZH, 2011, COMPLEMENT THER MED, V19, PS26, DOI 10.1016/j.ctim.2010.11.005
   Lowe C, 2017, NEUROGASTROENT MOTIL, V29, P13040
   Lu DP, 2001, AM J CLIN HYPN, V44, P141, DOI 10.1080/00029157.2001.10403469
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Main CJ, 2016, PAIN, V157, P1387, DOI 10.1097/j.pain.0000000000000457
   Manchikanti L, 2015, PAIN PHYSICIAN, V18, P39
   Molnar FJ, 2008, CAN MED ASSOC J, V179, P751
   Patel KC, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD004871.pub4
   Que QH, 2013, TRIALS, V14, P0, DOI 10.1186/1745-6215-14-186
   Salter GC, 2006, BMC MUSCULOSKEL DIS, V7, P0, DOI 10.1186/1471-2474-7-99
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Sim J, 2006, CLIN J PAIN, V22, P820, DOI 10.1097/01.ajp.0000210937.58439.39
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2013, ACUPUNCT MED, V31, P98, DOI 10.1136/acupmed-2013-010312
   Witt CM, 2006, PAIN, V125, P98, DOI 10.1016/j.pain.2006.05.013
   World Health Organization, 2010, ACTA CHIRURGICA IUGOSLAVICA, V56, P65
   Yeung PLC, 2004, HEAD NECK-J SCI SPEC, V26, P1031, DOI 10.1002/hed.20102
   Yuan QL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0117146
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 41
TC 32
Z9 39
U1 11
U2 78
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD MAR 15
PY 2021
VL 162
IS 3
BP 728
EP 739
DI 10.1097/j.pain.0000000000002071
PG 12
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA SL0UO
UT WOS:000656631900009
PM 32947547
DA 2026-01-16
ER

PT J
AU Chien, A
   Yang, CC
   Chang, SC
   Jan, YM
   Yang, CH
   Hsieh, YL
AF Chien, Andy
   Yang, Chen-Chia
   Chang, Sheng-Chi
   Jan, Yi-Min
   Yang, Ching-Hsiang
   Hsieh, Yueh-Ling
TI Ultrasound Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Patients With Colorectal Cancer: A Pilot Study
SO PM&R
LA English
DT Article
ID quality-of-life; nerve surgery; chemotherapy; pain; therapy; feasibility; stimulation; recovery; model
AB Background Oxaliplatin is frequently used in the treatment of metastatic colorectal cancer. However, peripheral neuropathy is a severe adverse effect of oxaliplatin that may persist and impact quality of life. Objective To assess the potential effects of ultrasound acupuncture for the alleviation of symptoms related to oxaliplatin-induced peripheral neuropathy (OIPN) among patients with metastatic colorectal cancer. Design Prospective cohort pilot study. Setting Education and research hospital. Participants Patients with a diagnosis of stage II-IV colorectal cancer undergoing oxaliplatin-based treatment regimens who experienced OIPN symptoms (n = 17). Interventions Pulsed therapeutic ultrasound (1 MHz) at bilateral acupuncture points of PC6, PC7, BL60, and KI1 was administered for 5 minutes per point daily for 12 days. Main Outcome Measurements Pain Quality Assessment Scale (PQAS), Chemotherapy-induced Neurotoxicity Questionnaire (CINQ), quantitative touch-detection threshold, cold-trigger pain withdrawal latency, and quality of life (EORTC QLQ-C30) were measured at baseline (day 0), pre-intervention (day 12, post wash-out period), post-intervention (day 24), and final follow-up (day 54). A P value of less than .05 was considered statistically significant. Results Scores of PQAS and CINQ significantly improved after ultrasound acupuncture at post-intervention and follow-up compared to both baseline and pre-intervention. Similar trends were also observed for the quantitative sensory testing, where touch-detection threshold significantly decreased and cold-trigger pain withdrawal latency significantly increased after ultrasound acupuncture. Patients also showed an improvement on quality of life outcomes as measured by QLQ-C30 post-intervention and at follow-up. Conclusions Ultrasound acupuncture could be an effective intervention for OIPN symptoms for patients with colorectal cancer. However, larger and randomized clinical trials with placebo controls are needed to confirm such effects.
C1 [Chien, Andy; Yang, Ching-Hsiang; Hsieh, Yueh-Ling] China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan.
   [Yang, Chen-Chia] Kao An Rehabil & Pain Clin, Taichung, Taiwan.
   [Chang, Sheng-Chi] China Med Univ Hosp, Dept Colorectal Surg, Taichung, Taiwan.
   [Jan, Yi-Min] China Med Univ, Ctr Gen Educ, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan
RP Hsieh, YL (corresponding author), China Med Univ, Grad Inst Rehabil Sci, Dept Phys Therapy, Taichung, Taiwan.
EM sherrie@mail.cmu.edu.tw
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Akhlaghi Zhamak, 2012, IRANIAN BIOMEDICAL JOURNAL, V16, P107, DOI 10.6091/IBJ.942.2012
   An KE, 2010, NEUROL RES, V32, PS22, DOI 10.1179/016164109X12537002793760
   Bergmeister KD, 2018, NEURAL REGEN RES, V13, P1530, DOI 10.4103/1673-5374.237113
   Chang WD, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6568976
   Chang YW, 2014, BMC MUSCULOSKEL DIS, V15, P0, DOI 10.1186/1471-2474-15-399
   Chen CC, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016516
   Chen Ling, 2017, ZHONGGUO ZHEN JIU, V37, P479, DOI 10.13703/j.0255-2930.2017.05.007
   Clark RJ, 2012, ACUPUNCT MED, V30, P298, DOI 10.1136/acupmed-2012-010183
   Colquhoun D, 2013, ANESTH ANALG, V116, P1360, DOI 10.1213/ANE.0b013e31828f2d5e
   Daeschler SC, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-21540-5
   Deng SZ, 2015, EXP THER MED, V10, P1247, DOI 10.3892/etm.2015.2653
   Dimitrova A, 2020, PAIN MED, V21, PE232, DOI 10.1093/pm/pnz276
   Ding Ming-hui, 2009, ZHONGGUO ZHEN JIU, V29, P603
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ernst E, 2006, J INTERN MED, V259, P125, DOI 10.1111/j.1365-2796.2005.01584.x
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Fayers P, 1995, EORTC QLQC30 SCORING MANUAL. EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER, V0, P0
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   He Y, 2019, JAMA ONCOL, V0, P0
   Hou S, 2018, PAIN PHYSICIAN, V21, P571, DOI 10.36076/ppj.2018.6.571
   Hsieh YL, 2016, SUPPORT CARE CANCER, V24, P233, DOI 10.1007/s00520-015-2773-y
   Hsieh YL, 2017, ULTRASOUND MED BIOL, V43, P1466, DOI 10.1016/j.ultrasmedbio.2017.03.002
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Hsieh YL, 2012, J COMP NEUROL, V520, P2903, DOI 10.1002/cne.23072
   Leonard GD, 2005, BMC CANCER, V5, P0, DOI 10.1186/1471-2407-5-116
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Macklin EA, 2006, HYPERTENSION, V48, P838, DOI 10.1161/01.HYP.0000241090.28070.4c
   McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436
   Mei Jun-hua, 2015, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V35, P1463
   Mi Yi-Qun, 2009, ZHONGGUO ZHEN JIU, V29, P48
   Pachman DR, 2016, SUPPORT CARE CANCER, V24, P5059, DOI 10.1007/s00520-016-3373-1
   Pulvers JN, 2017, ASIA-PAC J CLIN ONCO, V13, P345, DOI 10.1111/ajco.12694
   Qin Yu-ge, 2010, ZHONGGUO ZHEN JIU, V30, P121
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seco J, 2011, SPINE J, V11, P966, DOI 10.1016/j.spinee.2011.02.002
   Tofthagen C, 2013, SUPPORT CARE CANCER, V21, P3307, DOI 10.1007/s00520-013-1905-5
   Tsuruoka N, 2019, COMPLEMENT MED RES, V26, P404, DOI 10.1159/000501149
   Tsuruta A, 2016, DRUG DES DEV THER, V10, P3827, DOI 10.2147/DDDT.S112322
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Xu Wei-Ru, 2010, ZHONGGUO ZHEN JIU, V30, P457
   Yang Yu-Hua, 2012, ZHEN CI YAN JIU, V37, P333
   Yoo SS, 2014, COMPLEMENT THER MED, V22, P592, DOI 10.1016/j.ctim.2014.05.010
   Zeng YJ, 2018, LASER MED SCI, V33, P295, DOI 10.1007/s10103-017-2367-7
   Zhang WP, 2010, J ACUPUNCT MERIDIAN, V3, P43, DOI 10.1016/S2005-2901(10)60007-6
   Zhao Jian-ling, 2008, ZHONGGUO ZHEN JIU, V28, P13
NR 47
TC 5
Z9 5
U1 2
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-1482
EI 1934-1563
J9 PM&R
JI PM&R
PD JAN 15
PY 2021
VL 13
IS 1
BP 55
EP 65
DI 10.1002/pmrj.12361
EA APR 2020
PG 11
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA PW3CS
UT WOS:000526959500001
PM 32168417
DA 2026-01-16
ER

PT J
AU Yang, J
   Wahner-Roedler, DL
   Zhou, X
   Johnson, LA
   Do, A
   Pachman, DR
   Chon, TY
   Salinas, M
   Millstine, D
   Bauer, BA
AF Yang, Juan
   Wahner-Roedler, Dietlind L.
   Zhou, Xuan
   Johnson, Lesley A.
   Do, Alex
   Pachman, Deirdre R.
   Chon, Tony Y.
   Salinas, Manisha
   Millstine, Denise
   Bauer, Brent A.
TI Acupuncture for palliative cancer pain management: systematic review
SO BMJ SUPPORTIVE & PALLIATIVE CARE
LA English
DT Review
DE cancer; pain; supportive care
ID symptom management; of-life; care; statistics; patient; women
AB Background Pain is one of the most common and problematic symptoms encountered by patients with cancer. Due to the multifactorial aetiology, pain management of these patients frequently requires multidisciplinary interventions including conventional support and specialty palliative care. Acupuncture has been identified as a possible adjunctive therapy for symptom management in cancer pain, and there is currently no systematic review focused solely on the evidence of acupuncture on cancer pain in palliative care. Objective To critically analyse currently available publications regarding the use of acupuncture for pain management among patients with cancer in palliative care settings. Methods Multiple academic databases were searched from inception to 29 October 2020. Randomised controlled trials involving acupuncture in palliative care for treatment of cancer-related pain were synthesised. Data were extracted by two independent reviewers, and methodological quality of each included study was assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2011 Levels of Evidence. Results Five studies (n=189) were included in this systematic review. Results indicated a favourable effect of acupuncture on pain relief in palliative care for patients with cancer. According to OCEBM 2011 Levels of Evidence, they were level 2 in one case (20%), level 3 in two cases (40%) and level 4 in the remaining (40%). Low-level evidence adversely affects the reliability of findings. Conclusions Acupuncture may be an effective and safe treatment associated with pain reduction in the palliative care of patients with cancer. Further high-quality, adequately powered studies are needed in the future.
C1 [Yang, Juan; Wahner-Roedler, Dietlind L.; Do, Alex; Chon, Tony Y.; Bauer, Brent A.] Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA.
   [Zhou, Xuan] Jinan Univ, Sch Tradit Chinese Med, Formula Pattern Res Ctr, Guangzhou, Peoples R China.
   [Johnson, Lesley A.; Millstine, Denise] Mayo Clin, Dept Womens Hlth Internal Med, Scottsdale, AZ USA.
   [Pachman, Deirdre R.] Mayo Clin, Ctr Palliat Med, Rochester, MN USA.
   [Salinas, Manisha] Mayo Clin, Div Family Med, Jacksonville, FL 32224 USA.
C3 Mayo Clinic; Jinan University; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic
RP Bauer, BA (corresponding author), Mayo Clin, Div Gen Internal Med, Rochester, MN 55905 USA.
EM Bauer.Brent@mayo.edu
FU HEAD Foundation, Singapore
CR Are M, 2017, J SURG ONCOL, V115, P637, DOI 10.1002/jso.24585
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Bruera Eduardo, 2015, AM SOC CLIN ONCOL EDUC BOOK, V0, PPE593, DOI 10.14694/edbook_am.2015.35.e593
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cho YH, 2015, PAIN PRACT, V15, P279, DOI 10.1111/papr.12208
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Hartl S, 2019, RESPIRATORY MEDICINE, V0, P249
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Helms JM, 1995, ACUPUNCTURE ENERGETICS: A CLINICAL APPROACH FOR PHYSICIANS, V0, P0
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hjermstad MJ, 2018, BMJ SUPPORT PALLIAT, V8, P456, DOI 10.1136/bmjspcare-2015-000997
   Holm M, 2015, BMC PALLIAT CARE, V14, P0, DOI 10.1186/s12904-015-0015-1
   Howick J, 2011, OCEBM LEVELS OF EVIDENCE WORKING GROUP. THE OXFORD 2011 LEVELS OF EVIDENCE, V0, P0
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hudson P, 2001, INT J PALLIAT NURS, V7, P427
   Johnstone PAS, 2002, PALLIATIVE MED, V16, P235, DOI 10.1191/0269216302pm540oa
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Liberati A, 2009, ANN INTERN MED, V151, PW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Lim JTW, 2011, ACUPUNCT MED, V29, P173, DOI 10.1136/aim.2011.004044
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Murakami M, 2017, PAIN MED, V18, P551, DOI 10.1093/pm/pnw215
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Rodriguez C, 2019, J HOSP PALLIAT NURS, V21, P116, DOI 10.1097/NJH.0000000000000507
   Sanft T, 2019, J NATL COMPR CANC NE, V17, P785, DOI 10.6004/jnccn.2019.0034
   Silverman J, 2019, ACAD PAIN MED, V0, P177
   Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367
   Soares LGL, 2019, ANN PALLIAT MED, V8, P523, DOI 10.21037/apm.2019.04.01
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wiffen PJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012592.pub2
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Wu XY, 2017, DTSCH Z AKUPUNKT, V60, P28, DOI 10.1016/S0415-6412(17)30048-6
NR 47
TC 56
Z9 70
U1 0
U2 20
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2045-435X
EI 2045-4368
J9 BMJ SUPPORT PALLIAT
JI BMJ Support. Palliat. Care
PD SEP 15
PY 2021
VL 11
IS 3
BP 264
EP 270
DI 10.1136/bmjspcare-2020-002638
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA UO4GR
UT WOS:000694654100004
PM 33441387
DA 2026-01-16
ER

PT J
AU Shao, JK
   Liu, Q
   Pei, W
   Wang, Y
   Yang, NN
   Qi, LY
   Huang, J
   Yang, JW
   Liu, CZ
AF Shao, Jia-Kai
   Liu, Qian
   Pei, Wei
   Wang, Yu
   Yang, Na-Na
   Qi, Ling-Yu
   Huang, Jin
   Yang, Jing-Wen
   Liu, Cun-zhi
TI Electroacupuncture for postoperative ileus after laparoscopic surgery on colorectal cancer: study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Postoperative ileus; Electroacupuncture; Single acupoint; Randomized controlled trial
ID opioid receptor antagonist; enhanced recovery; alvimopan; pathophysiology; acupuncture; definition; mechanisms
AB Background: Postoperative ileus (POI) occurs in almost all patients after abdominal laparoscopic surgery, resulting in complications and increasing the length of hospitalization. Electroacupuncture has been used as an alternative therapy for gastrointestinal dysfunction, but its efficacy for POI is inconclusive. The study is designed to determine whether electroacupuncture can accelerate recovery from POI. Methods/design: This study is a three-arm, randomized controlled trial. A total of 105 patients will be randomized into a group receiving electroacupuncture at Tianshu (ST25), a group receiving electroacupuncture at Zusanli (ST36), or a control group in a 1:1:1 ratio. Patients in the electroacupuncture groups will receive electroacupuncture treatment for 4 days from the first day after surgery. The primary outcome consists of the time to first flatus and the time to first defecation. Secondary outcomes include the time to first tolerance of liquid and semiliquid food; the length of the hospital stay; postoperative pain, nausea, and vomiting; abdominal distension; the time to first get out of bed; and postoperative complications. The outcomes will be assessed by the patients themselves every day during hospitalization. Surgeons, nurses, assessors, and statisticians will be blinded to the group assignments. Patients in the two electroacupuncture groups, but not in the control group, will be blinded to the group assignments. The acupuncturists will not be blinded. Discussion: The aim of this trial is to provide a nonpharmacological therapy for POI and may provide evidence of the effect of electroacupuncture at ST25 or ST36 on POI.
C1 [Shao, Jia-Kai; Wang, Yu; Yang, Na-Na; Qi, Ling-Yu; Huang, Jin; Yang, Jing-Wen; Liu, Cun-zhi] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Int Acupuncture & Moxibust Innovat Inst, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
   [Liu, Qian; Pei, Wei] Chinese Acad Med Sci, Dept Colorectal Surg, Canc Inst & Hosp, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College
RP Yang, JW (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Int Acupuncture & Moxibust Innovat Inst, 11 Bei San Huan Dong Lu, Beijing 100029, Peoples R China.
EM yangjw0626@126.com
FU National Science Fund for Distinguished Young Scholars [81825024]; Project of National Natural Science Foundation of China [2019YFC1712100]
CR Adam MA, 2016, ANN SURG, V264, P141, DOI 10.1097/SLA.0000000000001428
   Artinyan A, 2008, WORLD J SURG, V32, P1495, DOI 10.1007/s00268-008-9491-2
   Boeckxstaens GE, 2009, GUT, V58, P1300, DOI 10.1136/gut.2008.169250
   Chen JDZ, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13393
   Cornwall HL, 2020, CLIN NUTR, V39, P1385, DOI 10.1016/j.clnu.2019.06.003
   Delaney CP, 2004, NEUROGASTROENT MOTIL, V16, P61, DOI 10.1111/j.1743-3150.2004.00559.x
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Edna PGM, 2016, COCHRANE DB SYST REV, V10, P0
   Fang JF, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39801
   Gero D, 2017, LANGENBECK ARCH SURG, V402, P149, DOI 10.1007/s00423-016-1485-1
   Harnsberger CR, 2019, CLIN COLON RECT SURG, V32, P166, DOI 10.1055/s-0038-1677003
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Kauf TL, 2014, J UROLOGY, V191, P1721, DOI 10.1016/j.juro.2013.12.015
   Kehlet H, 2008, NAT CLIN PRACT GASTR, V5, P552, DOI 10.1038/ncpgasthep1230
   Keller DS, 2016, AM J SURG, V212, P851, DOI 10.1016/j.amjsurg.2016.02.016
   Kraft MD, 2008, EXPERT OPIN INV DRUG, V17, P1365, DOI 10.1517/13543784.17.9.1365
   Lee CT, 2014, EUR UROL, V66, P265, DOI 10.1016/j.eururo.2014.02.036
   Liang C, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13318
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952
   Nair Abhijit, 2016, ACTA ANAESTHESIOL TAIWAN, V54, P97, DOI 10.1016/j.aat.2016.10.001
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Pacelli F, 2014, GASTRIC CANCER, V17, P725, DOI 10.1007/s10120-013-0319-x
   Park SM, 2016, INT J DERMATOL, V55, P757, DOI 10.1111/ijd.12914
   Qingguang Q, 2013, WORLD CHIN MED, V03, P262
   Rollins KE, 2019, ANN SURG, V270, P43, DOI 10.1097/SLA.0000000000003145
   Scarborough JE, 2017, JAMA SURG, V152, P0, DOI 10.1001/jamasurg.2016.4681
   Stakenborg N, 2017, HANDB EXP PHARMACOL, V239, P39, DOI 10.1007/164_2016_108
   Teixeira FM, 2012, BRAZ J MED BIOL RES, V45, P1209, DOI 10.1590/S0100-879X2012007500133
   van Bree S, 2011, GASTROENTEROLOGY, V141, P872, DOI 10.1053/j.gastro.2011.05.034
   van Bree SHW, 2014, ANN SURG, V259, P708, DOI 10.1097/SLA.0b013e318293ee55
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   WHO Regional Office for the Western Pacific, 2008, WHO STAND AC POINT L, V0, P0
   World Health Organization, 2002, PROGRAMME ON TRADITIONAL MEDICINE. WHO TRADITIONAL MEDICINE STRATEGY 2002-2005, V0, P0
   Xu LL, 2016, J SURG RES, V203, P211, DOI 10.1016/j.jss.2016.01.027
   Ya-Quan H, 2019, JILIN J CHIN MED, V39, P124
   Yang Y, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep37826
   Yi-Hua L, 2017, EVID BASED COMPLEMEN, V2017, P0
   Zhou JZ, 2017, NEUROMODULATION, V20, P767, DOI 10.1111/ner.12602
NR 40
TC 7
Z9 9
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 9
PY 2021
VL 22
IS 1
BP 
EP 
DI 10.1186/s13063-021-05564-3
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA UO7TC
UT WOS:000694894400002
PM 34503565
DA 2026-01-16
ER

PT J
AU Chen, Q
   Feng, J
   Liu, Z
   An, D
   Li, Y
   Zhou, S
   Weng, Z
AF Chen, Qi
   Feng, Jiaming
   Liu, Zhidan
   An, Dongyang
   Li, Yadan
   Zhou, Shaohu
   Weng, Zhiwei
TI Research trends of prostatitis over past 20 years: A bibliometric analysis.
SO Andrologia
LA English
DT Journal Article
DE VOSviewer; bibliographic item co-occurrence matrix builder; bibliometric analysis; prostatitis; research trends
AB In the past two decades, thousands of documents in the field of prostatitis have  been published. This bibliometric analysis aimed to assess the characteristics,  hotspots and frontiers trend of global scientific output on prostatitis. With the  trend of moderate growth, altogether 2,423 papers were reviewed. The leading role  of the United States in global prostatitis research was obvious, while China had  developed rapidly in recent years. Queen's University and JOURNAL OF UROLOGY were  the most prolific affiliation and journal respectively. Nickel, J. C made the  greatest contribution to the field of prostatitis. Five hotspots have been  confirmed: (a) male infertility associated with prostatitis and the molecular  mechanisms; (b) diagnosis and treatment of prostatitis; (c) inflammation, pain  and bladder irritation symptoms; (d) relationship between chronic  prostatitis/chronic pelvic pain syndrome, benign prostatic hyperplasia and  prostate cancer; (e) epidemiology, complications of prostatitis and improvement  of acupuncture. This bibliometric analysis reveals that the international  cooperation was becoming more and more close. Hotspot analysis shows that the  molecular mechanism of prostatitis will be a hotspot in the future, mainly  focussing on inflammatory immunity and oxidative stress.
C1 The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   Lingnan Medical Research Center, Guangzhou University of Chinese Medicine, 
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Affiliated Hospital, Guangzhou University of Chinese Medicine, 
   The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
   The First Affiliated Hospital, Guangzhou University of Chinese Medicine,
NR 0
TC 0
SN 1439-027
EI 
J9 Andrologia
PD AUG 9
PY 2021
VL 53
IS 10
BP e14206
EP e14206
DI 10.1111/and.14206
PG 1
WC Acupuncture Therapy; Bibliometrics; China; epidemiology; Humans; Male; Prostatic Hyperplasia; epidemiology; Prostatitis; epidemiology; United States
UT PubMed:34365673
PM 34365673
DA 2021-08-09
ER

PT J
AU Liou, KT
   Mao, JJ
AF Liou, Kevin T.
   Mao, Jun J.
TI In reply to "could acupuncture be a treatment option for cancer patients with attitudinal barriers to pharmacological pain management?" by Kako, Kajiwara, and Kobayashi
SO SUPPORTIVE CARE IN CANCER
LA English
DT Letter
C1 [Liou, Kevin T.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Liou, KT (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM liouk@mskcc.org
FU National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [3P30CA008748-50, 3P30CA008748-50] Funding Source: Medline
CR Bauml JM, 2015, CANCER-AM CANCER SOC, V121, P2431, DOI 10.1002/cncr.29173
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
   Mao JJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/798098
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
NR 4
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN 15
PY 2021
VL 29
IS 1
BP 5
EP 5
DI 10.1007/s00520-020-05844-9
EA OCT 2020
PG 1
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA RI9WR
UT WOS:000585671300001
PM 33111181
DA 2026-01-16
ER

PT J
AU Yildirim, D
   Yildiz, CC
AF Yildirim, Dilek
   Yildiz, Cennet Ciris
TI The effect of acupressure on vital signs, acute pain, stress and satisfaction during venipuncture: Single-blind, randomized controlled study
SO EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE Acupressure; Vital signs; Acute pain; Stress; Satisfaction; Venipuncture; Randomized controlled trial
ID acupuncture; anxiety; cancer; point
AB Introduction: Pain increases the patient's anxiety levels and prolongs examination and other medical processes. This study was conducted as a single-blind, randomized controlled study to determine the effects of acupressure applied on adult patients and whether it changed their vital signs, acute pain, stress and satisfaction during venipuncture. Methods: Patients who had a BMI of 18.5-30 kg/m(2), presence of an internal disease, were attending a routine clinic check-up, had requested to have a blood sample, were examined by a physician, had no sign of pain, hematoma, necrosis, scar, incision or infection on the skin around the venipuncture site and had taken no analgesic drug for the last six hours were included in the trial. Patients were randomly allocated to either an acupressure group (n=100) or a no-intervention control group (n=100). Acupressure (LI 4, LI 11 and HT 7 points) was applied once by a certified researcher for 10 min prior to venipuncture. Pain, satisfaction, stress, heart rate and oxygen saturation levels of the patients in the acupressure and control groups were assessed 15 min before and immediately after the venipuncture procedure. The Visual Analog Scale for the Measurement of Pain Severity, the Visual Analog Patient Satisfaction Scale and the State-Trait Anxiety Inventory were used to collect the data. Results: The acupressure group had a significantly lower mean pain score than the control group (respectively, 1.23 +/- 1.09 and 1.95 +/- 1.95, p<0.05). The acupressure group had a significantly higher mean satisfaction score than the control group (respectively, 9.13 +/- 1.31 and 8.51 +/- 1.86, p<0.05). The acupressure group had a significantly lower mean stress score than the control group (respectively, 34.66 +/- 7.99 and 41.91 +/- 9.21, p<0.05). Conclusion: Acupressure reduced acute pain and stress and increased satisfaction levels in adult patients undergoing venipuncture.
C1 [Yildirim, Dilek] Istanbul Aydin Univ, Fac Hlth Sci, Dept Nursing, Istanbul, Turkey.
   [Yildiz, Cennet Ciris] Istanbul Kent Univ, Fac Hlth Sci, Dept Nursing, Istanbul, Turkey.
C3 Istanbul Aydin University; Istanbul Kent University
RP Yildirim, D (corresponding author), Florya Campus,Halit Aydin Campus,Inonu St 38, TR-34295 Kucukcekmece Istanbul, Turkey.
EM dilekaticiyildirim@gmail.com; cennetciris.yildiz@kent.edu.tr
CR Acar K, 2016, JOURNAL OF ANATOLIA NURSING AND HEALTH SCIENCES, V19, P0, DOI 10.17049/ahsbd.03291
   Alavi NM, 2007, ACUTE PAIN, V9, P201, DOI 10.1016/J.ACPAIN.2007.09.002
   Arai YCP, 2008, ANESTH ANALG, V107, P661, DOI 10.1213/ane.0b013e31817b8495
   Aslan FE, 2005, AGRI, V17, P44
   Basampur S, 2008, J NURS MIDWIFERY TEH, V2, P23
   Birgili F, 2011, NURS J, V18, P17
   Byju Anju, 2018, CAN ONCOL NURS J, V28, P132, DOI 10.5737/23688076282132138
   Cheung DST, 2022, EUR J CANCER CARE, V31, P0, DOI 10.1111/ecc.13314
   FAHS PSS, 1991, NURS RES, V40, P204
   Fassoulaki A, 2003, ANESTH ANALG, V96, P885, DOI 10.1213/01.ANE.0000048713.41657.D3
   Harris RE, 2005, J ALTERN COMPLEM MED, V11, P673, DOI 10.1089/acm.2005.11.673
   Hosseinabadi R, 2015, J INFUS MURS, V38, P397, DOI 10.1097/NAN.0000000000000065
   Inan G, 2019, CLIN J PAIN, V35, P140, DOI 10.1097/AJP.0000000000000666
   Inangil D, 2020, J CLIN NURS, V29, P1094, DOI 10.1111/jocn.15172
   Kendrick C, 2016, INT J CLIN EXP HYP, V64, P75, DOI 10.1080/00207144.2015.1099405
   Kim HJ, 2017, PAIN, V158, P194, DOI 10.1097/j.pain.0000000000000731
   Kuguoglu S, 2014, NATURE CONTROL PAIN, V2nd, P51
   Liu MM, 2021, PAIN MANAG NURS, V22, P268, DOI 10.1016/j.pmn.2020.07.007
   Marco CA, 2017, AM J EMERG MED, V35, P183, DOI 10.1016/j.ajem.2016.10.021
   Murphy SL, 2019, PAIN MED, V20, P2588, DOI 10.1093/pm/pnz138
   Nemati M H, 2015, J MED LIFE, V8, P144
   Oakes LL, 2011, COMPACT CLINICAL GUIDE TO INFANT AND CHILD PAIN MANAGEMENT: AN EVIDENCE-BASED APPROACH FOR NURSES, V0, P1
   Oner N, 1985, STATE TRAIT ANXIETY, V0, P0
   Özkan TK, 2020, WORLDV EVID-BASED NU, V17, P221, DOI 10.1111/wvn.12437
   PRICE DD, 1994, PAIN, V56, P217, DOI 10.1016/0304-3959(94)90097-3
   Rahim-Williams B, 2012, PAIN MED, V13, P522, DOI 10.1111/j.1526-4637.2012.01336.x
   Rhudy JL, 2000, PAIN, V84, P65, DOI 10.1016/S0304-3959(99)00183-9
   Rizi MS, 2017, COMPLEMENT THER CLIN, V29, P136, DOI 10.1016/j.ctcp.2017.09.002
   Sand-Jecklin K, 2018, J HOSP PALLIAT NURS, V20, P521, DOI 10.1097/NJH.0000000000000484
   Spielberger CD, 1973, STATE TRAIT ANXIETY, V0, P0
   Suhrabi Zainab, 2014, IRAN J NURS MIDWIFERY RES, V19, P24
   Susam Volkan, 2018, ACTA BIOMED, V89, P6, DOI 10.23750/abm.v89i6-S.7378
   Tu YH, 2019, NEUROIMAGE, V202, P0, DOI 10.1016/j.neuroimage.2019.116049
   Walco Gary A, 2008, PEDIATRICS, V122 Suppl 3, PS125, DOI 10.1542/peds.2008-1055d
   Wang SM, 2001, ANESTH ANALG, V92, P548, DOI 10.1213/00000539-200102000-00049
   Wieland LS, 2018, EUR J INTEGR MED, V17, P141, DOI 10.1016/j.eujim.2017.12.010
   World Health Organization, 2008, WHO STAND AC PIONT L, V0, P0
   Yeganeh M, 2017, COMPLEMENT THER CLIN, V27, P11, DOI 10.1016/j.ctcp.2016.11.012
   You E, 2019, PAIN MANAG NURS, V20, P17, DOI 10.1016/j.pmn.2018.07.010
   Zeyrek AS, 2019, J ADV NURS, V75, P3346, DOI 10.1111/jan.14183
NR 40
TC 15
Z9 16
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1876-3820
EI 1876-3839
J9 EUR J INTEGR MED
JI Eur. J. Integr. Med.
PD JUN 15
PY 2021
VL 44
IS 
BP 
EP 
DI 10.1016/j.eujim.2021.101343
EA JUN 2021
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA SQ6NH
UT WOS:000660469600007
DA 2026-01-16
ER

PT J
AU Huang, CC
   Ho, TJ
   Ho, HY
   Chen, PY
   Tu, CH
   Huang, YC
   Lee, YC
   Sun, MF
   Chen, YH
AF Huang, Chien-Chen
   Ho, Tsung-Jung
   Ho, Hsin-Yueh
   Chen, Pei-Yu
   Tu, Cheng-Hao
   Huang, Yu-Chuen
   Lee, Yu-Chen
   Sun, Mao-Feng
   Chen, Yi-Hung
TI Acupuncture Relieved Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast Cancer: A Pilot Randomized Sham-Controlled Trial
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE acupuncture; chemotherapy; peripheral neuropathy; breast cancer; Semmes-Weinstein monofilament; neuropathic pain
ID brief pain inventory; functional-assessment; oncology; neurotoxicity; validation; safety; electroacupuncture; stimulation; duloxetine; reduction
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect caused by neurotoxic chemotherapy. This randomized controlled trial aimed to evaluate the effect of manual acupuncture on CIPN. Twenty eligible breast cancer patients receiving taxane chemotherapy treatment were recruited and randomly divided into verum acupuncture and sham acupuncture groups. Each group received 15 treatments over 9 weeks. Quantitative tactile detection thresholds were measured using Semmes-Weinstein monofilament testing (SWM). The World Health Organization Quality of Life scale (WHOQOL-BREF), the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), and the Brief Pain Inventory-Short Form (BPI-SF) were measured before and after treatment. The between-group comparison of SWM revealed that the verum acupuncture group had more improvement of touch perception thresholds compared to the sham acupuncture group. The average pain severity in the BPI-SF of the verum acupuncture group was significantly lower than that of the sham acupuncture group. There were no significant differences in the FACT/GOG-Ntx trial outcome index and WHOQOL-BREF scores between the acupuncture and sham groups. The results suggest that acupuncture can alleviate the neuropathic pain of CIPN and improve touch perception thresholds.
C1 [Huang, Chien-Chen; Lee, Yu-Chen] China Med Univ, Coll Chinese Med, Sch Chinese Med, Grad Inst Chinese Med, Taichung 40402, Taiwan.
   [Huang, Chien-Chen] China Med Univ, An Nan Hosp, Dept Tradit Chinese Med, Tainan 709, Taiwan.
   [Ho, Tsung-Jung] Hualien Tzu Chi Hosp, Dept Chinese Med, Hualien 970, Taiwan.
   [Ho, Tsung-Jung] Tzu Chi Univ, Sch Postbaccalaureate Chinese Med, Hualien 970374, Taiwan.
   [Ho, Tsung-Jung] Hualien Tzu Chi Hosp, Integrat Ctr Tradit Chinese & Modern Med, Hualien 970, Taiwan.
   [Ho, Hsin-Yueh] China Med Univ, An Nan Hosp, Dept Surg, Tainan 709, Taiwan.
   [Chen, Pei-Yu] China Med Univ, An Nan Hosp, Canc Ctr, Tainan 709, Taiwan.
   [Tu, Cheng-Hao; Sun, Mao-Feng; Chen, Yi-Hung] China Med Univ, Grad Inst Acupuncture Sci, Taichung 40402, Taiwan.
   [Huang, Yu-Chuen] China Med Univ, China Med Univ Hosp, Sch Chinese Med, Dept Med Res, Taichung 40402, Taiwan.
   [Lee, Yu-Chen; Sun, Mao-Feng] China Med Univ Hosp, Dept Acupuncture, Taichung 404332, Taiwan.
   [Chen, Yi-Hung] China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.
   [Chen, Yi-Hung] Asia Univ, Dept Photon & Commun Engn, Taichung 41354, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan
RP Chen, YH (corresponding author), China Med Univ, Grad Inst Acupuncture Sci, Taichung 40402, Taiwan.; Chen, YH (corresponding author), China Med Univ, Chinese Med Res Ctr, Taichung 40402, Taiwan.; Chen, YH (corresponding author), Asia Univ, Dept Photon & Commun Engn, Taichung 41354, Taiwan.
EM chenchinh2013@gmail.com; jeron888@gmail.com; n71721@mail.tmanh.org.tw; n73362@mail.tmanh.org.tw; lordowentu@gmail.com; yuchuen@mail.cmu.edu.tw; d5167@mail.cmuh.org.tw; maofeng@mail.cmuh.org.tw; yihungchen@mail.cmu.edu.tw
FU An Nan Hospital, China Medical University in Tainan, Taiwan [ANHRF106-02]; China Medical University Hospital, Taichung, Taiwan [DMR-109-160, DMR-108-BC-8]; Chinese Medicine Research Center of China Medical University under the Featured Areas Research Center Program
CR Arifin W, 2012, EDUCATION IN MEDICINE JOURNAL, V4, P129, DOI 10.5959/eimj.v4i1.4
   Banach M, 2017, BRAIN BEHAV, V7, P0, DOI 10.1002/brb3.558
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Brown TJ, 2019, JAMA ONCOL, V5, P750, DOI 10.1001/jamaoncol.2018.6771
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Chae Y, 2011, COMPLEMENT THER MED, V19, PS8, DOI 10.1016/j.ctim.2010.09.002
   Chen YS, 2001, AM J CHINESE MED, V29, P377, DOI 10.1142/S0192415X01000393
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   DAlessandro EG, 2022, BMJ SUPPORT PALLIAT, V12, P64, DOI 10.1136/bmjspcare-2018-001542
   Dubrovsky G, 2020, MED ACUPUNCT, V32, P16, DOI 10.1089/acu.2019.1381
   Focks C, 2008, ATLAS OF ACUPUNCTURE, V0, P0
   Ger LP, 1999, J PAIN SYMPTOM MANAG, V18, P316, DOI 10.1016/S0885-3924(99)00087-1
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Ho CY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/514610
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Kaiser K, 2020, WORLD J GASTRO ONCOL, V12, P0, DOI 10.4251/wjgo.v12.i2.205
   Kamei N, 2005, J DIABETES COMPLICAT, V19, P47, DOI 10.1016/j.jdiacomp.2003.12.006
   Krumova EK, 2012, CURR DIABETES REP, V12, P393, DOI 10.1007/s11892-012-0282-7
   Kumar SP, 2011, INDIAN J PALLIAT CAR, V17, P108, DOI 10.4103/0973-1075.84531
   Lin CY, 2019, J FORMOS MED ASSOC, V118, P215, DOI 10.1016/j.jfma.2018.03.018
   Lin JG, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/875284
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu ZX, 2017, J ALTERN COMPLEM MED, V23, P964, DOI 10.1089/acm.2017.0052
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Neligan A, 2010, EUR NEUROL, V63, P11, DOI 10.1159/000258635
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Postma TJ, 2000, ANN ONCOL, V11, P509, DOI 10.1023/A:1008345613594
   Rolke R, 2006, PAIN, V123, P231, DOI 10.1016/j.pain.2006.01.041
   Schober P, 2020, ANESTH ANALG, V131, P1862, DOI 10.1213/ANE.0000000000005101
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smith EML, 2013, JAMA-J AM MED ASSOC, V309, P1359, DOI 10.1001/jama.2013.2813
   Suresh Kp, 2011, J HUM REPROD SCI, V4, P8, DOI 10.4103/0974-1208.82352
   Tracey EH, 2012, PHYSIOL BEHAV, V105, P982, DOI 10.1016/j.physbeh.2011.11.002
   Velasco R, 2021, ANTI-CANCER DRUG, V32, P88, DOI 10.1097/CAD.0000000000001005
   Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b
   Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8
   Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315
   Wong Raimond, 2006, ACUPUNCT MED, V24, P87
   Wong R, 2016, INTEGR CANCER THER, V15, P153, DOI 10.1177/1534735415627926
   Yamashita H, 2008, EVID-BASED COMPL ALT, V5, P391, DOI 10.1093/ecam/nem086
   Yang Y, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/329392
   Yoshida Y, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-56969-9
   Zhang Q, 2016, SHANGHAI J ACUPUNCT, V35, P1025
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhi WI, 2019, BREAST CANCER RES TR, V178, P587, DOI 10.1007/s10549-019-05416-4
NR 50
TC 24
Z9 28
U1 5
U2 29
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG 15
PY 2021
VL 10
IS 16
BP 
EP 
DI 10.3390/jcm10163694
PG 17
WC Medicine, General & Internal
SC General & Internal Medicine
GA UG6GU
UT WOS:000689349100001
PM 34441990
DA 2026-01-16
ER

PT J
AU Bari, S
   Chineke, I
   Darwin, A
   Umar, A
   Jim, H
   Muzaffar, J
   Singh, S
   Kucuk, O
AF Bari, Shahla
   Chineke, Iloabueke
   Darwin, Alicia
   Umar, Anam
   Jim, Heather
   Muzaffar, Jameel
   Singh, Shailesh
   Kucuk, Omer
TI Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM)
SO Integrative cancer therapies
LA English
DT Journal Article
DE CAM; alternative medicine; complementary medicine; health disparity; integrative medicine
AB Integrative oncology aims to coordinate the delivery of conventional medicine and  evidence-supported complementary and alternative medicine (CAM) to patients  receiving cancer care. This field developed out of an increased interest in CAM  usage among cancer patients. However, CAM use among medically underserved cancer  patients remains to be well characterized. We evaluated CAM awareness as well as  prevalence and characteristics of CAM use in 170 consecutive, medically  underserved cancer patients presenting to a large, academic, inner-city cancer  clinic, using a survey tool. Fifty-three participants declined participation and  17 survey results were incomplete. Therefore, 100 survey results were included in  the final analysis. There were 65 males and 35 females in the survey with a mean  age of 64.2 years. About 98% of the respondents were African American while 2%  identified themselves as Hispanic. About 45% of patients had metastatic cancer,  24% had early-stage disease while 31% of patients were not aware of the stage of  their cancer. About 55% patients had elementary school or lower level of  education while only 16% had a college degree or higher. About 92% of respondents  were unemployed. Some knowledge of CAM was reported by 22% of patients, while CAM  use was reported in only 16% of patients. Female sex and college degree were  significantly associated with CAM use. The most commonly used CAM modality was  meditation (56%), followed by herbal remedies (31%), yoga (31%), and acupuncture  (12%). Among CAM users, a majority used multiple CAM therapies. All users  reported benefit from CAM use. Emotional wellbeing was the most common benefit  followed by improvement in treatment related adverse effects, chemotherapy  related symptoms, pain, and sleep. Even though the majority of our surveyed  patients never used CAM, 90% of non-users were interested in gaining more  information about the various CAM options and exploring its use and potential  benefits. The majority (70%) wanted their primary oncologist to provide  information about CAM options and discuss its safety and potential complementary  benefit in management of their cancer and associated symptoms.
C1 Moffitt Cancer Center, Tampa, FL, USA.
   Morehouse School of Medicine, Atlanta, GA, USA.
   Morehouse School of Medicine, Atlanta, GA, USA.
   University of Arizona Cancer Center, Tucson, AZ, USA
   University of South Florida, Tampa, FL, USA
   Morehouse School of Medicine, Atlanta, GA, USA.
   Moffitt Cancer Center, Tampa, FL, USA.
   Moffitt Cancer Center, Tampa, FL, USA.
   Morehouse School of Medicine, Atlanta, GA, USA.
   Emory University, Atlanta, GA, USA
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD DEC 21
PY 2021
VL 20
IS 
BP 15347354211051622
EP 15347354211051622
DI 10.1177/15347354211051622
PG 1
WC Complementary Therapies; methods; Female; Humans; Male; Medically Underserved Area; Medically Uninsured; Middle Aged; Neoplasms; therapy; Surveys and Questionnaires; Yoga
UT PubMed:34923869
PM 34923869
DA 2021-12-21
ER

PT J
AU Li, DH
   Su, YF
   Fan, HF
   Guo, N
   Sun, CX
AF Li, De-hui
   Su, Yi-fan
   Fan, Huan-fang
   Guo, Na
   Sun, Chun-xia
TI Acupuncture Combined with Three-Step Analgesic Drug Therapy for Treatment of Cancer Pain: A Systematic Review and Meta-Analysis of Randomised Clinical Trials
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID mechanism
AB Objective. The purpose of this study was to systematically evaluate the efficacy and safety of acupuncture combined with the WHO three-step analgesic drug ladder for cancer pain. Methods. The Cochrane Library, PubMed, and CNKI Database of Systematic Reviews were searched. Using the Cochrane Register for Randomized Controlled Trials, the quality of the included literature was evaluated, and the meta-analysis was carried out with RevMan 5.3 software. Results. Compared with three-step analgesia alone, acupuncture combined with three-step analgesia for cancer pain increased pain relief response rates (RR = 1.12, 95% CI: 1.08 similar to 1.17, P<0.00001), reduced NRS score (SMD = -1.10, 95% CI: -1.86 similar to-0.35, P=0.004), reduced the rate of side effects (RR = 0.45, 95% CI: 0.38 similar to 0.53, P<0.00001), including nausea (P<0.00001), vomiting (P=0.008), constipation (P<0.00001), and dizziness (P=0.010), reduced the burst pain rate (SMD = -1.38; 95% CI: -2.44 similar to-0.32, P=0.01), shortened analgesia effect onset time (P=0.004), and extended the duration of response (P<0.0001). Conclusion. For the treatment of cancer pain, acupuncture combined with three-step analgesic drugs is better than using only three-step analgesic drugs.
C1 [Li, De-hui; Su, Yi-fan; Fan, Huan-fang; Guo, Na; Sun, Chun-xia] Hebei Univ Chinese Med, Affiliated Hosp 1, Hebei Prov Hosp Chinese Med, Shijiazhuang 050011, Hebei, Peoples R China.
   [Su, Yi-fan] Hebei Univ Chinese Med, Grad Sch, Shijiazhuang 050091, Hebei, Peoples R China.
C3 Hebei University of Chinese Medicine; Hebei University of Chinese Medicine
RP Li, DH (corresponding author), Hebei Univ Chinese Med, Affiliated Hosp 1, Hebei Prov Hosp Chinese Med, Shijiazhuang 050011, Hebei, Peoples R China.
EM 258289951@qq.com; 2088302387@qq.com; fhf701024@163.com; guona731@163.com; schx1975@163.com
FU National Natural Science Foundation of China [81603412]; Key R&D Projects of Hebei Province [18277731D]; Scientific Research Project of Hebei Administration of Traditional Chinese Medicine [2017163, 2019008, 2020014]; General Projects for Improving Scientific Research Capacity of Hebei College of Traditional Chinese Medicine [KTY2019009]; Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease; Key Laboratory of Integrated Traditional Chinese and Western Medicine Hepatonephrosis in Hebei Province [A201902]; Hebei Province "Three Three Three Talent Project" [A202002008]
CR Ali U, 2020, CHIN J INTEGR MED, V26, P643, DOI 10.1007/s11655-019-3175-7
   Unknown -, 2010, LIAONING J TRAD CHINESE MED, V0, P0, DOI DOI 10.13192/J.LJTCM.2010.10.166.MIJP.061
   Bai WJ, 2019, CHINESE MANIPULATION AND REHABILITATION MEDICINE (CHIN), V10, P14, DOI 10.19787/j.issn.1008-1879.2019.15.007
   Bao WQ, 2021, MOD CHIN CLIN MED, V28, P22
   Bouhassira D, 2017, PAIN, V158, P1118, DOI 10.1097/j.pain.0000000000000895
   Chen XX, 2020, WORLD CHINESE MED, V15, P2346
   丁超, 2015, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V21, P626
   Dong SM, 2018, J CLIN NURSINGS PRAC, V3, P99
   Fallah A, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0043407
   Fan LY, 2017, HEBEI J TRADITIONAL CHINESE MED., V29, P36, DOI 10.3969/j.issn.1672-0369.2017.11.017
   Feng RM, 2019, CANCER COMMUN, V39, P0, DOI 10.1186/s40880-019-0368-6
   [付烊 Fu Yang], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P768
   George B, 2019, SUPPORT CARE CANCER, V27, P3105, DOI 10.1007/s00520-019-04828-8
   He YH, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-025564
   Hou XR, 2019, WORLD J ACUPUNCT-MOX, V29, P285, DOI 10.1016/j.wjam.2019.12.005
   Huang Y, 2018, INNER MONGOLIA J TRA, V37, P58
   [惠建荣 Hui Jianrong], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P146
   Jiang B, 2016, ZHEJIANG J TRADITION, V51, P270
   Li DH, 2017, J GUANGZHOU UNIV TRADIT CHIN MED, V34, P344
   Li WJ, 2021, HER MED, V40, P45, DOI 10.1016/j.accpm.2021.100902
   Liu J, 2011, CLINIC RESEARCH ON HEPATIC CARCINOMA PAIN RELIVED BY NEEDLING WITH EIGHT METHODS OF INTELLIGENT TURTLE AND WESTERN MEDICINE, V0, P0
   Liu Y, 2018, EFFECT ANAL SAFETY E, V0, P0
   Middleton DRS, 2020, ENVIRON GEOCHEM HLTH, V42, P1047, DOI 10.1007/s10653-019-00303-9
   Paiey CA, 2019, MEDICINA KAUNAS LITH, V56, P6
   Peng J, 2012, SHANG J ACUPUNCT MOXIBUST, V31, P236
   Sun RR, 2016, CLIN RES ACUPUNCTURE, V0, P0
   Tan GS, 2012, WORLD J INTEGR MED, V7, P147
   Tang FP, 2020, J GUANGXI MED U, V37, P1716
   Wang DJ, 2018, CLIN RES ACUPUNCTURE, V0, P0
   Wang LM, 2013, SHANGHAI J ACUPUNCTU, V32, P964
   Wang Y, 2016, CLIN RES ELECTROACUP CLIN RES ELECTROACUP, V0, P0
   Wu Qiu-Lan, 2019, ZHONGGUO ZHEN JIU, V39, P1051, DOI 10.13703/j.0255-2930.2019.10.005
   Zhang JW, 2014, INTERNATIONAL JOURNAL OF CLINICAL ACUPUNCTURE, V0, P0
   Zhong AH, 2015, CHINESE J CLIN ONCOL, V22, P112
   Zhong H, 2016, CHINESE J ACUPUNCTUR, V5, P148
   Zivaljevic A, 2019, WORLD J TRAD CHINESE, V5, P181, DOI 10.4103/wjtcm.wjtcm_24_19
NR 37
TC 22
Z9 24
U1 1
U2 35
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD JUL 26
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/5558590
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA TZ2YW
UT WOS:000684343100007
PM 34349826
DA 2026-01-16
ER

PT J
AU Lu, T
   Zhang, J
   Lv, Y
   Wu, Y
AF Lu, Tianchen
   Zhang, Junfeng
   Lv, Ying
   Wu, Yaochi
TI The effect of warm needle moxibustion on lumbar disc herniation.
SO American journal of translational research
LA English
DT Journal Article
DE Warm needle moxibustion; lumbar disc herniation; therapeutic effect
AB OBJECTIVE: To investigate the effect of warm needle moxibustion on patients with  lumbar disc herniation (LDH). METHODS: A total of 100 patients with lumbar disc  herniation treated in our hospital were recruited as the study cohort and  randomly assigned into a control group and an observation group. The patients in  the control group underwent routine acupuncture treatment, while those in the  observation group underwent warm needle moxibustion treatment. The observed  indexes, including the clinical efficacy, the visual analogue scale (VAS) scores,  the Japanese Orthopedic Association (JOA) scores, the Oswestry disability index  (ODI) scores, and the serum inflammatory factor levels were compared between the  control group and the observation group. RESULTS: The total cure rate in the  observation group was significantly higher than it was in the control group  (76.0% vs 92%, P=0.029). Compared with the patients in the control group after  the treatment, the patients' VAS and ODI scores in the observation group were  significantly lower, but their JOA scores were significantly higher, and the  differences were statistically significant (all P<0.001). Moreover, the serum  IL-6 and tumor necrosis factor α (TNF-α) levels in the observation group were  remarkably lower than the corresponding levels in the control group (all  P<0.001). CONCLUSIONS: Warm needle moxibustion has a significant effect on  patients with lumbar disc herniation, because it helps to relieve the pain and  other symptoms and reduces the serum inflammatory factor levels.
C1 Department of Acupuncture and Massage, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University Shanghai, China.
   Department of Acupuncture and Massage, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University Shanghai, China.
   Department of Acupuncture and Massage, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University Shanghai, China.
   Department of Acupuncture and Massage, The Sixth People's Hospital Affiliated to Shanghai Jiaotong University Shanghai, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD JUN 22
PY 2021
VL 13
IS 5
BP 5059
EP 5065
DI 
PG 6
UT PubMed:34150092
PM 34150092
DA 2021-06-22
ER

PT J
AU Zhou, X
   Cao, SG
   Tan, XJ
   Liu, XD
   Li, ZQ
   Kong, LX
   Tian, YL
   Liu, D
   Shen, S
   Sun, YQ
   Jiang, HT
   Zhou, YB
AF Zhou, Xin
   Cao, Shou-Gen
   Tan, Xiao-Jie
   Liu, Xiao-Dong
   Li, Ze-Qun
   Kong, Ling-Xin
   Tian, Yu-Long
   Liu, Dan
   Shen, Shuai
   Sun, Yu-Qi
   Jiang, Hai-Tao
   Zhou, Yan-Bing
TI Effects of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Postoperative
SO Cancer management and research
LA English
DT Journal Article
DE acupuncture therapy; enhanced recovery after surgery; gastrointestinal function; pain management; stomach neoplasms
AB PURPOSE: Transcutaneous electrical acupoint stimulation (TEAS) is an innovative  choice for postoperative pain management. However, the safety and effectiveness  of this traditional Chinese medicine (TCM) therapy for patients who underwent  gastrectomy is largely unknown. So, the purpose of this study is to evaluate the  safety and effectiveness of TEAS for patients who underwent gastrectomy. PATIENTS  AND METHODS: We recruited 96 patients with gastric cancer from May 2019 to  November 2019; 82 patients were enrolled, and 81 patients completed. Patients  were randomly assigned to TEAS group (TG) received TEAS on postoperative day  (POD) 1-3 or control group (CG) at a 1:1 ratio. The primary outcomes were pain  score and consumption of analgesics. The secondary were the time of first  postoperative flatus and defecation, frequency of postoperative nausea, vomiting,  distention, diarrhea, comfort of semi-fluid diet, Clavien-Dindo grade (C-D grade)  and length of postoperative day. We performed hematological analysis to explore  the possible mechanisms. RESULTS: Overall, 81 patients were enrolled included in  the analysis. Compared with CG, pain scores in TG were lower on POD 1-5 (average:  2.55±0.21 vs 3.10±0.42, P<0.001), and the use rate of opioids was lower (43.9 vs  75.0, P=0.004); time of first postoperative flatus (55.63±16.74 vs 72.60±20.92,  P<0.001) and defecation (72.20±16.24 vs 95.78±17.75, P<0.001) were shorter; the  frequency of nausea were fewer (1.88±1.09 vs 2.58±0.77, P=0.029) and patients  were more comfortable with semi-fluid diet (7.63±0.63 vs 6.93±0.69, P<0.001);  among the hematologic results, β-endorphin (β-End), interleukin-2 (IL-2), motilin  (MTL) on POD 3, POD 5 were lower, 5-hydroxytryptamine (5-HT), interleukin-6  (IL-6), tumor necrosis factor-α (TNF-α) were higher. And no adverse event was  reported. CONCLUSION: TEAS can relieve postoperative pain and promote the  recovery of gastrointestinal function. Consequently, it can be an adjunctive  therapy to enhance postoperative recovery for patients after gastrectomy.
C1 Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Rehabilitation, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
   Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, People's Republic of China.
NR 0
TC 0
SN 1179-132
EI 1179-132
J9 Cancer Manag Res
PD FEB 20
PY 2021
VL 13
IS 
BP 1449
EP 1458
DI 10.2147/CMAR.S292325
PG 9
UT PubMed:33603487
PM 33603487
DA 2021-02-20
ER

PT J
AU Li, G
   Zhang, C
   Wang, C
   Xiao, L
AF Li, Gang
   Zhang, Changxi
   Wang, Congyi
   Xiao, Ling
TI Acupuncture against chronic postsurgical pain in non-small cell lung cancer
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Video-assisted thoracoscopic lobectomy is the prior recommended  treatment for non-small cell lung cancer (NSCLC), with the advantages of small  trauma, less postoperative pain, and quick recovery. However, a large number of  patients may suffer chronic postsurgical pain (CPSP), which makes the patients  unwilling to practice pulmonary exercises, and it would directly affect patient's  cough, sputum expectoration, and mobility. Opioids could greatly improve the  quality of postoperative analgesia and the quality of life after surgery, but it  is accompanied with obvious side effects. A number of clinical studies have  proved that acupuncture could improve postoperative pain and reduce opioid use.  In this study, we try to conduct a randomized controlled study to evaluate the  efficacy and safety of plum-blossom needle acupuncture combined with Tramadol in  improving CPSP after lobectomy in NSCLC patients. METHODS: Patients will be  randomly divided into treatment group (acupuncture plus Tramadol) and control  group (sham acupuncture plus Tramadol) with a random number table in 1:1 ratio.  The patients, outcome assessor, and statistician will be blinded. The outcomes  are changes of numerical rating scale, Karnofsky performance score, brief pain  inventory, blood routine, liver and kidney function. The data will be analyzed by  SPSS 22.0. CONCLUSIONS: The results will help to evaluate the efficacy and safety  of plum-blossom needle acupuncture in improving CPSP after lobectomy in NSCLC  patients.
C1 Department of Thoracic Surgery, Chongqing Steel General Hospital, Dadukou District, Chongqing, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD OCT 9
PY 2021
VL 100
IS 40
BP e27461
EP e27461
DI 10.1097/MD.0000000000027461
PG 1
WC Acupuncture Therapy; methods; Adult; Aged; Analgesics, Opioid; administration & dosage; Carcinoma, Non-Small-Cell Lung; surgery; Combined Modality Therapy; Female; Humans; Lung Neoplasms; surgery; Male; Middle Aged; Pain Measurement; Pain, Postoperative; drug therapy; Pneumonectomy; adverse effects; Research Design; Thoracic Surgery, Video-Assisted; adverse effects; Tramadol; administration & dosage; Randomized Controlled Trials as Topic
UT PubMed:34622872
PM 34622872
DA 2021-10-09
ER

PT J
AU Gao, Y
   Ma, T
   Han, M
   Yu, M
   Wang, X
   Lv, Y
   Wang, X
AF Gao, Yu
   Ma, Tingting
   Han, Mei
   Yu, Mingwei
   Wang, Xiuhui
   Lv, Yiren
   Wang, Xiaomin
TI Effects of Acupuncture and Moxibustion on Breast Cancer-Related Lymphedema: A
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; breast cancer-related lymphedema; moxibustion
AB OBJECTIVE: The aim of this systematic review and meta-analysis of randomized  controlled trials (RCTs) was to evaluate the effects of acupuncture and  moxibustion (AM) in women with breast cancer-related lymphedema (BCRL). METHODS:  We retrieved RCTs published before January 24, 2021, from the MEDLINE, EMBASE,  Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI),  Chongqing VIP (VIP), and Wanfang databases. RCTs that compared acupuncture and/or  moxibustion intervention with other treatments were included. A random effects or  fixed effects model was used based on the heterogeneity findings. Study quality  was evaluated using the Cochrane risk of bias tool. RESULTS: We included 14 RCTs  in the analyses, of which 4 RCTs adopted acupuncture, 4 RCTs used moxibustion,  and the rest used both. AM significantly reduced arm circumference at the elbow  crease compared to routine care (Mean deviation (MD) = -7.26, 95% confidence  interval (CI) = -8.30 to -6.21, P < .00001). There was a significant difference  between AM and diosmin tablets in the effective index for upper limb lymphedema  (MD = 24.68, 95% CI = 24.82-30.53, P < .00001), the range of motion of the  shoulder during protraction (MD = 6.77, 95% CI = 2.81-10.73, P = .0008), and  adduction (MD = 4.17, 95% CI = 1.02-7.32, P = .01). There was a significant  difference between moxibustion and pneumatic circulation (MD = -0.51, 95%  CI = -0.85 to -0.17, P = .003) in the visual analog score (VAS) for swelling.  Finally, compared to the blank control, acupuncture reduced the VAS for pain  (MD = -1.33, 95% CI = -1.52 to -1.15, P < .00001; heterogeneity (I(2)) = 0%,  P = .57). CONCLUSION: Our results suggest that AM is effective in the treatment  of BCRL. AM may reduce arm circumference at the elbow crease (compared to routine  care), increase effective index for upper limb lymphedema (compared to oral  diosmin tablets), improve the range of motion of the shoulder during protraction  and adduction (compared to oral diosmin tablets), and decrease the VAS for both  swelling (compared to pneumatic circulation) and pain (compared to blank  control).
C1 Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Beijing University of Chinese Medicine, Beijing, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD SEP 16
PY 2021
VL 20
IS 
BP 15347354211044107
EP 15347354211044107
DI 10.1177/15347354211044107
PG 1
WC Acupuncture Therapy; Breast Neoplasms; complications; Female; Humans; Lymphedema; etiology; Moxibustion; Randomized Controlled Trials as Topic
UT PubMed:34521235
PM 34521235
DA 2021-09-16
ER

PT J
AU Ma, M
   Zhang, L
   Wang, X
AF Ma, Mengjie
   Zhang, Liuqiao
   Wang, Xiangli
TI Effect of auricular point pressing therapy on hyperplasia of mammary glands: A
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: In recent years, with the accelerated pace of life, diet,  environmental problems occur frequently. External factors are easily to cause  endocrine disorders and hormone sensitivity of breast tissue, which can lead to  mammary hyperplasia. The incidence rate of hyperplasia of mammary glands is  increasing year by year, and the age of onset is also getting lower and lower. If  not treated in time, there is a crisis of breast cancer.Clinical studies have  found that auricular point pressing therapy is widely used in clinical treatment  of mammary hyperplasia recently, but the efficacy of massage in the treatment of  mammary hyperplasia has not been systematically reviewed. The purpose of this  study is to explore the efficacy, safety and effectiveness of auricular point  pressing therapy in the treatment of hyperplasia of mammary glands. METHODS: We  will search PubMed, Web of Science, Cochrane Library, EMBASE, Wan fang Database,  Chinese Scientific Journal Database, CNKI, VIP, and Chinese Biomedical Literature  Database. The retrieval date was January 10, 2021. RevMan 5.3 software was used  to evaluate the quality and risk of included studies. The efficacy, recurrence  rate, and symptom score of breast hyperplasia were analyzed, and the results were  observed and measured. RESULTS: This study will be from the clinical efficiency,  improvement rate, pain symptoms disappear rate, tumor size improvement rate, and  other aspects of the existing evidence for a high quality synthesis, as well as  auricular point pressing therapy adverse events. CONCLUSION: the conclusion of  this review will provide the basis for judging whether auricular point pressing  therapy is safe and effective in the treatment of hyperplasia of mammary glands.  ETHICS AND DISSEMINATION: This systematic will evaluate the effectiveness and  safety of auricular point pressing therapy in the treatment of hyperplasia of  mammary glands. As all data used in this systematic review and meta-analysis have  been published, ethical approval is not required for this review. PROTOCOL  REGISTRATION NUMBER: INPLASY202110028.
C1 Henan University of Traditional Chinese Medicine, 156 Jinshui East Road, Zhengdong New District, Zhengzhou City, Henan Province, China.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD APR 1
PY 2021
VL 100
IS 13
BP e24875
EP e24875
DI 10.1097/MD.0000000000024875
PG 1
WC Acupuncture Points; Breast Diseases; pathology; Clinical Trials as Topic; Ear Auricle; Female; Humans; Hyperplasia; therapy; Mammary Glands, Human; pathology; Massage; methods; Meta-Analysis as Topic; Research Design; Systematic Reviews as Topic; Treatment Outcome
UT PubMed:33787577
PM 33787577
DA 2021-04-01
ER

PT J
AU Mao, JJ
   Liou, KT
   Baser, RE
   Bao, T
   Panageas, KS
   Romero, SAD
   Li, QS
   Gallagher, RM
   Kantoff, PW
AF Mao, Jun J.
   Liou, Kevin T.
   Baser, Raymond E.
   Bao, Ting
   Panageas, Katherine S.
   Romero, Sally A. D.
   Li, Q. Susan
   Gallagher, Rollin M.
   Kantoff, Philip W.
TI Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors The PEACE Randomized Clinical Trial
SO JAMA ONCOLOGY
LA English
DT Article
ID united-states; outcm; mechanisms; scores; impact
AB IMPORTANCE The opioid crisis creates challenges for cancer pain management. Acupuncture confers clinical benefits for chronic nonmalignant pain, but its effectiveness in cancer survivors remains uncertain. OBJECTIVE To determine the effectiveness of electroacupuncture or auricular acupuncture for chronic musculoskeletal pain in cancer survivors. DESIGN, SETTING, AND PARTICIPANTS The Personalized Electroacupuncture vs Auricular Acupuncture Comparativeness Effectiveness (PEACE) trial is a randomized clinical trial that was conducted from March 2017 to October 2019 (follow-up completed April 2020) across an urban academic cancer center and 5 suburban sites in New York and New Jersey. Study statisticians were blinded to treatment assignments. The 360 adults included in the study had a prior cancer diagnosis but no current evidence of disease, reported musculoskeletal pain for at least 3 months, and self-reported pain intensity on the Brief Pain Inventory (BPI) ranging from 0 (no pain) to 10 (worst pain imaginable). INTERVENTIONS Patients were randomized 2:2:1 to electroacupuncture (n = 145), auricular acupuncture (n = 143), or usual care (n = 72). Intervention groups received 10 weekly sessions of electroacupuncture or auricular acupuncture. Ten acupuncture sessions were offered to the usual care group from weeks 12 through 24. MAIN OUTCOMES AND MEASURES The primary outcomewas change in average pain severity score on the BPI from baseline to week 12. Using a gatekeeping multiple-comparison procedure, electroacupuncture and auricular acupuncture were compared with usual care using a linear mixed model. Noninferiority of auricular acupuncture to electroacupuncture was tested if both interventions were superior to usual care. RESULTS Among 360 cancer survivors (mean [SD] age, 62.1 [12.7] years; mean [SD] baseline BPI score, 5.2 [1.7] points; 251 [69.7%] women; and 88 [24.4%] non-White), 340 (94.4%) completed the primary end point. Compared with usual care, electroacupuncture reduced pain severity by 1.9 points (97.5% CI, 1.4-2.4 points; P <.001) and auricular acupuncture reduced by 1.6 points (97.5% CI, 1.0-2.1 points; P <.001) from baseline to week 12. Noninferiority of auricular acupuncture to electroacupuncture was not demonstrated. Adverse events were mild; 15 of 143 (10.5%) patients receiving auricular acupuncture and 1 of 145 (0.7%) patients receiving electroacupuncture discontinued treatments due to adverse events (P <.001). CONCLUSIONS AND RELEVANCE In this randomized clinical trial among cancer survivors with chronic musculoskeletal pain, electroacupuncture and auricular acupuncture produced greater pain reduction than usual care. However, auricular acupuncture did not demonstrate noninferiority to electroacupuncture, and patients receiving it had more adverse events.
C1 [Mao, Jun J.; Liou, Kevin T.; Bao, Ting; Li, Q. Susan] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
   [Baser, Raymond E.; Panageas, Katherine S.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Romero, Sally A. D.] Univ Calif San Diego, Sch Med, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.
   [Kantoff, Philip W.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
   [Gallagher, Rollin M.] Michael J Crescenz VA Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of California System; University of California San Diego; Memorial Sloan Kettering Cancer Center; University of Pennsylvania
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU Department of Defense office of the Congressionally Directed Medical Research Programs through the Peer Reviewed Medical Research Program Clinical Trial Award [W81XWH-15-1-0245]; National Institutes of Health/National Cancer Institute Cancer Center grant [P30 CA008748]
CR Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Dmitrienko A, 2011, BIOMETRICAL J, V53, P875, DOI 10.1002/bimj.201100036
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Fan AY, 2018, COMPLEMENT THER MED, V41, P295, DOI 10.1016/j.ctim.2018.10.015
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hays RD, 2009, QUAL LIFE RES, V18, P873, DOI 10.1007/s11136-009-9496-9
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Liou KT, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020085
   Liu GHF, 2009, STAT MED, V28, P2509, DOI 10.1002/sim.3639
   Lu K, 2008, THE INTERNATIONAL JOURNAL OF BIOSTATISTICS, V4, P1, DOI 10.2202/1557-4679.1098
   Mao Jun J, 2007, ACUPUNCT MED, V25, P158
   Mao JJ, 2007, J AM BOARD FAM MED, V20, P434, DOI 10.3122/jabfm.2007.05.060225
   Niemtzow R, 2018, MIL MED, V183, PE486, DOI 10.1093/milmed/usy028
   Niemtzow RC, 2018, MED ACUPUNCT, V30, P57, DOI 10.1089/acu.2018.29077.rcn
   Paice JA, 2019, J NATL COMPR CANC NE, V17, P595, DOI 10.6004/jnccn.2019.5010
   Revicki DA, 2009, QUAL LIFE RES, V18, P783, DOI 10.1007/s11136-009-9489-8
   Robinson-Papp J, 2015, J PAIN SYMPTOM MANAG, V50, P381, DOI 10.1016/j.jpainsymman.2015.03.013
   Steglitz J, 2012, TRANSL BEHAV MED, V2, P6, DOI 10.1007/s13142-012-0110-2
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Vitzthum LK, 2020, JAMA ONCOL, V6, P1103, DOI 10.1001/jamaoncol.2020.0779
   Zeliadt SB, 2020, MED CARE, V58, PS101, DOI 10.1097/MLR.0000000000001368
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zylla D, 2017, SUPPORT CARE CANCER, V25, P1687, DOI 10.1007/s00520-017-3614-y
NR 29
TC 149
Z9 177
U1 13
U2 140
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD MAY 15
PY 2021
VL 7
IS 5
BP 720
EP 727
DI 10.1001/jamaoncol.2021.0310
EA MAR 2021
PG 8
WC Oncology
SC Oncology
GA SF3PH
UT WOS:000630524200002
PM 33734288
DA 2026-01-16
ER

PT J
AU Yuan, M
   Wang, X
   Yan, X
   Ding, H
   Yi, J
   Xia, H
   Yu, X
AF Yuan, Minghua
   Wang, Xiaoyuan
   Yan, Xiaoyan
   Ding, Hong
   Yi, Jing
   Xia, Hongmei
   Yu, Xueqin
TI Effects of heat-sensitive moxibustion combined with naprapathy and warming needle
SO American journal of translational research
LA English
DT Journal Article
DE Heat-sensitive moxibustion; inflammatory factor; naprapathy; periarthritis of shoulder; shoulder function; warming needle moxibustion
AB OBJECTIVE: To evaluate the effects of heat-sensitive moxibustion (HSM) combined  with naprapathy and warming needle moxibustion (WNM) combined with naprapathy on  shoulder function and serum levels of calcitonin gene-related peptide (CGRP),  substance P (SP), tumor necrosis factor-α (TNF-α) and interleukin-2 (IL-2) in  patients with periarthritis of shoulder (POS). METHODS: From July 2017 to July  2020, sixty patients with POS admitted to our hospital were selected as the study  subjects, and divided into HSM group (n=29) receiving HSM combined with  naprapathy and WNM group receiving WNM combined with naprapathy (n=31). The  changes in shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-α  and IL-2 were compared between the two groups. RESULTS: After treatment, the  scores of myodynamia, pain, range of motion (ROM) of shoulder joint and  activities of daily living (ADLs) were improved in both groups (P<0.05), and the  scores in HSM group were remarkably higher than those in WNM group (P<0.05).  Visual analogue scale (VAS) scores after 3 courses of treatment were lower than  those after 1 and 2 courses of treatment respectively (P<0.05), and the VAS  scores in HSM group were markedly lower than those in WNM group after 1, 2, and 3  courses of treatment (P<0.05). After treatment, the serum levels of CGRP, SP,  TNF-α and IL-2 were decreased in both groups (P<0.05), and the levels in HSM  group were noticeably lower than those in WNM group (P<0.05). CONCLUSION: HSM  combined with naprapathy is superior to WNM combined with naprapathy in  inhibition of inflammatory factors of pain and serum inflammatory factors,  alleviating the pain and promoting the restoration of shoulder function in  patients with POS.
C1 Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
   Rehabilitation Department, Yichun People's Hospital Yichun 336000, Jiangxi, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD AUG 12
PY 2021
VL 13
IS 7
BP 7804
EP 7811
DI 
PG 7
UT PubMed:34377257
PM 34377257
DA 2021-08-12
ER

PT J
AU Wu, MM
   Liu, XH
   Wang, LJ
   Chen, XY
   Li, YX
AF Wu, Min-Min
   Liu, Xiao-Hua
   Wang, Li-Jiao
   Chen, Xiao-Yu
   Li, Ya-Xue
TI [Clinical observation on deep needling at Xiaguan (ST 7) with round sharp needle
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Point ST 7 (Xiaguan); inflammatory cytokine; plum-blossom needle; round sharp needle; trigeminal neuralgia
AB OBJECTIVE: To compare the clinical therapeutic effect between deep needling at  Xiaguan (ST 7) with round sharp needle combined with plum-blossom needle and  conventional acupuncture in patients with trigeminal neuralgia (TN) of wind and  heat, and explore its mechanism. METHODS: A total of 60 patients with TN of wind  and heat were randomized into an observation group (30 cases) and a control group  (30 cases). In the observation group, deep needling with round sharp needle was  applied at Xiaguan (ST 7), and tapping with plum-blossom needle was applied at  Yangbai (GB 14), Quanliao (SI 18), Dicang (ST 4), Sibai (ST 2), etc. of affected  side. In the control group, conventional acupuncture was applied at the same  acupoints selected in the observation group. The treatment was given once a day,  5 times a week for 4 weeks in the both groups. Before and after treatment, the  scores of short-form McGill pain questionnaire (SF-MPQ), TCM syndrome, patient  global impression of change (PGIC) and comprehensive symptom were observed, the  serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), vasoactive  intestinal peptide (VIP) and β-endorphin (β-EP) were detected, and the adverse  reaction was observed in the both groups. RESULTS: After treatment, the scores of  PRI, PPI, VAS, TCM syndrome, PGIC and comprehensive symptom and the serum levels  of IL-6, TNF-α and VIP were decreased compared before treatment in the both  groups (P<0.05), and the variations of above indexes in the observation group  were larger than those in the control group (P<0.05). After treatment, the serum  levels of β-EP were increased compared before treatment in the both groups  (P<0.05), and the variation of that in the observation group was larger than the  control group (P<0.05). No severe adverse reaction was observed in the both  groups. CONCLUSION: Deep needling at Xiaguan (ST 7) with round sharp needle  combined with plum-blossom needle can effectively treat the trigeminal neuralgia  of wind and heat and relieve pain, its therapeutic effect is superior to  conventional acupuncture. The mechanism may be related to the regulation of serum  IL-6, TNF-α, VIP and β-EP.
C1 Graduate School of Heilongjiang University of CM, Harbin 150040, China.
   Graduate School of Heilongjiang University of CM, Harbin 150040, China.
   Graduate School of Heilongjiang University of CM, Harbin 150040, China.
   Graduate School of Heilongjiang University of CM, Harbin 150040, China.
   Department of Acupuncture and Moxibustion, First Affiliated Hospital of Heilongjiang University of CM, Harbin 150040.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD OCT 11
PY 2021
VL 41
IS 10
BP 1089
EP 94
DI 10.13703/j.0255-2930.20210318-0003
PG -995
WC Flowers; Hot Temperature; Humans; Prunus domestica; Trigeminal Neuralgia; therapy; Wind
UT PubMed:34628740
PM 34628740
DA 2021-10-11
ER

PT J
AU Ma, MJ
   Zhang, LQ
   Wang, XL
AF Ma, Mengjie
   Zhang, Liuqiao
   Wang, Xiangli
TI Effect of auricular point pressing therapy on hyperplasia of mammary glands A protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE auricular point pressing; hyperplasia of mammary glands; meta-analysis; systematic review
ID acupressure; pain
AB Background: In recent years, with the accelerated pace of life, diet, environmental problems occur frequently. External factors are easily to cause endocrine disorders and hormone sensitivity of breast tissue, which can lead to mammary hyperplasia. The incidence rate of hyperplasia of mammary glands is increasing year by year, and the age of onset is also getting lower and lower. If not treated in time, there is a crisis of breast cancer. Clinical studies have found that auricular point pressing therapy is widely used in clinical treatment of mammary hyperplasia recently, but the efficacy of massage in the treatment of mammary hyperplasia has not been systematically reviewed. The purpose of this study is to explore the efficacy, safety and effectiveness of auricular point pressing therapy in the treatment of hyperplasia of mammary glands. Methods: We will search PubMed, Web of Science, Cochrane Library, EMBASE, Wan fang Database, Chinese Scientific Journal Database, CNKI, VIP, and Chinese Biomedical Literature Database. The retrieval date was January 10, 2021. RevMan 5.3 software was used to evaluate the quality and risk of included studies. The efficacy, recurrence rate, and symptom score of breast hyperplasia were analyzed, and the results were observed and measured. Results: This study will be from the clinical efficiency, improvement rate, pain symptoms disappear rate, tumor size improvement rate, and other aspects of the existing evidence for a high quality synthesis, as well as auricular point pressing therapy adverse events. Conclusion: the conclusion of this review will provide the basis for judging whether auricular point pressing therapy is safe and effective in the treatment of hyperplasia of mammary glands. Ethics and dissemination: This systematic will evaluate the effectiveness and safety of auricular point pressing therapy in the treatment of hyperplasia of mammary glands. As all data used in this systematic review and meta-analysis have been published, ethical approval is not required for this review. Protocol registration number: INPLASY202110028.
C1 [Ma, Mengjie; Zhang, Liuqiao; Wang, Xiangli] Henan Univ Tradit Chinese Med, 156 Jinshui East Rd, Zhengzhou, Henan, Peoples R China.
C3 Henan University of Traditional Chinese Medicine
RP Zhang, LQ (corresponding author), Henan Univ Tradit Chinese Med, Affiliated Hosp 2, Henan Hosp Tradit Chinese Med, 6 Dongfeng Rd, Zhengzhou, Henan, Peoples R China.
EM 2553868697@qq.com
FU Special Project of Traditional Chinese Medicine Research in Henan Province [2019ZY2148]
CR Chai L, 2020, PAIN MANAG NURS, V20, P17
   Chen SG, 1997, ORTHODOX SURG, V0, P436
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gao JL, 2020, EUR J CARDIOVASC NUR, V19, P20, DOI 10.1177/1474515119876778
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   Jie Y, 2021, CHIN J TRADIT CHIN M, V1, P1005
   Jin L, 2012, HEILONGJIANG TRADIT, V41, P62
   KAWAKITA K, 1991, AM J CHINESE MED, V19, P199, DOI 10.1142/S0192415X91000272
   Ko YL, 2016, J CLIN NURS, V25, P332, DOI 10.1111/jocn.13053
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Li Wan-shan, 2011, ZHONGGUO ZHEN JIU, V31, P349
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Ye Yu-Fei, 2019, ZHONGGUO ZHEN JIU, V39, P605, DOI 10.13703/j.0255-2930.2019.06.010
   Yeh CH, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-4016-x
   Yeh CH, 2012, J ALTERN COMPLEM MED, V18, P334, DOI 10.1089/acm.2011.0102
   Yu J, 2017, J ACUPUNCT TUINA SCI, V15, P219, DOI 10.1007/s11726-017-1004-0
   Zhang Z, 2012, SHANGHAI J ACUPUNCT, V31, P730
   Zhao X, 2020, J GUANGZHOU UNIVERS, V37, P1259
   Zhou M, 2016, HUBEI J TRADIT CHIN, V38, P76
   Zhu D, 2019, WORLD J INTEGR TRADI, V14, P292
NR 20
TC 4
Z9 6
U1 1
U2 43
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD APR 2
PY 2021
VL 100
IS 13
BP 
EP 
DI 10.1097/MD.0000000000024875
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA SO4RD
UT WOS:000658960700012
PM 33787577
DA 2026-01-16
ER

PT J
AU Li, HJ
   Wang, B
   Chen, CY
AF Li, Hanjing
   Wang, Biao
   Chen, Chuanyuan
TI Acupuncture around the greater tuberosity of the femur combined with acupuncture at Xuehai acupoint alleviates the postoperative pain of elderly patients with intertrochanteric fracture
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Greater tuberosity of the femur; Xuehai acupoint; intertrochanteric fracture; pain
ID hip; management
AB Objective: To determine the efficacy of acupuncture around the greater tuberosity of the femur (AGTF) combined with acupuncture at Xuehai acupoint for postoperative pain in elderly patients with intertrochanteric fracture. Methods: A total of 97 elderly patients with intertrochanteric fracture treated by proximal femoral nail antirotation (PFNA) were enrolled and randomly assigned into an observation group (Obs group, n=48) and a control group (Con group, n=49). The Obs group was treated by aspirin and AGTF combined with acupuncture at Xuehai acupoint for analgesia, while the Con group was treated by aspirin alone for analgesia. Both groups were treated for 7 consecutive days. The two groups were compared in pain degree (visual analog scale (VAS) score) after operation and hip joint function (Harris score), daily living ability (modified Barthel index (MBI) score), bone metabolism-related indexes, and inflammatory factors before and after treatment. Results: At 1-7 d after operation, both groups had gradually lower VAS scores, and at 5 and 7 d after operation, the Obs group had a lower VAS score than the Con group (both P<0.05). Additionally, at 2 months after operation, both groups had higher Harris scores and MBI scores, and the scores of the Obs group were both higher than those of the Con group (both P<0.05). At 7 d after operation, both groups showed a decrease in serum beta collagen degradation products (beta-CTx) and an increase in procollagen type I amino-terminal propeptide (PINP) (both P<0.05), but the differences between the two groups in beta-CTx and PINP were insignificant (P>0.05). Moreover, at 7 d after operation, both groups showed a decrease in C-reactive protein (CRP) and tumor necrosis factor-alpha (TNF-alpha), and the two levels in the Obs group were lower than those in the Con group (both P<0.05). Conclusion: For elderly patients with intertrochanteric fracture, AGTF combined with acupuncture at the Xuehai acupoint can more effectively relieve their postoperative pain and postoperative inflammation and more strongly promote their postoperative recovery of hip joint function.
C1 [Li, Hanjing] Xiamen Univ, Fuzhou Hosp Affiliated 2, Dept Tradit Chinese Med, Fuzhou, Fujian, Peoples R China.
   [Wang, Biao; Chen, Chuanyuan] Xiamen Univ, Fuzhou Hosp Affiliated 2, Dept Orthoped, 47 Shangteng Rd, Fuzhou 350007, Fujian, Peoples R China.
C3 Xiamen University; Xiamen University
RP Chen, CY (corresponding author), Xiamen Univ, Fuzhou Hosp Affiliated 2, Dept Orthoped, 47 Shangteng Rd, Fuzhou 350007, Fujian, Peoples R China.
EM chenchuanyuan118@163.com
CR Audigé L, 2017, ACTA ORTHOP, V88, P133, DOI 10.1080/17453674.2016.1258534
   Cavalier E, 2019, CLIN CHEM LAB MED, V57, P1546, DOI 10.1515/cclm-2019-0174
   Gaffney CJ, 2017, ORTHOP CLIN N AM, V48, P407, DOI 10.1016/j.ocl.2017.05.001
   Hoffmann MF, 2019, J ORTHOP SURG RES, V14, P0, DOI 10.1186/s13018-019-1431-3
   Horwitz DS, 2016, J AM ACAD ORTHOP SUR, V24, PE50, DOI 10.5435/JAAOS-D-15-00325
   Jia Chengjie, 2015, ZHONGGUO ZHEN JIU, V35, P1131
   Kalinichenko LS, 2019, FRONT NEUROENDOCRIN, V55, P0, DOI 10.1016/j.yfrne.2019.100783
   Karakus O, 2018, J ORTHOP SURG RES, V13, P0, DOI 10.1186/s13018-018-0911-1
   Lisowska B, 2018, DRUG DES DEV THER, V12, P1809, DOI 10.2147/DDDT.S164565
   Liu F, 2020, J STROKE CEREBROVASC, V29, P0, DOI 10.1016/j.jstrokecerebrovasdis.2020.105033
   Liu LY, 2019, EUR J MED RES, V24, P0, DOI 10.1186/s40001-019-0398-1
   Marsland AL, 2017, BRAIN BEHAV IMMUN, V64, P208, DOI 10.1016/j.bbi.2017.01.011
   Medda S, 2019, J ORTHOP TRAUMA, V33, P341, DOI 10.1097/BOT.0000000000001442
   Mimouni M, 2019, CURR EYE RES, V44, P790, DOI 10.1080/02713683.2019.1589524
   Kien NT, 2019, DRUG DES DEV THER, V13, P2145, DOI 10.2147/DDDT.S202410
   Orchard T, 2017, J BONE MINER RES, V32, P1136, DOI 10.1002/jbmr.3070
   Sahin M, 2016, TURK J MED SCI, V46, P265, DOI 10.3906/sag-1409-66
   Socci AR, 2017, BONE JOINT J, V99B, P128, DOI 10.1302/0301-620X.99B1.BJJ-2016-0134.R1
   Wang Yu-Chen, 2019, ZHONGGUO GU SHANG, V32, P837, DOI 10.3969/j.issn.1003-0034.2019.09.013
   Weel H, 2017, ACTA ORTHOP BELG, V83, P98
   Xiao Qiang, 2019, ZHONGGUO XIU FU CHONG JIAN WAI KE ZA ZHI, V33, P1190, DOI 10.7507/1002-1892.201903026
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   Yao Min, 2019, ZHONGGUO ZHEN JIU, V39, P1181, DOI 10.13703/j.0255-2930.2019.11.012
   Yilmaz S, 2020, J TRADIT CHIN MED, V40, P275
   Zhang Malan, 2018, ZHONGGUO ZHEN JIU, V38, P591, DOI 10.13703/j.0255-2930.2018.06.006
   Zulauf N, 2019, ONCOLOGY-BASEL, V97, P236, DOI 10.1159/000500675
NR 26
TC 11
Z9 14
U1 0
U2 13
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2021
VL 13
IS 7
BP 8372
EP 8378
DI 
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA TT0LI
UT WOS:000680042800085
PM 34377330
DA 2026-01-16
ER

PT J
AU Lin, LL
   Li, HP
   Yang, JW
   Hao, XW
   Yan, SY
   Wang, LQ
   Yu, FT
   Shi, GX
   Liu, CZ
AF Lin, Lu-Lu
   Li, Hong-Ping
   Yang, Jing-Wen
   Hao, Xiao-Wan
   Yan, Shi-Yan
   Wang, Li-Qiong
   Yu, Fang-Ting
   Shi, Guang-Xia
   Liu, Cun-Zhi
TI Acupuncture for Psychological Disorders Caused by Chronic Pain: A Review and
SO Frontiers in neuroscience
LA English
DT Review
DE acupuncture; biological mechanisms; chronic pain; clinical trials; psychological states; review
AB Accumulating evidence supports an association between chronic pain and  psychological disorders, a connection that seems to be bidirectional. Treating  both the pain and psychological conditions together is essential for effective  treatment outcomes. Acupuncture is a somatosensory-guided mind-body therapy that  can tackle the multidimensional nature of pain with fewer or no serious adverse  effects. In this review, we discuss the use of acupuncture in some conditions  with a high incidence of psychological disorders caused by chronic pain:  headache, musculoskeletal pain, low back pain, and cancer pain, focusing on the  effect and potential mechanisms of acupuncture. Overall clinical studies  indicated that acupuncture might effectively contribute to management of  psychological disorders caused by chronic pain. Mechanistic studies showed that  acupuncture significantly alleviated such psychological disorders by regulating  the activity of amygdala and insula, and regulating functional connectivity of  insular and limbic regions/medial prefrontal cortex in humans and the  corresponding animal models. In addition, 5-HT in the dorsal raphe nucleus,  opioid receptors in the cingulate cortex, and plasma met-enkephalin are involved  in acupuncture relief of pain and psychological symptoms. Substantial evidences  from animal and human research support a beneficial effect of acupuncture in  psychological disorders caused by chronic pain.
C1 International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese 
   International Acupuncture and Moxibustion Innovation Institute, Beijing University of Chinese Medicine, Beijing, China.
   School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese
NR 0
TC 0
SN 1662-453
EI 1662-454
J9 Front Neurosci
PD FEB 16
PY 2021
VL 14
IS 
BP 626497
EP 626497
DI 10.3389/fnins.2020.626497
PG 0
UT PubMed:33584181
PM 33584181
DA 2021-02-16
ER

PT J
AU Mao, JJ
   Liou, KT
   Baser, RE
   Bao, T
   Panageas, KS
   Romero, SAD
   Li, QS
   Gallagher, RM
   Kantoff, PW
AF Mao, Jun J
   Liou, Kevin T
   Baser, Raymond E
   Bao, Ting
   Panageas, Katherine S
   Romero, Sally A D
   Li, Q Susan
   Gallagher, Rollin M
   Kantoff, Philip W
TI Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for
SO JAMA oncology
LA English
DT Journal Article
AB IMPORTANCE: The opioid crisis creates challenges for cancer pain management.  Acupuncture confers clinical benefits for chronic nonmalignant pain, but its  effectiveness in cancer survivors remains uncertain. OBJECTIVE: To determine the  effectiveness of electroacupuncture or auricular acupuncture for chronic  musculoskeletal pain in cancer survivors. DESIGN, SETTING, AND PARTICIPANTS: The  Personalized Electroacupuncture vs Auricular Acupuncture Comparative  Effectiveness (PEACE) trial is a randomized clinical trial that was conducted  from March 2017 to October 2019 (follow-up completed April 2020) across an urban  academic cancer center and 5 suburban sites in New York and New Jersey. Study  statisticians were blinded to treatment assignments. The 360 adults included in  the study had a prior cancer diagnosis but no current evidence of disease,  reported musculoskeletal pain for at least 3 months, and self-reported pain  intensity on the Brief Pain Inventory (BPI) ranging from 0 (no pain) to 10 (worst  pain imaginable). INTERVENTIONS: Patients were randomized 2:2:1 to  electroacupuncture (n = 145), auricular acupuncture (n = 143), or usual care  (n = 72). Intervention groups received 10 weekly sessions of electroacupuncture  or auricular acupuncture. Ten acupuncture sessions were offered to the usual care  group from weeks 12 through 24. MAIN OUTCOMES AND MEASURES: The primary outcome  was change in average pain severity score on the BPI from baseline to week 12.  Using a gatekeeping multiple-comparison procedure, electroacupuncture and  auricular acupuncture were compared with usual care using a linear mixed model.  Noninferiority of auricular acupuncture to electroacupuncture was tested if both  interventions were superior to usual care. RESULTS: Among 360 cancer survivors  (mean [SD] age, 62.1 [12.7] years; mean [SD] baseline BPI score, 5.2 [1.7]  points; 251 [69.7%] women; and 88 [24.4%] non-White), 340 (94.4%) completed the  primary end point. Compared with usual care, electroacupuncture reduced pain  severity by 1.9 points (97.5% CI, 1.4-2.4 points; P < .001) and auricular  acupuncture reduced by 1.6 points (97.5% CI, 1.0-2.1 points; P < .001) from  baseline to week 12. Noninferiority of auricular acupuncture to  electroacupuncture was not demonstrated. Adverse events were mild; 15 of 143  (10.5%) patients receiving auricular acupuncture and 1 of 145 (0.7%) patients  receiving electroacupuncture discontinued treatments due to adverse events  (P < .001). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial among  cancer survivors with chronic musculoskeletal pain, electroacupuncture and  auricular acupuncture produced greater pain reduction than usual care. However,  auricular acupuncture did not demonstrate noninferiority to electroacupuncture,  and patients receiving it had more adverse events. TRIAL REGISTRATION:  ClinicalTrials.gov Identifier: NCT02979574.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
   Department of Family Medicine and Public Health, University of California, San Diego School of Medicine, San Diego.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
   Center for Health Equity Research and Promotion, Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania.
   Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
NR 0
TC 0
SN 2374-244
EI 2374-243
J9 JAMA Oncol
PD MAR 19
PY 2021
VL 7
IS 5
BP 720
EP 727
DI 10.1001/jamaoncol.2021.0310
PG 7
WC Acupuncture, Ear; Adult; Cancer Survivors; Chronic Pain; therapy; Electroacupuncture; adverse effects; Female; Humans; Middle Aged; Musculoskeletal Pain; etiology; Neoplasms; complications; Treatment Outcome
UT PubMed:33734288
PM 33734288
DA 2021-03-19
ER

PT J
AU Henry, NL
   Unger, JM
   Till, C
   Crew, KD
   Fisch, MJ
   Hershman, DL
AF Henry, N Lynn
   Unger, Joseph M
   Till, Cathee
   Crew, Katherine D
   Fisch, Michael J
   Hershman, Dawn L
TI Predictors of Pain Reduction in Trials of Interventions for Aromatase
SO JNCI cancer spectrum
LA English
DT Journal Article
AB BACKGROUND: Almost one-half of aromatase inhibitor (AI)-treated breast cancer  patients experience AI-associated musculoskeletal symptoms (AIMSS); 20%-30%  discontinue treatment because of severe symptoms. We hypothesized that we could  identify predictors of pain reduction in AIMSS intervention trials by combining  data from previously conducted trials. METHODS: We pooled patient-level data from  3 randomized trials testing interventions (omega-3 fatty acids, acupuncture, and  duloxetine) for AIMSS that had similar eligibility criteria and the same  patient-reported outcome measures. Only patients with a baseline Brief Pain  Inventory average pain score of at least 4 of 10 were included. The primary  outcome examined was 2-point reduction in average pain from baseline to week 12.  Variable cut-point selection and logistic regression were used. Risk models were  built by summing the number of factors statistically significantly associated  with pain reduction. Analyses were stratified by study and adjusted for treatment  arm. RESULTS: For the 583 analyzed patients, the 4 factors statistically  significantly associated with pain reduction were Functional Assessment of Cancer  Therapy Functional Well-Being greater than 24 and Physical Well-Being greater  than 14 (higher scores reflect better function), and Western Ontario and McMaster  Universities Osteoarthritis Index less than 50 and Modified Score for the  Assessment and Quantification of Chronic Rheumatoid Affections of the Hands less  than 33 (lower scores reflect less pain). Patients with all 4 factors were  greater than 6 times more likely to experience at least a 2-point pain reduction  (odds ratio = 6.37, 95% confidence interval = 2.31 to 17.53, 2-sided P < .001);  similar results were found for secondary 30% and 50% pain reduction endpoints.  CONCLUSIONS: Patients with AIMSS who have lower symptom and functional distress  at study entry on AIMSS intervention trials are more likely to experience  meaningful pain reduction. Baseline symptom and functional status should be  considered as stratification factors in future interventional trials.
C1 Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
   SWOG Statistics and Data Management Center, Seattle, WA, USA.
   Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
   SWOG Statistics and Data Management Center, Seattle, WA, USA.
   Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, 
   Department of Medicine, Columbia University, New York, NY, USA.
   Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
   Department of Medicine, Columbia University, New York, NY, USA.
NR 0
TC 0
SN 2515-509
EI 
J9 JNCI Cancer Spectr
PD DEC 14
PY 2021
VL 5
IS 6
BP 
EP 
DI 10.1093/jncics/pkab087
PG 0
WC Acupuncture Analgesia; Adult; Aged; Aged, 80 and over; Analgesics; therapeutic use; Aromatase Inhibitors; adverse effects; Breast Neoplasms; drug therapy; Duloxetine Hydrochloride; therapeutic use; Fatty Acids, Omega-3; therapeutic use; Female; Humans; Logistic Models; Middle Aged; Musculoskeletal Pain; chemically induced; Pain Management; methods; Pain Measurement; drug effects; Patient Reported Outcome Measures; Randomized Controlled Trials as Topic
UT PubMed:34901744
PM 34901744
DA 2021-12-14
ER

PT J
AU Angeletti, C
   Angeletti, PM
   Paesani, M
   Guetti, C
   Gyra, A
   Perseo, G
   Ciccozzi, A
   Marinangeli, F
   Altobelli, E
AF Angeletti, Chiara
   Angeletti, Paolo Matteo
   Paesani, Martina
   Guetti, Cristiana
   Gyra, Aglaia
   Perseo, Gianluca
   Ciccozzi, Alessandra
   Marinangeli, Franco
   Altobelli, Emma
TI Assessment of Pain and Associated Comorbidities: A Survey of Real Life Experiences Among Nurses in Italy
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE pain management; nurse education; psychological comorbidities
ID mental-health; american-society; united-states; neck pain; disorders; prevalence; management; epidemiology; metaanalysis; education
AB Purpose: Pain is a symptom that should be evaluated along with its comorbidities in order to plan an effective holistic treatment strategy involving specific pharmacological interventions, side effect management, psychological support, control of therapeutic effects over time, and dialogue with the patient and their relatives. In this holistic process of caring for patients with pain, nurses play a central role as they deal with suffering patients directly and continuously. The purpose of this study was to evaluate the types of pain identified by nurses in their daily clinical practice and the associated comorbidities (anamnestic history taking) by geographical region and to evaluate the pharmacological strategies used. Methods: A cross-sectional survey was performed among 696 registered nurses in Italy. Data were collected using an online questionnaire. Results: There was a significant difference between geographical regions in terms of reports of acute and chronic pain: acute pain was more frequently reported in the South (63.5%), while chronic pain was more frequent in the Central region (32.3%; p=0.0008). Additionally, chronic oncological pain was more frequent in the Northeast (29.6%), while chronic nononcological pain was more frequently reported in the Central region (33.9%; p=0.0001). The underlying pain disorders reported were also different between geographical regions; rheumatic pain (21.8%) and neurological pain (18.6%) were more frequent in the Central region, while musculoskeletal pain was significantly more frequent in the South (43.4%; p=0.004). Anxiety, sleep disorders and somatization were found in acute pain (60.82%, 43.56% and 53.12%), while depression and mood disorders were more frequently detected in chronic pain condition (p<0.001). Conclusion: Our study showed differences among Italian regions in pain assessment. Specific education on pain management nursing is essential for nurses. Promotion of optimal nursing care for people affected by pain is the main focus of pain management nursing. Nowadays, nurses should focus on personalized complex care and research in order to improve the patient's quality of life.
C1 [Angeletti, Chiara; Paesani, Martina; Perseo, Gianluca] Civil Hosp G Mazzini Teramo, Operat Unit Anaesthesiol Intens Care & Pain Med, Teramo, Italy.
   [Angeletti, Paolo Matteo; Gyra, Aglaia; Ciccozzi, Alessandra; Marinangeli, Franco] Univ Aquila, Dept Life Hlth & Environm Sci, Laquila, Italy.
   [Guetti, Cristiana] Azienda Osped Univ Careggi, Emergency Dept, Intens Care Unit, Florence, Italy.
   [Guetti, Cristiana] Azienda Osped Univ Careggi, Reg ECMO Referral Ctr, Florence, Italy.
   [Altobelli, Emma] Univ Aquila, Dept Life Hlth & Environm Sci, Epidemiol & Biostat Unit, AUSL Teramo, Laquila, Italy.
C3 University of L'Aquila; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of L'Aquila
RP Angeletti, C (corresponding author), Civil Hosp G Mazzini Teramo, Piazza Italia 1, I-64100 Teramo, Italy.
EM chiara.angeletti@gmail.com
CR Adams LM, 2015, CURR RHEUMATOL REV, V11, P96, DOI 10.2174/1573397111666150619095330
   Allegri M, 2016, CURR MED RES OPIN, V32, P377, DOI 10.1185/03007995.2015.1129321
   American Society for Pain Management Nursing & American Nurses Association, 2016, PAIN MAN NURS SCOP S, V0, P0
   Angeletti C, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/5165262
   Unknown -, 1996, CANCER PAIN RELIEF, V0, P0
   Unknown -, 2015, COD ETH NURS, V0, P0
   Unknown -, 2013, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, V0, P0
   Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030
   Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55
   Correa-de-Araujo R, 2016, HEALTH CARE WOMEN IN, V37, P2, DOI 10.1080/07399332.2015.1102269
   Demyttenaere K, 2007, PAIN, V129, P332, DOI 10.1016/j.pain.2007.01.022
   Derry S, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD008609.pub2
   Doorenbos AZ, 2013, J PAIN, V14, P1533, DOI 10.1016/j.jpain.2013.07.006
   Dowell D, 2016, AM FAM PHYSICIAN, V93, P970
   Ferrell Betty, 2005, PAIN MANAG NURS, V6, P83, DOI 10.1016/j.pmn.2005.06.001
   Flaskerud JH, 2015, ISSUES MENT HEALTH N, V36, P74, DOI 10.3109/01612840.2014.932873
   Garcia-Larrea L, 2013, PAIN, V154, PS29, DOI 10.1016/j.pain.2013.09.001
   Heikkinen J, 2019, MATURITAS, V127, P18, DOI 10.1016/j.maturitas.2019.05.011
   Henschke N, 2015, MAYO CLIN PROC, V90, P139, DOI 10.1016/j.mayocp.2014.09.010
   Hooten WM, 2016, MAYO CLIN PROC, V91, P955, DOI 10.1016/j.mayocp.2016.04.029
   Hoy D, 2014, ANN RHEUM DIS, V73, P1309, DOI 10.1136/annrheumdis-2013-204431
   Jomar RT, 2014, ECANCERMEDICALSCIENC, V8, P0, DOI 10.3332/ecancer.2014.462
   Kudlow PA, 2015, J AFFECT DISORDERS, V188, P134, DOI 10.1016/j.jad.2015.08.030
   Limón D, 2015, EUR J PHARM BIOPHARM, V96, P421, DOI 10.1016/j.ejpb.2015.09.007
   Mansfield KE, 2016, PAIN, V157, P55, DOI 10.1097/j.pain.0000000000000314
   Mathews L, 2011, INDIAN J PALLIAT CAR, V17, P70, DOI 10.4103/0973-1075.76247
   Meghani SH, 2012, PAIN MED, V13, P5, DOI 10.1111/j.1526-4637.2011.01289.x
   Mercadante S, 2015, EXPERT REV NEUROTHER, V15, P1249, DOI 10.1586/14737175.2015.1101347
   Miceli L, 2017, MINERVA ANESTESIOL, V83, P33, DOI 10.23736/S0375-9393.16.11099-5
   Naranjo C, 2019, EXPERT REV NEUROTHER, V19, P1201, DOI 10.1080/14737175.2019.1653760
   Nguyen TA, 2013, J DRUGS DERMATOL, V12, P1131
   Pasero C, 2016, PAIN MANAG NURS, V17, P170, DOI 10.1016/j.pmn.2016.03.001
   Peptu C, 2015, CURR PHARM DESIGN, V21, P6125, DOI 10.2174/1381612821666151027152752
   Reme SE, 2011, EUR J PAIN, V15, P1075, DOI 10.1016/j.ejpain.2011.04.012
   Steel Z, 2014, INT J EPIDEMIOL, V43, P476, DOI 10.1093/ije/dyu038
   Van Oudenhove L, 2016, GASTROENTEROLOGY, V150, P866, DOI 10.1053/j.gastro.2015.11.010
   Von Korff M, 2005, PAIN, V113, P331, DOI 10.1016/j.pain.2004.11.010
   West SJ, 2015, NEUROSCIENCE, V300, P254, DOI 10.1016/j.neuroscience.2015.05.020
NR 38
TC 2
Z9 2
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2021
VL 14
IS 
BP 107
EP 115
DI 10.2147/JPR.S245792
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA QA8WO
UT WOS:000613723600001
PM 33531830
DA 2026-01-16
ER

PT J
AU Mott, T
   Jones, G
   Roman, K
AF Mott, Timothy
   Jones, Gregory
   Roman, Kimberly
TI Costochondritis: Rapid Evidence Review
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Review
ID noncardiac chest-pain; primary-care; clinical-prediction; diagnosis; patient; validation; management; emergency; wall; outpatients
AB Costochondritis is a common cause of chest pain. It most commonly occurs in adults between 40 and 50 years of age, with a slight predominance in women. Although musculoskeletal and other chest wall conditions are the most common etiology for chest pain presenting to primary care, an initial differential diagnosis should include cardiovascular, psychogenic, pulmonary, gastrointestinal, and miscellaneous or unknown sources (more to less common, respectively). Additionally, physicians should remain vigilant throughout the work-up because a notable portion of patients with chest wall tenderness to palpation may also have acute myocardial infarction. After a musculoskeletal or chest wall source is determined, differential diagnosis includes costochondritis, muscle trauma (including postoperative) or overuse, arthritis, fibromyalgia, neoplasm, infection, herpes zoster, Tietze syndrome, painful xyphoid syndrome, and slipping rib syndrome. The diagnosis of costochondritis is largely based on history and a physical examination that demonstrates reproduction of pain through palpation of the parasternal region of the chest wall, performance of a crowing rooster maneuver, and/or a crossed-chest adduction maneuver. Although high-quality evidence is lacking, treatment options include local application of heat, oral or topical nonsteroidal anti-inflammatory drugs, lidocaine patches, capsaicin cream, physical therapy, and acupuncture. Most patients will have complete resolution of symptoms in a few weeks' time with conservative therapy. Recalcitrant cases may respond to corticosteroid injections. Copyright (C) 2021 American Academy of Family Physicians.
C1 [Mott, Timothy; Jones, Gregory; Roman, Kimberly] South Baldwin Reg Med Ctr, Family Med Residency Program, Foley, AL 36535 USA.
RP Mott, T (corresponding author), South Baldwin Reg Med Ctr, 1613 N McKenzie St, Foley, AL 36535 USA.
EM timothy_mott@chs.net
CR Unknown -, 2008, SWISS MED WKLY, V138, P340
   Ayloo A, 2013, PRIMARY CARE, V40, P863, DOI 10.1016/j.pop.2013.08.007
   Bhuiya Farida A, 2010, NCHS DATA BRIEF, V0, P1
   Bösner S, 2010, CAN MED ASSOC J, V182, P1295, DOI 10.1503/cmaj.100212
   Boran M, 2017, WORLD JOURNAL OF PHARMACEUTICAL RESEARCH, V0, PP76, DOI 10.20959/wjpr20178-9026
   Bosner S, 1900, P363, V0, P0
   CHICARILLI ZN, 1986, PLAST RECONSTR SURG, V77, P50, DOI 10.1097/00006534-198601000-00009
   Cilia C, 2010, INTERN EMERG MED, V5, P427, DOI 10.1007/s11739-010-0401-x
   Dale AP, 2019, BRIT J GEN PRACT, V69, PE444, DOI 10.3399/bjgp19X704297
   DIEHR P, 1984, J CHRON DIS, V37, P215, DOI 10.1016/0021-9681(84)90149-8
   DISLA E, 1994, ARCH INTERN MED, V154, P2466, DOI 10.1001/archinte.154.21.2466
   Do AMP, 2009, AM FAM PHYSICIAN, V80, P617
   Ebell MH, 2011, AM FAM PHYSICIAN, V83, P603
   EPSTEIN SE, 1979, JAMA-J AM MED ASSOC, V241, P2793, DOI 10.1001/jama.241.26.2793
   Gregory PL, 2002, SPORTS MED, V32, P235, DOI 10.2165/00007256-200232040-00003
   Haasenritter J, 2015, CROAT MED J, V56, P422, DOI 10.3325/cmj.2015.56.422
   Harskamp RE, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-027081
   Hoorweg BBN, 2017, HEART, V103, P1727, DOI 10.1136/heartjnl-2016-310905
   How Jennifer, 2005, EUR J INTERN MED, V16, P432, DOI 10.1016/j.ejim.2005.07.002
   Hsiao Chun-Ju, 2010, NATL HEALTH STAT REPORT, V0, P1
   Imazio M, 2011, ANN INTERN MED, V155, P409, DOI 10.7326/0003-4819-155-7-201110040-00359
   Kamel M, 1997, BRIT J RHEUMATOL, V36, P547
   KLINKMAN MS, 1994, J FAM PRACTICE, V38, P345
   Li B, 1998, J TRADIT CHIN MED, V18, P195
   Löwe B, 2003, J PSYCHOSOM RES, V55, P515, DOI 10.1016/S0022-3999(03)00072-2
   Maisch B, 2004, EUR HEART J, V25, P587, DOI 10.1016/j.ehj.2004.02.002
   McConaghy JR, 2013, AM FAM PHYSICIAN, V87, P177
   Metlay JP, 1997, JAMA-J AM MED ASSOC, V278, P1440, DOI 10.1001/jama.278.17.1440
   Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256
   PANTELL RH, 1983, PEDIATRICS, V71, P881
   Ronga A, 2012, BMC FAM PRACT, V13, P0, DOI 10.1186/1471-2296-13-74
   Rovetta G, 2009, G ITAL MED LAV ERGON, V31, P169
   Saltzman DA, 2001, PAEDIATR ANAESTH, V11, P740, DOI 10.1046/j.1460-9592.2001.00754.x
   Smythe HA, 1985, MUSCULOSKELETAL CHES, V0, P0
   Spalding L, 2003, J ROY SOC MED, V96, P122, DOI 10.1258/jrsm.96.3.122
   Tamariz LJ, 2004, AM J MED, V117, P676, DOI 10.1016/j.amjmed.2004.04.021
   Tietze A, 1921, BERLINER KLINISCHE WOCHENSCHRIFT, V30, P829
   Van den Berg P, 2018, EUR HEART J-ACUTE CA, V7, P111, DOI 10.1177/2048872617710788
   Verdon F, 2007, BMC FAM PRACT, V8, P0, DOI 10.1186/1471-2296-8-51
   von Kodolitsch Y, 2000, ARCH INTERN MED, V160, P2977, DOI 10.1001/archinte.160.19.2977
   Wang CS, 2005, JAMA-J AM MED ASSOC, V294, P1944, DOI 10.1001/jama.294.15.1944
   Wang WH, 2005, ARCH INTERN MED, V165, P1222, DOI 10.1001/archinte.165.11.1222
   Wells PS, 2001, ANN INTERN MED, V135, P98, DOI 10.7326/0003-4819-135-2-200107170-00010
   Wertli MM, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0211615
   WISE CM, 1992, ARCH PHYS MED REHAB, V73, P147
   WOLF E, 1976, ARCH INTERN MED, V136, P189, DOI 10.1001/archinte.136.2.189
   ZAPATERO J, 1988, BRIT J DIS CHEST, V82, P341, DOI 10.1016/0007-0971(88)90086-1
   Zimmerman J, 2004, SCAND J GASTROENTERO, V39, P212, DOI 10.1080/00365520310005333
NR 51
TC 1
Z9 1
U1 1
U2 4
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
EI 1532-0650
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD JUL 1
PY 2021
VL 104
IS 1
BP 73
EP 78
DI 
PG 6
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA TQ3GI
UT WOS:000678171700022
PM 34264599
DA 2026-01-16
ER

PT J
AU Guo, Q
   Di, Z
   Tian, HF
   Zhang, QA
AF Guo, Qin
   Di, Zhong
   Tian, Hong-Fang
   Zhang, Quan-Ai
TI Contralateral Acupuncture for the Treatment of Phantom Limb Pain and Phantom Limb
SO Frontiers in neuroscience
LA English
DT Journal Article
DE acupuncture; contralateral acupuncture; phantom limb; phantom limb pain (PLP); phantom limb sensation (PLS)
AB Phantom limb pain (PLP) and phantom limb sensation (PLS) are common and  distressing sequelae of amputation. Current pain management following amputation  is challenging and unsatisfying. In this case study, a 74-year-old woman  underwent above-knee amputation because of the rhabdomyosarcoma in the right leg.  Despite several analgesics, pain was poorly controlled. The phantom limb pain and  sensation were immediately reduced by the contralateral acupuncture, and  abolished after the third session with no side-effects, no relapse during the  next 9 months. Contralateral acupuncture showed positive effect on PLP and PLS in  this case, but more robust evidence would be needed to support the efficacy of  this treatment technique for indication.
C1 Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
NR 0
TC 0
SN 1662-453
EI 1662-454
J9 Front Neurosci
PD NOV 9
PY 2021
VL 15
IS 
BP 713548
EP 713548
DI 10.3389/fnins.2021.713548
PG 0
UT PubMed:34744604
PM 34744604
DA 2021-11-09
ER

PT J
AU Magee, DJ
   Schutzer-Weissmann, J
   Pereira, EAC
   Brown, MRD
AF Magee, David J
   Schutzer-Weissmann, John
   Pereira, Erlick A C
   Brown, Matthew R D
TI Neuromodulation techniques for cancer pain management.
SO Current opinion in supportive and palliative care
LA English
DT Review
AB PURPOSE OF REVIEW: Advanced pain management techniques may be indicated in 5-15%  of cancer patients. Despite this, a recent review identified that, over the  course of 1 year in England, only 458 patients received a procedure intended to  provide analgesia and only 30 patients had intrathecal drug delivery (ITDD)  devices implanted. This article describes the emerging evidence for ITDD in  cancer pain and provides a narrative review of other neuromodulatory techniques  (including spinal cord stimulation, peripheral nerve stimulation and  acupuncture), approaches that might be employed to address this area of  significant unmet clinical need. RECENT FINDINGS: Numerous studies have been  published within the last year reporting positive outcomes associated with ITDD  in cancer pain management. Neuromodulation represents an important strategy in  the management of persistent pain. Whilst the nonmalignant pain evidence-base is  rapidly growing, it remains sparse for cancer pain management. The growing cohort  of cancer survivors may significantly benefit from neuromodulatory techniques.  SUMMARY: ITDD and other neuromodulatory techniques for cancer pain management  appear underutilised in the UK and offer the prospect of better treatment for  cancer patients with refractory pain or intolerable side-effects from systemic  analgesics.
C1 Signalling and Cancer Metabolism Team, Division of Cancer Biology, The Institute of Cancer Research.
   Pain Medicine Department, The Royal Marsden Hospital.
   Pain Medicine Department, The Royal Marsden Hospital.
   Neurosciences Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London.
   Department of Neurosurgery, St George's University Hospital.
   Pain Medicine Department, The Royal Marsden Hospital.
   Targeted Approaches to Cancer Pain Group, The Institute of Cancer Research,
NR 0
TC 0
SN 1751-426
EI 
J9 Curr Opin Support Palliat Care
PD APR 13
PY 2021
VL 15
IS 2
BP 77
EP 83
DI 10.1097/SPC.0000000000000549
PG 6
WC Analgesics; Cancer Pain; drug therapy; Humans; Neoplasms; complications; Pain; Pain Management
UT PubMed:33843762
PM 33843762
DA 2021-04-13
ER

PT J
AU Jiang, L
   Deng, ZX
   Zhang, HC
   Li, Y
   Wang, TT
   Xie, W
AF Jiang, Li
   Deng, Zhaoxia
   Zhang, Hongcai
   Li, Yuan
   Wang, Tingting
   Xie, Wen
TI Acupoint for angina pectoris A protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE acupoint therapies; angina pectoris; protocol; systematic review
ID acupuncture
AB Introduction: Patients with angina pectoris (AP) often experience heavy psychological distress, especially anxiety and depression, which results in poorer quality of life, shorter survival time. Acupoint therapies, including massage, acupuncture, acupoints injection, acupressure, and moxibustion, showed clinical and long-lasting benefits for AP, but the efficiency of acupoint therapies was poorly evaluated. The current review is attempted to evaluate the efficacy and safety of the different acupoint-based therapies for AP. Methods and analysis: A literature search will be conducted in MEDLINE, EMBASE, Web of Science, Cochrane Library, Web of Science, PubMed, Science Direct, Wan Fang Data Knowledge Service Platform, Chinese Biomedical Literature Database (CBM), Chinese Scientific Journal Database (VIP database), and China National Knowledge Infrastructure (CNKI). Observational studies regarding the association between liver cancer and depression and anxiety written in English or Chinese will be included. Study inclusion, data extraction, and quality assessment will be performed independently by 2 reviewers. We will use RevMan V.5.0 and STATA V.12.0 software for statistical analysis. The I-2 test will be used to identify the extent of heterogeneity. Publication bias will be assessed by generating a funnel plot and performing the Begg and Egger test. The quality of the systematic review will be evaluated using the Measurement Tool to Assess Systematic Reviews (AMSTAR) and Grading of Recommendations Assessment Development and Evaluation (GRADE) criteria. With the permitted numeric data, we will carry out a meta-analysis. Results: This study will provide a high-quality synthesis of pain VAS and functional disability or the quality of life, the success treatment rate, the recurrent rate and the complications rate to assess the effectiveness and safety of acupoint for AP patients. This systematic review will provide evidence to judge whether acupoint is an effective intervention for patients with AP. Conclusion: This systematic review and meta-analysis will provide evidence to judge whether acupoint is an effective intervention for patients with AP and provide evidence for designing early targeted interventions for high-risk survivors that can attenuate negative reactions. PROSPERO registration number: 10.17605/OSF.IO/VNXWE.
C1 [Jiang, Li; Deng, Zhaoxia; Li, Yuan; Wang, Tingting; Xie, Wen] Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610072, Sichuan, Peoples R China.
   [Zhang, Hongcai] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Xie, W (corresponding author), Hosp Chengdu Univ Tradit Chinese Med, 39 Shi Er Qiao Rd, Chengdu 610072, Sichuan, Peoples R China.
EM 1131649799@qq.com
FU Chengdu University of Traditional Chinese Medicine Science and Technology Development Fund [ZRYB201014]
CR Fox K, 2006, EUR HEART J, V27, P1341, DOI 10.1093/eurheartj/ehl001
   Institute for Health Metrics and Evaluation (IHME), 2019, GBD COMP DAT VIS EB, V0, P0
   Lee H, 2016, INT J CARDIOL, V222, P321, DOI 10.1016/j.ijcard.2016.07.195
   Li YD, 2017, FRONT PHYSIOL, V8, P0, DOI 10.3389/fphys.2017.00358
   Montalescot G, 2013, EUR HEART J, V34, P2949, DOI 10.1093/eurheartj/eht296
   Shi Jing, 2018, ZHEN CI YAN JIU, V43, P277, DOI 10.13702/j.1000-0607.180123
   Yang J, 2018, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.C.D008821.pub2
   Zhao L, 2019, JAMA INTERN MED, V0, P0
NR 9
TC 1
Z9 2
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 22
PY 2021
VL 100
IS 3
BP 
EP 
DI 10.1097/MD.0000000000024080
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA PZ6FV
UT WOS:000612835100092
PM 33546012
DA 2026-01-16
ER

PT J
AU Wang, W
   Zhou, Y
   Cai, YQ
   Wang, SS
   Shao, FB
   Du, JY
   Fang, JF
   Liu, JG
   Shao, XM
   Liu, BY
   Fang, JQ
   Liang, Y
AF Wang, Wen
   Zhou, You
   Cai, Yangqian
   Wang, Sisi
   Shao, Fangbing
   Du, Junying
   Fang, Junfan
   Liu, Jinggen
   Shao, Xiaomei
   Liu, Boyi
   Fang, Jianqiao
   Liang, Yi
TI Phosphoproteomic Profiling of Rat's Dorsal Root Ganglia Reveals mTOR as a Potential Target in Bone Cancer Pain and Electro-Acupuncture's Analgesia
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE proteomic profiling; protein microarray; mTOR; bone cancer pain; mechanism; electro-acupuncture
ID mammalian target; neuropathic pain; cell-growth; rapamycin; electroacupuncture; phosphorylation; activation; expression; rictor; model
AB Bone cancer pain (BCP) is a clinical refractory mixed pain involving neuropathic and inflammatory pain, with the underlying mechanisms remaining largely unknown. Electro-acupuncture (EA) can partly alleviate BCP according to previous research. We aim to explore the proteins and major pathways involved in BCP and EA treatment through phosphoproteomic profiling. BCP rat model was built by tibial inoculation of MRMT-1 mammary gland carcinoma cells. Mechanical hyperalgesia determined by paw withdrawal thresholds (PWTs) and bone destruction manifested on the radiographs confirmed the success of modeling, which were attenuated by EA treatment. The differentially expressed phosphorylated proteins (DEPs) co-regulated by BCP modeling and EA treatment in rat dorsal root ganglions (DRGs) were analyzed through PEX100 Protein microarray. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that DEPs were significantly enriched in mammalian target of rapamycin (mTOR) signaling pathway. The phosphorylations of mTOR at Ser2448 and Thr2446 were increased in BCP and downregulated by EA. In addition, the phosphorylation of S6K and Akt, markers of the mTOR complex, were also increased in BCP and downregulated by EA. Inhibition of mTOR signaling alleviated the PWTs of BCP rats, while the mTOR agonist impaired the analgesic effect of EA. Thus, our study provided a landscape of protein phosphorylation changes in DRGs of EA-treated BCP rats and revealed that mTOR signaling can be potentially targeted to alleviate BCP by EA treatment.
C1 [Wang, Wen; Zhou, You; Cai, Yangqian; Wang, Sisi; Shao, Fangbing; Du, Junying; Fang, Junfan; Liu, Jinggen; Shao, Xiaomei; Liu, Boyi; Fang, Jianqiao; Liang, Yi] Zhejiang Chinese Med Univ, Dept Neurobiol & Acupuncture Res, Clin Med Coll 3, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.
   [Wang, Wen] Quzhou Municipal Hosp Tradit Chinese Med, Quzhou, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Fang, JQ; Liang, Y (corresponding author), Zhejiang Chinese Med Univ, Dept Neurobiol & Acupuncture Res, Clin Med Coll 3, Key Lab Acupuncture & Neurol Zhejiang Prov, Hangzhou, Peoples R China.
EM fangjianqiao7532@163.com; liangyiwww@zcmu.edu.cn
FU Natural Science Foundation of Zhejiang Province [LGF21H270006]; National Natural Science Foundation of China [81674061]; Foundation of the Zhejiang Health Committee [2014KYA162]
CR Ahmad I, 2018, CUREUS J MED SCIENCE, V10, P0, DOI 10.7759/cureus.3286
   Arthur J, 2019, CURR TREAT OPTION ON, V20, P0, DOI 10.1007/s11864-019-0636-3
   Bennett MI, 2017, PAIN, V158, PS74, DOI 10.1097/j.pain.0000000000000825
   Berta T, 2017, EXPERT OPIN THER TAR, V21, P695, DOI 10.1080/14728222.2017.1328057
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Chang KH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/324039
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen L, 2020, ADV SCI, V7, P0, DOI 10.1002/advs.201900949
   Chen Y, 2008, P NATL ACAD SCI USA, V105, P16773, DOI 10.1073/pnas.0801793105
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Cheng JK, 2000, ANESTHESIOLOGY, V92, P1126, DOI 10.1097/00000542-200004000-00031
   Cheng SWY, 2004, J BIOL CHEM, V279, P15719, DOI 10.1074/jbc.C300534200
   Choi S, 2020, NEUROSCI LETT, V718, P0, DOI 10.1016/j.neulet.2020.134742
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
   Deng HS, 2019, MOL MED REP, V20, P4695, DOI 10.3892/mmr.2019.10702
   Du JY, 2016, EXP THER MED, V12, P2568, DOI 10.3892/etm.2016.3647
   Du JY, 2021, ACUPUNCT MED, V39, P478, DOI 10.1177/0964528420968845
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   Ducourneau VRR, 2014, PAIN, V155, P275, DOI 10.1016/j.pain.2013.10.008
   Fang D, 2015, PAIN, V156, P1124, DOI 10.1097/j.pain.0000000000000158
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Gaspari S, 2017, NEUROPSYCHOPHARMACOL, V42, P1548, DOI 10.1038/npp.2017.4
   Guan XH, 2015, J NEUROCHEM, V134, P590, DOI 10.1111/jnc.13139
   Han Y, 2012, NEUROSCI BULL, V28, P165, DOI 10.1007/s12264-012-1211-0
   Hanamura K, 2017, PLOS BIOL, V15, P0, DOI 10.1371/journal.pbio.2002457
   Hao MM, 2020, ACTA BIOCH BIOPH SIN, V52, P231, DOI 10.1093/abbs/gmz162
   He D, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-019-13911-x
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hsieh CJ, 2015, INT J ONCOL, V46, P555, DOI 10.3892/ijo.2014.2769
   Iwaszkiewicz KS, 2013, FRONT PHARMACOL, V4, P0, DOI 10.3389/fphar.2013.00132
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033
   Jasmin L, 2001, J NEUROSCI METH, V110, P81, DOI 10.1016/S0165-0270(01)00420-4
   Jiang Y X, 2001, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V21, P923
   Jiang ZM, 2016, INT J CANCER, V138, P2013, DOI 10.1002/ijc.29927
   Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582
   Kogasaka Y, 2013, MOL REPROD DEV, V80, P334, DOI 10.1002/mrd.22166
   Largent-Milnes TM, 2008, J PAIN, V9, P700, DOI 10.1016/j.jpain.2008.03.005
   Li XM, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep39397
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang Y, 2018, INTEGR CANCER THER, V17, P401, DOI 10.1177/1534735417728335
   Liang Y, 2016, ACUPUNCT MED, V34, P40, DOI 10.1136/acupmed-2015-010773
   Liu Q, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919866529
   Lu GF, 2018, PAIN PHYSICIAN, V21, PE509, DOI 10.36076/ppj.2018.5.e509
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4
   Moustafa-Kamal M, 2020, CELL REP, V33, P0, DOI 10.1016/j.celrep.2020.108230
   Nadler RB, 2000, J UROLOGY, V164, P214, DOI 10.1016/S0022-5347(05)67497-6
   Napolitano G, 2020, NATURE, V585, P597, DOI 10.1038/s41586-020-2444-0
   Ni HD, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919831909
   PADMANABHAN R, 1979, ACTA ANAT, V105, P378
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Paley CA, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq020
   Pareek TK, 2007, P NATL ACAD SCI USA, V104, P660, DOI 10.1073/pnas.0609916104
   Ryu HK, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/191347
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shih MH, 2012, J PAIN, V13, P338, DOI 10.1016/j.jpain.2011.12.006
   Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Wang YJ, 2019, BIOL RES NURS, V21, P5, DOI 10.1177/1099800418804896
   Werfel TA, 2018, CANCER RES, V78, P1845, DOI 10.1158/0008-5472.CAN-17-2388
   WESSELS WJT, 1990, DEV BRAIN RES, V54, P273, DOI 10.1016/0165-3806(90)90150-W
   Woodward E, 2011, BONE, V48, P160, DOI 10.1016/j.bone.2010.09.008
   Xia ZJ, 2017, J PAIN RES, V10, P1943, DOI 10.2147/JPR.S128533
   Xiang XN, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20133248
   Xu SP, 2019, CELL DEATH DIS, V10, P0, DOI 10.1038/s41419-019-2137-5
   Yonezawa K, 2003, CURR TOP MICROBIOL, V279, P271
   Yuan GX, 2019, CANCER LETT, V443, P135, DOI 10.1016/j.canlet.2018.11.038
   Zhang YQ, 2002, PAIN, V99, P525, DOI 10.1016/S0304-3959(02)00268-3
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao D, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919857981
   Zhu HL, 2017, ACTA BIOCH BIOPH SIN, V49, P1008, DOI 10.1093/abbs/gmx103
NR 75
TC 16
Z9 20
U1 2
U2 27
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 29
PY 2021
VL 12
IS 
BP 
EP 
DI 10.3389/fphar.2021.593043
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA SB1XJ
UT WOS:000649794500001
PM 33995007
DA 2026-01-16
ER

PT J
AU Ji, YJ
   Li, SY
   Zhang, XY
   Li, Q
   Lu, Q
   Chen, WL
   Liu, Y
   Sheng, JY
   Liang, HL
   Jiang, K
   Li, MT
   Sha, SY
   Wu, HG
   Huang, Y
   Xue, XH
AF Ji, Yajie
   Li, Siyu
   Zhang, Xinyue
   Li, Qiong
   Lu, Qing
   Chen, Weili
   Liu, Yu
   Sheng, Jiayu
   Liang, Hongli
   Jiang, Ke
   Li, Mengting
   Sha, Shanyan
   Wu, Huangan
   Huang, Yan
   Xue, Xiaohong
TI The Efficacy of Moxibustion for Breast Cancer Patients with Chemotherapy-Induced Myelosuppression during Adjuvant Chemotherapy: A Randomized Controlled Study
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID colony-stimulating factors; acute myeloid-leukemia; myelodysplastic syndrome; regimens
AB Objective. The randomized controlled clinical trial aims to investigate the clinical efficacy of moxibustion for breast cancer patients with chemotherapy-induced myelosuppression (CIM) during adjuvant chemotherapy. Methods. Surgically resected breast cancer patients were randomly divided into the moxibustion group (MOX; n = 48) and control group (CON; n = 44). Routine adjuvant chemotherapy (every 21 days, 4-8 cycles) and supportive recombinant human granulocyte colony-stimulating factor were given to both groups, while MOX received an additional moxibustion treatment (once daily after each cycle of chemotherapy). Primary endpoints included the grade of myelosuppression in terms of white blood cell (W BC) and absolute neutrophil count (ANC) and the incidence of myelosuppression-related serious adverse events (SAES). Other measures included treatment compliance, adverse events (AEs), and survival. Results. WBC counts were generally higher in MOX and were dramatically higher than those in CON at the 7th course of chemotherapy (P = 0.008), while grade 1 ANC reduction was dramatically lower than that in CON at the 7th course of chemotherapy (P = 0.006). These effects were particularly significant in patients receiving anthracycline-taxane combination regimens. Moreover, MOX had fewer febrile neutropenia than CON (P = 0.051). MOX demonstrated a lower incidence of grade 3-4 myelosuppression (P < 0.05). AEs including grade 2-3 severe nausea, various kinds of pains, and vertigo occurred less frequently in MOX (P < 0.05). No difference in survival was observed between the two groups (P > 0.05). Conclusion. Moxibustion is effective for treating CIM in breast cancer patients during adjuvant chemotherapy, especially for patients receiving high-dose, long-term, and combined chemotherapy regimens. Moxibustion can reduce the incidence of myelosuppression-related SAE and improve the compliance and safety of chemotherapy in breast cancer.
C1 [Ji, Yajie; Li, Siyu; Zhang, Xinyue; Li, Qiong; Lu, Qing; Chen, Weili; Liu, Yu; Sheng, Jiayu; Liang, Hongli; Jiang, Ke; Li, Mengting; Sha, Shanyan; Xue, Xiaohong] Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Chinese & Western Med, Dept Breast Surg, Shanghai 200437, Peoples R China.
   [Ji, Yajie; Wu, Huangan; Huang, Yan] Shanghai Univ Tradit Chinese Med, Shanghai Res Inst Acupuncture & Meridian, Shanghai 200030, Peoples R China.
   [Wu, Huangan; Huang, Yan] Shanghai Univ Tradit Chinese Med, Key Lab Acupuncture & Immunol Effects, Shanghai 200030, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Xue, XH (corresponding author), Shanghai Univ Tradit Chinese Med, Yueyang Hosp Integrated Chinese & Western Med, Dept Breast Surg, Shanghai 200437, Peoples R China.
EM 195641459@qq.com
FU Three-Year Program of Shanghai Hospital Development Center [16CR2026B]; National Natural Science Foundation of China [82004446]
CR ANTMAN KS, 1988, NEW ENGL J MED, V319, P593, DOI 10.1056/NEJM198809083191001
   Baden LR, 2016, J NATL COMPR CANC NE, V14, P882, DOI 10.6004/jnccn.2016.0093
   [曹威 Cao Wei], 2018, 中华普通外科杂志 CHINESE JOURNAL OF GENERAL SURGERY, V33, P223, DOI 10.3760/cma.j.issn.1007-631x.2018.03.012
   Chinese Association for Clinical Oncologists The Chinese Anti-Cancer Association the Society of Chemotherapy and Editorial Committee National Medical Journal of China, 2015, NATL MED J CHINA, V95, P3001
   de Miguel SC, 2015, SUPPORT CARE CANCER, V23, P547, DOI 10.1007/s00520-014-2459-x
   Hershman D, 2007, JNCI-J NATL CANCER I, V99, P196, DOI 10.1093/jnci/djk028
   Ito Y, 2008, BREAST CANCER-TOKYO, V14, P393
   Ji Y, 2019, GUANGMING J CHIN MED, V34, P2266
   Ji YJ, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04749-6
   Jiang Jin-Feng, 2013, ZHONGGUO ZHEN JIU, V33, P860
   Jiang ShuangFeng Jiang ShuangFeng, 2019, JOURNAL OF GUANGDONG PHARMACEUTICAL UNIVERSITY, V35, P451
   Joerger M, 2013, EXPERT REV ANTICANC, V13, P165, DOI 10.1586/era.12.172
   Li C, 2012, J QIQIHAR U MED, V24, P3451
   Lidan Z, 2018, ZHONGYI LINCHUANG YANJIU, V10, P117
   Lin H, 2015, SHENZHEN J INTEGRATE, V8, P29
   Lu J, 2007, J PRACTICAL ONCOLOGY, V6, P527
   Lyman GH, 2010, J CLIN ONCOL, V28, P2914, DOI 10.1200/JCO.2009.25.8723
   Mamounas EP, 2001, SEMIN ONCOL, V28, P24, DOI 10.1053/sonc.2001.26432
   NCCN, 2015, NCCN CLIN PRACTICE G, V6, P0
   Ni G, 2014, WORLD J INTEGRATED T, V9, P101
   Shen X, 2016, SCI MERIDIANS ACUPOI, V0, P0
   Smith TJ, 2015, J CLIN ONCOL, V33, P3199, DOI 10.1200/JCO.2015.62.3488
   Su Q, 2013, GUANGMING J CHINESE, V11, P2107
   Tian H, 2015, CLIN. J. CHIN. MED., V10, P35
   Wu h, 2013, MODERN RES CHINESE M, V0, P0
   Zhang W, 2017, NEI MONGOL. J. TRADIT. CHIN. MED., V5, P72
   Zhang W, 2013, ASIA PACIFIC TRADITI, V11, P75
   Zhou H, 2016, CHINA J CHINESE MAT, V0, P0
NR 28
TC 8
Z9 13
U1 5
U2 40
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD APR 26
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/1347342
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA SK7GA
UT WOS:000656383500004
PM 33986813
DA 2026-01-16
ER

PT J
AU Ostovar-Kermani, T
   Arnaud, D
   Almaguer, A
   Garcia, I
   Gonzalez, S
   Mendez, Martinez YH
   Surani, S
AF Ostovar-Kermani, Tiffany
   Arnaud, Daniel
   Almaguer, Andrea
   Garcia, Ismael
   Gonzalez, Stephanie
   Mendez Martinez, Yamely Haydee
   Surani, Salim
TI Painful Sleep: Insomnia in Patients with Chronic Pain Syndrome and its
SO Folia medica
LA English
DT Review
DE chronic pain syndrome; insomnia; lifestyle impact; mental health; pain; sleep apnea; sleep disorder; somnolence
AB Insomnia is a chronic condition that occurs a minimum of three times per week  over a period of three or more subsequent months. There are multiple causes of  insomnia, and even though it is considered a symptom, it can be associated with  chronic illnesses. Chronic pain syndrome, which is defined as pain that persists  for a period longer than 3 months, is one of several etiologies of insomnia. The  prevalence of insomnia among chronic pain patients is greater in comparison with  the general population (percentage or ratio). Chronic pain is common in patients  with rheumatoid arthritis, spinal pain (such as chronic back pain) and  fibromyalgia. The prevalence of in-somnia is also higher in cancer patients when  compared to the general population. When the clinical history indicates a  straightforward diagnosis of chronic pain syndrome, patients will complain of  insomnia as part of their symptomatology. It is imperative to manage their  underlying illness to alleviate their sleep disorder. Various medications may be  used to relieve and even improve pain symptoms. Other than pharmacological  interventions, non-pharmacological alternatives such as yoga, meditation,  acupuncture, and psychotherapy can help improve the quality of life of these  patients. The purpose of this article is to review the diagnosis and management  of insomnia in chronic pain syndrome and its impact on the quality of life.
C1 Baylor College of Medicine, Houston, United States of America.
   Horizon Clinical Research, Houston, United States of America.
   Baylor College of Medicine, Houston, United States of America.
   Texas Medical Center, Houston, United States of America.
   Clinical Research Solution, Houston, United States of America.
   Baylor College of Medicine, Houston, United States of America.
   Texas A&M University, Corpus Christi, United States of America.
NR 0
TC 0
SN 1314-214
EI 
J9 Folia Med (Plovdiv)
PD JAN 9
PY 2021
VL 62
IS 4
BP 645
EP 654
DI 10.3897/folmed.62.e50705
PG 9
WC Chronic Pain; complications; Global Health; Humans; Incidence; Quality of Life; Sleep; physiology; Sleep Initiation and Maintenance Disorders; epidemiology; Syndrome
UT PubMed:33415907
PM 33415907
DA 2021-01-09
ER

PT J
AU Han, ZZ
   Zhang, Y
   Wang, PQ
   Tang, QL
   Zhang, K
AF Han, Zhenzhen
   Zhang, Yang
   Wang, Pengqian
   Tang, Qilin
   Zhang, Kai
TI Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy
SO BRIEFINGS IN BIOINFORMATICS
LA English
DT Article
DE acupuncture; interventions; COVID-19; bioinformatics; network topology
ID beta-endorphin; electroacupuncture; hypothalamus; cancer; rats; pain; metaanalysis; expression; mechanism; therapy
AB Acupuncture is an important part of Chinese medicine that has been widely used in the treatment of inflammatory diseases. During the coronavirus disease 2019 (COVID-19) epidemic, acupuncture has been used as a complementary treatment for COVID-19 in China. However, the underlying mechanism of acupuncture treatment of COVID-19 remains unclear. Based on bioinformatics/topology, this paper systematically revealed the multi-target mechanisms of acupuncture therapy for COVID-19 through text mining, bioinformatics, network topology, etc. TWo active compounds produced after acupuncture and 180 protein targets were identified. A total of 522 Gene Ontology terms related to acupuncture for COVID-19 were identified, and 61 pathways were screened based on the Kyoto Encyclopedia of Genes and Genomes. Our findings suggested that acupuncture treatment of COVID-19 was associated with suppression of inflammatory stress, improving immunity and regulating nervous system function, including activation of neuroactive ligand-receptor interaction, calcium signaling pathway, cancer pathway, viral carcinogenesis, Staphylococcus aureus infection, etc. The study also found that acupuncture may have additional benefits for COVID-19 patients with cancer, cardiovascular disease and obesity. Our study revealed for the first time the multiple synergistic mechanisms of acupuncture on COVID-19. Acupuncture may play an active role in the treatment of COVID-19 and deserves further promotion and application. These results may help to solve this pressing problem currently facing the world.
C1 [Wang, Pengqian] China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Dongzhimennei, Beijing 100700, Peoples R China.
   [Han, Zhenzhen] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China.
   [Zhang, Yang] Tianjin Hosp Integrated Tradit Chinese & Western, Tianjin, Peoples R China.
   [Tang, Qilin] Hebei Univ Chinese Med, Shijiazhuang, Hebei, Peoples R China.
   [Zhang, Kai] Tianjin Gong An Hosp, Tianjin, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS; Hebei University of Chinese Medicine
RP Zhang, K (corresponding author), Tianjin Gong An Hosp, Dept Acupuncture & Moxibust, 78 Nanjing Rd, Tianjin 300042, Peoples R China.; Tang, QL (corresponding author), Hebei Univ Chinese Med, Sch Basic Med Sci, 3 Xingyuan Rd, Shijiazhuang 050200, Hebei, Peoples R China.; Wang, PQ (corresponding author), China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Dongzhimennei, Beijing 100700, Peoples R China.
EM pengqian.wang@163.com; tqilin123@126.com; coolzhangkai@163.com
CR Unknown -, 2020, COVID-19 DASHBOARD BY THE CENTER FOR SYSTEMS SCIENCE AND ENGINEERING (CSSE) AT JOHNS HOPKINS, V0, P0
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Beltrán-García J, 2020, ANTIOXIDANTS-BASEL, V9, P0, DOI 10.3390/antiox9100936
   Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5
   Boezio B, 2017, MOL INFORM, V36, P0, DOI 10.1002/minf.201700048
   Bone NB, 2017, J LEUKOCYTE BIOL, V101, P357, DOI 10.1189/jlb.3HI0216-068RR
   Cavalli G, 2020, LANCET RHEUMATOL, V2, PE325, DOI 10.1016/S2665-9913(20)30127-2
   Chang S, 2019, SCI ADV, V5, P0, DOI 10.1126/sciadv.aax1342
   Chen T, 2020, BMJ-BRIT MED J, V368, P0, DOI 10.1136/bmj.m1091
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/editorial-conti-3
   Costantino S, 2016, J PHYSIOL-LONDON, V594, P2061, DOI 10.1113/JP270538
   Cui HT, 2020, TRADIT MED RES, V5, P65, DOI 10.53388/TMR20200222165
   Cummings M, 2018, BMJ-BRIT MED J, V360, P0, DOI 10.1136/bmj.k970
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Daina A, 2019, NUCLEIC ACIDS RES, V47, PW357, DOI 10.1093/nar/gkz382
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Deng XL, 2018, BIOL RES, V51, P0
   Dennis G Jr, 2003, GENOME BIOL, V4, P0, DOI 10.1186/gb-2003-4-9-r60
   Dhakal BP, 2020, HEART LUNG CIRC, V29, P973, DOI 10.1016/j.hlc.2020.05.101
   Dhall A, 2021, BRIEF BIOINFORM, V22, P936, DOI 10.1093/bib/bbaa259
   Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818
   Drozdzal S, 2020, BRAIN SCI, V10, P0, DOI 10.3390/brainsci10070465
   Fu YJ, 2020, VIROL SIN, V35, P266, DOI 10.1007/s12250-020-00207-4
   Gong YB, 2021, ZHONGGUO ZHEN JIU, V41, P142
   Guan Jin-Shuai, 2019, SICHUAN DA XUE XUE BAO YI XUE BAN, V50, P203
   Han HJ, 2021, INT IMMUNOPHARMACOL, V90, P0, DOI 10.1016/j.intimp.2020.107247
   He XF, 2018, EXP THER MED, V15, P4014, DOI 10.3892/etm.2018.5914
   Hussain A, 2020, OBES RES CLIN PRACT, V14, P295, DOI 10.1016/j.orcp.2020.07.002
   Immler R, 2018, EUR J CLIN INVEST, V48, P0, DOI 10.1111/eci.12964
   Jia HW, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021317
   Jiang CX, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/9580670
   Kamate M, 2018, NEUROL INDIA, V66, PS141, DOI 10.4103/0028-3886.226449
   Kim SJ, 2013, KOREAN J PHYSIOL PHA, V17, P505, DOI 10.4196/kjpp.2013.17.6.505
   Knigge A, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0120742
   Korakas E, 2020, AM J PHYSIOL-ENDOC M, V319, PE105, DOI 10.1152/ajpendo.00198.2020
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Kwoh CK, 2007, CELL MOL LIFE SCI, V64, P1739, DOI 10.1007/s00018-007-7053-7
   Lai F, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3620741
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Li J, 2016, ACUPUNCT MED, V34, P107, DOI 10.1136/acupmed-2014-010674
   Li J, 2019, INT J HYPERTENS, V2019, P0, DOI 10.1155/2019/8676490
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Liu JL, 2010, CHIN J INTEGR MED, V16, P315, DOI 10.1007/s11655-010-0503-3
   Liu WH, 2020, WORLD J ACUPUNCT-MOX, V30, P1, DOI 10.1016/j.wjam.2020.03.005
   Liu YM, 2010, J NEUROIMMUNOL, V220, P25, DOI 10.1016/j.jneuroim.2009.12.005
   Liu Y, 2019, COMPLEMENT THER CLIN, V34, P247, DOI 10.1016/j.ctcp.2018.12.012
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Luan YH, 2017, J CLIN ANESTH, V37, P123, DOI 10.1016/j.jclinane.2016.12.016
   Mohammed N, 2018, J COMPLEMENT INTEGR, V15, P0
   Moser JAS, 2019, INFLUENZA OTHER RESP, V13, P3, DOI 10.1111/irv.12618
   Napier BA, 2016, J EXP MED, V213, P2365, DOI 10.1084/jem.20160027
   Oliveira D, 2018, TOXINS, V10, P0, DOI 10.3390/toxins10060252
   Oliveros JC, 2015, VENNY. AN INTERACTIVE TOOL FOR COMPARING LISTS WITH VENNS DIAGRAMS, V0, P0
   Osei-Owusu P, 2019, NATURE, V574, P57, DOI 10.1038/s41586-019-1570-z
   Perera Supun, 2017, APPL NETW SCI, V2, P33, DOI 10.1007/s41109-017-0053-0
   PLUMMER JP, 1981, AM J CHINESE MED, V9, P1, DOI 10.1142/S0192415X81000020
   Pozzobon T, 2016, IMMUNOL LETT, V177, P6, DOI 10.1016/j.imlet.2016.06.006
   Ren JL, 2020, PHARMACOL RES, V155, P0, DOI 10.1016/j.phrs.2020.104743
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schulze-Topphoff U, 2009, NAT MED, V15, P788, DOI 10.1038/nm.1980
   Son YS, 2002, NEUROSCI LETT, V319, P45, DOI 10.1016/S0304-3940(01)02538-1
   Stelzer Gil, 2016, CURR PROTOC BIOINFORMATICS, V54, P0, DOI 10.1002/cpbi.5
   Sun N, 2019, ACUPUNCT MED, V37, P261, DOI 10.1136/acupmed-2017-011608
   Sunil D, 2017, CURR TOP MED CHEM, V17, P959, DOI 10.2174/1568026616666160927150839
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, PD380, DOI 10.1093/nar/gkv1277
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, PD433, DOI 10.1093/nar/gki005
   von Trott P, 2020, J PAIN SYMPTOM MANAG, V59, P327, DOI 10.1016/j.jpainsymman.2019.09.007
   Wang BL, 2020, AGING-US, V12, P6049, DOI 10.18632/aging.103000
   Wang LH, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5796381
   Wang W, 2019, IMMUNITY, V51, P1102, DOI 10.1016/j.immuni.2019.10.002
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Winden AWJOV, 2012, BREAST CANCER RES TR, V134, P1, DOI 10.1007/s10549-011-1907-2
   Wooller SK, 2017, BIOSCIENCE REP, V37, P0, DOI 10.1042/BSR20160180
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yan YQ, 2015, CELL, V160, P62, DOI 10.1016/j.cell.2014.11.047
   Ye H, 2016, CURR TOP MED CHEM, V16, P3646, DOI 10.2174/1568026616666160530181328
   Yoo YC, 2011, YONSEI MED J, V52, P1016, DOI 10.3349/ymj.2011.52.6.1016
   Zhang BZ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020701
   Zhang K, 2020, AM J EMERG MED, V38, P2238, DOI 10.1016/j.ajem.2020.03.046
   Zhang K, 2020, EUR J PREV CARDIOL, V27, P2063, DOI 10.1177/2047487319889721
   Zhang K, 2019, PANCREAS, V48, P1136, DOI 10.1097/MPA.0000000000001399
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang QS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000021039
   Zhang XF, 2018, J INTEGR MED-JIM, V16, P418, DOI 10.1016/j.joim.2018.10.003
   Zhang XF, 2014, J INTEGR MED-JIM, V12, P417, DOI 10.1016/S2095-4964(14)60040-6
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou J, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7061972
NR 90
TC 40
Z9 47
U1 3
U2 50
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1467-5463
EI 1477-4054
J9 BRIEF BIOINFORM
JI Brief. Bioinform.
PD SEP 15
PY 2021
VL 22
IS 5
BP 
EP 
DI 10.1093/bib/bbab110
EA APR 2021
PG 11
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA WK0YX
UT WOS:000709461800135
PM 33866350
DA 2026-01-16
ER

PT J
AU Saraswati, W
   Wardani, R
   Suhatno, S
   Hartono, P
   Imandiri, A
AF Saraswati, Wita
   Wardani, Ratih
   Suhatno, Suhatno
   Hartono, Pudjo
   Imandiri, Ario
TI The Effect of Electroacupuncture Therapy on Pain, Plasma β-Endorphin, and Quality
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
DE Cervical cancer; Electroacupuncture; Quality of life; VAS; β-endorphin
AB BACKGROUND: Pain is a major complaint in cancer patients and a global problem  that requires medical attention, including pain in cervical cancer. Although  pharmacotherapy has been used for the treatment of cancer pain, there are still  around 40% cannot be treated only with pharmacotherapy. OBJECTIVES: To determine  the effects of electroacupuncture (EA) on pain in stage III cervical cancer  patients. METHODS: Twenty-eight stage III cervical cancer patients were divided  into two groups (14 treatments and 14 controls) with randomized control trial  design. The treatment group received EA with a frequency of 2/20-25 Hz at points  of ST36, SP6, LI4 and LR3 for 30 minutes, while the control group did not receive  EA. Both groups were given paracetamol and codeine at the same dose. Assessment  was carried out by measuring pain scale (VAS), plasma β-endorphin levels, and  quality of life/QoL (EORTC QLQ-C30) before and after therapy. RESULTS: The  average reduction in VAS in the treatment group (2.71 ± 1.14) compared to the  control group (0.71 ± 1.33; p < 0.001), average increase in plasma β-endorphin  levels in the treatment group (88.57 ± 52.46 pg/ml) compared to the control group  (12.86 ± 56.76 pg/ml; p = 0.001), and in QoL, there were significant differences  in symptom improvement between the treatment and control groups in the domain of  fatigue, pain, insomnia and overall QoL (p < 0.05). CONCLUSION: Medical therapy  combined with EA decreased pain scale, increased plasma β-endorphin levels, and  improved the QoL for stage III cervical cancer patients.
C1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Traditional Healer, Faculty of Vocations, Universitas Airlangga, Surabaya, Indonesia.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD FEB 28
PY 2021
VL 14
IS 1
BP 4
EP 12
DI 10.51507/j.jams.2021.14.1.4
PG 8
WC Electroacupuncture; Female; Humans; Pain; Quality of Life; Uterine Cervical Neoplasms; therapy; beta-Endorphin
UT PubMed:35770596
PM 35770596
DA 2021-02-28
ER

PT J
AU Wang, YN
   Tao, SY
   Yu, ZY
   Luo, Y
   Li, Y
   Tang, J
   Chen, GH
   Shuai, RX
   Hu, XY
   Wu, P
   Lei, W
AF Wang, Yingni
   Tao, Siyu
   Yu, Zeyun
   Luo, Yun
   Li, Yuan
   Tang, Jie
   Chen, Guanhua
   Shuai, Rouxian
   Hu, Xinyue
   Wu, Ping
   Lei, Wei
TI Effect of Moxibustion on β-EP and Dyn Levels of Pain-Related Indicators in Patients with Rheumatoid Arthritis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
AB Background. Rheumatoid arthritis (RA) is a systemic immunodeficiency disease characterized by persistent synovial inflammation, pannus formation, and bone and cartilage destruction, resulting in joint malformations and function decline. Objective. The purpose of this study is to evaluate the effect of moxibustion on clinical symptoms and levels of pain-related indicators beta-endorphin (beta-EP) and dynorphin (Dyn) in patients with RA and to explore the potential anti-inflammatory and analgesic mechanisms of moxibustion in RA treatment. Methods. A total of 64 patients with RA who met the inclusion criteria were randomly and equally classified into the control and treatment groups. The control group received conventional treatment (oral methotrexate, folate, or leflunomide prescribed for a long time). The treatment group was treated with moxibustion at ST36 (Zusanli), BL23 (Shenshu), and Ashi points with respect to the control group. Patients' clinical symptoms and routine inspection indexes (rheumatoid factor [RF], erythrocyte sedimentation rate [ESR], and C-reactive protein [CRP]) were recorded before and after treatment. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), beta-EP, and Dyn were determined by enzyme-linked immunosorbent assay (ELISA). The software SPSS24.0 was used for statistical analysis. Results. (1) Compared with the pretreatment result, both of the two groups' clinical symptoms and routine inspection indexes (RF, ESR, and CRP) improved (P < 0.05), and the improvement of clinical symptoms in the treatment group outperformed that in the control group (P < 0.05). (2) TNF-alpha and IL-1 beta levels decreased significantly in the treatment group after treatment (P < 0.01), while no significant difference was observed in the control group (P > 0.05). (3) beta-EP and Dyn levels in the treatment group were significantly increased after treatment (P < 0.01, P < 0.01), but the control group showed no significant difference (P > 0.05, P > 0.05). It is worth mentioning that the serum TNF-alpha, IL-1 beta, beta-EP, and Dyn levels between the two groups were significantly different after 8 weeks of treatment (P < 0.05). (4) Differences in the serum beta-EP and Dyn levels in the patients of the treatment group were correlated with TNF-alpha and IL-1 beta levels after treatment, and the correlation was mainly negative (r < 0). Conclusion. Moxibustion can improve joint pain in patients with RA using conventional western medicine. One of the mechanisms may affect the serum beta-EP and Dyn levels by downregulating the inflammatory factors to play an anti-inflammatory and analgesic role.
C1 [Wang, Yingni; Tao, Siyu; Yu, Zeyun; Luo, Yun; Tang, Jie; Chen, Guanhua; Shuai, Rouxian; Hu, Xinyue; Wu, Ping; Lei, Wei] Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
   [Li, Yuan] Hosp Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine
RP Wu, P (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
EM wuping_33@163.com
FU National Natural Science Foundation of China [81373738]; Education Department of Sichuan Province [2017JY0016]
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Fan YP, 2014, STUDY ROLE LOCAL ATP, V0, P0
   Gong YY, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/4705247
   HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705
   Jiang YL, 2015, EXP THER MED, V9, P2344, DOI 10.3892/etm.2015.2407
   Jin S, 2019, CHIN J BASIC MED TCM, V25, P1404
   Li Y, 2019, CHIN. ARCH. TRADIT. CHIN. MED., V37, P142
   Liu Fei, 2006, ZHONGGUO ZHEN JIU, V26, P436
   Liu HR, 2010, WORLD J GASTROENTERO, V16, P4079, DOI 10.3748/wjg.v16.i32.4079
   Liu Zhidan, 2017, ZHONGGUO ZHEN JIU, V37, P1083, DOI 10.13703/j.0255-2930.2017.10.015
   Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3
   Mousa SA, 2003, ADV EXP MED BIOL, V521, P77
   Naqvi AA, 2019, J PAK MED ASSOC, V69, P389
   [任继刚 Ren Jigang], 2017, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V28, P3048
   Rittner HL, 2005, J LEUKOCYTE BIOL, V78, P1215, DOI 10.1189/jlb.0405223
   Sehgal N, 2011, PAIN PHYSICIAN, V14, P249
   Shen BY, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016413
   STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935
   STEIN C, 1989, J PHARMACOL EXP THER, V248, P1269
   唐玉芝, 2019, 时珍国医国药 LISHIZHEN MEDICINE AND MATERIA MEDICA RESEARCH, V30, P2187
   Wasserman AM, 2011, AM FAM PHYSICIAN, V84, P1245
   Zheng Bao-Zhu, 2013, ZHONGGUO ZHEN JIU, V33, P433
   Zhu GF, 2015, WORLD CHINESE MED, V10, P629
   Zhu WL, 2011, MODERN CHINESE CLIN, V18, P1
NR 25
TC 19
Z9 23
U1 1
U2 22
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD APR 5
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/6637554
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA RP3AP
UT WOS:000641605000001
PM 33884025
DA 2026-01-16
ER

PT J
AU Pysarevska, S
   Plotycya, S
   Dubenska, L
AF Pysarevska, Solomiya
   Plotycya, Serhiy
   Dubenska, Liliya
TI Voltammetry of local anesthetics: theoretical and practical aspects
SO CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY
LA English
DT Review
DE Chemically modified electrodes; electrochemical oxidation; local anesthetics; voltammetry
ID nanotube modified electrode; glassy-carbon electrodes; pharmaceutical-preparations; liquid-chromatography; paste electrode; sensitive determination; procaine hydrochloride; human serum; lidocaine; benzocaine
AB Local anesthetics (LAs) are widely used in anesthesiology, ophthalmology, and otolaryngology as well as for treatment of chronic and oncological pain. However, anesthetics can cause adverse effects up to lethal ones. In this work, we cited reviews on chromatographic and spectroscopic methods of local anesthetics determination published earlier, and the main purpose was to review the possibilities and advantages of voltammetric methods used for the LAs determination. The electrochemical behavior, mechanism of LAs transformation on the various working electrodes and analytical parameters of voltammetric methods used for their determination were reviewed in the work. Vast majority of these methods were developed for the most widely used anesthetics in medicine like benzocaine, lidocaine and procaine. Special attention was paid to possible mechanisms of electrochemical oxidation and in some cases reduction of LAs or their derivatives. Voltammetry is used for the determination of LAs in pharmaceutical formulations and in biological fluids. The analytical characteristics in terms of sensitivity, selectivity, reproducibility also were discussed in the article.
C1 [Pysarevska, Solomiya] Ivan Franko Natl Univ Lviv, Life Safety Dept, Doroshenko 41, UA-79000 Lvov, Ukraine.
   [Plotycya, Serhiy; Dubenska, Liliya] Ivan Franko Natl Univ Lviv, Analyt Chem Dept, Lvov, Ukraine.
   [Plotycya, Serhiy] State Sci Res Control Inst Vet Med Prod & Feed Ad, Lvov, Ukraine.
C3 Ministry of Education & Science of Ukraine; Ivan Franko National University Lviv; Ministry of Education & Science of Ukraine; Ivan Franko National University Lviv; Institute of Veterinary Medicinal Products & Feed Additives
RP Pysarevska, S (corresponding author), Ivan Franko Natl Univ Lviv, Life Safety Dept, Doroshenko 41, UA-79000 Lvov, Ukraine.
EM solomiya.pysarevska@lnu.edu.ua
CR Adamova EM, 2016, J ANAL CHEM+, V71, P1169, DOI 10.1134/S1061934816120029
   Ahmadi M, 2018, J CHROMATOGR B, V1095, P177, DOI 10.1016/j.jchromb.2018.07.036
   Al Nebaihi HM, 2017, PHARMACEUTICS, V9, P0, DOI 10.3390/pharmaceutics9040052
   Unknown -, 2016, THE INTERNATIONAL ENCYCLOPEDIA OF ADVERSE DRUG REACTIONS AND INTERACTIONS, V0, P0
   Attia AK, 2017, INSIGHTS ANAL ELECTR, V3, P1, DOI 10.21767/2470-9867.100018
   Baniceru M, 2004, J PHARMACEUT BIOMED, V35, P593, DOI 10.1016/j.jpba.2004.02.012
   Baniceru M, 2011, J PHARMACEUT BIOMED, V54, P1, DOI 10.1016/j.jpba.2010.07.013
   Becker Daniel E, 2012, ANESTH PROG, V59, P90, DOI 10.2344/0003-3006-59.2.90
   Bergamini MF, 2007, J PHARMACEUT BIOMED, V43, P315, DOI 10.1016/j.jpba.2006.06.001
   Cavalheiro ETG, 2012, BIOANAL. REV, V4, P31, DOI 10.1007/S12566-012-0027-8
   Dejmkova H, 2011, ELECTROANAL, V23, P662, DOI 10.1002/elan.201000646
   Demir E, 2018, ANAL SCI, V34, P771, DOI 10.2116/analsci.17P589
   Doménech-Carbó A, 2014, REV ANAL CHEM, V33, P173, DOI 10.1515/revac-2013-0027
   DONG S, 1984, J ELECTROCHEM SOC, V131, P813, DOI 10.1149/1.2115705
   Dong S, 1985, CHIN J APPL CHEM, V2, P34
   DONG SJ, 1985, ACTA CHIM SINICA, V43, P712
   Dubenska L, 2017, VISNYK LVIV U C, V58, P231
   Dubenska L, 2018, VOPROSY KHIM KHIM TE, V5, P12
   Dubenska LO, 2017, METHODS OBJECTS CHEM, V12, P61, DOI 10.17721/moca.2017.61-75
   Dubenska LO, 2016, 15 UKR POL S THEOR E, V0, P0
   de Lima RMF, 2018, ELECTROANAL, V30, P283, DOI 10.1002/elan.201700554
   Ganzberg Steven, 2010, DENT CLIN NORTH AM, V54, P601, DOI 10.1016/j.cden.2010.06.001
   Guan XW, 2016, ELECTROANAL, V28, P2007, DOI 10.1002/elan.201600007
   Guo W, 2013, INT J ELECTROCHEM SC, V8, P5369
   Gupta VK, 2011, ANAL BIOCHEM, V408, P179, DOI 10.1016/j.ab.2010.09.027
   Jadach M, 2012, ACTA POL PHARM, V69, P397
   2019, 1900, V8, V0, P0, DOI DOI 10.7598/cst2019.1527
   Kachoosangi RT, 2008, ELECTROANAL, V20, P2495, DOI 10.1002/elan.200804385
   Koehler A, 2005, J CHROMATOGR A, V1088, P126, DOI 10.1016/j.chroma.2005.03.071
   Komorsky-Lovric S, 2003, ELECTROANAL, V15, P544, DOI 10.1002/elan.200390067
   Li NB, 2003, ANAL SCI, V19, P1587, DOI 10.2116/analsci.19.1587
   Lirk P, 2018, ANESTH ANALG, V126, P1381, DOI 10.1213/ANE.0000000000002665
   Liu AL, 2012, J SOLID STATE ELECTR, V16, P1343, DOI 10.1007/s10008-011-1517-2
   Lu Q, 2008, BIOSENS BIOELECTRON, V24, P767, DOI 10.1016/j.bios.2008.06.056
   Lund Henning, 1991, ORGANIC ELECTROCHEMISTRY: AN INTRODUCTION AND A GUIDE, V0, P0
   Matos CRS, 2017, MICROCHIM ACTA, V184, P1755, DOI 10.1007/s00604-017-2165-8
   Mekassa B, 2017, SENS BIO-SENS RES, V16, P46, DOI 10.1016/j.sbsr.2017.11.002
   MELICHAREK M, 1970, J ELECTROANAL CHEM, V26, P201, DOI 10.1016/S0022-0728(70)80304-7
   Merkoçi A, 2006, MICROCHIM ACTA, V152, P157, DOI 10.1007/s00604-005-0439-z
   Muzyka K, 2019, ANAL METHODS-UK, V11, P397, DOI 10.1039/c8ay02197j
   Norouzi P, 2007, ANAL CHIM ACTA, V590, P74, DOI 10.1016/j.aca.2007.03.019
   Oliveira RTS, 2007, ELECTROANAL, V19, P1189, DOI 10.1002/elan.200603840
   Pinar PT, 2020, DIAM RELAT MATER, V101, P0, DOI 10.1016/j.diamond.2019.107649
   Plotycya S, 2016, VISNYK LVIV U C, V57, P203
   Plotycya S, 2018, INT J ELECTROCHEM, V2018, P0, DOI 10.1155/2018/1376231
   Plotycya S, 2016, ELECTROANAL, V28, P2575, DOI 10.1002/elan.201600134
   Pysarevska S, 2018, SENSOR ACTUAT B-CHEM, V270, P9, DOI 10.1016/j.snb.2018.05.012
   Rahbar N, 2015, JUNDISHAPUR J NAT PH, V10, P0
   Rahbar N, 2016, CHINESE CHEM LETT, V27, P837, DOI 10.1016/j.cclet.2016.04.017
   Reddy TM, 2006, CROAT CHEM ACTA, V79, P253
   Saad AS, 2019, J ELECTROCHEM SOC, V166, PB103, DOI 10.1149/2.0921902jes
   Siddiqui MR, 2017, ARAB J CHEM, V10, PS1409, DOI 10.1016/j.arabjc.2013.04.016
   Sivakumar V, 2014, J MATER SCI-MATER EL, V25, P1485, DOI 10.1007/s10854-014-1757-x
   Song J, 2011, MICROCHIM ACTA, V172, P117, DOI 10.1007/s00604-010-0470-6
   Sousa CP, 2019, CHEMELECTROCHEM, V6, P2350, DOI 10.1002/celc.201801742
   SUZUKI O, 2005, HDB PRACTICAL ANAL, V0, P0
   Taguchi J, 2003, J ELECTROANAL CHEM, V557, P91, DOI 10.1016/S0022-0728(03)00351-6
   Tan G, 2012, TURK J CHEM, V36, P593, DOI 10.3906/kim-1112-6
   Tonooka K, 2016, FORENSIC SCI INT, V265, P182, DOI 10.1016/j.forsciint.2016.02.044
   Uslu B, 2007, ANAL LETT, V40, P817, DOI 10.1080/00032710701242121
   Wang CY, 2002, J PHARMACEUT BIOMED, V30, P131, DOI 10.1016/S0731-7085(02)00204-2
   Wang J, 1988, ELECTROANALYTICAL TECHNIQUES IN CLINICAL CHEMISTRY AND LABORATORY MEDICINE, V0, P0
   Wang YR, 2008, CHINESE J ANAL CHEM, V36, P1011, DOI 10.1016/S1872-2040(08)60052-3
   Wei M, 2008, ELECTROANAL, V20, P137, DOI 10.1002/elan.200704024
   Wu KB, 2006, BIOELECTROCHEMISTRY, V68, P144, DOI 10.1016/j.bioelechem.2005.05.002
   Xu Q, 2009, CURR PHARM ANAL, V5, P144, DOI 10.2174/157341209788172889
   Yang GM, 2014, J MATER CHEM C, V2, P10201, DOI 10.1039/c4tc02039a
   Zhang JJ, 2018, MICROCHIM ACTA, V185, P0, DOI 10.1007/s00604-017-2551-2
   Zhang XH, 2010, MICROCHIM ACTA, V169, P153, DOI 10.1007/s00604-010-0330-4
   ZHOU JX, 1993, ELECTROANAL, V5, P295, DOI 10.1002/elan.1140050406
   Zyiatdinova GK, 2013, SERIES PROBLEMS ANAL, V0, P0
NR 71
TC 12
Z9 14
U1 0
U2 32
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8347
EI 1547-6510
J9 CRIT REV ANAL CHEM
JI Crit. Rev. Anal. Chem.
PD JUN 15
PY 2021
VL 51
IS 4
BP 339
EP 352
DI 10.1080/10408347.2020.1729691
EA FEB 2020
PG 14
WC Chemistry, Analytical
SC Chemistry
GA SW2EK
UT WOS:000516671400001
PM 32096424
DA 2026-01-16
ER

PT J
AU Li, HJ
   Schlaeger, JM
   Jang, MK
   Lin, YF
   Park, C
   Liu, TT
   Sun, M
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M.
   Jang, Min Kyeong
   Lin, Yufen
   Park, Chang
   Liu, Tingting
   Sun, Min
   Doorenbos, Ardith Z.
TI Acupuncture Improves Multiple Treatment-Related Symptoms in Breast Cancer Survivors: A Systematic Review and Meta-Analysis
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE acupuncture; breast cancer; meta-analysis; symptom; symptom cluster
ID inhibitor-related arthralgia; hot flashes; controlled-trial; double-blind; alternative medicine; sleep disturbances; vasomotor symptoms; hormone-therapy; placebo needle; dual-center
AB Introduction: Acupuncture has demonstrated effectiveness for symptom management among breast cancer survivors. This meta-analysis aims to evaluate the effect of acupuncture on treatment-related symptoms among breast cancer survivors. Methods: The authors searched PubMed, CINAHL, and EMBASE for relevant randomized clinical trials (RCTs) of acupuncture for managing treatment-related symptoms published in English through June 2021. They appraised the quality of each article using the Cochrane Collaboration Risk of Bias Criteria. The primary outcomes were pain, hot flashes, sleep disturbance, fatigue, depression, lymphedema, and neuropathy as individual symptoms. They also evaluated adverse events reported in acupuncture studies. Results: Of 26 selected trials (2055 patients), 20 (1709 patients) were included in the meta-analysis. Acupuncture was more effective than control groups in improving pain intensity [standardized mean difference (SMD) = -0.60, 95% confidence intervals (CI) -1.06 to -0.15], fatigue [SMD = -0.62, 95% CI -1.03 to -0.20], and hot flash severity [SMD = -0.52, 95% CI -0.82 to -0.22]. The subgroup analysis indicated that acupuncture showed trends but not significant effects on all the treatment-related symptoms compared with the sham acupuncture groups. Compared with waitlist control and usual care groups, the acupuncture groups showed significant reductions in pain intensity, fatigue, depression, hot flash severity, and neuropathy. No serious adverse events were reported related to acupuncture intervention. Mild adverse events (i.e., bruising, pain, swelling, skin infection, hematoma, headache, menstrual bleeding) were reported in 11 studies. Conclusion: This systematic review and meta-analysis suggest that acupuncture significantly reduces multiple treatment-related symptoms compared with the usual care or waitlist control group among breast cancer survivors. The safety of acupuncture was inadequately reported in the included studies. Based on the available data, acupuncture seems to be generally a safe treatment with some mild adverse events. These findings provide evidence-based recommendations for incorporating acupuncture into clinical breast cancer symptom management. Due to the high risk of bias and blinding issues in some RCTs, more rigorous trials are needed to confirm the efficacy of acupuncture in reducing multiple treatment-related symptoms among breast cancer survivors.
C1 [Li, Hongjin; Schlaeger, Judith M.] Univ Illinois, Coll Nursing, Dept Human Dev Nursing Sci, 845 S Damen Ave,MC 802, Chicago, IL 60612 USA.
   [Li, Hongjin; Jang, Min Kyeong; Doorenbos, Ardith Z.] Univ Illinois, Dept Canc Prevent & Control, Canc Ctr, Chicago, IL 60612 USA.
   [Jang, Min Kyeong; Doorenbos, Ardith Z.] Univ Illinois, Coll Nursing, Dept Biobehav Nursing Sci, Chicago, IL 60612 USA.
   [Lin, Yufen] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA.
   [Park, Chang] Univ Illinois, Coll Nursing, Dept Populat Hlth Nursing Sci, Chicago, IL 60612 USA.
   [Liu, Tingting] Univ Arkansas, Eleanor Mann Sch Nursing, Little Rock, AR 72204 USA.
   [Sun, Min] Univ Pittsburgh, Sch Med, Hillman Canc Ctr, Dept Hematol & Oncol, Pittsburgh, PA USA.
C3 University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Emory University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arkansas System; University of Arkansas Little Rock; University of Arkansas Fayetteville; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh
RP Li, HJ (corresponding author), Univ Illinois, Coll Nursing, Dept Human Dev Nursing Sci, 845 S Damen Ave,MC 802, Chicago, IL 60612 USA.
EM hongjin@uic.edu
FU National Institute of Nursing Research of the National Institutes of Health [K24NR015340]
CR Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bell Iris R, 2004, BMC COMPLEMENT ALTERN MED, V4, P1, DOI 10.1186/1472-6882-4-1
   Biglia N, 2012, EUR J CANCER CARE, V21, P485, DOI 10.1111/j.1365-2354.2011.01320.x
   Birch S, 2019, INTEGR MED RES, V8, P33, DOI 10.1016/j.imr.2018.07.005
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Chien TJ, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0180918
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Deng G, 2013, SUPPORT CARE CANCER, V21, P1735, DOI 10.1007/s00520-013-1720-z
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Haque R, 2016, JNCI-J NATL CANCER I, V108, P0, DOI 10.1093/jnci/djv337
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Higgins Julian P T, 2011, BMJ, V343, Pd5928, DOI 10.1136/bmj.d5928
   Hu H, 2016, EVIDENCE BASED RES M, V0, PP55, DOI 10.1007/978-981-10-2290-64
   Jia LB, 2012, CHIN J INTEGR MED, V18, P325, DOI 10.1007/s11655-011-0950-5
   Kim HJ, 2008, J PAIN SYMPTOM MANAG, V36, P468, DOI 10.1016/j.jpainsymman.2007.11.011
   Kim JEE, 2009, J PAIN SYMPTOM MANAG, V37, P715, DOI 10.1016/j.jpainsymman.2008.04.018
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li HJ, 2020, J PAIN SYMPTOM MANAG, V59, P233, DOI 10.1016/j.jpainsymman.2019.10.002
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lupo Molly, 2015, J ADV PRACT ONCOL, V6, P322, DOI 10.6004/jadpro.2015.6.4.3
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Moeyaert M, 2017, INT J SOC RES METHOD, V20, P559, DOI 10.1080/13645579.2016.1252189
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   National Center for Complementary and Integrative Health (NCCIH), 2020, NATL HLTH INTERVIEW, V0, P0
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Ng CG, 2015, HEALTH QUAL LIFE OUT, V13, P0, DOI 10.1186/s12955-015-0401-7
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Otte JL, 2011, CLIN NURSE SPEC, V25, P228, DOI 10.1097/NUR.0b013e318229950b
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   RevMan, 2014, REV MAN REVMAN COMP, V0, P0
   Salehi A, 2016, SUPPORT CARE CANCER, V24, P4895, DOI 10.1007/s00520-016-3345-5
   Salomon RE, 2020, NURS RES, V69, P133, DOI 10.1097/NNR.0000000000000412
   Siotos C, 2020, COCHRANE DB SYST REV, V0, P0
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Smith CA, 2014, ACUPUNCT MED, V32, P387, DOI 10.1136/acupmed-2014-010593
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Sullivan CW, 2018, J PAIN SYMPTOM MANAG, V55, P39, DOI 10.1016/j.jpainsymman.2017.08.008
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takakura N, 2018, ANAESTHESIA, V73, P258, DOI 10.1111/anae.14208
   Takakura N, 2013, ISRN PAIN, V0, P0, DOI DOI 10.1155/2013/825751
   Takakura N, 2011, ACUPUNCT MED, V29, P203, DOI 10.1136/aim.2010.002857
   Takakura Nobuari, 2007, BMC COMPLEMENT ALTERN MED, V7, P31, DOI 10.1186/1472-6882-7-31
   Tavel ME, 2014, AM J MED, V127, P484, DOI 10.1016/j.amjmed.2014.02.002
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Yoo TK, 2018, J BREAST CANCER, V21, P37, DOI 10.4048/jbc.2018.21.1.37
   Zhang XY, 2019, ACUPUNCT MED, V37, P16, DOI 10.1136/acupmed-2018-011668
   Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P190
   Zhu D, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/628907
   Zhuo Lian-Shi, 2011, ZHONGGUO ZHEN JIU, V31, P75
NR 67
TC 30
Z9 36
U1 2
U2 29
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD DEC 1
PY 2021
VL 27
IS 12
BP 1084
EP 1097
DI 10.1089/acm.2021.0133
EA AUG 2021
PG 14
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA XL2VJ
UT WOS:000690379700001
PM 34449251
DA 2026-01-16
ER

PT J
AU Kuang, R
   Xiong, G
   Lv, W
   Zhao, Y
   Yu, M
   Jiang, J
AF Kuang, Renqing
   Xiong, Guojiang
   Lv, Wei
   Zhao, Yun
   Yu, Min
   Jiang, Jiawang
TI Efficacy and safety of acupuncture combined with analgesics on lung cancer pain:
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Lung cancer (LC) is the malignant tumor with the highest incidence in  the world, and treatment methods include surgery, radiotherapy, chemotherapy, and  immunotherapy. Cancer pain is a common symptom in patients with LC, and the  clinical treatment is to relieve it with analgesics. Acupuncture can relieve  cancer pain. This study aims to systematically study the efficacy and safety of  acupuncture combined with analgesics on cancer pain in patients with LC. METHODS:  From the beginning to April 2021, search Medline, Embase, Cochrane Central  Controlled Trials Register (Central), China National Knowledge Infrastructure  (CNKI), Wanfang Database, China Biomedical Literature Database (CBM), and Chinese  Science Journal Database (VIP database). Search the international clinical trial  registration platform and the Chinese clinical trial registration platform to  find ongoing or unpublished trials. The main outcome indicator is the total  effective rate of analgesia, and the secondary outcome indicator is pain  intensity score and adverse reactions. The RevMan 5.4 software will be used for  statistical analysis. RESULTS: This study will provide the latest evidence for  acupuncture combined with analgesics to relieve LC pain. CONCLUSION: The  conclusion of this study is to evaluate the effectiveness and safety of  acupuncture combined with analgesics in alleviating LC pain. INPLASY REGISTRATION  NUMBER: INPLASY202150051.
C1 Jiangxi University of Chinese Medicine.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
   The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China.
   Jiangxi University of Chinese Medicine.
   Jiangxi University of Chinese Medicine.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD JUN 12
PY 2021
VL 100
IS 23
BP e26225
EP e26225
DI 10.1097/MD.0000000000026225
PG 1
WC Acupuncture Therapy; methods; Analgesics; standards; Cancer Pain; drug therapy; Clinical Protocols; Combined Modality Therapy; methods; Humans; Lung Neoplasms; complications; Pain Management; methods; Patient Safety; standards; Treatment Outcome
UT PubMed:34115008
PM 34115008
DA 2021-06-12
ER

PT J
AU Lyu, ZX
   Guo, YM
   Gong, YA
   Fan, W
   Dou, BM
   Li, NC
   Wang, SJ
   Xu, Y
   Liu, YY
   Chen, B
   Guo, Y
   Xu, ZF
   Lin, XW
AF Lyu, Zhongxi
   Guo, Yongming
   Gong, Yinan
   Fan, Wen
   Dou, Baomin
   Li, Ningcen
   Wang, Shenjun
   Xu, Yuan
   Liu, Yangyang
   Chen, Bo
   Guo, Yi
   Xu, Zhifang
   Lin, Xiaowei
TI The Role of Neuroglial Crosstalk and Synaptic Plasticity-Mediated Central Sensitization in Acupuncture Analgesia
SO NEURAL PLASTICITY
LA English
DT Review
ID spinal-cord astrocytes; relieves neuropathic pain; peripheral-nerve injury; bone cancer pain; inflammatory pain; dorsal-horn; electroacupuncture analgesia; glutamate transporters; mechanical allodynia; receptor antagonists
AB Although pain is regarded as a global public health priority, analgesic therapy remains a significant challenge. Pain is a hypersensitivity state caused by peripheral and central sensitization, with the latter considered the culprit for chronic pain. This study summarizes the pathogenesis of central sensitization from the perspective of neuroglial crosstalk and synaptic plasticity and underlines the related analgesic mechanisms of acupuncture. Central sensitization is modulated by the neurotransmitters and neuropeptides involved in the ascending excitatory pathway and the descending pain modulatory system. Acupuncture analgesia is associated with downregulating glutamate in the ascending excitatory pathway and upregulating opioids, ?-aminobutyric acid, norepinephrine, and 5-hydroxytryptamine in the descending pain modulatory system. Furthermore, it is increasingly appreciated that neurotransmitters, cytokines, and chemokines are implicated in neuroglial crosstalk and associated plasticity, thus contributing to central sensitization. Acupuncture produces its analgesic action by inhibiting cytokines, such as interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha, and upregulating interleukin-10, as well as modulating chemokines and their receptors such as CX3CL1/CX3CR1, CXCL12/CXCR4, CCL2/CCR2, and CXCL1/CXCR2. These factors are regulated by acupuncture through the activation of multiple signaling pathways, including mitogen-activated protein kinase signaling (e.g., the p38, extracellular signal-regulated kinases, and c-Jun-N-terminal kinase pathways), which contribute to the activation of nociceptive neurons. However, the responses of chemokines to acupuncture vary among the types of pain models, acupuncture methods, and stimulation parameters. Thus, the exact mechanisms require future clarification. Taken together, inhibition of central sensitization modulated by neuroglial plasticity is central in acupuncture analgesia, providing a novel insight for the clinical application of acupuncture analgesia.
C1 [Lyu, Zhongxi; Guo, Yongming; Gong, Yinan; Fan, Wen; Dou, Baomin; Li, Ningcen; Wang, Shenjun; Xu, Yuan; Liu, Yangyang; Chen, Bo; Guo, Yi; Xu, Zhifang; Lin, Xiaowei] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin 301617, Peoples R China.
   [Lyu, Zhongxi; Guo, Yongming; Wang, Shenjun; Xu, Yuan; Liu, Yangyang; Chen, Bo; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, Tianjin 301617, Peoples R China.
   [Lyu, Zhongxi; Guo, Yongming; Wang, Shenjun; Xu, Yuan; Liu, Yangyang; Chen, Bo; Guo, Yi; Xu, Zhifang; Lin, Xiaowei] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin 300381, Peoples R China.
   [Fan, Wen] Suzuka Univ Med Sci, Suzuka 5100293, Japan.
   [Guo, Yi; Lin, Xiaowei] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Tianjin 301617, Peoples R China.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Suzuka University of Medical Science; Tianjin University of Traditional Chinese Medicine
RP Xu, ZF; Lin, XW (corresponding author), Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin 301617, Peoples R China.; Xu, ZF (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, Tianjin 301617, Peoples R China.; Xu, ZF; Lin, XW (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin 300381, Peoples R China.; Lin, XW (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Tianjin 301617, Peoples R China.
EM 1025117807@qq.com; guoymxr@163.com; 1457907206@qq.com; 452181040@qq.com; 1624528149@qq.com; 517654179@qq.com; shenjunwang@163.com; xuyuan_87@sina.com; lyy02211@163.com; tjutcmchenbo@163.com; guoyi_168@163.com; xuzhifangmsn@hotmail.com; linxiaoweiwqhz@163.com
FU National Key R&D Program of China [2019YFC1709003]; National Natural Science Foundation of China (NSFC) [81704146, 81873369, 81873368]; Natural Science Foundation of Tianjin [20JCQNJC00280]
CR Abou El Hassan M, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0126466
   Ali U, 2020, BIOMED PHARMACOTHER, V125, P0, DOI 10.1016/j.biopha.2020.109898
   Baral P, 2019, NAT REV IMMUNOL, V19, P433, DOI 10.1038/s41577-019-0147-2
   Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028
   Boadas-Vaello P, 2016, SPINAL CORD, V54, P330, DOI 10.1038/sc.2015.225
   Cao DL, 2014, EXP NEUROL, V261, P328, DOI 10.1016/j.expneurol.2014.05.014
   Cao J, 2015, SPINAL CORD, V53, P92, DOI 10.1038/sc.2014.188
   Cao L, 2018, NEUROSCIENCE, V372, P225, DOI 10.1016/j.neuroscience.2017.12.048
   [陈军 Chen Jun], 2014, 中国疼痛医学杂志 CHINESE JOURNAL OF PAIN MEDICINE, V20, P70
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Choi DC, 2012, EXP NEUROL, V236, P268, DOI 10.1016/j.expneurol.2012.05.014
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Clark AK, 2007, P NATL ACAD SCI USA, V104, P10655, DOI 10.1073/pnas.0610811104
   Clark AK, 2014, FRONT CELL NEUROSCI, V8, P0, DOI 10.3389/fncel.2014.00121
   Cole LJ, 2018, PAIN MED, V19, P2177, DOI 10.1093/pm/pnx301
   Crofford Leslie J, 2015, TRANS AM CLIN CLIMATOL ASSOC, V126, P167
   Dai WJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/8413576
   Dawes JM, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-57
   de Miguel Marcia, 2014, INFLAMMATION & ALLERGY DRUG TARGETS, V13, P339, DOI 10.2174/1871528114666150114170004
   Deval E, 2008, EMBO J, V27, P3047, DOI 10.1038/emboj.2008.213
   Doolen S, 2012, MOL PAIN, V8, P0, DOI 10.1186/1744-8069-8-56
   Dworkin RH, 2010, MAYO CLIN PROC, V85, PS3, DOI 10.4065/mcp.2009.0649
   Fang JQ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-285
   Fang JQ, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-13
   Finnerup NB, 2019, NEW ENGL J MED, V380, P2440, DOI 10.1056/NEJMra1807061
   François A, 2017, NEURON, V93, P822, DOI 10.1016/j.neuron.2017.01.008
   Gao YH, 2017, PURINERG SIGNAL, V13, P215, DOI 10.1007/s11302-016-9552-1
   Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002
   Gao YJ, 2009, J NEUROSCI, V29, P4096, DOI 10.1523/JNEUROSCI.3623-08.2009
   Gosselin RD, 2005, J NEUROCHEM, V95, P1023, DOI 10.1111/j.1471-4159.2005.03431.x
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guo W, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-10251-y
   Guo Y, 2017, CHIN J INTEGR MED, V23, P864, DOI 10.1007/s11655-016-2750-4
   Han KY, 2019, PAIN, V160, P712, DOI 10.1097/j.pain.0000000000001450
   Han P, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0129576
   Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009
   Hsu HC, 2019, ACUPUNCT MED, V37, P356, DOI 10.1136/acupmed-2017-011469
   Hu JH, 2012, BRAIN RES, V1465, P1, DOI 10.1016/j.brainres.2012.05.020
   Hu ML, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7531060
   Hu QM, 2020, J PAIN, V21, P1060, DOI 10.1016/j.jpain.2020.01.007
   Huang CP, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6784735
   Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3
   Jayaraj ND, 2018, J CLIN INVEST, V128, P2205, DOI 10.1172/JCI92117
   Ji RR, 2018, ANESTHESIOLOGY, V129, P343, DOI 10.1097/ALN.0000000000002130
   Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334
   Ji RR, 2013, PAIN, V154, PS10, DOI 10.1016/j.pain.2013.06.022
   Jiang SW, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/8041820
   Kim HN, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/643973
   Kim JH, 2011, J NEUROPHYSIOL, V105, P2050, DOI 10.1152/jn.00853.2010
   Kingwell K, 2016, NAT REV DRUG DISCOV, V15, P677, DOI 10.1038/nrd.2016.204
   Kissiwaa SA, 2020, BRIT J PHARMACOL, V177, P420, DOI 10.1111/bph.14877
   Kumar A, 2018, PHARMACOL REP, V70, P206, DOI 10.1016/j.pharep.2017.09.009
   Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012
   Lau YM, 2014, NEUROPATH APPL NEURO, V40, P452, DOI 10.1111/nan.12078
   Lee JY, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0073948
   Lee KM, 2010, EUR J PAIN, V14, P0, DOI 10.1016/j.ejpain.2009.10.017
   Lee YS, 2013, MOL MED REP, V8, P1130, DOI 10.3892/mmr.2013.1633
   Li AH, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq016
   Li Chao, 2018, SHENGLI XUEBAO, V70, P237, DOI 10.13294/j.aps.2018.0035
   Li HP, 2019, J PAIN RES, V12, P1259, DOI 10.2147/JPR.S191900
   Li J, 2017, ALCOHOL CLIN EXP RES, V41, P637, DOI 10.1111/acer.13332
   Li SS, 2018, MOL MED REP, V17, P6961, DOI 10.3892/mmr.2018.8766
   Li Y, 2012, J NEUROCHEM, V121, P662, DOI 10.1111/j.1471-4159.2012.07717.x
   Li YH, 2019, J PAIN RES, V12, P2663, DOI 10.2147/JPR.S205987
   Liang Y, 2016, ACUPUNCT MED, V34, P40, DOI 10.1136/acupmed-2015-010773
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Lisman J, 2012, NAT REV NEUROSCI, V13, P169, DOI 10.1038/nrn3192
   Liu L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1846296
   Liu Q, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919866529
   Loggia ML, 2015, BRAIN, V138, P604, DOI 10.1093/brain/awu377
   Love PE, 2011, NAT REV IMMUNOL, V11, P469, DOI 10.1038/nri2989
   Luo X, 2016, MOL PAIN, V12, P0, DOI 10.1177/1744806916636385
   Martin BI, 2008, JAMA-J AM MED ASSOC, V299, P656, DOI 10.1001/jama.299.6.656
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Miller RJ, 2008, J NEUROSCI, V28, P11792, DOI 10.1523/JNEUROSCI.3588-08.2008
   Milligan E, 2005, EUR J NEUROSCI, V22, P2775, DOI 10.1111/j.1460-9568.2005.04470.x
   Neugebauer V, 2002, PAIN, V98, P1, DOI 10.1016/S0304-3959(02)00140-9
   Nutt D, 2006, J CLIN SLEEP MED, V2, P0
   PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0
   Pei P, 2019, ACUPUNCT MED, V37, P47, DOI 10.1136/acupmed-2017-011410
   Pinho-Ribeiro FA, 2017, TRENDS IMMUNOL, V38, P5, DOI 10.1016/j.it.2016.10.001
   Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007
   Pu L, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/818451
   Qiao YY, 2012, NEURAL REGEN RES, V7, P1630, DOI 10.3969/j.issn.1673-5374.2012.21.005
   Rahman W, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-45
   Rajkowska G, 2007, CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, V6, P219, DOI 10.2174/187152707780619326
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Ren K, 2010, NAT MED, V16, P1267, DOI 10.1038/nm.2234
   Rodríguez-Muñoz M, 2012, NEUROPSYCHOPHARMACOL, V37, P338, DOI 10.1038/npp.2011.155
   Romero SSB, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21072628
   Savarin-Vuaillat C, 2007, NEUROTHERAPEUTICS, V4, P590, DOI 10.1016/j.nurt.2007.07.004
   Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021
   Shao XM, 2016, NEURAL PLAST, V2016, P0, DOI 10.1155/2016/5320641
   Silva RL, 2017, NEUROBIOL DIS, V105, P109, DOI 10.1016/j.nbd.2017.06.001
   Somers DL, 2009, J PAIN, V10, P221, DOI 10.1016/j.jpain.2008.08.008
   Spicarova D, 2014, NEUROPHARMACOLOGY, V81, P75, DOI 10.1016/j.neuropharm.2014.01.041
   Sung BK, 2003, J NEUROSCI, V23, P2899
   Swartjes M, 2011, ANESTHESIOLOGY, V115, P165, DOI 10.1097/ALN.0b013e31821bdb9b
   Talbot S, 2016, ANNU REV IMMUNOL, V34, P421, DOI 10.1146/annurev-immunol-041015-055340
   Tamano R, 2016, NEUROSCI LETT, V615, P78, DOI 10.1016/j.neulet.2016.01.025
   Thacker MA, 2007, ANESTH ANALG, V105, P838, DOI 10.1213/01.ane.0000275190.42912.37
   Todd AJ, 2010, NAT REV NEUROSCI, V11, P823, DOI 10.1038/nrn2947
   Tong CK, 2008, MOL PAIN, V4, P0, DOI 10.1186/1744-8069-4-44
   da Silva JRT, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/205316
   Tu WZ, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/642081
   Tu WZ, 2018, INT J MOL MED, V41, P3307
   Ultenius C, 2006, NEUROSCI LETT, V399, P85, DOI 10.1016/j.neulet.2006.01.018
   Verret M, 2019, SYST REV-LONDON, V8, P0, DOI 10.1186/s13643-018-0906-3
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vincent A, 2015, BMJ OPEN, V5, P0, DOI 10.1136/bmjopen-2014-006681
   Wang JY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2134-8
   Wang JY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8403064
   Wang SL, 2012, EUR J NEUROSCI, V36, P2293, DOI 10.1111/j.1460-9568.2012.08142.x
   Weng ZJ, 2015, PURINERG SIGNAL, V11, P321, DOI 10.1007/s11302-015-9447-6
   Willis WD Jr, 1999, EXP BRAIN RES, V124, P395, DOI 10.1007/s002210050637
   Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765
   Woolf CJ, 2007, NEURON, V55, P353, DOI 10.1016/j.neuron.2007.07.016
   Woolf CJ, 2011, PAIN, V152, PS2, DOI 10.1016/j.pain.2010.09.030
   Wu Justin Cy, 2010, J NEUROGASTROENTEROL MOTIL, V16, P306, DOI 10.5056/jnm.2010.16.3.306
   Wu YY, 2017, EXP THER MED, V14, P107, DOI 10.3892/etm.2017.4479
   Xu J, 2014, J NEUROINFLAMM, V11, P0, DOI 10.1186/1742-2094-11-38
   Yan XS, 2013, J BIOL CHEM, V288, P30544, DOI 10.1074/jbc.M113.495465
   Yowtak J, 2013, PAIN, V154, P2469, DOI 10.1016/j.pain.2013.07.024
   Yu ML, 2020, INFLAMMATION, V43, P1233, DOI 10.1007/s10753-020-01203-2
   Yuan XC, 2018, FRONT MOL NEUROSCI, V11, P0, DOI 10.3389/fnmol.2018.00112
   Zeng J, 2016, NEUROSCI LETT, V620, P38, DOI 10.1016/j.neulet.2016.03.041
   Zhang HM, 2013, J NEUROPHYSIOL, V110, P1663, DOI 10.1152/jn.01088.2012
   Zhang Q, 2019, J ALTERN COMPLEM MED, V25, P869, DOI 10.1089/acm.2019.29077.jjw
   Zhang SY, 2014, NEURAL REGEN RES, V9, P1365, DOI 10.4103/1673-5374.137589
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhang Y, 2012, BRIT J ANAESTH, V109, P245, DOI 10.1093/bja/aes136
   Zhang Y, 2011, NEUROCHEM RES, V36, P1785, DOI 10.1007/s11064-011-0495-1
   Zhang Y, 2011, BRAIN RES, V1395, P38, DOI 10.1016/j.brainres.2011.04.037
   Zhang ZJ, 2013, PAIN, V154, P2185, DOI 10.1016/j.pain.2013.07.002
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhao WS, 2019, CHIN J INTEGR MED, V25, P462, DOI 10.1007/s11655-018-3057-4
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zhou J, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7061972
   Zhou LJ, 2008, EXP NEUROL, V212, P507, DOI 10.1016/j.expneurol.2008.04.034
   Zhou YQ, 2015, CURR PHARM DESIGN, V21, P5029, DOI 10.2174/1381612821666150831141931
   Zhu H, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00484
   Zhuang ZY, 2007, BRAIN BEHAV IMMUN, V21, P642, DOI 10.1016/j.bbi.2006.11.003
   Zhuo M, 2008, TRENDS NEUROSCI, V31, P199, DOI 10.1016/j.tins.2008.01.003
   Zhuo M, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917699212
   Zhuo M, 2011, MOL BRAIN, V4, P0, DOI 10.1186/1756-6606-4-31
NR 146
TC 48
Z9 62
U1 7
U2 55
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-5904
EI 1687-5443
J9 NEURAL PLAST
JI Neural. Plast.
PD JAN 18
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/8881557
PG 18
WC Neurosciences
SC Neurosciences & Neurology
GA QE4NJ
UT WOS:000616183900001
PM 33531894
DA 2026-01-16
ER

PT J
AU Zhang, Y
   Sun, Y
   Li, D
   Liu, X
   Fang, C
   Yang, C
   Luo, T
   Lu, H
   Li, H
   Zhang, H
   Liang, Q
   Wu, J
   Huang, L
   Xu, R
   Ren, L
   Chen, Q
AF Zhang, Yuzhu
   Sun, Yang
   Li, Dongmei
   Liu, Xiaoyuan
   Fang, Chen
   Yang, Chunmin
   Luo, Tianyu
   Lu, Hai
   Li, Huachao
   Zhang, Hongyan
   Liang, Qianyi
   Wu, Jiahua
   Huang, Limei
   Xu, Rui
   Ren, Liping
   Chen, Qianjun
TI Acupuncture for Breast Cancer: A Systematic Review and Meta-Analysis of
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture; breast cancer; meta-analysis; patient-reported outcome; systematic review
AB ABSTRACT: The present systematic review and meta-analysis was undertaken to  evaluate the effects of acupuncture in women with breast cancer (BC), focusing on  patient-reported outcomes (PROs). METHODS: A comprehensive literature search was  carried out for randomized controlled trials (RCTs) reporting PROs in BC patients  with treatment-related symptoms after undergoing acupuncture for at least four  weeks. Literature screening, data extraction, and risk bias assessment were  independently carried out by two researchers. RESULTS: Out of the 2, 524  identified studies, 29 studies representing 33 articles were included in this  meta-analysis. At the end of treatment (EOT), the acupuncture patients' quality  of life (QoL) was measured by the QLQ-C30 QoL subscale, the Functional Assessment  of Cancer Therapy-Endocrine Symptoms (FACT-ES), the Functional Assessment of  Cancer Therapy-General/Breast (FACT-G/B), and the Menopause-Specific Quality of  Life Questionnaire (MENQOL), which depicted a significant improvement. The use of  acupuncture in BC patients lead to a considerable reduction in the scores of all  subscales of the Brief Pain Inventory-Short Form (BPI-SF) and Visual Analog Scale  (VAS) measuring pain. Moreover, patients treated with acupuncture were more  likely to experience improvements in hot flashes scores, fatigue, sleep  disturbance, and anxiety compared to those in the control group, while the  improvements in depression were comparable across both groups. Long-term  follow-up results were similar to the EOT results. CONCLUSIONS: Current evidence  suggests that acupuncture might improve BC treatment-related symptoms measured  with PROs including QoL, pain, fatigue, hot flashes, sleep disturbance and  anxiety. However, a number of included studies report limited amounts of certain  subgroup settings, thus more rigorous, well-designed and larger RCTs are needed  to confirm our results.
C1 Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Department, Zhuhai Hospital of Guangdong Province Hospital of Chinese Medicine, Zhuhai, China.
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of 
   Breast Clinic Center, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
   Breast Clinic Center, The Second Affiliated Hospital of Guangzhou University of
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD JUN 29
PY 2021
VL 11
IS 
BP 646315
EP 646315
DI 10.3389/fonc.2021.646315
PG 0
UT PubMed:34178633
PM 34178633
DA 2021-06-29
ER

PT J
AU Huang, L
   Zhao, YQ
   Xiang, MH
AF Huang, Li
   Zhao, Yanqing
   Xiang, Minhong
TI Knowledge Mapping of Acupuncture for Cancer Pain: A Scientometric Analysis (2000-2019)
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE knowledge mapping; acupuncture; cancer pain; CiteSpace; scientometric analysis
ID induced peripheral neuropathy; chemotherapy-induced nausea; stress reduction program; quality-of-life; breast-cancer; alternative medicine; controlled-trial; joint symptoms; clinical-trial; management
AB Objective: This study aimed to demonstrate the state of the present situation and trends concerning the global use of acupuncture for cancer pain in the past 20 years. Methods: Searched the Web of Science database from 2000 to 2019 related to acupuncture for cancer pain, and then used CiteSpace to conduct scientometric analysis to acquire the knowledge mapping. Results: Yearly output has increased year by year, and the growth rate has become faster after 2012. According to the cluster analysis of institutions, authors, cited references, and keywords, 4, 4, 15, and 14 categories were obtained, respectively. The most productive countries, institutions, and authors are the USA, Mem Sloan Kettering Cancer Center, and Mao JJ, whose frequencies are 196, 24, and 17, respectively. However, the most important of them are Australia, Univ. Maryland, and Bao T, owing to their highest centrality, they are 0.90, 0.21, and 0.09 separately. Moreover, cited references that contributed to the most cocitations are Crew KD (2010), however, the most key cited reference is Roscoe JA (2003). Keywords such as acupuncture, pain, breast cancer, palliative care, and quality of life are the most frequently used. But auricular acupuncture is the crucial keyword. In the cluster analysis of institutions, authors, cited references, and keywords, the more convincing research categories are multiple myeloma, placebo effect, neck malignancies, and early breast cancer, with S values of 0.990, 0.991, 0.990, and 0.923, respectively. Therefore, they can be regarded as research hotspots in this field. Conclusion: Based on the scientometric analysis in the past 20 years, the knowledge mapping of the country, institution, author, cited reference, and the keyword is gained, which has an important guiding significance for quickly and accurately positioning the trend in this field.
C1 [Huang, Li; Zhao, Yanqing; Xiang, Minhong] Shanghai Univ Tradit Chinese Med, Putuo Hosp, 164 Lanxi Rd, Shanghai 200062, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine
RP Xiang, MH (corresponding author), Shanghai Univ Tradit Chinese Med, Putuo Hosp, 164 Lanxi Rd, Shanghai 200062, Peoples R China.
EM xiangminhong1977@126.com
FU National Natural Science Foundation of China [82,074,495]; Shanghai University of Chinese Medicine [2019WK118]; Scientific Research Project of Putuo Hospital, Shanghai University of Traditional Chinese Medicine [2020304A]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2006, COCHRANE DATABASE SY, V0, P0
   Unknown -, 2016, INT J ENV RES PUBLIC, V0, P0
   Badenhorst A, 2016, J GLOB HEALTH, V6, P0, DOI 10.7189/jogh.06.010504
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Barrera ME, 2002, PSYCHO-ONCOL, V11, P379, DOI 10.1002/pon.589
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Bornmann L, 2012, J INFORMETR, V6, P285, DOI 10.1016/j.joi.2011.11.001
   Buffart LM, 2012, BMC CANCER, V12, P0, DOI 10.1186/1471-2407-12-559
   Can G, 2019, SEMIN ONCOL NURS, V35, P315, DOI 10.1016/j.soncn.2019.04.014
   Carlson LE, 2003, PSYCHOSOM MED, V65, P571, DOI 10.1097/01.PSY.0000074003.35911.41
   Carlson LE, 2001, SUPPORT CARE CANCER, V9, P112, DOI 10.1007/s005200000206
   Chen CM, 2014, EXPERT OPIN BIOL TH, V14, P1295, DOI 10.1517/14712598.2014.920813
   Chen CM, 2006, J AM SOC INF SCI TEC, V57, P359, DOI 10.1002/asi.20317
   Chen CM, 2004, P NATL ACAD SCI USA, V101, P5303, DOI 10.1073/pnas.0307513100
   Chen Q, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019659
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cho HJ, 2010, J ETHNOPHARMACOL, V127, P662, DOI 10.1016/j.jep.2009.12.007
   Cho JH, 2008, J ALTERN COMPLEM MED, V14, P523, DOI 10.1089/acm.2007.0793
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Crew KD, 2007, J CLIN ONCOL, V25, P3877, DOI 10.1200/JCO.2007.10.7573
   Crew KD, 2007, J CLIN ONCOL, V25, P1089, DOI 10.1200/JCO.2006.09.1710
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   DeMoss P, 2018, FRONT NEUROL, V9, P0, DOI 10.3389/fneur.2018.00219
   Deng G, 2008, J THORAC CARDIOV SUR, V136, P1464, DOI 10.1016/j.jtcvs.2008.07.053
   Dodd MJ, 2000, ORAL SURG ORAL MED O, V90, P39, DOI 10.1067/moe.2000.105713
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Guo SM, 2019, WORLD NEUROSURG, V132, PE246, DOI 10.1016/j.wneu.2019.08.191
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Ho CM, 1996, ACTA ANAESTH SCAND, V40, P372, DOI 10.1111/j.1399-6576.1996.tb04448.x
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Liossi C, 1999, INT J CLIN EXP HYP, V47, P104, DOI 10.1080/00207149908410025
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu W, 2005, MED PHYS, V32, P890, DOI 10.1118/1.1870152
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Machado-Silva A, 2019, BMC PUBLIC HEALTH, V19, P0, DOI 10.1186/s12889-019-6842-x
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mao JJ, 2012, J AM BOARD FAM MED, V25, P323, DOI 10.3122/jabfm.2012.03.110165
   Meghani SH, 2014, J CLIN ONCOL, V32, P2773, DOI 10.1200/JCO.2013.54.7992
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Miao Y, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000006924
   Molassiotis A, 2005, ANN ONCOL, V16, P655, DOI 10.1093/annonc/mdi110
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ng JY, 2021, PAIN PRACT, V21, P454, DOI 10.1111/papr.12964
   Noble S, 2013, LUNG CANCER, V79, PS39, DOI 10.1016/S0169-5002(13)70114-4
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Olson K, 2003, J PAIN SYMPTOM MANAG, V26, P990, DOI 10.1016/S0885-3924(03)00334-8
   Paice JA, 2011, CA-CANCER J CLIN, V61, P157, DOI 10.3322/caac.20112
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004
   Streitberger K, 2003, CLIN CANCER RES, V9, P2538
   Su CF, 2018, J INTEGR MED-JIM, V16, P208, DOI 10.1016/j.joim.2018.04.003
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Vinjamury SP, 2013, CHIN MED-UK, V8, P0, DOI 10.1186/1749-8546-8-15
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Wang SQ, 2020, MED SCI MONITOR, V26, P0, DOI 10.12659/MSM.920795
   Wang SM, 2002, ANESTHESIOLOGY, V97, P359, DOI 10.1097/00000542-200208000-00012
   Xie L, 2020, WORLD NEUROSURG, V137, P435, DOI 10.1016/j.wneu.2020.01.171
   Yin M, 2020, GLOBAL SPINE J, V0, P0
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zhao YQ, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000012643
   Zhou SM, 2019, PEERJ, V7, P0, DOI 10.7717/peerj.8145
NR 82
TC 9
Z9 11
U1 1
U2 32
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2021
VL 14
IS 
BP 343
EP 358
DI 10.2147/JPR.S292657
PG 16
WC Clinical Neurology
SC Neurosciences & Neurology
GA QI1PN
UT WOS:000618745500001
PM 33574698
DA 2026-01-16
ER

PT J
AU Kuang, RQ
   Xiong, GJ
   Lv, W
   Zhao, Y
   Yu, M
   Jiang, JW
AF Kuang, Renqing
   Xiong, Guojiang
   Lv, Wei
   Zhao, Yun
   Yu, Min
   Jiang, Jiawang
TI Efficacy and safety of acupuncture combined with analgesics on lung cancer pain A protocol for systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE acupuncture; lung cancer; pain; protocol; systematic review
ID symptom prevalence; electroacupuncture; distress; time
AB Background: Lung cancer (LC) is the malignant tumor with the highest incidence in the world, and treatment methods include surgery, radiotherapy, chemotherapy, and immunotherapy. Cancer pain is a common symptom in patients with LC, and the clinical treatment is to relieve it with analgesics. Acupuncture can relieve cancer pain. This study aims to systematically study the efficacy and safety of acupuncture combined with analgesics on cancer pain in patients with LC. Methods: From the beginning to April 2021, search Medline, Embase, Cochrane Central Controlled Trials Register (Central), China National Knowledge Infrastructure (CNKI), Wanfang Database, China Biomedical Literature Database (CBM), and Chinese Science Journal Database (VIP database). Search the international clinical trial registration platform and the Chinese clinical trial registration platform to find ongoing or unpublished trials. The main outcome indicator is the total effective rate of analgesia, and the secondary outcome indicator is pain intensity score and adverse reactions. The RevMan 5.4 software will be used for statistical analysis. Results: This study will provide the latest evidence for acupuncture combined with analgesics to relieve LC pain. Conclusion: The conclusion of this study is to evaluate the effectiveness and safety of acupuncture combined with analgesics in alleviating LC pain.
C1 [Kuang, Renqing; Yu, Min; Jiang, Jiawang] Jiangxi Univ Chinese Med, Nanchang, Jiangxi, Peoples R China.
   [Xiong, Guojiang; Lv, Wei; Zhao, Yun] Jiangxi Univ Chinese Med, Affiliated Hosp, Nanchang, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine
RP Xiong, GJ (corresponding author), Jiangxi Univ Chinese Med, Affiliated Hosp, Dept Thorac Surg, 445 Bayi Ave, Nanchang 330006, Jiangxi, Peoples R China.
EM 1160888698@qq.com
FU Traditional Chinese Medicine Research Project of Jiangxi Province [2019A140]
CR Chen JH, 2020, THORAC CANCER, V11, P928, DOI 10.1111/1759-7714.13343
   Cooley ME, 2003, PSYCHO-ONCOLOGY, V12, P694, DOI 10.1002/pon.694
   Duma N, 2019, MAYO CLIN PROC, V94, P1623, DOI 10.1016/j.mayocp.2019.01.013
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Fountas A, 2020, LANCET DIABETES ENDO, V8, P68, DOI 10.1016/S2213-8587(19)30254-2
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004
   2011, 1900, V343, V0, PPD5928, DOI 10.1136/BMJ.D5928
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Iyer S, 2013, LUNG CANCER, V81, P288, DOI 10.1016/j.lungcan.2013.03.008
   Lee HJ, 2009, ACUPUNCTURE ELECTRO, V34, P27, DOI 10.3727/036012909803861095
   Mercadante S, 2019, CNS DRUGS, V33, P943, DOI 10.1007/s40263-019-00660-0
   Muscat JE, 2011, CANCER-AM CANCER SOC, V117, P5370, DOI 10.1002/cncr.26236
   Potter J, 2004, LUNG CANCER-J IASLC, V43, P247, DOI 10.1016/j.lungcan.2003.08.030
   Potter VT, 2003, PSYCHO-ONCOLOGY, V12, P153, DOI 10.1002/pon.627
   Shamseer L, 2015, BMJ-BRIT MED J, V349, P0, DOI 10.1136/bmj.g7647
   Simmons CPL, 2012, CLIN MED INSIGHTS-ON, V6, P0, DOI 10.4137/CMO.S8360
   Stiles BM, 2016, SURG ONCOL CLIN N AM, V25, P469, DOI 10.1016/j.soc.2016.02.002
   Tishelman C, 2007, J CLIN ONCOL, V25, P5381, DOI 10.1200/JCO.2006.08.7874
   Yang FM, 2020, CHIN J INTEGR MED, V26, P310, DOI 10.1007/s11655-019-3150-3
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 21
TC 3
Z9 3
U1 2
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN 11
PY 2021
VL 100
IS 23
BP 
EP 
DI 10.1097/MD.0000000000026225
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA SS3FH
UT WOS:000661625000031
PM 34115008
DA 2026-01-16
ER

PT J
AU Lu, YZ
   Chen, YX
   Qian, Y
   Yu, ML
   Lu, SF
AF Lu, Yi-Zhou
   Chen, Yu-Xuan
   Qian, Yi
   Yu, Mei-Ling
   Lu, Sheng-Feng
TI [Bibliometric analysis on the clinical researches of tumor treated with
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture-moxibustion; bibliometrics; clinical research; tumor
AB OBJECTIVE: To analyze the literature characteristics of the clinical researches  on tumor treatment with acupuncture-moxibustion in PubMed database so as to  provide the references for the study of acupuncture-moxibusion in intervention of  tumor. METHODS: The articles on the clinical researches of acupuncture-moxibusion  in treatment of tumor were retrieved from PubMed database listed till December  31, 2018. Using bibliometric methodology, the analysis was conducted on  publication year, publication journal, author, country or region, research  institution, disease spectrum and therapeutic regimen. RESULTS: A total of 143  articles are included. The publications are increased steadily since 2004. The  articles are published in 64 international journals, of which, Acupuncture in  Medicine (12 articles) and Integrative Cancer Therapies (10 articles) occupy the  the largest number of publications. They are distributed in 18 countries and  regions, of which, the top two countries are America (44 articles) and China (34  articles. The involved types of cancer include breast cancer, prostate cancer,  gastric cancer, etc. Acupuncture-moxibustion is mainly for complication and the  comorbid disorders after treatment, such as pain, nausea and vomiting and fatigue  at most. The regimen of acupuncture-moxibustion is determined by the symptoms and  electroacupuncture is the main measure of treatment. CONCLUSION:  Acupuncture-moxibustion is quite extensively involved in the treatment of tumor  in the field of nervous (mental) system and digestive system. But the regimen of  acupuncture- moxibustion needs to be further optimized and promoted.
C1 Key Laboratory of Acupuncture and Medicine Education Division, Nanjing University of CM, Nanjing 210023, Jiangsu Province, China
   Meical College/HolisticIntegrative Medical College, Nanjing University of CM, Nanjing 210023, JiangsuProvince.
   Key Laboratory of Acupuncture and Medicine Education Division, Nanjing University of CM, Nanjing 210023, Jiangsu Province, China
   Meical College/HolisticIntegrative Medical College, Nanjing University of CM, Nanjing 210023, JiangsuProvince.
   Key Laboratory of Acupuncture and Medicine Education Division, Nanjing University of CM, Nanjing 210023, Jiangsu Province, China
   Meical College/HolisticIntegrative Medical College, Nanjing University of CM, Nanjing 210023, JiangsuProvince.
   Key Laboratory of Acupuncture and Medicine Education Division, Nanjing University of CM, Nanjing 210023, Jiangsu Province, China.
   Key Laboratory of Acupuncture and Medicine Education Division, Nanjing University of CM, Nanjing 210023, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD FEB 10
PY 2021
VL 41
IS 1
BP 111
EP 4
DI 10.13703/j.0255-2930.20191125-0007
PG -107
WC Acupuncture Therapy; Bibliometrics; China; Humans; Moxibustion; PubMed
UT PubMed:33559454
PM 33559454
DA 2021-02-10
ER

PT J
AU Zhang, JL
   Yang, MX
   So, TH
   Chang, TY
   Qin, ZS
   Chen, HY
   Lam, WL
   Yeung, WF
   Chung, KF
   Jiang, F
   Lao, LX
   Zhang, ZJ
AF Zhang, Jialing
   Yang, Mingxiao
   So, Tsz Him
   Chang, Tien Yee
   Qin, Zongshi
   Chen, Haiyong
   Lam, Wing Lok
   Yeung, Wing Fai
   Chung, Ka Fai
   Jiang, Fei
   Lao, Lixing
   Zhang, Zhang-Jin
TI Electroacupuncture Plus Auricular Acupressure on Chemotherapy-Related Insomnia in Patients With Breast Cancer (EACRI): Study Protocol for a Randomized, Sham-Controlled Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE insomnia; breast cancer; chemotherapy; electroacupuncture; auricular acupressure; sham control
ID cognitive-behavioral therapy; sleep quality index; hospital anxiety; chinese version; cantonese-version; severity index; fact-b; acupuncture; validation; pain
AB Objective Insomnia is a highly prevalent and disturbing symptom in breast cancer patients under or post chemotherapy. If not appropriately treated, it can persist for years after the completion of cancer treatments. Acupuncture has been widely used for alleviating insomnia. The aim of this study is to examine the feasibility, efficacy and safety of acupuncture for chemotherapy-related insomnia among patients with breast cancer. Materials and Methods This is a trial protocol for a randomized, sham-controlled, subject- and assessor-blinded clinical trial. A total of 138 eligible participants will be assigned randomly to acupuncture or sham control group at a ratio of 1:1. Participants in acupuncture group will receive electroacupuncture (EA) plus auricular acupressure (AA) treatment, while subjects in sham acupuncture group will receive sham EA plus sham AA. Both acupuncture and sham treatments will be given twice weekly for 6 weeks, followed by maintenance treatments once every 4 weeks for 12 weeks (15 sessions totally). The primary outcome is the change of Insomnia Severity Index score between baseline and the end of 6-week treatment. Secondary outcome measurements include Actiwatch, sleep diary, Pittsburgh Sleep Quality Index, Functional Assessment of Cancer Therapy-Breast Cancer, Hospital Anxiety and Depression Scale, Brief Pain Inventory-Short Form, Brief Fatigue Inventory, Acupuncture Expectancy Scale, credibility, and adverse events. Participants will be followed up to 42 weeks. Conclusions This trial will expand our understanding of the feasibility, efficacy, and safety of acupuncture as a treatment for alleviating chemotherapy-related insomnia in patients with breast cancer. EA plus AA, if proven to be effective, can be implemented into routine settings to play a role in insomnia management for patients with breast cancer.
C1 [Zhang, Jialing; Zhang, Zhang-Jin] Univ Hong Kong, Shenzhen Hosp HKU SZH, Dept Chinese Med, Shenzhen, Guangdong, Peoples R China.
   [Zhang, Jialing; Yang, Mingxiao; Qin, Zongshi; Chen, Haiyong; Lam, Wing Lok; Lao, Lixing; Zhang, Zhang-Jin] Univ Hong Kong, LKS Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [So, Tsz Him; Chang, Tien Yee] Univ Hong Kong, LKS Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Chang, Tien Yee] Hong Kong Sanat Hosp, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Yeung, Wing Fai] Hong Kong Polytech Univ, Sch Nursing, Hong Kong, Peoples R China.
   [Chung, Ka Fai] Univ Hong Kong, LKS Fac Med, Dept Psychiat, Hong Kong, Peoples R China.
   [Jiang, Fei] Univ Hong Kong, Dept Stat & Actuarial Sci, Hong Kong, Peoples R China.
   [Lao, Lixing] Virginia Univ Integrat Med, 9401 Mathy Dr, Fairfax, VA 22031 USA.
C3 University of Hong Kong; University of Hong Kong; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong; University of Hong Kong
RP Lao, LX (corresponding author), Virginia Univ Integrat Med, 9401 Mathy Dr, Fairfax, VA 22031 USA.; Zhang, ZJ (corresponding author), Univ Hong Kong, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong, Peoples R China.
EM llao@vuim.edu; zhangzj@hku.hk
FU National Key R&D Program of China [2018YFC1705801]; Health and Medical Research Fund, Government of the Hong Kong Special Administrative Region of China Health and Medical Research Fund [16172761]
CR American Psychiatric Pub, 2013, DSM-5: EVIDENCE OF ITS UNIDIMENSIONALITY, V0, P0
   Unknown -, 2014, ACUPUNCTURE AND MOXIBUSTION (INTERNATIONAL STANDARD LIBRARY OF CHINESE MEDICINE), V0, P0
   Bang H, 2016, CONT CLIN TRIAL COMM, V3, P117, DOI 10.1016/j.conctc.2016.05.003
   Bergdahl L, 2017, COMPLEMENT THER CLIN, V28, P220, DOI 10.1016/j.ctcp.2017.06.006
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1002/smll.202408771
   Carney CE, 2012, SLEEP, V35, P287, DOI 10.5665/sleep.1642
   Cheng KKF, 2013, EUR J CANCER CARE, V22, P70, DOI 10.1111/j.1365-2354.2012.01372.x
   Chong AML, 2012, SLEEP BIOL RHYTHMS, V10, P118, DOI 10.1111/j.1479-8425.2011.00532.x
   Delgado-Guay M, 2011, J PAIN SYMPTOM MANAG, V41, P819, DOI 10.1016/j.jpainsymman.2010.07.015
   Devilly GJ, 2000, J BEHAV THER EXP PSY, V31, P73, DOI 10.1016/S0005-7916(00)00012-4
   Dhingra L, 2011, ONCOLOGIST, V16, P523, DOI 10.1634/theoncologist.2010-0330
   Fakih R, 2018, INDIAN J PALLIAT CAR, V24, P35, DOI 10.4103/IJPC.IJPC_137_17
   Fleming L, 2019, SLEEP, V42, P0, DOI 10.1093/sleep/zsy245
   Fleming L, 2010, PSYCHO-ONCOLOGY, V19, P991, DOI 10.1002/pon.1652
   Fu C, 2017, SLEEP, V40, P0, DOI 10.1093/sleep/zsx153
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Haque R, 2021, J WOMENS HEALTH, V30, P1604, DOI 10.1089/jwh.2019.8135
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Ho RTH, 2014, SLEEP MED, V15, P565, DOI 10.1016/j.sleep.2013.10.019
   Howell D, 2014, ANN ONCOL, V25, P791, DOI 10.1093/annonc/mdt506
   Hoang HTX, 2020, SLEEP BREATH, V24, P241, DOI 10.1007/s11325-019-01839-x
   Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x
   Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730
   Liu Yi, 2017, ZHONGGUO ZHEN JIU, V37, P19, DOI 10.13703/j.0255-2930.2017.01.004
   Ma Y, 2021, SLEEP MED REV, V55, P0, DOI 10.1016/j.smrv.2020.101376
   MacPherson H, 2010, PLOS MED, V7, P0, DOI 10.1371/journal.pmed.1000261
   Mao JJ, 2007, EXPLORE-NY, V3, P372, DOI 10.1016/j.explore.2006.12.003
   Mendoza T, 2006, EUR J PAIN, V10, P353, DOI 10.1016/j.ejpain.2005.06.002
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Moore TA, 2011, PSYCHO-ONCOLOGY, V20, P321, DOI 10.1002/pon.1756
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   National Institutes of Health, 2018, DATA SAFETY MONITORI, V0, P0
   Palesh O, 2012, NAT SCI SLEEP, V4, P151, DOI 10.2147/NSS.S18895
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Purnell JQ, 2014, MED RADIOL DIAGN IMA, V0, PP257, DOI 10.1007/978-3-540-72314-1_17
   Ng R, 2012, BREAST CANCER RES TR, V131, P619, DOI 10.1007/s10549-011-1764-z
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Savard J, 2018, BEHAV SLEEP MED, V16, P294, DOI 10.1080/15402002.2016.1210148
   Savard J, 2015, CANCER-AM CANCER SOC, V121, P1703, DOI 10.1002/cncr.29244
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Savard J, 2009, SLEEP, V32, P1155, DOI 10.1093/sleep/32.9.1155
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Suen LKP, 2002, AM J CHINESE MED, V30, P429, DOI 10.1142/S0192415X0200051X
   USDepartment of Health and Human Services, 2017, COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE) V5.0, V0, P0
   Vincent C, 1990, COMPLEMENTARY MEDICAL RESEARCH, V4, P8
   Wan CH, 2007, BREAST CANCER RES TR, V106, P413, DOI 10.1007/s10549-007-9511-1
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Yang XY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/319734
   Yang XG, 2010, J TRADIT CHIN MED, V30, P309, DOI 10.1016/S0254-6272(10)60063-5
   Yeung W-F, 2010, ACUPUNCTURE FOR INSOMNIA: A SYSTEMATIC REVIEW AND RANDOMIZED PLACEBO-CONTROLLED TRIALS, V0, P0
   Yeung WF, 2009, SLEEP, V32, P1039, DOI 10.1093/sleep/32.8.1039
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
   Zhang JL, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019103
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
   Zou C, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0122724
NR 60
TC 6
Z9 6
U1 3
U2 9
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD NOV 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/15347354211058695
PG 11
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA XB9CY
UT WOS:000721620000001
PM 34802291
DA 2026-01-16
ER

PT J
AU Dong, B
   Lin, L
   Chen, Q
   Qi, Y
   Wang, F
   Qian, K
   Tian, L
AF Dong, Bei
   Lin, Lu
   Chen, Qiuyun
   Qi, Yishu
   Wang, Fen
   Qian, Keyan
   Tian, Li
TI Wrist-ankle acupuncture has a positive effect on cancer pain: a meta-analysis.
SO BMC complementary medicine and therapies
LA English
DT Journal Article
DE Cancer; Meta-analysis; Pain; Randomized controlled trial; Wrist-ankle acupuncture
AB BACKGROUND: Wrist-ankle acupuncture (WAA) as a kind of micro acupuncture therapy  has been used to management cancer pain, however, the effects of WAA on cancer  pain were controversial in the current studies. Therefore, the purpose of this  meta-analysis was to critically evaluate the effect of wrist-ankle acupuncture  (WAA) on cancer pain. METHODS: Seven digital databases were searched from the  inception of databases to July 2020, including CNKI, Wanfang, VIP, CBM, Cochrane  Library, PubMed and Embase. Randomized controlled trials conforming to the  inclusion and exclusion criteria were screened and extracted; the risk of bias  was evaluated using the Cochrane Collaboration criteria. The primary outcome  indicators included pain relief rate and pain score, and the secondary outcome  was adverse reaction incidence. All analyses were performed with Review Manager  5.3. RESULTS: A total of 13 studies with 1005 cancer patients (intervention  group: 568, control group: 437) were included in this meta-analysis. The results  demonstrated that the pain relief rate of experimental group (WAA / WAA + drug  intervention) was better than that of control group (analgesic drug  intervention), and the difference was statistically significant [RR = 1.31,  95%CI: 1.15 ~ 1.49, P < 0.01]. CONCLUSIONS: WAA has certain effect on cancer  pain, and the effect of WAA combined with pharmacological intervention is better  than that of drug therapy alone.
C1 Oncology Department of the First Affiliated Hospital of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.
   School of Nursing, Medical College of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.
   Oncology Department of the First Affiliated Hospital of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.
   School of Nursing, Medical College of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.
   Oncology Department of the First Affiliated Hospital of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China.
   Radiotherapy Department of the First Affiliated Hospital of Soochow University, Suzhou, China.
   Oncology Department of the First Affiliated Hospital of Soochow University, No. 188 Shizi Road, Suzhou, 215006, China. tianlisz@suda.edu.cn.
   School of Nursing, Medical College of Soochow University, No. 188 Shizi Road,
NR 0
TC 0
SN 2662-767
EI 
J9 BMC Complement Med Ther
PD JAN 9
PY 2021
VL 21
IS 1
BP 24
EP 24
DI 10.1186/s12906-020-03193-y
PG 0
WC Acupuncture Points; Acupuncture Therapy; methods; Adult; Aged; Aged, 80 and over; Ankle; Bias; Cancer Pain; therapy; Female; Humans; Male; Middle Aged; Pain Management; methods; Pain Measurement; Wrist; Young Adult
UT PubMed:33413347
PM 33413347
DA 2021-01-09
ER

PT J
AU Han, XC
   Xing, QZ
   Li, Y
   Dong, X
   Ma, XW
   Zhang, L
   Wang, QQ
AF Han, Xue-Chang
   Xing, Qun-Zhi
   Li, Yu
   Dong, Xu
   Ma, Xiao-Wu
   Zhang, Lu
   Wang, Qian-Qian
TI [Clinical trial of electroacupuncture at Neimadian-point for cancer pain].
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Analgesia; Cancer; Eletroacupuncture; Neimadian-point; Pain
AB OBJECTIVE: To observe the clinical efficacy and safety of electroacupuncture (EA)  at Neimadian-point for cancer pain. METHODS: A total of 140 cancer patients with  pain were randomly divided into EA and control groups, with 70 cases in each  group. The patients of the EA group received EA at Neimadian-point plus analgesia  pump (all prepared with normal saline). The patients of the control group were  treated by Sufentanil patient-controlled intravenous analgesia plus sham EA  (without stimulation). The treatment was conducted once daily for two days at 8  o'clock every morning. Respectively, in 1 h before treatment (T0), 1 h (T1), 8 h  (T2), 24 h (T3) after treatment of the first day, 1 h (T4), 8 h (T5), 24 h (T6)  after treatment of the second day, the visual analogue scale (VAS) score of pain,  and the plasma levels of norepinephrine, 5-HT, leucine enkephalin, β-endorphin  and dynorphin A1-13 were tested. The security level (1-4 grade) was assessed  during the treatment. RESULTS: Compared with their own pre-treatment, in T1 to  T6, the VAS scores, and the contents of plasma norepinephrine and 5-HT obviously  decreased in both groups （P<0.05）, and the contents of leucine enkephalin,  β-endorphin and dynorphin A1-13 all increased (P<0.05) in the EA group. The  analgesia effects were significantly higher in the EA group than in the control  group in T1, T2, T4 and T5 (P<0.05,P<0.01). The therapeutic effect of EA at  Neimadian-point was significantly superior to that of the Sufentanil in  down-regulating plasma norepinephrine and 5-HT levels, and in up-regulating  leucine enkephalin, β-endorphin and dynorphin A1-13 levels (P<0.05,P<0.01).  CONCLUSION: EA at Neimadian-point can effectively relieve the pain of cancer  patients and improve their quality of daily life.
C1 Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
   Department of Anesthesiology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang 471003,Henan Province, China.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD APR 1
PY 2021
VL 45
IS 10
BP 845
EP 50
DI 10.13702/j.1000-0607.200131
PG -795
WC Cancer Pain; therapy; Electroacupuncture; Humans; Neoplasms; complications; Pain; etiology; Pain Management; beta-Endorphin
UT PubMed:33788453
PM 33788453
DA 2021-04-01
ER

PT J
AU Zhu, XY
   Li, Z
   Chen, C
   Feng, RL
   Cheng, BR
   Liu, RY
   Wang, RT
   Xu, L
   Wang, Y
   Tao, X
   Zhao, P
AF Zhu, Xue-Ying
   Li, Zhong
   Chen, Cong
   Feng, Ru-Li
   Cheng, Bai-Ru
   Liu, Ruo-Yi
   Wang, Rui-Ting
   Xu, Li
   Wang, Yue
   Tao, Xin
   Zhao, Peng
TI Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by
SO Frontiers in oncology
LA English
DT Journal Article
DE acupuncture; aromatase inhibitors; breast cancer; exercise; pain; physical therapies; quality of life
AB OBJECTIVE: To evaluate the effects of Physical Therapies (PTs) on improvement in  psychosomatic symptoms and quality of life (QOL) in breast cancer patients. DATA  SOURCES: Seven databases (MEDLINE, EMBASE, Cochrane CENTRAL, China National  Knowledge Infrastructure, Wangfang, VIP, and China Biology Medicine disc  databases) were systematically searched from the database inception through May  18, 2021. STUDY SELECTION: Randomized controlled trials (RCTs) which compared  acupuncture or exercise with a sham control or usual care for the treatment of  aromatase inhibitors (AIs)-related psychosomatic symptoms and QOL. DATA  EXTRACTION AND SYNTHESIS: Data were screened and extracted independently using  predesigned forms. The quality of RCTs was assessed with the Cochrane Handbook  for Systematic Reviews of Interventions. The effect size was calculated via  random-effects modeling. The quality of evidence was evaluated with the Grading  of Recommendations Assessment, Development and Evaluation approach. MAIN OUTCOMES  AND MEASURES: The score of pain was measured with BPI scale and Western Ontario  and the McMaster Universities Index (WOMAC) scale. Emotional state was measured  with Pittsburgh Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale  (HADS-A), and Functional Assessment of Chronic Illness Therapy-Fatigue  (FACIT-Fatigue). The QOL score was measured by self-reported measurements,  including the Functional Assessment of Cancer Therapy-General (FACT-G) scale and  36-Item Short Form Survey (SF-36) scale. RESULTS: Eleven RCTs (with 830 patients)  were included in the systematic review, and data from 10 RCTs (with 798 patients)  were used in the meta-analysis. Results showed acupuncture significantly reduced  worst pain scores (P < 0.00001, I (2) = 83.5%) [SMD = -0.81, 95% CI (-1.51,  -0.11)], but the effect of exercise therapies was not significant in overall  change in worst pain scores (P =0.006, I (2) = 72.3%) [SMD = -0.30, 95% CI  (-0.76, 0.16)]. Both acupuncture and exercise resulted in little to no difference  in overall change in HADS-A subscale (P = 0.026<0.05, I (2) = 79.8%)  [WMD = -0.21, 95% CI (-3.44, 3.03)], PSQI subscale (P = 0.488, I (2) = 0%)  [WMD = 0.98, 95% CI (-0.57, 2.53)], and FACIT-Fatigue subscale (P = 0.022<0.05, I  (2) = 81.0%) [WMD = 1.6, 95% CI (-5.75, 8.94)]. Exercise (compared with usual  care) was associated with improving overall change in health-related QOL  (subscales of SF-36 tool) (P = 0, I (2) = 72.1%) [WMD = 7.97, 95% CI (5.68,  10.25)] and cancer-specific QOL (subscales of FACT-G tool) (P = 0.304, I  (2) = 16%) [WMD = 1.16, 95% CI (0.34, 1.97)]. CONCLUSIONS AND RELEVANCE: This  systematic review and meta-analysis suggested that based on moderate-level  evidence, acupuncture was associated with significant reductions in pain  intensity, and exercise might improve QOL in breast cancer patients treated with  AIs. However, in psychosomatic symptoms such as anxiety, sleep disturbance, and  fatigue, acupuncture and exercise training did not result in significant  improvements.
C1 Department of Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Oncology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Department of Gynecology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
   Graduate School of Beijing University of Chinese Medicine, Beijing, China.
   School of Medical Humanities, Capital Medical University, Beijing, China.
   Department of Cardiology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD DEC 7
PY 2021
VL 11
IS 
BP 745280
EP 745280
DI 10.3389/fonc.2021.745280
PG 0
UT PubMed:34868943
PM 34868943
DA 2021-12-07
ER

PT J
AU Li, MJ
   Peng, HW
   Wei, BX
   Deng, QX
   Qian, F
   Liu, X
   Wang, J
   Zhu, XD
AF Li, Maojun
   Peng, Huawen
   Wei, Binxiu
   Deng, Qiuxia
   Qian, Fen
   Liu, Xin
   Wang, Jian
   Zhu, Xiaodong
TI Effect of acupuncture anesthesia based on nanomaterial sensor on cognitive function after one-lung ventilation thoracotomy
SO MATERIALS EXPRESS
LA English
DT Article
DE One-Lung Ventilation and Thoracotomy; Acupuncture Anesthesia; Nanomaterials; Inflammatory Factors; Cognitive Function
ID open-heart-surgery; stress-response; tnf-alpha; il-6; pain
AB In this work, a new type of nanomaterial sensing acupuncture needle was developed to improve patient comfort and treatment effectiveness. Based on the convenient electrochemical casting process, multilayer nano-tapered holes were constructed on the needle surface to form a porous nano-sensing acupuncture needle (PNAN), which further increases the interface area of the acupuncture needle. To evaluate the effect of PNAN-induced anesthesia on cognitive function after one-lung ventilation and thoracotomy, 60 patients with esophageal cancer undergoing thoracotomy were randomly divided into an acupuncture-induced anesthesia (AIA) group and a conventional anesthesia (CA) group. The recovery time for cognitive function and the incidence of cognitive impairment in the PNAN-induced anesthesia group after one-lung ventilation and thoracotomy were significantly lower than those of the CA group (P < 0.05). The scores from the Mini Mental State Examination Scale (MMSE) and Self-Rating Anxiety Scale (SAS) for the AIA group were lower than the preoperative scores and were better than those for the CA group (P < 0.05). In addition, after one-lung ventilation and thoracotomy, the concentrations of cytokines and catecholamines (CAs) in both groups were lower than the preoperative values, and the levels of cytokines and CAs in the AIA group were significantly lower than those of the CA group. Therefore, acupuncture anesthesia based on a nanomaterial sensor can significantly improve the cognitive function of patients after one-lung ventilation and thoracotomy, inhibit inflammatory factors, and provide an optimal curative effect.
C1 [Li, Maojun; Wei, Binxiu; Deng, Qiuxia; Qian, Fen; Liu, Xin] Peoples Hosp Linshui Cty, Dept Anesthesiol, Guangan 638500, Sichuan, Peoples R China.
   [Peng, Huawen; Zhu, Xiaodong] Peoples Hosp Linshui Cty, Dept Orthoped, Guangan 638500, Sichuan, Peoples R China.
   [Wang, Jian] Peoples Hosp Linshui Cty, Dept Cardiothorac Surg, Guangan 638500, Sichuan, Peoples R China.
RP Zhu, XD (corresponding author), Peoples Hosp Linshui Cty, Dept Orthoped, Guangan 638500, Sichuan, Peoples R China.; Wang, J (corresponding author), Peoples Hosp Linshui Cty, Dept Cardiothorac Surg, Guangan 638500, Sichuan, Peoples R China.
FU Guang'an Municipal Science and Technology Innovation Project [2019SYF11]
CR Cheng TO, 2000, HEART, V83, P256, DOI 10.1136/heart.83.3.256
   Chung A, 2003, CAN FAM PHYSICIAN, V49, P985
   DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V
   Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795
   HOLLINGER I, 1979, AM J CHINESE MED, V7, P77, DOI 10.1142/S0192415X79000064
   HYODO M, 1977, AM J CHINESE MED, V5, P63, DOI 10.1142/S0192415X77000075
   In SL, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep34061
   Ji Shu-Mei, 2007, ZHONGGUO ZHEN JIU, V27, P306
   Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kato S, 1995, NOSHUYO BYORI, V12, P125
   Langevin Helene M, 2002, ANATOMICAL RECORD, V269, P257, DOI 10.1002/ar.10185
   Lee BR, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-11213-0
   Liu Xiao-ying, 2007, ZHONGHUA YI XUE ZA ZHI, V87, P1025
   Lu YJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-178
   Mao Jinfeng, 2018, ZHONGGUO ZHEN JIU, V38, P761, DOI 10.13703/j.0255-2930.2018.07.021
   Shang AB, 2003, DRUGS, V63, P855, DOI 10.2165/00003495-200363090-00002
   Taguchi R, 2008, EVID-BASED COMPL ALT, V5, P153, DOI 10.1093/ecam/nem056
   TSUJIMOTO T, 1978, MEDICAL JOURNAL OF OSAKA UNIVERSITY, V28, P355
   Wang D, 1990, FUKUSHIMA J MED SCI, V35, P45
   Weber GF, 2000, J MOL MED-JMM, V78, P404, DOI 10.1007/s001090000138
   White Adrian, 2006, ACUPUNCT MED, V24, P39
   ZANELLA G, 1968, TRANSPLANTATION, V6, P885, DOI 10.1097/00007890-196811000-00003
   Zhen Hong-Liang, 2008, ZHONGGUO ZHEN JIU, V28, P736
   Zhou J, 2011, INT J CARDIOL, V150, P12, DOI 10.1016/j.ijcard.2011.04.002
NR 25
TC 2
Z9 2
U1 5
U2 27
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 2158-5849
EI 2158-5857
J9 MATER EXPRESS
JI Mater. Express
PD JUL 15
PY 2021
VL 11
IS 7
BP 1051
EP 1056
DI 10.1166/mex.2021.2027
PG 6
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA TM7JZ
UT WOS:000675725600006
DA 2026-01-16
ER

PT J
AU Wang, W
   Zhou, Y
   Cai, Y
   Wang, S
   Shao, F
   Du, J
   Fang, J
   Liu, J
   Shao, X
   Liu, B
   Fang, J
   Liang, Y
AF Wang, Wen
   Zhou, You
   Cai, Yangqian
   Wang, Sisi
   Shao, Fangbing
   Du, Junying
   Fang, Junfan
   Liu, Jinggen
   Shao, Xiaomei
   Liu, Boyi
   Fang, Jianqiao
   Liang, Yi
TI Phosphoproteomic Profiling of Rat's Dorsal Root Ganglia Reveals mTOR as a
SO Frontiers in pharmacology
LA English
DT Journal Article
DE bone cancer pain; electro-acupuncture; mTOR; mechanism; protein microarray; proteomic profiling
AB Bone cancer pain (BCP) is a clinical refractory mixed pain involving neuropathic  and inflammatory pain, with the underlying mechanisms remaining largely unknown.  Electro-acupuncture (EA) can partly alleviate BCP according to previous research.  We aim to explore the proteins and major pathways involved in BCP and EA  treatment through phosphoproteomic profiling. BCP rat model was built by tibial  inoculation of MRMT-1 mammary gland carcinoma cells. Mechanical hyperalgesia  determined by paw withdrawal thresholds (PWTs) and bone destruction manifested on  the radiographs confirmed the success of modeling, which were attenuated by EA  treatment. The differentially expressed phosphorylated proteins (DEPs)  co-regulated by BCP modeling and EA treatment in rat dorsal root ganglions (DRGs)  were analyzed through PEX100 Protein microarray. Kyoto Encyclopedia of Genes and  Genomes (KEGG) analysis revealed that DEPs were significantly enriched in  mammalian target of rapamycin (mTOR) signaling pathway. The phosphorylations of  mTOR at Ser2448 and Thr2446 were increased in BCP and downregulated by EA. In  addition, the phosphorylation of S6K and Akt, markers of the mTOR complex, were  also increased in BCP and downregulated by EA. Inhibition of mTOR signaling  alleviated the PWTs of BCP rats, while the mTOR agonist impaired the analgesic  effect of EA. Thus, our study provided a landscape of protein phosphorylation  changes in DRGs of EA-treated BCP rats and revealed that mTOR signaling can be  potentially targeted to alleviate BCP by EA treatment.
C1 Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Quzhou Municipal Hospital of Traditional Chinese Medicine, Quzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
   Key Laboratory of Acupuncture and Neurology of Zhejiang Province, Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College,Zhejiang Chinese Medical University, Hangzhou, China.
NR 0
TC 0
SN 1663-981
EI 1663-981
J9 Front Pharmacol
PD MAY 18
PY 2021
VL 12
IS 
BP 593043
EP 593043
DI 10.3389/fphar.2021.593043
PG 0
UT PubMed:33995007
PM 33995007
DA 2021-05-18
ER

PT J
AU Li, Y
   Wu, YQ
   Xiang, YQ
   Zhang, SN
AF Li, Ying
   Wu, Y. Q.
   Xiang, Y. Q.
   Zhang, S. N.
TI Effect of Acupuncture Combined with Tuina on Cervical Curvature and Serum Inflammatory Cytokine Levels in Patients with Cervical Spondylosis
SO INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Cervical spondylosis; acupuncture; tuina; cervical curvature; interleukin-4; interleukin-8; tumor necrosis factor-alpha
ID fusion; diskectomy; myelopathy; cage
AB To study the effects of acupuncture and tuina by stages on cervical curvature, serum interleukin-4, interleukin-8 and tumor necrosis factor-alpha in patients with cervical spondylosis. A total of 94 patients with cervical spondylosis admitted from June 2020 to June 2021 were divided into the control group and the study group through random number table with 47 cases in each group. Patients in the control group were treated with tuina and patients in the study group were treated with acupuncture and tuina by stages. One course of treatment was 21 d and both groups were treated for 2 courses. The clinical effects of the patients in the two groups after treatment were compared, the cervical spine curvature and visual analogue scale scores of patients in the two groups before and after treatment were compared and the serum levels of interleukin-4, interleukin-8 and tumor necrosis factor-alpha before and after treatment were compared. The total clinical effective rate of patients in the study group was 91.48 % (43/47), which was higher than 68.09 % (32/47) of patients in the control group. After treatment, the C value of cervical spine physiological curvature of patients in the two groups was higher than that before treatment and the visual analog scale scores, serum interleukin-4, interleukin-8, tumor necrosis factor-alpha levels decreased. The improvement of patients in the study group was better than that in the control group (all p<0.05). Acupuncture and tuina to treat patients with cervical spondylosis by stages can better improve the curvature of the patient's cervical spines, reduce pain, inhibit inflammation in the body and improve the therapeutic effect.
C1 [Zhang, S. N.] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   [Li, Ying; Wu, Y. Q.; Xiang, Y. Q.] Gannan Med Univ, Sch Rehabil Med, Ganzhou 341000, Jiangxi, Peoples R China.
C3 Nanjing University of Chinese Medicine; Gannan Medical University
RP Zhang, SN (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China.
EM zhangshinian@sina.com
FU scientific research project of traditional Chinese medicine of Jiangxi Provincial Health and Family Planning Commission [2018A103]
CR Angevine PD, 2003, SPINE, V28, P931, DOI 10.1097/00007632-200305010-00016
   Barbagallo GMV, 2013, EUR SPINE J, V22, PS868, DOI 10.1007/s00586-013-3005-0
   Bartels RHMA, 2005, NEUROSURGERY, V57, PE194, DOI 10.1227/01.NEU.0000163419.59635.78
   Brkaric M, 2007, J SPINAL DISORD TECH, V20, P248, DOI 10.1097/BSD.0b013e318030d2f3
   Chen Y, 2016, CLIN NEUROL NEUROSUR, V144, P72, DOI 10.1016/j.clineuro.2016.03.010
   Cheung ZB, 2019, GLOB SPINE J, V9, P446, DOI 10.1177/2192568218774576
   Korinth MC, 2008, ZBL NEUROCHIR, V69, P113, DOI 10.1055/s-2008-1081201
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   Matz PG, 2007, NEUROSURGERY, V60, P64, DOI 10.1227/01.NEU.0000215399.67006.05
   Nouri A, 2017, SPINE, V42, P1058, DOI 10.1097/BRS.0000000000001981
   Nouri A, 2015, SPINE, V40, PE675, DOI 10.1097/BRS.0000000000000913
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Tasiou Anastasia, 2017, J SPINE SURG, V3, P444, DOI 10.21037/jss.2017.08.03
NR 13
TC 1
Z9 1
U1 3
U2 24
PU INDIAN PHARMACEUTICAL ASSOC
PI MUMBAI
PA KALINA, SANTA CRUZ EAST, MUMBAI, 00000, INDIA
SN 0250-474X
EI 1998-3743
J9 INDIAN J PHARM SCI
JI Indian J. Pharm. Sci.
PD JUN 15
PY 2021
VL 83
IS 
BP 205
EP 209
DI 10.36468/pharmaceutical-sciences.spl.395
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA ZP1JF
UT WOS:000766180500032
DA 2026-01-16
ER

PT J
AU Tao, S
   Wang, X
   Liao, C
   Xiong, Y
   Tang, J
   Jiang, N
   Li, Y
   Hu, X
   Shuai, R
   Wang, Y
   Wu, P
AF Tao, Siyu
   Wang, Xue
   Liao, Chenxi
   Xiong, Yan
   Tang, Jie
   Jiang, Nannan
   Li, Yuan
   Hu, Xinyue
   Shuai, Rouxian
   Wang, Yueyue
   Wu, Ping
TI The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients
SO Pain research & management
LA English
DT Journal Article
AB OBJECTIVE: This study aims to evaluate the efficacy of moxibustion on joint  swelling and pain and the levels of C-X-C motif chemokine ligand 1 (CXCL1),  β-endorphin (β-EP) in serum of rheumatoid arthritis (RA) patients and to  investigate the anti-inflammatory and analgesic mechanism of moxibustion on  improving RA. METHODS: Sixty-eight patients with RA were randomly and equally  classified into the control and treatment groups. The control group was treated  with routine drug therapy, while the treatment group received routine drug  therapy and moxibustion. Both groups were treated for eight weeks. The symptoms  and laboratory indicators of RA patients were compared in the two groups before  and after intervention. RESULTS: Sixty-one patients completed the study: four  patients dropped out from the treatment group and three from the control group.  Trial endpoints were change (∆) in symptoms, measured by Ritchie's articular  index (RAI), swollen joint count (SJC), and laboratory indicators, measured by  the level of CXCL1, β-EP, tumor necrosis factor-a (TNF-α), and interleukin-1β  (IL-1β). ∆RAI, ∆SJC, ∆CXCL1, ∆β-EP, ∆TNF-α, and ∆IL-1β in the treatment group  were superior to the control group (13.50 [14.50] versus 6.00 [13.00] in ∆RAI,  4.00 [3.00] versus 2.00 [4.00] in ∆SJC, 0.04 ± 0.79 ng/mL versus  -0.01 ± 0.86 ng/mL in ∆CXCL1, -2.43 [5.52] pg/mg versus -0.04 [4.09] pg/mg in  ∆β-EP, 3.45 [5.90] pg/mL versus 1.55 [8.29] pg/mL in ∆TNF-α, and 6.15 ± 8.65  pg/mL versus 1.28 ± 8.51 pg/mL in ∆IL-1β; all P < 0.05). CONCLUSION: Moxibustion  can improve the joint swelling and pain symptoms in patients with RA, which may  be related to the fact that moxibustion can reduce the release of inflammatory  factors in patients with RA and downregulate the level of CXCL1 and increase the  level of β-EP at the same time. This trial is registered with  ChiCTR-IOR-17012282.
C1 Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   West China Fourth Hospital, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
   Sichuan Integrative Medicine Hospital, Chengdu 610075, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan Province, China.
NR 0
TC 0
SN 1918-152
EI 1203-676
J9 Pain Res Manag
PD OCT 26
PY 2021
VL 2021
IS 
BP 7466313
EP 7466313
DI 10.1155/2021/7466313
PG 0
WC Anti-Inflammatory Agents; Arthritis, Rheumatoid; therapy; Chemokine CXCL1; Humans; Moxibustion; Tumor Necrosis Factor-alpha; beta-Endorphin
UT PubMed:34691317
PM 34691317
DA 2021-10-26
ER

PT J
AU Oberoi, DV
   Longo, CJ
   Reed, EN
   Landmann, J
   Piedalue, KAL
   Carlson, LE
AF Oberoi, Devesh V.
   Longo, Christopher J.
   Reed, Erica N.
   Landmann, Jessa
   Piedalue, Katherine-ann L.
   Carlson, Linda E.
TI GROUP ACUPUNCTURE IS MORE COST-EFFECTIVE THAN INDIVIDUAL ACUPUNCTURE FOR TREATING CANCER-RELATED PAIN
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Oberoi, Devesh V.; Reed, Erica N.; Piedalue, Katherine-ann L.; Carlson, Linda E.] Univ Calgary, Calgary, AB, Canada.
   [Longo, Christopher J.] McMaster Univ, DeGroote Sch Business, Burlington, ON, Canada.
   [Landmann, Jessa] Vive Integrat Hlth Grp, Calgary, AB, Canada.
C3 University of Calgary; McMaster University
EM devesh.oberoi@ahs.ca
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD APR 15
PY 2021
VL 55
IS 
BP S243
EP S243
DI 
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA RZ9MM
UT WOS:000648922700492
DA 2026-01-16
ER

PT J
AU Li, DH
   Su, YF
   Fan, HF
   Guo, N
   Sun, CX
AF Li, De-Hui
   Su, Yi-Fan
   Fan, Huan-Fang
   Guo, Na
   Sun, Chun-Xia
TI Acupuncture Combined with Three-Step Analgesic Drug Therapy for Treatment of
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB OBJECTIVE: The purpose of this study was to systematically evaluate the efficacy  and safety of acupuncture combined with the WHO three-step analgesic drug ladder  for cancer pain. METHODS: The Cochrane Library, PubMed, and CNKI Database of  Systematic Reviews were searched. Using the Cochrane Register for Randomized  Controlled Trials, the quality of the included literature was evaluated, and the  meta-analysis was carried out with RevMan 5.3 software. RESULTS: Compared with  three-step analgesia alone, acupuncture combined with three-step analgesia for  cancer pain increased pain relief response rates (RR = 1.12, 95% CI: 1.08∼1.17, P  < 0.00001), reduced NRS score (SMD = -1.10, 95% CI: -1.86∼-0.35, P=0.004),  reduced the rate of side effects (RR = 0.45, 95% CI: 0.38∼0.53, P < 0.00001),  including nausea (P < 0.00001), vomiting (P=0.008), constipation (P < 0.00001),  and dizziness (P=0.010), reduced the burst pain rate (SMD = -1.38; 95% CI:  -2.44∼-0.32, P=0.01), shortened analgesia effect onset time (P=0.004), and  extended the duration of response (P < 0.0001). CONCLUSION: For the treatment of  cancer pain, acupuncture combined with three-step analgesic drugs is better than  using only three-step analgesic drugs.
C1 Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
   Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
   Graduate School of Hebei University of Chinese Medicine, Shijiazhuang 050091, 
   Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
   Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
   Hebei Province Hospital of Chinese Medicine, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang 050011, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD AUG 6
PY 2021
VL 2021
IS 
BP 5558590
EP 5558590
DI 10.1155/2021/5558590
PG 0
UT PubMed:34349826
PM 34349826
DA 2021-08-06
ER

PT J
AU Zou, J
   Dong, XY
   Wang, K
   Shi, J
   Sun, N
AF Zou, Jing
   Dong, Xueyang
   Wang, Ke
   Shi, Jing
   Sun, Ning
TI Electroacupuncture Inhibits Autophagy of Neuron Cells in Postherpetic Neuralgia by Increasing the Expression of miR-223-3p
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
AB Postherpetic neuralgia (PHN) is a complication of herpes zoster viral infection. Its main manifestations are continuous or intermittent burning-like and electroshock-like pain in the affected nerves. Electroacupuncture (EA) is widely used in clinical treatment and exerts effects in alleviating neuropathic pain. In this study, we investigated the effect and underlying mechanism of EA on PHN. Sprague-Dawley rats were treated with resiniferatoxin (RTX) to establish a PHN model and subjected to EA and/or miR-223-3p overexpression (OV) or interference. Mechanical withdrawal latency was measured as an indication of pain sensitivity. Hematoxylin-eosin staining and transmission electron microscopy were performed to observe neuron cell morphology and autophagic vacuoles, respectively. ELISA was performed to detect reactive oxygen species (ROS) production and the levels of tumor necrosis factor- (TNF-) alpha, inducible nitric oxide synthase (iNOS), interleukin- (IL-) 6, and IL-10. Changes in autophagy and apoptosis-related miRNAs were detected by immunofluorescence and qRT-PCR, respectively. In RTX-treated rats, OV and EA reduced pain sensitivity, decreased the number of eosinophils, and increased that of nerve cells. ROS generation and the levels of TNF-alpha and iNOS were significantly reduced, while those of IL-6 and IL-10 were increased. OV and EA induced fewer autophagic vacuoles than those in the model group. The expression of autophagy-related protein microtubule-associated protein 1 light chain 3-II, ATG9, and Rab1 was decreased by OV and EA, whereas that of P62 was increased. qRT-PCR revealed that miR-223-3p expression in the model group decreased but was increased by EA. EA inhibits neuron cell autophagy in PHN by increasing miR-223-3p expression.
C1 [Zou, Jing; Shi, Jing; Sun, Ning] Huazhong Univ Sci & Technol, Dept Neurobiol, Sch Basic Med, Tongji Med Coll, Wuhan, Peoples R China.
   [Zou, Jing] Huazhong Univ Sci & Technol, Dept Acupuncture & Moxibust, Wuhan Hosp Integrated Chinese & Western Med, Tongji Med Coll, Wuhan, Peoples R China.
   [Dong, Xueyang] Wuhan Hosp Integrated Chinese & Western Med, Wuhan, Peoples R China.
   [Wang, Ke] Hubei Univ Tradit Chinese Med, Acupuncture Coll, Wuhan, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of Science & Technology; Hubei University of Chinese Medicine
RP Sun, N (corresponding author), Huazhong Univ Sci & Technol, Dept Neurobiol, Sch Basic Med, Tongji Med Coll, Wuhan, Peoples R China.
EM 2709104613@qq.com; 291130015@qq.com; 1047948620@qq.com; sj@mails.tjmu.edu.cn; nsun@hust.edu.cn
FU National Natural Science Foundation of China [31471015, 31771126, 81271452]; Fundamental Research Funds for the Central Universities, HUST [2016YXMS193]
CR Abraham TS, 2011, J CHEM NEUROANAT, V41, P129, DOI 10.1016/j.jchemneu.2011.01.001
   Armstrong DA, 2017, CLIN EPIGENETICS, V9, P0, DOI 10.1186/s13148-017-0355-1
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Chen C, 2014, J MOL ENDOCRINOL, V52, P311, DOI 10.1530/JME-14-0013
   Chen WJ, 2017, NEUROCHEM RES, V42, P634, DOI 10.1007/s11064-016-2119-2
   Chua CEL, 2011, CELL MOL LIFE SCI, V68, P3349, DOI 10.1007/s00018-011-0748-9
   Ding QP, 2018, PATHOL RES PRACT, V214, P1330, DOI 10.1016/j.prp.2018.05.012
   Ding SS, 2014, QJM-INT J MED, V107, P341, DOI 10.1093/qjmed/hct196
   DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9
   Dong HC, 2019, INFLAMMATION, V42, P1265, DOI 10.1007/s10753-019-00986-3
   Dong N, 2017, MOL MED REP, V15, P731, DOI 10.3892/mmr.2016.6044
   Eacker SM, 2009, NAT REV NEUROSCI, V10, P837, DOI 10.1038/nrn2726
   Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086
   Gozuacik D, 2017, FRONT ONCOL, V7, P0, DOI 10.3389/fonc.2017.00065
   Huang J, 2011, AUTOPHAGY, V7, P17, DOI 10.4161/auto.7.1.13840
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Ji LJ, 2018, J CELL BIOCHEM, V119, P1017, DOI 10.1002/jcb.26269
   Jiang HL, 2016, J TRADIT CHIN MED, V36, P85
   Jiang QY, 2016, ACUPUNCT MED, V34, P223, DOI 10.1136/acupmed-2015-010951
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Lan HY, 2015, BIOMED RES INT-UK, V2015, P0, DOI 10.1155/2015/125094
   李卉丽, 2003, 生理科学进展 PROGRESS IN PHYSIOLOGICAL SCIENCES, V34, P45
   Li JQ, 2009, J CLIN ANESTH, V25, P0
   Li Qiu-Yue, 2017, ZHONGGUO ZHONG YAO ZA ZHI, V42, P3709, DOI 10.19540/j.cnki.cjcmm.20170907.004
   Li Z, 2017, FRONT CELL INFECT MI, V7, P0, DOI 10.3389/fcimb.2017.00155
   Liu K, 2018, J CELL BIOCHEM, V6, P0
   Mao JR, 2002, J NEUROSCI, V22, P7650
   Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x
   Sakai A, 2013, BRAIN, V136, P2738, DOI 10.1093/brain/awt191
   Sekiguchi M, 2009, EUR SPINE J, V18, P1978, DOI 10.1007/s00586-009-1064-z
   Sorge RE, 2012, NAT MED, V18, P595, DOI 10.1038/nm.2710
   Su SX, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00126
   Sun YZ, 2015, CHINESE ACUPUNCTURE, V1, P4
   Sun YH, 2017, BMC CARDIOVASC DISOR, V17, P0, DOI 10.1186/s12872-017-0549-7
   Szabo G, 2013, NAT REV GASTRO HEPAT, V10, P542, DOI 10.1038/nrgastro.2013.87
   Tsuda M, 2009, P NATL ACAD SCI USA, V106, P8032, DOI 10.1073/pnas.0810420106
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Wang JY, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/204367
   Wang JY, 2015, BIOMED RES INT, V2015, P0, DOI 10.1155/2015/249013
   Wu CH, 2016, MOL NEUROBIOL, V53, P5640, DOI 10.1007/s12035-015-9482-x
   Wu CH, 2013, MOL PAIN, V9, P0, DOI 10.1186/1744-8069-9-18
   Xie XJ, 2017, CELL PHYSIOL BIOCHEM, V41, P181, DOI 10.1159/000455987
   Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728
   Yan XT, 2017, INT IMMUNOPHARMACOL, V46, P156, DOI 10.1016/j.intimp.2017.01.027
   Yao CL, 2017, ONCOTARGET, V8, P57670, DOI 10.18632/oncotarget.16917
   Zhou CQ, 2017, CELL RES, V27, P184, DOI 10.1038/cr.2016.146
   Zou J, 2019, NEUROTOX RES, V36, P387, DOI 10.1007/s12640-019-00052-8
NR 47
TC 24
Z9 32
U1 3
U2 30
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD MAR 8
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/6637693
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA RN3UN
UT WOS:000640278500001
PM 33860046
DA 2026-01-16
ER

PT J
AU He, LH
   Tan, KP
   Lin, XM
   Yi, H
   Wang, XL
   Zhang, JS
   Lin, JT
   Lin, LZ
AF He, Lihua
   Tan, Keping
   Lin, Xianming
   Yi, Hui
   Wang, Xueliang
   Zhang, Jiangsong
   Lin, Jietao
   Lin, Lizhu
TI Multicenter, randomized, double-blind, controlled trial of transcutaneous electrical nerve stimulation for pancreatic cancer related pain
SO MEDICINE
LA English
DT Article
DE pain; pancreatic cancer; transcutaneous electrical nerve stimulation
ID opioid analgesic requirement; low-frequency; acupuncture; tens
AB Background: Up to 80% of patients with pancreatic cancer experience abdominal and back pain. Although pharmacologic medications provide some relief, many report inadequate analgesia and adverse effects. Transcutaneous electrical nerve stimulation (TENS) is a non-invasive physical modality and had been widely applied for pain relieving, yet no study has investigated the effectiveness of TENS for pain in pancreatic cancer. Methods: Eligible patients were randomly assigned in a 1:1 ratio to TENS group or control group. The primary outcome was percentage change of numerous rating scale (NRS) after treatment. Secondary outcomes included percentage change of analgesic medication consumption and effect on constipation and poor appetite. Results: One hundred seventy-one patients were recruited (84 to control group and 87 to TENS group). NRS in TENS group has been largely decreased 77.9% right after treatment and 27.1% in 2 hours, before applying any analgesic medication, while that in control group was slightly downregulated right after treatment but gave a trend to increase at 1, 2, and 3 hours. When comparing both groups, pain was significantly well controlled without analgesic medication supplement in TENS group at 0 hour (difference in mean percent change in NRS = 50.0 [95% CI, 50-51.4], P < .01) and 3 hours (difference in mean percent change in NRS = 134.0 [95% CI, 130.0-142.7], P < .01) after treatment, and this analgesic effect last to 3 weeks after treatment cycle (difference in mean percent change in NRS = 22.5 [95% CI, 17.6-27.3], P < .01) without increase of analgesic medication consumption. Conclusions: TENS reduces pain without increase analgesic medication consumption in patients with pancreatic cancer pain. It provides an alternative therapy for pain in pancreatic cancer.
C1 [He, Lihua] Jinan Univ, Fuda Canc Hosp, Dept Tradit Chinese Med, Jinan, Peoples R China.
   [He, Lihua] Guangzhou Univ Chinese Med, Guangzhou, Peoples R China.
   [He, Lihua; Yi, Hui; Wang, Xueliang] Jinan Univ, Fuda Canc Hosp, Dept Tradit Chinese Med, Guangzhou, Guangdong, Peoples R China.
   [Tan, Keping] Zhejiang Univ Tradit Chinese Med, Dept Acupuncture, Prov Tongde Hosp Zhejiang, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Xianming; Zhang, Jiangsong] Zhejiang Univ Tradit Chinese Med, Dept Acupuncture, Affiliated Hosp 3, Hangzhou, Zhejiang, Peoples R China.
   [Lin, Jietao; Lin, Lizhu] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China.
C3 University of Jinan; Guangzhou University of Chinese Medicine; Jinan University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Guangzhou University of Chinese Medicine
RP Lin, LZ (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Dept Oncol, Guangzhou, Guangdong, Peoples R China.
EM quincyhe@163.com
FU Guangdong provincial administration of traditional Chinese medicine [20162040]; National Clinical Key Specialty [ZX001232]
CR Arcidiacono PG, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007519.pub2
   Beck SL, 2010, J PAIN SYMPTOM MANAG, V39, P100, DOI 10.1016/j.jpainsymman.2009.06.009
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Bergeron-Vézina K, 2015, PAIN, V156, P2093, DOI 10.1097/j.pain.0000000000000276
   Chen AP, 2012, J AM ACAD DERMATOL, V67, P1025, DOI 10.1016/j.jaad.2012.02.010
   Chen L, 1998, ANESTH ANALG, V87, P1129, DOI 10.1097/00000539-199811000-00028
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Gibson W, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011976.pub2
   Guo Y, 2015, SHANGHAI J ACUPUNCT, V5, P464
   Hamza MA, 1999, ANESTHESIOLOGY, V91, P1232, DOI 10.1097/00000542-199911000-00012
   HAN JS, 1991, PAIN, V47, P295, DOI 10.1016/0304-3959(91)90218-M
   Hurlow A, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006276.pub3
   Inoue T, 2003, J NEUROL SCI, V211, P43, DOI 10.1016/S0022-510X(03)00038-8
   JEFFREY L, 2015, PAIN MED, V16, P1204, DOI 10.1111/pme.12038
   Johnson MI, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006142.pub3
   Kuai Le, 2012, ZHONGGUO ZHEN JIU, V32, P331
   LEEM JW, 1995, NEUROSCI LETT, V192, P197, DOI 10.1016/0304-3940(95)11644-C
   Lisi TL, 2006, J NEUROSCI METH, V150, P74, DOI 10.1016/j.jneumeth.2005.06.001
   Lisón JF, 2017, OBSTET GYNECOL, V129, P363, DOI 10.1097/AOG.0000000000001842
   Maedai Y, 2007, BRAIN RES, V1136, P43, DOI 10.1016/j.brainres.2006.11.061
   Meng FF, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013736
   Nagels W, 2013, PAIN MED, V14, P1140, DOI 10.1111/pme.12176
   Network, 2018, OPIOID PRINCIPLES PR, V0, P7
   Rakel BA, 2014, PAIN, V155, P2599, DOI 10.1016/j.pain.2014.09.025
   Robb K, 2009, J PAIN SYMPTOM MANAG, V37, P746, DOI 10.1016/j.jpainsymman.2008.03.022
   Turk DC, 2006, PAIN, V125, P208, DOI 10.1016/j.pain.2006.09.028
   Zheng YC, 2014, COMPLEMENT THER MED, V22, P724, DOI 10.1016/j.ctim.2014.05.005
NR 27
TC 11
Z9 13
U1 2
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD FEB 5
PY 2021
VL 100
IS 5
BP 
EP 
DI 10.1097/MD.0000000000023748
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA QB6GS
UT WOS:000614237200018
PM 33592831
DA 2026-01-16
ER

PT J
AU Li, WJ
   Gao, C
   An, LX
   Ji, YW
   Xue, FS
   Du, Y
AF Li, Wen-jing
   Gao, Chao
   An, Li-xin
   Ji, Yu-wei
   Xue, Fu-shan
   Du, Yi
TI Perioperative transcutaneous electrical acupoint stimulation for improving postoperative gastrointestinal function: A randomized controlled trial
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Transcutaneous electrical acupoint stimulation; Postoperative period; Gastrointestinal disorders; Substance P
ID colorectal-cancer resection; recovery; ileus; acupuncture; responses; risk; pain
AB Background: Postoperative gastrointestinal dysfunction (PGD) is one of the most common complications in patients undergoing major abdominal surgery. Acupuncture has been used widely in gastrointestinal diseases due to its effectiveness and minimally invasive nature. Objective: This study evaluated the efficacy of using transcutaneous electrical acupoint stimulation (TEAS) during the surgery and postoperative recovery in patients with gastric and colorectal surgery for improving postoperative gastrointestinal function. Design, setting, participants and interventions: A total of 280 patients undergoing abdominal surgery were stratified by type of surgery (i.e., gastric or colorectal surgery) and randomly allocated into the TEAS group (group T) or the sham group (group S). Patients in group T received TEAS at LI4, PC6, ST36 and ST37. Patients in group S received pseudo-TEAS at sham acupoints. The stimulation was given from 30 min before anesthesia until the end of surgery. The same treatment was performed at 9 am on the 1st, 2nd and 3rd days after surgery, until the recovery of flatus in patients. Main outcome measures: The primary outcome was the time to the first bowel motion, as detected by auscultation. The secondary outcomes included the first flatus and ambulation time, changes of perioperative substance P (SP), incidence of PGD, postoperative pain, postoperative nausea and vomiting (PONV) and some economic indicators. Results: The time to first bowel motion, first flatus and first ambulation in group T was much shorter than that in group S (P < 0.01). In patients undergoing colorectal surgery, the concentration of SP was lower in group T than in group S on the third day after the operation (P < 0.05). The average incidence of PGD in all patients was 25%, and the frequency of PGD was significantly lower in group T than in group S (18.6% vs. 31.4%, respectively; P < 0.05). TEAS treatment (odds ratio = 0.498; 95% confidence interval: 0.232-0.786) and type of surgery were relevant factors for the development of PGD. Postoperative pain score and PONV occurrence were significantly lower in group T (P < 0.01). Postoperative hospitalization days and the resulting cost to patients were greatly reduced in the TEAS group (P < 0.01). Conclusion: Perioperative TEAS was able to promote the recovery of postoperative gastrointestinal function, reduce the incidence of PGD and PONV. The concentration of SP was decreased by TEAS treatment, which indicates that the brain-gut axis may play a role in how TEAS regulates gastrointestinal function. Trial registration: Chinese Clinical Trial Registry, ChiCTR1900023263. Please cite this article as: Li WJ, Gao C, An LX, Ji YW, Xue FS, Du Y. Perioperative transcutaneous electrical acupoint stimulation for improving postoperative gastrointestinal function: A randomized controlled trial. J Integr Med. Perioperative transcutaneous electrical acupoint stimulation for improving postoperative gastrointestinal function: A randomized controlled trial. J Integr Med. 2021; 19(3): 211-218. (C) 2021 Shanghai Changhai Hospital. Published by ELSEVIER B.V. All rights reserved.
C1 [Li, Wen-jing; An, Li-xin; Ji, Yu-wei; Xue, Fu-shan] Capital Med Univ, Beijing Friendship Hosp, Dept Anesthesiol, Beijing 100050, Peoples R China.
   [Gao, Chao] Beijing Hui Min Hosp, Dept Anesthesiol, Beijing 100053, Peoples R China.
   [Du, Yi] Capital Med Univ, Beijing Friendship Hosp, Dept Tradit Chinese Med, Beijing 100050, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP An, LX (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Anesthesiol, Beijing 100050, Peoples R China.
EM anlixin8120@163.com
FU Beijing Administration of Traditional Chinese Medicine, PR China [JJ-2020-62]
CR An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682
   Bai YF, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04470-4
   Bragg D, 2015, CLIN NUTR, V34, P367, DOI 10.1016/j.clnu.2015.01.016
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen YZ, 2020, J GASTROEN HEPATOL, V35, P1549, DOI 10.1111/jgh.15020
   Cheng H, 2011, CHINESE MED J-PEKING, V124, P1229, DOI 10.3760/cma.j.issn.0366-6999.2011.08.020
   Chi YL, 2019, AM J CHINESE MED, V47, P1445, DOI 10.1142/S0192415X19500745
   Fu CW, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000020301
   Hedrick TL, 2018, ANESTH ANALG, V126, P1896, DOI 10.1213/ANE.0000000000002742
   Hou LL, 2016, J TRADIT CHIN MED, V36, P450
   Huang W, 2019, J TRADIT CHIN MED, V39, P433
   Liu LS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019610
   Liu YH, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/3178472
   Martin CR, 2018, CELL MOL GASTROENTER, V6, P133, DOI 10.1016/j.jcmgh.2018.04.003
   Murphy MM, 2016, J SURG RES, V201, P279, DOI 10.1016/j.jss.2015.10.047
   Paulasir S, 2015, DIS COLON RECTUM, V58, P870, DOI 10.1097/DCR.0000000000000430
   Qu Li Zhe, 2020, ZHEN CI YAN JIU, V45, P136, DOI 10.13702/j.1000-0607.1904016
   Shin KM, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/918392
   Steinhoff MS, 2014, PHYSIOL REV, V94, P265, DOI 10.1152/physrev.00031.2013
   Venara A, 2016, J VISC SURG, V153, P439, DOI 10.1016/j.jviscsurg.2016.08.010
   Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738
   Xue ZZ, 2019, LIFE SCI, V233, P0, DOI 10.1016/j.lfs.2019.116749
   Yang FM, 2020, CHIN J INTEGR MED, V26, P310, DOI 10.1007/s11655-019-3150-3
   Yang Y, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep37826
   Yu YC, 2019, FRONT CELL NEUROSCI, V13, P0, DOI 10.3389/fncel.2019.00030
   Yuan HC, 2020, CHIN J INTEGR MED, V26, P769, DOI 10.1007/s11655-019-3048-0
NR 26
TC 58
Z9 69
U1 13
U2 72
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
EI 
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD MAY 15
PY 2021
VL 19
IS 3
BP 211
EP 218
DI 10.1016/j.joim.2021.01.005
EA MAY 2021
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA RZ5ZR
UT WOS:000648676000003
PM 33495134
DA 2026-01-16
ER

PT J
AU Tola, YO
   Chow, KM
   Liang, W
AF Tola, Yetunde Oluwafunmilayo
   Chow, Ka Ming
   Liang, Wei
TI Effects of non-pharmacological interventions on preoperative anxiety and
SO Journal of clinical nursing
LA English
DT Journal Article
DE anxiety; breast cancer surgery; non-medicine; non-pharmacological; pain
AB BACKGROUND: Poorly managed preoperative anxiety and pain were reported to slow  the postoperative recovery of breast cancer patients. Thus, proactive management  using non-pharmacological interventions becomes essential for decreasing opioid  or anxiolytics consumption, anxiety level, pain intensity, postoperative  complications and improving patients' haemodynamics and satisfaction with care.  PURPOSE: To identify, analyse and synthesise the effects of non-pharmacological  interventions on preoperative anxiety and acute postoperative pain in women  undergoing breast cancer surgery. METHOD: For this systematic review, 12  databases including Ovid Nursing, PsycInfo, British Nursing Index, CINAHL,  Cochrane Library were searched to identify relevant studies. A total of 6,012  articles were identified from the search, six RCTs and one quasi-experimental  study that met the inclusion criteria were included after eligibility screening.  Narrative synthesis was used to analyse data extracted from the included  articles. The review adhered to the PRISMA guideline. RESULTS: Twelve outcomes  were measured in the included studies, including preoperative anxiety, and acute  postoperative pain. Music, massage, aromatherapy and acupuncture were the  interventions delivered. Music had a small-to-large effect size and aromatherapy  had a small effect size on reducing preoperative anxiety. Also, music had a large  effect size whilst acupuncture had a medium effect size on minimising  postoperative pain in women undergoing breast cancer surgery. CONCLUSION: Music,  aromatherapy and acupuncture appeared to be effective for reducing preoperative  anxiety and postoperative pain in women undergoing breast cancer surgery.  However, the small number of studies available for each intervention prevents  conclusive statements about which the most effective method. IMPLICATION FOR  CLINICAL PRACTICE: A nursing care pathway that standardises the use of  non-pharmacological interventions for the management of both preoperative anxiety  and postoperative pain in breast cancer surgery patients should be developed.
C1 The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China.
   Institute of Nursing Research, Osogbo, Nigeria.
   The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China.
   The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong, China.
NR 0
TC 0
SN 1365-270
EI 
J9 J Clin Nurs
PD MAY 5
PY 2021
VL 30
IS 23-24
BP 3369
EP 3384
DI 10.1111/jocn.15827
PG 15
WC Anxiety; prevention & control; Aromatherapy; Breast Neoplasms; surgery; Female; Humans; Music Therapy; Pain, Postoperative; therapy
UT PubMed:33942405
PM 33942405
DA 2021-05-05
ER

PT J
AU Sung, SH
   Kim, JW
   Han, JE
   Shin, BC
   Park, JK
   Lee, G
AF Sung, Soo-Hyun
   Kim, Ji-Won
   Han, Ji-Eun
   Shin, Byung-Cheul
   Park, Jang-Kyung
   Lee, Gihyun
TI Animal Venom for Medical Usage in Pharmacopuncture in Korean Medicine: Current
SO Toxins
LA English
DT Review
DE animal venom; bee venom; pharmacopuncture; snake venom; toad venom
AB Animal venoms, widespread throughout the world, are complex mixtures, the  composition of which depends on the venom-producing species. The objective of  this study was to contribute to the development of animal venom-based medicines  by investigating the use of animal venom pharmacopuncture in Korean medicine (KM)  institutions. We surveyed 256 public health centers from 1 through 31 October  2019 as guided by the Ministry of Health and Welfare (MoHW). A questionnaire  developed by an expert group was distributed and collected for statistical  analysis. The survey identified three types of animal venom-based  pharmacopuncture: bee, snake, and toad venoms. The medications are based on a  single animal venom ingredient and produced in 11 external herbal dispensaries  (EHDs). Each animal venom is processed, refined, and freeze-dried in a cleanroom  to produce a powder formulation that is later measured, diluted, filtered,  filled, sealed, sterilized, and packaged as pharmacopuncture injections used in  KM institutions. Bee venom therapy is effective in treating musculoskeletal pain,  snake venom therapy is effective in controlling bleeding during surgery, and toad  venom therapy is effective in cancer treatment. The study suggests that bee,  snake, and toad venoms could be used in medical institutions and have the  potential for drug development.
C1 Department of Policy Development, National Development Institute of Korean Medicine, Seoul 04554, Korea.
   Department of Policy Development, National Development Institute of Korean Medicine, Seoul 04554, Korea.
   Department of Policy Development, National Development Institute of Korean Medicine, Seoul 04554, Korea.
   Division of Clinical Medicine, School of Korean Medicine, Pusan National University, Yangsan 50612, Korea.
   Division of Clinical Medicine, School of Korean Medicine, Pusan National University, Yangsan 50612, Korea.
   College of Korean Medicine, Dongshin University, Naju 58245, Korea.
NR 0
TC 0
SN 2072-665
EI 
J9 Toxins (Basel)
PD FEB 5
PY 2021
VL 13
IS 2
BP 
EP 
DI 10.3390/toxins13020105
PG 0
WC Acupuncture Therapy; adverse effects; Amphibian Venoms; adverse effects; Animals; Bee Venoms; adverse effects; Humans; Medicine, Korean Traditional; Republic of Korea; Snake Venoms; adverse effects; Treatment Outcome
UT PubMed:33535603
PM 33535603
DA 2021-02-05
ER

PT J
AU Wang, Y
   Tao, S
   Yu, Z
   Luo, Y
   Li, Y
   Tang, J
   Chen, G
   Shuai, R
   Hu, X
   Wu, P
AF Wang, Yingni
   Tao, Siyu
   Yu, Zeyun
   Luo, Yun
   Li, Yuan
   Tang, Jie
   Chen, Guanhua
   Shuai, Rouxian
   Hu, Xinyue
   Wu, Ping
TI Effect of Moxibustion on β-EP and Dyn Levels of Pain-Related Indicators in
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Journal Article
AB BACKGROUND: Rheumatoid arthritis (RA) is a systemic immunodeficiency disease  characterized by persistent synovial inflammation, pannus formation, and bone and  cartilage destruction, resulting in joint malformations and function decline.  OBJECTIVE: The purpose of this study is to evaluate the effect of moxibustion on  clinical symptoms and levels of pain-related indicators beta-endorphin (β-EP) and  dynorphin (Dyn) in patients with RA and to explore the potential  anti-inflammatory and analgesic mechanisms of moxibustion in RA treatment.  METHODS: A total of 64 patients with RA who met the inclusion criteria were  randomly and equally classified into the control and treatment groups. The  control group received conventional treatment (oral methotrexate, folate, or  leflunomide prescribed for a long time). The treatment group was treated with  moxibustion at ST36 (Zusanli), BL23 (Shenshu), and Ashi points with respect to  the control group. Patients' clinical symptoms and routine inspection indexes  (rheumatoid factor [RF], erythrocyte sedimentation rate [ESR], and C-reactive  protein [CRP]) were recorded before and after treatment. Serum levels of tumor  necrosis factor-α (TNF-α), interleukin-1β (IL-1β), β-EP, and Dyn were determined  by enzyme-linked immunosorbent assay (ELISA). The software SPSS24.0 was used for  statistical analysis. RESULTS: (1) Compared with the pretreatment result, both of  the two groups' clinical symptoms and routine inspection indexes (RF, ESR, and  CRP) improved (P < 0.05), and the improvement of clinical symptoms in the  treatment group outperformed that in the control group (P < 0.05). (2) TNF-α and  IL-1β levels decreased significantly in the treatment group after treatment  (P < 0.01), while no significant difference was observed in the control group  (P > 0.05). (3) β-EP and Dyn levels in the treatment group were significantly  increased after treatment (P < 0.01, P < 0.01), but the control group showed no  significant difference (P > 0.05, P > 0.05). It is worth mentioning that the  serum TNF-α, IL-1β, β-EP, and Dyn levels between the two groups were  significantly different after 8 weeks of treatment (P < 0.05). (4) Differences in  the serum β-EP and Dyn levels in the patients of the treatment group were  correlated with TNF-α and IL-1β levels after treatment, and the correlation was  mainly negative (r < 0). CONCLUSION: Moxibustion can improve joint pain in  patients with RA using conventional western medicine. One of the mechanisms may  affect the serum β-EP and Dyn levels by downregulating the inflammatory factors  to play an anti-inflammatory and analgesic role.
C1 Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Hospital of Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
   Chengdu University of Traditional Chinese Medicine, Sichuan, Chengdu 610075, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD APR 23
PY 2021
VL 2021
IS 
BP 6637554
EP 6637554
DI 10.1155/2021/6637554
PG 0
UT PubMed:33884025
PM 33884025
DA 2021-04-23
ER

PT J
AU Han, C
   Liu, Y
   Fan, H
   Li, D
   Guo, N
AF Han, Changhui
   Liu, Yingjuan
   Fan, Huanfang
   Li, Dehui
   Guo, Na
TI Acupuncture Relieves Opioid-Induced Constipation in Clinical Cancer Therapy - A
SO Clinical epidemiology
LA English
DT Review
DE acupuncture; cancer; meta-analysis; opioid-induced constipation; pain
AB Cancer pain is a common problem in clinical cancer therapy. Opioid analgesia is  one of the most effective drugs for pain relief with satisfying performance  besides the side effect of opioid-induced constipation (OIC). Acupuncture, as a  Chinese traditional non-invasive intervention, has been applied to clinical  cancer pain management and functional constipation therapy. However, only a few  studies have adopted this treatment for OIC patients. Due to limited numbers of  investigated subjects and variability of application methods, including treatment  apparatus, acupoints, durations, and sessions, the interpretation of  acupuncture's therapy effects from single-site randomized clinical trials (RCT)  is limited. Therefore, we conducted a meta-analysis by collecting published data  from Pubmed, Embase, Cochrane library, and Web of Science. Five RCTs focusing on  the application of acupuncture with or without medication in OIC patients were  included. An overall remission rate of 86.8% in the acupuncture-treated group was  achieved, higher than the control group (78.9%; RR, 1.10, 95% CI [1.03, 1.18]).  The symptom scores, reporting on defecation frequency, defecation straining,  abdominal pain, defection time, and stool property, in acupuncture groups were  lower than control groups with a standardized mean difference (SMD) of -2.21  [-4.15, -0.27]. The quality of life (QOL) for patients in the acupuncture treated  group increased compared to the control group with reduced PAC-QOL scores (SMD,  -1.02 [-1.78, -0.26]). Referring to the effects from pure acupuncture treatment  (SMD, -0.43 [-0.83, -0.03]), the co-intervention of acupuncture and drugs (SMD,  -1.77 [-2.51, -1.02]) improved the life quality of patients more remarkably (P <  0.05). Overall, our data confirmed the therapeutic effects of acupuncture in the  treatment of OIC. The co-intervention of acupuncture with drugs improves the  outcomes of OIC patients better than a single strategy. Combined therapy with  both medicine and acupuncture has insightful potential for future clinical cancer  patient management on constipation problems.
C1 Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, People'sRepublic of China.
   Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
   Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, People'sRepublic of China.
   Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, People'sRepublic of China.
   Affiliated Hospital of Hebei University of Traditional Chinese Medicine, Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, People'sRepublic of China.
NR 0
TC 0
SN 1179-134
EI 1179-134
J9 Clin Epidemiol
PD OCT 12
PY 2021
VL 13
IS 
BP 907
EP 919
DI 10.2147/CLEP.S324193
PG 12
UT PubMed:34629905
PM 34629905
DA 2021-10-12
ER

PT J
AU Olson, EA
   Metzger, AK
   Mallory, MJ
   Mackey, RM
AF Olson, Emily A.
   Metzger, Abbey K.
   Mallory, Molly J.
   Mackey, Regina M.
TI Opioid-Induced Constipation and Acupuncture: A Case Discussion
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Key Acupuncture; cancer; opioid-induced constipation; palliative medicine; opioid
ID management; safety; pain
AB Background. Use of acupuncture for treatment of functional constipation is well studied; however, studies examining use of acupuncture for opioid-induced constipation are limited. Case Description. A 70-year-old woman with newly diagnosed multiple myeloma discovered after presentation to the emergency room with severe back pain. Pain management required use of opioids, escalating to effect. Hospital course was complicated by opioid-induced constipation causing abdominal pain, nausea, and ileus despite aggressive titration of stimulant and osmotic laxatives as well as administration of suppositories and enemas on multiple occasions. Prior to nasogastric tube placement for the ileus, the patient requested acupuncture treatment in attempt to relieve constipation. Shortly after acupuncture session, patient passed multiple stools with improvement in abdominal pain and nausea and avoidance of nasogastric tube. Conclusion. Acupuncture for opioid-induced constipation may provide symptom relief through use of nonpharmacologic interventions; however, further studies are needed to determine the optimal therapeutic approach. J Pain Symptom Manage 2021;62:876-880. (c) 2021 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Olson, Emily A.; Metzger, Abbey K.; Mackey, Regina M.] Mayo Clin, Ctr Palliat Med, Gen Internal Med, Rochester, MN 55905 USA.
   [Mallory, Molly J.] Mayo Clin, Integrat Med & Hlth, Gen Internal Med, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Olson, EA (corresponding author), Mayo Clin, Ctr Palliat Med, Dept Internal Med, 200 First St SW, Rochester, MN 55905 USA.
EM Olson.emily3@mayo.edu
CR Briggs JP, 2017, JAMA-J AM MED ASSOC, V317, P2489, DOI 10.1001/jama.2017.7214
   Chan MWC, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-03272-0
   Cybularz PA, 2015, MED ACUPUNCT, V27, P224, DOI 10.1089/acu.2015.1099
   Eigenschink M, 2020, WIEN KLIN WOCHENSCHR, V132, P260, DOI 10.1007/s00508-020-01625-w
   Ernst E, 2011, PAIN, V152, P755, DOI 10.1016/j.pain.2010.11.004
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Ketwaroo Gyanprakash A, 2013, CURR GASTROENTEROL REP, V15, P344, DOI 10.1007/s11894-013-0344-2
   Kouch DJ, 2011, ACUPUNCTURE DESK REF, V2, P0
   Ladas EJ, 2010, SUPPORT CARE CANCER, V18, P1487, DOI 10.1007/s00520-010-0926-6
   Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee HY, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2243-4
   Liu ZS, 2016, ANN INTERN MED, V165, P761, DOI 10.7326/M15-3118
   MacPherson H, 2004, QUAL SAF HEALTH CARE, V13, P349, DOI 10.1136/qshc.2003.009134
   Müller-Lissner S, 2017, PAIN MED, V18, P1837, DOI 10.1093/pm/pnw255
   Pergolizzi JV, 2020, DRUG DES DEV THER, V14, P1009, DOI 10.2147/DDDT.S221278
   Qin MX, 2010, JOURNAL OF QIQIHAR MEDICAL COLLEGE, V31, P3921, DOI 10.3969/J.ISSN.1002-1256.2010.24.039
   Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518
   Samolsky Dekel Boaz Gedaliahu, 2019, J OPIOID MANAG, V15, P375, DOI 10.5055/jom.2019.0527
   Thompson LMA, 2016, ASCO POST, V0, P0
   White Adrian, 2006, ACUPUNCTURE IN MEDICINE, V24, PS53, DOI 10.1136/aim.24.Suppl.53
   Wu J, 2014, MEDICINE, V93, P0, DOI 10.1097/MD.0000000000000284
   Xu XH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-423
   Yang XY, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0187723
   Yin T, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3410-8
   Zhang Feng-Li, 2009, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V29, P922
   Zheng H, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13307
   Zhou J, 2019, BIOMED RES INT, V2019, P0, DOI 10.1155/2019/7491281
   Zhou SL, 2017, ACUPUNCT MED, V35, P324, DOI 10.1136/acupmed-2016-011127
NR 30
TC 3
Z9 4
U1 2
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD OCT 15
PY 2021
VL 62
IS 4
BP 876
EP 880
DI 10.1016/j.jpainsymman.2021.01.135
EA SEP 2021
PG 5
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA WC6ML
UT WOS:000704370200025
PM 33556492
DA 2026-01-16
ER

PT J
AU Lu, ZH
   Wang, Q
   Sun, XD
   Zhang, W
   Min, S
   Zhang, JQ
   Zhao, WX
   Jiang, JF
   Wang, YH
   Zhu, YM
   Zheng, LL
   Wang, Y
   Guo, YY
   Zhang, LY
   Wang, LN
   Lei, C
   Liu, TT
   Yang, X
   Zhang, JB
   Li, C
   Zhang, N
   Dong, HL
   Xiong, LZ
AF Lu, Zhihong
   Wang, Qiang
   Sun, Xude
   Zhang, Wei
   Min, Su
   Zhang, Jiaqiang
   Zhao, Weixian
   Jiang, Jianfeng
   Wang, Yonghui
   Zhu, Yaomin
   Zheng, Lanlan
   Wang, Ying
   Guo, Yuanyuan
   Zhang, Liyuan
   Wang, Lini
   Lei, Chong
   Liu, Tingting
   Yang, Xue
   Zhang, Junbao
   Li, Chen
   Zhang, Nian
   Dong, Hailong
   Xiong, Lize
TI Transcutaneous electrical acupoint stimulation before surgery reduces chronic pain after mastectomy: A randomized clinical trial
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE Postoperative pain; Chronic pain; Mastectomy; Acupoint stimulation; Combined acupoints
ID breast-cancer; receptor antagonists; neuropathic pain; persistent pain; acupuncture; electroacupuncture; remifentanil; combination; consumption; mechanisms
AB Study objective: Despite multiple interventions, the incidence of chronic pain after mastectomy could be as high as 50% after surgery. This study aimed to determine the efficacy of transcutaneous electrical acupoint stimulation (TEAS) before anesthesia induction in reducing chronic pain and to compare the effect of combined acupoint TEAS with that of single acupoint TEAS. Design: A multicenter randomized clinical trial. Setting: The study was conducted at six medical centers in China from May 2016 to April 2018. Final follow-up was on October 26, 2018. Participants: Eligible patients were women scheduled for radical mastectomy under general anesthesia. Interventions: Patients were randomly and equally grouped into sham control (n = 188), single acupoint (PC6, n = 198), or combined acupoints (PC6 and CV17, n = 190) TEAS groups using a centralized computer-generated randomization system. TEAS was applied for 30 min before anesthesia induction. The sham-operated control group received electrode attachment but without stimulation. Anesthesiologists, surgeons, and outcome assessors were blinded to the interventions. Measures: The primary endpoint was the incidence of chronic pain 6 months after surgery. Incidences were compared among the groups using the unadjusted chi 2 test. Results: Of the 576 randomized patients, 568 completed the trial. In the intention-to-treat analysis, postmastectomy pain at 6 months was reported in 42 of 190 patients (22.1%) in the combined acupoints group, 65 of 188 patients (34.6%) in the sham-operated group (P = 0.007; relative risk [RR], 95% confidence interval [CI]: 0.68, 0.52-0.89), and 72 of 198 patients (36.4%) in the single acupoint group (P = 0.002; RR, 95% CI: 0.72,0.55-0.93). Remifentanil consumption during surgery and postoperative nausea and vomiting at 24 h after surgery were lower in the combined acupoint group than that in the sham-operated group. Conclusion: TEAS at combined acupoints before surgery was associated with reduced chronic pain 6 months after surgery. Trial registration: Clinicaltrials.gov identifier: NCT02741726. Registered on April 13, 2016.
C1 [Lu, Zhihong; Jiang, Jianfeng; Wang, Yonghui; Wang, Lini; Lei, Chong; Liu, Tingting; Yang, Xue; Zhang, Junbao; Dong, Hailong; Xiong, Lize] Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol & Perioperat Med, Changle West Rd 127, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Qiang; Zhu, Yaomin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Anesthesiol, Xian 710061, Shaanxi, Peoples R China.
   [Sun, Xude; Zhang, Nian] Fourth Mil Med Univ, Tangdu Hosp, Dept Anesthesiol, Xian 710038, Shaanxi, Peoples R China.
   [Zhang, Wei] Zhengzhou Univ, Affiliated Hosp 1, Dept Anesthesiol, Zhengzhou 450052, Henan, Peoples R China.
   [Min, Su] Chongqing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Chongqing 400016, Peoples R China.
   [Zhang, Jiaqiang] Zhengzhou Univ, Dept Anesthesiol & Perioperat Med, Peoples Hosp, Zhengzhou 450003, Henan, Peoples R China.
   [Zhao, Weixian] Guangdong Univ Tradit Chinese Med, Dept Anesthesiol, Affiliated Hosp 2, Guangzhou 510120, Guangdong, Peoples R China.
   [Li, Chen] Fourth Mil Med Univ, Dept Med Stat, Xian 710032, Shaanxi, Peoples R China.
   [Xiong, Lize] Tongji Univ, Translat Res Inst Brain & Brain Intelligence, Dept Anesthesiol & Perioperat Med, Shanghai Peoples Hosp 4,Sch Med, Shanghai 200434, Peoples R China.
C3 Air Force Medical University; Xi'an Jiaotong University; Air Force Medical University; Zhengzhou University; Chongqing Medical University; Zhengzhou University; Guangzhou University of Chinese Medicine; Air Force Medical University; Tongji University
RP Lu, ZH (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Anesthesiol & Perioperat Med, Changle West Rd 127, Xian 710032, Shaanxi, Peoples R China.; Xiong, LZ (corresponding author), Tongji Univ, Translat Res Inst Brain & Brain Intelligence, Dept Anesthesiol & Perioperat Med, Shanghai Peoples Hosp 4,Sch Med, Sanmen Rd 1279, Shanghai 200434, Peoples R China.
EM deerlu23@163.com; lizexiong@tongji.edu.cn
FU National Key Basic Research Pro-gram of China [2014CB543200]; Overseas, Hong Kong & Macao Scholars Collaborative Researching Fund [81228022]; Major Program of National Natural Science Foundation of China [81590954]; National Natural Science Foundation of China [81730032, 81871028]; Natural Science Foundation of Shaanxi Province [2018SF-277]
CR Abbas DN, 2018, PAIN PHYSICIAN, V21, P351, DOI 10.36076/ppj.2018.4.351
   Alizadeh R, 2014, J ACUPUNCT MERIDIAN, V7, P71, DOI 10.1016/j.jams.2013.04.005
   Andersen KG, 2015, PAIN, V156, P2413, DOI 10.1097/j.pain.0000000000000298
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Cabañero D, 2009, ANESTHESIOLOGY, V111, P1334, DOI 10.1097/ALN.0b013e3181bfab61
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen T, 2020, AM J CHINESE MED, V48, P793, DOI 10.1142/S0192415X20500408
   Cho AR, 2013, ANESTH ANALG, V116, P685, DOI 10.1213/ANE.0b013e31827ee372
   Claunch JD, 2012, AM J CHINESE MED, V40, P695, DOI 10.1142/S0192415X12500528
   Gärtner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568
   Glare P, 2019, LANCET, V393, P1537, DOI 10.1016/S0140-6736(19)30352-6
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang CP, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/312184
   Lu Z, 2015, BRIT J ANAESTH, V115, P183, DOI 10.1093/bja/aev227
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Meretoja TJ, 2014, JAMA-J AM MED ASSOC, V311, P90, DOI 10.1001/jama.2013.278795
   Mohamed SAB, 2013, J CLIN ANESTH, V25, P20, DOI 10.1016/j.jclinane.2012.05.006
   Fabro EAN, 2012, BREAST, V21, P321, DOI 10.1016/j.breast.2012.01.019
   Qiao L, 2020, AM J CHINESE MED, V48, P245, DOI 10.1142/S0192415X20500135
   Salengros JC, 2010, J CARDIOTHOR VASC AN, V24, P608, DOI 10.1053/j.jvca.2009.10.006
   Sessler DI, 2019, LANCET, V394, P1807, DOI 10.1016/S0140-6736(19)32313-X
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Woodworth GE, 2017, REGION ANESTH PAIN M, V42, P609, DOI 10.1097/AAP.0000000000000641
   Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021
   Yan Li-Ping, 2012, ZHEN CI YAN JIU, V37, P458
   Yang MJ, 2013, SCI WORLD J, V0, P0, DOI DOI 10.1155/2013/159732
   Yonehara N, 2001, NEUROSCI RES, V40, P45, DOI 10.1016/S0168-0102(01)00207-3
   Yoo JE, 2015, FORSCH KOMPLEMENTMED, V22, P111, DOI 10.1159/000381360
   Yu Jian-ming, 2010, ZHEN CI YAN JIU, V35, P43
   Zeng J, 2016, NEUROSCI LETT, V620, P38, DOI 10.1016/j.neulet.2016.03.041
   Zhang H, 2016, INT J CLIN EXP MED, V9, P23060
   Zhang JP, 2016, J ALTERN COMPLEM MED, V22, P800, DOI 10.1089/acm.2016.0016
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2012, BRIT J ANAESTH, V109, P245, DOI 10.1093/bja/aes136
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zhou J, 2011, INT J CARDIOL, V150, P12, DOI 10.1016/j.ijcard.2011.04.002
NR 39
TC 44
Z9 56
U1 3
U2 59
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD NOV 15
PY 2021
VL 74
IS 
BP 
EP 
DI 10.1016/j.jclinane.2021.110453
EA JUL 2021
PG 7
WC Anesthesiology
SC Anesthesiology
GA WC6DV
UT WOS:000704347600023
PM 34271271
DA 2026-01-16
ER

PT J
AU Zhang, X
   Qiu, H
   Li, C
   Cai, P
   Qi, F
AF Zhang, Xiaoyi
   Qiu, Hua
   Li, Chensheng
   Cai, Pingping
   Qi, Fanghua
TI The positive role of traditional Chinese medicine as an adjunctive therapy for
SO Bioscience trends
LA English
DT Review
DE Chinese herbal medicines; Traditional Chinese Medicine (TCM); acupuncture; anti-cancer therapy-related adverse reactions and complications; cancer-related symptoms
AB Traditional Chinese medicine (TCM), especially Chinese herbal medicines and  acupuncture, has been traditionally used to treat patients with cancers in China  and other East Asian countries. Numerous studies have indicated that TCM not only  alleviates the symptoms (e.g., fatigue, chronic pain, anorexia/cachexia, and  insomnia) of patients with cancer and improves their quality of life (QOL) but  also diminishes adverse reactions and complications caused by chemotherapy,  radiotherapy, or targeted-therapy. Therefore, Chinese herbal medicines and  acupuncture and other alternative therapies need to be understood by TCM  physicians and other health care providers. This review mainly summarizes the  experimental results and conclusions from literature published since 2010, and a  search of the literature as been performed in the PubMed, MEDLINE, Web of  Science, Scopus, Springer, ScienceDirect, and China Hospital Knowledge Database  (CHKD) databases. Some Chinese herbal medicines (e.g., Panax ginseng, Panax  quinquefolius, Astragali radix, Bu-zhong-yi-qi-tang (TJ-41), Liu-jun-zi-tang  (TJ-43), Shi-quan-da-bu-tang (TJ-48), and Ban-xia-xie-xin-tang (TJ-14)) and some  acupuncture points (e.g., Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6) and  Baihui (GV20)) that are commonly used to treat cancer-related symptoms and/or to  reduce the toxicity of chemotherapy, radiotherapy, or targeted-therapy are  highlighted and summarized. Through a review of literature, we conclude that TCM  can effectively alleviate adverse gastrointestinal reactions (including diarrhea,  nausea, and vomiting) to these anti-cancer therapies, decrease the incidence of  bone marrow suppression, alleviate cardiotoxicity, and protect against  chemotherapy-induced peripheral neuropathy and radiation-induced pneumonitis.  Moreover, TCM can alleviate epidermal growth factor receptor-tyrosine kinase  inhibitor (EGFR-TKI)-related acneiform eruptions, diarrhea, and other adverse  reactions. The hope is that this review can contribute to an understanding of TCM  as an adjuvant therapy for cancer and that it can provide useful information for  the development of more effective anti-cancer therapies. However, more rigorously  designed trials involving cancer treatment must be conducted in the future,  including complete quality control and standardized models at the cellular,  organic, animal and clinical levels, in order to study TCM in multiple forms and  at multiple levels.
C1 Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
   Gynecology, Jinan Municipal Hospital of Traditional Chinese Medicine, Ji'nan, China.
   Gastrointestinal Surgery, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
   Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
   Traditional Chinese Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Ji'nan, China.
NR 0
TC 0
SN 1881-782
EI 
J9 Biosci Trends
PD AUG 24
PY 2021
VL 15
IS 5
BP 283
EP 298
DI 10.5582/bst.2021.01318
PG 15
WC Animals; Combined Modality Therapy; Databases, Factual; Drugs, Chinese Herbal; therapeutic use; Humans; Medicine, Chinese Traditional; Neoplasms; complications; Quality of Life
UT PubMed:34421064
PM 34421064
DA 2021-08-24
ER

PT J
AU Fu, YB
   Chen, JW
   Li, B
   Yuan, F
   Sun, JQ
AF Fu, Yuan-Bo
   Chen, Jun-Wei
   Li, Bin
   Yuan, Fang
   Sun, Jing-Qing
TI [Effect of fire needling on mild to moderate knee osteoarthritis and related
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Western Ontario and McMaster Universities osteoarthritis index (WOMAC) score; fire needling; inflammatory cytokine; knee osteoarthritis
AB OBJECTIVE: To compare the clinical effect of fire needling and filiform needling  for mild to moderate knee osteoarthritis (KOA) and observe the influence on  related serum inflammatory sytokines. METHODS: A total of 60 patients with mild  to moderate KOA were randomly divided into an observation group (30 cases, 4  cases dropped off) and a control group (30 cases, 4 cases dropped off). Both  groups were given basic health management, and the acupoints of the two groups  were Liangqiu (ST 34), Xuehai (SP 10), Neixiyan (EX-LE 4), Dubi (ST 35),  Yanglingquan (GB 34) and ashi point. The observation group was treated with fire  needling, while the control group was treated with filiform needling. Both groups  were treated once every other day, 3 times a week for 2 weeks. The Western  Ontario and McMaster University osteoarthritis index (WOAMC) scores of the two  groups were compared before treatment, in 1, 2 weeks of treatment and 2, 6 weeks  of follow-up. ELISA method was used to detect the levels of serum interleukin 1α  (IL-1α), tumor necrosis factor α (TNF-α) and matrix metalloproteinase 3 (MMP-3)  before treatment and in 2 weeks of treatment. The clinical effect of the two  groups was evaluated in 1, 2 weeks of treatment and 2, 6 weeks of follow-up.  RESULTS: At each time point of treatment and follow-up, the pain, stiffness,  difficulty of daily activities scores and WOMAC total scores of the two groups  were lower than those before treatment (P<0.05); the stiffness score of the  observation group was lower than that of the control group in 1 week of treatment  (P<0.05); the various scores and total scores of the WOMAC scale of the  observation group were lower than those of the control group in 1, 2 weeks of  treatment and 2, 6 weeks of follow-up (P<0.05). In 2 weeks of treatment, the  levels of serum MMP-3 and IL-1α in the observation group and IL-1α in the control  group were higher than those before treatment (P<0.05). In 1 week of treatment  and 2, 6 weeks of follow-up, the total effective rates of the observation group  were higher than those in the control group (P<0.05). CONCLUSION: Fire needling  can improve the pain, stiffness and joint dysfunction of patients with mild to  moderate KOA, and increase serum MMP-3 and IL-1α levels. Its short and long term  clinical effects are better than filiform needling.
C1 Department of Acupuncture and Moxibustion, Capital Medical University, Beijing 100010, China
   Beijing Key Laboratory of Acupuncture Neuromodulation, BeijingHospital of TCM, Capital Medical University, Beijing 100010, China
   BeijingHuairou District Hospital of TCM, Beijing 101400.
   Department of Acupuncture and Moxibustion, Capital Medical University, Beijing 100010, China
   Beijing Key Laboratory of Acupuncture Neuromodulation, BeijingHospital of TCM, Capital Medical University, Beijing 100010, China
   BeijingUniversity of CM.
   Department of Acupuncture and Moxibustion, Beijing Hospital of TCM, Capital Medical University, Beijing 100010, China
   Beijing Key Laboratory of AcupunctureNeuromodulation, Beijing Hospital of TCM, Capital Medical University, Beijing100010, China.
   Department of Acupuncture and Moxibustion, Beijing Hospital of TCM, Capital Medical University, Beijing 100010, China
   Beijing Key Laboratory of AcupunctureNeuromodulation, Beijing Hospital of TCM, Capital Medical University, Beijing100010, China.
   Department of Acupuncture and Moxibustion, Beijing Hospital of TCM, Capital Medical University, Beijing 100010, China;Beijing Key Laboratory of AcupunctureNeuromodulation, Beijing Hospital of TCM, Capital Medical University, Beijing100010, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 19
PY 2021
VL 41
IS 5
BP 493
EP 7
DI 10.13703/j.0255-2930.20200708-k0003
PG -486
WC Acupuncture Points; Acupuncture Therapy; Cytokines; Humans; Osteoarthritis, Knee; therapy; Treatment Outcome
UT PubMed:34002561
PM 34002561
DA 2021-05-19
ER

PT J
AU Mele, C
AF Mele, Cheryl
TI Intrathecal Pain Pump for Pediatric Perverse Oncological Pain
SO JOURNAL OF PEDIATRIC NURSING-NURSING CARE OF CHILDREN & FAMILIES
LA English
DT Editorial Material
ID morphine
C1 [Mele, Cheryl] Drexel Univ, Philadelphia, PA 19104 USA.
   [Mele, Cheryl] Community Hosp & Palliat Care, Jacksonville, FL USA.
C3 Drexel University
RP Mele, C (corresponding author), Drexel Univ, Philadelphia, PA 19104 USA.
EM Cm3242@drexel.edu
CR Unknown -, 2019, WHAT IS INTR PUMP, V0, P0
   Bengali R, 2014, J PEDIAT HEMATOL ONC, V36, PE162, DOI 10.1097/MPH.0b013e31828e5dca
   Flowonix Medical Inc, 2019, TEEN GUID PROM 2 PRO, V0, P0
   Kim E, 2018, CLIN J PAIN, V34, P983, DOI 10.1097/AJP.0000000000000632
   Kleinmann B, 2017, NEUROMODULATION, V20, P719, DOI 10.1111/ner.12617
   Rauck R, 2010, NEUROMODULATION, V13, P102, DOI 10.1111/j.1525-1403.2009.00257.x
   Rosen SM, 2013, PAIN MED, V14, P865, DOI 10.1111/pme.12077
NR 7
TC 3
Z9 3
U1 2
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0882-5963
EI 
J9 J PEDIATR NURS
JI J. Pediatr. Nurs.
PD JAN-FEB 15
PY 2021
VL 56
IS 
BP 99
EP 100
DI 10.1016/j.pedn.2020.10.012
EA JAN 2021
PG 2
WC Nursing; Pediatrics
SC Nursing; Pediatrics
GA QB6QA
UT WOS:000614263600029
PM 33131926
DA 2026-01-16
ER

PT J
AU Kocot-Kępska, M
   Zajączkowska, R
   Zhao, J
   Wordliczek, J
   Tomasik, PJ
   Przeklasa-Muszyńska, A
AF Kocot-Kępska, Magdalena
   Zajączkowska, Renata
   Zhao, Jing
   Wordliczek, Jerzy
   Tomasik, Przemysław J
   Przeklasa-Muszyńska, Anna
TI The role of complementary and alternative methods in the treatment of pain in
SO Contemporary oncology (Poznan, Poland)
LA English
DT Review
DE acupuncture; cancer pain; complementary and alternative methods; pain management; physical activity
AB INTRODUCTION: Pain related to cancer, despite the numerous treatment options  available, is still a challenge in contemporary pain medicine. The unsatisfactory  treatment of cancer pain is one of the main reasons why patients seek  complementary and alternative methods (CAM) and a more integrative/holistic  approach to pain management. The popularity of CAM forces healthcare  professionals to provide patients with current and evidence-based information on  the effectiveness and safety of CAM. The aim of the paper is to present current  evidence and limitations regarding CAM commonly used in the pain management of  cancer patients. MATERIAL AND METHODS: The paper comprehensively reviews the  current and most relevant literature considering the integrative approach to  management of pain due to cancer disease and/or cancer treatment. RESULTS: The  available data from clinical trials, meta-analyses, and systematic reviews  supports the effectiveness of acupuncture, massage, physical exercises, music  therapy, and mind-body therapies as adjunct therapies for alleviating pain in  cancer patients, although the supporting evidence is weak or moderate.  CONCLUSIONS: Based on the available knowledge, physicians should be capable of  advising the cancer patient as to which CAM methods can be used safely, which are  contraindicated, and what therapeutic effects they may expect, especially when  standard pain treatment fails or induces serious side effects. An integrative  approach to cancer pain management may improve the quality of pain treatment,  patients' quality of life, and satisfaction with pain relief.
C1 Department for Pain Research and Treatment, Jagiellonian University Medical College, Krakow, Poland.
   Department of Interdisciplinary Intensive Care, Jagiellonian University Medical College, Krakow, Poland.
   Institute of Basic Research in Clinical Medicine, TCM Clinic, China Academy of Chinese Medical Sciences, Beijing, China.
   Department of Interdisciplinary Intensive Care, Jagiellonian University Medical College, Krakow, Poland.
   Department of Clinical Biochemistry, Polish-American Children's Hospital, Jagiellonian University Medical College, Krakow, Poland.
   Department for Pain Research and Treatment, Jagiellonian University Medical College, Krakow, Poland.
NR 0
TC 0
SN 1897-430
EI 1428-252
J9 Contemp Oncol (Pozn)
PD OCT 21
PY 2021
VL 25
IS 2
BP 88
EP 94
DI 10.5114/wo.2021.105969
PG 6
UT PubMed:34667434
PM 34667434
DA 2021-10-21
ER

PT J
AU Saraswati, W
   Wardani, R
   Suhatno
   Hartono, P
   Imandiri, A
AF Saraswati, Wita
   Wardani, Ratih
   Suhatno
   Hartono, Pudjo
   Imandiri, Ario
TI WITHDRAWN: The Effect of Electroacupuncture Therapy on Pain, Plasma β-Endorphin,
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
AB This article has been withdrawn at the request of the editor. The Publisher  apologizes for any inconvenience this may cause. The full Elsevier Policy on  Article Withdrawal can be found at  https://www.elsevier.com/about/our-business/policies/article-withdrawal.
C1 Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
   Department of Traditional Healer, Faculty of Vocations, Universitas Airlangga, Surabaya, Indonesia.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD JAN 8
PY 2021
VL 0
IS 
BP 
EP 
DI 10.1016/j.jams.2020.12.005
PG 0
UT PubMed:33412296
PM 33412296
DA 2021-01-08
ER

PT J
AU Zhang, XY
   Qiu, H
   Li, CS
   Cai, PP
   Qi, FH
AF Zhang, Xiaoyi
   Qiu, Hua
   Li, Chensheng
   Cai, Pingping
   Qi, Fanghua
TI The positive role of traditional Chinese medicine as an adjunctive therapy for cancer
SO BIOSCIENCE TRENDS
LA English
DT Review
DE Traditional Chinese Medicine (TCM); Chinese herbal medicines; acupuncture; cancer-related symptoms; anti-cancer therapy-related adverse reactions and complications
ID induced peripheral neuropathy; herbal medicine; hangeshashinto tj-14; adjuvant treatment; chemotherapy; fatigue; ginseng; insomnia; pharmacology; acupuncture
AB Traditional Chinese medicine (TCM), especially Chinese herbal medicines and acupuncture, has been traditionally used to treat patients with cancers in China and other East Asian countries. Numerous studies have indicated that TCM not only alleviates the symptoms (e.g., fatigue, chronic pain, anorexia/ cachexia, and insomnia) of patients with cancer and improves their quality of life (QOL) but also diminishes adverse reactions and complications caused by chemotherapy, radiotherapy, or targetedtherapy. Therefore, Chinese herbal medicines and acupuncture and other alternative therapies need to be understood by TCM physicians and other health care providers. This review mainly summarizes the experimental results and conclusions from literature published since 2010, and a search of the literature as been performed in the PubMed, MEDLINE, Web of Science, Scopus, Springer, ScienceDirect, and China Hospital Knowledge Database (CHKD) databases. Some Chinese herbal medicines (e.g., Panax ginseng, Panax quinquefolius, Astragali radix, Bu-zhong-yi-qi-tang (TJ-41), Liu-jun-zi-tang (TJ-43), Shi-quan-da-bu-tang (TJ-48), and Ban-xia-xie-xin-tang (TJ-14)) and some acupuncture points (e.g., Zusanli (ST36), Zhongwan (CV12), Neiguan (PC6) and Baihui (GV20)) that are commonly used to treat cancer-related symptoms and/or to reduce the toxicity of chemotherapy, radiotherapy, or targeted-therapy are highlighted and summarized. Through a review of literature, we conclude that TCM can effectively alleviate adverse gastrointestinal reactions (including diarrhea, nausea, and vomiting) to these anti-cancer therapies, decrease the incidence of bone marrow suppression, alleviate cardiotoxicity, and protect against chemotherapy-induced peripheral neuropathy and radiation-induced pneumonitis. Moreover, TCM can alleviate epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-related acneiform eruptions, diarrhea, and other adverse reactions. The hope is that this review can contribute to an understanding of TCM as an adjuvant therapy for cancer and that it can provide useful information for the development of more effective anti-cancer therapies. However, more rigorously designed trials involving cancer treatment must be conducted in the future, including complete quality control and standardized models at the cellular, organic, animal and clinical levels, in order to study TCM in multiple forms and at multiple levels.
C1 [Zhang, Xiaoyi; Cai, Pingping; Qi, Fanghua] Shandong First Med Univ, Shandong Prov Hosp, Tradit Chinese Med, Jinan, Peoples R China.
   [Qiu, Hua] Jinan Municipal Hosp Tradit Chinese Med, Gynecol, Jinan, Peoples R China.
   [Li, Chensheng] Shandong First Med Univ, Gastrointestinal Surg, Shandong Prov Hosp, Jinan, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences
RP Qi, FH (corresponding author), Shandong First Med Univ, Shandong Prov Hosp, Tradit Chinese Med, Jinan, Peoples R China.
EM qifanghua2006@126.com
FU National Natural Science Foundation of China [81603449]; Natural Science Foundation of Shandong Province [ZR2015HQ015]; Shandong Province Plan for Scientific and Technological Development of Traditional Chinese Medicine [20190310]
CR Arring NM, 2019, CANCER J, V25, P349, DOI 10.1097/PPO.0000000000000396
   Babiker HM, 2018, CRIT REV ONCOL HEMAT, V126, P186, DOI 10.1016/j.critrevonc.2018.03.014
   Barton DL, 2013, JNCI-J NATL CANCER I, V105, P1230, DOI 10.1093/jnci/djt181
   Behzadmehr R, 2020, COMPLEMENT THER MED, V49, P0, DOI 10.1016/j.ctim.2020.102318
   Bennett MI, 2019, PAIN, V160, P38, DOI 10.1097/j.pain.0000000000001363
   Berger Ann M, 2015, J NATL COMPR CANC NETW, V13, P1012
   Bledsoe TJ, 2017, CLIN CHEST MED, V38, P201, DOI 10.1016/j.ccm.2016.12.004
   Cai PL, 2018, MEDICINE, V97, P0, DOI 10.1097/md.0000000000009965
   Cai PP, 2019, BIOSCI TRENDS, V13, P367, DOI 10.5582/bst.2019.01244
   Cao MM, 2020, CANCER COMMUN, V40, P205, DOI 10.1002/cac2.12025
   Chang YD, 2018, AM J HOSP PALLIAT ME, V35, P144, DOI 10.1177/1049909117695733
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chen ZJ, 2020, J ETHNOPHARMACOL, V258, P0, DOI 10.1016/j.jep.2020.112895
   Cheng KC, 2012, CURR PHARM DESIGN, V18, P4819, DOI 10.2174/138161212803216979
   Cheng XL, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00344
   Cheon C, 2018, BMJ OPEN, V8, P0, DOI 10.1136/bmjopen-2017-021242
   Cheon C, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/8780325
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Cui YM, 2018, BIOMED PHARMACOTHER, V108, P1081, DOI 10.1016/j.biopha.2018.09.095
   Dan WC, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7498525
   Davis MP, 2014, CANCER J, V20, P330, DOI 10.1097/PPO.0000000000000071
   Deng B, 2016, J CHINA JAPAN FRIEND, V30, P30, DOI 10.3969/J.ISSN.1001-0025.2016.01.009
   Deng B, 2017, J TRADIT CHIN MED, V37, P35
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Fu J, 2014, PHYTOTHER RES, V28, P1275, DOI 10.1002/ptr.5188
   Fu L, 2014, CHIN CLIN ONCOL, V19, P739
   Ghosh R, 2020, MOLECULES, V25, P0, DOI 10.3390/molecules25245854
   Gu JL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2363262
   He HL, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/426207
   He Q, 2020, BIOL PHARM BULL, V43, P110, DOI 10.1248/bpb.b19-00616
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Herrmann J, 2014, TRENDS CARDIOVAS MED, V24, P285, DOI 10.1016/j.tcm.2014.07.003
   Hulvat MC, 2020, SURG CLIN N AM, V100, P469, DOI 10.1016/j.suc.2020.01.002
   Ichiki M, 2017, ONCOTARGETS THER, V10, P5107, DOI 10.2147/OTT.S145613
   Ishiura Yoshihisa, 2016, GAN TO KAGAKU RYOHO, V43, P331
   Jain Diwakar, 2019, HOSP PRACT (1995), V47, P6, DOI 10.1080/21548331.2018.1530831
   Jeong JS, 2010, INTEGR CANCER THER, V9, P331, DOI 10.1177/1534735410383170
   Johannes CM, 2019, VET CLIN N AM-SMALL, V49, P837, DOI 10.1016/j.cvsm.2019.04.008
   Kawai H, 2020, MOL CLIN ONCOL, V13, P0, DOI 10.3892/mco.2020.2083
   Kiefer D, 2003, AM FAM PHYSICIAN, V68, P1539
   Kim JW, 2020, EUR J CANCER, V130, P51, DOI 10.1016/j.ejca.2020.02.018
   Kim KI, 2018, PLOS ONE, V13, P0, DOI 10.1371/journal.pone.0198015
   Ko MH, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/15347354211019107
   Lam TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-1838-5
   Li FZ, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000019330
   Li TM, 2018, J ETHNOPHARMACOL, V213, P92, DOI 10.1016/j.jep.2017.10.031
   Li Wanying, 2018, ZHONGGUO ZHEN JIU, V38, P695, DOI 10.13703/j.0255-2930.2018.07.003
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Litscher G, 2002, LASER MED SCI, V17, P19, DOI 10.1007/s10103-002-8262-9
   Liu MX, 2014, J ETHNOPHARMACOL, V152, P575, DOI 10.1016/j.jep.2014.02.012
   Lv C, 2018, CURR OPIN SUPPORT PA, V12, P174, DOI 10.1097/SPC.0000000000000348
   Ma SJ, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1037-9
   Madeddu Clelia, 2012, CRITICAL REVIEWS IN ONCOGENESIS, V17, P305
   Metri Kashinath, 2013, J STEM CELLS, V8, P115
   Minagawa Tomonori, 2019, NIHON HINYOKIKA GAKKAI ZASSHI, V110, P86, DOI 10.5980/jpnjurol.110.86
   Mohandas H, 2017, J CANCER RES THER, V13, P916, DOI 10.4103/jcrt.JCRT_50_17
   Murai T, 2020, J RADIAT RES, V61, P140, DOI 10.1093/jrr/rrz025
   Nishikawa K, 2018, J CANCER, V9, P1725, DOI 10.7150/jca.24733
   OBrien K, 2016, J ALTERN COMPLEM MED, V22, P684, DOI 10.1089/acm.2016.0044
   ODonnell Joseph F, 2004, CLIN CORNERSTONE, V6 Suppl 1D, PS6, DOI 10.1016/S1098-3597(05)80002-X
   Ozawa N, 2020, CANCER MANAG RES, V12, P1069, DOI 10.2147/CMAR.S238306
   Peng YM, 2018, BIOSCI TRENDS, V12, P537, DOI 10.5582/bst.2018.01246
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Qi FH, 2010, BIOSCI TRENDS, V4, P297
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Shergis JL, 2017, PHYTOMEDICINE, V34, P38, DOI 10.1016/j.phymed.2017.07.004
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tian B, 2020, PHARM BIOL, V58, P265, DOI 10.1080/13880209.2020.1741651
   Urushiyama H, 2018, J CLIN MED, V7, P0, DOI 10.3390/jcm7090246
   Walker WH, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20112780
   Wang Ya-Ling, 2019, ZHONGGUO ZHEN JIU, V39, P1269, DOI 10.13703/j.0255-2930.2019.12.004
   Wang YS, 2020, BIOMED PHARMACOTHER, V121, P0, DOI 10.1016/j.biopha.2019.109570
   Wang ZX, 2018, BIOSCI TRENDS, V12, P220, DOI 10.5582/bst.2018.01144
   Wu BY, 2015, COMPLEMENT THER MED, V23, P251, DOI 10.1016/j.ctim.2015.01.006
   Xiao H, 2021, MEDICINE, V100, P0, DOI 10.1097/MD.0000000000025848
   Xiao Z, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000004517
   Xu LL, 2021, MOLECULES, V26, P0, DOI 10.3390/molecules26134000
   Xu RH, 2020, PHARMACOL RES, V152, P0, DOI 10.1016/j.phrs.2019.104623
   Yan ZK, 2017, COMB CHEM HIGH T SCR, V20, P423, DOI 10.2174/1386207320666170116141818
   Yennurajalingam S, 2015, INTEGR CANCER THER, V14, P419, DOI 10.1177/1534735415580676
   Zhou QH, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00076
NR 84
TC 307
Z9 354
U1 40
U2 217
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003, JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD OCT 15
PY 2021
VL 15
IS 5
BP 283
EP 298
DI 10.5582/bst.2021.01318
EA AUG 2021
PG 16
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA WX4FW
UT WOS:000697085800001
PM 34421064
DA 2026-01-16
ER

PT J
AU Carvalho, FS
   Carvalho, S
   Conde, R
   Esteves, S
AF Carvalho, Filipe Silva
   Carvalho, Susana
   Conde, Rita
   Esteves, Susana
TI Cynotherapy in Cancer Pain Management: A Pilot Study
SO PAIN MEDICINE
LA English
DT Article
DE Oncological Pain; Pain Management; Emotional Distress; Therapy Dog; Animal Assisted Therapy
ID animal-assisted therapy; pet-therapy; improve; health; dogs; intervention; satisfaction; guidelines; pathogens; distress
AB Objectives. This was a pilot study to evaluate the feasibility and impact of a single dog-assisted therapy (cynotherapy) session in reducing pain and emotional distress in oncological outpatients compared with typical waiting room experience (control). Design. This was a quasi-experimental before-after controlled study that took place at a chronic pain outpatient clinic of a tertiary cancer center, whose participants were adult oncological patients, able to consent and without medical contraindication. Setting. Chronic pain outpatient clinic of a tertiary cancer center. Participants. Adult oncological patients able to consent and without medical contraindication. Methods. All participants completed self-reported questionnaires including a numeric rating scale for pain and distress thermometer at admission and immediately before departure from the clinic. Results. Eighty-one patients were enrolled over a 10-month study period, 41 in the cynotherapy group and 40 controls. Improvement was greater in cynotherapy than control group for pain (median difference score = -1.0 vs 0.0; P = 0.037), distress levels (median = -1.0 vs 0.0; P = 0.017), and depression (median = -1.0 vs 0.0; P = 0.030). The proportion of patients with a clinically relevant improvement in pain (reduction >= 2 points) was approximately twofold in the cynotherapy group when compared with controls, although not statistically significant (39% vs 20%, odds ratio = 2.53, 95% confidence interval = 0.86-8.02; P = 0.088). The mean satisfaction rate was 9.3/10, and no negative occurrences were reported. Conclusion. A single session of dog-assisted therapy can provide immediate improvement in the perception of pain and distress for patients with chronic cancer pain in an outpatient setting, with high satisfaction rates and no negative occurrences. This nonrandomized pilot study points toward the clinical relevance of implementing cynotherapy at a cancer pain clinic and developing a larger scale, more directed study.
C1 [Carvalho, Filipe Silva] EPE, Unidade Psiquiatria, Inst Portugues Oncol Lisboa Francisco Gentil, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal.
   [Carvalho, Susana] EPE, Clin Dor, Inst Portugues Oncol Lisboa Francisco Gentil, Lisbon, Portugal.
   [Conde, Rita] EPE, Serv Oncol Med, Inst Portugues Oncol Lisboa Francisco Gentil, Lisbon, Portugal.
   [Esteves, Susana] EPE, Unidade Investigaqeo Clin, Inst Portugues Oncol Lisboa Francisco Gentil, Lisbon, Portugal.
RP Carvalho, FS (corresponding author), EPE, Unidade Psiquiatria, Inst Portugues Oncol Lisboa Francisco Gentil, Rua Prof Lima Basto, P-1099023 Lisbon, Portugal.
EM fcarvalho@ipolisboa.min-saude.pt
FU Liga Portuguesa Contra o Cancro
CR Abate SV, 2011, J CARDIOVASC NURS, V26, P224, DOI 10.1097/JCN.0b013e3182010bd6
   Unknown -, 1994, NURS STAND, V9, P55, DOI 10.7748/ns.9.11.55.s69
   Unknown -, 2018, R LANG ENV STAT COMP, V0, P0, DOI DOI 10.1111/J.1752-4571.2007.00013.X
   Barak Y, 2001, AM J GERIAT PSYCHIAT, V9, P439
   Bert F, 2016, EUR J INTEGR MED, V8, P695, DOI 10.1016/j.eujim.2016.05.005
   Caprilli S, 2006, EVID-BASED COMPL ALT, V3, P379, DOI 10.1093/ecam/nel029
   Carlson LE, 2004, BRIT J CANCER, V90, P2297, DOI 10.1038/sj.bjc.6601887
   Cole KM, 2007, AM J CRIT CARE, V16, P575
   Contalbrigo L, 2017, INT J ENV RES PUB HE, V14, P0, DOI 10.3390/ijerph14070683
   Charry-Sánchez JD, 2018, COMPLEMENT THER CLIN, V32, P169, DOI 10.1016/j.ctcp.2018.06.011
   Davidson JE, 2007, CRIT CARE MED, V35, P605, DOI 10.1097/01.CCM.0000254067.14607.EB
   Decat Cristiane SantAnna, 2009, PSICO-USF, V14, P253
   DeCourcey M, 2010, DIMENS CRIT CARE NUR, V29, P211, DOI 10.1097/DCC.0b013e3181e6c71a
   Ferreira-Valente MA, 2011, PAIN, V152, P2399, DOI 10.1016/j.pain.2011.07.005
   Filan SL, 2006, INT PSYCHOGERIATR, V18, P597, DOI 10.1017/S1041610206003322
   Fiocco AJ, 2017, INT J ENV RES PUB HE, V14, P0, DOI 10.3390/ijerph14070707
   Fleishman SB, 2015, J COMMUNITY SUPPORT, V13, P22, DOI 10.12788/jcso.0102
   Harper CM, 2015, CLIN ORTHOP RELAT R, V473, P372, DOI 10.1007/s11999-014-3931-0
   Hopko DR, 2008, J PSYCHOSOC ONCOL, V26, P31, DOI 10.1300/J077v26n01_03
   Jadoon NA, 2010, BMC CANCER, V10, P0, DOI 10.1186/1471-2407-10-594
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Lefebvre SL, 2008, ZOONOSES PUBLIC HLTH, V55, P470, DOI 10.1111/j.1863-2378.2008.01145.x
   Lefebvre SL, 2008, AM J INFECT CONTROL, V36, P78, DOI 10.1016/j.ajic.2007.09.005
   Lefebvre SL, 2009, JAVMA-J AM VET MED A, V234, P1404, DOI 10.2460/javma.234.11.1404
   Leonardi RJ, 2017, INT J ENV RES PUB HE, V14, P0, DOI 10.3390/ijerph14080945
   Mandrá PP, 2019, CODAS, V31, P0
   Marcus DA, 2013, PAIN MED, V14, P43, DOI 10.1111/j.1526-4637.2012.01522.x
   Marcus DA, 2012, PAIN MED, V13, P45, DOI 10.1111/j.1526-4637.2011.01294.x
   Martin F, 2002, WESTERN J NURS RES, V24, P657, DOI 10.1177/019394502320555403
   Mayo Clinic, 2020, ANIMAL ASSISTED THER, V0, P0
   Murthy R, 2015, INFECT CONT HOSP EP, V36, P495, DOI 10.1017/ice.2015.15
   MUSCHEL IJ, 1984, SOC CASEWORK-JCSW, V65, P451, DOI 10.1177/104438948406500801
   Odendaal JSJ, 2003, VET J, V165, P296, DOI 10.1016/S1090-0233(02)00237-X
   Orlandi M, 2007, ANTICANCER RES, V27, P4301
   Racine M, 2018, PROG NEURO-PSYCHOPH, V87, P269, DOI 10.1016/j.pnpbp.2017.08.020
   Rogers AH, 2018, PSYCHOL HEALTH MED, V23, P1231, DOI 10.1080/13548506.2018.1454598
   Ruchman R, 2001, AM J ROENTGENOL, V196, P0
   Silveira Isa Rodrigues, 2011, REV. ESC. ENFERM. USP, V45, P283
   Tribet J, 2008, ENCEPHALE, V34, P183, DOI 10.1016/j.encep.2007.01.006
   Urbanski BL, 2012, J PEDIATR ONCOL NURS, V29, P272, DOI 10.1177/1043454212455697
   Yamauchi T, 2008, AM J INFECT CONTROL, V11, P17
NR 44
TC 6
Z9 7
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD DEC 15
PY 2021
VL 22
IS 12
BP 3051
EP 3061
DI 10.1093/pm/pnab118
EA MAR 2021
PG 11
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA YI1JL
UT WOS:000743612400032
PM 33760046
DA 2026-01-16
ER

PT J
AU Magee, DJ
   Schutzer-Weissmann, J
   Pereira, EAC
   Brown, MRD
AF Magee, David J.
   Schutzer-Weissmann, John
   Pereira, Erlick A. C.
   Brown, Matthew R. D.
TI Neuromodulation techniques for cancer pain management
SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
LA English
DT Review
DE cancer; intrathecal drug delivery; neuromodulation; pain
ID spinal-cord stimulation; intrathecal morphine infusion; peripheral-nerve stimulation; breast-cancer; controlled-trial; delivery-system; opioid therapy; acupuncture; electroacupuncture; multicenter
AB Purpose of review Advanced pain management techniques may be indicated in 5-15% of cancer patients. Despite this, a recent review identified that, over the course of 1 year in England, only 458 patients received a procedure intended to provide analgesia and only 30 patients had intrathecal drug delivery (ITDD) devices implanted. This article describes the emerging evidence for ITDD in cancer pain and provides a narrative review of other neuromodulatory techniques (including spinal cord stimulation, peripheral nerve stimulation and acupuncture), approaches that might be employed to address this area of significant unmet clinical need. Recent findings Numerous studies have been published within the last year reporting positive outcomes associated with ITDD in cancer pain management. Neuromodulation represents an important strategy in the management of persistent pain. Whilst the nonmalignant pain evidence-base is rapidly growing, it remains sparse for cancer pain management. The growing cohort of cancer survivors may significantly benefit from neuromodulatory techniques. ITDD and other neuromodulatory techniques for cancer pain management appear underutilised in the UK and offer the prospect of better treatment for cancer patients with refractory pain or intolerable side-effects from systemic analgesics.
C1 [Magee, David J.] Inst Canc Res, Div Canc Biol, Signalling & Canc Metab Team, London, England.
   [Magee, David J.; Schutzer-Weissmann, John; Brown, Matthew R. D.] Royal Marsden Hosp, Pain Med Dept, London, England.
   [Pereira, Erlick A. C.] St Georges Univ London, Neurosci Res Ctr, Mol & Clin Sci Inst, London, England.
   [Pereira, Erlick A. C.] St Georges Univ Hosp, Dept Neurosurg, London, England.
   [Brown, Matthew R. D.] Inst Canc Res, Targeted Approaches Canc Pain Grp, London, England.
C3 Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; King's College London; City St Georges, University of London; City St Georges, University of London; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust
RP Magee, DJ (corresponding author), Royal Marsden Hosp, Pain Management Dept, Fulham Rd, London SW3 6JJ, England.
EM davidmagee@nhs.net
FU NHS; NIHR
CR Abd-Elsayed A, 2016, J CLIN ANESTH, V28, P74, DOI 10.1016/j.jclinane.2015.08.011
   Ballantyne JC, 2016, BMJ-BRIT MED J, V352, P0, DOI 10.1136/bmj.i20
   Basler MH, 2016, BMJ-BRIT MED J, V352, P0, DOI 10.1136/bmj.i589
   Becker R, 2000, STEREOT FUNCT NEUROS, V75, P16, DOI 10.1159/000048379
   Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001
   Brogan SE, 2020, ANESTH ANALG, V130, P1035, DOI 10.1213/ANE.0000000000004276
   Brown M, 2017, BRIT J ANAESTH, V119, P723, DOI 10.1093/bja/aex202
   Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759
   Caylor Jacob, 2019, BIOELECTRON MED, V5, P0, DOI 10.1186/s42234-019-0023-1
   Celestin J, 2009, PAIN MED, V10, P639, DOI 10.1111/j.1526-4637.2009.00632.x
   Chakravarthy K, 2018, NEUROMODULATION, V21, P431, DOI 10.1111/ner.12756
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Cheng Y, 2020, ANN PALLIAT MED, V9, P2163, DOI 10.21037/apm-20-1293
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   de Vos CC, 2014, PAIN, V155, P2426, DOI 10.1016/j.pain.2014.08.031
   Deer T, 2016, NEUROMODULATION, V19, P91, DOI 10.1111/ner.12381
   Deer TR, 2020, PAIN MED, V21, P1590, DOI 10.1093/pm/pnaa030
   Dorfer L, 1998, SCIENCE, V282, P242
   Duarte RV, 2020, NEUROMODULATION, V23, P1029, DOI 10.1111/ner.13264
   Dupoiron D, 2019, CURR OPIN SUPPORT PA, V13, P75, DOI 10.1097/SPC.0000000000000427
   Farrell SM, 2020, NEUROCHIRURGIE, V0, P0
   Filshie J, 2016, MED ACUPUNCTURE W SC, V0, P0
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Gupta M, 2020, PAIN PRACT, V20, P908, DOI 10.1111/papr.12929
   Hagedorn JM, 2020, J PAIN RES, V13, P3295, DOI 10.2147/JPR.S263857
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hayek SM, 2011, PAIN PHYSICIAN, V14, P219
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Huang WJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0032960
   Jin YX, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/8875433
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lopes A, 2020, BRAZ NEUROSURG, V39, P228, DOI 10.1055/s-0040-1709985
   Ma K, 2020, PAIN, V161, P2502, DOI 10.1097/j.pain.0000000000001957
   Mainkar O, 2020, NEUROMODULATION, V23, P819, DOI 10.1111/ner.13139
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   MEGLIO M, 1989, J NEUROSURG, V70, P519, DOI 10.3171/jns.1989.70.4.0519
   Mekhail NA, 2010, PAIN PRACT, V10, P103, DOI 10.1111/j.1533-2500.2009.00341.x
   Meyer-Friessem CH, 2019, CLIN J PAIN, V35, P111, DOI 10.1097/AJP.0000000000000661
   Minchom A, 2016, EUR J CANCER, V61, P102, DOI 10.1016/j.ejca.2016.03.078
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   NHS England, 2015, CLIN COMM POL INTR P, V0, P0
   ONOFRIO BM, 1990, J NEUROSURG, V72, P200, DOI 10.3171/jns.1990.72.2.0200
   Peng LH, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009389.pub3
   PENN RD, 1987, J NEUROSURG, V67, P182, DOI 10.3171/jns.1987.67.2.0182
   Puntillo F, 2020, PAIN THER, V9, P783, DOI 10.1007/s40122-020-00169-1
   Qin WJ, 2020, J PAIN RES, V13, P231, DOI 10.2147/JPR.S233905
   Rauck RL, 2003, J PAIN, V4, P441, DOI 10.1067/S1526-5900(03)00730-2
   Sdrulla AD, 2018, PAIN PRACT, V18, P1048, DOI 10.1111/papr.12692
   SHIMOJI K, 1993, ANESTH ANALG, V77, P110
   Sindt JE, 2020, NEUROMODULATION, V23, P978, DOI 10.1111/ner.13175
   Sindt JE, 2020, ANESTH ANALG, V131, P280, DOI 10.1213/ANE.0000000000004639
   Sivanesan E, 2019, PAIN REP, V4, P0, DOI 10.1097/PR9.0000000000000785
   Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118
   Sparkes E, 2010, PAIN, V150, P284, DOI 10.1016/j.pain.2010.05.001
   Spiegel MA, 2021, J PALLIAT MED, V24, P418, DOI 10.1089/jpm.2020.0206
   Stearns LJ, 2016, NEUROMODULATION, V19, P196, DOI 10.1111/ner.12384
   Stearns LM, 2020, ANESTH ANALG, V130, P289, DOI 10.1213/ANE.0000000000004425
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Yakovlev AE, 2012, AM J HOSP PALLIAT ME, V29, P93, DOI 10.1177/1049909111410414
   Yakovlev AE, 2010, AM J HOSP PALLIAT ME, V277, P552, DOI 10.1177/1049909110373240
NR 64
TC 10
Z9 10
U1 3
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1751-4258
EI 1751-4266
J9 CURR OPIN SUPPORT PA
JI Curr. Opin Support Palliat. Car.
PD JUN 15
PY 2021
VL 15
IS 2
BP 77
EP 83
DI 10.1097/SPC.0000000000000549
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA ST1XK
UT WOS:000662243900002
PM 33843762
DA 2026-01-16
ER

PT J
AU Bari, S
   Chineke, I
   Darwin, A
   Umar, A
   Jim, H
   Muzaffar, J
   Kucuk, O
AF Bari, Shahla
   Chineke, Iloabueke
   Darwin, Alicia
   Umar, Anam
   Jim, Heather
   Muzaffar, Jameel
   Kucuk, Omer
TI Awareness, Use and Outlook of Complementary and Alternative Medicine (CAM) Options in an Underserved, Uninsured Minority Cancer Patient Population
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE complementary medicine; alternative medicine; integrative medicine; health disparity; CAM
ID disclosure; communication; therapy
AB Integrative oncology aims to coordinate the delivery of conventional medicine and evidence-supported complementary and alternative medicine (CAM) to patients receiving cancer care. This field developed out of an increased interest in CAM usage among cancer patients. However, CAM use among medically underserved cancer patients remains to be well characterized. We evaluated CAM awareness as well as prevalence and characteristics of CAM use in 170 consecutive, medically underserved cancer patients presenting to a large, academic, inner-city cancer clinic, using a survey tool. Fifty-three participants declined participation and 17 survey results were incomplete. Therefore, 100 survey results were included in the final analysis. There were 65 males and 35 females in the survey with a mean age of 64.2 years. About 98% of the respondents were African American while 2% identified themselves as Hispanic. About 45% of patients had metastatic cancer, 24% had early-stage disease while 31% of patients were not aware of the stage of their cancer. About 55% patients had elementary school or lower level of education while only 16% had a college degree or higher. About 92% of respondents were unemployed. Some knowledge of CAM was reported by 22% of patients, while CAM use was reported in only 16% of patients. Female sex and college degree were significantly associated with CAM use. The most commonly used CAM modality was meditation (56%), followed by herbal remedies (31%), yoga (31%), and acupuncture (12%). Among CAM users, a majority used multiple CAM therapies. All users reported benefit from CAM use. Emotional wellbeing was the most common benefit followed by improvement in treatment related adverse effects, chemotherapy related symptoms, pain, and sleep. Even though the majority of our surveyed patients never used CAM, 90% of non-users were interested in gaining more information about the various CAM options and exploring its use and potential benefits. The majority (70%) wanted their primary oncologist to provide information about CAM options and discuss its safety and potential complementary benefit in management of their cancer and associated symptoms.
C1 [Bari, Shahla; Jim, Heather; Muzaffar, Jameel] H Lee Moffitt Canc Ctr & Res Inst, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.
   [Bari, Shahla; Chineke, Iloabueke; Umar, Anam] Morehouse Sch Med, Atlanta, GA 30310 USA.
   [Darwin, Alicia] Univ S Florida, Tampa, FL 33620 USA.
   [Kucuk, Omer] Emory Univ, Atlanta, GA 30322 USA.
C3 State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; Morehouse School of Medicine; State University System of Florida; University of South Florida; Emory University
RP Bari, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 USF Magnolia Dr, Tampa, FL 33612 USA.
EM Shahla.bari@moffitt.org
CR Unknown -, 2010, QUICKFACTS, V0, P0
   Barry CA, 2006, SOC SCI MED, V62, P2646, DOI 10.1016/j.socscimed.2005.11.025
   Black DS, 2016, J ALTERN COMPLEM MED, V22, P473, DOI 10.1089/acm.2015.0332
   Cassileth BR, 2005, J CLIN ONCOL, V23, P2590, DOI 10.1200/JCO.2005.11.922
   Chao MT, 2008, ETHNIC DIS, V18, P65
   Collins Sara R, 2015, ISSUE BRIEF (COMMONW FUND), V2, P1
   Davis EL, 2012, ONCOLOGIST, V17, P1475, DOI 10.1634/theoncologist.2012-0223
   Grotmol KS, 2017, J PAIN SYMPTOM MANAG, V54, P889, DOI 10.1016/j.jpainsymman.2017.04.010
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Jones D, 2018, INTEGR CANCER THER, V17, P371, DOI 10.1177/1534735417735892
   Luo QL, 2017, INTEGR CANCER THER, V16, P104, DOI 10.1177/1534735416643384
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Markman M, 2002, J CLIN ONCOL, V20, P39S, DOI 10.1200/JCO.2002.07.036
   Paltiel O, 2001, J CLIN ONCOL, V19, P2439, DOI 10.1200/JCO.2001.19.9.2439
   Robinson A, 2004, COMPLEMENT THER MED, V12, P90, DOI 10.1016/j.ctim.2004.09.006
   Robotin MC, 2006, MED J AUSTRALIA, V185, P377, DOI 10.5694/j.1326-5377.2006.tb00614.x
   Sohl SJ, 2015, CANCER-AM CANCER SOC, V121, P900, DOI 10.1002/cncr.29138
   Wanchai A, 2010, CLIN J ONCOL NURS, V14, P431, DOI 10.1188/10.CJON.E45-E55
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 21
TC 15
Z9 16
U1 2
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD DEC 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/15347354211051622
PG 6
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA XV2BL
UT WOS:000734753900003
PM 34923869
DA 2026-01-16
ER

PT J
AU Yang, W
   Zhang, Y
   Yang, G
   Geng, Y
   Chen, D
   Wang, J
   Ye, Y
   Wang, H
   Xia, D
   Hu, F
   Jiang, J
   Xu, X
AF Yang, Wei
   Zhang, Yeke
   Yang, Gaoyi
   Geng, Yanhua
   Chen, Da
   Wang, Jun
   Ye, Yang
   Wang, Huaichong
   Xia, Dajing
   Hu, Fuliang
   Jiang, Jing
   Xu, Xiaofeng
TI Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A
SO Frontiers in oncology
LA English
DT Journal Article
DE PD-1 inhibitor; STING pathway; apitherapy; bee venom; complementary medicine; immunotherapy; innate immunity; liposarcoma
AB Cancer immunotherapies, including immune checkpoint inhibitors, elicit long-term  clinical responses but many cancer patients do not respond. Intensive efforts are  therefore underway to identify additional immune pathways that may be modulated  to enhance the efficacy of existing immunotherapies. Bee venom strongly  stimulates the immune system, and is used as a complementary therapy to treat  cancer pain in patients with advanced tumors in China. Bee venom contains several  allergenic protease inhibitors and peptides. It triggers hypersensitivity  reactions; that is, it is an immune system agonist. The generation of a  spontaneous T cell response against tumor-associated antigens requires innate  immune activation; this drives type I interferon production. We report a patient  with a relapsed and refractory liposarcoma who had undergone several operations,  chemotherapies, and radiotherapies. The tumor was large. The patient had attained  the maximum radiation exposure dose. The tumor was resistant to chemotherapy and  was infiltrating the pericardium, lungs, and diaphragm. The patient was a poor  candidate for resection. He thus received apitherapy (a combination of bee venom  and acupuncture) to control pain; then apatinib (an anti-angiogenic drug) was  given to inhibit tumor growth but was terminated early because the patient could  not tolerate the side effects. Subsequently, a programmed death 1 inhibitor was  combined with apitherapy. Bee venom served as an innate immune system agonist  promoting immune cell priming and recruitment in the tumor microenvironment. The  patient was finally able to undergo radical liposarcoma resection, and no  evidence of recurrence was found at re-examination 16 months after surgery.
C1 Department of Oncology, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Oncology, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Medical Imaging, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Pathology, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Thoracic Surgery, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Traditional Chinese Medicine, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Traditional Chinese Medicine, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Pharmacy, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Toxicology of School of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
   College of Animal Sciences, Zhejiang University, Hangzhou, China.
   Department of Oncology, Hangzhou Red Cross Hospital, Hangzhou, China.
   Department of Oncology, Hangzhou Red Cross Hospital, Hangzhou, China.
NR 0
TC 0
SN 2234-943
EI 2234-943
J9 Front Oncol
PD MAY 18
PY 2021
VL 11
IS 
BP 668992
EP 668992
DI 10.3389/fonc.2021.668992
PG 0
UT PubMed:33996596
PM 33996596
DA 2021-05-18
ER

PT J
AU Popescu, RA
   Roila, F
   Arends, J
   Metro, G
   Lustberg, M
AF Popescu, Razvan Andrei
   Roila, Fausto
   Arends, Jann
   Metro, Giulio
   Lustberg, Maryam
TI Supportive Care: Low Cost, High Value.
SO American Society of Clinical Oncology educational book. American Society of
LA English
DT Journal Article
AB Supportive care aims to prevent and manage adverse effects of cancer and its  treatment across the entire disease continuum. Research and clinical experience  in dedicated centers have demonstrated that early appropriate supportive care  interventions improve symptoms, quality of life, and overall survival in a  cost-effective manner. The challenge is to assess symptoms and needs with  validated tools regularly and, ideally, between clinic appointments; electronic  patient-reported outcome measures and dedicated easily accessible supportive care  units can help. As management of certain problems improves, others come to the  fore. Cancer-related fatigue and malnutrition are very frequent and need regular  screening, assessment of treatable causes, and early intervention to improve.  Pharmacologic agents and phytopharmaceuticals are of little use, but other  interventions are valuable: physical exercise, counseling on fatigue, and  cognitive behavioral therapy/mind-body interventions (e.g., for fatigue).  Nutrition should be oral, rich in proteins, and accompanied by muscle training  adapted to the patient's condition. Psychological and societal counseling is  often useful; nausea or other problems such as gastrointestinal dysmotility or  metabolic derangements must be tackled. Chemotherapy-induced peripheral  neuropathy frequently worsens quality of life and has no established prevention  strategy (notwithstanding current interest in cryotherapy and compression  therapy) and thus requires careful assessment of patient predisposition to  develop it with the consideration of feasible dose and treatment alternatives.  When painful, duloxetine helps. Nonpharmacologic strategies, including  acupuncture, physical exercise, cryotherapy/compression, and scrambler therapy,  are promising but require large phase III trials to become the accepted standard.  Personalization of chemotherapy, dependent on realistic goals, is key.
C1 Tumor Zentrum Aarau and Hirslanden Clinic Aarau, Aarau, Switzerland.
   Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
   Department of Medicine I, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
   Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
   Division of Medical Oncology, The Ohio State University, Columbus, OH.
NR 0
TC 0
SN 1548-875
EI 
J9 Am Soc Clin Oncol Educ Book
PD APR 9
PY 2021
VL 41
IS 
BP 1
EP 11
DI 10.1200/EDBK_320041
PG 10
WC Exercise; Fatigue; Humans; Neoplasms; diagnosis; Pain; Quality of Life
UT PubMed:33830830
PM 33830830
DA 2021-04-09
ER

PT J
AU Huang, CC
   Ho, TJ
   Ho, HY
   Chen, PY
   Tu, CH
   Huang, YC
   Lee, YC
   Sun, MF
   Chen, YH
AF Huang, Chien-Chen
   Ho, Tsung-Jung
   Ho, Hsin-Yueh
   Chen, Pei-Yu
   Tu, Cheng-Hao
   Huang, Yu-Chuen
   Lee, Yu-Chen
   Sun, Mao-Feng
   Chen, Yi-Hung
TI Acupuncture Relieved Chemotherapy-Induced Peripheral Neuropathy in Patients with
SO Journal of clinical medicine
LA English
DT Journal Article
DE Semmes–Weinstein monofilament; acupuncture; breast cancer; chemotherapy; neuropathic pain; peripheral neuropathy
AB Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect  caused by neurotoxic chemotherapy. This randomized controlled trial aimed to  evaluate the effect of manual acupuncture on CIPN. Twenty eligible breast cancer  patients receiving taxane chemotherapy treatment were recruited and randomly  divided into verum acupuncture and sham acupuncture groups. Each group received  15 treatments over 9 weeks. Quantitative tactile detection thresholds were  measured using Semmes-Weinstein monofilament testing (SWM). The World Health  Organization Quality of Life scale (WHOQOL-BREF), the Functional Assessment of  Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), and the  Brief Pain Inventory-Short Form (BPI-SF) were measured before and after  treatment. The between-group comparison of SWM revealed that the verum  acupuncture group had more improvement of touch perception thresholds compared to  the sham acupuncture group. The average pain severity in the BPI-SF of the verum  acupuncture group was significantly lower than that of the sham acupuncture  group. There were no significant differences in the FACT/GOG-Ntx trial outcome  index and WHOQOL-BREF scores between the acupuncture and sham groups. The results  suggest that acupuncture can alleviate the neuropathic pain of CIPN and improve  touch perception thresholds.
C1 Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Department of Traditional Chinese Medicine, An Nan Hospital, China Medical 
   Department of Chinese Medicine, Hualien Tzu Chi Hospital, Hualien 970, Taiwan.
   School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien 
   Integration Center of Traditional Chinese and Modern Medicine, Hualien Tzu Chi Hospital, Hualien 970, Taiwan.
   Department of Surgery, An Nan Hospital, China Medical University, Tainan City 709, Taiwan.
   Cancer Center, An Nan Hospital, China Medical University, Tainan City 709, Taiwan.
   Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
   Department of Medical Research, China Medical University Hospital, School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Graduate Institute of Chinese Medicine, School of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 40402, Taiwan.
   Department of Acupuncture, China Medical University Hospital, Taichung 404332, 
   Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
   Department of Acupuncture, China Medical University Hospital, Taichung 404332, 
   Graduate Institute of Acupuncture Science, China Medical University, Taichung 40402, Taiwan.
   Chinese Medicine Research Center, China Medical University, Taichung 40402, 
   Department of Photonics and Communication Engineering, Asia University, Taichung 41354, Taiwan.
NR 0
TC 0
SN 2077-038
EI 2077-038
J9 J Clin Med
PD AUG 28
PY 2021
VL 10
IS 16
BP 
EP 
DI 10.3390/jcm10163694
PG 0
UT PubMed:34441990
PM 34441990
DA 2021-08-28
ER

PT J
AU Ben-Arye, E
   Zohar, S
   Keshet, Y
   Gressel, O
   Samuels, N
   Eden, A
   Vagedes, J
   Kassem, S
AF Ben-Arye, Eran
   Zohar, Shaked
   Keshet, Yael
   Gressel, Orit
   Samuels, Noah
   Eden, Arieh
   Vagedes, Jan
   Kassem, Sameer
TI Sensing the lightness: a narrative analysis of an integrative medicine program
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Burnout; COVID-19; Integrative medicine; Narrative-based medicine; Pain; Palliative care
AB OBJECTIVES: The research addressing physical and emotional exhaustion among  healthcare providers (HCPs) in COVID-19 departments is limited. We examined the  impact of integrative medicine (IM) intervention for HCPs working in isolated  COVID-19 in-patient departments, addressing concerns and well-being. METHODS:  HCPs working in 3 isolated COVID-19 in-patient departments underwent 40-min IM  treatment sessions (including acupuncture, manual movement, and/or mind-body  modalities) provided by integrative oncology practitioners. The MYCAW (Measure  Yourself Concerns and Well-being) questionnaire examined HCP concerns and  free-text narratives following IM treatments. Data were qualitatively analyzed  using ATLAS.Ti software for systematic coding. RESULTS: A total of 181 HCPs  underwent 305 IM treatments. Narrative themes focused on physical symptoms  (primarily pain and fatigue) and emotional concerns, including perceived  communication barriers with patients, and reflections on well-being and insights  following IM treatments. HCPs reported feeling a sense of "relief" which was  likely related to the 3 main effects of the IM intervention: a sense of "being  cared for" and treated; experiencing emotional, sometimes spiritual effects of  the treatment; and the feeling of relaxation, combined with the relief of pain.  Qualitative analysis identified clusters of emotional and spiritual-related  keywords such as "calming," "release," "relaxation," and "disengagement"  following the first IM session (119 of 181 narratives, 65.7%). CONCLUSIONS: HCPs  working in isolated COVID-19 departments reported improved well-being and the  addressing of their concerns following IM treatment sessions provided during  their work shift. Further research is needed to explore the impact of IM on HCP  burnout and resilience in palliative care settings.
C1 Integrative Oncology Program, The Oncology Service, Lin, Carmel, and Zebulun Medical Centers, Clalit Health Services, 35 Rothschild St., Haifa, Israel.eranben@netvision.net.il.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of 
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Sociology, Western Galilee Academic College, Galilee, Israel.
   Integrative Oncology Program, The Oncology Service, Lin, Carmel, and Zebulun Medical Centers, Clalit Health Services, 35 Rothschild St., Haifa, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of 
   Center for Integrative Complementary Medicine, Shaarei Zedek Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Depatment of Anesthesiology, Critical Care and Pain Medicine, Lady Davis Carmel 
   ARCIM Institute, Research Institute, Filderstadt, Germany.
   Department of Neonatology, University Hospital Tuebingen, University Tuebingen, 
   Ruth and Bruch Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
   Department of Internal Medicine, Lady Davis Carmel Medical Center, Haifa, Israel.
NR 0
TC 0
SN 1433-733
EI 0941-435
J9 Support Care Cancer
PD SEP 17
PY 2021
VL 30
IS 2
BP 1419
EP 1426
DI 10.1007/s00520-021-06546-6
PG 7
WC COVID-19; Health Personnel; Humans; Integrative Medicine; Integrative Oncology; SARS-CoV-2
UT PubMed:34528124
PM 34528124
DA 2021-09-17
ER

PT J
AU Wang, J
   Zhang, Q
   Deng, Y
   Deng, G
   Huang, F
   Zhou, Y
   Jia, M
   Yi, H
AF Wang, Jinlong
   Zhang, Quanhui
   Deng, Yongwen
   Deng, Gen
   Huang, Feihong
   Zhou, Yiduo
   Jia, Mingyan
   Yi, Haoran
TI Efficacy and safety of heat-sensitive moxibustion in the treatment of ulcerative
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Ulcerative colitis (UC) is a chronic nonspecific intestinal  inflammatory disease with unclear etiology occurring in the colonic mucosa. Its  clinical manifestations are characterized by recurrent abdominal pain, diarrhea,  mucous pus, and blood stool. The severity of the disease varies, and itis  characterized by a high recurrence rate. Because of its long course of disease,  easy to relapse, protracted and difficult to recover, seriously affect the  quality of life, increase the economic burden of patients and society, and even  the risk of developing cancer, it has become one of the hot issues of general  concern in the medical field. Heat-sensitive moxibustion therapy has shown strong  advantages in the treatment of UC, and the curative effect is accurate.  therefore, this paper will carry out a systematic evaluation and meta analysis of  the efficacy and safety of heat-sensitive moxibustion in the treatment of UC.  METHODS: We will be searching 8 electronic databases, including PubMed, Embase,  Web of Science, Cochrane Library, the China National Knowledge Infrastructure,  Chinese Science and Technology Periodical Database, Wanfang Database, and Chinese  Biomedical Literature Database. We will search above electronic databases from  the beginning to December 2020, without any language restriction. Clinical  efficacy, including total effective rate or cure rate, clinical symptom integral  (abdominal pain, diarrhea, purulent stool), and recurrence rate will be accepted  as the primary outcomes. The changes of cytokine Hs-CRP, IL-6, TNF-αlevels in  serum, and improvement of colorectal mucosa will be used as secondary outcomes.  RevMan 5.3 software will be used for statistical analysis. The result about the  curative effect and safety of heat-sensitive moxibustion for UC will be presented  as risk ratio for dichotomous data and mean differences with a 95% confidence  interval for continuous data. RESULTS: When this research program is completed,  the relevant results can be obtained. CONCLUSIONS: The results of this study will  provide reliable evidence for the efficacy and safety of heat-sensitive  moxibustion in the treatment of UC. INPLASY REGISTRATION NUMBER:  INPLASY20201101034.
C1 College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, China.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
   College of clinical medicine, Jiangxi University of Traditional Chinese Medicine.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD FEB 4
PY 2021
VL 100
IS 4
BP e24078
EP e24078
DI 10.1097/MD.0000000000024078
PG 1
WC Colitis, Ulcerative; therapy; Cytokines; metabolism; Humans; Intestinal Mucosa; metabolism; Moxibustion; adverse effects; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Research Design; Severity of Illness Index; Temperature; Meta-Analysis as Topic; Systematic Reviews as Topic
UT PubMed:33530201
PM 33530201
DA 2021-02-04
ER

PT J
AU Coveler, AL
   Mizrahi, J
   Eastman, BM
   Apisarnthanarax, S
   Dalal, S
   McNearney, T
   Pant, S
AF Coveler, Andrew L.
   Mizrahi, Jonathan
   Eastman, Boryana M.
   Apisarnthanarax, Smith Jim
   Dalal, Shalini
   McNearney, Terry
   Pant, Shubham
TI Pancreas Cancer-Associated Pain Management
SO ONCOLOGIST
LA English
DT Article
DE Pancreatic neoplasms; Pain management; Palliative care
ID celiac plexus block; intensity focused ultrasound; quality-of-life; alternative medicine use; release capsules creon; double-blind; palliative radiotherapy; opioid treatment; clinical-trial; electroacupuncture
AB Pain is highly prevalent in patients with pancreas cancer and contributes to the morbidity of the disease. Pain may be due to pancreatic enzyme insufficiency, obstruction, and/or a direct mass effect on nerves in the celiac plexus. Proper supportive care to decrease pain is an important aspect of the overall management of these patients. There are limited data specific to the management of pain caused by pancreatic cancer. Here we review the literature and offer recommendations regarding multiple modalities available to treat pain in these patients. The dissemination and adoption of these best supportive care practices can improve quantity and quality of life for patients with pancreatic cancer. Implications for Practice Pain management is important to improve the quality of life and survival of a patient with cancer. The pathophysiology of pain in pancreas cancer is complex and multifactorial. Despite tumor response to chemotherapy, a sizeable percentage of patients are at risk for ongoing cancer-related pain and its comorbid consequences. Accordingly, the management of pain in patients with pancreas cancer can be challenging and often requires a multifaceted approach.
C1 [Coveler, Andrew L.] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA.
   [Mizrahi, Jonathan; Apisarnthanarax, Smith Jim; Pant, Shubham] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA.
   [Eastman, Boryana M.] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA.
   [Dalal, Shalini] Univ Texas MD Anderson Canc Ctr, Dept Palliat Rehabil & Integrat Med, Houston, TX 77030 USA.
   [McNearney, Terry] Pancreat Canc Act Network, Manhattan Beach, CA USA.
C3 University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center
RP Coveler, AL (corresponding author), 825 Eastlake Ave East,Mailstop LG-465, Seattle, WA 98109 USA.
EM acoveler@uw.edu
FU NCI NIH HHS [T32 CA009666] Funding Source: Medline
CR Abrams DI, 2016, CURR ONCOL, V23, PS8, DOI 10.3747/co.23.3099
   Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154
   Arcidiacono PG, 2011, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007519.pub2
   Barreto SG, 2012, PANCREATOLOGY, V12, P104, DOI 10.1016/j.pan.2012.02.010
   Buckner CA, 2018, CURR ONCOL, V25, PE275, DOI 10.3747/co.25.3884
   Bunchorntavakul C, 2013, CLIN LIVER DIS, V17, P587, DOI 10.1016/j.cld.2013.07.005
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Buwenge M, 2018, J PAIN RES, V11, P2169, DOI 10.2147/JPR.S167994
   Carmichael AN, 2016, SUBST ABUSE REHABIL, V7, P71, DOI 10.2147/SAR.S85409
   Carvajal G, 2018, ANESTH ANALG, V126, P2038, DOI 10.1213/ANE.0000000000002903
   Ceyhan GO, 2009, GASTROENTEROLOGY, V136, P177, DOI 10.1053/j.gastro.2008.09.029
   Chandran P, 2003, PAIN, V102, P195, DOI 10.1016/S0304-3959(02)00381-0
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen JDZ, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13393
   Chen SP, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/609594
   Chiba T, 2020, BIOL PHARM BULL, V43, P873, DOI 10.1248/bpb.b19-01086
   Choi S, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0182794
   Corder G, 2018, ANNU REV NEUROSCI, V41, P453, DOI 10.1146/annurev-neuro-080317-061522
   Cornman-Homonoff J, 2017, SEMIN INTERVENT RAD, V34, P376, DOI 10.1055/s-0037-1608861
   Costamagna G, 1999, CAN J GASTROENTEROL, V13, P481, DOI 10.1155/1999/123210
   Cranford JA, 2016, DRUG ALCOHOL DEPEN, V169, P41, DOI 10.1016/j.drugalcdep.2016.10.008
   DHaese JG, 2014, WORLD J GASTROENTERO, V20, P9154, DOI 10.3748/wjg.v20.i27.9154
   Dababou S, 2017, J THER ULTRASOUND, V5, P0, DOI 10.1186/s40349-017-0080-4
   Dalal Shalini, 2019, AM SOC CLIN ONCOL EDUC BOOK, V39, P24, DOI 10.1200/edbk_100020
   Demir IE, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0060529
   Dobosz L, 2016, ANZ J SURG, V86, P756, DOI 10.1111/ans.13609
   Drewes AM, 2017, PANCREATOLOGY, V17, P720, DOI 10.1016/j.pan.2017.07.006
   Dupoiron D, 2019, PAIN MED, V20, P2033, DOI 10.1093/pm/pnz096
   Dupoiron D, 2019, CURR OPIN SUPPORT PA, V13, P75, DOI 10.1097/SPC.0000000000000427
   Ebrahimi G, 2018, ACTA ONCOL, V57, P697, DOI 10.1080/0284186X.2017.1400692
   Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Gear RW, 2008, J PAIN, V9, P337, DOI 10.1016/j.jpain.2007.11.011
   Gendron L, 2016, PHARMACOL REV, V68, P631, DOI 10.1124/pr.114.008979
   Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869
   Gubergrits N, 2011, ALIMENT PHARM THER, V33, P1152, DOI 10.1111/j.1365-2036.2011.04631.x
   Guindon J, 2009, CNS NEUROL DISORD-DR, V8, P403, DOI 10.2174/187152709789824660
   Hameed Mariam, 2010, CANCERS (BASEL), V3, P43, DOI 10.3390/cancers3010043
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hao SJ, 2014, SURG LAPARO ENDO PER, V24, P31, DOI 10.1097/SLE.0000000000000032
   Hendifar AE, 2019, ONCOLOGIST, V24, P691, DOI 10.1634/theoncologist.2018-0266
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Hirai I, 2002, PANCREAS, V24, P15, DOI 10.1097/00006676-200201000-00003
   Hubner RA, 2019, EUR J CANCER, V106, P24, DOI 10.1016/j.ejca.2018.09.029
   Huo ZJ, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-118
   Jain PN, 2005, J PAIN PALLIAT CARE, V19, P15, DOI 10.1300/J354v19n03_04
   Jermini M, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-41532-3
   John GM, 2016, J CANCER SURVIV, V10, P850, DOI 10.1007/s11764-016-0530-y
   Johnson CD, 2009, PANCREATOLOGY, V9, P755, DOI 10.1159/000199441
   Kim YJ, 2016, J PAIN SYMPTOM MANAG, V51, P762, DOI 10.1016/j.jpainsymman.2015.11.012
   Knezevic NN, 2017, ANESTH ANALG, V125, P1714, DOI 10.1213/ANE.0000000000002442
   Koulouris AI, 2017, DIGEST DIS SCI, V62, P861, DOI 10.1007/s10620-017-4488-z
   Lahoud MJ, 2016, WORLD J GASTRO ONCOL, V8, P599, DOI 10.4251/wjgo.v8.i8.599
   Lake S, 2019, PLOS MED, V16, P0, DOI 10.1371/journal.pmed.1002967
   Land BB, 2008, J NEUROSCI, V28, P407, DOI 10.1523/JNEUROSCI.4458-07.2008
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lawrence YR, 2018, J CLIN ONCOL, V36, P0, DOI 10.1200/JCO.2018.36.15_suppl.10098
   Lee IS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/1304152
   Leppert W, 2015, DRUG DES DEV THER, V9, P2215, DOI 10.2147/DDDT.S32684
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   LILLEMOE KD, 1993, ANN SURG, V217, P447, DOI 10.1097/00000658-199305010-00004
   Lohse I, 2020, ANTICANCER RES, V40, P1789, DOI 10.21873/anticanres.14133
   Magee DJ, 2019, BRIT J ANAESTH, V123, PE412, DOI 10.1016/j.bja.2019.02.028
   Maloney E, 2015, INT J HYPERTHER, V31, P302, DOI 10.3109/02656736.2014.969789
   Marinova M, 2017, SCHMERZ, V31, P31, DOI 10.1007/s00482-016-0140-7
   Marinova M, 2019, ROFO-FORTSCHR RONTG, V191, P216, DOI 10.1055/a-0820-5564
   McNearney TA, 2013, CLIN EXP RHEUMATOL, V31, P0
   MERCADANTE S, 1993, PAIN, V52, P187, DOI 10.1016/0304-3959(93)90130-H
   Mercadante S, 2015, EUR J PHARMACOL, V769, P71, DOI 10.1016/j.ejphar.2015.10.049
   Michalski CW, 2008, INT J CANCER, V122, P742, DOI 10.1002/ijc.23114
   Morganti AG, 2003, J PALLIAT CARE, V19, P258, DOI 10.1177/082585970301900407
   Morrone LA, 2017, CURR NEUROPHARMACOL, V15, P444, DOI 10.2174/1570159X14666161101092822
   Müller MW, 2008, AM J SURG, V195, P221, DOI 10.1016/j.amjsurg.2007.02.026
   Nagels W, 2013, PAIN MED, V14, P1140, DOI 10.1111/pme.12176
   Nersesyan Hrachya, 2007, THER CLIN RISK MANAG, V3, P381
   OBrien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970
   ONOFRIO BM, 1981, MAYO CLIN PROC, V56, P516
   Palta M, 2019, PRACT RADIAT ONCOL, V9, P322, DOI 10.1016/j.prro.2019.06.016
   Pérez-Hernández C, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-54195-x
   Ryan John F, 2018, ONCOTARGET, V9, P16427, DOI 10.18632/oncotarget.24713
   Sallam H, 2007, DIGEST DIS SCI, V52, P1329, DOI 10.1007/s10620-006-9257-3
   Sanchez, 2021, ROUTES ADM CANNABIS, V0, P0
   Sarosiek I, 2017, J NEUROGASTROENTEROL, V23, P245, DOI 10.5056/jnm16097
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009596.pub4
   Siegel Rebecca L, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sivanesan E, 2016, ANESTH ANALG, V123, P836, DOI 10.1213/ANE.0000000000001417
   Smith HS, 2009, PAIN PHYSICIAN, V12, P269
   Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7
   Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118
   So WKW, 2009, ONCOL NURS FORUM, V36, P405, DOI 10.1188/09.ONF.E205-E214
   Staats PS, 2001, PAIN MED, V2, P28, DOI 10.1046/j.1526-4637.2001.002001028.x
   Starowicz K, 2017, ADV PHARMACOL, V80, P437, DOI 10.1016/bs.apha.2017.05.003
   Starowicz K, 2012, PHILOS T R SOC B, V367, P3286, DOI 10.1098/rstb.2011.0392
   Stefaniak T, 2005, EJSO-EUR J SURG ONC, V31, P768, DOI 10.1016/j.ejso.2005.03.012
   Strunk HM, 2016, ROFO-FORTSCHR RONTG, V188, P662, DOI 10.1055/s-0042-105517
   Stub T, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1326-3
   Trapnell BC, 2009, J CYST FIBROS, V8, P370, DOI 10.1016/j.jcf.2009.08.008
   Trescot AM, 2008, PAIN PHYSICIAN, V11, P0
   Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070
   van den Beuken-van Everdingen MHJ, 2018, CANCERS, V10, P0, DOI 10.3390/cancers10120502
   van Geenen RCI, 2002, WORLD J SURG, V26, P715, DOI 10.1007/s00268-002-6210-2
   Vance CGT, 2014, PAIN MANAG, V4, P197, DOI 10.2217/PMT.14.13
   VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0
   Vella-Brincat Jane, 2007, J PAIN PALLIAT CARE PHARMACOTHER, V21, P15, DOI 10.1300/J354v21n01_05
   Vidal-Jove J, 2015, ULTRASON SONOCHEM, V27, P703, DOI 10.1016/j.ultsonch.2015.05.026
   Wang CP, 2008, J ALTERN COMPLEM MED, V14, P833, DOI 10.1089/acm.2008.0107
   Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1
   Warshaw AL, 1998, GASTROENTEROLOGY, V115, P765, DOI 10.1016/S0016-5085(98)70157-X
   Wehrmann T, 2005, EUR J GASTROEN HEPAT, V17, P1395, DOI 10.1097/00042737-200512000-00020
   Westermann A, 2019, J CLIN ONCOL, V37, P0, DOI 10.1200/JCO.2019.37.4_suppl.429
   Whitcomb DC, 2010, AM J GASTROENTEROL, V105, P2276, DOI 10.1038/ajg.2010.201
   Winkelmuller M, 1996, J NEUROSURG, V85, P458, DOI 10.3171/jns.1996.85.3.0458
   Wolfgang CL, 2013, CA-CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Wolny-Rokicka E, 2016, MOL CLIN ONCOL, V4, P1088, DOI 10.3892/mco.2016.851
   Wong AA, 2005, AM J CLIN ONCOL-CANC, V28, P227, DOI 10.1097/01.coc.0000145290.06582.c3
   Wong GY, 2004, JAMA-J AM MED ASSOC, V291, P1092, DOI 10.1001/jama.291.9.1092
   Wyse JM, 2011, J CLIN ONCOL, V29, P3541, DOI 10.1200/JCO.2010.32.2750
   Xin JJ, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/9708094
   Xiong LL, 2009, J PANCREAS, V10, P123
   Zhang CL, 2008, DIGEST DIS SCI, V53, P856, DOI 10.1007/s10620-007-9905-2
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao H, 2010, ANTI-CANCER DRUG, V21, P447, DOI 10.1097/CAD.0b013e32833641a7
   Zhong W, 2014, PAIN PRACT, V14, P43, DOI 10.1111/papr.12083
   Zhou Xian, 2019, MEDICINES (BASEL), V6, P0, DOI 10.3390/medicines6010014
   Zhou YF, 2014, GASTROENT RES PRACT, V2014, P0, DOI 10.1155/2014/205325
   Zhu ZW, 2002, MOL CARCINOGEN, V35, P138, DOI 10.1002/mc.10083
NR 127
TC 66
Z9 72
U1 7
U2 29
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUN 15
PY 2021
VL 26
IS 6
BP E971
EP E982
DI 10.1002/onco.13796
EA MAY 2021
PG 12
WC Oncology
SC Oncology
GA SN2ZZ
UT WOS:000649456000001
PM 33885205
DA 2026-01-16
ER

PT J
AU Mao, JJ
   Pillai, GG
   Andrade, CJ
   Ligibel, JA
   Basu, P
   Cohen, L
   Khan, IA
   Mustian, KM
   Puthiyedath, R
   Dhiman, KS
   Lao, L
   Ghelman, R
   Cáceres, Guido P
   Lopez, G
   Gallego-Perez, DF
   Salicrup, LA
AF Mao, Jun J
   Pillai, Geetha Gopalakrishna
   Andrade, Carlos Jose
   Ligibel, Jennifer A
   Basu, Partha
   Cohen, Lorenzo
   Khan, Ikhlas A
   Mustian, Karen M
   Puthiyedath, Rammanohar
   Dhiman, Kartar Singh
   Lao, Lixing
   Ghelman, Ricardo
   Cáceres Guido, Paulo
   Lopez, Gabriel
   Gallego-Perez, Daniel F
   Salicrup, Luis Alejandro
TI Integrative oncology: Addressing the global challenges of cancer prevention and
SO CA: a cancer journal for clinicians
LA English
DT Review
DE alternative; and integrative medicine; cancer prevention; complementary; global health; health policy; survivorship
AB The increase in cancer incidence and mortality is challenging current cancer care  delivery globally, disproportionally affecting low- and middle-income countries  (LMICs) when it comes to receiving evidence-based cancer prevention, treatment,  and palliative and survivorship care. Patients in LMICs often rely on  traditional, complementary, and integrative medicine (TCIM) that is more  familiar, less costly, and widely available. However, spheres of influence and  tensions between conventional medicine and TCIM can further disrupt efforts in  evidence-based cancer care. Integrative oncology provides a framework to research  and integrate safe, effective TCIM alongside conventional cancer treatment and  can help bridge health care gaps in delivering evidence-informed,  patient-centered care. This growing field uses lifestyle modifications, mind and  body therapies (eg, acupuncture, massage, meditation, and yoga), and natural  products to improve symptom management and quality of life among patients with  cancer. On the basis of this review of the global challenges of cancer control  and the current status of integrative oncology, the authors recommend: 1)  educating and integrating TCIM providers into the cancer control workforce to  promote risk reduction and culturally salient healthy life styles; 2) developing  and testing TCIM interventions to address cancer symptoms or treatment-related  adverse effects (eg, pain, insomnia, fatigue); and 3) disseminating and  implementing evidence-based TCIM interventions as part of comprehensive  palliative and survivorship care so patients from all cultures can live with or  beyond cancer with respect, dignity, and vitality. With conventional medicine and  TCIM united under a cohesive framework, integrative oncology may provide citizens  of the world with access to safe, effective, evidence-informed, and culturally  sensitive cancer care.
C1 Bendheim Integrative Medicine Center, Memorial Sloan Kettering Cancer Center, New York, New York.
   Traditional, Complementary and Integrative Medicine Unit, Service Delivery and Safety Department, World Health Organization, Geneva, Switzerland.
   Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
   Leonard P. Zakim Center for Integrative Therapies and Healthy Living, Dana-Farber Cancer Institute, Boston, Massachusetts.
   Harvard Medical School, Boston, Massachusetts.
   International Agency for Research on Cancer, World Health Organization, Lyon, France.
   Integrative Medicine Program, Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston,Texas.
   National Center for Natural Products Research, University of Mississippi, Jackson, Mississippi.
   Wilmot Cancer Institute, Department of Surgery, University of Rochester Medical Center, Rochester, New York.
   Amrita Vishwa Vidyapeetham University, Amritapuri, Kerala, India.
   Central Council for Research in Ayurvedic Sciences, New Delhi, India.
   Virginia University of Integrative Medicine, Fairfax, Virginia.
   Brazilian Academic Consortium for Integrative Health, University of São Paulo, São Paulo, Brazil.
   Pharmacokinetics and Research in Clinical Pharmacology and Integrative Medicine Group, Garrahan Pediatric Hospital, Buenos Aires, Argentina.
   Traditional, Complementary, and Integrative Medicine Network of the Americas, São 
   Integrative Medicine Program, Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston,Texas.
   Traditional, Complementary, and Integrative Medicine Network of the Americas, São Paulo, Brazil.
   Boston University School of Public Health, Boston, Massachusetts.
   Center for Global Health and Office of Cancer Complementary and Alternative Medicine, Division of Cancer Treatment and Diagnosis, National Cancer Institute,National Institutes of Health, Rockville, Maryland.
NR 0
TC 0
SN 1542-486
EI 
J9 CA Cancer J Clin
PD NOV 10
PY 2021
VL 72
IS 2
BP 144
EP 164
DI 10.3322/caac.21706
PG 20
WC Complementary Therapies; Delivery of Health Care; Humans; Integrative Medicine; Integrative Oncology; Neoplasms; prevention & control; Quality of Life
UT PubMed:34751943
PM 34751943
DA 2021-11-10
ER

PT J
AU Diller, ML
   Master, VA
AF Diller, Maggie L.
   Master, Viraj A.
TI Integrative surgical oncology: A model of acute integrative oncology
SO CANCER
LA English
DT Review
DE acute integrative oncology; complementary medicine; integrative surgery; integrative surgical oncology
ID chemotherapy-induced nausea; cancer-related fatigue; postoperative pain; preoperative anxiety; p6 acustimulation; music interventions; risk-factors; acupuncture; acupressure; hypnosis
AB Integrative oncology has emerged as a recognized medical subspecialty because of growing interest in the use of integrative medicine in modern cancer care on behalf of both patients and providers. Acutherapy and mind-body techniques, such as meditation and yoga, have been shown to aid in symptom control and improve quality of life in oncologic patient populations, and the Society of Integrative Oncology and American Society of Clinical Oncology have recently endorsed a set of guidelines for the implementation of these techniques specifically in patients with breast cancer. Although the current guidelines focus largely on the management of chronic symptoms, there exists evidence to support the use of these techniques in acute symptom management as well. With surgical resection representing the backbone of many cancer treatment regimens, symptoms that arise during the perioperative period are prime examples of the acute symptomatology common among patients with cancer. Here, the authors provide a detailed literature review of the current evidence supporting the use of integrative techniques during the perioperative period and demonstrate their applicability for acute symptom management within oncologic and surgical populations. In doing so, the authors introduce a new paradigm of surgical practice they call integrative surgical oncology and integrative surgery.
C1 [Diller, Maggie L.] Emory Univ, Dept Surg, Atlanta, GA 30322 USA.
   [Diller, Maggie L.; Master, Viraj A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Master, Viraj A.] Emory Univ, Dept Urol, Atlanta, GA 30322 USA.
C3 Emory University; Emory University; Emory University
RP Master, VA (corresponding author), Emory Univ, Sch Med, 1365 Clifton Rd, Atlanta, GA 30322 USA.
EM vmaster@emory.edu
CR Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E
   Awaludin S, 2020, ADV HLTH SCI RES, V20, P276
   Bhavanani Ananda Balayogi, 2011, INT J YOGA THERAP, V0, P73
   Bidgoli MM, 2016, J CARDIOVASC THORAC, V8, P170, DOI 10.15171/jcvtr.2016.34
   Cao Zhiliang, 2017, ZHONGGUO ZHEN JIU, V37, P247, DOI 10.13703/j.0255-2930.2017.03.007
   Chandrababu R, 2019, CLIN EPIDEMIOL GLOB, V7, P606, DOI 10.1016/j.cegh.2019.01.009
   Chang QY, 2002, ACUPUNCTURE ELECTRO, V27, P191, DOI 10.3727/036012902816025951
   Chen KW, 2012, DEPRESS ANXIETY, V29, P545, DOI 10.1002/da.21964
   Chlan L, 2000, GASTROENTEROL NURS, V23, P148, DOI 10.1097/00001610-200007000-00003
   Cramer H, 2014, INT J CARDIOL, V173, P170, DOI 10.1016/j.ijcard.2014.02.017
   DeLoach Walworth Darcy, 2005, J PEDIATR NURS, V20, P276
   Deng Gary E, 2009, J SOC INTEGR ONCOL, V7, P85
   Di Iulio A, 2020, JOURNAL OF ADVANCED HEALTH CARE, V0, PP21, DOI 10.36017/jahc2001-002
   El-Deeb AM, 2011, J ANESTH, V25, P698, DOI 10.1007/s00540-011-1198-0
   Ertas G, 2015, HOLIST NURS PRACT, V29, P6, DOI 10.1097/HNP.0000000000000061
   Escobar Y, 2015, SUPPORT CARE CANCER, V23, P2833, DOI 10.1007/s00520-015-2809-3
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Flory N, 2007, INT J CLIN EXP HYP, V55, P303, DOI 10.1080/00207140701338670
   Frey UH, 2009, ACTA ANAESTH SCAND, V53, P1341, DOI 10.1111/j.1399-6576.2009.02081.x
   Frey UH, 2009, BRIT J ANAESTH, V102, P620, DOI 10.1093/bja/aep014
   Gan TJ, 2014, CURR MED RES OPIN, V30, P149, DOI 10.1185/03007995.2013.860019
   Garland EL, 2017, J GEN INTERN MED, V32, P1106, DOI 10.1007/s11606-017-4116-9
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hole J, 2015, LANCET, V386, P1659, DOI 10.1016/S0140-6736(15)60169-6
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Jung BF, 2003, PAIN, V104, P1, DOI 10.1016/S0304-3959(03)00241-0
   Kabat-Zin Jon, 1990, FULL CATASTROPHE LIV, V0, P0
   Kane EO, 1914, JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, V57, P1829, DOI 10.1001/JAMA.1914.02560480063031
   Kane-Gill Sandra L, 2014, J PAIN PALLIAT CARE PHARMACOTHER, V28, P282, DOI 10.3109/15360288.2014.938889
   Katz J, 2005, PAIN, V119, P16, DOI 10.1016/j.pain.2005.09.008
   Kim KH, 2017, BMJ OPEN, V7, P0, DOI 10.1136/bmjopen-2016-013457
   Kim KS, 2006, ANESTH ANALG, V103, P709, DOI 10.1213/01.ane.0000228864.74691.9f
   Kotani N, 2001, ANESTHESIOLOGY, V95, P349, DOI 10.1097/00000542-200108000-00015
   Kühlmann AYR, 2018, BJS-BRIT J SURG, V105, P773, DOI 10.1002/bjs.10853
   Lam WL, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-017-2359-8
   Lang EV, 2002, RADIOLOGY, V222, P375, DOI 10.1148/radiol.2222010528
   Lee A, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub4
   Lew MW, 2011, INT J CLIN EXP HYP, V59, P406, DOI 10.1080/00207144.2011.594737
   Ling WM, 2014, ONCOL NURS FORUM, V41, P581, DOI 10.1188/14.ONF.581-592
   Liu YH, 2017, AM J CHINESE MED, V45, P1127, DOI 10.1142/S0192415X17500616
   Lopez G, 2017, MED CLIN N AM, V101, P977, DOI 10.1016/j.mcna.2017.04.011
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Maraghi E, 2020, PAK J MED HLTH SCI, V14, P1260
   Maranets I, 1999, ANESTH ANALG, V89, P1346, DOI 10.1097/00000539-199912000-00003
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Miao J, 2017, INT J NURS STUD, V70, P27, DOI 10.1016/j.ijnurstu.2017.02.014
   Molassiotis A, 2013, HEALTH TECHNOL ASSES, V17, P0, DOI 10.3310/hta17260
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052
   Nair DC, 2020, AMRITA J MED, V16, P6, DOI 10.4103/AMJM.AMJM120
   Parker PA, 2009, J CLIN ONCOL, V27, P3169, DOI 10.1200/JCO.2007.16.0036
   Pérez F, 2006, J TELEMED TELECARE, V12, P41, DOI 10.1258/135763306777978506
   Pitman A, 2018, BMJ-BRIT MED J, V361, P0, DOI 10.1136/bmj.k1415
   Ralston-Wilson J, 2016, J ALTERN COMPLEM MED, V22, P458, DOI 10.1089/acm.2015.0347
   Rudin D, 2007, ENDOSCOPY, V39, P507, DOI 10.1055/s-2007-966362
   Saadat H, 2006, ANESTH ANALG, V102, P1394, DOI 10.1213/01.ane.0000204355.36015.54
   Sadhasivam S, 1999, ANESTH ANALG, V89, P1340, DOI 10.1097/00000539-199912000-00002
   Shires A, 2020, PAIN, V161, P1698, DOI 10.1097/j.pain.0000000000001877
   Soo MS, 2016, J AM COLL RADIOL, V13, P526, DOI 10.1016/j.jacr.2015.12.004
   Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004
   STEVENS PE, 1995, PAIN, V61, P61, DOI 10.1016/0304-3959(94)00162-8
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   The Joint Commission, 2017, JOINT COMMISSION PER, V37, P1
   Turankar AV, 2013, INDIAN J MED RES, V137, P916
   Ugras GA, 2018, COMPLEMENT THER CLIN, V31, P158, DOI 10.1016/j.ctcp.2018.02.012
   Usichenko TI, 2005, PAIN, V114, P320, DOI 10.1016/j.pain.2004.08.021
   Valentine KE, 2019, INT J CLIN EXP HYP, V67, P336, DOI 10.1080/00207144.2019.1613863
   Vaughn Felicia, 2007, AORN J, V85, P589, DOI 10.1016/S0001-2092(07)60130-6
   Watkins AA, 2014, J AM COLL SURGEONS, V219, P511, DOI 10.1016/j.jamcollsurg.2014.03.057
   Williams C, 2018, COMPLEMENT THER MED, V37, P110, DOI 10.1016/j.ctim.2018.02.002
   Zhong Q, 2019, CHIN J INTEGR MED, V25, P225, DOI 10.1007/s11655-019-3063-1
NR 72
TC 1
Z9 1
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD NOV 1
PY 2021
VL 127
IS 21
BP 3929
EP 3938
DI 10.1002/cncr.33688
EA AUG 2021
PG 10
WC Oncology
SC Oncology
GA WG1XH
UT WOS:000685803300001
PM 34407223
DA 2026-01-16
ER

PT J
AU Yang, J
   Wahner-Roedler, DL
   Zhou, X
   Johnson, LA
   Do, A
   Pachman, DR
   Chon, TY
   Salinas, M
   Millstine, D
   Bauer, BA
AF Yang, Juan
   Wahner-Roedler, Dietlind L
   Zhou, Xuan
   Johnson, Lesley A
   Do, Alex
   Pachman, Deirdre R
   Chon, Tony Y
   Salinas, Manisha
   Millstine, Denise
   Bauer, Brent A
TI Acupuncture for palliative cancer pain management: systematic review.
SO BMJ supportive & palliative care
LA English
DT Journal Article
DE cancer; pain; supportive care
AB BACKGROUND: Pain is one of the most common and problematic symptoms encountered  by patients with cancer. Due to the multifactorial aetiology, pain management of  these patients frequently requires multidisciplinary interventions including  conventional support and specialty palliative care. Acupuncture has been  identified as a possible adjunctive therapy for symptom management in cancer  pain, and there is currently no systematic review focused solely on the evidence  of acupuncture on cancer pain in palliative care. OBJECTIVE: To critically  analyse currently available publications regarding the use of acupuncture for  pain management among patients with cancer in palliative care settings. METHODS:  Multiple academic databases were searched from inception to 29 October 2020.  Randomised controlled trials involving acupuncture in palliative care for  treatment of cancer-related pain were synthesised. Data were extracted by two  independent reviewers, and methodological quality of each included study was  assessed using the Oxford Centre for Evidence-Based Medicine (OCEBM) 2011 Levels  of Evidence. RESULTS: Five studies (n=189) were included in this systematic  review. Results indicated a favourable effect of acupuncture on pain relief in  palliative care for patients with cancer. According to OCEBM 2011 Levels of  Evidence, they were level 2 in one case (20%), level 3 in two cases (40%) and  level 4 in the remaining (40%). Low-level evidence adversely affects the  reliability of findings. CONCLUSIONS: Acupuncture may be an effective and safe  treatment associated with pain reduction in the palliative care of patients with  cancer. Further high-quality, adequately powered studies are needed in the  future.
C1 Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
   Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
   Department of Women's Health/Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
   Center for Palliative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
   Division of Family Medicine, Mayo Clinic, Jacksonville, Florida, USA.
   Department of Women's Health/Internal Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
   Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA Bauer.Brent@mayo.edu.
NR 0
TC 0
SN 2045-436
EI 2045-435
J9 BMJ Support Palliat Care
PD JAN 15
PY 2021
VL 11
IS 3
BP 264
EP 270
DI 10.1136/bmjspcare-2020-002638
PG 6
WC Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications; Pain Management; Palliative Care; Reproducibility of Results
UT PubMed:33441387
PM 33441387
DA 2021-01-15
ER

PT J
AU Bao, T
   Baser, R
   Chen, C
   Weitzman, M
   Zhang, YL
   Seluzicki, C
   Li, QS
   Piulson, L
   Zhi, WI
AF Bao, Ting
   Baser, Raymond
   Chen, Connie
   Weitzman, Matthew
   Zhang, Yi Lily
   Seluzicki, Christina
   Li, Qing Susan
   Piulson, Lauren
   Zhi, W. Iris
TI Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial
SO ONCOLOGIST
LA English
DT Article
DE Acupuncture; Neuropathy; Quality of life; Cancer; Anxiety; Insomnia
ID insomnia severity index; acupuncture; symptoms; prevalence; pain; validation; anxiety; risk
AB Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating adverse effect of neurotoxic chemotherapy that significantly worsens the quality of life of cancer survivors. Materials and Methods Survivors of solid tumors with persistent moderate-to-severe CIPN defined as numbness, tingling, or pain rated >= 4 on an 11-point numeric rating scale (NRS) were randomized in a 1:1:1 ratio to 8 weeks of real acupuncture (RA) versus sham acupuncture (SA) versus usual care (UC). We previously reported the primary endpoint (NRS); here we report the following health-related quality of life endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS), Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI). For each endpoint, the mean changes from baseline and 95% confidence intervals were estimated within each arm and compared between arms using linear mixed models. Results We enrolled 75 survivors of solid tumors with moderate-to-severe CIPN into the study. Compared with baseline, at week 8, FACT/GOG-Ntx, HADS anxiety, and ISI scores significantly improved in RA and SA, but not in UC. Compared with UC, at week 8, FACT/GOG-Ntx scores significantly increased in RA and SA arms indicating improved CIPN-related symptoms and quality of life (p = .001 and p = .01). There was no statistically significant difference between RA and SA. There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8 and 12. Conclusion Acupuncture may improve CIPN-related symptoms and quality of life in cancer survivors with persistent CIPN. Further large sample size studies are needed to delineate placebo effects. Implications for Practice The authors conducted a randomized sham acupuncture- and usual care-controlled clinical trial to evaluate the impact of acupuncture on health-related quality of life outcomes in patients with solid tumors with chemotherapy-induced peripheral neuropathy (CIPN). Statistically significant improvements in quality of life, anxiety, insomnia, and fatigue were achieved with 8 weeks of real acupuncture when compared with baseline, without statistically significant differences between real and sham acupuncture. These findings suggest that acupuncture may be effective for improving CIPN-related symptoms and quality of life and reducing anxiety and insomnia in cancer survivors with persistent CIPN, with further study needed to delineate placebo effects.
C1 [Bao, Ting; Weitzman, Matthew; Zhang, Yi Lily; Seluzicki, Christina; Li, Qing Susan; Piulson, Lauren] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1275 York Ave, New York, NY 10021 USA.
   [Baser, Raymond] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
   [Chen, Connie] NYU, Winthrop Hosp, Dept Med, Mineola, NY USA.
   [Zhi, W. Iris] Mem Sloan Kettering Canc Ctr, Dept Med, Breast Med Serv, Commack, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; New York University; Memorial Sloan Kettering Cancer Center
RP Bao, T (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Bendheim Integrat Med Ctr, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM baot@mskcc.org
FU National Institutes of Health/National Cancer Institute Cancer Center grant [P30 CA008748]; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center; Frueauff Foundation; National Cancer Institute [R37CA248563, R01CA251470, R01CA240417]; National Cancer Institute [R01CA251470, R01CA240417, R37CA248563, P30CA008748] Funding Source: NIH RePORTER
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Argyriou AA, 2020, SUPPORT CARE CANCER, V28, P1991, DOI 10.1007/s00520-019-05023-5
   Bao T, 2020, JAMA NETW OPEN, V3, P0, DOI 10.1001/jamanetworkopen.2020.0681
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bauml Joshua, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP302, DOI 10.1093/jncimonographs/lgu029
   Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006
   Bjelland I, 2002, JOURNAL OF PSYCHOSOMATIC RESEARCH, V52, P69, DOI 10.1016/s0022-3999(01)00296-3
   Calhoun EA, 2003, INT J GYNECOL CANCER, V13, P741, DOI 10.1111/j.1525-1438.2003.13603.x
   Cohen P, 1999, MULTIVAR BEHAV RES, V34, P315, DOI 10.1207/S15327906MBR3403_2
   de Heer EW, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0106907
   Ewertz M, 2015, ACTA ONCOL, V54, P587, DOI 10.3109/0284186X.2014.995775
   Fuentes AC, 2017, SOUTH MED J, V110, P37, DOI 10.14423/SMJ.0000000000000585
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gerrits MMJG, 2014, BMC PSYCHIATRY, V14, P0, DOI 10.1186/1471-244X-14-187
   Huang HQ, 2007, INT J GYNECOL CANCER, V17, P387, DOI 10.1111/j.1525-1438.2007.00794.x
   Jaracz J, 2016, CNS DRUGS, V30, P293, DOI 10.1007/s40263-016-0328-5
   Kenward MG, 2010, STAT MED, V29, P1455, DOI 10.1002/sim.3868
   Kolb NA, 2016, JAMA NEUROL, V73, P860, DOI 10.1001/jamaneurol.2016.0383
   Lao LX, 1999, ARCH OTOLARYNGOL, V125, P567, DOI 10.1001/archotol.125.5.567
   Lemay KR, 2019, J CARDIOPULM REHABIL, V39, PE6, DOI 10.1097/HCR.0000000000000379
   Loprinzi CL, 2020, J CLIN ONCOL, V38, P0, DOI 10.1200/JCO.20.01399
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, P0, DOI 10.1186/1477-7525-6-46
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Schneider BP, 2015, ADV EXP MED BIOL, V862, P77, DOI 10.1007/978-3-319-16366-6_6
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Smid DE, 2017, J AM MED DIR ASSOC, V18, P53, DOI 10.1016/j.jamda.2016.08.002
   Vincent C, 2001, BRIT MED J, V323, P467, DOI 10.1136/bmj.323.7311.467
   Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340
NR 32
TC 41
Z9 43
U1 4
U2 35
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD NOV 15
PY 2021
VL 26
IS 11
BP E2070
EP E2078
DI 10.1002/onco.13933
EA AUG 2021
PG 9
WC Oncology
SC Oncology
GA WS3HH
UT WOS:000688482800001
PM 34390283
DA 2026-01-16
ER

PT J
AU Villegas, F
   Martínez-Borba, V
   Suso-Ribera, C
   Castilla, D
   Zaragoza, I
   García-Palacios, A
   Ferrer, C
AF Villegas, Francisco
   Martinez-Borba, Veronica
   Suso-Ribera, Carlos
   Castilla, Diana
   Zaragoza, Irene
   Garcia-Palacios, Azucena
   Ferrer, Carlos
TI Characterizing Breakthrough Cancer Pain Using Ecological Momentary Assessment with a Smartphone App: Feasibility and Clinical Findings
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE breakthrough cancer pain; ecological momentary assessment; smartphone application; pain management; pain characterization
ID low-back-pain; american society; management; prevalence; fatigue; symptoms; fentanyl; efficacy; beliefs; system
AB Background: mobile applications (apps) facilitate cancer pain ecological momentary assessment (EMA) and provide more reliable data than retrospective monitoring. The aims of this study are (a) to describe the status of persons with cancer pain when assessed ecologically, (b) to analyze the utility of clinical alarms integrated into the app, and (c) to test the feasibility of implementing an app for daily oncological pain monitoring. Methods: in this feasibility study, 21 patients (mean age = 56.95 years, SD = 10.53, 81.0% men) responded to an app-based evaluation of physical status (baseline and breakthrough cancer pain (BTcP)) and mental health variables (fatigue, mood, and coping) daily during 30 days. Results: cancer pain characterization with the app was similar to data from the literature using retrospective assessments in terms of BTcP duration and perceived medication effectiveness. However, BTcP was less frequent when evaluated ecologically. Pain, fatigue, and mood were comparable in the morning and evening. Passive coping strategies were the most employed daily. Clinical alarms appear to be useful to detect and address adverse events. App implementation was feasible and acceptable. Conclusion: apps reduce recall bias and facilitate a rapid response to adverse events in oncological care. Future efforts should be addressed to integrate EMA and ecological momentary interventions to facilitate pain self-management via apps.
C1 [Villegas, Francisco; Ferrer, Carlos] Consorcio Hosp Prov Castellon, Pain & Radiotherapy Units, Castellon de La Plana 12002, Spain.
   [Martinez-Borba, Veronica; Suso-Ribera, Carlos; Garcia-Palacios, Azucena] Univ Jaume 1, Dept Basic & Clin Psychol & Psychobiol, Castellon de La Plana 12071, Spain.
   [Martinez-Borba, Veronica] Inst Invest Sanitaria Aragon, Zaragoza 50009, Spain.
   [Castilla, Diana] Univ Valencia, Dept Personal Assessment & Psychol Treatments, Valencia 46010, Spain.
   [Castilla, Diana; Zaragoza, Irene; Garcia-Palacios, Azucena] CIBER Physiopathol Obes & Nutr CIBERON, Madrid 28029, Spain.
C3 Universitat Jaume I; University of Valencia
RP Suso-Ribera, C (corresponding author), Univ Jaume 1, Dept Basic & Clin Psychol & Psychobiol, Castellon de La Plana 12071, Spain.
EM franvilles@hotmail.com; borba@uji.es; susor@uji.es; diana.castilla@uv.es; irenezaragoza@gmail.com; azucena@uji.es; carlos.ferrer@hospitalprovincial.es
FU CASTELLON PROVINCIAL HOSPITAL FOUNDATION [CAF-16-033, CAF-21-014]
CR Alvarez-Salvago F, 2018, SUPPORT CARE CANCER, V26, P3649, DOI 10.1007/s00520-018-4240-z
   Andersen BL, 2014, J CLIN ONCOL, V32, P1605, DOI 10.1200/JCO.2013.52.4611
   Armstrong Kathleen A, 2014, J MED INTERNET RES, V16, Pe213, DOI 10.2196/jmir.3528
   Balestrieri M, 2013, EPIDEMIOL PSYCH SCI, V22, P81, DOI 10.1017/S2045796012000480
   Bangor A, 2008, INT J HUM-COMPUT INT, V24, P574, DOI 10.1080/10447310802205776
   Beute F, 2016, INT J ENV RES PUB HE, V13, P0, DOI 10.3390/ijerph13040420
   Boceta J, 2019, JMIR CANCER, V5, P0, DOI 10.2196/10187
   Bower JE, 2014, J CLIN ONCOL, V32, P1840, DOI 10.1200/JCO.2013.53.4495
   Brooke John, 1996, SUS QUICK DIRTY USAB, V0, P0, DOI DOI 10.1201/9781498710411-35
   Calvo Verges N, 2015, DIO 360 ABORDAJE INT, V0, P0
   Canal-Sotelo J, 2018, BMC PALLIAT CARE, V17, P0, DOI 10.1186/s12904-018-0336-y
   Cheng C, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/18946
   Chien TW, 2021, EUR J CANCER CARE, V30, P0, DOI 10.1111/ecc.13403
   Christe G, 2021, MUSCULOSKEL SCI PRAC, V52, P0, DOI 10.1016/j.msksp.2021.102342
   Colombo D, 2020, EMOTION, V20, P30, DOI 10.1037/emo0000671
   Crafoord MT, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/17058
   Zapata BC, 2015, J MED SYST, V39, P0, DOI 10.1007/s10916-014-0182-2
   Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009
   Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014
   Davies AN, 2018, BMJ SUPPORT PALLIAT, V8, P241, DOI 10.1136/bmjspcare-2017-001467
   Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI 10.1586/ern.11.63
   Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015
   Denis F, 2019, JAMA-J AM MED ASSOC, V321, P306, DOI 10.1001/jama.2018.18085
   Esteve R, 2007, ANN BEHAV MED, V33, P179, DOI 10.1007/BF02879899
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Ferrero VT, 2019, CLIN TRANSL ONCOL, V21, P1707, DOI 10.1007/s12094-019-02102-1
   Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136
   Gonzalez-Guerrero JF, 2019, J CLIN ONCOL, V37, P0, DOI 10.1200/JCO.2019.37.15_suppl.e23113
   Garcia-Palacios A, 2014, EUR J PAIN, V18, P862, DOI 10.1002/j.1532-2149.2013.00425.x
   Gatti A, 2012, ADV THER, V29, P464, DOI 10.1007/s12325-012-0022-z
   Golinelli D, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/22280
   Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185
   Kaasa S, 2018, LANCET ONCOL, V19, PE588, DOI 10.1016/S1470-2045(18)30415-7
   Kirchner T R, 2013, THE WILEY-BLACKWELL HANDBOOK OF ADDICTION PSYCHOPHARMACOLOGY, V0, PP541, DOI 10.1002/9781118384404.CH20
   Kongshaug N, 2021, JMIR FORM RES, V5, P0, DOI 10.2196/20636
   Kratz AL, 2017, ARCH PHYS MED REHAB, V98, P2142, DOI 10.1016/j.apmr.2017.07.002
   Lang-Rollin I, 2018, DIALOGUES CLIN NEURO, V20, P13
   Lohre ET, 2020, CURR OPIN SUPPORT PA, V14, P94, DOI 10.1097/SPC.0000000000000494
   Low Carissa A, 2020, JMIR PERIOPER MED, V3, Pe17292, DOI 10.2196/17292
   May M, 2018, J PAIN, V19, P699, DOI 10.1016/j.jpain.2018.01.006
   Mercadante S, 2020, ONCOLOGIST, V25, P156, DOI 10.1634/theoncologist.2019-0542
   Mercadante S, 2018, CANCERS, V10, P0, DOI 10.3390/cancers10060175
   Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721
   Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224
   Moloney NA, 2021, PAIN MED, V22, P915, DOI 10.1093/pm/pnaa363
   Moradian S, 2018, JMIR CANCER, V4, P0, DOI 10.2196/10932
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8
   Ramond A, 2011, FAM PRACT, V28, P12, DOI 10.1093/fampra/cmq072
   Ripamonti CI, 2011, ANN ONCOL, V22, Pvi69, DOI 10.1093/annonc/mdr390
   Salazar A, 2018, JMIR MHEALTH UHEALTH, V6, P0, DOI 10.2196/10718
   Sheppes G, 2011, PSYCHOL SCI, V22, P1391, DOI 10.1177/0956797611418350
   Smyth JM, 2003, J HAPPINESS STUD, V4, P35, DOI 10.1023/A:1023657221954
   Spook JE, 2013, J MED INTERNET RES, V15, P278, DOI 10.2196/jmir.2617
   Suso-Ribera C, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17186568
   Suso-Ribera C, 2018, CLIN J PAIN, V34, P900, DOI 10.1097/AJP.0000000000000618
   Suso-Ribera C, 2018, TRIALS, V19, P0, DOI 10.1186/s13063-018-2539-1
   Suso-Ribera C, 2016, J HEALTH PSYCHOL, V21, P1015, DOI 10.1177/1359105314544133
   Tan G, 2011, CLIN J PAIN, V27, P769, DOI 10.1097/AJP.0b013e31821d8f5a
   Theobald Dale E, 2004, CLIN CORNERSTONE, V6 Suppl 1D, PS15, DOI 10.1016/S1098-3597(05)80003-1
   Timmerman JG, 2015, EUR J ONCOL NURS, V19, P162, DOI 10.1016/j.ejon.2014.09.005
   Vowles KE, 2014, CLIN J PAIN, V30, P324, DOI 10.1097/AJP.0b013e31829ea187
   Yang J, 2019, JMIR MHEALTH UHEALTH, V7, P0, DOI 10.2196/12542
   Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9
   Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020
   Zhao P, 2019, BMC MED INFORM DECIS, V19, P0, DOI 10.1186/s12911-019-0827-7
   Zheng J, 2021, BREAST CANC GYNECOLO, V0, P39
   Zimmermann M, 2014, PAIN PRACT, V14, P757, DOI 10.1111/papr.12156
NR 68
TC 13
Z9 15
U1 1
U2 19
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD JUN 15
PY 2021
VL 18
IS 11
BP 
EP 
DI 10.3390/ijerph18115991
PG 21
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health
GA SP9DR
UT WOS:000659963200001
PM 34204871
DA 2026-01-16
ER

PT J
AU Hu, H
   Li, Z
   Zhang, Y
   Gao, H
AF Hu, Hantong
   Li, Zengtu
   Zhang, Yajun
   Gao, Hong
TI Comment on: Transcutaneous electrical acupoint stimulation before surgery reduces
SO Journal of clinical anesthesia
LA English
DT Letter
C1 Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
   Department of Massage, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
   The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China. 
   Department of Acupuncture and Moxibustion, The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.
EM qtgh@vip.qq.com
NR 0
TC 0
SN 1873-452
EI 
J9 J Clin Anesth
PD SEP 5
PY 2021
VL 75
IS 
BP 110501
EP 110501
DI 10.1016/j.jclinane.2021.110501
PG 0
WC Acupuncture Points; Breast Neoplasms; Chronic Pain; etiology; Female; Humans; Mastectomy; adverse effects; Transcutaneous Electric Nerve Stimulation
UT PubMed:34481364
PM 34481364
DA 2021-09-05
ER

PT J
AU Liu, X
   Lu, J
   Wang, G
   Chen, X
   Xv, H
   Huang, J
   Xue, M
   Tang, J
AF Liu, Xiaomeng
   Lu, Jing
   Wang, Guoxin
   Chen, Xiu
   Xv, Haiping
   Huang, Jing
   Xue, Mingxin
   Tang, Jinhai
TI Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; aromatase inhibitor-induced arthralgia; breast cancer; meta-analysis
AB BACKGROUND: Aromatase inhibitor-induced arthralgia (AIA) is the most common side  effect of aromatase inhibitors (AIs) used in breast cancer patients and is  related to the rate of adherence to AIs. The clinical effects of acupuncture on  AIA have been assessed by some randomized controlled trials (RCTs). However, some  studies reported that acupuncture was effective, while others claimed that it was  ineffective. To clarify the clinical and placebo effects of acupuncture in  treating AIA, we conducted this meta-analysis. METHODS: Two reviewers (XL and GW)  independently searched for RCTs in 5 English databases (PubMed, Web of Science,  Embase, Springer, Cochrane Library) and 4 Chinese databases (China National  Knowledge Infrastructure Database (CNKI), SinoMed, VIP and Wanfang Database) from  their inception to 30 November 2019. Following the Preferred Reporting Items for  Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this meta-analysis was  performed by fixed or random-effects models, and data were pooled with mean  differences (MDs). RESULTS: Seven trials involving 603 patients were reviewed.  The primary outcome, the Brief Pain Inventory (BPI) score, significantly differed  between the acupuncture and control groups [pain-related interference:  MD = -1.89, 95% confidence interval (CI) [-2.99, -0.79], Z = 3.36  (P = .008 < .05), pain severity: MD = -1.57, 95% CI [-2.46, -0.68], Z = 3.45  (P = .0006 < .05), worst pain: MD = -2.31, 95% CI [-3.15, -1.48], Z = 5.47  (P < .0001 < .05)]. No severe adverse events were reported in any study.  CONCLUSION: This meta-analysis showed that acupuncture is a safe and effective  treatment for breast cancer patients with AIA. Additional research with improved  blinding methods is warranted to further explore the nature of non-specific and  placebo effects in true and sham acupuncture.
C1 Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's 
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
   Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
   Third Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
   Nanjing University of Chinese Medicine, Nanjing, People's Republic of China.
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's 
   The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD FEB 16
PY 2021
VL 20
IS 
BP 1534735420980811
EP 1534735420980811
DI 10.1177/1534735420980811
PG 1
WC Acupuncture Therapy; Aromatase Inhibitors; adverse effects; Arthralgia; chemically induced; Breast Neoplasms; drug therapy; Female; Humans; Treatment Outcome
UT PubMed:33586504
PM 33586504
DA 2021-02-16
ER

PT J
AU Yuan, MH
   Wang, XY
   Yan, XY
   Ding, H
   Yi, J
   Xia, HM
   Yu, XQ
AF Yuan, Minghua
   Wang, Xiaoyuan
   Yan, Xiaoyan
   Ding, Hong
   Yi, Jing
   Xia, Hongmei
   Yu, Xueqin
TI Effects of heat-sensitive moxibustion combined with naprapathy and warming needle moxibustion combined with naprapathy in patients with periarthritis of shoulder
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Heat-sensitive moxibustion; warming needle moxibustion; naprapathy; periarthritis of shoulder; shoulder function; inflammatory factor
AB Objective: To evaluate the effects of heat-sensitive moxibustion (HSM) combined with naprapathy and warming needle moxibustion (WNM) combined with naprapathy on shoulder function and serum levels of calcitonin gene-related peptide (CGRP), substance P (SP), tumor necrosis factor-a (TNF-a) and interleukin-2 (IL-2) in patients with periarthritis of shoulder (POS). Methods: From July 2017 to July 2020, sixty patients with POS admitted to our hospital were selected as the study subjects, and divided into HSM group (n=29) receiving HSM combined with naprapathy and WNM group receiving WNM combined with naprapathy (n=31). The changes in shoulder function, degrees of pain and serum levels of CGRP, SP, TNF-a and IL-2 were compared between the two groups. Results: After treatment, the scores of myodynamia, pain, range of motion (ROM) of shoulder joint and activities of daily living (ADLs) were improved in both groups (P<0.05), and the scores in HSM group were remarkably higher than those in WNM group (P<0.05). Visual analogue scale (VAS) scores after 3 courses of treatment were lower than those after 1 and 2 courses of treatment respectively (P<0.05), and the VAS scores in HSM group were markedly lower than those in WNM group after 1, 2, and 3 courses of treatment (P<0.05). After treatment, the serum levels of CGRP, SP, TNF-a and IL-2 were decreased in both groups (P<0.05), and the levels in HSM group were noticeably lower than those in WNM group (P<0.05). Conclusion: HSM combined with naprapathy is superior to WNM combined with naprapathy in inhibition of inflammatory factors of pain and serum inflammatory factors, alleviating the pain and promoting the restoration of shoulder function in patients with POS.
C1 [Yuan, Minghua; Wang, Xiaoyuan; Yan, Xiaoyan; Ding, Hong; Yi, Jing; Xia, Hongmei; Yu, Xueqin] Yichun Peoples Hosp, Rehabil Dept, 88 Zhongshan West Rd, Yichun 336000, Jiangxi, Peoples R China.
RP Yu, XQ (corresponding author), Yichun Peoples Hosp, Rehabil Dept, 88 Zhongshan West Rd, Yichun 336000, Jiangxi, Peoples R China.
EM yuxueqin@21cn.com
CR Chen BS, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000013598
   Chen LA, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000014959
   Cho CH, 2019, J SHOULDER ELB SURG, V28, P1265, DOI 10.1016/j.jse.2018.11.072
   Jiao Lin, 2019, ZHONGGUO ZHEN JIU, V39, P54, DOI 10.13703/j.0255-2930.2019.01.012
   Kanagalingam T, 2019, IMMUN INFLAMM DIS, V7, P112, DOI 10.1002/iid3.249
   Lu CX, 2017, EXP THER MED, V14, P4935, DOI 10.3892/etm.2017.5126
   Merolla G, 2019, INT ORTHOP, V43, P659, DOI 10.1007/s00264-018-4088-3
   Mortadza SAS, 2018, GLIA, V66, P562, DOI 10.1002/glia.23265
   NDiaye A, 2017, FRONT ENDOCRINOL, V8, P0, DOI 10.3389/fendo.2017.00015
   Nemade SV, 2019, TURK ARCH OTORHINOL, V57, P34, DOI 10.5152/tao.2019.3091
   Roy U, 2019, PROTEIN J, V38, P525, DOI 10.1007/s10930-019-09833-8
   Schiefer M, 2017, J SHOULDER ELB SURG, V26, P49, DOI 10.1016/j.jse.2016.04.026
   Singh Y, 2017, CNS NEUROSCI THER, V23, P457, DOI 10.1111/cns.12696
   Stein DJ, 2017, GASTROENTEROL CLIN N, V46, P875, DOI 10.1016/j.gtc.2017.08.015
   Stutz Thomas, 2017, JMIR REHABIL ASSIST TECHNOL, V4, Pe6, DOI 10.2196/rehab.7085
   Whelton C, 2018, EUR J ORTHOP SURG TRAUMATOL, V28, P363, DOI 10.1007/s00590-017-2068-8
   Woo HL, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011007
   Wu WT, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-10895-w
   Yan DM, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-39170-w
   Zhang Haifeng, 2017, ZHONGGUO ZHEN JIU, V37, P1315, DOI 10.13703/j.0255-2930.2017.12.016
NR 20
TC 8
Z9 10
U1 1
U2 10
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2021
VL 13
IS 7
BP 7804
EP 7811
DI 
PG 8
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA TT0LI
UT WOS:000680042800012
PM 34377257
DA 2026-01-16
ER

PT J
AU Ruan, A
   Wang, Q
   Ma, Y
   Zhang, D
   Yang, L
   Wang, Z
   Xie, Q
   Yin, Y
AF Ruan, Anmin
   Wang, Qingfu
   Ma, Yufeng
   Zhang, Dong
   Yang, Lili
   Wang, Zhongpeng
   Xie, Qi
   Yin, Yueshan
TI Efficacy and Mechanism of Electroacupuncture Treatment of Rabbits With Different
SO Frontiers in physiology
LA English
DT Journal Article
DE electro-acupuncture; innate immune response; knee osteoarthritis; mechanism research; signaling pathway
AB Knee osteoarthritis (KOA) is a chronic degenerative bone and joint disease, which  is often clinically manifested as pain, joint swelling, and deformity. Its  pathological manifestations are mainly synovial inflammation and cartilage  degeneration. This study aims to investigate the efficacy of electro-acupuncture  (EA) on model rabbits with varying degrees of KOA and to study the mechanism of  EA on KOA based on the innate immune response. Mild and moderate rabbit KOA  models were established using a modified Hluth method, and EA was given to both  the mild and moderate model groups. The Lequesne-MG index was used to evaluate  the behavioral changes in the rabbits before and after EA treatment.  Morphological changes in the synovial membrane and cartilage of each group were  observed by H&E staining. The Mankin scoring standard and the Krenn scoring  standard were used to score the pathology of the cartilage tissue and synovial  tissue, respectively. The inflammatory factors and metalloproteinases were  detected in the serum of each group by ELISA. The protein and messenger RNA  (mRNA) expressions of important elements related to Toll-like receptors  (TLRs)-mediated innate immune response in the synovial tissue were detected by  Western blot and quantitative PCR (qPCR). The Lequesne-MG index score of the  rabbits gradually increased with the modeling prolonged but decreased  significantly after EA treatment, indicating that EA has a better effect on  alleviating the pain and improving the dysfunction. The morphological analysis  showed that the inflammation of and the damage to the synovial membrane and the  cartilage tissue gradually deteriorated with the modeling prolonged. However, the  synovial membrane inflammation was significantly relieved after EA treatment, and  the cartilage injury showed signs of repair. The ELISA analysis showed that, with  the modeling prolonged, the serum-related inflammatory factors and mechanism of  metalloproteinases gradually increased but decreased after EA treatment. The  tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and matrix  metalloproteinase3 (MMP3) of EA1 group were significantly lower than those of EA2  group. Both Western blot and qPCR results showed that the protein and mRNA  expressions of the elements related to the innate immune response in the synovial  membrane increased gradually with the modeling prolonged, but decreased  significantly after EA treatment. Additionally, the expression of some components  in EA1 group was significantly lower than that in EA2 group. These results  confirm that synovial inflammation gradually aggravated with time from the early  to mid-stage of KOA. EA alleviated the inflammation and histological changes in  KOA rabbits by inhibiting the TLRs-mediated innate synovial immune response. This  suggests that using EA in the early stage of KOA may achieve a desirable  efficacy.
C1 Department of Orthopedics, Beijing Longfu Hospital, Beijing, China.
   Department of Tendon and Injury, The Third Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
   Department of Tendon and Injury, The Third Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
   Department of General Surgery, The Second Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
   Department of Orthopedics, Beijing Longfu Hospital, Beijing, China.
   Acupuncture and Moxibustion Department, The Third Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
   Graduate School, Beijing University of Chinese Medicine, Beijing, China.
   Acupuncture and Moxibustion Department, The Third Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China.
NR 0
TC 0
SN 1664-042
EI 1664-042
J9 Front Physiol
PD AUG 24
PY 2021
VL 12
IS 
BP 642178
EP 642178
DI 10.3389/fphys.2021.642178
PG 0
UT PubMed:34421630
PM 34421630
DA 2021-08-24
ER

PT J
AU Lu, TC
   Zhang, JF
   Lv, Y
   Wu, YC
AF Lu, Tianchen
   Zhang, Junfeng
   Lv, Ying
   Wu, Yaochi
TI The effect of warm needle moxibustion on lumbar disc herniation
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Warm needle moxibustion; lumbar disc herniation; therapeutic effect
ID nonoperative treatment; management; acupuncture; efficacy
AB Objective: To investigate the effect of warm needle moxibustion on patients with lumbar disc herniation (LDH). Methods: A total of 100 patients with lumbar disc herniation treated in our hospital were recruited as the study cohort and randomly assigned into a control group and an observation group. The patients in the control group underwent routine acupuncture treatment, while those in the observation group underwent warm needle moxibustion treatment. The observed indexes, including the clinical efficacy, the visual analogue scale (VAS) scores, the Japanese Orthopedic Association (JOA) scores, the Oswestry disability index (ODI) scores, and the serum inflammatory factor levels were compared between the control group and the observation group. Results: The total cure rate in the observation group was significantly higher than it was in the control group (76.0% vs 92%, P=0.029). Compared with the patients in the control group after the treatment, the patients' VAS and ODI scores in the observation group were significantly lower, but their JOA scores were significantly higher, and the differences were statistically significant (all P<0.001). Moreover, the serum IL-6 and tumor necrosis factor alpha (TNF-alpha) levels in the observation group were remarkably lower than the corresponding levels in the control group (all P<0.001). Conclusions: Warm needle moxibustion has a significant effect on patients with lumbar disc herniation, because it helps to relieve the pain and other symptoms and reduces the serum inflammatory factor levels.
C1 [Lu, Tianchen; Zhang, Junfeng; Lv, Ying; Wu, Yaochi] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Acupuncture & Massage, 600 Yishan Rd, Shanghai 200233, Peoples R China.
C3 Shanghai Jiao Tong University
RP Wu, YC (corresponding author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Acupuncture & Massage, 600 Yishan Rd, Shanghai 200233, Peoples R China.
EM wuyaochi_tcm@163.com
FU Alliance Construction Project of Shanghai Chinese Medicine Specialty (Special disease) [ZY (2018-2020)-FWTX-4020]
CR Benzakour T, 2019, INT ORTHOP, V43, P841, DOI 10.1007/s00264-018-4247-6
   Buchmann N, 2016, WORLD NEUROSURG, V89, P382, DOI 10.1016/j.wneu.2016.02.028
   Carlson BB, 2019, INT ORTHOP, V43, P853, DOI 10.1007/s00264-019-04309-x
   Chen BL, 2018, CLIN REHABIL, V32, P146, DOI 10.1177/0269215517719952
   Chen RX, 2014, EVID-BASED COMPL ALT, V2014, P0, DOI 10.1155/2014/154941
   Chen RX, 2012, J TRADIT CHIN MED, V32, P322, DOI 10.1016/S0254-6272(13)60032-1
   Choi TY, 2017, MATURITAS, V100, P33, DOI 10.1016/j.maturitas.2017.03.314
   Cunha C, 2018, ARTHRITIS RES THER, V20, P0, DOI 10.1186/s13075-018-1743-4
   Gao XY, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/168393
   Huang XY, 2017, GENET TEST MOL BIOMA, V21, P17, DOI 10.1089/gtmb.2016.0189
   Jacobs WCH, 2011, EUR SPINE J, V20, P513, DOI 10.1007/s00586-010-1603-7
   Jegede KA, 2010, ORTHOP CLIN N AM, V41, P217, DOI 10.1016/j.ocl.2010.01.003
   Joos S, 2006, SCAND J GASTROENTERO, V41, P1056, DOI 10.1080/00365520600580688
   Karademir M, 2017, J BACK MUSCULOSKELET, V30, P347, DOI 10.3233/BMR-160572
   Karcioglu O, 2018, AM J EMERG MED, V36, P707, DOI 10.1016/j.ajem.2018.01.008
   Lee JD, 2005, EVID-BASED COMPL ALT, V2, P79, DOI 10.1093/ecam/neh070
   Li XH, 2016, J EVID-BASED INTEGR, V21, P311, DOI 10.1177/2156587215605419
   Liu H, 2015, J ORTHOP RES, V33, P294, DOI 10.1002/jor.22732
   Liu XY, 2018, J NEUROSURG-SPINE, V28, P317, DOI 10.3171/2017.6.SPINE172
   Luo D, 2018, ACUPUNCT MED, V36, P215, DOI 10.1136/acupmed-2016-011227
   Mo ZM, 2018, J MANIP PHYSIOL THER, V41, P771, DOI 10.1016/j.jmpt.2018.04.005
   Postacchini F, 2011, ACTA NEUROCHIR SUPPL, V108, P17, DOI 10.1007/978-3-211-99370-5_4
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Wang Yan-Ling, 2013, ZHONGGUO ZHEN JIU, V33, P605
   Wang Y, 2019, J TRADIT CHIN MED, V39, P599
   Yang L, 2018, INT J NURS STUD, V82, P129, DOI 10.1016/j.ijnurstu.2018.03.013
   Yang SD, 2017, ONCOTARGET, V8, P84204, DOI 10.18632/oncotarget.20453
   Yuan QL, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0117146
   Zhang B, 2017, BIOSCI TRENDS, V11, P406, DOI 10.5582/bst.2017.01199
   Zhang D, 2018, J TRADIT CHIN MED, V38, P218
   Zhang XF, 2018, J INTEGR MED-JIM, V16, P418, DOI 10.1016/j.joim.2018.10.003
   Zhong M, 2017, PAIN PHYSICIAN, V20, PE45, DOI 10.36076/ppj.2017.1.e45
NR 33
TC 10
Z9 12
U1 1
U2 16
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
EI 
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PD JUN 15
PY 2021
VL 13
IS 5
BP 5059
EP 5065
DI 
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA SM3BJ
UT WOS:000657484200049
PM 34150092
DA 2026-01-16
ER

PT J
AU Li, H
   Schlaeger, JM
   Jang, MK
   Lin, Y
   Park, C
   Liu, T
   Sun, M
   Doorenbos, AZ
AF Li, Hongjin
   Schlaeger, Judith M
   Jang, Min Kyeong
   Lin, Yufen
   Park, Chang
   Liu, Tingting
   Sun, Min
   Doorenbos, Ardith Z
TI Acupuncture Improves Multiple Treatment-Related Symptoms in Breast Cancer
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture; breast cancer; meta-analysis; symptom; symptom cluster
AB Introduction: Acupuncture has demonstrated effectiveness for symptom management  among breast cancer survivors. This meta-analysis aims to evaluate the effect of  acupuncture on treatment-related symptoms among breast cancer survivors. Methods:  The authors searched PubMed, CINAHL, and EMBASE for relevant randomized clinical  trials (RCTs) of acupuncture for managing treatment-related symptoms published in  English through June 2021. They appraised the quality of each article using the  Cochrane Collaboration Risk of Bias Criteria. The primary outcomes were pain, hot  flashes, sleep disturbance, fatigue, depression, lymphedema, and neuropathy as  individual symptoms. They also evaluated adverse events reported in acupuncture  studies. Results: Of 26 selected trials (2055 patients), 20 (1709 patients) were  included in the meta-analysis. Acupuncture was more effective than control groups  in improving pain intensity [standardized mean difference (SMD) = -0.60, 95%  confidence intervals (CI) -1.06 to -0.15], fatigue [SMD = -0.62, 95% CI -1.03 to  -0.20], and hot flash severity [SMD = -0.52, 95% CI -0.82 to -0.22]. The subgroup  analysis indicated that acupuncture showed trends but not significant effects on  all the treatment-related symptoms compared with the sham acupuncture groups.  Compared with waitlist control and usual care groups, the acupuncture groups  showed significant reductions in pain intensity, fatigue, depression, hot flash  severity, and neuropathy. No serious adverse events were reported related to  acupuncture intervention. Mild adverse events (i.e., bruising, pain, swelling,  skin infection, hematoma, headache, menstrual bleeding) were reported in 11  studies. Conclusion: This systematic review and meta-analysis suggest that  acupuncture significantly reduces multiple treatment-related symptoms compared  with the usual care or waitlist control group among breast cancer survivors. The  safety of acupuncture was inadequately reported in the included studies. Based on  the available data, acupuncture seems to be generally a safe treatment with some  mild adverse events. These findings provide evidence-based recommendations for  incorporating acupuncture into clinical breast cancer symptom management. Due to  the high risk of bias and blinding issues in some RCTs, more rigorous trials are  needed to confirm the efficacy of acupuncture in reducing multiple  treatment-related symptoms among breast cancer survivors.
C1 Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.
   Department of Cancer Prevention and Control, University of Illinois Cancer 
   Department of Human Development Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.
   Department of Cancer Prevention and Control, University of Illinois Cancer Center, Chicago, IL, USA.
   Department of Biobehavioral Nursing Science, College of Nursing, University of 
   School of Nursing, Emory University, Atlanta, GA, USA.
   Department of Population Health Nursing Science, College of Nursing, University of Illinois Chicago, Chicago, IL, USA.
   Eleanor Mann School of Nursing, University of Arkansas, Little Rock, AR, USA.
   Department of Hematology and Oncology, Hillman Cancer Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
   Department of Cancer Prevention and Control, University of Illinois Cancer Center, Chicago, IL, USA.
   Department of Biobehavioral Nursing Science, College of Nursing, University of
NR 0
TC 0
SN 1557-770
EI 1075-553
J9 J Altern Complement Med
PD AUG 28
PY 2021
VL 27
IS 12
BP 1084
EP 1097
DI 10.1089/acm.2021.0133
PG 13
WC Acupuncture Therapy; Breast Neoplasms; complications; Cancer Survivors; Fatigue; etiology; Female; Humans; Survivors
UT PubMed:34449251
PM 34449251
DA 2021-08-28
ER

PT J
AU Olson, EA
   Metzger, AK
   Mallory, MJ
   Mackey, RM
AF Olson, Emily A
   Metzger, Abbey K
   Mallory, Molly J
   Mackey, Regina M
TI Opioid-Induced Constipation and Acupuncture: A Case Discussion.
SO Journal of pain and symptom management
LA English
DT Journal Article
DE Acupuncture; cancer; opioid; opioid-induced constipation; palliative medicine
AB BACKGROUND: Use of acupuncture for treatment of functional constipation is well  studied; however, studies examining use of acupuncture for opioid-induced  constipation are limited. CASE DESCRIPTION: A 70-year-old woman with newly  diagnosed multiple myeloma discovered after presentation to the emergency room  with severe back pain. Pain management required use of opioids, escalating to  effect. Hospital course was complicated by opioid-induced constipation causing  abdominal pain, nausea, and ileus despite aggressive titration of stimulant and  osmotic laxatives as well as administration of suppositories and enemas on  multiple occasions. Prior to nasogastric tube placement for the ileus, the  patient requested acupuncture treatment in attempt to relieve constipation.  Shortly after acupuncture session, patient passed multiple stools with  improvement in abdominal pain and nausea and avoidance of nasogastric tube.  CONCLUSION: Acupuncture for opioid-induced constipation may provide symptom  relief through use of nonpharmacologic interventions; however, further studies  are needed to determine the optimal therapeutic approach.
C1 General Internal Medicine, Center for Palliative Medicine, Mayo Clinic, Rochester, Minnesota. 
   General Internal Medicine, Center for Palliative Medicine, Mayo Clinic, Rochester, Minnesota.
   General Internal Medicine, Integrative Medicine and Health, Mayo Clinic, Rochester, Minnesota.
   General Internal Medicine, Center for Palliative Medicine, Mayo Clinic, Rochester, Minnesota.
EM Olson.emily3@mayo.edu
NR 0
TC 0
SN 1873-651
EI 
J9 J Pain Symptom Manage
PD FEB 9
PY 2021
VL 62
IS 4
BP 876
EP 880
DI 10.1016/j.jpainsymman.2021.01.135
PG 4
WC Acupuncture Therapy; adverse effects; Aged; Analgesics, Opioid; adverse effects; Constipation; chemically induced; Female; Humans; Laxatives; therapeutic use; Opioid-Induced Constipation
UT PubMed:33556492
PM 33556492
DA 2021-02-09
ER

PT J
AU Jin, Y
   Zhou, J
   Xu, FF
   Ren, ZQ
   Hu, J
   Zhang, C
   Ge, KW
   Liu, LY
AF Jin, Ying
   Zhou, Jie
   Xu, Fangfang
   Ren, Zeqin
   Hu, Jun
   Zhang, Cong
   Ge, Kaiwen
   Liu, Lanying
TI Electroacupuncture alleviates the transition from acute to chronic pain through the p38 MAPK/TNF-α signalling pathway in the spinal dorsal horn
SO ACUPUNCTURE IN MEDICINE
LA English
DT Article
DE electroacupuncture; hyperalgesic priming; p38 mitogen-activated protein kinase; tumour necrosis factor alpha; spinal dorsal horn
ID activated protein-kinase; neuropathic pain; tnf-alpha; map kinase; receptor; rat; contributes; expression; plasticity; allodynia
AB Background: Hyperalgesic priming (HP) is a model of the transition from acute to chronic pain. Electroacupuncture (EA) could inhibit pain development through the peripheral dorsal root ganglia; however, it is unclear whether it can mitigate the transition from acute to chronic pain by attenuating protein expression in the p38 MAPK (mitogen-activated protein kinase)/tumour necrosis factor alpha (TNF-alpha) pathway in the spinal dorsal horn. Aims: We aimed to determine whether EA could prevent the transition from acute to chronic pain by affecting the p38 MAPK/TNF-alpha pathway in the spinal dorsal horn in a rat model established using HP. Methods: We first randomly subdivided 30 male Sprague-Dawley (SD) rats into 5 groups (n = 6 per group): control (N), sham HP (Sham-HP), HP, HP + SB203580p38 MAPK (HP+SB203580), and HP + Lenalidomide (CC-5013) (HP+Lenalidomide). We then randomly subdivided a further 30 male SD rats into 5 groups (n = 6 per group): Sham-HP, HP, sham EA (Sham EA), EA (EA), and EA + U-46619 p38 MAPK agonist (EA+U-46619). We assessed the effects of EA on the mechanical paw withdrawal threshold and p38 MAPK/TNF-alpha expression in the spinal dorsal horn of rats subjected to chronic inflammatory pain. Results: Rats in the EA group had reduced p38 MAPK and TNF-alpha expression and had significantly reduced mechanical hyperalgesia compared with rats in the other groups. Conclusion: Our findings indicate that EA could increase the mechanical pain threshold in rats and inhibit the transition from acute pain to chronic pain. This mechanism could involve reduced p38 MAPK/TNF-alpha expression in the spinal dorsal horn.
C1 [Jin, Ying; Hu, Jun; Zhang, Cong; Ge, Kaiwen; Liu, Lanying] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Acupuncture & Rehabil, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Jin, Ying; Xu, Fangfang] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China.
   [Zhou, Jie] Zhejiang Chinese Med Univ, Affiliated Hosp 3, Hangzhou, Peoples R China.
   [Ren, Zeqin] Dali Univ, Affiliated Hosp 1, Dept Rehabil Tradit Chinese Med, Dali City, Peoples R China.
C3 Nanjing University of Chinese Medicine; Zhejiang University; Zhejiang Chinese Medical University; Dali University
RP Liu, LY (corresponding author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Acupuncture & Rehabil, Affiliated Hosp, 155 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM bluelany@163.com
FU Natural Science Foundation of Zhejiang Province [LQ21H270008, LQ18H270001]; Zhejiang Province Top Discipline of Chinese Medicine [ZTK2017A03, ZTK2017A04]
CR Abbas M, 2019, PHARMACOL REP, V71, P1168, DOI 10.1016/j.pharep.2019.07.001
   Berta T, 2016, J DENT RES, V95, P1124, DOI 10.1177/0022034516653604
   Berta T, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/9383184
   Berta T, 2014, J CLIN INVEST, V124, P1173, DOI 10.1172/JCI72230
   CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9
   Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008
   Choi SR, 2019, BIOMED PHARMACOTHER, V118, P0, DOI 10.1016/j.biopha.2019.109299
   Ferrari LF, 2015, J NEUROSCI, V35, P495, DOI 10.1523/JNEUROSCI.5147-13.2015
   Hu ML, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/7531060
   Huang Q, 2017, BRAIN BEHAV IMMUN, V62, P64, DOI 10.1016/j.bbi.2017.02.005
   Ji RR, 2007, MOL PAIN, V3, P0, DOI 10.1186/1744-8069-3-33
   Jiang GX, 2019, ACUPUNCT MED, V37, P116, DOI 10.1136/acupmed-2017-011559
   Kim JYV, 2016, PAIN, V157, P1314, DOI 10.1097/j.pain.0000000000000513
   Kim JYV, 2015, J NEUROSCI, V35, P6307, DOI 10.1523/JNEUROSCI.3481-14.2015
   Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231
   Li SS, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-4064-2
   Liu H, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/848603
   Luo X, 2018, BRAIN BEHAV IMMUN, V72, P34, DOI 10.1016/j.bbi.2017.11.007
   Ma F, 2015, NEUROSCIENCE, V300, P493, DOI 10.1016/j.neuroscience.2015.05.046
   Megat S, 2018, J NEUROSCI, V38, P379, DOI 10.1523/JNEUROSCI.2110-17.2017
   Olmos G, 2014, MEDIAT INFLAMM, V2014, P0, DOI 10.1155/2014/861231
   Parada CA, 2005, PAIN, V113, P185, DOI 10.1016/j.pain.2004.10.021
   Park R, 2020, ANESTH ANALG, V131, P764, DOI 10.1213/ANE.0000000000004673
   Takahata S, 2011, J ORTHOP SCI, V16, P313, DOI 10.1007/s00776-011-0052-4
   Taves S, 2016, BRAIN BEHAV IMMUN, V55, P70, DOI 10.1016/j.bbi.2015.10.006
   Tsuda M, 2004, GLIA, V45, P89, DOI 10.1002/glia.10308
   Tu WZ, 2012, NEUROCHEM INT, V60, P379, DOI 10.1016/j.neuint.2012.01.006
   Wang JY, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8403064
   Wang WS, 2014, J NEUROSCI RES, V92, P1703, DOI 10.1002/jnr.23451
   Yamamoto S, 2013, CELL MOL NEUROBIOL, V33, P167, DOI 10.1007/s10571-012-9881-8
   Zhang T, 2018, J NEUROINFLAMM, V15, P0, DOI 10.1186/s12974-018-1358-3
   Zhou YF, 2018, PURINERG SIGNAL, V14, P359, DOI 10.1007/s11302-018-9617-4
NR 32
TC 12
Z9 14
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0964-5284
EI 1759-9873
J9 ACUPUNCT MED
JI Acupunct. Med.
PD DEC 15
PY 2021
VL 39
IS 6
BP 708
EP 715
DI 10.1177/09645284211020766
EA JUL 2021
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA WJ3YR
UT WOS:000678082100001
PM 34308662
DA 2026-01-16
ER

PT J
AU Znidarsic, J
   Kirksey, KN
   Dombrowski, SM
   Tang, AN
   Lopez, R
   Blonsky, H
   Todorov, I
   Schneeberger, D
   Doyle, J
   Libertini, L
   Jamie, S
   Segall, T
   Bang, A
   Barringer, K
   Judi, B
   Ehrman, JP
   Roizen, MF
   Golubic, M
AF Znidarsic, Josie
   Kirksey, Kellie N.
   Dombrowski, Stephen M.
   Tang, Anne
   Lopez, Rocio
   Blonsky, Heather
   Todorov, Irina
   Schneeberger, Dana
   Doyle, Jonathan
   Libertini, Linda
   Jamie, Starkey
   Segall, Tracy
   Bang, Andrew
   Barringer, Kathy
   Judi, Bar
   Ehrman, Jane Pernotto
   Roizen, Michael F.
   Golubic, Mladen
TI "Living Well with Chronic Pain": Integrative Pain Management via Shared Medical Appointments
SO PAIN MEDICINE
LA English
DT Article
DE Chronic Pain; Opioids; Pain Management
ID adults
AB Objective. To evaluate the effectiveness of a multidisciplinary, nonpharmacological, integrative approach that uses shared medical appointments to improve health-related quality of life and reduce opioid medication use in patients with chronic pain. Design. This is a retrospective, pre-post review of "Living Well with Chronic Pain" shared medical appointments (August 2016 through May 2018). Setting. The appointments included eight 3-hour-long visits held once per week at an outpatient wellness facility. Subjects. Patients with chronic, non-cancer-related pain. Methods. Patients received evaluation and evidence-based therapies from a team of integrative and lifestyle medicine professionals, as well as education about nonpharmacological therapeutic approaches, the etiology of pain, and the relationship of pain to lifestyle factors. Experiential elements focused on the relaxation techniques of meditation, yoga, breathing, and hypnotherapy, while patients also received acupuncture, acupressure, massage, cognitive behavioral therapy, and chiropractic education. Patients self-reported data via the Patient-Reported Outcomes Measurement Information System (PROMIS-57) standardized questionnaire. Use of opioid medications was evaluated in morphine milligram equivalents. Results. A total of 178 participants completed the PROMIS-57 questionnaire at the first and the last visits. Statistically significant improvements in all domains (Physical Functioning, Anxiety, Depression, Fatigue, Social Roles, Pain Interference, and Sleep Disturbance) were observed (P<0.001) between the pre-intervention (visit 1) and post-intervention (visit 8) scores. Average opioid use decreased nonsignificantly over the 8-week intervention, but the lower rate of opioid use was not sustained at 6 and 12 months' follow-up. Conclusions. Patients suffering from chronic pain who participated in a multidisciplinary, nonpharmacological treatment approach delivered via shared medical appointments experienced reduced pain and improved measures of physical, mental, and social health without increased use of opioid pain medications.
C1 [Znidarsic, Josie; Kirksey, Kellie N.; Dombrowski, Stephen M.; Tang, Anne; Lopez, Rocio; Blonsky, Heather; Todorov, Irina; Schneeberger, Dana; Doyle, Jonathan; Libertini, Linda; Jamie, Starkey; Segall, Tracy; Bang, Andrew; Barringer, Kathy; Judi, Bar; Ehrman, Jane Pernotto; Roizen, Michael F.; Golubic, Mladen] Cleveland Clin, Ctr Integrat & Lifestyle Med, 1950 Richmond Rd,TR2-341, Lyndhurst, OH 44124 USA.
C3 Cleveland Clinic Foundation
RP Golubic, M (corresponding author), Cleveland Clin, Ctr Integrat & Lifestyle Med, 1950 Richmond Rd,TR2-341, Lyndhurst, OH 44124 USA.
EM golubim@ccf.org
FU Center for Integrative and Lifestyle Medicine, Cleveland Clinic Community Care; Center for Population Health Research, Department of Quantitative Health Sciences, Cleveland Clinic
CR Bernstein DN, 2019, SPINE, V44, PE852, DOI 10.1097/BRS.0000000000002979
   Bernstein DN, 2019, FOOT ANKLE INT, V40, P139, DOI 10.1177/1071100718803314
   Chao MT, 2015, PAIN MANAG NURS, V16, P920, DOI 10.1016/j.pmn.2015.07.007
   Chen CX, 2018, PAIN, V159, P775, DOI 10.1097/j.pain.0000000000001121
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Colloca L, 2020, NEW ENGL J MED, V382, P554, DOI 10.1056/NEJMra1907805
   Coulter ID, 2018, SPINE J, V18, P866, DOI 10.1016/j.spinee.2018.01.013
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2
   Ersek M, 2003, CLIN J PAIN, V19, P156, DOI 10.1097/00002508-200305000-00003
   Franovic Sreten, 2019, JB JS OPEN ACCESS, V4, Pe0019, DOI 10.2106/jbjs.oa.19.00019
   Gardiner P, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0225540
   Gardiner Paula, 2014, GLOB ADV HEALTH MED, V3, P20, DOI 10.7453/gahmj.2014.011
   Garland EL, 2020, JAMA INTERN MED, V180, P91, DOI 10.1001/jamainternmed.2019.4917
   Geller Jeffrey S, 2015, GLOB ADV HEALTH MED, V4, P27, DOI 10.7453/gahmj.2015.057
   Gomes T, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.0217
   Hassan S, 2020, PAIN MED, V21, P836, DOI 10.1093/pm/pnz291
   Kazmers NH, 2020, J HAND SURG-AM, V45, P399, DOI 10.1016/j.jhsa.2019.12.002
   Kendall R, 2018, PAIN MED, V19, P1720, DOI 10.1093/pm/pnx310
   Khalifeh JM, 2019, J NEUROSURG-SPINE, V31, P165, DOI 10.3171/2019.2.SPINE181237
   Kortlever JTP, 2015, CLIN ORTHOP RELAT R, V473, P3511, DOI 10.1007/s11999-015-4419-2
   Kroenke K, 2019, MED CARE, V57, P890, DOI 10.1097/MLR.0000000000001185
   Law T, 2019, HOLIST NURS PRACT, V33, P354, DOI 10.1097/HNP.0000000000000353
   Li LW, 2018, ARTHRIT CARE RES, V70, P221, DOI 10.1002/acr.23262
   Marchant J, 2016, NATURE, V535, PS14, DOI 10.1038/535S14a
   McCormack S, 2019, BOOKSHELF ID NBK5460, V0, P0
   Mehl-Madrona L, 2016, J ALTERN COMPLEM MED, V22, P621, DOI 10.1089/acm.2015.0212
   Nicholas MK, 2020, PAIN, V161, P509, DOI 10.1097/j.pain.0000000000001763
   Nielsen A, 2019, EXPLORE-NY, V15, P434, DOI 10.1016/j.explore.2019.08.009
   Preuss CV, 2020, STATPEARLS, V0, P0
   Qaseem A, 2017, ANN INTERN MED, V166, P514, DOI 10.7326/M16-2367
   Romanelli Robert J, 2017, J PATIENT EXP, V4, P144, DOI 10.1177/2374373517706837
   Schneeberger D, 2019, J ALTERN COMPLEM MED, V25, P40, DOI 10.1089/acm.2018.0154
   Shibuya K, 2018, CLEV CLIN J MED, V85, P699, DOI 10.3949/ccjm.85a.18006
   Soelberg CD, 2017, ANESTH ANALG, V125, P1675, DOI 10.1213/ANE.0000000000002403
   Srivastava G, 2018, FRONT PEDIATR, V6, P0, DOI 10.3389/fped.2018.00101
   Suso-Ribera C, 2017, PAIN RES MANAG, V2017, P0, DOI 10.1155/2017/9762864
   The Joint Commission Division of Healthcare Improvement, 2018, QUICK SAFETY, V0, P0
   Vaughan EM, 2019, CURR DIABETES REV, V15, P372, DOI 10.2174/1573399814666181112145910
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
NR 40
TC 18
Z9 22
U1 1
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD JAN 15
PY 2021
VL 22
IS 1
BP 181
EP 190
DI 10.1093/pm/pnaa418
EA FEB 2021
PG 10
WC Anesthesiology; Medicine, General & Internal
SC Anesthesiology; General & Internal Medicine
GA SA5NC
UT WOS:000649349100020
PM 33543263
DA 2026-01-16
ER

PT J
AU Tao, S
   Wang, X
   Liao, C
   Xiong, Y
   Tang, J
   Jiang, N
   Li, Y
   Hu, X
   Shuai, R
   Wang, Y
   Wu, P
AF Tao, Siyu
   Wang, Xue
   Liao, Chenxi
   Xiong, Yan
   Tang, Jie
   Jiang, Nannan
   Li, Yuan
   Hu, Xinyue
   Shuai, Rouxian
   Wang, Yueyue
   Wu, Ping
TI The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis
SO PAIN RESEARCH & MANAGEMENT
LA English
DT Article
ID disease-activity score; pain; chemokines; cytokines; inhibition; receptors
AB Objective. This study aims to evaluate the efficacy of moxibustion on joint swelling and pain and the levels of C-X-C motif chemokine ligand 1 (CXCL1), beta-endorphin (beta-EP) in serum of rheumatoid arthritis (RA) patients and to investigate the anti-inflammatory and analgesic mechanism of moxibustion on improving RA. Methods. Sixty-eight patients with RA were randomly and equally classified into the control and treatment groups. The control group was treated with routine drug therapy, while the treatment group received routine drug therapy and moxibustion. Both groups were treated for eight weeks. The symptoms and laboratory indicators of RA patients were compared in the two groups before and after intervention. Results. Sixty-one patients completed the study: four patients dropped out from the treatment group and three from the control group. Trial endpoints were change (Delta) in symptoms, measured by Ritchie's articular index (RAI), swollen joint count (SJC), and laboratory indicators, measured by the level of CXCL1, beta-EP, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta). Delta RAI, Delta SJC, Delta CXCL1, Delta beta-EP, Delta TNF-alpha, and Delta IL-1 beta in the treatment group were superior to the control group (13.50 [14.50] versus 6.00 [13.00] in Delta RAI, 4.00 [3.00] versus 2.00 [4.00] in Delta SJC, 0.04 +/- 0.79 ng/mL versus -0.01 +/- 0.86 ng/mL in Delta CXCL1, -2.43 [5.52] pg/mg versus -0.04 [4.09] pg/mg in Delta beta-EP, 3.45 [5.90] pg/mL versus 1.55 [8.29] pg/mL in Delta TNF-alpha, and 6.15 +/- 8.65 pg/mL versus 1.28 +/- 8.51 pg/mL in Delta IL-1 beta; all P < 0.05). Conclusion. Moxibustion can improve the joint swelling and pain symptoms in patients with RA, which may be related to the fact that moxibustion can reduce the release of inflammatory factors in patients with RA and downregulate the level of CXCL1 and increase the level of beta-EP at the same time.
C1 [Tao, Siyu; Wang, Xue; Liao, Chenxi; Tang, Jie; Jiang, Nannan; Hu, Xinyue; Shuai, Rouxian; Wu, Ping] Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
   [Xiong, Yan] West China Fourth Hosp, Chengdu 610075, Sichuan, Peoples R China.
   [Li, Yuan] Chengdu Univ Tradit Chinese Med Affiliated Hosp, Chengdu 610075, Sichuan, Peoples R China.
   [Wang, Yueyue] Sichuan Integrat Med Hosp, Chengdu 610075, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Wu, P (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu 610075, Sichuan, Peoples R China.
EM wuping_33@163.com
FU National Natural Science Foundation of China [81373738]; Education Department of Sichuan Province [2017JY0016]
CR Aletaha D, 2010, ARTHRITIS RHEUM-US, V62, P2569, DOI 10.1002/art.27584
   Bas DB, 2016, PAIN MANAG, V6, P265, DOI 10.2217/pmt.16.4
   Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389
   Cañete JD, 2009, ANN RHEUM DIS, V68, P751, DOI 10.1136/ard.2008.089284
   Chen Y, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6436420
   Chou RC, 2010, IMMUNITY, V33, P266, DOI 10.1016/j.immuni.2010.07.018
   dos Santos GG, 2020, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.03061
   Elemam NM, 2020, IMMUNOTARGETS THER, V9, P43, DOI 10.2147/ITT.S243636
   Fransen J, 2004, RHEUMATOLOGY, V43, P1252, DOI 10.1093/rheumatology/keh297
   Gerlag DM, 2008, BEST PRACT RES CL RH, V22, P311, DOI 10.1016/j.berh.2008.02.002
   Gong YY, 2019, PAIN RES MANAG, V2019, P0, DOI 10.1155/2019/4705247
   Hale KD, 2001, NEUROIMMUNOMODULAT, V9, P34, DOI 10.1159/000049005
   He XF, 2018, EXP THER MED, V15, P4014, DOI 10.3892/etm.2018.5914
   Herenius MMJ, 2011, ANN RHEUM DIS, V70, P1160, DOI 10.1136/ard.2010.141549
   Huang CC, 2019, J PINEAL RES, V66, P0, DOI 10.1111/jpi.12560
   Izquierdo E, 2009, PLOS ONE, V4, P0, DOI 10.1371/journal.pone.0008131
   Karlson EW, 2012, RHEUM DIS CLIN N AM, V38, P405, DOI 10.1016/j.rdc.2012.04.002
   Lai DL, 2019, CHIN ARCH TRADIT CHI, V37, P45
   Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3
   Mehrad B, 2007, THROMB HAEMOSTASIS, V97, P755, DOI 10.1160/TH07-01-0040
   MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8
   Miller MC, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18102088
   Mousa SA, 2003, ADV EXP MED BIOL, V521, P77
   Qin XM, 2005, J NEUROSCI RES, V82, P51, DOI 10.1002/jnr.20612
   Ridgley LA, 2018, CURR OPIN RHEUMATOL, V30, P207, DOI 10.1097/BOR.0000000000000470
   Rittner HL, 2005, J LEUKOCYTE BIOL, V78, P1215, DOI 10.1189/jlb.0405223
   Salaffi F, 2000, RHEUMATOLOGY, V39, P90, DOI 10.1093/rheumatology/39.1.90
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4
   Spetea M, 2013, CURR PHARM DESIGN, V19, P7382
   Studenic P, 2012, ARTHRITIS RHEUM-US, V64, P2814, DOI 10.1002/art.34543
   Szekanecz Z, 2001, CURR OPIN RHEUMATOL, V13, P202, DOI 10.1097/00002281-200105000-00009
   Vetter I, 2006, J PAIN, V7, P488, DOI 10.1016/j.jpain.2006.01.456
   Walker JS, 2003, ADV EXP MED BIOL, V521, P148
   Wang QQ, 2019, BMC GENOMICS, V20, P0, DOI 10.1186/s12864-019-5510-y
   Wasserman A, 2018, AM FAM PHYSICIAN, V97, P455
   Wigerblad G, 2016, ANN RHEUM DIS, V75, P730, DOI 10.1136/annrheumdis-2015-208094
   Wu Xiao, 2018, ZHONGGUO ZHEN JIU, V38, P1189, DOI 10.13703/j.0255-2930.2018.11.014
   Xu Y, 2018, AM J CHINESE MED, V46, P997, DOI 10.1142/S0192415X18500520
   Yu ZY, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7150605
   Zhang ZJ, 2013, PAIN, V154, P2185, DOI 10.1016/j.pain.2013.07.002
   Zhong YM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6108619
   Zhong Yu-Mei, 2020, ZHONGGUO ZHEN JIU, V40, P976, DOI 10.13703/j.0255-2930.20190729-0002
NR 42
TC 13
Z9 19
U1 2
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1203-6765
EI 1918-1523
J9 PAIN RES MANAG
JI Pain Res. Manag.
PD OCT 13
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/7466313
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 5Z2DP
UT WOS:000879787500001
PM 34691317
DA 2026-01-16
ER

PT J
AU Ben-Arye, E
   Paller, CJ
   Lopez, AM
   White, S
   Pendleton, E
   Kienle, GS
   Samuels, N
   Abbawaajii, N
   Balneaves, LG
AF Ben-Arye, Eran
   Paller, Channing J.
   Lopez, Ana Maria
   White, Shelley
   Pendleton, Eva
   Kienle, Gunver S.
   Samuels, Noah
   Abbawaajii, Nuria
   Balneaves, Lynda G.
TI The Society for Integrative Oncology Practice Recommendations for online consultation and treatment during the COVID-19 pandemic
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Integrative oncology; Telemedicine; Practice guidelines; Supportive care; Doctor-patient communication
ID clinical-practice guidelines; cancer-related fatigue; breast-cancer; controlled-trial; acupuncture; mindfulness; interventions; therapy; program; pain
AB Objective The Society for Integrative Oncology (SIO) Online Task Force was created in response to the challenges facing continuity of integrative oncology care resulting from the COVID-19 pandemic. The Task Force set out to guide integrative oncology practitioners in providing effective and safe online consultations and treatments for quality-of-life-concerns and symptom management. Online treatments include manual, acupuncture, movement, mind-body, herbal, and expressive art therapies. Methods The SIO Online Practice Recommendations employed a four-phase consensus process: (1) literature review and discussion among an international panel of SIO members, identifying key elements essential in an integrative oncology visit; (2) development, testing, and refinement of a questionnaire defining challenges and strategies; (3) refinement input from integrative oncology experts from 19 countries; and (4) SIO Executive Committee review identifying the most high-priority challenges and strategies. Results The SIO Online Practice Recommendations address ten challenges, providing practical suggestions for online treatment/consultation. These include overcoming unfamiliarity, addressing resistance among patients and healthcare practitioners to online consultation/treatment, exploring ethical and medical-legal aspects, solving technological issues, preparing the online treatment setting, starting the online treatment session, maintaining effective communication, promoting specific treatment effects, involving the caregiver, concluding the session, and ensuring continuity of care. Conclusions The SIO Online Practice Recommendations are relevant for ensuring continuity of care beyond the present pandemic. They can be implemented for patients with limited accessibility to integrative oncology treatments due to geographic constraints, financial difficulties, physical disability, or an unsupportive caregiver. These recommendations require further study in practice settings.
C1 [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Zebulon Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Clalit Hlth Serv, Integrat Oncol Program, Carmel Med Ctr, 35 Rothschild St, Haifa, Israel.
   [Ben-Arye, Eran] Technion Israel Inst Technol, Fac Med, 35 Rothschild St, Haifa, Israel.
   [Paller, Channing J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Lopez, Ana Maria] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
   [White, Shelley] Univ Utah, Huntsman Canc Inst, Wellness & Integrat Hlth Ctr, Salt Lake City, UT USA.
   [Pendleton, Eva] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   [Kienle, Gunver S.] Univ Freiburg, Fac Med, Inst Infect Prevent & Hosp Epidemiol, Ctr Complementary Med,Med Ctr, Freiburg, Germany.
   [Kienle, Gunver S.] Univ Witten Herdecke, Inst Appl Epistemol & Med Methodol, Freiburg, Germany.
   [Samuels, Noah] Shaarei Zedek Med Ctr, Ctr Integrat Complementary Med, Jerusalem, Israel.
   [Samuels, Noah] Tel Aviv Univ, Fac Med, Tel Aviv, Israel.
   [Abbawaajii, Nuria; Balneaves, Lynda G.] Univ Manitoba, Coll Nursing, Winnipeg, MB, Canada.
C3 Clalit Health Services; Clalit Health Services; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Johns Hopkins University; Thomas Jefferson University; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Memorial Sloan Kettering Cancer Center; University of Freiburg; Witten Herdecke University; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Tel Aviv University; University of Manitoba
RP Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Lin Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Zebulon Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Clalit Hlth Serv, Integrat Oncol Program, Carmel Med Ctr, 35 Rothschild St, Haifa, Israel.; Ben-Arye, E (corresponding author), Technion Israel Inst Technol, Fac Med, 35 Rothschild St, Haifa, Israel.
EM eranben@netvision.net.il
CR Al-Shamsi HO, 2020, ONCOLOGIST, V25, PE936, DOI 10.1634/theoncologist.2020-0213
   American Society of Clinical Oncology, 2020, ASCO 2020 CANC OPINI, V0, P0
   Unknown -, 2014, WHO HANDBOOK FOR GUIDELINE DEVELOPMENT, V2nd, P0
   Unknown -, 2018, WEB CONTENT ACCESSIBILITY GUIDELINES 2.1 (WCAG 2.1), V0, P0
   Unknown -, 2018, LICENSE CC BY-NC-SA 3.0 IGO, V0, P0
   Archer S, 2020, PSYCHO-ONCOLOGY, V29, P1430, DOI 10.1002/pon.5486
   Ben-Arye E, 2013, MED ONCOL, V30, P0, DOI 10.1007/s12032-013-0511-1
   BENARYE E, 2021, SUPPORT CARE CANCER, V0, P0
   Brouwers MC, 2010, CAN MED ASSOC J, V182, PE839, DOI 10.1503/cmaj.090449
   Cassileth BR, 2007, CHEST, V132, P340S, DOI 10.1378/chest.07-1389
   Chung WW, 2018, COMPUT BIOL MED, V101, P146, DOI 10.1016/j.compbiomed.2018.08.014
   Freeman LW, 2015, PSYCHO-ONCOLOGY, V24, P910, DOI 10.1002/pon.3656
   Goode AD, 2015, J CANCER SURVIV, V9, P660, DOI 10.1007/s11764-015-0442-2
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Grégoire C, 2020, PSYCHO-ONCOLOGY, V29, P1165, DOI 10.1002/pon.5395
   Huberty J, 2019, BMC COMPLEM ALTERN M, V19, P0, DOI 10.1186/s12906-019-2530-8
   Hwang NK, 2020, HEALTHCARE-BASEL, V8, P0, DOI 10.3390/healthcare8040355
   Kelleher SA, 2019, PSYCHO-ONCOLOGY, V28, P1671, DOI 10.1002/pon.5141
   Kubo A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419850634
   Kutikov A, 2020, ANN INTERN MED, V172, P756, DOI 10.7326/M20-1133
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mikolasek M, 2018, INT J BEHAV MED, V25, P1, DOI 10.1007/s12529-017-9679-7
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Murphy MK, 1998, HEALTH TECHNOL ASSES, V2, P1
   Narayanan S, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735421999101
   Newton RU, 2020, JCO ONCOL PRACT, V16, P656, DOI 10.1200/OP.20.00210
   Ng DWL, 2020, PSYCHO-ONCOLOGY, V29, P1380, DOI 10.1002/pon.5437
   Passaro A, 2020, ESMO OPEN, V5, P0, DOI 10.1136/esmoopen-2019-000598
   Rithirangsriroj K, 2015, GYNECOL ONCOL, V136, P82, DOI 10.1016/j.ygyno.2014.10.025
   Russell L, 2019, SUPPORT CARE CANCER, V27, P2735, DOI 10.1007/s00520-018-4574-6
   Shankar A, 2020, ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, V21, P569, DOI 10.31557/apjcp.2020.21.3.569
   Sierpina V, 2006, EXPLORE-NY, V2, P368, DOI 10.1016/j.explore.2006.05.018
   Sutherland AE, 2020, BMJ SUPPORT PALLIAT, V10, P271, DOI 10.1136/bmjspcare-2020-002326
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, V0, P1
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   World Health Organization, 2019, LICENCE: CC BY-NC-SA 3.0 IGO, V0, P0
   Zernicke KA, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-34
   Zick SM, 2018, JNCI CANCER SPECT, V2, P0, DOI 10.1093/jncics/pky064
NR 42
TC 27
Z9 29
U1 1
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD OCT 15
PY 2021
VL 29
IS 10
BP 6155
EP 6165
DI 10.1007/s00520-021-06205-w
EA APR 2021
PG 11
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA UL1DT
UT WOS:000640131900003
PM 33852088
DA 2026-01-16
ER

PT J
AU Chan, YT
   Wang, N
   Tam, CW
   Tan, HY
   Lu, YJ
   So, TH
   Chau-Leung Yu, E
   Lao, LX
   Feng, YB
AF Chan, Yau-Tuen
   Wang, Ning
   Tam, Chi-Wing
   Tan, Hor-Yue
   Lu, Yuanjun
   So, Tsz-Him
   Chau-Leung Yu, Edwin
   Lao, Lixing
   Feng, Yibin
TI Systematic Review with Meta-Analysis: Effectiveness and Safety of Acupuncture as Adjuvant Therapy for Side Effects Management in Drug Therapy-Receiving Breast Cancer Patients
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID musculoskeletal symptoms; sham acupuncture; trial; women; electroacupuncture; chemotherapy; pain; benefits; efficacy; medicine
AB Objective. To investigate the potential benefits and safety of acupuncture on managing side effects induced by drug therapies in patients with breast cancer using a PRISMA standard systematic review and meta-analysis. Methods. Published randomised controlled trials from nine databases in English and Chinese language were searched. Trials with a real acupuncture treatment group and a control group with sham acupuncture, no treatment, or waitlist control were included. The primary outcome of this study was the therapeutic effects on five symptoms induced by drug therapies, including gastrointestinal disorder, neuropathy, arthralgia, joint symptoms, and cognitive impairment. The quality of life was assessed as a secondary outcome. The risk of bias of each study was analysed according to the Cochrane Handbook. Results. Sixteen randomised controlled trials with 1189 participants were included in the meta-analysis. The primary outcome and all subgroup analyses showed statistically significant improvements in the management of side effects by real acupuncture. The quality of life of patients has enhanced during the treatment. Conclusion. Although the number of publications is limited, a clear preliminary conclusion could be drawn by the meta-analysis, suggesting the beneficial adjuvant role of acupuncture in patients with breast cancer who receive drug therapies. No serious adverse events were observed from all the RCTs, and the safety of acupuncture is ascertained. More standardised and sophisticated large-scale randomised controlled trials are needed to evaluate the findings further.
C1 [Chan, Yau-Tuen; Wang, Ning; Tam, Chi-Wing; Tan, Hor-Yue; Lu, Yuanjun; Feng, Yibin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [So, Tsz-Him] Univ Hong Kong, Li Ka Shing Fac Med, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Chau-Leung Yu, Edwin] Hong Kong Assoc Integrat Chinese Western Med, Hong Kong, Peoples R China.
   [Lao, Lixing] Virginia Univ Integrat Med, 9401 Mathy Dr, Fairfax, VA 22031 USA.
C3 University of Hong Kong; University of Hong Kong
RP Feng, YB (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
EM ecyt@connect.hku.hk; ckwang@hku.hk; tcw8@connect.hku.hk; hyhtan@hkbu.edu.hk; yjlu@connect.hku.hk; sth495@hku.hk; yuedwin@yahoo.com; llao@vuim.edu; yfeng@hku.hk
FU Wong's Donation [200006276]; Gaia Family Trust for Modern Oncology of Chinese Medicine [200007008]; Research Grant Council, HKSAR [RGC GRF 17152116]; Innovation and Technology Commission: The 2nd Phase of Integrative Joint Organizational Platform (IJOP) Disease Collaborative Panel [200009062]; Health and Medical Research Fund [15162961, 16172751, 17181101]
CR Appleyard I, 2014, EUR J INTEGR MED, V6, P234, DOI 10.1016/j.eujim.2014.03.004
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Birch S, 2019, INTEGR MED RES, V8, P160, DOI 10.1016/j.imr.2019.05.002
   Bown MJ, 2010, EUR J VASC ENDOVASC, V40, P669, DOI 10.1016/j.ejvs.2010.07.011
   Chon TY, 2013, MAYO CLIN PROC, V88, P1141, DOI 10.1016/j.mayocp.2013.06.009
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Ferlay J, 2013, GLOBOCAN 2012 CANC I, V0, P0
   Gradishar WJ, 2017, J NATL COMPR CANC NE, V15, P433, DOI 10.6004/jnccn.2017.0044
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han XY, 2019, COMPLEMENT THER CLIN, V37, P109, DOI 10.1016/j.ctcp.2019.09.004
   [何佩珊 He Peishan], 2017, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V32, P2805
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Higgins JP, 2011, COCHRANE HDB SYSTEMA, V5, P0
   Higgins JPT, 2019, COCHRANE HANDBOOK FOR SYSTEMATIC REVIEWS OF INTERVENTIONS, V0, P0, DOI DOI 10.1002/9781119536604
   John PA, 2017, BMJ-BRIT MED J, V356, P0, DOI 10.1136/bmj.j408
   Kaptchuk TJ, 2002, ANN INTERN MED, V136, P374, DOI 10.7326/0003-4819-136-5-200203050-00010
   Kim W, 2015, COMPLEMENT THER MED, V23, P626, DOI 10.1016/j.ctim.2015.03.011
   Kong J, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0081049
   Li D, 2017, THE EFFECT OF ACUPUNCTURE COMBINED WITH 5-HT RECEPTOR ANTAGONISTS ON ACUTE GASTROINTESTINAL REACTIONS IN BREAST CANCER CHEMOTHERAPY, V0, P0
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu D, 2014, CLIN RES ACUTE GASTR, V0, P0
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Pan YQ, 2018, INTEGR CANCER THER, V17, P602, DOI 10.1177/1534735418786801
   Park Jongbae, 2002, ACUPUNCT MED, V20, P168
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Shi X, 2019, CLINICAL STUDY ON THE SIDE-EFFECT OF "TIAOREN TONGDU" ACUPUNCTURE METHOD ON CHEMOTHERAPEUTIC DRUGS FOR BREAST CANCER, V0, P0
   Su CX, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-014-0545-5
   Tao JJ, 2015, BREAST, V24, PS149, DOI 10.1016/j.breast.2015.07.035
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   VanderPloeg K, 2009, J ACUPUNCT MERIDIAN, V2, P26, DOI 10.1016/S2005-2901(09)60012-1
   Zhang C, 2018, GUID J TRADIT CHIN MED PHARM, V24, P49, DOI 10.13862/j.cnki.cn43-1446/r.2018.09.014
   Zhang LL, 2016, CHIN J INTEGR MED, V22, P483, DOI 10.1007/s11655-016-2458-5
   [张玉 Zhang Yu], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P509
   Zhang ZJ, 2020, BRAIN BEHAV IMMUN, V88, P88, DOI 10.1016/j.bbi.2020.04.035
NR 40
TC 7
Z9 9
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD OCT 12
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/9949777
PG 15
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA YO5DI
UT WOS:000747959300013
PM 34675990
DA 2026-01-16
ER

PT J
AU Huang, L
   Zhao, Y
   Xiang, M
AF Huang, Li
   Zhao, Yanqing
   Xiang, Minhong
TI Knowledge Mapping of Acupuncture for Cancer Pain: A Scientometric Analysis
SO Journal of pain research
LA English
DT Journal Article
DE CiteSpace; acupuncture; cancer pain; knowledge mapping; scientometric analysis
AB OBJECTIVE: This study aimed to demonstrate the state of the present situation and  trends concerning the global use of acupuncture for cancer pain in the past 20  years. METHODS: Searched the Web of Science database from 2000 to 2019 related to  acupuncture for cancer pain, and then used CiteSpace to conduct scientometric  analysis to acquire the knowledge mapping. RESULTS: Yearly output has increased  year by year, and the growth rate has become faster after 2012. According to the  cluster analysis of institutions, authors, cited references, and keywords, 4, 4,  15, and 14 categories were obtained, respectively. The most productive countries,  institutions, and authors are the USA, Mem Sloan Kettering Cancer Center, and Mao  JJ, whose frequencies are 196, 24, and 17, respectively. However, the most  important of them are Australia, Univ. Maryland, and Bao T, owing to their  highest centrality, they are 0.90, 0.21, and 0.09 separately. Moreover, cited  references that contributed to the most co-citations are Crew KD (2010), however,  the most key cited reference is Roscoe JA (2003). Keywords such as acupuncture,  pain, breast cancer, palliative care, and quality of life are the most frequently  used. But auricular acupuncture is the crucial keyword. In the cluster analysis  of institutions, authors, cited references, and keywords, the more convincing  research categories are multiple myeloma, placebo effect, neck malignancies, and  early breast cancer, with S values of 0.990, 0.991, 0.990, and 0.923,  respectively. Therefore, they can be regarded as research hotspots in this field.  CONCLUSION: Based on the scientometric analysis in the past 20 years, the  knowledge mapping of the country, institution, author, cited reference, and the  keyword is gained, which has an important guiding significance for quickly and  accurately positioning the trend in this field.
C1 Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
   Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
   Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China.
NR 0
TC 0
SN 1178-709
EI 1178-709
J9 J Pain Res
PD FEB 13
PY 2021
VL 14
IS 
BP 343
EP 358
DI 10.2147/JPR.S292657
PG 15
UT PubMed:33574698
PM 33574698
DA 2021-02-13
ER

PT J
AU Chen, Q
   Feng, JM
   Liu, ZD
   An, DY
   Li, YD
   Zhou, SH
   Weng, ZW
AF Chen, Qi
   Feng, Jiaming
   Liu, Zhidan
   An, Dongyang
   Li, Yadan
   Zhou, Shaohu
   Weng, Zhiwei
TI Research trends of prostatitis over past 20 years: A bibliometric analysis
SO ANDROLOGIA
LA English
DT Article
DE bibliographic item co-occurrence matrix builder; bibliometric analysis; prostatitis; research trends; VOSviewer
ID pelvic pain syndrome; oxidative stress; h-index; symptoms; men; epidemiology; health
AB In the past two decades, thousands of documents in the field of prostatitis have been published. This bibliometric analysis aimed to assess the characteristics, hotspots and frontiers trend of global scientific output on prostatitis. With the trend of moderate growth, altogether 2,423 papers were reviewed. The leading role of the United States in global prostatitis research was obvious, while China had developed rapidly in recent years. Queen's University and JOURNAL OF UROLOGY were the most prolific affiliation and journal respectively. Nickel, J. C made the greatest contribution to the field of prostatitis. Five hotspots have been confirmed: (a) male infertility associated with prostatitis and the molecular mechanisms; (b) diagnosis and treatment of prostatitis; (c) inflammation, pain and bladder irritation symptoms; (d) relationship between chronic prostatitis/chronic pelvic pain syndrome, benign prostatic hyperplasia and prostate cancer; (e) epidemiology, complications of prostatitis and improvement of acupuncture. This bibliometric analysis reveals that the international cooperation was becoming more and more close. Hotspot analysis shows that the molecular mechanism of prostatitis will be a hotspot in the future, mainly focussing on inflammatory immunity and oxidative stress.
C1 [Chen, Qi; Feng, Jiaming; Liu, Zhidan; An, Dongyang; Li, Yadan; Zhou, Shaohu; Weng, Zhiwei] Guangzhou Univ Chinese Med, Clin Med Sch 1, Guangzhou, Peoples R China.
   [Chen, Qi; Feng, Jiaming] Guangzhou Univ Chinese Med, Lingnan Med Res Ctr, Guangzhou, Peoples R China.
   [Zhou, Shaohu; Weng, Zhiwei] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510400, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine
RP Weng, ZW (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou 510400, Peoples R China.
EM lcwzw@126.com
FU State Administration of Traditional Chinese Medicine of Guangdong Province [20181097]; Research Development Project of Guangzhou University of Chinese Medicine [2021xk64]; Youth Research Fund of the First Affiliated Hospital of Guangzhou University of Chinese Medicine [2019QN30]
CR Alexander RB, 2004, ANN INTERN MED, V141, P581, DOI 10.7326/0003-4819-141-8-200410190-00005
   Alshahrani S, 2013, J REPROD IMMUNOL, V100, P30, DOI 10.1016/j.jri.2013.05.004
   Bertoli-Barsotti L, 2017, SCIENTOMETRICS, V111, P1415, DOI 10.1007/s11192-017-2351-9
   Brown T, 2019, SCAND J OCCUP THER, V26, P475, DOI 10.1080/11038128.2018.1473489
   Chen R, 2003, UROLOGY, V61, P1156, DOI 10.1016/S0090-4295(03)00141-9
   Cooper ID, 2015, J MED LIBR ASSOC, V103, P217, DOI 10.3163/1536-5050.103.4.013
   Delongchamps NB, 2008, J UROLOGY, V179, P1736, DOI 10.1016/j.juro.2008.01.034
   Dennis LK, 2002, UROLOGY, V60, P78, DOI 10.1016/S0090-4295(02)01637-0
   Devos P, 2019, J HYPERTENS, V37, P2116, DOI 10.1097/HJH.0000000000002143
   Durieux V, 2010, RADIOLOGY, V255, P342, DOI 10.1148/radiol.09090626
   Garfield E, 1999, CAN MED ASSOC J, V161, P979
   Glander Hans-Jurgen, 2007, J DTSCH DERMATOL GES, V5, P924, DOI 10.1111/j.1610-0387.2007.06526.x
   Huang TJ, 2020, SPINE, V45, PE721, DOI 10.1097/BRS.0000000000003381
   Hui JL, 2020, INT J IMPOT RES, V32, P409, DOI 10.1038/s41443-019-0161-8
   Ihsan AU, 2018, BIOMED PHARMACOTHER, V106, P714, DOI 10.1016/j.biopha.2018.06.139
   Ioannidis JPA, 2020, PLOS BIOL, V18, P0, DOI 10.1371/journal.pbio.3000918
   Khan FU, 2017, BIOMED PHARMACOTHER, V94, P1064, DOI 10.1016/j.biopha.2017.08.016
   Krieger JN, 2008, INT J ANTIMICROB AG, V31, PS85, DOI 10.1016/j.ijantimicag.2007.08.028
   Liang CZ, 2009, J UROLOGY, V182, P558, DOI 10.1016/j.juro.2009.04.011
   Magistro G, 2016, EUR UROL, V69, P286, DOI 10.1016/j.eururo.2015.08.061
   Magri V, 2018, ARCH ITAL UROL ANDRO, V90, P227, DOI 10.4081/aiua.2018.4.227
   Mandar R, 2020, ANDROLOGY-US, V8, P101, DOI 10.1111/andr.12647
   Meng LQ, 2018, PROSTATE, V78, P790, DOI 10.1002/pros.23536
   Motrich RD, 2020, BJU INT, V126, P379, DOI 10.1111/bju.15117
   Nickel JC, 2001, J UROLOGY, V165, P842, DOI 10.1016/S0022-5347(05)66541-X
   Nowak JK, 2018, CROAT MED J, V59, P25, DOI 10.3325/cmj.2018.59.25
   Paulis G, 2018, RES REP UROL, V10, P75, DOI 10.2147/RRU.S170400
   Polackwich AS, 2016, PROSTATE CANCER P D, V19, P132, DOI 10.1038/pcan.2016.8
   RASMUSSEN M, 2004, TR04021 UMNCS, V0, P0
   Rees J, 2015, BJU INT, V116, P509, DOI 10.1111/bju.13101
   Sahin S, 2015, PROSTATE CANCER P D, V18, P249, DOI 10.1038/pcan.2015.13
   Schaeffer AJ, 2003, ANDROLOGIA, V35, P252, DOI 10.1046/j.1439-0272.2003.00584.x
   Schagdarsurengin U, 2017, UROL INT, V98, P89, DOI 10.1159/000452251
   Schoeb DS, 2017, WORLD J UROL, V35, P1659, DOI 10.1007/s00345-017-2054-0
   Schoor Richard A, 2002, CURR UROL REP, V3, P324, DOI 10.1007/s11934-002-0058-8
   Shoskes DA, 2013, WORLD J UROL, V31, P755, DOI 10.1007/s00345-013-1075-6
   Tao L, 2020, ANN TRANSL MED, V8, P0, DOI 10.21037/atm.2020.02.67
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Wang CY, 2021, FRONT ENDOCRINOL, V12, P0, DOI 10.3389/fendo.2021.665912
   Wiygul Regula Doggweiler, 2005, CURR UROL REP, V6, P282, DOI 10.1007/s11934-005-0025-2
   Zhang LG, 2020, PROSTATE, V80, P1394, DOI 10.1002/pros.24065
   Zhao QX, 2020, ANDROLOGY-US, V8, P747, DOI 10.1111/andr.12747
   Zhu DF, 2017, BIOMED RES INT, V2017, P0, DOI 10.1155/2017/3473796
NR 43
TC 9
Z9 12
U1 0
U2 40
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-4569
EI 1439-0272
J9 ANDROLOGIA
JI Andrologia
PD NOV 15
PY 2021
VL 53
IS 10
BP 
EP 
DI 10.1111/and.14206
EA AUG 2021
PG 13
WC Andrology
SC Endocrinology & Metabolism
GA UZ8ZF
UT WOS:000682605500001
PM 34365673
DA 2026-01-16
ER

PT J
AU Liu, XM
   Lu, J
   Wang, GX
   Chen, X
   Xv, HP
   Huang, J
   Xue, MX
   Tang, JH
AF Liu, Xiaomeng
   Lu, Jing
   Wang, Guoxin
   Chen, Xiu
   Xv, Haiping
   Huang, Jing
   Xue, Mingxin
   Tang, Jinhai
TI Acupuncture for Arthralgia Induced by Aromatase Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; aromatase inhibitor-induced arthralgia; breast cancer; meta-analysis
ID adjuvant endocrine therapy; clinical-practice; sham acupuncture; musculoskeletal symptoms; randomized-trials; american society; joint symptoms; women; management; guideline
AB Background: Aromatase inhibitor-induced arthralgia (AIA) is the most common side effect of aromatase inhibitors (AIs) used in breast cancer patients and is related to the rate of adherence to AIs. The clinical effects of acupuncture on AIA have been assessed by some randomized controlled trials (RCTs). However, some studies reported that acupuncture was effective, while others claimed that it was ineffective. To clarify the clinical and placebo effects of acupuncture in treating AIA, we conducted this meta-analysis. Methods: Two reviewers (XL and GW) independently searched for RCTs in 5 English databases (PubMed, Web of Science, Embase, Springer, Cochrane Library) and 4 Chinese databases (China National Knowledge Infrastructure Database (CNKI), SinoMed, VIP and Wanfang Database) from their inception to 30 November 2019. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, this meta-analysis was performed by fixed or random-effects models, and data were pooled with mean differences (MDs). Results: Seven trials involving 603 patients were reviewed. The primary outcome, the Brief Pain Inventory (BPI) score, significantly differed between the acupuncture and control groups [pain-related interference: MD = -1.89, 95% confidence interval (CI) [-2.99, -0.79], Z = 3.36 (P = .008 < .05), pain severity: MD = -1.57, 95% CI [-2.46, -0.68], Z = 3.45 (P = .0006 < .05), worst pain: MD = -2.31, 95% CI [-3.15, -1.48], Z = 5.47 (P < .0001 < .05)]. No severe adverse events were reported in any study. Conclusion: This meta-analysis showed that acupuncture is a safe and effective treatment for breast cancer patients with AIA. Additional research with improved blinding methods is warranted to further explore the nature of non-specific and placebo effects in true and sham acupuncture.
C1 [Liu, Xiaomeng; Wang, Guoxin; Xue, Mingxin] Nanjing Univ Chinese Med, Nanjing, Peoples R China.
   [Liu, Xiaomeng; Lu, Jing; Chen, Xiu; Xv, Haiping; Xue, Mingxin; Tang, Jinhai] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China.
   [Huang, Jing] Kunming Med Univ, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing Medical University; Kunming Medical University
RP Tang, JH (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Peoples R China.; Xue, MX (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Acupuncture Dept, Nanjing 210029, Peoples R China.
EM jhtang@njmu.edu.cn
FU National Key Research and Development Program of China [2016YFC0905900]; National Natural Science Foundation of China [81872365]; Jiangsu Provincial Key Research Development Program [BE2019731]; Jiangsu Provincial Key Funding Project for Maternal and Child Health Research [F201821]; Clinical Research Project of Jiangsu Province Hospital [JSPH-511C-2018-8]
CR Anand K, 2019, CURR ONCOL REP, V21, P0, DOI 10.1007/s11912-019-0795-1
   Armijo-Olivo S, 2017, AM J PHYS MED REHAB, V96, P34, DOI 10.1097/PHM.0000000000000521
   Bae K, 2015, INTEGR CANCER THER, V14, P496, DOI 10.1177/1534735415596573
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Boutron I, 2007, PLOS MED, V4, P370, DOI 10.1371/journal.pmed.0040061
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Chen L, 2017, BREAST, V33, P132, DOI 10.1016/j.breast.2017.03.015
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Felson DT, 2005, ARTHRITIS RHEUM-US, V52, P2594, DOI 10.1002/art.21364
   Fregni F, 2010, AM J PHYS MED REHABI, V89, P0
   Ghoncheh Mahshid, 2016, ASIAN PAC J CANCER PREV, V17, P43, DOI 10.7314/apjcp.2016.17.s3.43
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Hadji P, 2014, ANN ONCOL, V25, P372, DOI 10.1093/annonc/mdt513
   Halsey EJ, 2015, ACUPUNCT MED, V33, P188, DOI 10.1136/acupmed-2014-010735
   Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   HIGGINS J, 2020, COCHRANE DB SYST REV, V0, P0
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Ingle JN, 2010, J CLIN ONCOL, V28, P4674, DOI 10.1200/JCO.2010.28.5064
   Kawakita K, 2006, J PHARMACOL SCI, V100, P443, DOI 10.1254/jphs.CRJ06004X
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Lan Kun-Chan, 2019, MEDICINES (BASEL), V6, P0, DOI 10.3390/medicines6030087
   Li J, 2019, CHINA MED HERALD, V16, P132
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356
   Moher D, 2009, PLOS MED, V6, P0, DOI 10.1371/journal.pmed.1000097
   Müller ST, 2018, LAB ANIM-UK, V52, P479, DOI 10.1177/0023677218756455
   Murphy CC, 2012, BREAST CANCER RES TR, V134, P459, DOI 10.1007/s10549-012-2114-5
   Nahm N, 2018, ASIA-PAC J CLIN ONCO, V14, P374, DOI 10.1111/ajco.12845
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Papaioannou A, 2007, DRUG AGING, V24, P37, DOI 10.2165/00002512-200724010-00003
   Qin W, 2008, MOL PAIN, V4, P0, DOI 10.1186/1744-8069-4-55
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Schulz KF, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c869
   Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9
   Tang Y, 2019, BRAIN RES BULL, V151, P144, DOI 10.1016/j.brainresbull.2018.10.015
   The Nordic Cochrane Centre TCC, 2014, COP REV MAN REVMAN, V0, P0
   Vase L, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0119612
   Vodicka E, 2015, CONTEMP CLIN TRIALS, V43, P1, DOI 10.1016/j.cct.2015.04.004
   Wu MT, 2002, NEUROIMAGE, V16, P1028, DOI 10.1006/nimg.2002.1145
   Ye J, 2015, SHANGHAI J ACUP MOXIB, V34, P642
NR 44
TC 15
Z9 20
U1 0
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD FEB 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/1534735420980811
PG 14
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA QI2AL
UT WOS:000618775300001
PM 33586504
DA 2026-01-16
ER

PT J
AU Gao, Y
   Ma, TT
   Han, M
   Yu, MW
   Wang, XH
   Lv, YR
   Wang, XM
AF Gao, Yu
   Ma, Tingting
   Han, Mei
   Yu, Mingwei
   Wang, Xiuhui
   Lv, Yiren
   Wang, Xiaomin
TI Effects of Acupuncture and Moxibustion on Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Review
DE acupuncture; moxibustion; breast cancer-related lymphedema
AB Objective: The aim of this systematic review and meta-analysis of randomized controlled trials (RCTs) was to evaluate the effects of acupuncture and moxibustion (AM) in women with breast cancer-related lymphedema (BCRL). Methods: We retrieved RCTs published before January 24, 2021, from the MEDLINE, EMBASE, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Chongqing VIP (VIP), and Wanfang databases. RCTs that compared acupuncture and/or moxibustion intervention with other treatments were included. A random effects or fixed effects model was used based on the heterogeneity findings. Study quality was evaluated using the Cochrane risk of bias tool. Results: We included 14 RCTs in the analyses, of which 4 RCTs adopted acupuncture, 4 RCTs used moxibustion, and the rest used both. AM significantly reduced arm circumference at the elbow crease compared to routine care (Mean deviation (MD) = -7.26, 95% confidence interval (CI) = -8.30 to -6.21, P < .00001). There was a significant difference between AM and diosmin tablets in the effective index for upper limb lymphedema (MD = 24.68, 95% CI = 24.82-30.53, P < .00001), the range of motion of the shoulder during protraction (MD = 6.77, 95% CI = 2.81-10.73, P = .0008), and adduction (MD = 4.17, 95% CI = 1.02-7.32, P = .01). There was a significant difference between moxibustion and pneumatic circulation (MD = -0.51, 95% CI = -0.85 to -0.17, P = .003) in the visual analog score (VAS) for swelling. Finally, compared to the blank control, acupuncture reduced the VAS for pain (MD = -1.33, 95% CI = -1.52 to -1.15, P < .00001; heterogeneity (I-2) = 0%, P = .57). Conclusion: Our results suggest that AM is effective in the treatment of BCRL. AM may reduce arm circumference at the elbow crease (compared to routine care), increase effective index for upper limb lymphedema (compared to oral diosmin tablets), improve the range of motion of the shoulder during protraction and adduction (compared to oral diosmin tablets), and decrease the VAS for both swelling (compared to pneumatic circulation) and pain (compared to blank control).
C1 [Gao, Yu; Ma, Tingting; Yu, Mingwei; Wang, Xiuhui; Lv, Yiren; Wang, Xiaomin] Capital Med Univ, Beijing Hosp Tradit Chinese Med, 23 Back Rd Art Gallery, Beijing 100010, Peoples R China.
   [Han, Mei] Beijing Univ Chinese Med, Beijing, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine
RP Wang, XM (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, 23 Back Rd Art Gallery, Beijing 100010, Peoples R China.
EM wangxiaomin_bhtcm@126.com
FU Beijing Science and Technology Plan Project [Z191100008319006]
CR Unknown -, 2012, CHIN J CLIN RES, V0, P0
   Unknown -, 2019, WORLD CHIN MED, V0, P0
   Ba T, 2019, CLIN OBSERVATION WAR, V0, P0
   Bao T, 2018, BREAST CANCER RES TR, V170, P77, DOI 10.1007/s10549-018-4743-9
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Cal A, 2016, CANCER NURS, V39, PE17, DOI 10.1097/NCC.0000000000000326
   Cassileth BR, 2013, CANCER-AM CANCER SOC, V119, P2455, DOI 10.1002/cncr.28093
   Chien TJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866910
   Crawford C M, 1986, J BURN CARE REHABIL, V7, P323, DOI 10.1097/00004630-198607000-00005
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   Huang HT, 2014, CHEKIANG J TRADIT CHIN MED, V49, P59
   Invernizzi M, 2019, J CLIN MED, V8, P0, DOI 10.3390/jcm8020138
   Jiao HF, 2017, NEI MONGOL J TRADIT CHIN MED, V130, P23
   Jin HM, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/3237451
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu YN, 2019, SHANGHAI J ACU-MOX, V38, P634, DOI 10.13460/j.issn.1005-0957.2019.06.0634
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Omidi Z, 2020, QUAL LIFE RES, V29, P1789, DOI 10.1007/s11136-020-02455-z
   Runowicz CD, 2016, CA-CANCER J CLIN, V66, P44, DOI 10.3322/caac.21319
   Shen J, 2019, STUDY EVALUATION EFF, V0, P0
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7
   Smith CA, 2014, ACUPUNCT MED, V32, P387, DOI 10.1136/acupmed-2014-010593
   Stuiver MM, 2017, BMJ-BRIT MED J, V357, P0, DOI 10.1136/bmj.j2330
   Wang CH, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866919
   White A, 2007, RHEUMATOLOGY, V46, P384, DOI 10.1093/rheumatology/kel413
   Wu C, 2018, CHIN MED J METALL IND, V35, P324
   Yang MX, 2017, PLOS ONE, V12, P0, DOI 10.1371/journal.pone.0170952
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Yu SW, 2019, FRONT NEUROL, V10, P0, DOI 10.3389/fneur.2019.01114
   Yu SB, 2020, EXPLORE-NY, V16, P97, DOI 10.1016/j.explore.2019.06.002
   Zhan Jing, 2017, CHIN J WOMAN CHILD HEALTH RES, V28, P570
   Zhang FR, 2020, WORLD JOURNAL OF INTEGRATED TRADITIONAL AND WEST- ERN MEDICINE, V15, P1934, DOI 10.13935/J.CNKI.SJZX.201038
   Zhang XY, 2019, ACUPUNCT MED, V37, P16, DOI 10.1136/acupmed-2018-011668
NR 36
TC 10
Z9 11
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD SEP 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/15347354211044107
PG 13
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA UU3EJ
UT WOS:000698682300001
PM 34521235
DA 2026-01-16
ER

PT J
AU Liu, CT
   Hsieh, TM
   Shih, FY
   Lai, WH
   Hsieh, CH
   Wu, BY
   Chen, YH
AF Liu, Chun-Ting
   Hsieh, Ting-Min
   Shih, Fu-Yuan
   Lai, Wei-Hung
   Hsieh, Ching-Hua
   Wu, Bei-Yu
   Chen, Yung-Hsiang
TI The effects of electroacupuncture and laser acupuncture therapy for patients with major trauma A study protocol
SO MEDICINE
LA English
DT Article
DE acupuncture; cholinergic anti-inflammatory pathway; inflammation; laser acupuncture; major trauma
ID vagus nerve-stimulation; severity; injury
AB Background: Major trauma is the leading cause of death in the young population. The inflammatory and anti-inflammatory responses are associated with posttraumatic morbidity and mortality; however, it is not fully clear how to reestablish the homeostasis in patients with major trauma. Methods: This study will be a prospective, randomized, placebo-controlled, partially double-blinded, three-armed trial. One hundred eighty participants diagnosed with major trauma will be randomly assigned to an electroacupuncture (EA), a laser acupuncture (LA), or a sham laser acupuncture group in a 1:1:1 ratio. All participants will undergo EA, LA, or sham laser acupuncture intervention once a day on 5 acupoints (LI4, PC6, ST36, SP6, and EX-HN1) for 14 consecutive days after enrollment. The primary outcome measure will be the length of hospital stay. Secondary outcomes will be inflammatory mediators, including serum C-reactive protein, interleukin (IL)-6, tumor necrosis factor-alpha, IL-1 beta, and IL-10. Clinical outcomes will be numeric rating scale scores for pain, sequential organ failure assessment, ICU length of stay, 30-day mortality, and WHO Disability Assessment Schedule. Data will be analyzed by chi-square test or t test for pairwise comparisons, as well as one-way ANOVA followed by post hoc Tukey method between groups. Objectives: The aim of this protocol is to investigate the clinical effects of EA and LA on major trauma.
C1 [Liu, Chun-Ting; Wu, Bei-Yu] Kaohsiung Chang Gung Mem Hosp, Dept Chinese Med, Kaohsiung, Taiwan.
   [Liu, Chun-Ting; Hsieh, Ting-Min; Shih, Fu-Yuan; Lai, Wei-Hung; Hsieh, Ching-Hua; Wu, Bei-Yu] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
   [Liu, Chun-Ting; Wu, Bei-Yu; Chen, Yung-Hsiang] China Med Univ, Grad Inst Integrated Med, Coll Chinese Med, Res Ctr Chinese Med & Acupuncture, Taichung, Taiwan.
   [Liu, Chun-Ting] Jen Ai Hosp, Dept Chinese Med, Dali Branch, Taichung, Taiwan.
   [Hsieh, Ting-Min; Lai, Wei-Hung] Kaohsiung Chang Gung Mem Hosp, Div Trauma Surg, Kaohsiung, Taiwan.
   [Shih, Fu-Yuan] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan.
   [Hsieh, Ching-Hua] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Div Plast & Reconstruct Surg, Kaohsiung, Taiwan.
   [Wu, Bei-Yu] Fooyin Univ Coll Nursing, Kaohsiung, Taiwan.
   [Chen, Yung-Hsiang] Asia Univ, Coll Med & Hlth Sci, Dept Psychol, Taichung, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; China Medical University Taiwan; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Asia University Taiwan
RP Chen, YH (corresponding author), China Med Univ, Coll Chinese Med, Grad Inst Integrated Med, Taichung, Taiwan.
EM yhchen@mail.cmu.edu.tw
FU Ministry of Science and Technology, Taiwan [MOST 110-2320-B-182A-008-MY3]
CR Abedzadeh-Kalahroudi M, 2015, ARCH TRAUMA RES, V4, P0, DOI 10.5812/atr.29393
   BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001
   Balogh ZJ, 2011, EUR J TRAUMA EMERG S, V37, P537, DOI 10.1007/s00068-011-0162-x
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Giannoudis PV, 2004, J BONE JOINT SURG BR, V86B, P313, DOI 10.1302/0301-620X.86B3.15035
   Guisasola MC, 2015, ORTHOP TRAUMATOL-SUR, V101, P607, DOI 10.1016/j.otsr.2015.03.014
   Irnich D, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq009
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kim E, 2011, AM J CHINESE MED, V39, P243, DOI 10.1142/S0192415X11008786
   Kobbe P, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9072287
   Koopman FA, 2016, P NATL ACAD SCI USA, V113, P8284, DOI 10.1073/pnas.1605635113
   Lambden S, 2019, CRIT CARE, V23, P0, DOI 10.1186/s13054-019-2663-7
   Liang H, 2012, CRITICAL CARE, V16, P0
   Luo D, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7924985
   Ma JX, 2019, NEUROCHEM INT, V131, P0, DOI 10.1016/j.neuint.2019.104539
   MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006
   Meng JB, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000010555
   Meyer-Hamme G, 2018, BMC NEUROL, V18, P0, DOI 10.1186/s12883-018-1037-0
   Sauaia A, 2017, CRIT CARE CLIN, V33, P167, DOI 10.1016/j.ccc.2016.08.006
   Stavrakis S, 2020, JACC-CLIN ELECTROPHY, V6, P467, DOI 10.1016/j.jacep.2020.02.014
   Tranca Sebastian Daniel, 2014, ROM J ANAESTH INTENSIVE CARE, V21, P118
   Wang JD, 2002, AUTON NEUROSCI-BASIC, V100, P90, DOI 10.1016/S1566-0702(02)00150-9
   Wang WM, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-026147
   Wheless JW, 2018, EPILEPSY BEHAV, V88, P2, DOI 10.1016/j.yebeh.2018.06.032
   Zhou L, 2014, NEURAL REGEN RES, V9, P1585, DOI 10.4103/1673-5374.141783
NR 25
TC 1
Z9 2
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC 30
PY 2021
VL 100
IS 52
BP 
EP 
DI 10.1097/MD.0000000000028367
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA XX2RO
UT WOS:000736149900044
PM 34967368
DA 2026-01-16
ER

PT J
AU Zhang, YZ
   Sun, Y
   Li, DM
   Liu, XY
   Fang, C
   Yang, CM
   Luo, TY
   Lu, H
   Li, HC
   Zhang, HY
   Liang, QY
   Wu, JH
   Huang, LM
   Xu, R
   Ren, LP
   Chen, QJ
AF Zhang, Yuzhu
   Sun, Yang
   Li, Dongmei
   Liu, Xiaoyuan
   Fang, Chen
   Yang, Chunmin
   Luo, Tianyu
   Lu, Hai
   Li, Huachao
   Zhang, Hongyan
   Liang, Qianyi
   Wu, Jiahua
   Huang, Limei
   Xu, Rui
   Ren, Liping
   Chen, Qianjun
TI Acupuncture for Breast Cancer: A Systematic Review and Meta-Analysis of Patient-Reported Outcomes
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE acupuncture; patient-reported outcome; breast cancer; systematic review; meta-analysis
ID menopausal hot flashes; controlled-trial; vasomotor symptoms; double-blind; dual-center; women; electroacupuncture; fatigue; therapy; arthralgia
AB The present systematic review and meta-analysis was undertaken to evaluate the effects of acupuncture in women with breast cancer (BC), focusing on patient-reported outcomes (PROs). Methods A comprehensive literature search was carried out for randomized controlled trials (RCTs) reporting PROs in BC patients with treatment-related symptoms after undergoing acupuncture for at least four weeks. Literature screening, data extraction, and risk bias assessment were independently carried out by two researchers. Results Out of the 2, 524 identified studies, 29 studies representing 33 articles were included in this meta-analysis. At the end of treatment (EOT), the acupuncture patients' quality of life (QoL) was measured by the QLQ-C30 QoL subscale, the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), the Functional Assessment of Cancer Therapy-General/Breast (FACT-G/B), and the Menopause-Specific Quality of Life Questionnaire (MENQOL), which depicted a significant improvement. The use of acupuncture in BC patients lead to a considerable reduction in the scores of all subscales of the Brief Pain Inventory-Short Form (BPI-SF) and Visual Analog Scale (VAS) measuring pain. Moreover, patients treated with acupuncture were more likely to experience improvements in hot flashes scores, fatigue, sleep disturbance, and anxiety compared to those in the control group, while the improvements in depression were comparable across both groups. Long-term follow-up results were similar to the EOT results. Conclusions Current evidence suggests that acupuncture might improve BC treatment-related symptoms measured with PROs including QoL, pain, fatigue, hot flashes, sleep disturbance and anxiety. However, a number of included studies report limited amounts of certain subgroup settings, thus more rigorous, well-designed and larger RCTs are needed to confirm our results.
C1 [Zhang, Yuzhu; Sun, Yang; Liu, Xiaoyuan; Fang, Chen; Yang, Chunmin; Luo, Tianyu; Lu, Hai; Li, Huachao; Zhang, Hongyan; Liang, Qianyi; Wu, Jiahua; Huang, Limei; Xu, Rui; Ren, Liping; Chen, Qianjun] Guangdong Prov Hosp Chinese Med, Breast Clin Ctr, Guangzhou, Peoples R China.
   [Zhang, Yuzhu; Sun, Yang; Liu, Xiaoyuan; Fang, Chen; Yang, Chunmin; Luo, Tianyu; Lu, Hai; Li, Huachao; Zhang, Hongyan; Liang, Qianyi; Wu, Jiahua; Huang, Limei; Xu, Rui; Ren, Liping; Chen, Qianjun] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Breast Clin Ctr, Guangzhou, Peoples R China.
   [Zhang, Yuzhu] China Acad Chinese Med Sci, Natl Resource Ctr Chinese Mat Med, Beijing, Peoples R China.
   [Li, Dongmei] Zhuhai Hosp Guangdong Prov Hosp Chinese Med, Breast Dept, Zhuhai, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; National Resource Center for Chinese Materia Medica, CACMS; China Academy of Chinese Medical Sciences
RP Xu, R; Ren, LP; Chen, QJ (corresponding author), Guangdong Prov Hosp Chinese Med, Breast Clin Ctr, Guangzhou, Peoples R China.; Xu, R; Ren, LP; Chen, QJ (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Breast Clin Ctr, Guangzhou, Peoples R China.
EM catdoctor007@163.com; mastcell@aliyun.com; cqj55@163.com
FU National Natural Science Foundation of China [81904206, 81974571]; Guangdong Natural Science Foundation [2017A030313719]; Foundation Project of Guangzhou University of Traditional Chinese Medicine [XKP2019002]
CR Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Unknown -, 2014, REV MAN REVMAN VERS, V0, P0
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bokmand S, 2013, BREAST, V22, P320, DOI 10.1016/j.breast.2012.07.015
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Deng G, 2007, J CLIN ONCOL, V25, P5584, DOI 10.1200/JCO.2007.12.0774
   Ee C, 2017, MENOPAUSE, V24, P980, DOI 10.1097/GME.0000000000000850
   Ee C, 2016, ANN INTERN MED, V164, P146, DOI 10.7326/M15-1380
   European Medicines Agency Committee for Medicinal Products for Human Use, 2016, EMACHMP2924642014, V0, P0
   FDA-NIH Biomarker Working Group, 2016, BEST BIOM ENDPOINTS, V0, P0
   Frisk J, 2008, CLIMACTERIC, V11, P166, DOI 10.1080/13697130801958709
   Frisk J, 2012, SUPPORT CARE CANCER, V20, P715, DOI 10.1007/s00520-011-1134-8
   Garcia MK, 2015, CANCER-AM CANCER SOC, V121, P3948, DOI 10.1002/cncr.29630
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Garland SN, 2017, MENOPAUSE, V24, P517, DOI 10.1097/GME.0000000000000779
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   Greenlee H, 2017, CA-CANCER J CLIN, V67, P195, DOI 10.3322/caac.21397
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Han, 2019, ACUPUNCTURE COMBINED, V0, P28
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hervik J, 2009, BREAST CANCER RES TR, V116, P311, DOI 10.1007/s10549-008-0210-3
   Huang MI, 2006, FERTIL STERIL, V86, P700, DOI 10.1016/j.fertnstert.2006.02.100
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Johnston MF, 2011, BMC COMPLEM ALTERN M, V11, P0, DOI 10.1186/1472-6882-11-49
   Lagendijk M, 2018, EJSO-EUR J SURG ONC, V44, P963, DOI 10.1016/j.ejso.2018.03.009
   Lee MS, 2009, CLIMACTERIC, V12, P16, DOI 10.1080/13697130802566980
   Lee MS, 2009, BREAST CANCER RES TR, V115, P497, DOI 10.1007/s10549-008-0230-z
   Lesi G, 2016, J CLIN ONCOL, V34, P1795, DOI 10.1200/JCO.2015.63.2893
   Li J, 2019, CHINA MED HERALD, V16, P132
   Liljegren A, 2012, BREAST CANCER RES TR, V135, P791, DOI 10.1007/s10549-010-1283-3
   Lotfi-Jam K, 2008, J CLIN ONCOL, V26, P5618, DOI 10.1200/JCO.2007.15.9053
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Mao JJ, 2015, J CLIN ONCOL, V33, P3615, DOI 10.1200/JCO.2015.60.9412
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Moher D, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b2535
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Nedstrand E, 2006, J PSYCHOSOM OBST GYN, V27, P193, DOI 10.1080/01674820600724797
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Page, 2020, COCHRANE HDB SYSTEMA, V0, P0
   Pe M, 2018, LANCET ONCOL, V19, PE459, DOI 10.1016/S1470-2045(18)30418-2
   PRIESTMAN TJ, 1976, LANCET, V1, P899
   Smith C, 2013, ACUPUNCT MED, V31, P9, DOI 10.1136/acupmed-2012-010228
   Smith CA, 2014, ACUPUNCT MED, V32, P387, DOI 10.1136/acupmed-2014-010593
   Tong TS, 2018, MED SCI MONITOR, V24, P2919, DOI 10.12659/MSM.909712
   Walker EM, 2010, J CLIN ONCOL, V28, P634, DOI 10.1200/JCO.2009.23.5150
   Yao C, 2016, CURR ONCOL, V23, PE27, DOI 10.3747/co.23.2788
   Yu M, 2017, CHINA MED HERALD, V14, P89
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   [张玉 Zhang Yu], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P509
NR 55
TC 36
Z9 45
U1 1
U2 37
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD JUN 10
PY 2021
VL 11
IS 
BP 
EP 
DI 10.3389/fonc.2021.646315
PG 13
WC Oncology
SC Oncology
GA SX1LO
UT WOS:000664973500001
PM 34178633
DA 2026-01-16
ER

PT J
AU Ke, MY
   Qian, JJ
   Hao, F
   Li, XY
   Wu, HJ
   Luo, X
   Xu, B
   Gu, CY
   Yang, Y
AF Ke, Mengying
   Qian, Jinjun
   Hao, Feng
   Li, Xinying
   Wu, Hongjie
   Luo, Xian
   Xu, Bin
   Gu, Chunyan
   Yang, Ye
TI Acupuncture Synergized With Bortezomib Improves Survival of Multiple Myeloma Mice via Decreasing Metabolic Ornithine
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE ornithine; metabolomics; multiple myeloma; acupuncture; ODC1
ID induced peripheral neuropathy; therapeutic targets; breast-cancer; pain; electroacupuncture; proliferation
AB Multiple myeloma (MM) is a hematological malignancy worldwide in urgent need for novel therapeutic strategies. Since Velcade (bortezomib) was approved for the treatment of relapsed/refractory MM in 2003, we have seen considerable improvement in extending MM patient survival. However, most patients are fraught with high recurrence rate and incurability. Acupuncture is known for alleviating patient symptoms and improving the quality of life, but it is not well investigated in MM, especially in combination with bortezomib. In this study, we employed LC-MS and UHPLC-MS together with bioinformatics methods to test serum samples from 5TMM3VT MM murine model mice with four different treatments [control (C) group, bortezomib (V) treatment group, acupuncture (A) group, and combined (VA) group]. MM mice in group VA had longer survival time than mice in group A or group V. Joint pathway analysis indicated the underlying arginine and proline metabolism pathway among the 32 significantly decreased metabolites in group VA. CCK-8 assay and in vivo experiments validated that ornithine, the metabolite of arginine, promoted MM cell proliferation. In addition, gene expression omnibus (GEO) database analysis suggested that MM patients with higher ornithine decarboxylase 1 (ODC1) expression were evidently associated with poor overall survival. In summary, this study demonstrates the synergistic effects of acupuncture and bortezomib on extending the survival of MM model mice and provides potential therapeutic targets in the treatment of MM.
C1 [Ke, Mengying; Gu, Chunyan] Nanjing Univ Chinese Med, Large Data Ctr, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.
   [Ke, Mengying; Qian, Jinjun; Li, Xinying; Wu, Hongjie; Luo, Xian; Gu, Chunyan; Yang, Ye] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China.
   [Hao, Feng; Xu, Bin] Nanjing Univ Chinese Med, Acupuncture & Tuina Coll, Nanjing, Peoples R China.
   [Xu, Bin] Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Gu, CY (corresponding author), Nanjing Univ Chinese Med, Large Data Ctr, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.; Gu, CY; Yang, Y (corresponding author), Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Nanjing, Peoples R China.; Xu, B (corresponding author), Nanjing Univ Chinese Med, Acupuncture & Tuina Coll, Nanjing, Peoples R China.; Xu, B (corresponding author), Nanjing Univ Chinese Med, Key Lab Acupuncture & Med Res, Minist Educ, Nanjing, Peoples R China.
EM xubin@njucm.edu.cn; guchunyan@njucm.edu.cn; yangye876@sina.com
CR Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bednarz-Misa I, 2021, BIOMOLECULES, V11, P0, DOI 10.3390/biom11081086
   Bianchi-Smiraglia A, 2018, J CLIN INVEST, V128, P4682, DOI 10.1172/JCI70712
   Blimark CH, 2018, HAEMATOLOGICA, V103, P506, DOI 10.3324/haematol.2017.178103
   Chao LF, 2009, BREAST CANCER RES TR, V118, P255, DOI 10.1007/s10549-009-0533-8
   Chen Y, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.736373
   Chen Y, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.00767
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Chong J, 2018, NUCLEIC ACIDS RES, V46, PW486, DOI 10.1093/nar/gky310
   Colombero C, 2020, BIOCHIMIE, V171, P147, DOI 10.1016/j.biochi.2020.02.014
   Dou RJ, 2021, CELL DEATH DIS, V12, P0, DOI 10.1038/s41419-021-03510-4
   Du T, 2021, FRONT CELL DEV BIOL, V9, P0, DOI 10.3389/fcell.2021.658861
   Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473
   Fernandez-Garcia JC, 2019, J CLIN MED, V8, P0, DOI 10.3390/jcm8010071
   Gamble LD, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13081807
   Gamble LD, 2019, SCI TRANSL MED, V11, P0, DOI 10.1126/scitranslmed.aau1099
   Gan CF, 2020, J STEROID BIOCHEM, V202, P0, DOI 10.1016/j.jsbmb.2020.105709
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Grzywa TM, 2020, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.00938
   Gu CY, 2021, MOL CANCER, V20, P0, DOI 10.1186/s12943-021-01380-0
   Gu CY, 2021, LEUKEMIA, V35, P1803, DOI 10.1038/s41375-020-01033-z
   Guo MJ, 2021, FRONT CELL DEV BIOL, V9, P0, DOI 10.3389/fcell.2021.675939
   Guo T, 2019, CANCER MED-US, V8, P7754, DOI 10.1002/cam4.2637
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He W, 2017, NPJ PRECIS ONCOL, V1, P0, DOI 10.1038/s41698-017-0014-1
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hou JH, 2020, ONCOTARGETS THER, V13, P959, DOI 10.2147/OTT.S235944
   Joshua DE, 2019, MED J AUSTRALIA, V210, P375, DOI 10.5694/mja2.50129
   Ke MY, 2021, J HEMATOL ONCOL, V14, P0, DOI 10.1186/s13045-021-01101-6
   Khan A, 2021, NAT COMMUN, V12, P0, DOI 10.1038/s41467-021-20896-z
   Kourelis TV, 2013, J CLIN ONCOL, V31, P4319, DOI 10.1200/JCO.2013.50.8499
   Kus K, 2018, BREAST CANCER RES, V20, P0, DOI 10.1186/s13058-018-1075-y
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Lee YC, 2018, INT J MED SCI, V15, P953, DOI 10.7150/ijms.24146
   Lemos H, 2019, NAT REV CANCER, V19, P162, DOI 10.1038/s41568-019-0106-z
   Li Z, 2017, INT J MOL SCI, V18, P0, DOI 10.3390/ijms18122550
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P287, DOI 10.1016/j.tibs.2016.01.004
   Lim HD, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0151882
   Lin JG, 2002, PAIN, V99, P509, DOI 10.1016/S0304-3959(02)00261-0
   Lin Y, 2019, INT J CANCER, V145, P1679, DOI 10.1002/ijc.32190
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mavrommatis CI, 2012, PAIN, V153, P1720, DOI 10.1016/j.pain.2012.05.005
   Mi WL, 2008, BRAIN RES BULL, V77, P98, DOI 10.1016/j.brainresbull.2008.04.008
   Minnie SA, 2020, J CLIN INVEST, V130, P1565, DOI 10.1172/JCI129205
   Miret JJ, 2019, J IMMUNOTHER CANCER, V7, P0, DOI 10.1186/s40425-019-0504-5
   ORegan D, 2010, AUTON NEUROSCI-BASIC, V157, P96, DOI 10.1016/j.autneu.2010.05.001
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Qiao L, 2020, AM J CHINESE MED, V48, P245, DOI 10.1142/S0192415X20500135
   Robinson AJ, 2020, CANCER RES, V80, P937, DOI 10.1158/0008-5472.CAN-19-1920
   Seo SY, 2017, AM J CHINESE MED, V45, P1573, DOI 10.1142/S0192415X17500859
   Song X, 2019, CANCER RES, V79, P5288, DOI 10.1158/0008-5472.CAN-19-1504
   Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, P0, DOI 10.1186/s40425-017-0308-4
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Wang CH, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419866919
   Yan Wusheng, 2012, BMC RES NOTES, V5, P73, DOI 10.1186/1756-0500-5-73
   Yao WF, 2016, INT J MOL SCI, V17, P0, DOI 10.3390/ijms17091514
   Ye Z, 2019, ONCOTARGETS THER, V12, P4081, DOI 10.2147/OTT.S198341
   Zhang C, 2019, FRONT ONCOL, V9, P0, DOI 10.3389/fonc.2019.00681
   Zhao HY, 2021, BIOMED PHARMACOTHER, V142, P0, DOI 10.1016/j.biopha.2021.112045
   Zou Y, 2021, J INFLAMM RES, V14, P3501, DOI 10.2147/JIR.S312385
NR 61
TC 4
Z9 5
U1 5
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 2
PY 2021
VL 11
IS 
BP 
EP 
DI 10.3389/fonc.2021.779562
PG 14
WC Oncology
SC Oncology
GA WZ0BH
UT WOS:000719639500001
PM 34804983
DA 2026-01-16
ER

PT J
AU Xu, G
   Lei, H
   Zhou, Y
   Huang, L
   Tian, H
   Zhou, Z
   Zhao, L
   Liang, F
AF Xu, Guixing
   Lei, Hanzhou
   Zhou, Yuanfang
   Huang, Liuyang
   Tian, Hao
   Zhou, Zhuo
   Zhao, Ling
   Liang, Fanrong
TI Acupuncture for Quality of Life of Patients with Defecation Dysfunction after
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB PURPOSE: To evaluate the effectiveness and safety of acupuncture for quality of  life of patients with defecation dysfunction (DD) after sphincter preserving  surgery for rectal cancer. METHODS: We searched nine online databases from  inception to July 1, 2021, and did not restrict the type of language. Then,  studies were independently selected by two research team members with screening  criteria and risk bias assessment, and the data were extracted. The primary  outcome was Quality of Life Questionnaire-Core 29 (QLQ-CR29). The data were then  synthesized using the RevMan V.5.2 by random-effects model. Also, we used the  standardized mean differences with 95% credible interval (CI) to describe the  outcome of the analysis. RESULTS: A total of 6 randomized controlled trials  (RCTs) (with 439 patients) were included in the systematic review, and data from  2 RCTs (with 200 patients) were used in the meta-analysis. Five studies (83%)  were judged to have a medium risk of bias, and one was at high risk of bias. For  synthesis, data from two medium-risk studies found that acupuncture or  electropuncture may improve the QLQ-CR29 with urination (mean difference, -0.39  points; 95%CI, -0.46 to -0.32; I (2) = 34%), abdominal pain (mean difference,  -0.71 points; 95%CI, -0.89 to -0.54; I (2) = 9%), stool (mean difference, -0.49  points; 95%CI, -0.77 to -0.20; I (2) = 57%), defecation (mean difference, -0.59  points; 95% CI, -0.85 to -0.33; I (2) = 51%), sexual function (mean difference,  0.93 points; 95% CI, 0.48 to 1.38; I (2) = 90%), and self-feelings (mean  difference, 1.04 points; 95% CI, 0.36 to 1.73; I (2) = 94%). CONCLUSION: Findings  in this study indicate that acupuncture or electropuncture may be effective and  safe for DD, but the quality of included studies was very low. So, more  large-scale, multicenter, long-term, and high-quality original research is still  expected in the future.
C1 Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
   Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD DEC 28
PY 2021
VL 2021
IS 
BP 7858252
EP 7858252
DI 10.1155/2021/7858252
PG 0
UT PubMed:34956383
PM 34956383
DA 2021-12-28
ER

PT J
AU Jiang, L
   Deng, Z
   Zhang, H
   Li, Y
   Wang, T
   Xie, W
AF Jiang, Li
   Deng, Zhaoxia
   Zhang, Hongcai
   Li, Yuan
   Wang, Tingting
   Xie, Wen
TI Acupoint for angina pectoris: A protocol for systematic review and meta-analysis.
SO Medicine
LA English
DT Journal Article
AB INTRODUCTION: Patients with angina pectoris (AP) often experience heavy  psychological distress, especially anxiety and depression, which results in  poorer quality of life, shorter survival time. Acupoint therapies, including  massage, acupuncture, acupoints injection, acupressure, and moxibustion, showed  clinical and long-lasting benefits for AP, but the efficiency of acupoint  therapies was poorly evaluated. The current review is attempted to evaluate the  efficacy and safety of the different acupoint-based therapies for AP. METHODS AND  ANALYSIS: A literature search will be conducted in MEDLINE, EMBASE, Web of  Science, Cochrane Library, Web of Science, PubMed, Science Direct, Wan Fang Data  Knowledge Service Platform, Chinese Biomedical Literature Database (CBM), Chinese  Scientific Journal Database (VIP database), and China National Knowledge  Infrastructure (CNKI). Observational studies regarding the association between  liver cancer and depression and anxiety written in English or Chinese will be  included. Study inclusion, data extraction, and quality assessment will be  performed independently by 2 reviewers. We will use RevMan V.5.0 and STATA V.12.0  software for statistical analysis. The I2 test will be used to identify the  extent of heterogeneity. Publication bias will be assessed by generating a funnel  plot and performing the Begg and Egger test. The quality of the systematic review  will be evaluated using the Measurement Tool to Assess Systematic Reviews  (AMSTAR) and Grading of Recommendations Assessment Development and Evaluation  (GRADE) criteria. With the permitted numeric data, we will carry out a  meta-analysis. RESULTS: This study will provide a high-quality synthesis of pain  VAS and functional disability or the quality of life, the success treatment rate,  the recurrent rate and the complications rate to assess the effectiveness and  safety of acupoint for AP patients. This systematic review will provide evidence  to judge whether acupoint is an effective intervention for patients with AP.  CONCLUSION: This systematic review and meta-analysis will provide evidence to  judge whether acupoint is an effective intervention for patients with AP and  provide evidence for designing early targeted interventions for high-risk  survivors that can attenuate negative reactions. PROSPERO REGISTRATION NUMBER:  10.17605/OSF.IO/VNXWE.
C1 Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
   Chengdu University of Traditional Chinese Medicine, PR China.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
   Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province.
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD FEB 7
PY 2021
VL 100
IS 3
BP e24080
EP e24080
DI 10.1097/MD.0000000000024080
PG 1
WC Acupuncture Points; Angina Pectoris; therapy; Humans; Meta-Analysis as Topic; Systematic Reviews as Topic
UT PubMed:33546012
PM 33546012
DA 2021-02-07
ER

PT J
AU Mongardi, L
   Visani, J
   Mantovani, G
   Vitali, C
   Ricciardi, L
   Giordano, F
   Cavallo, MA
   Lofrese, G
   D'andrea, M
   Roblot, P
   De Bonis, P
   Scerrati, A
AF Mongardi, Lorenzo
   Visani, Jacopo
   Mantovani, Giorgio
   Vitali, Costanza
   Ricciardi, Luca
   Giordano, Flavio
   Cavallo, Michele Alessandro
   Lofrese, Giorgio
   D'andrea, Marcello
   Roblot, Paul
   De Bonis, Pasquale
   Scerrati, Alba
TI Long term results of Dorsal Root Entry Zone (DREZ) lesions for the treatment of intractable pain: A systematic review of the literature on 1242 cases
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Review
DE Root entry zone; DREZ; DREZotomy; Chronic pain; Intractable pain
ID brachial-plexus avulsion; phantom limb pain; microsurgical drezotomy; deafferentation pain; neuropathic pain; follow-up; central sensitization; conus medullaris; horn; experience
AB Background: Different Dorsal root entry zone (DREZ) lesion techniques have been reported as effective treatment for intractable painful conditions, though with contradictory results. Overall, good results were reported especially in specific conditions, such as pain due to brachial plexus avulsion, spinal cord injuries and oncological pain management. However, data on long term results in different clinical conditions are still missing. Objective: This study aims to systematically review the pertinent literature to evaluate indications, clinical outcomes, and complications of DREZ lesion (DREZotomy), in chronic pain management. Methods: A systematic literature review was conducted according to the PRISMA statement. Papers on DREZotomy for chronic pain in cancer, brachial plexus avulsion, spinal cord injury, post herpetic neuralgia, and phantom limb pain were considered for eligibility. For each category we further identified two sub-group according to the length of follow up: medium term and long term follow up (more than 3 years) respectively. Results: 46 papers, and 1242 patients, were included in the present investigation. When considering long term results DREZotomy provided favorable clinical outcomes in brachial plexus avulsion and spinal cord injury, in 60.8% and 55.8% of the cases respectively. Conversely, the success rate was 35.3% in phantom limb pain and 28.2% in post herpetic neuralgia. A poor clinical outcome was reported in over than 25% of the patients suffering from phantom limb pain, post herpetic neuralgia and spinal cord injury. The mean complications rate was 23.58%. While BPA and SCI patients presented stable improvement over time, good outcomes among PHN and PLP groups dropped by - 46.2%; and - 14.7% at long term follow up respectively. Conclusion: DREZotomy seems to be an effective treatment for chronic pain conditions, especially for brachial plexus avulsion, spinal cord injury and intractable cancer/post-radiation pain. According to the low level of evidence of the pertinent literature, further studies are strongly recommended, to better define potential benefits and limitations of this technique
C1 [Mongardi, Lorenzo; Visani, Jacopo; Mantovani, Giorgio; Cavallo, Michele Alessandro; De Bonis, Pasquale; Scerrati, Alba] St Anna Univ Hosp, Dept Neurosurg, Ferrara, Italy.
   [Vitali, Costanza] Univ Ferrara, Sect Anaesthesia & Intens Care, Azienda Osped Univ St Anna, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Ricciardi, Luca] Pia Fdn Culto & Relig Cardinal G Panico, UO Neurochirurg, Tricase, LE, Italy.
   [Giordano, Flavio] Univ Florence, Childrens Hosp A Meyer, Dept Neurosurg, Florence, Italy.
   [Cavallo, Michele Alessandro; De Bonis, Pasquale; Scerrati, Alba] Univ Ferrara, Dept Morphol Surg & Expt Med, Ferrara, Italy.
   [Lofrese, Giorgio; D'andrea, Marcello] Bufalini Hosp, Neurosurg, Cesena, Italy.
   [Roblot, Paul] Univ Hosp Bordeaux, Dept Neurosurg, Bordeaux, France.
C3 University of Ferrara; Arcispedale Sant'Anna; University of Ferrara; Arcispedale Sant'Anna; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Ferrara; Universite de Bordeaux; CHU Bordeaux
RP Mongardi, L (corresponding author), St Anna Univ Hosp, Dept Neurosurg, Ferrara, Italy.
EM lorenzo.mongardi@student.unife.it
CR Aichaoui F, 2011, PAIN, V152, P1923, DOI 10.1016/j.pain.2011.03.037
   Awad Ahmed J, 2013, SURG NEUROL INT, V4, P64, DOI 10.4103/2152-7806.112182
   Bernard E J Jr, 1987, BR J NEUROSURG, V1, P81, DOI 10.3109/02688698709034343
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   BRUXELLE J, 1988, CLIN ORTHOP RELAT R, V0, P87
   Bullard DE, 1997, STEREOT FUNCT NEUROS, V68, P168, DOI 10.1159/000099918
   CAMPBELL JN, 1988, APPL NEUROPHYSIOL, V51, P170
   Chen HJ, 2006, ACTA NEUROCHIR SUPPL, V99, P73, DOI 10.1007/978-3-211-35205-2_14
   Chivukula S, 2015, WORLD NEUROSURG, V84, P494, DOI 10.1016/j.wneu.2015.04.025
   Chun HJ, 2011, WORLD NEUROSURG, V75, P551, DOI 10.1016/j.wneu.2010.12.005
   DREVAL ON, 1993, ACTA NEUROCHIR, V122, P76, DOI 10.1007/BF01446990
   Emery E, 1997, STEREOT FUNCT NEUROS, V68, P155, DOI 10.1159/000099916
   Esposito S, 1988, J NEUROSURG SCI, V32, P113
   FRIEDMAN AH, 1984, J NEUROSURG, V60, P1258, DOI 10.3171/jns.1984.60.6.1258
   FRIEDMAN AH, 1988, NEUROSURGERY, V22, P369, DOI 10.1227/00006123-198802000-00016
   FRIEDMAN AH, 1986, J NEUROSURG, V65, P465, DOI 10.3171/jns.1986.65.4.0465
   Gadgil N, 2012, STEREOT FUNCT NEUROS, V90, P356, DOI 10.1159/000341072
   Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332
   Gebreyohanes AMH, 2021, OPER NEUROSURG, V20, P324, DOI 10.1093/ons/opaa447
   Guenot M, 2003, J CLIN NEUROPHYSIOL, V20, P143, DOI 10.1097/00004691-200304000-00009
   ISHIJIMA B, 1988, APPL NEUROPHYSIOL, V51, P175
   JEANMONOD D, 1989, ELECTROEN CLIN NEURO, V72, P450, DOI 10.1016/0013-4694(89)90050-3
   Ko AL, 2016, J NEUROSURG, V124, P1470, DOI 10.3171/2015.2.JNS142572
   KUMAGAI Y, 1992, ACTA NEUROCHIR, V115, P71, DOI 10.1007/BF01406361
   LEVY WJ, 1983, J NEUROSURG, V59, P884, DOI 10.3171/jns.1983.59.5.0884
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu MX, 2015, STEREOT FUNCT NEUROS, V93, P178, DOI 10.1159/000375174
   LOESER JD, 1968, J NEUROSURG, V29, P48, DOI 10.3171/jns.1968.29.1.0048
   MOOSSY JJ, 1988, APPL NEUROPHYSIOL, V51, P198
   NASHOLD BS, 1981, J NEUROSURG, V55, P414, DOI 10.3171/jns.1981.55.3.0414
   NASHOLD BS, 1979, J NEUROSURG, V51, P59, DOI 10.3171/jns.1979.51.1.0059
   Nashold BS, 1982, MODERN NEUROSURGERY, V1, P460
   Pereira EAC, 2013, NEUROSURG FOCUS, V35, P0, DOI 10.3171/2013.7.FOCUS1346
   Piyawattanametha N, 2017, ACTA NEUROCHIR, V159, P2431, DOI 10.1007/s00701-017-3345-3
   POWERS SK, 1988, APPL NEUROPHYSIOL, V51, P243
   Prestor B, 2006, CROAT MED J, V47, P271
   Prestor B, 2001, SURG NEUROL, V56, P259, DOI 10.1016/S0090-3019(01)00600-0
   Quinn TJ, 2017, FRONT NEUROL, V8, P0, DOI 10.3389/fneur.2017.00275
   Rath SA, 1996, ACTA NEUROCHIR, V138, P364, DOI 10.1007/BF01420297
   Ruiz-Juretschke F, 2011, NEUROLOGIA, V26, P26, DOI 10.1016/j.nrl.2010.10.003
   Sakellariou Vasileios I, 2014, ISRN ORTHOP, V2014, P314137, DOI 10.1155/2014/314137
   Samii M, 2001, NEUROSURGERY, V48, P1269, DOI 10.1097/00006123-200106000-00016
   SAMII M, 1984, NEUROSURGERY, V15, P953, DOI 10.1227/00006123-198412000-00037
   SAMPSON JH, 1995, J NEUROSURG, V82, P28, DOI 10.3171/jns.1995.82.1.0028
   SARIS SC, 1985, J NEUROSURG, V62, P72, DOI 10.3171/jns.1985.62.1.0072
   SINDOU M, 1982, ADV PAIN RES THER, V4, P199
   SINDOU M, 1974, NEUROCHIRURGIE, V20, P391
   SINDOU M, 1974, J COMP NEUROL, V153, P15, DOI 10.1002/cne.901530103
   SINDOU M, 1995, ACTA NEUROCHIR, V137, P1, DOI 10.1007/BF02188771
   Sindou M, 2001, PAIN, V92, P159, DOI 10.1016/S0304-3959(00)00487-5
   SINDOU M, 1989, NEUROSURGERY, V24, P655, DOI 10.1227/00006123-198905000-00002
   Sindou MP, 2005, J NEUROSURG, V102, P1018, DOI 10.3171/jns.2005.102.6.1018
   Son BC, 2015, STEREOT FUNCT NEUROS, V93, P240, DOI 10.1159/000381556
   Spaic M, 2002, ACTA NEUROCHIR S, V144, P1092
   Suzuki R, 2005, NEUROSIGNALS, V14, P175, DOI 10.1159/000087656
   Takai K, 2017, J NEUROSURG-SPINE, V27, P178, DOI 10.3171/2017.1.SPINE16234
   Teixeira MJ, 2007, SPINE, V32, PE316, DOI 10.1097/01.brs.0000261541.97749.e7
   Teixeira MJ, 2015, BMC NEUROL, V15, P0, DOI 10.1186/s12883-015-0329-x
   THOMAS DGT, 1984, NEUROSURGERY, V15, P966, DOI 10.1227/00006123-198412000-00040
   THOMAS DGT, 1994, J NEUROL NEUROSUR PS, V57, P737, DOI 10.1136/jnnp.57.6.737
   Yamanaka Hiroki, 2012, BRAIN AND NERVE (TOKYO), V64, P1255
   YOUNG RF, 1990, J NEUROSURG, V72, P715, DOI 10.3171/jns.1990.72.5.0715
   ZEIDMAN SM, 1993, J SPINAL DISORD, V6, P44
   Zhang XH, 2008, CHINESE MED J-PEKING, V121, P1089
   Zheng Z, 2009, STEREOT FUNCT NEUROS, V87, P249, DOI 10.1159/000225978
NR 65
TC 16
Z9 19
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0303-8467
EI 1872-6968
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD NOV 15
PY 2021
VL 210
IS 
BP 
EP 
DI 10.1016/j.clineuro.2021.107004
EA OCT 2021
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA WS1ZS
UT WOS:000714988200004
PM 34739884
DA 2026-01-16
ER

PT J
AU Lin, LL
   Li, HP
   Yang, JW
   Hao, XW
   Yan, SY
   Wang, LQ
   Yu, FT
   Shi, GX
   Liu, CZ
AF Lin, Lu-Lu
   Li, Hong-Ping
   Yang, Jing-Wen
   Hao, Xiao-Wan
   Yan, Shi-Yan
   Wang, Li-Qiong
   Yu, Fang-Ting
   Shi, Guang-Xia
   Liu, Cun-Zhi
TI Acupuncture for Psychological Disorders Caused by Chronic Pain: A Review and Future Directions
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE acupuncture; chronic pain; psychological states; review; clinical trials; biological mechanisms
ID anterior cingulate cortex; dorsal raphe nucleus; low-back-pain; tension-type headache; quality-of-life; controlled-trial; dopamine system; shoulder pain; depression; management
AB Accumulating evidence supports an association between chronic pain and psychological disorders, a connection that seems to be bidirectional. Treating both the pain and psychological conditions together is essential for effective treatment outcomes. Acupuncture is a somatosensory-guided mind-body therapy that can tackle the multidimensional nature of pain with fewer or no serious adverse effects. In this review, we discuss the use of acupuncture in some conditions with a high incidence of psychological disorders caused by chronic pain: headache, musculoskeletal pain, low back pain, and cancer pain, focusing on the effect and potential mechanisms of acupuncture. Overall clinical studies indicated that acupuncture might effectively contribute to management of psychological disorders caused by chronic pain. Mechanistic studies showed that acupuncture significantly alleviated such psychological disorders by regulating the activity of amygdala and insula, and regulating functional connectivity of insular and limbic regions/medial prefrontal cortex in humans and the corresponding animal models. In addition, 5-HT in the dorsal raphe nucleus, opioid receptors in the cingulate cortex, and plasma met-enkephalin are involved in acupuncture relief of pain and psychological symptoms. Substantial evidences from animal and human research support a beneficial effect of acupuncture in psychological disorders caused by chronic pain.
C1 [Lin, Lu-Lu; Li, Hong-Ping; Yang, Jing-Wen; Hao, Xiao-Wan; Yan, Shi-Yan; Wang, Li-Qiong; Yu, Fang-Ting; Shi, Guang-Xia; Liu, Cun-Zhi] Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Beijing, Peoples R China.
   [Lin, Lu-Lu; Li, Hong-Ping; Yang, Jing-Wen; Hao, Xiao-Wan; Yan, Shi-Yan; Wang, Li-Qiong; Yu, Fang-Ting; Shi, Guang-Xia; Liu, Cun-Zhi] Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Shi, GX (corresponding author), Beijing Univ Chinese Med, Int Acupuncture & Moxibust Innovat Inst, Beijing, Peoples R China.; Shi, GX (corresponding author), Beijing Univ Chinese Med, Sch Acupuncture Moxibust & Tuina, Beijing, Peoples R China.
EM shiguangxia2008@126.com
FU National Key R&D Program of China [2019YFC1712100]
CR Acker H, 2015, MED HYPOTHESES, V85, P371, DOI 10.1016/j.mehy.2015.05.013
   Alba-Delgado C, 2013, BIOL PSYCHIAT, V73, P54, DOI 10.1016/j.biopsych.2012.06.033
   Unknown -, 2019, MUSCULOSKELETAL CONDITIONS, V0, P0
   Arango V, 2001, NEUROPSYCHOPHARMACOL, V25, P892, DOI 10.1016/S0893-133X(01)00310-4
   Arnold M, 2018, CEPHALALGIA, V38, P1, DOI 10.1177/0333102417738202
   As-Sanie S, 2016, J PAIN, V17, P1, DOI 10.1016/j.jpain.2015.09.008
   Barthas F, 2015, BIOL PSYCHIAT, V77, P236, DOI 10.1016/j.biopsych.2014.08.004
   Baxter MG, 2002, NAT REV NEUROSCI, V3, P563, DOI 10.1038/nrn875
   Benarroch EE, 2016, NEUROLOGY, V87, P1720, DOI 10.1212/WNL.0000000000003243
   Berman B, 2007, JAMA-J AM MED ASSOC, V297, P1697, DOI 10.1001/jama.297.15.1697
   Bliss TVP, 2016, NAT REV NEUROSCI, V17, P485, DOI 10.1038/nrn.2016.68
   Burston JJ, 2019, PAIN, V160, P658, DOI 10.1097/j.pain.0000000000001445
   Canadian Mental Health Association, 2008, THE RELATIONSHIP BETWEEN MENTAL HEALTH, V0, P0
   Carlsson Christer, 2002, ACUPUNCT MED, V20, P82
   Cho YJ, 2013, SPINE, V38, P549, DOI 10.1097/BRS.0b013e318275e601
   Coeytaux RR, 2005, HEADACHE, V45, P1113, DOI 10.1111/j.1526-4610.2005.00235.x
   Cottam WJ, 2018, PAIN, V159, P929, DOI 10.1097/j.pain.0000000000001209
   Dahlhamer J, 2018, MMWR-MORBID MORTAL W, V67, P1001, DOI 10.15585/mmwr.mm6736a2
   de Tommaso M, 2014, CNS NEUROSCI THER, V20, P565, DOI 10.1111/cns.12280
   de Velasco IR, 2003, CEPHALALGIA, V23, P892, DOI 10.1046/j.1468-2982.2003.00599.x
   Di Carlo M, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/9869250
   Evans RW, 2013, HEADACHE, V53, P168, DOI 10.1111/head.12014
   Fasick V, 2015, NEUROSCI BIOBEHAV R, V53, P139, DOI 10.1016/j.neubiorev.2015.03.014
   Feine JS, 1997, PAIN, V71, P5, DOI 10.1016/S0304-3959(96)03287-3
   Finan PH, 2013, SLEEP MED REV, V17, P173, DOI 10.1016/j.smrv.2012.03.003
   Freitas RL, 2008, EXP NEUROL, V213, P410, DOI 10.1016/j.expneurol.2008.07.003
   Gaspersz R, 2018, PSYCHOTHER PSYCHOSOM, V87, P308, DOI 10.1159/000491933
   Georgoudis G, 2018, J PAIN RES, V11, P2527, DOI 10.2147/JPR.S178110
   Giron PS, 2016, SUPPORT CARE CANCER, V24, P2491, DOI 10.1007/s00520-015-3054-5
   GODDARD GV, 1964, PSYCHOL BULL, V62, P89, DOI 10.1037/h0044853
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Hansson Ylva, 2007, ACUPUNCT MED, V25, P148
   He D, 2004, PAIN, V109, P299, DOI 10.1016/j.pain.2004.01.018
   He Dong, 2005, ACUPUNCT MED, V23, P52
   Hua T, 2020, NAT NEUROSCI, V23, P854, DOI 10.1038/s41593-020-0632-8
   Huang KW, 2019, ELIFE, V8, P0, DOI 10.7554/eLife.46464
   Jackson T, 2015, LANCET, V385, P10, DOI 10.1016/S0140-6736(15)60805-4
   James SL, 2018, LANCET, V392, P1789, DOI 10.1016/S0140-6736(18)32279-7
   Jelinski SE, 2007, NEUROLOGY, V68, P489, DOI 10.1212/01.wnl.0000253183.57001.b3
   Jiang Y, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.01190
   Kalaydjian A, 2008, PSYCHOSOM MED, V70, P773, DOI 10.1097/PSY.0b013e31817f9e80
   Karst M, 2001, CEPHALALGIA, V21, P637, DOI 10.1046/j.1468-2982.2001.00198.x
   Kerns RD, 2011, ANNU REV CLIN PSYCHO, V7, P411, DOI 10.1146/annurev-clinpsy-090310-120430
   Kirkby LA, 2018, CELL, V175, P1688, DOI 10.1016/j.cell.2018.10.005
   KISER RS, 1983, LANCET, V2, P1394
   Kristoffersen ES, 2012, J HEADACHE PAIN, V13, P113, DOI 10.1007/s10194-011-0391-8
   Lee GE, 2016, EUR J INTEGR MED, V8, P373, DOI 10.1016/j.eujim.2016.06.020
   Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4
   LEWITH GT, 1984, SOC SCI MED, V19, P1367, DOI 10.1016/0277-9536(84)90026-1
   Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118
   Linde K, 2006, RHEUMATOLOGY, V45, P222, DOI 10.1093/rheumatology/kei252
   Liu JX, 2017, HUM BRAIN MAPP, V38, P4386, DOI 10.1002/hbm.23667
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   MacPherson H, 2017, PAIN, V158, P784, DOI 10.1097/j.pain.0000000000000747
   Mahmood T, 2001, J AFFECT DISORDERS, V66, P1, DOI 10.1016/S0165-0327(00)00226-3
   Martin DP, 2006, MAYO CLIN PROC, V81, P749, DOI 10.4065/81.6.749
   Matthews PR, 2012, J AFFECT DISORDERS, V137, P125, DOI 10.1016/j.jad.2011.10.043
   McDevitt RA, 2011, BIOL PSYCHIAT, V69, P780, DOI 10.1016/j.biopsych.2010.12.029
   Mehling WE, 2007, J PAIN SYMPTOM MANAG, V33, P258, DOI 10.1016/j.jpainsymman.2006.09.016
   Melchart D, 2006, HEADACHE, V46, P632, DOI 10.1111/j.1526-4610.2006.00365.x
   Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F
   Namkung H, 2017, TRENDS NEUROSCI, V40, P200, DOI 10.1016/j.tins.2017.02.002
   Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003
   Napadow V, 2009, NEUROIMAGE, V47, P1055, DOI 10.1016/j.neuroimage.2009.05.079
   Narita M, 2006, NEUROPSYCHOPHARMACOL, V31, P739, DOI 10.1038/sj.npp.1300858
   Narusyte J, 2020, PAIN, V161, P1005, DOI 10.1097/j.pain.0000000000001787
   National Cancer Institute, 2018, NATIONAL CANCER INSTITUTE2. CANCER STAT FACTS:STOMACH CANCER, V0, P0
   Nicholson RA, 2011, CURR TREAT OPTION NE, V13, P28, DOI 10.1007/s11940-010-0102-9
   Ossipov MH, 2010, J CLIN INVEST, V120, P3779, DOI 10.1172/JCI43766
   Powers SW, 2003, PEDIATRICS, V112, PE1, DOI 10.1542/peds.112.1.e1
   Reid MC, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h532
   Salzman CD, 2010, ANNU REV NEUROSCI, V33, P173, DOI 10.1146/annurev.neuro.051508.135256
   Sanford NN, 2019, CANCER-AM CANCER SOC, V125, P4310, DOI 10.1002/cncr.32450
   Sawazaki K, 2008, IND HEALTH, V46, P336, DOI 10.2486/indhealth.46.336
   Sellmeijer J, 2018, J NEUROSCI, V38, P3102, DOI 10.1523/JNEUROSCI.3195-17.2018
   Serafini RA, 2020, BIOL PSYCHIAT, V87, P64, DOI 10.1016/j.biopsych.2019.10.018
   Sleijser-Koehorst MLS, 2019, PAIN, V160, P600, DOI 10.1097/j.pain.0000000000001441
   Stancak A, 2013, FRONT HUM NEUROSCI, V7, P0, DOI 10.3389/fnhum.2013.00552
   Stein DJ, 2010, PSYCHOL MED, V40, P1759, DOI 10.1017/S0033291709992261
   Stovner LJ, 2018, LANCET NEUROL, V17, P954, DOI 10.1016/S1474-4422(18)30322-3
   Streng A, 2006, HEADACHE, V46, P1492, DOI 10.1111/j.1526-4610.2006.00598.x
   TOOMEY TC, 1977, PAIN, V3, P137, DOI 10.1016/0304-3959(77)90077-X
   Vaswani M, 2003, PROG NEURO-PSYCHOPH, V27, P85, DOI 10.1016/S0278-5846(02)00338-X
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704
   Wang SM, 2007, ANESTH ANALG, V105, P499, DOI 10.1213/01.ane.0000270216.71234.f5
   Williamson L, 2007, RHEUMATOLOGY, V46, P1445, DOI 10.1093/rheumatology/kem119
   Witt C, 2005, LANCET, V366, P136, DOI 10.1016/S0140-6736(05)66871-7
   Wu YY, 2017, EXP THER MED, V14, P107, DOI 10.3892/etm.2017.4479
   Wu YY, 2019, J PAIN RES, V12, P3067, DOI 10.2147/JPR.S211826
   Yang TY, 2017, BMC COMPLEM ALTERN M, V17, P0, DOI 10.1186/s12906-017-2039-y
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhang Y, 2011, NEUROCHEM RES, V36, P2104, DOI 10.1007/s11064-011-0534-y
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zhou WJ, 2019, NAT NEUROSCI, V22, P1649, DOI 10.1038/s41593-019-0468-2
NR 96
TC 15
Z9 20
U1 1
U2 22
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD JAN 27
PY 2021
VL 14
IS 
BP 
EP 
DI 10.3389/fnins.2020.626497
PG 11
WC Neurosciences
SC Neurosciences & Neurology
GA QE9EL
UT WOS:000616506700001
PM 33584181
DA 2026-01-16
ER

PT J
AU Guo, Q
   Di, Z
   Tian, HF
   Zhang, QA
AF Guo, Qin
   Di, Zhong
   Tian, Hong-Fang
   Zhang, Quan-Ai
TI Contralateral Acupuncture for the Treatment of Phantom Limb Pain and Phantom Limb Sensation in Oncologic Lower Limb Amputee: A Case Report
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE acupuncture; contralateral acupuncture; phantom limb pain (PLP); phantom limb sensation (PLS); phantom limb
AB Phantom limb pain (PLP) and phantom limb sensation (PLS) are common and distressing sequelae of amputation. Current pain management following amputation is challenging and unsatisfying. In this case study, a 74-year-old woman underwent above-knee amputation because of the rhabdomyosarcoma in the right leg. Despite several analgesics, pain was poorly controlled. The phantom limb pain and sensation were immediately reduced by the contralateral acupuncture, and abolished after the third session with no side-effects, no relapse during the next 9 months. Contralateral acupuncture showed positive effect on PLP and PLS in this case, but more robust evidence would be needed to support the efficacy of this treatment technique for indication.</p>
C1 [Guo, Qin; Di, Zhong; Tian, Hong-Fang; Zhang, Quan-Ai] Zhejiang Chinese Med Univ, Dept Acupuncture & Moxibust, Affiliated Hosp 3, Hangzhou, Peoples R China.
C3 Zhejiang Chinese Medical University
RP Zhang, QA (corresponding author), Zhejiang Chinese Med Univ, Dept Acupuncture & Moxibust, Affiliated Hosp 3, Hangzhou, Peoples R China.
EM marvinguoo@126.com
CR Aternali Andrea, 2019, F1000RES, V8, P0, DOI 10.12688/f1000research.19355.1
   Becker S, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/9305026
   BING Z, 1990, NEUROSCIENCE, V37, P809, DOI 10.1016/0306-4522(90)90110-P
   BING Z, 1991, NEUROSCIENCE, V44, P693, DOI 10.1016/0306-4522(91)90088-6
   Black JA, 2008, ANN NEUROL, V64, P644, DOI 10.1002/ana.21527
   Bouhassira D, 2004, PAIN, V108, P248, DOI 10.1016/j.pain.2003.12.024
   Bradbrook David, 2004, ACUPUNCT MED, V22, P93
   Cheng B, 1996, J TRADIT CHIN MED, V16, P35
   Colquhoun Liz, 2019, BR J NURS, V28, P638, DOI 10.12968/bjon.2019.28.10.638
   Cruz VT, 2003, NEUROREHABILITATION, V18, P299
   Davies A, 2013, ACUPUNCT MED, V31, P101, DOI 10.1136/acupmed-2012-010270
   Erlenwein J, 2021, PAIN REP, V6, P0, DOI 10.1097/PR9.0000000000000888
   Flor H, 2002, LANCET NEUROL, V1, P182, DOI 10.1016/S1474-4422(02)00074-1
   Flor H, 2006, NAT REV NEUROSCI, V7, P873, DOI 10.1038/nrn1991
   Fuchs X, 2018, PAIN RES MANAG, V2018, P0, DOI 10.1155/2018/5080123
   Gao Z, 2021, J PAIN RES, V14, P0, DOI 10.2147/JPR.S300911
   Hayhoe S, 2016, ACUPUNCT MED, V34, P55, DOI 10.1136/acupmed-2015-211984rep
   HE LF, 1987, PAIN, V31, P99, DOI 10.1016/0304-3959(87)90011-X
   Jacobs MB, 2011, MED ACUPUNCT, V23, P57, DOI 10.1089/acu.2010.0785
   KATZ J, 1990, PAIN, V43, P319, DOI 10.1016/0304-3959(90)90029-D
   Kaur A, 2018, CHIN J TRAUMATOL, V21, P366, DOI 10.1016/j.cjtee.2018.04.006
   Lai HC, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/6173412
   Li ZJ, 2017, NEUROIMAGE-CLIN, V15, P367, DOI 10.1016/j.nicl.2017.05.013
   Lin LL, 2021, FRONT NEUROSCI-SWITZ, V14, P0, DOI 10.3389/fnins.2020.626497
   Lu F, 1997, J TRADIT CHIN MED, V17, P124
   Lyu ZX, 2021, NEURAL PLAST, V2021, P0, DOI 10.1155/2021/8881557
   Mannix SM, 2013, MED ACUPUNCT, V25, P23, DOI 10.1089/acu.2012.0928
   Nikolajsen L, 1996, PAIN, V67, P69, DOI 10.1016/0304-3959(96)03080-1
   Raggi A, 2019, EUR NEUROL, V81, P302, DOI 10.1159/000503103
   Shi Y, 2020, NEURAL PLAST, V2020, P0, DOI 10.1155/2020/8865096
   Stankevicius A, 2021, EUR J PAIN, V25, P23, DOI 10.1002/ejp.1657
   Sui Shuxue, 2004, J TRADIT CHIN MED, V24, P46
   Sun J, 2015, BEHAV BRAIN FUNCT, V11, P0, DOI 10.1186/s12993-015-0055-y
   Trevelyan EG, 2016, TRIALS, V17, P0, DOI 10.1186/s13063-016-1639-z
   Tseng CC, 2014, ACUPUNCT MED, V32, P356, DOI 10.1136/acupmed-2014-010556
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Yi M, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-61
   Zhang HL, 2016, ACUPUNCT MED, V34, P164, DOI 10.1136/acupmed-2015-010947
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
NR 39
TC 8
Z9 9
U1 0
U2 30
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD OCT 22
PY 2021
VL 15
IS 
BP 
EP 
DI 10.3389/fnins.2021.713548
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA WU2DS
UT WOS:000716361500001
PM 34744604
DA 2026-01-16
ER

PT J
AU Shu, W
   Ran, JC
   Chen, BL
   Li, CN
   Ruan, SQ
   Hou, WG
AF Shu, Wen
   Ran, Jin-Chuan
   Chen, Bing-Li
   Li, Chao-Nan
   Ruan, Shuo-Quan
   Hou, Wen-Guang
TI [Acupuncture at xing-spring point, shu-stream point and lower he-sea point for
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE acupuncture; back-shu point; lower he-sea point; shu-stream point; type-2 diabetic peripheral neuropathy; xing-spring point
AB OBJECTIVE: To observe the effect of acupuncture at xing-spring point, shu-stream  point and lower he-sea point on neurological function and clinical symptoms in  patients with type-2 diabetic peripheral neuropathy. METHODS: Sixty patients with  type-2 diabetic peripheral neuropathy were randomly divided into an observation  group and a control group, 30 cases in each one. Both groups were treated with  basic treatment, and the observation group was additionally treated with  acupuncture at Neiting (ST 44), Xiangu (ST 43), Dadu (SP 2), Taibai (SP 3),  Zusanli (ST 36), etc. once every other day, 3 times a week for 4 weeks. The  changes of TCM symptom score, Toronto clinical assessment (TCSS) score, visual  analogue scale (VAS) score of pain and serum tumor necrosis factor α(TNF-α) level  were observed before and after treatment in the two groups, and the clinical  effects of the two groups were evaluated. RESULTS: Compared before treatment, the  TCM syndrome score and the TCSS score in the two groups were reduced after  treatment (P<0.05), and the TCM syndrome score after treatment in the observation  group was lower than that in the control group (P<0.05). After treatment, the VAS  in the observation group was reduced (P<0.05), and the VAS score of pain in the  observation group was lower than that in the control group (P<0.05). There was no  significant difference in the level of serum TNF-α within and between the two  groups (P>0.05). The total effective rate was 76.7% (23/30) in the observation  group, which was superior to 33.3% (10/30) in the control group (P<0.05).  CONCLUSION: Acupuncture at xing-spring point, shu-stream point and lower he-sea  point could effectively improve the neurological function and clinical symptoms  in patients with type-2 diabetic peripheral neuropathy.
C1 Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
   Department of Acupuncture and Moxibustion, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of TCM, Shanghai200437, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD AUG 10
PY 2021
VL 41
IS 8
BP 866
EP 70
DI 10.13703/j.0255-2930.20200720-0007
PG -796
WC Acupuncture Points; Acupuncture Therapy; Diabetes Mellitus, Type 2; complications; Diabetic Neuropathies; therapy; Humans; Rivers; Treatment Outcome
UT PubMed:34369696
PM 34369696
DA 2021-08-10
ER

PT J
AU Ruan, AM
   Wang, QF
   Ma, YF
   Zhang, D
   Yang, LL
   Wang, ZP
   Xie, Q
   Yin, YS
AF Ruan, Anmin
   Wang, Qingfu
   Ma, Yufeng
   Zhang, Dong
   Yang, Lili
   Wang, Zhongpeng
   Xie, Qi
   Yin, Yueshan
TI Efficacy and Mechanism of Electroacupuncture Treatment of Rabbits With Different Degrees of Knee Osteoarthritis: A Study Based on Synovial Innate Immune Response
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE electro-acupuncture; knee osteoarthritis; innate immune response; signaling pathway; mechanism research
ID articular-cartilage; pain; inflammation; acupuncture; arthritis; weight; system; model; risk
AB Knee osteoarthritis (KOA) is a chronic degenerative bone and joint disease, which is often clinically manifested as pain, joint swelling, and deformity. Its pathological manifestations are mainly synovial inflammation and cartilage degeneration. This study aims to investigate the efficacy of electro-acupuncture (EA) on model rabbits with varying degrees of KOA and to study the mechanism of EA on KOA based on the innate immune response. Mild and moderate rabbit KOA models were established using a modified Hluth method, and EA was given to both the mild and moderate model groups. The Lequesne-MG index was used to evaluate the behavioral changes in the rabbits before and after EA treatment. Morphological changes in the synovial membrane and cartilage of each group were observed by H&E staining. The Mankin scoring standard and the Krenn scoring standard were used to score the pathology of the cartilage tissue and synovial tissue, respectively. The inflammatory factors and metalloproteinases were detected in the serum of each group by ELISA. The protein and messenger RNA (mRNA) expressions of important elements related to Toll-like receptors (TLRs)-mediated innate immune response in the synovial tissue were detected by Western blot and quantitative PCR (qPCR). The Lequesne-MG index score of the rabbits gradually increased with the modeling prolonged but decreased significantly after EA treatment, indicating that EA has a better effect on alleviating the pain and improving the dysfunction. The morphological analysis showed that the inflammation of and the damage to the synovial membrane and the cartilage tissue gradually deteriorated with the modeling prolonged. However, the synovial membrane inflammation was significantly relieved after EA treatment, and the cartilage injury showed signs of repair. The ELISA analysis showed that, with the modeling prolonged, the serum-related inflammatory factors and mechanism of metalloproteinases gradually increased but decreased after EA treatment. The tumor necrosis factor alpha (TNF-alpha), interleukin 6 (IL-6), and matrix metalloproteinase3 (MMP3) of EA1 group were significantly lower than those of EA2 group. Both Western blot and qPCR results showed that the protein and mRNA expressions of the elements related to the innate immune response in the synovial membrane increased gradually with the modeling prolonged, but decreased significantly after EA treatment. Additionally, the expression of some components in EA1 group was significantly lower than that in EA2 group. These results confirm that synovial inflammation gradually aggravated with time from the early to mid-stage of KOA. EA alleviated the inflammation and histological changes in KOA rabbits by inhibiting the TLRs-mediated innate synovial immune response. This suggests that using EA in the early stage of KOA may achieve a desirable efficacy.
C1 [Ruan, Anmin; Yang, Lili] Beijing Longfu Hosp, Dept Orthoped, Beijing, Peoples R China.
   [Wang, Qingfu; Ma, Yufeng] Beijing Univ Chinese Med, Dept Tendon & Injury, Hosp 3, Beijing, Peoples R China.
   [Zhang, Dong] Beijing Univ Chinese Med, Dept Gen Surg, Hosp 2, Beijing, Peoples R China.
   [Wang, Zhongpeng; Yin, Yueshan] Beijing Univ Chinese Med, Acupuncture & Moxibust Dept, Hosp 3, Beijing, Peoples R China.
   [Xie, Qi] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine
RP Yin, YS (corresponding author), Beijing Univ Chinese Med, Acupuncture & Moxibust Dept, Hosp 3, Beijing, Peoples R China.
EM yinyueshan1984@163.com
FU School-level Young Teachers Project of Beijing University of Chinese Medicine [2018-JYBZZJS199]
CR Ahsin S, 2009, PAIN, V147, P60, DOI 10.1016/j.pain.2009.08.004
   Atukorala I, 2016, ANN RHEUM DIS, V75, P390, DOI 10.1136/annrheumdis-2014-205894
   Band PA, 2015, OSTEOARTHR CARTILAGE, V23, P70, DOI 10.1016/j.joca.2014.09.017
   Barnes Patricia M, 2008, NATL HEALTH STAT REPORT, V0, P1
   Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012
   Chen HH, 2017, MOL MED REP, V16, P5807, DOI 10.3892/mmr.2017.7366
   Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763
   Deyle GD, 2020, NEW ENGL J MED, V382, P1420, DOI 10.1056/NEJMoa1905877
   Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041
   García-Arnandis I, 2010, ARTHRITIS RES THER, V12, P0, DOI 10.1186/ar3124
   Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1
   Hawker GA, 2019, CLIN EXP RHEUMATOL, V37, P3
   Krenn V, 2002, PATHOL RES PRACT, V198, P317, DOI 10.1078/0344-0338-5710261
   Kwon YD, 2006, RHEUMATOLOGY, V45, P1331, DOI 10.1093/rheumatology/kel207
   MANKIN HJ, 1981, J BONE JOINT SURG AM, V63, P131, DOI 10.2106/00004623-198163010-00017
   Mata J, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-0766-2
   Miller RE, 2019, SEMIN IMMUNOPATHOL, V41, P583, DOI 10.1007/s00281-019-00762-3
   Neogi T, 2017, CLIN EXP RHEUMATOL, V35, P0
   Piccinini AM, 2010, MEDIAT INFLAMM, V2010, P0, DOI 10.1155/2010/672395
   Qin YX, 2013, ACUPUNCT MED, V31, P214, DOI 10.1136/acupmed-2012-010289
   Roemer FW, 2011, ANN RHEUM DIS, V70, P1804, DOI 10.1136/ard.2011.150243
   Rogart JN, 1999, OSTEOARTHR CARTILAGE, V7, P539, DOI 10.1053/joca.1999.0258
   Scanzello CR, 2008, CURR OPIN RHEUMATOL, V20, P565, DOI 10.1097/BOR.0b013e32830aba34
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Seo BK, 2013, RHEUMATOL INT, V33, P1177, DOI 10.1007/s00296-012-2502-5
   Sidiropoulos PI, 2008, ANN RHEUM DIS, V67, P1382, DOI 10.1136/ard.2007.078014
   Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868
   Sun Guang-Hua, 2018, ZHEN CI YAN JIU, V43, P781, DOI 10.13702/j.1000-0607.170591
   Thomas E, 2014, RHEUMATOLOGY, V53, P338, DOI 10.1093/rheumatology/ket346
   van den Bosch MHJ, 2019, CLIN EXP IMMUNOL, V195, P153, DOI 10.1111/cei.13237
   van Lent PLEM, 2012, ARTHRITIS RHEUM-US, V64, P1466, DOI 10.1002/art.34315
   Wang CC, 2008, ARTHRIT RHEUM-ARTHR, V59, P1249, DOI 10.1002/art.24009
   Wang H, 2018, J CELL PHYSIOL, V233, P1342, DOI 10.1002/jcp.26011
   Wu GW, 2019, CHIN J INTEGR MED, V25, P677, DOI 10.1007/s11655-018-2916-8
NR 34
TC 19
Z9 23
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 
EI 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD AUG 5
PY 2021
VL 12
IS 
BP 
EP 
DI 10.3389/fphys.2021.642178
PG 10
WC Physiology
SC Physiology
GA UD2NP
UT WOS:000687049600001
PM 34421630
DA 2026-01-16
ER

PT J
AU Xu, M
   Fei, Y
   He, Q
   Fu, J
   Zhu, J
   Tao, J
   Ni, C
   Xu, C
   Zhou, Q
   Yao, M
   Ni, H
AF Xu, Miao
   Fei, Yong
   He, Qiuli
   Fu, Jie
   Zhu, Jianjun
   Tao, Jiachun
   Ni, Chaobo
   Xu, Chengfei
   Zhou, Qinghe
   Yao, Ming
   Ni, Huadong
TI Electroacupuncture Attenuates Cancer-Induced Bone Pain via NF-κB/CXCL12 Signaling
SO ACS chemical neuroscience
LA English
DT Journal Article
DE CXCL12; Electroacupuncture; NF-κB; PAG; cancer-induced bone pain
AB Electroacupuncture (EA) is effective in various chronic pains. NF-κB and CXCL12  modulate the formation of chronic pain. Herein, we hypothesized that EA  alleviates cancer-induced bone pain (CIBP) through NF-κB/CXCL12 axis in midbrain  periaqueductal gray (PAG), which participates in "top-down" pain modulatory  circuits. In order to filter the optimum EA frequency for CIBP treatment, 2, 100,  or 2/100 Hz EA was set up. In addition, ipsilateral, contralateral, and bilateral  EA groups were established to affirm the optimal EA scheme. Bilateral 2/100 Hz EA  was considered as the optimal therapeutic scheme and was applied in a subsequent  experiment. Western blotting along with immunofluorescence illustrated that CIBP  induces a rapid and substantial increase in CXCL12 protein level and NF-κB  phosphorylation in vlPAG from day 6 to day 12. Anti-CXCL12 neutralizing antibody  and pAAV-U6-shRNA(CXCL12)-CMV-EGFP-WPRE in vlPAG remarkably improved the  mechanical pain threshold of the hind paw in CIBP model relative to the control.  EA inhibited the upregulation of pNF-κB and CXCL12 in vlPAG of CIBP. The  recombinant CXCL12 and pAAV-CMV-CXCL12-EF1a-EGFP-3Xflag-WPRE reversed the  abirritation of EA in the CIBP rat model. NF-κB phosphorylation mediated-CXCL12  expression contributed to CIBP allodynia, whereas EA suppressed NF-κB  phosphorylation in CIBP. According to the above evidence, we conclude that  bilateral 2/100 Hz EA is an optimal therapeutic scheme for CIBP. The abirritation  mechanism of EA might reduce the expression of CXCL12 by inhibiting the  activation of NF-κB, which might lead to the restraint of descending facilitation  of CIBP.
C1 Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
   Department of Anesthesiology and Pain Research Center, The Affiliated Hospital of Jiaxing University, 1882 Zhonghuan South Road, Jiaxing 314001, China.
NR 0
TC 0
SN 1948-719
EI 
J9 ACS Chem Neurosci
PD AUG 31
PY 2021
VL 12
IS 18
BP 3323
EP 3334
DI 10.1021/acschemneuro.1c00224
PG 11
WC Animals; Electroacupuncture; NF-kappa B; metabolism; Neoplasms; Pain Threshold; Periaqueductal Gray; metabolism; Rats; Rats, Sprague-Dawley
UT PubMed:34460214
PM 34460214
DA 2021-08-31
ER

PT J
AU Liou, KT
   Trevino, KM
   Meghani, SH
   Li, QS
   Deng, G
   Korenstein, D
   Mao, JJ
AF Liou, Kevin T.
   Trevino, Kelly M.
   Meghani, Salimah H.
   Li, Q. Susan
   Deng, Gary
   Korenstein, Deborah
   Mao, Jun J.
TI Fear of analgesic side effects predicts preference for acupuncture: a cross-sectional study of cancer patients with pain in the USA
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Cancer; Pain management; Barriers; Preference; Acupuncture; Analgesics; Opioids
ID alternative medicine use; educational interventions; african-americans; opioid analgesics; barriers; management; survivors; complementary; outpatients; prevalence
AB Purpose Approximately one in two cancer patients globally are under-treated for pain. Opioids and other analgesics represent the mainstay of cancer pain management; however, barriers to their use are well-documented. We evaluated whether acupuncture would be a preferable treatment option among cancer patients with attitudinal barriers to pharmacological pain management. Methods We conducted a cross-sectional survey of cancer patients at a tertiary urban cancer center and eleven suburban/rural hospitals in the Northeastern United States. We assessed attitudinal barriers to pharmacological pain management with the Barriers Questionnaire (BQ-13). The BQ-13 consists of two subscales: pain management beliefs and analgesic side effects. We also asked patients whether they prefer acupuncture, analgesics, or have no preference between these two modalities for pain management. Covariates included sociodemographics, clinical characteristics, and attitudes/beliefs about acupuncture. We used logistic regression to examine the association between attitudinal barriers and acupuncture preference. Results Among 628 patients, 197 (31.4%) preferred acupuncture for pain management, 146 (23.3%) preferred analgesics, and 285 (45.4%) had no preference. The highest reported attitudinal barriers were fear of addiction and fear of analgesic-associated constipation and nausea. Adjusting for covariates, we found that attitudinal barriers related to fear of analgesic side effects were significantly associated with acupuncture preference (adjusted odds ratio [AOR] 1.45, 95% confidence interval [CI] 1.17-1.81), but barriers related to pain management beliefs were not (AOR 1.17, 95% CI 0.91-1.51). Attitudes/beliefs about acupuncture (i.e., greater expected benefits, fewer perceived barriers, and more positive social norms) and female gender also predicted acupuncture preference, whereas race and educational status did not. Conclusion Acupuncture may be a preferable treatment option among cancer patients at risk of inadequately controlled pain due to fear of analgesic side effects. Evidence-based integration of acupuncture and analgesics, guided by patient treatment preferences, represents an essential aspect of patient-centered care and has potential to address unmet cancer pain management needs.
C1 [Liou, Kevin T.; Li, Q. Susan; Deng, Gary; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
   [Liou, Kevin T.; Deng, Gary; Mao, Jun J.] Weill Cornell Med, Dept Med, New York, NY 10065 USA.
   [Trevino, Kelly M.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1275 York Ave, New York, NY 10021 USA.
   [Meghani, Salimah H.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA.
   [Korenstein, Deborah] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
   [Korenstein, Deborah] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, 1275 York Ave, New York, NY 10021 USA.
C3 Memorial Sloan Kettering Cancer Center; Cornell University; Weill Cornell Medicine; Memorial Sloan Kettering Cancer Center; University of Pennsylvania; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Liou, KT (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.; Liou, KT (corresponding author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.
EM liouk@mskcc.org
FU National Cancer Institute [2P30CA01652040, 3P30CA00874850]; Byrne Fund; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center; National Cancer Institute [P30CA008748, P30CA016520] Funding Source: NIH RePORTER
CR Adam R, 2015, PATIENT EDUC COUNS, V98, P269, DOI 10.1016/j.pec.2014.11.003
   Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1097/01.sa.0000484819.20819.8b
   Bishop FL, 2011, BMC HEALTH SERV RES, V11, P0, DOI 10.1186/1472-6963-11-129
   Boyd-Seale D, 2010, NURS RES, V59, P93, DOI 10.1097/NNR.0b013e3181d1a6de
   Bulls HW, 2019, J PAIN SYMPTOM MANAG, V57, P816, DOI 10.1016/j.jpainsymman.2019.01.013
   Chao MT, 2019, PAIN MED, V20, P2292, DOI 10.1093/pm/pnz117
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Dalal S, 2013, NAT REV CLIN ONCOL, V10, P108, DOI 10.1038/nrclinonc.2012.237
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Garland EL, 2020, JAMA INTERN MED, V180, P91, DOI 10.1001/jamainternmed.2019.4917
   Geneen LJ, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011279.pub3
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Gunnarsdottir S, 2017, SUPPORT CARE CANCER, V25, P3595, DOI 10.1007/s00520-017-3791-8
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hopton A, 2013, PLOS ONE, V8, P0, DOI 10.1371/journal.pone.0056806
   Judson PL, 2017, INTEGR CANCER THER, V16, P96, DOI 10.1177/1534735416660384
   King M, 2005, HEALTH TECHNOL ASSES, V9, P1
   Kligler B, 2015, J ALTERN COMPLEM MED, V21, P713, DOI 10.1089/acm.2014.0376
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lim MY, 2015, CHIN MED-UK, V10, P0, DOI 10.1186/s13020-015-0041-1
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lu WD, 2010, CURR TREAT OPTION ON, V11, P141, DOI 10.1007/s11864-010-0126-0
   Mao JJ, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/798098
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Mckee MD, 2012, J ALTERN COMPLEM MED, V18, P839, DOI 10.1089/acm.2011.0193
   Meghani SH, 2015, J PAIN, V16, P825, DOI 10.1016/j.jpain.2015.05.009
   Meghani SH, 2014, J CLIN ONCOL, V32, P2773, DOI 10.1200/JCO.2013.54.7992
   Meghani SH, 2012, PAIN MED, V13, P150, DOI 10.1111/j.1526-4637.2011.01310.x
   Montori VM, 2013, JAMA-J AM MED ASSOC, V310, P2503, DOI 10.1001/jama.2013.281422
   Morley KI, 2017, PAIN, V158, P1138, DOI 10.1097/j.pain.0000000000000892
   Oldenmenger WH, 2018, CANCER TREAT REV, V63, P96, DOI 10.1016/j.ctrv.2017.12.005
   Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Paller CJ, 2009, PAIN MED, V10, P289, DOI 10.1111/j.1526-4637.2008.00558.x
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Sindt Jill E, 2016, ANESTHESIOL CLIN, V34, P317, DOI 10.1016/j.anclin.2016.01.004
   Stein KD, 2016, PSYCHO-ONCOLOGY, V25, P1212, DOI 10.1002/pon.4218
   Valeberg BT, 2008, CLIN J PAIN, V24, P627, DOI 10.1097/AJP.0b013e31816fe020
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vickers AJ, 2012, ARCH INTERN MED, V172, P1444, DOI 10.1001/archinternmed.2012.3654
   Volkow ND, 2019, WORLD PSYCHIATRY, V18, P231, DOI 10.1002/wps.20633
   Weeks J, 2016, J ALTERN COMPLEM MED, V22, P947, DOI 10.1089/acm.2016.29016.jjw
   Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zhang Y, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/710750
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
   Zylla D, 2017, SUPPORT CARE CANCER, V25, P1687, DOI 10.1007/s00520-017-3614-y
NR 54
TC 24
Z9 29
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN 15
PY 2021
VL 29
IS 1
BP 427
EP 435
DI 10.1007/s00520-020-05504-y
EA MAY 2020
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA RI9WR
UT WOS:000530959400001
PM 32383073
DA 2026-01-16
ER

PT J
AU Li, S
   Huang, J
   Guo, Y
   Wang, J
   Lu, S
   Wang, B
   Gong, Y
   Qin, S
   Zhao, S
   Wang, S
   Liu, Y
   Fang, Y
   Guo, Y
   Xu, Z
   Ulloa, L
AF Li, Shanshan
   Huang, Jin
   Guo, Yi
   Wang, Jiaqi
   Lu, Shanshan
   Wang, Bin
   Gong, Yinan
   Qin, Siru
   Zhao, Suhong
   Wang, Shenjun
   Liu, Yangyang
   Fang, Yuxin
   Guo, Yongming
   Xu, Zhifang
   Ulloa, Luis
TI PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection
SO Frontiers in immunology
LA English
DT Journal Article
DE chemotherapy; electroacupuncture; hematopoiesis; immunosuppression; neuromodulation; neurotoxic
AB Platinum-based chemotherapy is an effective treatment used in multiple tumor  treatments, but produces severe side effects including neurotoxicity, anemia, and  immunosuppression, which limits its anti-tumor efficacy and increases the risk of  infections. Electroacupuncture (EA) is often used to ameliorate these side  effects, but its mechanism is unknown. Here, we report that EA on ST36 and SP6  prevents cisplatin-induced neurotoxicity and immunosuppression. EA induces  neuroprotection, prevents pain-related neurotoxicity, preserves bone marrow (BM)  hematopoiesis, and peripheral levels of leukocytes. EA activates sympathetic BM  terminals to release pituitary adenylate cyclase activating polypeptide (PACAP).  PACAP-receptor PAC1-antagonists abrogate the effects of EA, whereas PAC1-agonists  mimic EA, prevent neurotoxicity, immunosuppression, and preserve BM hematopoiesis  during cisplatin chemotherapy. Our results indicate that PAC1-agonists may  provide therapeutic advantages during chemotherapy to treat patients with  advanced neurotoxicity or neuropathies limiting EA efficacy.
C1 Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
   Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University, Durham, NC, United States.
NR 0
TC 0
SN 1664-322
EI 
J9 Front Immunol
PD SEP 24
PY 2021
VL 12
IS 
BP 714244
EP 714244
DI 10.3389/fimmu.2021.714244
PG 0
WC Animals; Bone Marrow Cells; metabolism; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; pharmacology; Disease Management; Disease Models, Animal; Electroacupuncture; methods; Hematopoiesis; genetics; Humans; Immunomodulation; genetics; Leukopenia; Mice; Neoplasms; genetics; Neuroimmunomodulation; genetics; Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type
UT PubMed:34552585
PM 34552585
DA 2021-09-24
ER

PT J
AU Khalil, A
   Elesawy, BH
   Ali, TM
   Ahmed, OM
AF Khalil, Abdelwahab
   Elesawy, Basem H.
   Ali, Tarek M.
   Ahmed, Osama M.
TI Bee Venom: From Venom to Drug
SO MOLECULES
LA English
DT Review
DE bee venom; inflammatory and chronic diseases; nanoparticles; bee venom products
ID apis-mellifera venom; in-vitro; cancer cells; melittin; peptide; antioxidant; arthritis; pain; acupuncture; activation
AB Insects of the order Hymenoptera have a defensive substance that contains many biologically active compounds. Specifically, venom from honeybees (Apis mellifera) contains many enzymes and peptides that are effective against various diseases. Different research papers stated the possibility of using bee venom (a direct bee sting or in an injectable form) in treating several complications; either in vivo or in vitro. Other reports used the active fractions of bee venom clinically or at labratory scale. Many reports and publications have stated that bee venom and its constituents have multiple biological activities including anti-microbial, anti-protozoan, anti-cancer, anti-inflammatory, and anti-arthritic properties. The present review aims to refer to the use of bee venom itself or its fractions in treating several diseases and counteracting drug toxicities as an alternative protocol of therapy. The updated molecular mechanisms of actions of bee venom and its components are discussed in light of the previous updated publications. The review also summarizes the potential of venom loaded on nanoparticles as a drug delivery vehicle and its molecular mechanisms. Finally, the products of bee venom available in markets are also demonstrated.
C1 [Khalil, Abdelwahab] Beni Suef Univ, Div Entomol, Dept Zool, Fac Sci, Bani Suwayf 62521, Egypt.
   [Elesawy, Basem H.] Taif Univ, Dept Clin Lab Sci, Coll Appl Med Sci, POB 11099, At Taif 21944, Saudi Arabia.
   [Elesawy, Basem H.] Mansoura Univ, Dept Pathol, Fac Med, Mansoura 35516, Egypt.
   [Ali, Tarek M.] Taif Univ, Dept Physiol, Coll Med, POB 11099, At Taif 21944, Saudi Arabia.
   [Ali, Tarek M.] Beni Suef Univ, Dept Physiol, Fac Med, Bani Suwayf 62521, Egypt.
   [Ahmed, Osama M.] Beni Suef Univ, Div Physiol, Dept Zool, Fac Sci, Bani Suwayf, Egypt.
C3 Egyptian Knowledge Bank (EKB); Beni Suef University; Taif University; Egyptian Knowledge Bank (EKB); Mansoura University; Taif University; Egyptian Knowledge Bank (EKB); Beni Suef University; Egyptian Knowledge Bank (EKB); Beni Suef University
RP Ahmed, OM (corresponding author), Beni Suef Univ, Div Physiol, Dept Zool, Fac Sci, Bani Suwayf, Egypt.
EM akhalil1980@gmail.com; basemelesawy2@gmail.com; tarek70ali@gmail.com; osamamoha@yahoo.com
CR Abd El-Rahim A, 2018, JOURNAL OF THE ARAB SOCIETY FOR MEDICAL RESEARCH, V13, P89, DOI 10.4103/jasmr.jasmr_24_18
   Ahmed O, 2018, ARCH RHEUMATOL, V33, P198, DOI 10.5606/ArchRheumatol.2018.6519
   Ahmed OM, 2020, BIOMOLECULES, V10, P0, DOI 10.3390/biom10091317
   Akre RD, 2009, ANTS WASPS BEES TXB, V2nd, P383
   Alalawy AI, 2020, INT J POLYM SCI, V2020, P0, DOI 10.1155/2020/2785304
   Ali MA, 2012, INT. J. ADV. RES. TECHNOL, V1, P69
   Asafova N, 2001, PHYSL ACTIVE BEE PRO, V0, P360
   Aufschnaiter A, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12020066
   Bachis A, 2010, EUR J NEUROSCI, V32, P570, DOI 10.1111/j.1460-9568.2010.07325.x
   Badawi JK, 2021, TOXINS, V13, P0, DOI 10.3390/toxins13050337
   Bhalotia S, 2016, JOURNAL OF BASIC AND APPLIED ENGINEERING RESEARCH, V3, P96
   Bilò BM, 2011, IMMUNOTHERAPY-UK, V3, P229, DOI 10.2217/IMT.10.88
   Bogdanov S, 2016, BEE PRODUCT SCIENCE, V25, P1
   Carpena M, 2020, NUTRIENTS, V12, P0, DOI 10.3390/nu12113360
   Casewell NR, 2013, TRENDS ECOL EVOL, V28, P219, DOI 10.1016/j.tree.2012.10.020
   Chen J, 2016, NEUROSCI BULL, V32, P265, DOI 10.1007/s12264-016-0024-y
   Chen J, 2010, PROG NEUROBIOL, V92, P151, DOI 10.1016/j.pneurobio.2010.06.006
   Cheon S, 2015, INTEGR MED RES, V4, P55, DOI 10.1016/j.imr.2015.04.045
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Chung KS, 2015, EXP BIOL MED, V240, P1656, DOI 10.1177/1535370215590823
   Cornara L, 2017, FRONT PHARMACOL, V8, P0, DOI 10.3389/fphar.2017.00412
   Danneels EL, 2015, TOXINS, V7, P4468, DOI 10.3390/toxins7114468
   Duffy C, 2020, NPJ PRECIS ONCOL, V4, P24, DOI 10.1038/s41698-020-00129-0
   El-Banby MA, 1994, HONEYBEES KORAN MED, V0, P268
   El-Hanoun A, 2020, PHYSIOL BEHAV, V223, P0, DOI 10.1016/j.physbeh.2020.112987
   Gajski G, 2016, TOXICON, V110, P56, DOI 10.1016/j.toxicon.2015.12.005
   Gajski G, 2013, ENVIRON TOXICOL PHAR, V36, P697, DOI 10.1016/j.etap.2013.06.009
   Gülmez Y, 2017, MARMARA PHARM J, V21, P251, DOI 10.12991/marupj.300329
   Habermehl G, 1981, VENOMOUS ANIMALS THE, V0, P0
   Han SM, 2013, PHARMACOGN MAG, V9, P220, DOI 10.4103/0973-1296.113271
   Hassan SA, 2021, J PHARM RES INT, V33, P200, DOI 10.9734/JPRI/2021/v33i29A31579
   Hauser RA, 2001, ALTERNATIVE AND COMPLEMENTARY THERAPIES, V7, P37, DOI https://doi.org/10.1089/107628001300000714
   Hong JJ, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24091775
   Im EJ, 2016, EVID-BASED COMPL ALT, V2016, P3704764, DOI 10.1155/2016/3704764
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kang SY, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/809062
   Kang SY, 2012, J PAIN, V13, P155, DOI 10.1016/j.jpain.2011.10.012
   Karimi A, 2011, THE JOURNAL OF AMERICAN SCIENCE, V7, P295
   Kim CMH, 2013, BIOTHERAPY - HISTORY, V0, P77, DOI 10.1007/978-94-007-6585-6_4
   Kim Hyun-Woo, 2004, J VET SCI, V5, P309
   Kim H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0114726
   Kim KH, 2013, INT J CLIN EXP PATHO, V6, P2896
   Kingsland J, 2020, HONEYBEE VENOM KILLS, V0, P0
   Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h
   Kolayli S, 2020, STUD NAT PROD CHEM, V66, P175, DOI 10.1016/B978-0-12-817907-9.00007-6
   Krell R, 1996, VALUE-ADDED PRODUCTS FROM BEEKEEPING, V0, P0
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Krylov V, 2007, THEORY AND AGENTS OF APITHERAPY, V0, P0
   Krylov V, 1995, PCELNI YAD BEE VENOM, V0, P221
   Kwon YB, 2001, PAIN, V90, P271, DOI 10.1016/S0304-3959(00)00412-7
   Leandro LF, 2015, AN ACAD BRAS CIENC, V87, P147, DOI 10.1590/0001-3765201520130511
   Lee CW, 1996, DERMATOLOGY, V193, P355, DOI 10.1159/000246293
   Lee G, 2016, MOLECULES, V21, P0, DOI 10.3390/molecules21050616
   Lee J, 2018, VET IMMUNOL IMMUNOP, V200, P40, DOI 10.1016/j.vetimm.2018.04.006
   Lee WR, 2014, J INVEST DERMATOL, V134, P1922, DOI 10.1038/jid.2014.75
   Lee YJ, 2020, INFLAMMOPHARMACOLOGY, V28, P253, DOI 10.1007/s10787-019-00646-w
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Lin TY, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12100618
   Liu SJ, 2008, HEPATOLOGY, V47, P1964, DOI 10.1002/hep.22240
   Liu X, 2003, J CONTROL RELEASE, V93, P293, DOI 10.1016/j.jconrel.2003.08.019
   Liu X, 2002, J PHARM PHARMACOL, V54, P1083, DOI 10.1211/002235702320266235
   Ludyanskii EA, 1994, APITERAPIA., V0, P0
   Meier J, 1995, HDB CLIN TOXICOLOGY, V0, P0
   Minton SA, 1974, VENOM DISEASES, V0, P0
   Mohamed WA, 2019, TOXICOLOGY, V419, P11, DOI 10.1016/j.tox.2019.03.003
   Moreau SJM, 2015, TOXINS, V7, P2385, DOI 10.3390/toxins7072385
   Moreau SJM, 2009, ADV PARASIT, V70, P217, DOI 10.1016/S0065-308X(09)70008-9
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Mousavi SM, 2012, J ARTHROPOD-BORNE DI, V6, P136
   Mraz C, 1995, HLTH HONEYBEE, V0, P0
   NIH, 1995, AP ALT MED EXP MED H, V0, P172
   Orsolic N, 2012, CANCER METAST REV, V31, P173, DOI 10.1007/s10555-011-9339-3
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Park JH, 2015, PLOS ONE, V10, P0, DOI 10.1371/journal.pone.0126971
   Park JH, 2010, ARCH PHARM RES, V33, P215, DOI 10.1007/s12272-010-0205-6
   Park MH, 2011, PROSTATE, V71, P801, DOI 10.1002/pros.21296
   Park MH, 2015, MOLECULES, V20, P15072, DOI 10.3390/molecules200815072
   Pucca MB, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00611
   Pucca MB, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.02090
   Qiao MX, 2007, INT J PHARMACEUT, V345, P116, DOI 10.1016/j.ijpharm.2007.05.056
   Raghuraman H, 2007, BIOSCIENCE REP, V27, P189, DOI 10.1007/s10540-006-9030-z
   REISMAN RE, 1988, ANN ALLERGY, V61, P383
   Rho Young Hee, 2009, KOREAN JOURNAL OF INTERNAL MEDICINE, V24, P283, DOI 10.3904/kjim.2009.24.3.283
   Rose A, 1994, BEES IN BALANCE, V0, P0
   Saidemberg DM, 2011, PEPTIDES, V32, P1924, DOI 10.1016/j.peptides.2011.08.001
   Sharma HC, 1983, PROCEEDINGS OF THE SECOND INTERNATIONAL CONFERENCE ON APICULTURE IN TROPICAL CLIMATES, V0, P0
   Shkenderov S, 1983, PCELNI PRODUKTI BEE, V0, P1
   Sig AK, 2019, TURKISH JOURNAL OF CLINICS AND LABORATORY, V10, P414, DOI 10.18663/tjcl.451586
   Singh D, 2020, COMMERCIAL BEEKEEPING (PRODUCTION, V0, P257
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Son DJ, 2007, PHARMACOL THERAPEUT, V115, P246, DOI 10.1016/j.pharmthera.2007.04.004
   Strait JE, 2013, NANOPARTICLES LOADED WITH BEE VENOM KILL HIV, V0, P0
   Sturm GJ, 2018, ALLERGY, V73, P744, DOI 10.1111/all.13262
   Szabat P, 2019, J EDUC HEALTH SPORT, V9, P384, DOI 10.5281/ZENODO.3376968
   TOSTESON MT, 1985, J MEMBRANE BIOL, V87, P35, DOI 10.1007/BF01870697
   Uddin M, 2016, J MICROBIOL, V54, P853
   Urtubey N, 2005, APITOXIN: FROM BEE VENOM TO APITOXIN FOR MEDICAL USE, V0, P0
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Wesselius T, 2005, NEUROLOGY, V65, P1764, DOI 10.1212/01.wnl.0000184442.02551.4b
   Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X
   Zhang S, 2018, TOXICON, V148, P64, DOI 10.1016/j.toxicon.2018.04.012
   Zheng J, 2015, ONCOTARGET, V6, P44437, DOI 10.18632/oncotarget.6295
NR 106
TC 83
Z9 91
U1 3
U2 123
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG 15
PY 2021
VL 26
IS 16
BP 
EP 
DI 10.3390/molecules26164941
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA UI0CI
UT WOS:000690286400001
PM 34443529
DA 2026-01-16
ER

PT J
AU Li, G
   Zhang, CX
   Wang, CY
   Xiao, L
AF Li, Gang
   Zhang, Changxi
   Wang, Congyi
   Xiao, Ling
TI Acupuncture against chronic postsurgical pain in non-small cell lung cancer patients A protocol of randomized controlled trial
SO MEDICINE
LA English
DT Article
DE acupuncture; lung cancer; pain; video-assisted thoracoscopic lobectomy
ID assisted thoracoscopic lobectomy; early-stage; thoracotomy; prevalence; therapy
AB Introduction: Video-assisted thoracoscopic lobectomy is the prior recommended treatment for non-small cell lung cancer (NSCLC), with the advantages of small trauma, less postoperative pain, and quick recovery. However, a large number of patients may suffer chronic postsurgical pain (CPSP), which makes the patients unwilling to practice pulmonary exercises, and it would directly affect patient's cough, sputum expectoration, and mobility. Opioids could greatly improve the quality of postoperative analgesia and the quality of life after surgery, but it is accompanied with obvious side effects. A number of clinical studies have proved that acupuncture could improve postoperative pain and reduce opioid use. In this study, we try to conduct a randomized controlled study to evaluate the efficacy and safety of plum-blossom needle acupuncture combined with Tramadol in improving CPSP after lobectomy in NSCLC patients. Methods: Patients will be randomly divided into treatment group (acupuncture plus Tramadol) and control group (sham acupuncture plus Tramadol) with a random number table in 1:1 ratio. The patients, outcome assessor, and statistician will be blinded. The outcomes are changes of numerical rating scale, Karnofsky performance score, brief pain inventory, blood routine, liver and kidney function. The data will be analyzed by SPSS 22.0. Conclusions: The results will help to evaluate the efficacy and safety of plum-blossom needle acupuncture in improving CPSP after lobectomy in NSCLC patients.
C1 [Li, Gang; Zhang, Changxi; Wang, Congyi; Xiao, Ling] Chongqing Steel Gen Hosp, Dept Thorac Surg, Chongqing, Peoples R China.
RP Li, G (corresponding author), Chongqing Steel Gen Hosp, 1 Dayan Sancun, Chongqing 400081, Peoples R China.
EM lg19771022@163.com
FU Research Fund Projects of Chinese Universities [0020110456]
CR Bendixen M, 2016, LANCET ONCOL, V17, P836, DOI 10.1016/S1470-2045(16)00173-X
   DellAmore A, 2022, SURG ENDOSC, V36, P1466, DOI 10.1007/s00464-021-08431-z
   Deng HY, 2021, WORLD J SURG, V45, P897, DOI 10.1007/s00268-020-05877-5
   Dong BQ, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.585709
   Dziedzic DA, 2021, J THORAC DIS, V13, P101, DOI 10.21037/jtd-20-2251
   Grosen K, 2013, EUR J CARDIO-THORAC, V43, P95, DOI 10.1093/ejcts/ezs159
   Gullo R, 2021, MINERVA SURG, V76, P80, DOI 10.23736/S2724-5691.20.08395-9
   Hirai K, 2019, J THORAC DIS, V11, P3896, DOI 10.21037/jtd.2019.09.07
   Li QY, 2020, ANN PALLIAT MED, V9, P1030, DOI 10.21037/apm-20-909
   Liang Q, 2020, AM J CHINESE MED, V48, P1769, DOI 10.1142/S0192415X20500883
   Liu CC, 2021, CHINESE J CANCER RES, V33, P79, DOI 10.21147/j.issn.1000-9604.2021.01.09
   Liu Y, 2021, CANCER MANAG RES, V13, P2447, DOI 10.2147/CMAR.S282617
   Magouliotis DE, 2021, LUNG, V199, P43, DOI 10.1007/s00408-020-00411-9
   Porrello C, 2019, G CHIR, V40, P115
   Sato A, 2021, BMC CANCER, V21, P0, DOI 10.1186/s12885-021-08011-3
   Sihoe ADL, 2020, RESPIROLOGY, V25, P49, DOI 10.1111/resp.13920
   Sun Y, 2008, BRIT J ANAESTH, V101, P151, DOI 10.1093/bja/aen146
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Yamashita Y, 2013, EUR J CARDIO-THORAC, V44, PE71, DOI 10.1093/ejcts/ezt107
   Yao J, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000022719
   Yun JK, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-72272-4
NR 21
TC 9
Z9 10
U1 5
U2 26
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 8
PY 2021
VL 100
IS 40
BP 
EP 
DI 10.1097/MD.0000000000027461
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA WC2CZ
UT WOS:000704071200040
PM 34622872
DA 2026-01-16
ER

PT J
AU Grant, SJ
   Kwon, K
   Naehrig, D
   Asher, R
   Lacey, J
AF Grant, Suzanne J
   Kwon, Ki
   Naehrig, Diana
   Asher, Rebecca
   Lacey, Judith
TI Characteristics and Symptom Burden of Patients Accessing Acupuncture Services at
SO Integrative cancer therapies
LA English
DT Journal Article
DE ESAS; acupuncture; cancer; integrative oncology; patient report outcome measures; symptom clusters
AB BACKGROUND: Patients with cancer are often impacted by a significant symptom  burden. Cancer hospitals increasingly recognize the value of complementary and  integrative therapies to support the management of cancer related symptoms. The  aim of this study is to provide a better understanding of the demographic  characteristics and symptoms experienced by cancer patients who access  acupuncture services in a tertiary hospital in Australia. METHODS: A  retrospective audit was conducted of patients that presented to the acupuncture  service at Chris O'Brien Lifehouse between July 2017 and December 2018. Edmonton  Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing  (MYCaW) outcome measures were used. The quantitative data was analyzed using  descriptive statistics and Principal Component Analysis. RESULTS: A total of 127  inpatients and outpatients (mean age 55, range 19-85) were included with 441  individual surveys completed (264 ESAS, 177 MYCaW). Patients were predominantly  female (76.8%) and breast cancer was the most prevalent primary diagnosis (48%).  The most prevalent symptoms in the ESAS were sleep problems (88.6%), fatigue  (88.3%), lack of wellbeing (88.1%), and memory difficulty (82.6%). Similarly,  symptoms with the highest mean scores were numbness, fatigue, sleep problems and  hot flushes, whilst neuropathy, and hot flashes were scored as the most severe  (score ≥7) by patients. Cluster analysis yielded 3 symptom clusters, 2 included  "physical symptoms" (pain, sleep problems, fatigue and numbness/neuropathy), and  (nausea, appetite, general well-being), whilst the third included "psychological"  symptoms (anxiety, depression, spiritual pain, financial distress). The most  frequent concerns expressed by patients (MyCaW) seeking acupuncture were side  effects of chemotherapy (24.6%) and pain (20.8%). CONCLUSION: This audit  highlights the most prevalent symptoms, the symptoms with the greatest burden and  the types of patients that receive acupuncture services at an Australian tertiary  hospital setting. The findings of this audit provide direction for future  acupuncture practices and research in hospital settings.
C1 NICM Health Research Institute, Western Sydney University, NSW, Australia.
   Chris O'Brien Comprehensive Cancer Centre, Camperdown, NSW, Australia.
   NICM Health Research Institute, Western Sydney University, NSW, Australia.
   Chris O'Brien Comprehensive Cancer Centre, Camperdown, NSW, Australia.
   University of Sydney, NSW, Australia.
   National Health Medical Research Council, Sydney, NSW, Australia.
   NICM Health Research Institute, Western Sydney University, NSW, Australia.
   Chris O'Brien Comprehensive Cancer Centre, Camperdown, NSW, Australia.
   University of Sydney, NSW, Australia.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD APR 13
PY 2021
VL 20
IS 
BP 15347354211002253
EP 15347354211002253
DI 10.1177/15347354211002253
PG 1
WC Acupuncture Therapy; Australia; epidemiology; Breast Neoplasms; Cancer Care Facilities; Fatigue; epidemiology; Female; Humans; Middle Aged; Neoplasms; epidemiology; Retrospective Studies
UT PubMed:33840252
PM 33840252
DA 2021-04-13
ER

PT J
AU Zhi, WI
   Gentile, D
   Diller, M
   Kinney, A
   Bao, T
   Master, V
   Wang, XS
AF Zhi, W Iris
   Gentile, Danielle
   Diller, Maggie
   Kinney, Anita
   Bao, Ting
   Master, Viraj
   Wang, Xin Shelley
TI Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology
SO Oncology (Williston Park, N.Y.)
LA English
DT Review
AB Pain is a primary concern among patients with cancer and cancer survivors.  Integrative interventions such as acupuncture, massage, and music therapy are  effective nonpharmacologic approaches for cancer pain with low cost and minimal  adverse events. Patient-reported outcomes (PROs) that have been validated in many  clinical and research settings can be used to evaluate pain intensity, associated  symptom burden, and quality of life. Clearly defined, reliable PROs can improve  patient satisfaction and symptom control. As integrative oncology continues to  evolve and expand, cancer-related pain PROs must be standardized to accurately  guide clinicians and researchers. Well-validated pain PROs, such as the Brief  Pain Inventory, are among the most commonly used for pain intensity assessment.  Multiple symptom assessment tools such as the MD Anderson Symptom Inventory, the  Memorial Symptom Assessment Scale, the Edmonton Symptom Assessment System, and  the Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events  measurement system can also capture pain-associated symptom burden. Electronic  PROs provide flexibility in collecting and analyzing PRO data. Clinical trials  using carefully selected PROs and rigorous statistical analysis plans are  fundamental to conducting high-quality integrative oncology research and  promoting utilization of effective integrative interventions to improve patient  outcomes. In this review, we aim to summarize current, validated PROs specific to  cancer-related pain to aid integrative oncology clinicians and researchers in  patient care and in study design and implementation.
C1 Breast Medicine Service, Solid Tumor Division, Memorial Sloan Kettering Cancer Center.
   Department of Supportive Oncology, Levine Cancer Institute.
   Department of Surgery, Winship Cancer Institute, Emory University School of Medicine.
   Department of Biostatistics and Epidemiology, School of Public Health, Rutgers Cancer Institute of New Jersey.
   Integrative Breast Oncology, Integrative Medicine and Breast Medicine Services, Memorial Sloan Kettering Cancer Center.
   Department of Urology, Winship Cancer Institute, Emory University School of Medicine.
   Department of Symptom Research, The University of Texas MD Anderson Cancer Center.
NR 0
TC 0
SN 
EI 0890-909
J9 Oncology (Williston Park)
PD JAN 15
PY 2021
VL 35
IS 1
BP 35
EP 41
DI 10.46883/ONC.2021.3501.0035
PG 6
WC Cancer Pain; therapy; Evidence-Based Practice; organization & administration; Humans; Integrative Oncology; methods; Pain Measurement; Patient Reported Outcome Measures; Patient Satisfaction; Quality of Life
UT PubMed:33443769
PM 33443769
DA 2021-01-15
ER

PT J
AU Oura, M
   Omata, F
   Nishikawa, Y
AF Oura, Mitsuaki
   Omata, Fumiya
   Nishikawa, Yoshitaka
TI Acupuncture for Cancer Survivors
SO JAMA ONCOLOGY
LA English
DT Letter
ID pain
C1 [Oura, Mitsuaki] Takeda Gen Hosp, Fukushima 9650876, Japan.
   [Omata, Fumiya] Hirata Cent Hosp, Dept Internal Med, Fukushima, Japan.
   [Nishikawa, Yoshitaka] Kyoto Univ, Sch Publ Hlth, Kyoto, Japan.
C3 Kyoto University
RP Oura, M (corresponding author), Takeda Gen Hosp, Fukushima 9650876, Japan.
EM mooura-tky@umin.ac.jp
CR Bankhead C, 2017, CATALOGUE OF BIAS, V0, P0
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Mao JJ, 2021, JAMA ONCOL, V7, P720, DOI 10.1001/jamaoncol.2021.0310
   Robinson-Papp J, 2015, J PAIN SYMPTOM MANAG, V50, P381, DOI 10.1016/j.jpainsymman.2015.03.013
   Zeliadt SB, 2020, MED CARE, V58, PS101, DOI 10.1097/MLR.0000000000001368
NR 5
TC 1
Z9 2
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2437
EI 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD SEP 15
PY 2021
VL 7
IS 9
BP 1399
EP 1400
DI 10.1001/jamaoncol.2021.2517
EA JUL 2021
PG 6
WC Oncology
SC Oncology
GA UR2VP
UT WOS:000679478800001
PM 34323934
DA 2026-01-16
ER

PT J
AU Dymackova, R
   Selingerova, I
   Kazda, T
   Slavik, M
   Halamkova, J
   Svajdova, M
   Slampa, P
   Slama, O
AF Dymackova, Radana
   Selingerova, Iveta
   Kazda, Tomas
   Slavik, Marek
   Halamkova, Jana
   Svajdova, Michaela
   Slampa, Pavel
   Slama, Ondrej
TI Effect of Acupuncture in Pain Management of Head and Neck Cancer Radiotherapy:
SO Journal of clinical medicine
LA English
DT Journal Article
DE acupuncture; head and neck cancer; pain; radiotherapy; toxicity
AB This prospective randomized open-label trial aimed to evaluate the role of  acupuncture in the treatment of pain related to curative and adjuvant  (chemo)radiotherapy of head and neck cancer. Patients in two arms (30 patients in  each arm) underwent standard oncology therapy and standard supportive care with  or without acupuncture. The stratification factors were the type of treatment and  chemotherapy indication. The toxicity assessed was represented by pain rated on a  10-point pain scale and analgesic use. Average pain (AP) and the worst pain  during the day (WP) were significantly lower in the acupuncture arm during  radiotherapy (AP median 0.16 vs. 1.36, p < 0.001; WP median 0.90 vs. 1.96, p <  0.001) and three months after radiotherapy (AP median 0.07 vs. 0.50, p < 0.001;  WP median 0.30 vs. 0.83, p = 0.002). The analgesic consumption between arms was  statistically significantly different. A median of the proportion of days when  the patients used analgesics was 8% and 32.5% during radiotherapy (p = 0.047) and  0% and 20.8% during three months after radiotherapy (p = 0.006) for the  acupuncture and control arm, respectively. Results point out lower analgesic  consumption and milder pain in acupuncture arm. Acupuncture consequently offers  another alternative to standard treatment leading to a reduction in the toxicity  of oncological treatment.
C1 Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, 
   Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
   Research Center for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer 
   Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, 
   Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
   Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 
   Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
   Clinic of Radiation and Clinical Oncology, Central Military Hospital-Teaching 
   Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
   Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic.
NR 0
TC 0
SN 2077-038
EI 2077-038
J9 J Clin Med
PD APR 4
PY 2021
VL 10
IS 5
BP 
EP 
DI 10.3390/jcm10051111
PG 0
UT PubMed:33799949
PM 33799949
DA 2021-04-04
ER

PT J
AU Tola, YO
   Chow, KM
   Liang, W
AF Tola, Yetunde Oluwafunmilayo
   Chow, Ka Ming
   Liang, Wei
TI Effects of non-pharmacological interventions on preoperative anxiety and postoperative pain in patients undergoing breast cancer surgery: A systematic review
SO JOURNAL OF CLINICAL NURSING
LA English
DT Review
DE anxiety; breast cancer surgery; non&#8208; medicine; non&#8208; pharmacological; pain
ID clinical-practice guideline; persistent pain; music-therapy; management; women; aromatherapy; anesthesia; society; impact; trial
AB Background Poorly managed preoperative anxiety and pain were reported to slow the postoperative recovery of breast cancer patients. Thus, proactive management using non-pharmacological interventions becomes essential for decreasing opioid or anxiolytics consumption, anxiety level, pain intensity, postoperative complications and improving patients' haemodynamics and satisfaction with care. Purpose To identify, analyse and synthesise the effects of non-pharmacological interventions on preoperative anxiety and acute postoperative pain in women undergoing breast cancer surgery. Method For this systematic review, 12 databases including Ovid Nursing, PsycInfo, British Nursing Index, CINAHL, Cochrane Library were searched to identify relevant studies. A total of 6,012 articles were identified from the search, six RCTs and one quasi-experimental study that met the inclusion criteria were included after eligibility screening. Narrative synthesis was used to analyse data extracted from the included articles. The review adhered to the PRISMA guideline. Results Twelve outcomes were measured in the included studies, including preoperative anxiety, and acute postoperative pain. Music, massage, aromatherapy and acupuncture were the interventions delivered. Music had a small-to-large effect size and aromatherapy had a small effect size on reducing preoperative anxiety. Also, music had a large effect size whilst acupuncture had a medium effect size on minimising postoperative pain in women undergoing breast cancer surgery. Conclusion Music, aromatherapy and acupuncture appeared to be effective for reducing preoperative anxiety and postoperative pain in women undergoing breast cancer surgery. However, the small number of studies available for each intervention prevents conclusive statements about which the most effective method. Implication for clinical practice A nursing care pathway that standardises the use of non-pharmacological interventions for the management of both preoperative anxiety and postoperative pain in breast cancer surgery patients should be developed.
C1 [Tola, Yetunde Oluwafunmilayo; Liang, Wei] Chinese Univ Hong Kong, Nethersole Sch Nursing, Hong Kong, Peoples R China.
   [Tola, Yetunde Oluwafunmilayo; Chow, Ka Ming] Inst Nursing Res, Osogbo, Nigeria.
C3 Chinese University of Hong Kong
RP Chow, KM (corresponding author), Chinese Univ Hong Kong, Nethersole Sch Nursing, Fac Med, 829 Esther Lee Bldg, Hong Kong, Peoples R China.
EM kmchow@cuhk.edu.hk
CR Anagnostopoulos Fotios, 2015, ENCYCLOPEDIA OF QUALITY OF LIFE AND WELL-BEING RESEARCH AND WELL-BEING RESEARCH, V141, P3855, DOI 10.1007/978-94-007-0753-5
   Andersen KG, 2015, PAIN, V156, P2413, DOI 10.1097/j.pain.0000000000000298
   Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005
   Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Unknown -, 2018, 2018 MID-YEAR REPORT, V0, P1
   Best JT, 2018, J PERIANESTH NURS, V33, P453, DOI 10.1016/j.jopan.2016.02.014
   Beyliklioglu A, 2019, J PERIANESTH NURS, V34, P587, DOI 10.1016/j.jopan.2018.10.002
   Binns-Turner Pamela G, 2011, AANA J, V79, P0
   Bradt J, 2013, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006908.pub2
   Bruce J, 2014, PAIN, V155, P232, DOI 10.1016/j.pain.2013.09.028
   Chen HN, 2010, COMMUN STAT-SIMUL C, V39, P860, DOI 10.1080/03610911003650383
   Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008
   Dion LJ, 2016, COMPLEMENT THER CLIN, V23, P82, DOI 10.1016/j.ctcp.2015.04.005
   Donelli D, 2019, PHYTOMEDICINE, V65, P0, DOI 10.1016/j.phymed.2019.153099
   Evans H, 2019, IRIS JOURNAL OF NURSING & CARE, V1, P0, DOI 10.33552/ijnc.2019.01.000512
   Fayazi Sadigheh, 2011, IRAN J NURS MIDWIFERY RES, V16, P278
   Franco L, 2016, J CLIN ANESTH, V33, P243, DOI 10.1016/j.jclinane.2016.02.032
   Goulet-Pelletier JC, 2018, QUANT METH PSYCHOL, V14, P242, DOI 10.20982/tqmp.14.4.p242
   Haun M, 2001, BEHAV MED, V27, P127, DOI 10.1080/08964280109595779
   Kayode Kayode KK, 2018, ACADEMIA, V4 4, P1
   Kühlmann AYR, 2018, BJS-BRIT J SURG, V105, P773, DOI 10.1002/bjs.10853
   Kulkarni AR, 2021, JPRAS OPEN, V30, P170, DOI 10.1016/j.jpra.2016.08.005
   Larsson IM, 2017, BREAST J, V23, P338, DOI 10.1111/tbj.12739
   Lee Jin-Hyung, 2015, THE EFFECTS OF MUSIC ON PAIN: A REVIEW OF SYSTEMATIC REVIEWS AND META-ANALYSIS, V0, P0
   Li XM, 2011, BREAST CANCER RES TR, V128, P411, DOI 10.1007/s10549-011-1533-z
   Liu Y, 2015, COMPLEMENT THER MED, V23, P714, DOI 10.1016/j.ctim.2015.08.002
   Loukas M, 2011, AM SURGEON, V77, P566
   Luan RL, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000015923
   McLeod SA, 2017, WHAT DOES EFFECT SIZ, V0, P0
   Nilsson Ulrica, 2008, AORN J, V87, P780, DOI 10.1016/j.aorn.2007.09.013
   Odejobi YO, 2019, INT NURS REV, V66, P434, DOI 10.1111/inr.12515
   Öztürk R, 2018, COMPLEMENT THER MED, V36, P107, DOI 10.1016/j.ctim.2017.12.005
   Paice JA, 2016, J ONCOL PRACT, V12, P757, DOI 10.1200/JOP.2016.014837
   Palmer JB, 2015, J CLIN ONCOL, V33, P3162, DOI 10.1200/JCO.2014.59.6049
   Polit DF, 2012, NURSING RESEARCH: GENERATING AND ASSESSING EVIDENCE FOR NURSING RESEARCH, V9th, P0, DOI 10.1097/00003465-199201000-00015
   Poulsen MJ, 2018, PAIN MANAG NURS, V19, P172, DOI 10.1016/j.pmn.2017.09.003
   Quinlan-Woodward J, 2016, ONCOL NURS FORUM, V43, P725, DOI 10.1188/16.ONF.725-732
   Robb SL, 2011, J HEALTH PSYCHOL, V16, P342, DOI 10.1177/1359105310374781
   Runowicz CD, 2016, J CLIN ONCOL, V34, P611, DOI 10.1200/JCO.2015.64.3809
   Schreiber KL, 2014, PAIN MANAG, V4, P445, DOI 10.2217/PMT.14.33
   Schreiber KL, 2013, PAIN, V154, P660, DOI 10.1016/j.pain.2012.11.015
   Sin WM, 2015, PAIN MANAG NURS, V16, P978, DOI 10.1016/j.pmn.2015.06.008
   Stamenkovic DM, 2018, MINERVA ANESTESIOL, V84, P1307, DOI 10.23736/S0375-9393.18.12520-X
   Tamaki K, 2017, BREAST CANCER RES TR, V162, P523, DOI 10.1007/s10549-017-4134-7
   Tufanaru C, 2017, JBI MANUAL EVIDENCE, V0, P0, DOI DOI 10.46658/JBIMES-20-04
   Ucuzal M, 2014, PAIN MANAG NURS, V15, P458, DOI 10.1016/j.pmn.2012.03.001
   Yinger OS, 2015, J MUSIC THER, V52, P1, DOI 10.1093/jmt/thv004
   Zhou KN, 2015, EUR J ONCOL NURS, V19, P54, DOI 10.1016/j.ejon.2014.07.010
NR 48
TC 74
Z9 98
U1 5
U2 53
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0962-1067
EI 1365-2702
J9 J CLIN NURS
JI J. Clin. Nurs.
PD DEC 15
PY 2021
VL 30
IS 23-24
BP 3369
EP 3384
DI 10.1111/jocn.15827
EA MAY 2021
PG 16
WC Nursing
SC Nursing
GA XE8JO
UT WOS:000646404000001
PM 33942405
DA 2026-01-16
ER

PT J
AU Berliere, M
   Piette, N
   Bernard, M
   Lacroix, C
   Gerday, A
   Samartzi, V
   Coyette, M
   Roelants, F
   Docquier, MA
   Touil, N
   Watremez, C
   Piette, P
   Duhoux, FP
AF Berliere, Martine
   Piette, Nathan
   Bernard, Marion
   Lacroix, Camille
   Gerday, Amandine
   Samartzi, Vasiliki
   Coyette, Maude
   Roelants, Fabienne
   Docquier, Marie-Agnes
   Touil, Nassim
   Watremez, Christine
   Piette, Philippe
   Duhoux, Francois P.
TI Hypnosis Sedation Reduces the Duration of Different Side Effects of Cancer Treatments in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
SO CANCERS
LA English
DT Article
DE polyneuropathy; postoperative pain; musculoskeletal pain; cancer-related fatigue; neoadjuvant chemotherapy; hypnosis sedation
ID induced peripheral neuropathy; quality-of-life; persistent pain; risk-factors; fatigue; inflammation; prevalence; surgery; acupuncture; predictors
AB Simple Summary Reducing side effects of cancer treatments is a major challenge for clinicians involved in the management of breast cancer patients. Among patients receiving neoadjuvant chemotherapy followed by surgery, radiotherapy and endocrine therapy, prolonged side effects frequently mentioned are: polyneuropathy, musculoskeletal pain, postoperative pain and cancer-related fatigue. Conventional drugs have proven to be ineffective in treating theses effects, except for postoperative pain. This is the reason why we prospectively tested the impact of hypnosis sedation used as anesthetic technique for breast cancer surgery on the different side effects of cancer treatment. Despite the limitations of this small non-randomized cohort, preliminary results are very encouraging. Background: Reducing side effects of cancer treatments is a major challenge for clinicians involved in the management of breast cancer patients. Methods: We analyzed data from 63 patients (32 in the general anesthesia group and 31 in the hypnosis sedation group) who were included in 1 prospective non-randomized trial evaluating hypnosis sedation in breast cancer treatment. The patients were followed every 3 months for 2 years. All patients received neoadjuvant chemotherapy with 4 cycles of epirubicin and cyclophosphamide followed by taxanes. Thereafter, patients underwent surgery while on general anesthesia or while on hypnosis sedation. Radiotherapy was administered according to institutional guidelines. Endocrine therapy was prescribed if tumors expressed hormone receptors. Prevalence, intensity and duration of polyneuropathy, musculoskeletal pain, postoperative pain and cancer-related fatigue were assessed at each medical visit. Results: Symptoms duration was statistically reduced for polyneuropathy (p < 0.05), musculoskeletal pain (p < 0.05) postoperative pain and cancer-related fatigue (p < 0.05) in the hypnosis group. Conclusion: Despite the limitations of this study (lack of randomization and small size) we conclude that hypnosis sedation may exert a role on different side effects of breast cancer treatment in patients receiving neoadjuvant chemotherapy, mainly by reducing their duration.
C1 [Berliere, Martine; Bernard, Marion; Lacroix, Camille; Gerday, Amandine; Coyette, Maude; Duhoux, Francois P.] Clin Univ St Luc, King Albert II Canc Inst, Breast Clin, B-1200 Woluwe St Lambert, Belgium.
   [Piette, Nathan] Clin St Pierre, Dept Oncol, B-1340 Ottignies, Belgium.
   [Samartzi, Vasiliki] Hop Jolimont, Dept Gynaecol, B-7100 La Louviere, Belgium.
   [Roelants, Fabienne; Docquier, Marie-Agnes; Touil, Nassim; Watremez, Christine] Catholic Univ Louvain, Clin Univ St Luc, Dept Anesthesiol, B-1340 Ottignies, Belgium.
   [Piette, Philippe] Grand Hop Charleroi, Med & Financial Dept, B-6000 Charleroi, Belgium.
C3 Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Groupe Jolimont; Universite Catholique Louvain; Grand Hopital De Charleroi
RP Berliere, M (corresponding author), Clin Univ St Luc, King Albert II Canc Inst, Breast Clin, B-1200 Woluwe St Lambert, Belgium.
EM martine.berliere@uclouvain.be; nathan.piette@student.uclouvain.be; marion.bernard@student.uclouvain.be; camille.lacroix@student.uclouvain.be; amandine.gerday@uclouvain.be; vassiliki.samartzi@jolimont.be; maude.coyette@uclouvain.be; fabienne.roelants@uclouvain.be; marie-agnes.docquier@uclouvain.be; nassim.touil@uclouvain.be; christine.watremez@uclouvain.be; Philippe.piette@ghdc.be; francois.duhoux@uclouvain.be
FU [2017-034]
CR Andersen KG, 2011, J PAIN, V12, P725, DOI 10.1016/j.jpain.2010.12.005
   Unknown -, 2013, R: A LANGUAGE AND ENVIRONMENT FOR STATISTICAL COMPUTING, V0, P0, DOI DOI 10.3389/FMED.2020.558696
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Berger AM, 2015, J NATL COMPR CANC NE, V13, P1012, DOI 10.6004/jnccn.2015.0122
   Berger AM, 2015, CA-CANCER J CLIN, V65, P190, DOI 10.3322/caac.21268
   Berlière M, 2018, BREAST, V37, P114, DOI 10.1016/j.breast.2017.10.017
   Berliere M, 2019, MECH INVOLVED HYPNOS, V79, P0
   Bower JE, 2007, BRAIN BEHAV IMMUN, V21, P863, DOI 10.1016/j.bbi.2007.03.013
   Ciruelos E, 2019, ONCOLOGIST, V24, PE1024, DOI 10.1634/theoncologist.2017-0664
   Cramer H, 2015, INTEGR CANCER THER, V14, P5, DOI 10.1177/1534735414550035
   Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105
   Defechereux T, 2000, ANN CHIR, V125, P539, DOI 10.1016/S0003-3944(00)00238-8
   Diakos CI, 2014, LANCET ONCOL, V15, PE493, DOI 10.1016/S1470-2045(14)70263-3
   Donovan KA, 2013, PSYCHO-ONCOLOGY, V22, P737, DOI 10.1002/pon.3085
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Fabi A, 2020, ANN ONCOL, V31, P713, DOI 10.1016/j.annonc.2020.02.016
   Faller H, 2013, J CLIN ONCOL, V31, P782, DOI 10.1200/JCO.2011.40.8922
   Forget P, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9123831
   Gärtner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568
   Gewandter JS, 2020, SUPPORT CARE CANCER, V28, P2553, DOI 10.1007/s00520-019-05063-x
   Goedendorp MM, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD006953.pub2
   Gorin SS, 2012, J CLIN ONCOL, V30, P539, DOI 10.1200/JCO.2011.37.0437
   Grégoire C, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-4607-z
   Guarino A, 2020, J CLIN MED, V9, P0, DOI 10.3390/jcm9010209
   Hammond DC, 2010, EXPERT REV NEUROTHER, V10, P263, DOI 10.1586/ERN.09.140
   Hamood R, 2018, BREAST CANCER RES TR, V167, P157, DOI 10.1007/s10549-017-4485-0
   Hurtz HJ, 2017, BREAST CANCER RES TR, V165, P721, DOI 10.1007/s10549-017-4365-7
   Ilhan E, 2017, PAIN, V158, P2082, DOI 10.1097/j.pain.0000000000001004
   Jensen MP, 2010, PAIN MED, V11, P1099, DOI 10.1111/j.1526-4637.2010.00880.x
   Jensen MP, 2005, INT J CLIN EXP HYP, V53, P198, DOI 10.1080/00207140590927545
   Johannsen M, 2013, BREAST CANCER RES TR, V138, P675, DOI 10.1007/s10549-013-2503-4
   Jordan B, 2019, BREAST CARE, V14, P79, DOI 10.1159/000499599
   Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X
   Lacroix C, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419869494
   Laird BJ, 2013, ONCOLOGIST, V18, P1050, DOI 10.1634/theoncologist.2013-0120
   Lancaster RB, 2016, CURR SURG REP, V4, P0, DOI 10.1007/s40137-016-0133-6
   Liampas A, 2021, PAIN THER, V10, P55, DOI 10.1007/s40122-020-00210-3
   Malik UR, 2001, CANCER, V92, P1664, DOI 10.1002/1097-0142(20010915)92:6+<1664::AID-CNCR1494>3.0.CO;2-9
   Meretoja TJ, 2017, J CLIN ONCOL, V35, P1660, DOI 10.1200/JCO.2016.70.3413
   Molassiotis A, 2013, ANN ONCOL, V24, P1645, DOI 10.1093/annonc/mdt034
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Montgomery GH, 2002, INT J CLIN EXP HYP, V50, P17, DOI 10.1080/00207140208410088
   Montgomery GH, 2002, ANESTH ANALG, V94, P1639, DOI 10.1097/00000539-200206000-00052
   Montgomery GH, 2007, JNCI-J NATL CANCER I, V99, P1304, DOI 10.1093/jnci/djm106
   Montgomery GH, 2009, HEALTH PSYCHOL, V28, P317, DOI 10.1037/a0013582
   Munn LL, 2017, WIRES SYST BIOL MED, V9, P0, DOI 10.1002/wsbm.1370
   Niravath P, 2013, ANN ONCOL, V24, P1443, DOI 10.1093/annonc/mdt037
   Fabro EAN, 2012, BREAST, V21, P321, DOI 10.1016/j.breast.2012.01.019
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Swain Sandra M, 2008, CLIN ADV HEMATOL ONCOL, V6, P455
   Syrjala KL, 2014, J CLIN ONCOL, V32, P1703, DOI 10.1200/JCO.2013.54.4825
   Wang L, 2016, CAN MED ASSOC J, V188, PE352, DOI 10.1503/cmaj.151276
NR 57
TC 11
Z9 12
U1 0
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG 15
PY 2021
VL 13
IS 16
BP 
EP 
DI 10.3390/cancers13164147
PG 14
WC Oncology
SC Oncology
GA UF8ZE
UT WOS:000688855600001
PM 34439301
DA 2026-01-16
ER

PT J
AU Zhang, J
   Yang, M
   So, TH
   Chang, TY
   Qin, Z
   Chen, H
   Lam, WL
   Yeung, WF
   Chung, KF
   Jiang, F
   Lao, L
   Zhang, ZJ
AF Zhang, Jialing
   Yang, Mingxiao
   So, Tsz Him
   Chang, Tien Yee
   Qin, Zongshi
   Chen, Haiyong
   Lam, Wing Lok
   Yeung, Wing Fai
   Chung, Ka Fai
   Jiang, Fei
   Lao, Lixing
   Zhang, Zhang-Jin
TI Electroacupuncture Plus Auricular Acupressure on Chemotherapy-Related Insomnia in
SO Integrative cancer therapies
LA English
DT Journal Article
DE auricular acupressure; breast cancer; chemotherapy; electroacupuncture; insomnia; sham control
AB OBJECTIVE: Insomnia is a highly prevalent and disturbing symptom in breast cancer  patients under or post chemotherapy. If not appropriately treated, it can persist  for years after the completion of cancer treatments. Acupuncture has been widely  used for alleviating insomnia. The aim of this study is to examine the  feasibility, efficacy and safety of acupuncture for chemotherapy-related insomnia  among patients with breast cancer. MATERIALS AND METHODS: This is a trial  protocol for a randomized, sham-controlled, subject- and assessor-blinded  clinical trial. A total of 138 eligible participants will be assigned randomly to  acupuncture or sham control group at a ratio of 1:1. Participants in acupuncture  group will receive electroacupuncture (EA) plus auricular acupressure (AA)  treatment, while subjects in sham acupuncture group will receive sham EA plus  sham AA. Both acupuncture and sham treatments will be given twice weekly for  6 weeks, followed by maintenance treatments once every 4 weeks for 12 weeks (15  sessions totally). The primary outcome is the change of Insomnia Severity Index  score between baseline and the end of 6-week treatment. Secondary outcome  measurements include Actiwatch, sleep diary, Pittsburgh Sleep Quality Index,  Functional Assessment of Cancer Therapy-Breast Cancer, Hospital Anxiety and  Depression Scale, Brief Pain Inventory-Short Form, Brief Fatigue Inventory,  Acupuncture Expectancy Scale, credibility, and adverse events. Participants will  be followed up to 42 weeks. CONCLUSIONS: This trial will expand our understanding  of the feasibility, efficacy, and safety of acupuncture as a treatment for  alleviating chemotherapy-related insomnia in patients with breast cancer. EA plus  AA, if proven to be effective, can be implemented into routine settings to play a  role in insomnia management for patients with breast cancer.
C1 Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital (HKU-SZH), Shenzhen, Guangdong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, 
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Clinical Oncology, Hong Kong Sanatorium Hospital, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China.
   Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
   Virginia University of Integrative Medicine, Fairfax, Virginia, USA.
   Department of Chinese Medicine, The University of Hong Kong-Shenzhen Hospital (HKU-SZH), Shenzhen, Guangdong, China.
   School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong,
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD NOV 23
PY 2021
VL 20
IS 
BP 15347354211058695
EP 15347354211058695
DI 10.1177/15347354211058695
PG 1
WC Acupressure; Acupuncture Therapy; Breast Neoplasms; drug therapy; Electroacupuncture; Female; Humans; Randomized Controlled Trials as Topic; Sleep Initiation and Maintenance Disorders; chemically induced; Sleep Quality; Treatment Outcome
UT PubMed:34802291
PM 34802291
DA 2021-11-23
ER

PT J
AU Narayanan, S
   Reddy, A
   Lopez, G
   Liu, W
   Ali, S
   Bruera, E
   Cohen, L
   Yennurajalingam, S
AF Narayanan, Santhosshi
   Reddy, Akhila
   Lopez, Gabriel
   Liu, Wenli
   Ali, Sara
   Bruera, Eduardo
   Cohen, Lorenzo
   Yennurajalingam, Sriram
TI Sleep disturbance in cancer patients referred to an ambulatory integrative
SO Supportive care in cancer : official journal of the Multinational Association of
LA English
DT Journal Article
DE Complementary medicine; Insomnia; Integrative oncology; Patient-reported outcomes; Sleep disturbance
AB BACKGROUND: Sleep disturbance (SD) is highly prevalent in oncology and negatively  affects quality of life and mortality. Evidence supports the use of integrative  oncology (IO) practices to treat SD, but there is limited published data on the  characteristics of SD and factors associated with SD in IO. We determined the  prevalence, severity, and factors associated with SD among cancer patients seen  in an ambulatory IO consultation. METHODS: Patients with cancer referred for  initial outpatient IO consultation in 2017 were eligible. Patient demographics,  clinical characteristics, and patient-reported outcomes (Edmonton Symptom  Assessment Scale (ESAS), Measure Yourself Concerns and Wellbeing (MYCaW),  PROMIS-10) were retrospectively reviewed. RESULTS: One thousand five hundred  twenty patients were included in the analysis. The majority (70%) were women with  breast cancer (42%). Nine hundred seventy-one (64%) patients reported significant  SD with ESAS Sleep ≥ 4, yet only 11% expressed poor sleep as their primary or  secondary concern for the IO consultation. The median SD (IQR) was 5 (3,7). ESAS  scores for fatigue (adjusted OR 1.16; CI 1.07-1.26, p < 0.001), pain (adjusted OR  1.07; CI 1.00-1.15, p < 0.05), hot flashes (adjusted OR 1.14; CI 1.07-1.22,  p < 0.001), well-being (adjusted OR 1.33; CI 1.22-1.46, p < 0.001), and  psychological distress score (anxiety and depression) (adjusted OR 1.16; CI  1.01-1.11, p < 0.01) were independently associated with SD in multivariate  analysis. Acupuncture was the most frequent intervention prescribed, 175 (35%).  Other modalities included oncology massage (15%), health psychology (5%), and  meditation (1%). CONCLUSIONS: Although 64% of patients seeking IO consultation  reported clinically significant SD, only 11% were seeking integrative approaches  for managing SD. ESAS fatigue, hot flashes, well-being, and psychological  symptoms were significantly associated with SD.
C1 Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA. snarayanan2@mdanderson.org.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
   Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer, Unit 1414, 1515 Holcombe Blvd., Houston,TX, 77030, USA.
NR 0
TC 0
SN 1433-733
EI 
J9 Support Care Cancer
PD NOV 12
PY 2021
VL 30
IS 3
BP 2417
EP 2425
DI 10.1007/s00520-021-06668-x
PG 8
WC Breast Neoplasms; Female; Humans; Integrative Oncology; Male; Neoplasms; complications; Quality of Life; Referral and Consultation; Retrospective Studies; Sleep
UT PubMed:34762218
PM 34762218
DA 2021-11-12
ER

PT J
AU Tack, L
   Lefebvre, T
   Blieck, V
   Cool, L
   Pottel, H
   Eygen, KV
   Derijcke, S
   Vergauwe, P
   Schofield, P
   Chandler, R
   Lane, P
   Boterberg, T
   Debruyne, PR
AF Tack, Laura
   Lefebvre, Tessa
   Blieck, Virginie
   Cool, Lieselot
   Pottel, Hans
   Eygen, Koen Van
   Derijcke, Sofie
   Vergauwe, Philippe
   Schofield, Patricia
   Chandler, Rebecca
   Lane, Pauline
   Boterberg, Tom
   Debruyne, Philip R
TI Acupuncture as a Complementary Therapy for Cancer Care: Acceptability and
SO Journal of acupuncture and meridian studies
LA English
DT Journal Article
DE Acupuncture; Cancer; Cancerrelated side effect; Complementary therapy; Informal caregiver
AB BACKGROUND: Acupuncture can effectively manage cancer-related side effects, for  both patients undergoing treatment and for cancer survivors. It may also be  effective in managing physiological and psychological symptoms common among  informal caregivers of cancer patients. OBJECTIVES: The aim of this survey was to  explore the acceptability and preferences of cancer patients, cancer survivors,  and their informal caregivers in relation to acupuncture. METHODS: The survey was  conducted from 20(th) November to 27(th) November 2018. The questionnaire was  developed to explore acceptability and preferences, including motivation,  symptoms to be addressed, and practical issues (location, cost, etc.), in  relation to acupuncture. RESULTS: The survey response rate was 94.5% in cancer  patients and cancer survivors and 100% in caregivers. Acceptability of  acupuncture was 34.5% (n = 40/116) and 48.0% (n = 26/54) in cancer patients and  caregivers, respectively. About 52.5% (n = 21/40) of patients preferred to  undergo acupuncture at the day center clinic, whereas caregivers had no specific  preference. Patients and cancer survivors would use acupuncture for symptoms of  fatigue (60%), listlessness (57.5%), and pain (47.5%). Informal caregivers  expressed an interest in using acupuncture for their pain, stress, and sleeping  difficulties 48.0% (n = 26/54). CONCLUSION: Cancer patients, cancer survivors,  and informal caregivers would accept acupuncture as a complementary therapy. This  openness and preference to acupuncture provide the foundations for this  complementary therapy to be incorporated into holistic and supportive cancer  care, both for patients and those supporting them.
C1 Department of Medical Oncology, Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
   Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
   Department of Medical Oncology, Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
   Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
   College for Traditional Chinese Medicine & Karel de Grote University College, Antwerp, Belgium.
   Department of Medical Oncology, Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
   Department of Public Health and Primary Care at Kulak, Catholic University Leuven Kulak, Kortrijk, Belgium.
   Department of Haematology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
   Department of Pneumology, General Hospital Groeninge, Kortrijk, Belgium.
   Department of Gastro-Enterology, General Hospital Groeninge, Kortrijk, Belgium.
   Sheffield Hallam University, Sheffield, United Kingdom.
   Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Chelmsford, United Kingdom.
   Faculty of Health, Education, Medicine and Social Care, Anglia Ruskin University, Chelmsford, United Kingdom.
   Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
   Department of Medical Oncology, Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium.
   School of Life Sciences, Anglia Ruskin University, Cambridge, United Kingdom.
NR 0
TC 0
SN 2093-815
EI 
J9 J Acupunct Meridian Stud
PD APR 30
PY 2021
VL 14
IS 2
BP 67
EP 74
DI 10.51507/j.jams.2021.14.2.67
PG 7
WC Acupuncture Therapy; Caregivers; psychology; Humans; Neoplasms; therapy; Pain; Surveys and Questionnaires
UT PubMed:35770541
PM 35770541
DA 2021-04-30
ER

PT J
AU Ho, EY
   Thompson-Lastad, A
   Lam, R
   Zhang, X
   Thompson, N
   Chao, MT
AF Ho, Evelyn Y
   Thompson-Lastad, Ariana
   Lam, Rachele
   Zhang, Xiaoyu
   Thompson, Nicole
   Chao, Maria T
TI Adaptations to Acupuncture and Pain Counseling Implementation in a Multisite
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture; cancer; implementation; inpatient; pain; pragmatic effectiveness
AB Objectives: As part of a pragmatic effectiveness trial of integrative pain  management among inpatients with cancer, the authors sought to understand the  clinical context and adaptations to implementation of two study interventions,  acupuncture and pain counseling (i.e., pain education and coping skills). Design:  The larger study uses a 2 × 2 factorial design with inpatients randomized to: (1)  usual care (UC), (2) UC with acupuncture, (3) UC with pain counseling, and (4) UC  with acupuncture and pain counseling. The study is being conducted in two  hospitals (one academic and one public) and three languages (Cantonese, English,  and Spanish). The authors conducted a process evaluation by interviewing study  interventionists. Analysis included deductive coding to describe context,  intervention, implementation, and inductive thematic coding related to  intervention delivery. Results: Interviewees included seven acupuncturists and  four pain counselors. Qualitative themes covered adaptations and recognizing  site-specific differences that affected implementation. Interventionists adhered  closely to protocols and made patient-centered adaptations that were then  standardized in broader implementation (e.g., including caregivers in pain  counseling sessions; working in culturally nuanced ways with non-English-speaking  patients). The public hospital included more patients with recent diagnoses and  advanced disease, more ethnically and linguistically diverse patients, less  continuity of staffing, and shared patient rooms. At the academic medical center,  more patients were familiar with integrative therapies and all were located in  single rooms. Providing acupuncture to hospital staff was a key strategy to  establish trust, experientially explain the intervention, and create camaraderie  and staff buy-in. Conclusions: Providing nonpharmacologic interventions for a  pragmatic trial requires adapting to a range of clinical factors. Site-specific  factors included greater coordination and resources needed for successful  implementation in the public hospital. The authors conclude that adaptation to  context and individual patient needs can be done without compromising  intervention fidelity and that intervention design should apply principles such  as centering at the margins to reduce participation barriers for diverse patient  populations.
C1 Department of Communication Studies, University of San Francisco, San Francisco, CA, USA.
   Asian American Research Center on Health and University of California, San 
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
   Department of Family and Community Medicine and Division of General Internal 
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, USA.
   Department of Medicine, Division of General Internal Medicine at Zuckerberg San
NR 0
TC 0
SN 1557-770
EI 1075-553
J9 J Altern Complement Med
PD APR 28
PY 2021
VL 27
IS 5
BP 398
EP 406
DI 10.1089/acm.2020.0387
PG 8
WC Acupuncture Therapy; Adult; Cancer Pain; therapy; Counseling; Female; Humans; Integrative Medicine; Male; Middle Aged; Pain Management; Qualitative Research; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult
UT PubMed:33902333
PM 33902333
DA 2021-04-28
ER

PT J
AU Zhi, WI
   Gentile, D
   Diller, M
   Kinney, A
   Bao, T
   Master, V
   Wang, XS
AF Zhi, W. Iris
   Gentile, Danielle
   Diller, Maggie
   Kinney, Anita
   Bao, Ting
   Master, Viraj
   Wang, Xin Shelley
TI Patient-Reported Outcomes of Pain and Related Symptoms in Integrative Oncology Practice and Clinical Research: Evidence and Recommendations
SO ONCOLOGY-NEW YORK
LA English
DT Review
AB Pain is a primary concern among patients with cancer and cancer survivors. Integrative interventions such as acupuncture, massage, and music therapy are effective nonpharmacologic approaches for cancer pain with low cost and minimal adverse events. Patient-reported outcomes (PROs) that have been validated in many clinical and research settings can be used to evaluate pain intensity, associated symptom burden, and quality of life. Clearly defined, reliable PROs can improve patient satisfaction and symptom control. As integrative oncology continues to evolve and expand, cancer-related pain PROs must be standardized to accurately guide clinicians and researchers. Well-validated pain PROs, such as the Brief Pain Inventory, are among the most commonly used for pain intensity assessment. Multiple symptom assessment tools such as the MD Anderson Symptom Inventory, the Memorial Symptom Assessment Scale, the Edmonton Symptom Assessment System, and the Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events measurement system can also capture pain-associated symptom burden. Electronic PROs provide flexibility in collecting and analyzing PRO data. Clinical trials using carefully selected PROs and rigorous statistical analysis plans are fundamental to conducting high-quality integrative oncology research and promoting utilization of effective integrative interventions to improve patient outcomes. In this review, we aim to summarize current, validated PROs specific to cancer-related pain to aid integrative oncology clinicians and researchers in patient care and in study design and implementation.
C1 [Zhi, W. Iris] Mem Sloan Kettering Canc Ctr, Solid Tumor Div, Breast Med Serv, 1275 York Ave, New York, NY 10021 USA.
   [Gentile, Danielle] Levine Canc Inst, Dept Support Oncol, Med, Charlotte, NC USA.
   [Diller, Maggie] Emory Univ, Winship Canc Inst, Dept Surg, Atlanta, GA 30322 USA.
   [Kinney, Anita] Sch Publ Hlth, Dept Biostat & Epidemiol, New Brunswick, NJ USA.
   [Kinney, Anita] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
   [Bao, Ting] Mem Sloan Kettering Canc Ctr, Integrat Breast Oncol Integrat Med & Breast Med S, 1275 York Ave, New York, NY 10021 USA.
   [Wang, Xin Shelley] Univ Texas MD Anderson Canc Ctr, Dept Symptom Res, Houston, TX 77030 USA.
   [Master, Viraj] Emory Univ, Sch Med, Winship Canc Inst, Integrat Oncol & Survivorship, Atlanta, GA 30322 USA.
C3 Memorial Sloan Kettering Cancer Center; Emory University; Rutgers University System; Rutgers University New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers Cancer Institute of New Jersey; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Emory University
RP Zhi, WI (corresponding author), Mem Sloan Kettering Canc Ctr, Solid Tumor Div, Breast Med Serv, 1275 York Ave, New York, NY 10021 USA.
CR Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cleeland C S, 1987, ONCOLOGY (WILLISTON PARK), V1, P19
   Cleeland CS, 2013, CANCER-AM CANCER SOC, V119, P4333, DOI 10.1002/cncr.28376
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Dowell Deborah, 2016, JAMA, V315, P1624, DOI 10.15585/mmwr.rr6501e1
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Gallagher LM, 2018, AM J HOSP PALLIAT ME, V35, P250, DOI 10.1177/1049909117696723
   Inst Med, 2011, RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, V0, P0
   Jemal A, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Lee SH, 2015, INTEGR CANCER THER, V14, P297, DOI 10.1177/1534735415572885
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Porta-Sales J, 2015, J PALLIAT MED, V18, P923, DOI 10.1089/jpm.2015.29002.jps
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
NR 15
TC 16
Z9 18
U1 1
U2 17
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
EI 2767-7389
J9 ONCOLOGY-NY
JI Oncology-NY
PD JAN 15
PY 2021
VL 35
IS 1
BP 35
EP 41
DI 
PG 7
WC Oncology
SC Oncology
GA PT5XQ
UT WOS:000608688400012
PM 33443769
DA 2026-01-16
ER

PT J
AU Ji, JF
   Ge, XX
   Xu, CM
   Jiang, Y
   Gu, JH
   Wei, GH
   Gu, JS
   Shi, YJ
   Ni, XJ
AF Ji, Jin-Feng
   Ge, Xiao-Xia
   Xu, Chun-Ming
   Jiang, Yang
   Gu, Jun-Hong
   Wei, Guo-Hua
   Gu, Ji-Shu
   Shi, Yong-Jie
   Ni, Xue-Jiao
TI [Intradermal needling combined with heat-sensitive moxibustion for moderate to
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE cancer pain; heat-sensitive moxibustion; intradermal needling; three-step analgesic method
AB OBJECTIVE: To observe the effect of intradermal needling combined with  heat-sensitive moxibustion for moderate to severe cancer pain. METHODS: A total  of 60 patients with moderate to severe cancer pain were randomly divided into an  observation group and a control group，30 cases in each one. In the control  group，opioids were taken to relief pain according to the three-step analgesic  method of World Health Organization. On the base of the treatment as the control  group, intradermal needling combined with heat-sensitive moxibustion were applied  at Neiguan (PC 6), Hegu (LI 4), Zusanli (ST 36), Taichong (LR 3), etc. in the  observation group, 14 days of treatment were required. The equivalent morphine  consumption at the first day and whole course, the scores of cancer quality of  life questionnaire-C30 (QLQ-C30) and Hamilton anxiety scale before and after  treatment, and the adverse reaction rate were compared in the two groups. The  total analgesic effective rate was evaluated. RESULTS: The total analgesic  effective rate was 93.3% (28/30) in the observation group, higher than 73.3%  (22/30) in the control group (P<0.05). The total equivalent morphine consumption  in the observation group was less than the control group (P<0.05). After  treatment, the QLQ-C30 scores were increased (P<0.001) and the HAMA scores were  decreased (P<0.001) in the both groups, and those in the observation group were  superior to the control group (P<0.001). The adverse reaction rates of fatigue,  dizziness, nausea and vomiting, constipation in the observation group were lower  than the control group (P<0.05). CONCLUSION: Intradermal needling combined with  heat-sensitive moxibustion can reduce the dose of opioids, improve the quality of  life, relief the anxiety in patients with moderate to severe cancer pain, and  reduce the incidence of common adverse reaction of opioids.
C1 Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Acupuncture and Moxibustion, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
   Department of Oncology of Integrated Chinese and Western Medicine, Jiangsu Tumor Hospital Affiliated to Nantong University, Nantong 226001, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD JUL 15
PY 2021
VL 41
IS 7
BP 725
EP 9
DI 10.13703/j.0255-2930.20200615-k0002
PG -716
WC Acupuncture Points; Cancer Pain; therapy; Hot Temperature; Humans; Moxibustion; Neoplasms; complications; Pain; Quality of Life; Treatment Outcome
UT PubMed:34259402
PM 34259402
DA 2021-07-15
ER

PT J
AU Han, QQ
   Fu, Y
   Le, JM
   Ma, YJ
   Wei, XD
   Ji, HL
   Jiang, HC
   Gao, YQ
   Wu, HL
AF Han, Qiu-Qin
   Fu, Yi
   Le, Jia-Mei
   Ma, Yu-Jie
   Wei, Xin-Dong
   Ji, Hou-Lin
   Jiang, Haochen
   Gao, Yueqiu
   Wu, Hailong
TI The Therapeutic Effects of Acupuncture and Electro-acupuncture on Cancer-related Symptoms and Side-Effects
SO JOURNAL OF CANCER
LA English
DT Review
DE acupuncture; electroacupuncture; cancer; surgery; chemotherapy; pain
ID chemotherapy-induced nausea; quality-of-life; inhibitor-related arthralgia; breast-cancer; psychological distress; pediatric oncology; double-blind; fatigue; pain; prevalence
AB In addition to cancer-related death, malignant progression also leads to a series of symptoms and side-effects, which would detrimentally affect cancer patients' the quality of life, adversely influence their adherence to treatments, and, therefore, negatively affect their long-term survival. Acupuncture and electroacupuncture (EA), as two classic treatment methods in traditional Chinese medicine, have been widely employed to cure various diseases. Recently, the clinical application of acupuncture and EA in cancer patients has received great attention. In this review, we summarized the clinical application of acupuncture and EA in alleviating the cancer symptoms, reducing the cancer treatment-related side-effects, and relieving the cancer pain. The symptoms and side-effects discussed in this review include fatigue, insomnia, chemotherapy-associated dyspepsia syndrome (CADS), pain, xerostomia, and anxiety and depression. The underlying mechanisms of the therapeutic effects of acupuncture and EA might be related to the regulation of the mitochondrial function, coordination of the activity of the nervous system, adjustment of the production of neurotransmitters, and alleviation of the immune responses. In conclusion, acupuncture and EA have been proved to be beneficial for cancer patients. More research, however, is required to clarify the potential mechanisms behind acupuncture and EA for widespread adoption in clinical application.
C1 [Han, Qiu-Qin; Fu, Yi; Le, Jia-Mei; Ma, Yu-Jie; Wei, Xin-Dong; Ji, Hou-Lin; Wu, Hailong] Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, Shanghai 201318, Peoples R China.
   [Han, Qiu-Qin; Fu, Yi; Le, Jia-Mei; Ma, Yu-Jie; Wei, Xin-Dong; Ji, Hou-Lin; Wu, Hailong] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
   [Han, Qiu-Qin; Fu, Yi; Le, Jia-Mei; Ma, Yu-Jie; Wei, Xin-Dong; Ji, Hou-Lin; Wu, Hailong] Shanghai Univ Med & Hlth Sci, Collaborat Innovat Ctr Biomed, Shanghai 201318, Peoples R China.
   [Jiang, Haochen; Gao, Yueqiu] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Cent Lab, Inst Clin Immunol,Dept Liver Dis, Shanghai 200021, Peoples R China.
   [Jiang, Haochen; Gao, Yueqiu] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Lab Cellular Immun, Shanghai 200021, Peoples R China.
C3 Shanghai University of Medicine & Health Sciences; Shanghai University of Medicine & Health Sciences; Shanghai University of Medicine & Health Sciences; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Wu, HL (corresponding author), Shanghai Univ Med & Hlth Sci, Affiliated Zhoupu Hosp, Shanghai 201318, Peoples R China.; Wu, HL (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.; Wu, HL (corresponding author), Shanghai Univ Med & Hlth Sci, Collaborat Innovat Ctr Biomed, Shanghai 201318, Peoples R China.; Gao, YQ (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Cent Lab, Inst Clin Immunol,Dept Liver Dis, Shanghai 200021, Peoples R China.; Gao, YQ (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Lab Cellular Immun, Shanghai 200021, Peoples R China.
EM gaoyueqiu@hotmail.com; wuhl@sumhs.edu.cn
FU National Natural Science Foundation of China [81830052, 31870905, 81673938, 81874436, 81903961]; Scientific Program of Shanghai Municipal Health Commission [SHWJ2019211]; Shanghai Municipal Education Commission [ZZJKYX19006]; Natural Science Foundation of Shanghai [19ZR1424000]; Construction Project of Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS, 2018-2020); School-level Fund [E3-0200-21-201011-73]; Hundred Teacher Talent Program of Shanghai University of Medicine and Health Sciences
CR ACUPUNCTURE, 2003, REV ANAL REPORTS CON, V0, P87
   Baek JY, 2019, BIOMOLECULES, V9, P0, DOI 10.3390/biom9100624
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bower JE, 2006, CANCER-AM CANCER SOC, V106, P751, DOI 10.1002/cncr.21671
   Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476
   Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737
   Dong Jia-Zi, 2018, ZHEN CI YAN JIU, V43, P335, DOI 10.13702/j.1000-0607.171010
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   Eisbruch A, 2001, INT J RADIAT ONCOL, V50, P695, DOI 10.1016/S0360-3016(01)01512-7
   Fan AY, 2018, COMPLEMENT THER MED, V41, P295, DOI 10.1016/j.ctim.2018.10.015
   Feng Y, 2011, J TRADIT CHIN MED, V31, P199, DOI 10.1016/S0254-6272(11)60042-3
   Fonte C, 2015, CRIT REV ONCOL HEMAT, V95, P214, DOI 10.1016/j.critrevonc.2015.02.010
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Gottschling S, 2008, KLIN PADIATR, V220, P365, DOI 10.1055/s-0028-1086039
   Grant SJ, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735418823266
   Groenvold M, 2007, BREAST CANCER RES TR, V105, P209, DOI 10.1007/s10549-006-9447-x
   Guo J, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/163850
   HA H, 1981, EXP NEUROL, V73, P298, DOI 10.1016/0014-4886(81)90063-7
   HAN JH, 1981, ACTA ZOOL SINICA, V27, P133
   Harrison LB, 1997, HEAD NECK-J SCI SPEC, V19, P169, DOI 10.1002/(SICI)1097-0347(199705)19:3<169::AID-HED1>3.3.CO;2-5
   Herrstedt J, 2002, SUPPORT CARE CANCER, V10, P85, DOI 10.1007/s00520-001-0339-7
   Induru RR, 2014, AM J HOSP PALLIAT ME, V31, P777, DOI 10.1177/1049909113508302
   Irman, 2020, MED ACUPUNCT, V32, P234, DOI 10.1089/acu.2020.1423
   Jiang ZY, 1978, ACTA ZOOL SINICA, V0, P1
   Kang KS, 2019, EXP THER MED, V17, P2587, DOI 10.3892/etm.2019.7250
   Karatay S, 2018, PAIN MED, V19, P615, DOI 10.1093/pm/pnx263
   Laird B, 2008, EUR J CANCER, V44, P1078, DOI 10.1016/j.ejca.2008.03.022
   Lawrence D, 2004, J NATL CANC INSTITUE, V32, P40, DOI 10.1093/JNCIMONOGRAPHS/LGH027
   Lee SY, 2009, AM J CHINESE MED, V37, P1013, DOI 10.1142/S0192415X09007624
   Lee SH, 2016, BMC COMPLEM ALTERN M, V16, P0, DOI 10.1186/s12906-016-1220-z
   Li AH, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq016
   Li XM, 2009, CURR OPIN ALLERGY CL, V9, P161, DOI 10.1097/ACI.0b013e328329226f
   Linden W, 2012, J AFFECT DISORDERS, V141, P343, DOI 10.1016/j.jad.2012.03.025
   Lindley C, 1998, J CLIN ONCOL, V16, P1380, DOI 10.1200/JCO.1998.16.4.1380
   Liu FS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5381028
   Liu Y, 2019, NEUROGASTROENT MOTIL, V31, P0, DOI 10.1111/nmo.13474
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2010, INTEGR CANCER THER, V9, P284, DOI 10.1177/1534735410378856
   Mao JJ, 2009, INTEGR CANCER THER, V8, P123, DOI 10.1177/1534735409332903
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao-Ying Qi-liang, 2008, ZHONG XI YI JIE HE XUE BAO, V6, P830, DOI 10.3736/jcim20080812
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Mohammed N, 2018, J COMPLEMENT INTEGR, V15, P0
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Morey SS, 1998, AM FAM PHYSICIAN, V57, P2545
   Nelson K, 2002, SUPPORT CARE CANCER, V10, P455, DOI 10.1007/s00520-002-0340-9
   Palesh OG, 2010, J CLIN ONCOL, V28, P292, DOI 10.1200/JCO.2009.22.5011
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Park HJ, 2011, CELL MOL NEUROBIOL, V31, P1123, DOI 10.1007/s10571-011-9718-x
   PEETS JM, 1978, NATURE, V273, P675, DOI 10.1038/273675a0
   Phillips KM, 2013, SUPPORT CARE CANCER, V21, P1097, DOI 10.1007/s00520-012-1630-5
   Poulson MJ, 2001, J CLIN ONCOL, V19, P4180, DOI 10.1200/JCO.2001.19.21.4180
   Quinten C, 2011, JNCI-J NATL CANCER I, V103, P1851, DOI 10.1093/jnci/djr485
   Reindl TK, 2006, SUPPORT CARE CANCER, V14, P172, DOI 10.1007/s00520-005-0846-z
   Research Group of Acupuncture Anesthesia PMC, 1974, SCI SIN, V17, P112
   Servaes P, 2007, PSYCHO-ONCOL, V16, P787, DOI 10.1002/pon.1120
   Smith HR, 2015, ONCOL LETT, V9, P1509, DOI 10.3892/ol.2015.2944
   Smith Mary Elizabeth, 2012, SEMIN ONCOL NURS, V28, P64, DOI 10.1016/j.soncn.2011.11.007
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Stark DPH, 2000, BRIT J CANCER, V83, P1261, DOI 10.1054/bjoc.2000.1405
   Su CF, 2018, J INTEGR MED-JIM, V16, P208, DOI 10.1016/j.joim.2018.04.003
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Xie J, 2017, CHIN J CANCER, V36, P0, DOI 10.1186/s40880-016-0176-1
   Xu LL, 2018, J CANCER RES THER, V14, P99, DOI 10.4103/jcrt.JCRT_736_17
   You Wei, 2010, ZHEN CI YAN JIU, V35, P261
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang Sai, 2019, ZHEN CI YAN JIU, V44, P516, DOI 10.13702/j.1000-0607.180390
   Zhang Y, 2018, SUPPORT CARE CANCER, V26, P415, DOI 10.1007/s00520-017-3955-6
   Zhang Ying, 2018, ZHEN CI YAN JIU, V43, P492, DOI 10.13702/j.1000-0607.170923
   Zhou Mintao, 2017, ZHONGGUO ZHEN JIU, V37, P705, DOI 10.13703/j.0255-2930.2017.07.006
   Zhou Yan-Li, 2012, ZHEN CI YAN JIU, V37, P302
   ZHOU Z-F, 1984, ACTA PHYSIOLOGICA SINICA, V36, P175
NR 78
TC 37
Z9 42
U1 4
U2 47
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
EI 
J9 J CANCER
JI J. Cancer
PD JUN 15
PY 2021
VL 12
IS 23
BP 7003
EP 7009
DI 10.7150/jca.55803
PG 7
WC Oncology
SC Oncology
GA WO2XI
UT WOS:000712322300008
PM 34729102
DA 2026-01-16
ER

PT J
AU Spiegel, MA
   Chen, GH
   Solla, AC
   Hingula, LP
   Legler, A
   Gulati, A
AF Spiegel, Matthew A.
   Chen, Grant H.
   Solla, Antonio C.
   Hingula, Lee P.
   Legler, Aron
   Gulati, Amitabh
TI Evaluation of an Intrathecal Drug Delivery Protocol Leads to Rapid Reduction of Systemic Opioids in the Oncological Population
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Article
DE bupivacaine; intrathecal drug delivery systems; morphine equivalents; oncological pain
ID cancer pain; nonmalignant pain; double-blind; analgesia; recommendations; bupivacaine; management; efficacy; infusion; safety
AB Objective:The article that follows is purposed at demonstrating how IT opioid plus bupivacaine achieves sustained acceptable pain relief while simultaneously rapidly reducing oral morphine equivalents (OME). Background:Cancer patients represent a population with significant morbidity, pain, and limited life expectancy. It is, therefore, vital to achieve satisfactory analgesia quickly and safely. To date, there is limited data in the literature that discusses efficacy of combined intrathecal (IT) medication therapy in reducing systemic opioids in the oncological population. Methods:This was a retrospective analysis that reviewed cancer pain patients from day of IT pump implantation through the six-month postoperative time point. A cohort of 50 oncological patients who had intrathecal drug delivery systems (IDDSs) implanted at Memorial Sloan Kettering Cancer Center between 2017 and 2019 were studied. Median OMEs were the primary modality of analysis for this review. Mean visual analogue scale scores were secondarily reviewed. Results:Median OMEs decreased from 503 preoperative to 105 at six months postoperative time point. Median time to discharge was 6.5 days. Unfortunately, due to malignant mortality, 27 patients did not make it to the 6-month postoperative time point. Discussion:IDDSs with opioid plus bupivacaine represent a safe and efficient route toward expeditious pain relief and decreased OMEs in the cancer pain population.
C1 [Spiegel, Matthew A.; Solla, Antonio C.] NewYork Presbyterian Weill Cornell Med, Dept Anesthesiol, New York, NY USA.
   [Chen, Grant H.; Hingula, Lee P.; Legler, Aron; Gulati, Amitabh] Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care Med, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine; Memorial Sloan Kettering Cancer Center
RP Chen, GH (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Anesthesiol & Crit Care, 1275 York Ave, New York, NY 10065 USA.
EM cheng@mskcc.org
FU Memorial Sloan Kettering Cancer Center Support Grant (P30 core grant); Department of Anesthesiology and Critical Care; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013
   Deer TR, 1900, V2, V0, P274
   Deer TR, 2017, NEUROMODULATION, V20, P155, DOI 10.1111/ner.12579
   Deer TR, 2012, NEUROMODULATION, V15, P436, DOI 10.1111/j.1525-1403.2012.00476.x
   Gadsden J, 2005, ANESTH ANALG, V101, PS62, DOI 10.1213/01.ANE.0000177100.08599.C8
   Hassenbusch SJ, 2000, J PAIN SYMPTOM MANAG, V20, PS4, DOI 10.1016/S0885-3924(00)00203-7
   Higginbotham Anastasia, 2018, NOT MY IDEA: A BOOK ABOUT WHITENESS, V0, P0
   Kiehelä L, 2017, SCAND J PAIN, V16, P140, DOI 10.1016/j.sjpain.2017.04.073
   Koulousakis A, 2007, ACTA NEUROCHIR SUPPL, V97, P43
   KRAMES ES, 1993, J PAIN SYMPTOM MANAG, V8, P539, DOI 10.1016/0885-3924(93)90083-8
   Kumar K, 2009, PAIN MED, V10, P819, DOI 10.1111/j.1526-4637.2009.00640.x
   Mercadante S, 2007, CLIN J PAIN, V23, P793, DOI 10.1097/AJP.0b013e3181565d17
   Miguel R, 2000, CANCER CONTROL, V7, P149
   Mironer YE, 2002, NEUROMODULATION, V5, P208, DOI 10.1046/j.1525-1403.2002.02031.x
   Paice JA, 1996, J PAIN SYMPTOM MANAG, V11, P71, DOI 10.1016/0885-3924(95)00099-2
   Pergolizzi JV, 2015, PRACT PAIN MANAG, V14, P1
   Rainov NG, 2001, J PAIN SYMPTOM MANAG, V22, P862, DOI 10.1016/S0885-3924(01)00319-0
   Ruan Xiulu, 2007, PAIN PHYSICIAN, V10, P357
   Samolsky Dekel BG, 1900, P375, V0, P0
   Sloan Paul A, 2007, CURR PAIN HEADACHE REP, V11, P283, DOI 10.1007/s11916-007-0205-5
   Smith Thomas J, 2004, SUPPORT CANCER THER, V1, P185, DOI 10.3816/SCT.2004.n.011
   Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118
   Stroeve P, 2017, DRUG DELIV SYST, V0, P1
   Sylvester Robert K, 2004, AM J HOSP PALLIAT CARE, V21, P143, DOI 10.1177/104990910402100214
   Tomaszewski D, 1900, V46, V0, P29
   van Dam CJ, 2020, ANN PALLIAT MED, V9, P528, DOI 10.21037/apm.2019.10.09
   ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M
NR 28
TC 9
Z9 9
U1 0
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD MAR 1
PY 2021
VL 24
IS 3
BP 418
EP 422
DI 10.1089/jpm.2020.0206
EA JUL 2020
PG 5
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA QP9GS
UT WOS:000547877100001
PM 32640912
DA 2026-01-16
ER

PT J
AU Oberoi, DV
   Longo, CJ
   Reed, EN
   Landmann, J
   Piedalue, KL
   Carlson, LE
AF Oberoi, Devesh V
   Longo, Christopher J
   Reed, Erica Nicole
   Landmann, Jessa
   Piedalue, Katherine-Ann Laura
   Carlson, Linda E
TI Cost-Utility of Group Versus Individual Acupuncture for Cancer-Related Pain Using
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE acupuncture; cost–utility analysis; group acupuncture; oncology; out-of-pocket costs for cancer care; quality of life
AB Introduction: Individual acupuncture (AP) is the gold standard method of AP  delivery for cancer-related pain; however, costs can be prohibitive. Group AP  allows four to six patients to be treated in a single session. This study sought  to examine the cost-utility of group AP compared with individual AP from a  patient perspective. Materials and Methods: Effectiveness and cost data from a  noninferiority randomized trial of group versus individual AP for cancer-related  pain were used. In the trial, 74 patients were randomly assigned to individual or  group AP treatments twice per week for 6 weeks. The EuroQol five-dimension five  level questionnaire (EQ-5D-5L) was used to assess health-related quality of life,  and the EQ-5D Utility Index was used as a composite measure constituted of five  domains (mobility, self-care, usual activities, anxiety-depression, and  pain-discomfort). Linear mixed models were used to compare the change in EQ-5D-5L  states pre-post intervention between the two arms. A cost-utility analysis was  performed in terms of the incremental costs per additional quality-adjusted life  year (QALY) gained. Results: Group AP participants experienced more significant  relief in the pain-discomfort subscale of the EQ-5D-5L measure compared with  individual AP participants (group × time, F = 6.18; p = 0.02). The effect size on  pain-discomfort for group AP (d = 0.80) was higher than that of individual AP  (d = 0.34). There were no significant differences between the two study arms for  other subscales of the EQ-5D-5L over time. QALYs at 6 weeks were slightly higher  for group AP (0.020) compared with individual AP (0.007) leading to an  incremental QALY gained by the group arm of 0.013, but this difference was not  statistically significant (p = 0.07). The cost of delivering AP treatment for the  group arm over 6 weeks ($201.25) was nearly half of the individual arm ($400).  Conclusions: Group AP was superior to individual AP in cancer patients. These  findings have implications for the use of group AP in low-resource settings and  in health care systems where AP for cancer patients is not covered by public  health insurance. ClinicalTrials.gov (NCT03641222). Registered July 10,  2018-Retrospectively registered,  https://clinicaltrials.gov/ct2/show/study/NCT03641222.
C1 Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
   Department of Psychosocial Oncology, Cancer Control Alberta, Holy Cross Centre 
   The DeGroote School of Business, McMaster University, Hamilton, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
   Vive Integrative Health Group, Calgary, Canada.
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
   Department of Psychosocial Oncology, Cancer Control Alberta, Holy Cross Centre 
   Division of Psychosocial Oncology, Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Canada.
   Department of Psychosocial Oncology, Cancer Control Alberta, Holy Cross Centre
NR 0
TC 0
SN 1557-770
EI 
J9 J Altern Complement Med
PD APR 28
PY 2021
VL 27
IS 5
BP 390
EP 397
DI 10.1089/acm.2020.0386
PG 7
WC Acupuncture Therapy; Adult; Cancer Pain; therapy; Cost-Benefit Analysis; Female; Health Expenditures; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Shared Medical Appointments
UT PubMed:33904784
PM 33904784
DA 2021-04-28
ER

PT J
AU Poo, CL
   Dewadas, HD
   Ng, FL
   Foo, CN
   Lim, YM
AF Poo, Chin Long
   Dewadas, Hemaniswarri Dewi
   Ng, Foong Leng
   Foo, Chai Nien
   Lim, Yang Mooi
TI Effect of Traditional Chinese Medicine on Musculoskeletal Symptoms in Breast Cancer: A Systematic Review and Meta-Analysis
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Review
DE Traditional Chinese Medicine (TCM); breast cancer; aromatase inhibitor-associated musculoskeletal symptoms (AIMSS); systematic review; meta-analysis
ID postmenopausal women; osteoarthritis index; tamoxifen therapy; randomized-trial; western-ontario; short-form; brief pain; osteoporosis; reliability; acupuncture
AB Context. Traditional Chinese Medicine (TCM) has been widely used as a complementary medical treatment for arthralgia and other types of pain. The available literature on the effectiveness of TCM on breast cancer patients with musculoskeletal symptoms reports controversial results. Objectives. The objective of this review is to assess the effectiveness of TCM as a treatment option for musculoskeletal symptoms in patients with breast cancer who were treated with aromatase inhibitors (AIs). Methods. A comprehensive literature search was conducted using PubMed, the Cochrane Library, SAGE journals, Scopus, EMBASE, Web of Science, Medline, Cumulated Index to Nursing and Allied Health Literature (CINAHL), Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Scientific Journal Database (VIP), Wanfang, and Chinese Medical Journal Database (CMJ) from May 2020 to November 2020. The literature review included randomized controlled trials (RCTs) of TCM for AI-related musculoskeletal symptoms. Results. Four RCTs incorporating TCM were assessed by meta-analysis and reported favorable effects in reducing worst pain score (n = 284, mean difference [MD]: 2.31; 95% CI, 1.74 to 2.88; P < 0.00001). Three trials showed favorable effects of TCM in reducing pain interference (n = 211, MD: 2.62; 95% CI, 1.29 to 3.94; P= 0.0001), while two trials reported no significant effects of TCM on stiffness (n = 147, MD: 1.21; 95% CI, -0.39 to 2.82; P= 0.14). The meta-analysis of three trials also found no significant effect of TCM on bone mineral density (n = 214, MD, -0.01; 95% CI, -0.07 to 0.05; P= 0.71). The physical aspect of quality of life was significantly increased in breast cancer patients after TCM treatment (n = 220, MD, 5.13; 95% CI, 2.04 to 8.22; P = 0.001). In addition, three RCTs reported minimal TCM-related adverse events. Conclusion. The results suggest that TCM could be an effective treatment in relieving pain especially worst pain and pain interference as well as improving quality of life caused by AI-related musculoskeletal symptoms. However, further investigation of the molecular pathway involved and in-depth safety profile are needed. J Pain Symptom Manage 2021;62:159e173. (c) 2020 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Poo, Chin Long; Dewadas, Hemaniswarri Dewi; Ng, Foong Leng; Foo, Chai Nien; Lim, Yang Mooi] Univ Tunku Abdul Rahman, Ctr Canc Res, Fac Med & Hlth Sci, Jalan Sungai Long, Kajang, Selangor, Malaysia.
   [Ng, Foong Leng] Univ Tunku Abdul Rahman, Dept Chinese Med, Fac Med & Hlth Sci, Jalan Sungai Long, Kajang, Selangor, Malaysia.
   [Foo, Chai Nien] Univ Tunku Abdul Rahman, Dept Populat Med, Fac Med & Hlth Sci, Jalan Sungai Long, Kajang, Selangor, Malaysia.
   [Lim, Yang Mooi] Univ Tunku Abdul Rahman, Dept Preclin Sci, Fac Med & Hlth Sci, Jalan Sungai Long, Kajang, Selangor, Malaysia.
C3 Universiti Tunku Abdul Rahman (UTAR); Universiti Tunku Abdul Rahman (UTAR); Universiti Tunku Abdul Rahman (UTAR); Universiti Tunku Abdul Rahman (UTAR)
RP Lim, YM (corresponding author), Univ Tunku Abdul Rahman, Dept Preclin Sci, Fac Med & Hlth Sci, Ctr Canc Res, Jalan Sungai Long, Kajang 43000, Selangor, Malaysia.
EM ymlim@utar.edu.my
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Baum M, 2002, LANCET, V359, P2131
   Boccardo F, 2005, J CLIN ONCOL, V23, P5138, DOI 10.1200/JCO.2005.04.120
   Coates AS, 2007, J CLIN ONCOL, V25, P486, DOI 10.1200/JCO.2006.08.8617
   Coombes RC, 2004, NEW ENGL J MED, V350, P1081, DOI 10.1056/NEJMoa040331
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Darby Susan B, 2009, NURS WOMENS HEALTH, V13, P198, DOI 10.1111/j.1751-486X.2009.01420.x
   Gandek B, 2015, ARTHRIT CARE RES, V67, P216, DOI 10.1002/acr.22415
   Gao Huimin, 2011, FRONT MED, V5, P195, DOI 10.1007/s11684-011-0134-x
   Goss PE, 2003, NEW ENGL J MED, V349, P1793, DOI 10.1056/NEJMoa032312
   Hawker GA, 2011, ARTHRIT CARE RES, V63, PS240, DOI 10.1002/acr.20543
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Henry NL, 2012, J CLIN ONCOL, V30, P936, DOI 10.1200/JCO.2011.38.0261
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Honma N, 2019, SUPPORT CARE CANCER, V27, P3813, DOI 10.1007/s00520-019-04674-8
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li YF, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/2478565
   Liu WG, 2013, J HENAN UNI CHIN MED, V0, P0
   Lombard JM, 2016, SUPPORT CARE CANCER, V24, P2139, DOI 10.1007/s00520-015-3001-5
   Macdonald G, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001930.pub3
   Mendoza T, 2006, EUR J PAIN, V10, P353, DOI 10.1016/j.ejpain.2005.06.002
   Muslimani AA, 2009, CLIN BREAST CANCER, V9, P34, DOI 10.3816/CBC.2009.n.006
   Peng N, 2018, BREAST, V37, P18, DOI 10.1016/j.breast.2017.08.003
   Pineda-Moncusí M, 2019, BREAST CANCER RES TR, V177, P53, DOI 10.1007/s10549-019-05289-7
   Salaffi F, 2003, OSTEOARTHR CARTILAGE, V11, P551, DOI 10.1016/S1063-4584(03)00089-X
   Suskin J, 2018, GLAND SURG, V7, P411, DOI 10.21037/gs.2018.07.05
   Victorson D, 2008, QUAL LIFE RES, V17, P1137, DOI 10.1007/s11136-008-9398-2
   Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8
   Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121
   Xu L, 2007, INTEGR CANCER THER, V6, P208, DOI 10.1177/1534735407305705
   Xue Jing-Xian, 2018, EVID BASED COMPLEMENT ALTERNAT MED, V2018, P6305645, DOI 10.1155/2018/6305645
   Ye J, 2015, SHANGHAI J ACUP MOXIB, V34, P642
   Zhong Y, 2017, THESIS GUANGZHOU U C, V0, P0
   Zhu LB, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/9469276
NR 36
TC 14
Z9 17
U1 3
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUL 15
PY 2021
VL 62
IS 1
BP 159
EP 173
DI 10.1016/j.jpainsymman.2020.11.024
EA JUN 2021
PG 15
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology
SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology
GA SW8AB
UT WOS:000664736200021
PM 33278502
DA 2026-01-16
ER

PT J
AU Bossi, P
   Antonuzzo, A
   Armento, G
   Consoli, F
   Giuliani, J
   Giusti, R
   Lucchesi, M
   Mirabile, A
   Palermo, L
   Scagliarini, S
AF Bossi, Paolo
   Antonuzzo, Andrea
   Armento, Grazia
   Consoli, Francesca
   Giuliani, Jacopo
   Giusti, Raffaele
   Lucchesi, Maurizio
   Mirabile, Aurora
   Palermo, Loredana
   Scagliarini, Sarah
TI What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE cancer pain; pain management; precision medicine; digital medicine
ID breakthrough-pain; prevalence; barriers
AB Background: Despite the prevalence of pain among patients with cancer and the availability of pertinent guidelines, the clinical management of oncological pain is decisively insufficient. To address this issue, we evaluated current trends in clinical practice and subsequently generated a list of ten corrective actions-five things to do and five things not to do-for the diagnosis, management, and monitoring of cancer pain. Methods: The survey included 18 questions about clinical practice surrounding background pain and breakthrough cancer pain (BTcP). Survey questions were developed by a scientific board of 10 physician experts and communicated via email to an expanded panel of physicians in Italy. Responses were tabulated descriptively for analysis. Results: Of 51 invited physicians, 32 (63%) provided complete survey responses. The responses revealed several incongruencies with current guideline recommendations: physicians did not always diagnose or monitor pain using diagnostically validated or disease-specific instruments; frequently based clinical decision-making on time availability or convenience; and pharmacological therapy was often inappropriate (eg, prescribing NSAIDs or corticosteroids for BTcP). The list of corrective actions generated by the scientific board favored a guideline-oriented approach that systematically characterizes oncological pain and implements treatment based on pain characteristics (eg, fast-acting transmucosal opioids for BTcP) and evidence-based recommendations. Conclusion: Oncologists require better education and training about the diagnosis, treatment, and monitoring of oncological pain. Physicians should be aware of current guideline recommendations as well as available pharmacological tools for BTcP.
C1 [Bossi, Paolo; Consoli, Francesca] ASST Spedali Civili, Dept Med Oncol, 1 Brescia, I-25123 Brescia, Italy.
   [Antonuzzo, Andrea] Azienda Osped Univ Pisana, Med Oncol Unit SSN 1, Oncol Ctr, Pisa, Italy.
   [Armento, Grazia] Dept Med Oncol, Campus Biomed Univ Hosp, Rome, Italy.
   [Giuliani, Jacopo] Mater Salutis Hosp, Unit Dept Med Oncol, Legnago, Italy.
   [Giusti, Raffaele] St Andrea Univ Hosp, Unit Dept Med Oncol, Rome, Italy.
   [Lucchesi, Maurizio] Azienda Osped Univ Pisana, Pneumol Unit, Thorac Oncol Serv, Pisa, Italy.
   [Mirabile, Aurora] San Raffaele Univ Hosp, Dept Oncol, Milan, Italy.
   [Palermo, Loredana] IRCCS Giovanni Paolo, Unit Dept Med Oncol, Bari, Italy.
   [Scagliarini, Sarah] AORN Cardarelli, Unit Dept Med Oncol, Naples, Italy.
C3 Hospital Spedali Civili Brescia; University of Pisa; Azienda Ospedaliero Universitaria Pisana; Fondazione Policlinico Universitario Campus Bio-Medico; University Campus Bio-Medico - Rome Italy; ULSS 9 Scaligera; Ospedale Mater Salutis di Legnago; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; University of Pisa; Azienda Ospedaliero Universitaria Pisana; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Bossi, P (corresponding author), ASST Spedali Civili, Dept Med Oncol, 1 Brescia, I-25123 Brescia, Italy.
EM paolo.bossi@unibs.it
FU Molteni Farmaceutici S.p.A.
CR Aapro M, 2020, SUPPORT CARE CANCER, V28, P4589, DOI 10.1007/s00520-020-05539-1
   Adam R, 2021, SUPPORT CARE CANCER, V29, P759, DOI 10.1007/s00520-020-05510-0
   Alvaro D, 2020, PAIN THER, V9, P657, DOI 10.1007/s40122-020-00195-z
   Antón A, 2012, EUR J PAIN, V16, P381, DOI 10.1002/j.1532-2149.2011.00036.x
   Azizoddin DR, 2021, SUPPORT CARE CANCER, V29, P5741, DOI 10.1007/s00520-021-06146-4
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bennett D, 2005, CONSENSUS PANEL RE 2, V30, P0
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680
   Hwang SS, 2003, PAIN, V101, P55, DOI 10.1016/S0304-3959(02)00293-2
   Kim HS, 2013, SUPPORT CARE CANCER, V21, P1751, DOI 10.1007/s00520-013-1722-x
   Knegtmans MF, 2020, PAIN PRACT, V20, P122, DOI 10.1111/papr.12830
   Kwon JH, 2014, J CLIN ONCOL, V32, P1727, DOI 10.1200/JCO.2013.52.4827
   Lesage, 1999, CANCER CONTROL, V6, P136
   Lizée T, 2019, J THORAC ONCOL, V14, P1012, DOI 10.1016/j.jtho.2019.02.005
   Mercadante S, 2019, EUR J PAIN, V23, P719, DOI 10.1002/ejp.1339
   Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721
   Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161
   Pavic M, 2020, ONCOLOGY-BASEL, V98, P386, DOI 10.1159/000501433
   Penedo FJ, 2020, LANCET ONCOL, V21, PE240, DOI 10.1016/S1470-2045(20)30021-8
   Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233
   Steindal SA, 2020, J MED INTERNET RES, V22, P0, DOI 10.2196/16218
   Webber K, 2015, J PAIN SYMPTOM MANAG, V50, P495, DOI 10.1016/j.jpainsymman.2015.05.006
   Wright AA, 2018, JCO CLIN CANCER INFO, V2, P0, DOI 10.1200/CCI.17.00149
   Zuccaro SM, 2012, CLIN DRUG INVEST, V32, P11, DOI 10.2165/11630040-000000000-00000
NR 31
TC 5
Z9 5
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
EI 
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PD JUN 15
PY 2021
VL 13
IS 
BP 5203
EP 5210
DI 10.2147/CMAR.S310651
PG 8
WC Oncology
SC Oncology
GA TB8WG
UT WOS:000668225900001
PM 34234563
DA 2026-01-16
ER

PT J
AU Wang, YX
   Zhang, JY
   Jin, YX
   Zhang, Q
AF Wang, Yunxia
   Zhang, Jiayuan
   Jin, Yuxia
   Zhang, Qi
TI Auricular Acupressure Therapy for Patients with Cancer with Sleep Disturbance: A Systematic Review and Meta-Analysis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID randomized controlled-trial; point acupressure; receiving chemotherapy; insomnia; melatonin; fatigue
AB Aim. We aim to provide available synthesized evidence of the efficacy and safety of auricular acupressure for cancer patients with sleep disturbance. Methods. Randomized controlled clinical trials (RCTs) were identified from PubMed, EMBASE, Web of Science, The Cochrane Library, PsycINFO, Chinese Biomedical Database, China National Knowledge Infrastructure, Chongqing VIP, and Wanfang Data, and the search date ranged from the inception of the databases to May 2021. Literature screening and data extraction were independently performed by three researchers. The Cochrane collaboration's tool for assessing the risk of bias was applied to evaluate the risk of bias of the RCTs included. The extracted data were analyzed using Rev-Man 5.4.1 software. Results. Nine trials involving 688 participants met the inclusion criteria and were included in the qualitative analysis; 6 trials involving 485 participants were included in the meta-analysis. Synthesized results showed that auricular acupressure had a significant effect on reducing the total Pittsburgh Sleep Quality Index (PSQI) score (MD = -3.88, 95% CI (-5.24, -2.53), P<0.00001), and the scores of five PSQI components, sleep latency (MD = -0.53, 95% CI (-0.73, -0.32), P<0.00001), subjective sleep quality (MD = -0.79, 95% CI (-1.05, -0.53), P<0.00001), sleep duration (MD = -0.50, 95% CI (-0.69, -0.31), P<0.0001), daytime dysfunction (MD = -0.53, 95% CI (-0.77, -0.29), P<0.0001), and sleep disturbances (MD = -0.54, 95% CI (-0.60, -0.49), P<0.00001), were also obviously decreased after the intervention of auricular acupressure. Shenmen and heart were the most commonly selected auricular acupoints, the main intervention durations ranged from 10 to 42 days, and the pressing times of auricular acupoints were 1-6 times a day, 1-5 min each time. One trial reported slight and transient pain caused by auricular acupressure, while the remaining 8 trials did not report obvious side effects. Conclusion. Auricular acupressure can significantly improve the sleep quality of cancer patients with sleep disturbance, with no obvious side effects. Rigorously designed clinical trials are necessary for the further support of the clinical application.
C1 [Wang, Yunxia; Zhang, Jiayuan; Jin, Yuxia; Zhang, Qi] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Zhang, Q (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China.
EM zhangqi@cdutcm.edu.cn
FU National Natural Science Foundation of China [81873222]
CR Acupuncture-Moxibustion CCoDaToAAPattCAo, 2008, NOM LOC AUR AC POINT, V0, P0
   Vallim ETA, 2019, REV ESC ENFERM USP, V53, P0, DOI 10.1590/S1980-220X2018043603525
   Ancoli-Israel S, 2009, J CLIN ONCOL, V27, P5864, DOI 10.1200/JCO.2009.24.5993
   Auld F, 2017, SLEEP MED REV, V34, P10, DOI 10.1016/j.smrv.2016.06.005
   Cheung MC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/182837
   Chun IF, 2015, JOURNAL OF NURSING & HEALTHCARE RESEARCH, V11, P3, DOI 10.6225/JNHR.11.1.3
   Dahiya S, 2013, CLEV CLIN J MED, V80, P722, DOI 10.3949/ccjm.80a.12170
   Davidson JR, 2007, PSYCHO-ONCOLOGY, V16, P1028, DOI 10.1002/pon.1183
   Eghbali M, 2016, COMPLEMENT THER CLIN, V24, P189, DOI 10.1016/j.ctcp.2016.06.006
   Garland SN, 2018, MED HYPOTHESES, V120, P72, DOI 10.1016/j.mehy.2018.08.019
   Gonzalez BD, 2018, SUPPORT CARE CANCER, V26, P4049, DOI 10.1007/s00520-018-4272-4
   Han Q, 2020, J ADV NURS, V76, P1924, DOI 10.1111/jan.14375
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Howell D, 2014, ANN ONCOL, V25, P791, DOI 10.1093/annonc/mdt506
   Hughes JG, 2015, EUR J INTEGR MED, V7, P623, DOI 10.1016/j.eujim.2015.08.003
   Induru RR, 2014, AM J HOSP PALLIAT ME, V31, P777, DOI 10.1177/1049909113508302
   Kuo HC, 2018, RES NURS HEALTH, V41, P469, DOI 10.1002/nur.21885
   Kwekkeboom KL, 2016, SEMIN ONCOL NURS, V32, P373, DOI 10.1016/j.soncn.2016.08.004
   Lan Y, 2015, BMC COMPLEM ALTERN M, V15, P0, DOI 10.1186/s12906-015-0606-7
   Lei YC, 2020, AURICULAR ACUPRESSURE BASED ON MERIDIANAL FLOW THEORY FOR LIVER STAGNATION AND SPLEEN DEFICIENCY TYPE PRIMARY LIVER CANCER PATIENTS WITH INSOMNIA: A PILOT RANDOMIZED CONTROLLED TRIAL, V0, P0
   Lin J, 2018, FUJIAN J TCM, V49, P75, DOI 10.13260/j.cnki.jfjtcm.011643
   Liu XL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/2591320
   Liu XR, 2020, HOLIST NURS PRACT, V34, P103, DOI 10.1097/HNP.0000000000000372
   Lu H, 2017, SHANGHAI NURSING JAN, V17, P41, DOI 10.3969/j.issn.1009-8399.2017.01.017
   Nguyen LT, 2018, J PAIN SYMPTOM MANAG, V55, P1459, DOI 10.1016/j.jpainsymman.2018.02.019
   Ma Y, 2021, SLEEP MED REV, V55, P0, DOI 10.1016/j.smrv.2020.101376
   Mercadante S, 2020, SUPPORT CARE CANCER, V28, P1089, DOI 10.1007/s00520-019-04912-z
   Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P786, DOI 10.1016/j.jpainsymman.2015.06.018
   Nishiura M, 2015, PALLIAT SUPPORT CARE, V13, P575, DOI 10.1017/S1478951513001119
   Omvik S, 2010, INT CLIN PSYCHOPHARM, V25, P91, DOI 10.1097/YIC.0b013e328334e5e6
   Palesh O, 2012, NAT SCI SLEEP, V4, P151, DOI 10.2147/NSS.S18895
   Palesh OG, 2012, SLEEP MED, V13, P1184, DOI 10.1016/j.sleep.2012.06.001
   Pei M, 2021, FRONT PSYCHIATRY, V12, P0, DOI 10.3389/fpsyt.2021.576050
   Ruel S, 2015, HEALTH PSYCHOL, V34, P983, DOI 10.1037/hea0000181
   Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895
   Savard J, 2015, CANCER-AM CANCER SOC, V121, P1703, DOI 10.1002/cncr.29244
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Schieber K, 2019, SLEEP MED, V58, P107, DOI 10.1016/j.sleep.2019.02.018
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Song YP, 2014, CHIN MED, V12, P47, DOI 10.3969/j.issn.1672-2779.2014.02.030
   Spence DW, 2004, J NEUROPSYCH CLIN N, V16, P19, DOI 10.1176/appi.neuropsych.16.1.19
   Suen LKP, 2003, COMPLEMENT THER MED, V11, P85, DOI 10.1016/S0965-2299(03)00041-4
   Takemura N, 2020, SLEEP MED REV, V53, P0, DOI 10.1016/j.smrv.2020.101334
   Wang L, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/763631
   Wei XL, 2019, S CHINA J PREVENTIVE, V45, P562, DOI 10.12183/J.SCJPM.2019.0562
   Wu YC, 2014, J ALTERN COMPLEM MED, V20, P356, DOI 10.1089/acm.2013.0319
   Yang YL, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/1618767
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Yeh CH, 2015, PAIN MANAG NURS, V16, P285, DOI 10.1016/j.pmn.2014.08.005
   Yoon HG, 2019, APPL NURS RES, V48, P45, DOI 10.1016/j.apnr.2019.05.009
   Zhao ZH, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7279486
NR 51
TC 32
Z9 38
U1 2
U2 21
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD OCT 14
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/3996101
PG 12
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA XB8SB
UT WOS:000721591700001
PM 34691214
DA 2026-01-16
ER

PT J
AU Jin, Y
   Zhou, J
   Xu, F
   Ren, Z
   Hu, J
   Zhang, C
   Ge, K
   Liu, L
AF Jin, Ying
   Zhou, Jie
   Xu, Fangfang
   Ren, Zeqin
   Hu, Jun
   Zhang, Cong
   Ge, Kaiwen
   Liu, Lanying
TI Electroacupuncture alleviates the transition from acute to chronic pain through
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE electroacupuncture; hyperalgesic priming; p38 mitogen-activated protein kinase; spinal dorsal horn; tumour necrosis factor alpha
AB BACKGROUND: Hyperalgesic priming (HP) is a model of the transition from acute to  chronic pain. Electroacupuncture (EA) could inhibit pain development through the  peripheral dorsal root ganglia; however, it is unclear whether it can mitigate  the transition from acute to chronic pain by attenuating protein expression in  the p38 MAPK (mitogen-activated protein kinase)/tumour necrosis factor alpha  (TNF-α) pathway in the spinal dorsal horn. AIMS: We aimed to determine whether EA  could prevent the transition from acute to chronic pain by affecting the p38  MAPK/TNF-α pathway in the spinal dorsal horn in a rat model established using HP.  METHODS: We first randomly subdivided 30 male Sprague-Dawley (SD) rats into 5  groups (n = 6 per group): control (N), sham HP (Sham-HP), HP, HP + SB203580p38  MAPK (HP+SB203580), and HP + Lenalidomide (CC-5013) (HP+Lenalidomide). We then  randomly subdivided a further 30 male SD rats into 5 groups (n = 6 per group):  Sham-HP, HP, sham EA (Sham EA), EA (EA), and EA + U-46619 p38 MAPK agonist  (EA+U-46619). We assessed the effects of EA on the mechanical paw withdrawal  threshold and p38 MAPK/TNF-α expression in the spinal dorsal horn of rats  subjected to chronic inflammatory pain. RESULTS: Rats in the EA group had reduced  p38 MAPK and TNF-α expression and had significantly reduced mechanical  hyperalgesia compared with rats in the other groups. CONCLUSION: Our findings  indicate that EA could increase the mechanical pain threshold in rats and inhibit  the transition from acute pain to chronic pain. This mechanism could involve  reduced p38 MAPK/TNF-α expression in the spinal dorsal horn.
C1 Department of Acupuncture and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Nanjing City, China.
   The Second Affiliated Hospital of Zhejiang University School of Medicine, 
   The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou City, China.
   The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China.
   Department of Rehabilitation in Traditional Chinese Medicine, The First Affiliated Hospital, Dali University, Dali City, China.
   Department of Acupuncture and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Nanjing City, China.
   Department of Acupuncture and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Nanjing City, China.
   Department of Acupuncture and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Nanjing City, China.
   Department of Acupuncture and Rehabilitation, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine,Nanjing City, China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD JUL 27
PY 2021
VL 39
IS 6
BP 708
EP 715
DI 10.1177/09645284211020766
PG 7
WC Acute Pain; genetics; Animals; Chronic Pain; genetics; Electroacupuncture; Humans; Male; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord Dorsal Horn; metabolism; Tumor Necrosis Factor-alpha; genetics; p38 Mitogen-Activated Protein Kinases; genetics
UT PubMed:34308662
PM 34308662
DA 2021-07-27
ER

PT J
AU Grushina, TI
   Konchugova, TV
   Kulchitskaya, DB
   Gushchina, NV
   Astakhova, KA
AF Grushina, T I
   Konchugova, T V
   Kulchitskaya, D B
   Gushchina, N V
   Astakhova, K A
TI [Rehabilitation methods for cancer patients with peripheral polyneuropathy
SO Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury
LA rus
DT Review
DE chemotherapy; neuropathy; neurotoxicity; polyneuropathy; rehabilitation
AB An analytical review of the methods of cancer patients' rehabilitation with  peripheral polyneuropathy induced by cytostatics (PNPIC) was carried out. Studies  from electronic databases were investigated: Scopus, Web of Science, MedLine,  World Health Organization, The Cochrane Central Register of Controlled Trials,  ScienceDirect, US National Library of Medicine National Institutes of Health,  PubMed Cancer, eLIBRARY, CyberLeninka. Despite the improvement of anticancer  therapy and an increase in patients' life expectancy, the emerging peripheral  polyneuropathy remains an urgent problem, since it significantly affects both the  patients' life quality and the selection of adequate therapy. The frequency of  detection of PNPIC is 90%, after discontinuation of treatment; symptoms of  damaged peripheral nerve fibers remain in 30% of patients. The clinical symptoms  of PNPIC are varied and most often include numbness in the extremities and / or  increased sensitivity to thermal or mechanical stimuli, neuropathic pain.  Currently, to prevent PNPIC, treatment is being modified with a reduction in the  duration of courses and doses of cytostatics, and interruption of treatment.  Official guidelines do not recommend any prophylaxis other than the possible use  of duloxetine or a topical gel containing baclofen, amitriptyline, and ketamine.  Over the past few years, there has been no significant progress in the prevention  and treatment of PNPIC. The most common drug treatment method in clinical  practice is the prescription of vitamins B. Among the non-drug treatment methods  of PNPIC, the authors used acupuncture, electro-acupuncture, manual therapy,  massage, gymnastics, yoga, sensorimotor training, general vibration therapy,  percutaneous electro-neuro-stimulation, electro-analgesia, local cryotherapy,  hydrotherapy, low-intensity alternating magnetic radiation. The studies included  in the review are heterogeneous in design and protocol, number of patients, and  time points for assessing outcomes. In connection with the existing differences,  it is not possible to carry out a comparative analysis of the results of these  rehabilitation types and to give an unambiguous answer about their effectiveness.  As the analysis has shown, peripheral PNPIC is well known all over the world,  however, the search for methods of its treatment is far from complete.
C1 National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.
   National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.
   National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.
   National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.
   National Medical Research Center for Rehabilitation and Balneology, Moscow, Russia.
NR 0
TC 0
SN 
EI 0042-878
J9 Vopr Kurortol Fizioter Lech Fiz Kult
PD FEB 20
PY 2021
VL 98
IS 1
BP 58
EP 63
DI 10.17116/kurort20219801158
PG 5
WC Cytostatic Agents; Humans; Neoplasms; drug therapy; Neuralgia; Pain Management; Polyneuropathies; drug therapy
UT PubMed:33605131
PM 33605131
DA 2021-02-20
ER

PT J
AU Que, B
   Tu, Q
   Shi, JL
   Wan, ZZ
   Li, YA
   Zhou, R
   Yu, H
   Gan, JH
   Yu, JM
AF Que, Bin
   Tu, Qing
   Shi, Jinlin
   Wan, Zhengzuo
   Li, Yanan
   Zhou, Rong
   Yu, Hong
   Gan, Jianhui
   Yu, Jianming
TI Effects of Transcutaneous Electrical Acupoint Stimulation on Systemic Inflammatory Response Syndrome of Patients after Percutaneous Nephrolithotomy: A Randomized Controlled Trial
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID electroacupuncture; acupuncture; rats; pain
AB Purpose. Transcutaneous electrical acupoint stimulation (TEAS) is widely used. However, no study evaluated TEAS on systemic inflammatory response syndrome (SIRS) of patients after percutaneous nephrolithotomy (PCNL). The study was to evaluate TEAS on SIRS of patients after PCNL. Methods. 67 patients were enrolled and divided into group TEAS and group sham TEAS. Data were collected from 60 participants finally. In the study, TEAS or sham TEAS on bilateral Shenshu (BL23), Yinlingquan (SP9), Hegu (LI4), and Neiguan (PC6) was performed continuously throughout the procedure. The primary outcome included the incidence of systemic inflammatory response syndrome (SIRS) within 48 h after surgery. The secondary outcomes included the serum levels of inflammatory cytokines, hemodynamics changes, complications, and hospital stay after surgery. The serum levels of tumor necrosis factor- (TNF-) alpha and interleukin- (IL-) 6, mean arterial pressure (MAP), and heart rate (HR) at 30 min before anesthesia (T-0), the time after surgery (T-1), 24 h postoperation (T-2), and 48 h postoperation (T-3) were recorded. The consumption of analgesic during surgery was also recorded, as well as the complications and duration of hospital stay after PCNL. Results. The incidence of SIRS in group TEAS was lower than group sham TEAS (30% vs. 6.67%, p=0.023). Compared with the sham TEAS group, both levels of TNF-alpha and IL-6 at T-1, T-2, and T-3 were lower in the TEAS group (p<0.05). The levels of MAP and HR in sham TEAS at T-1, T-2, and T-3 were markedly higher than that in the TEAS group (p<0.05). The total consumption of propofol and remifentanil during surgery in group TEAS was lower than that in the sham TEAS group. The incidence of hypotension, hypertension, emergence agitation, and postoperative nausea and vomiting (PONV) was also lower in group TEAS after PCNL (p<0.05). Conclusions. TEAS could effectively reduce the incidence of SIRS and inflammatory cytokines for patients who underwent PCNL. In addition, TEAS helped to maintain the hemodynamic stability and cut down the consumption of analgesics during PCNL, reducing the complications after PCNL.
C1 [Que, Bin; Wan, Zhengzuo; Li, Yanan; Zhou, Rong; Yu, Jianming] Zhejiang Chinese Med Univ, Dept Anesthesiol, Hangzhou TCM Hosp, Hangzhou 310000, Peoples R China.
   [Tu, Qing] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Anesthesiol, Sch Med, Shanghai 200000, Peoples R China.
   [Shi, Jinlin; Yu, Hong; Gan, Jianhui] North China Univ Sci & Technol, Tangshan Peoples Hosp, Dept Anesthesiol, Tangshan 063000, Hebei, Peoples R China.
C3 Zhejiang Chinese Medical University; Shanghai Jiao Tong University; North China University of Science & Technology
RP Yu, JM (corresponding author), Zhejiang Chinese Med Univ, Dept Anesthesiol, Hangzhou TCM Hosp, Hangzhou 310000, Peoples R China.; Gan, JH (corresponding author), North China Univ Sci & Technol, Tangshan Peoples Hosp, Dept Anesthesiol, Tangshan 063000, Hebei, Peoples R China.
EM ganjianhui666@163.com; sjlints@163.com
FU Tangshan Science and Technology Innovation Team Project [18130220A]
CR Akbulut F, 2016, SPRINGERPLUS, V5, P0, DOI 10.1186/s40064-016-2830-0
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Chen L, 2009, J PAIN, V10, P732, DOI 10.1016/j.jpain.2008.12.012
   El-Deeb AM, 2011, J ANESTH, V25, P698, DOI 10.1007/s00540-011-1198-0
   Gao Junlong, 2015, ZHONGGUO ZHEN JIU, V35, P269
   Hosseini MM, 2007, J ENDOUROL, V21, P1429, DOI 10.1089/end.2007.0092
   Huang ST, 2005, AM J CHINESE MED, V33, P157, DOI 10.1142/S0192415X0500276X
   Jones AYM, 2011, AM J CRIT CARE, V20, PE67, DOI 10.4037/ajcc2011142
   Kaukonen KM, 2015, NEW ENGL J MED, V372, P1629, DOI 10.1056/NEJMoa1415236
   Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008
   Kim E, 2011, AM J CHINESE MED, V39, P243, DOI 10.1142/S0192415X11008786
   Knoll T, 2017, WORLD J UROL, V35, P1361, DOI 10.1007/s00345-017-2001-0
   Kurdowska A, 2002, CRIT CARE MED, V30, P2335, DOI 10.1097/00003246-200210000-00024
   Li H, 2015, ACUPUNCT MED, V33, P400, DOI 10.1136/acupmed-2014-010752
   Liu CF, 2015, ITAL J PEDIATR, V41, P0, DOI 10.1186/s13052-015-0155-1
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Luo SH, 2009, J TRADIT CHIN MED, V24, P179
   Michel MS, 2007, EUR UROL, V51, P899, DOI 10.1016/j.eururo.2006.10.020
   Mo YC, 2017, MEDIAT INFLAMM, V2017, P0, DOI 10.1155/2017/8369737
   Ng MCS, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq015
   Olyaei G R, 2004, ELECTROMYOGR CLIN NEUROPHYSIOL, V44, P23
   Omar M, 2016, J UROLOGY, V196, P109, DOI 10.1016/j.juro.2016.01.104
   Qu F, 2017, J ZHEJIANG UNIV-SC B, V18, P186, DOI 10.1631/jzus.B1600437
   Su TF, 2011, MOL PAIN, V7, P0, DOI 10.1186/1744-8069-7-98
   Tu Q, 2019, UROLITHIASIS, V47, P279, DOI 10.1007/s00240-018-1056-8
   Wang GJ, 2015, J ACUPUNCT MERIDIAN, V8, P94, DOI 10.1016/j.jams.2014.10.009
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang H, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/419212
   Xiong LZ, 2007, CHINESE MED J-PEKING, V120, P394, DOI 10.1097/00029330-200703010-00009
   Yoo YC, 2011, YONSEI MED J, V52, P1016, DOI 10.3349/ymj.2011.52.6.1016
   Zhang ZD, 2012, ANESTH ANALG, V114, P879, DOI 10.1213/ANE.0b013e318246536d
   Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943
NR 33
TC 7
Z9 8
U1 1
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD AUG 12
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/5909956
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA UD8TI
UT WOS:000687474900003
PM 34422076
DA 2026-01-16
ER

PT J
AU Lyu, Z
   Guo, Y
   Gong, Y
   Fan, W
   Dou, B
   Li, N
   Wang, S
   Xu, Y
   Liu, Y
   Chen, B
   Guo, Y
   Xu, Z
   Lin, X
AF Lyu, Zhongxi
   Guo, Yongming
   Gong, Yinan
   Fan, Wen
   Dou, Baomin
   Li, Ningcen
   Wang, Shenjun
   Xu, Yuan
   Liu, Yangyang
   Chen, Bo
   Guo, Yi
   Xu, Zhifang
   Lin, Xiaowei
TI The Role of Neuroglial Crosstalk and Synaptic Plasticity-Mediated Central
SO Neural plasticity
LA English
DT Review
AB Although pain is regarded as a global public health priority, analgesic therapy  remains a significant challenge. Pain is a hypersensitivity state caused by  peripheral and central sensitization, with the latter considered the culprit for  chronic pain. This study summarizes the pathogenesis of central sensitization  from the perspective of neuroglial crosstalk and synaptic plasticity and  underlines the related analgesic mechanisms of acupuncture. Central sensitization  is modulated by the neurotransmitters and neuropeptides involved in the ascending  excitatory pathway and the descending pain modulatory system. Acupuncture  analgesia is associated with downregulating glutamate in the ascending excitatory  pathway and upregulating opioids, 𝛾-aminobutyric acid, norepinephrine, and  5-hydroxytryptamine in the descending pain modulatory system. Furthermore, it is  increasingly appreciated that neurotransmitters, cytokines, and chemokines are  implicated in neuroglial crosstalk and associated plasticity, thus contributing  to central sensitization. Acupuncture produces its analgesic action by inhibiting  cytokines, such as interleukin-1β, interleukin-6, and tumor necrosis factor-α,  and upregulating interleukin-10, as well as modulating chemokines and their  receptors such as CX3CL1/CX3CR1, CXCL12/CXCR4, CCL2/CCR2, and CXCL1/CXCR2. These  factors are regulated by acupuncture through the activation of multiple signaling  pathways, including mitogen-activated protein kinase signaling (e.g., the p38,  extracellular signal-regulated kinases, and c-Jun-N-terminal kinase pathways),  which contribute to the activation of nociceptive neurons. However, the responses  of chemokines to acupuncture vary among the types of pain models, acupuncture  methods, and stimulation parameters. Thus, the exact mechanisms require future  clarification. Taken together, inhibition of central sensitization modulated by  neuroglial plasticity is central in acupuncture analgesia, providing a novel  insight for the clinical application of acupuncture analgesia.
C1 Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Suzuka University of Medical Science, Suzuka 5100293, Japan.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   School of Acupuncture & Moxibustion and Tuina, Tianjin University of Traditional 
   National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China.
   Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
   National Clinical Research Center for Chinese Medicine Acupuncture and 
   School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
NR 0
TC 0
SN 1687-544
EI 2090-590
J9 Neural Plast
PD FEB 4
PY 2021
VL 2021
IS 
BP 8881557
EP 8881557
DI 10.1155/2021/8881557
PG 0
WC Acupuncture Analgesia; methods; Animals; Cytokines; immunology; Humans; Neuroglia; immunology; Neuronal Plasticity; physiology; Pain; immunology; Pain Management; methods
UT PubMed:33531894
PM 33531894
DA 2021-02-04
ER

PT J
AU Dai, L
   Liu, Y
   Ji, G
   Xu, YX
AF Dai, Liang
   Liu, Yang
   Ji, Guang
   Xu, Yangxian
TI Acupuncture and Derived Therapies for Pain in Palliative Cancer Management: Systematic Review and Meta-Analysis Based on Single-Arm and Controlled Trials
SO JOURNAL OF PALLIATIVE MEDICINE
LA English
DT Review
DE acupuncture; cancer pain; systematic review
ID induced peripheral neuropathy; quality-of-life; clinical-trials; symptoms; care; electrostimulation; placebos; outcm
AB Background: Acupuncture is a classical complementary therapy, but benefits in palliative cancer pain are still unclear due to lack of consistent evidence. Objectives: To comprehensively evaluate the effectiveness of acupuncture and derived therapies (such as electroacupuncture, laser acupuncture, and transcutaneous electrical nerve stimulation) for analgesia in palliative cancer care based on both single-arm and controlled trials. Design: Eight databases were searched from inception to August 31, 2020. Both single-arm trials and controlled trials were included. The primary outcome was the change in pain intensity, as evaluated by the numeric rating scale (NRS) and the visual analog scale. Subjects: Adults with cancer. Results: Forty-one controlled studies with 2685 participants and 18 single-arm studies with 1084 participants were included. For controlled trials, meta-analysis indicated that acupuncture and derived therapies in addition led to greater reductions in the NRS score than conventional analgesics alone (weighted mean difference [WMD]: 1.33 [0.85-1.82], p < 0.001). For single-arm trials, meta-analysis showed that both the immediate effect (WMD: 1.57 [1.43-1.71], p < 0.001) and long-term longitudinal effect (WMD: 1.81 [1.25-2.37], p < 0.001) of acupuncture on analgesia were positive, as evaluated by the NRS, respectively. The benefits of acupuncture and derived therapies were also seen in quality of life and the global improvement rate. LI4 (Hegu) was the most frequently used acupoint. Conclusions: This systematic review supported the application of acupuncture and derived therapies for managing pain during palliative cancer care from two dimensions. Further studies could explore the effect of acupuncture on other predominant symptoms in palliative cancer patients.
C1 [Dai, Liang; Ji, Guang] Shanghai Univ Tradit Chinese Med, Inst Digest Dis, Longhua Hosp, Shanghai, Peoples R China.
   [Liu, Yang; Xu, Yangxian] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Gastrointestinal Surg, 725 South Wanping Rd, Shanghai 200032, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine
RP Xu, YX (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Gastrointestinal Surg, 725 South Wanping Rd, Shanghai 200032, Peoples R China.
EM xuyangxian@163.com
FU Shanghai Three-year Action Plan for Accelerating the Development of Traditional Chinese Medicine [ZY(2018-2020)-CCCX-2002-01]
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2002, NIH CONSENS STATE SCI STATEMENTS, V19, P1
   Unknown -, 2019, MOD DIG INTERVENTION, V0, P0
   Unknown -, 2020, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: PROSTATE CANCER VERSION 2, V0, P0
   Unknown -, 2018, WHO GUIDELINES FOR THE PHARMACOLOGICAL AND RADIOTHERAPEUTIC MANAGEMENT OF CANCER PAIN IN ADULTS AND ADOLESCENTS, V0, P0
   Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   Bennett MI, 2010, J PAIN, V11, P351, DOI 10.1016/j.jpain.2009.08.002
   Booth CM, 2019, NAT REV CLIN ONCOL, V16, P312, DOI 10.1038/s41571-019-0167-7
   Caraceni A, 2002, J PAIN SYMPTOM MANAG, V23, P239, DOI 10.1016/S0885-3924(01)00409-2
   Chen H, 2013, PANCREATOLOGY, V13, P594, DOI 10.1016/j.pan.2013.10.007
   Chen JF, 1999, LANCET ONCOL, V18, P21
   CHIEN A, 2020, PM R, V0, P0
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Crew Katherine D, 2007, J CANCER SURVIV, V1, P283, DOI 10.1007/s11764-007-0034-x
   Daugherty CK, 2008, J CLIN ONCOL, V26, P1371, DOI 10.1200/JCO.2007.13.5335
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Deng, 2015, MOD J INTEGR TRADIT, V24, P608
   Deng G, 2020, PAIN MED, V21, P636, DOI 10.1093/pm/pnz190
   Du, 2018, MOD CHIN CLIN MED, V25, P17
   Du H, 2016, JAMA-J AM MED ASSOC, V51, P270
   Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Fan LY, 2017, HEBEI J TRADITIONAL CHINESE MED., V29, P36, DOI 10.3969/j.issn.1672-0369.2017.11.017
   Filshie J, 1996, PALLIATIVE MED, V10, P145, DOI 10.1177/026921639601000209
   Fu, 2017, PRACT CLIN J INTEGR, V17, P115
   [付烊 Fu Yang], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P768
   Gadsby JG, 1997, COMPLEMENTARY THER MED, V5, P13, DOI 10.1016/S0965-2299(97)80084-2
   Gao Xin, 2020, ZHONGGUO ZHEN JIU, V40, P601, DOI 10.13703/j.0255-2930.20190531-k0001
   Gao XL, 2002, MOD NURS, V8, P588
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Garcia MK, 2014, INTEGR CANCER THER, V13, P133, DOI 10.1177/1534735413510558
   Guo Z, 2015, INT J TRAD CHIN MED, V37, P371
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Hampton T, 2006, JAMA-J AM MED ASSOC, V296, P265, DOI 10.1001/jama.296.3.265
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   [惠建荣 Hui Jianrong], 2019, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V60, P146
   Jordan K, 2018, ANN ONCOL, V29, P36, DOI 10.1093/annonc/mdx757
   Kasymjanova G, 2013, CURR ONCOL, V20, P152, DOI 10.3747/co.20.1312
   Kim K, 2018, INTEGR CANCER THER, V17, P1137, DOI 10.1177/1534735418786797
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Li DH, 2017, J GUANGZHOU UNIV TRADIT CHIN MED, V34, P344
   Li Dan, 2020, ZHONGGUO ZHEN JIU, V40, P257, DOI 10.13703/j.0255-2930.20190311-k0001
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Lin L, 2017, PEOPLES MIL SURG, V60, P56
   Liu, 2018, EFFECCT ANAL SAFETY, V0, P0
   Liu J, 2011, CLINIC RESEARCH ON HEPATIC CARCINOMA PAIN RELIVED BY NEEDLING WITH EIGHT METHODS OF INTELLIGENT TURTLE AND WESTERN MEDICINE, V0, P0
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu DR, 2018, WORLD J INTEGR TRADIT WEST MED, V13, P116, DOI 10.13935/j.cnki.sjzx.180132
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Macdonald G, 2012, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD001930.pub3
   Makady A, 2017, VALUE HEALTH, V20, P858, DOI 10.1016/j.jval.2017.03.008
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   National Health Commission of the Peoples Republic of China, 2018, CHIN CLIN ONCOL, V23, P937
   Nystrom E, 2008, ACUPUNCT MED, V26, P27, DOI 10.1136/aim.26.1.27
   Peng J, 2012, SHANG J ACUPUNCT MOXIBUST, V31, P236
   Qiao DP, 2008, J PRACT ONCOL, V22, P446
   Ruela LD, 2018, REV ESC ENFERM USP, V52, P0, DOI 10.1590/S1980-220X2017040503402
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Sima L, 2009, J CLIN ONCOL, V27, P0
   Simone CB II, 2012, CLIN J PAIN, V28, P157, DOI 10.1097/AJP.0b013e318223be30
   Smith TJ, 2010, J PAIN SYMPTOM MANAG, V40, P883, DOI 10.1016/j.jpainsymman.2010.03.022
   Song SY, 2020, INTEGR CANCER THER, V19, P0, DOI 10.1177/1534735420925519
   Tan GS, 2012, WORLD J INTEGR MED, V7, P147
   Tao Y, 1998, RESP RES, V18, P17
   Thompson LMA, 2015, J ACUPUNCT MERIDIAN, V8, P127, DOI 10.1016/j.jams.2015.04.002
   Tofthagen C, 2015, J PALLIAT MED, V18, P878, DOI 10.1089/jpm.2015.0143
   Wang, 2014, J TRADIT CHIN MED RE, V27, P55
   Wang, 2007, J PRACT TRADIT CHIN, V21, P96
   Wang, 2017, MOL CLIN ONCOL, V52, P684
   Wang C, 2019, J NEW CHIN MED, V51, P242, DOI 10.13457/J.CNKI.JNCM.2019.10.069
   Wang DJ, 2018, CLIN RES ACUPUNCTURE, V0, P0
   Watanabe S, 2009, SUPPORT CARE CANCER, V17, P675, DOI 10.1007/s00520-008-0522-1
   Wells GA, 2019, THE NEWCASTLE-OTTAWA SCALE (NOS) FOR ASSESSING THE QUALITY OF NONRANDOMIZED STUDIES IN META-ANALYSES, V0, P0
   [文进 WEN Jin], 2007, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V7, P606
   Wu Qiu-Lan, 2019, ZHONGGUO ZHEN JIU, V39, P1051, DOI 10.13703/j.0255-2930.2019.10.005
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Xi, 2018, CLIN OBSERVATION ANA, V0, P0
   Yao, 2012, CHIN HLTH CARE NUTR, V19, P78
   Zhang, 2012, BREAST CANCER RES TR, V9, P244
   Zhang S, 2012, J EMERG TRADIT CHIN, V21, P1848
   Zhang X, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-025218
NR 90
TC 8
Z9 9
U1 1
U2 49
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-6218
EI 1557-7740
J9 J PALLIAT MED
JI J. Palliat. Med.
PD JUL 1
PY 2021
VL 24
IS 7
BP 1078
EP 1099
DI 10.1089/jpm.2020.0405
EA MAR 2021
PG 22
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA SS2QO
UT WOS:000628685000001
PM 33691493
DA 2026-01-16
ER

PT J
AU Ruiz-López, D
   Alonso-Babarro, A
AF Ruiz-Lopez, Diego
   Alonso-Babarro, Alberto
TI Questionnaire made to understand the opioid analgesics prescription habits in the community of Madrid (Spain)
SO ATENCION PRIMARIA
LA Spanish
DT Article
DE Pain; Primary Care; Palliative Care; Opioids
ID chronic noncancer pain; palliative-care; abuse; trends; management; addiction; mortality; patterns; misuse; risk
AB Objective: Pain is the fearest and disabling symptom for cancer patients. The cornerstone of treatment is opioid analgesics. The objective of this research was to relate the opioid consumption existing in the Community of Madrid (CM) with the prescription habits expressed by the Primary Care (PrC) and Palliative Care (PalC) physicians. Design: An opioid prescription habits questionnaire was designed. Sampling was consecutive non-probability. Site: PrC and specific PalC resources in the CM. Participants: The study population included all the family doctors who worked in PrC in the Madrid Public Health Service and all the physicians who worked in some specific PalC resources, both home-based teams and supportive hospital teams in the CM of the public and private/concerted health network services. Main measurements: We asked about the strong and weak opioids most used in moderate-severe oncological and non-oncological pain, the preferred administration route, the safety in the use of opioids in the treatment of pain and the preferred clinical practice guidelines. Results: The questionnaire was answered by 840 PrC physicians (20%) and 56 PaIC physicians (45%). For the treatment of moderate-severe cancer pain in both groups of professionals, the first choice was morphine; however, in non-cancer pain for PrC it was fentanyl and morphine for PalC professionals. Regarding the route of administration, 70% of family doctors and 87% of PalC physicians stated that the oral route was the first choice, compared to 27% in PrC and 5% in PalC who preferred the transdermal route. The PrC physicians rated their ability to use opioids as average (4-7/10), while the palliativists considered it as high (8-10/10). In PrC, they declared that they knew, above all, the European Association for Palliative Care (EAPC) and National Institute for Health and Care Excellence (NICE) guidelines, although the largest number answered that they trusted their experience. PaIC physicians preferred to use the EAPC guide. Conclusions: There is a clear disagreement between the actual consumption of opioids and the prescribing habits manifested by family doctors, as well as a false certainty in prescribing these drugs. (C) 2021 Published by Elsevier Espana, S.L.U.
C1 [Ruiz-Lopez, Diego] Ctr Salud Legazpi, Equipo Soporte Paliat Domiciliario ESAPD, Direcc Asistencial Noroeste Atenc Primaria, Serv Madrileno Salud, Madrid, Spain.
   [Alonso-Babarro, Alberto] Hosp Univ La Paz, Serv Madrileno Salud, Unidad Cuidados Paliat, Madrid, Spain.
C3 Hospital Universitario La Paz
RP Ruiz-López, D (corresponding author), Ctr Salud Legazpi, Equipo Soporte Paliat Domiciliario ESAPD, Direcc Asistencial Noroeste Atenc Primaria, Serv Madrileno Salud, Madrid, Spain.
EM diego.ruiz@salud.madrid.org
CR Alford DP, 2016, NEW ENGL J MED, V374, P301, DOI 10.1056/NEJMp1512932
   Andalucia Consejeria de Salud, 2011, US SEG OP PAC SIT TE, V0, P0
   Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524
   Belisario JSM, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.MR000042.pub2
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Chou R, 2009, J PAIN, V10, P131, DOI 10.1016/j.jpain.2008.10.009
   Clausen TG, 1997, ACTA ANAESTH SCAND, V41, P162, DOI 10.1111/j.1399-6576.1997.tb04632.x
   Correa-Casado M, 2017, ATEN PRIM, V49, P326, DOI 10.1016/j.aprim.2016.09.003
   Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI 10.1056/NEJMsa1406143
   de Marchis P, 2012, ESTUDIO MENSAJE PERI, V18, P0
   de Rada VD, 2012, PAPERS, V97, P193
   Duhagon MA, 2013, ANN ONCOL, V24, P558, DOI 10.1093/annonc/mds610
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917
   Giraudon I, 2013, BRIT J CLIN PHARMACO, V76, P823, DOI 10.1111/bcp.12133
   Valle MCGD, 2018, MED PALIATIVA, V25, P281, DOI 10.1016/j.medipa.2016.12.002
   Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006
   Hui D, 2019, JAMA-J AM MED ASSOC, V321, P511, DOI 10.1001/jama.2018.18640
   Jamison Robert N, 2014, J OPIOID MANAG, V10, P375, DOI 10.5055/jom.2014.0234
   Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710
   Katz NP, 2007, CLIN J PAIN, V23, P103, DOI 10.1097/01.ajp.0000210953.86255.8f
   Mansoa SL, 2018, FMC - FORMACIÓN MÉDICA CONTINUADA EN ATENCIÓN PRIMARIA, V25, P99, DOI 10.1016/j.fmc.2017.05.010
   Llaurado O, 2006, INVESTIGACION Y MARKETING, V91, P25
   Manjiani D, 2014, OCHSNER J, V14, P208
   Martínez-Nicolás I, 2016, REV CALID ASSIST, V31, P55, DOI 10.1016/j.cali.2015.06.009
   Nguyen LMT, 2013, J PAIN SYMPTOM MANAG, V45, P506, DOI 10.1016/j.jpainsymman.2012.02.023
   Peretti-Watel P, 2003, PALLIAT SUPPORT CARE, V1, P345
   Pezalla EJ, 2017, J PAIN RES, V10, P0, DOI 10.2147/JPR.S129553
   Portenoy RK, 2014, J CLIN ONCOL, V32, P1662, DOI 10.1200/JCO.2013.52.5188
   Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5
   Ray WA, 2016, JAMA-J AM MED ASSOC, V315, P2415, DOI 10.1001/jama.2016.7789
   Ruiz-Lopez D, 2019, REV CLIN ESP, V0, P0
   Scholten W, 2016, J PAIN PALLIAT CARE, V30, P4, DOI 10.3109/15360288.2015.1136368
   Scholten Willem, 2014, J PAIN PALLIAT CARE PHARMACOTHER, V28, P40, DOI 10.3109/15360288.2013.873513
   Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339
   Spitz A, 2011, BMC GERIATR, V11, P0, DOI 10.1186/1471-2318-11-35
   Sproule B, 2009, CAN FAM PHYSICIAN, V55, P68
   Stannard C, 2013, BMJ-BRIT MED J, V347, P0, DOI 10.1136/bmj.f5108
   Tong ST, 2019, ANN FAM MED, V17, P200, DOI 10.1370/afm.2357
   Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771
   von Gunten CF, 2016, J PALLIAT MED, V19, P348, DOI 10.1089/jpm.2016.0079
   Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1
   Weisberg DF, 2014, INT J DRUG POLICY, V25, P1124, DOI 10.1016/j.drugpo.2014.07.009
   Worrld Health Organization, 1996, CANC PAIN REL GUID O, V2nd, P0
NR 46
TC 1
Z9 1
U1 0
U2 5
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0212-6567
EI 1578-1275
J9 ATEN PRIM
JI Aten. Prim.
PD JUN-JUL 15
PY 2021
VL 53
IS 6
BP 
EP 
DI 10.1016/j.aprim.2021.102040
EA APR 2021
PG 9
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA SU3KV
UT WOS:000663040600007
PM 33857704
DA 2026-01-16
ER

PT J
AU Woodbury, A
   Myles, B
AF Woodbury, Anna
   Myles, Bati
TI Integrative Therapies in Cancer Pain.
SO Cancer treatment and research
LA English
DT Journal Article
AB Integrative medicine is an approach to medical care that embraces all effective  therapies including complementary treatments such as acupuncture and hypnosis.  There is growing use of complementary therapies in the cancer patient population,  making it important that health care providers be aware of both the risks and  benefits of treatments that lie outside of the traditional allopathic medicine  paradigm. This chapter will explore some of the most common and well-investigated  complementary therapies for the treatment and prevention of cancer-related pain.  This will include discussions of: acupuncture, dietary supplements, massage,  guided imagery and cryotherapy among others. The goal of this is to provide a  framework for discussions between medical providers and their patients to ensure  safety, discussion of all available treatments, and to facilitate open lines of  communication.
C1 Anesthesiology, Veterans Affairs Medical Center, Emory University School of Medicine, Atlanta Veterans Affairs Healthcare System, 1670 Clairmont Rd, Decatur,GA, 30033, USA. anna.woodbury@emory.edu.
   Emergency Medicine Physician, Palliative Care Fellow, Emory University School of Medicine, Atlanta, GA, USA.
NR 0
TC 0
SN 
EI 0927-304
J9 Cancer Treat Res
PD SEP 21
PY 2021
VL 182
IS 
BP 281
EP 302
DI 10.1007/978-3-030-81526-4_18
PG 21
WC Acupuncture Therapy; Cancer Pain; therapy; Complementary Therapies; Humans; Integrative Medicine; Massage; Neoplasms; complications
UT PubMed:34542889
PM 34542889
DA 2021-09-21
ER

PT J
AU Wu, CC
   Yang, JF
   Zhang, QY
   Liu, W
   Liao, K
   Hu, B
AF Wu, Chuncheng
   Yang, Juliana F.
   Zhang, Qiongying
   Liu, Wei
   Liao, Ke
   Hu, Bing
TI Successful cholangioscopic electrocoagulation for biliary papillomatosis: Report covering six cases (with video)
SO GASTROENTEROLOGIA Y HEPATOLOGIA
LA English
DT Article
DE Cholangioscopic; Electrocoagulation; Biliary papillomatosis
ID bile-ducts; therapy
AB Background: Biliary papillomatosis is a rare type of papillomatosis. Depending on the location of the disease, radical surgical resection or liver transplants are the treatment of choice. These radical surgical options may be unrealistic in patients who are not surgical candidates or who are unwilling to consider surgery. Aims: To evaluate the effectiveness of endoscopic electrocoagulation for the biliary papillomatosis. Methods: In this case series, we report six patients with unresectable biliary papillomatosis who underwent cholangioscopic electrocoagulation using needle knife and their clinic follow up information. Results: After patients received cholangioscopy with electrocoagulation of the residual biliary papilloma, the daily T-tube drainage volume increased to 200-400 ml with improvement in the drainage content and significant relief of clinical symptoms, such as jaundice and abdominal pain. Conclusion: This method of using electrocoagulation to directly target and destroy tumor tissue is a safe and effective alternative for those with unresectable disease, and this method has shown to enhance T-tube drainage volume and improve patients' overall clinical symptoms. (C) 2021 Elsevier Espana, S.L.U. All rights reserved.
C1 [Wu, Chuncheng; Zhang, Qiongying; Liu, Wei; Liao, Ke; Hu, Bing] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Peoples R China.
   [Yang, Juliana F.] Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Digest & Liver Dis, Nashville, TN USA.
C3 Sichuan University; Vanderbilt University
RP Hu, B (corresponding author), Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Peoples R China.
EM hubingnj@163.com
FU Sichuan Province Science and Technology Department (China) [2018SZ0134]
CR Adioui Tarik, 2014, J MED CASE REP, V8, P148, DOI 10.1186/1752-1947-8-148
   Baughman SM, 2005, J GASTROINTEST SURG, V9, P215, DOI 10.1016/j.gassur.2004.07.005
   Beavers K L, 2001, LIVER TRANSPL, V7, P264, DOI 10.1053/jlts.2001.22322
   Bechmann LP, 2008, WORLD J GASTROENTERO, V14, P4234, DOI 10.3748/wjg.14.4234
   Caroli J, 1973, CLIN GASTROENTEROL, V2, P147
   CHAPPET V, 1894, LYON MEDICAL, V76, P145
   DAbrigeon G, 1997, GASTROINTEST ENDOSC, V46, P237, DOI 10.1016/S0016-5107(97)70093-2
   Donnellan F, 2011, ENDOSCOPY, V43, PE86, DOI 10.1055/s-0030-1255976
   Gu CC, 2015, ONCOL LETT, V10, P3315, DOI 10.3892/ol.2015.3682
   Gunvén P, 2000, CANCER-AM CANCER SOC, V89, P69, DOI 10.1002/1097-0142(20000701)89:1<69::AID-CNCR10>3.0.CO;2-9
   HOLTKAMP W, 1994, AM J GASTROENTEROL, V89, P2253
   Hsu YQ, 2014, HONG KONG MED J, V20, P0
   Itoi T, 2009, DIGEST ENDOSC, V21, PS103, DOI 10.1111/j.1443-1661.2009.00849.x
   Iwasaki Y, 2002, SURG TODAY, V32, P1019, DOI 10.1007/s005950200206
   Jazrawi SR, 2009, GASTROINTEST ENDOSC, V69, P372, DOI 10.1016/j.gie.2008.03.1095
   Kim HJ, 2000, ENDOSCOPY, V32, P389, DOI 10.1055/s-2000-8996
   Kim YS, 1998, ENDOSCOPY, V30, P763, DOI 10.1055/s-2007-1001418
   Kim YS, 1998, GASTROINTEST ENDOSC, V47, P563
   Lee PSF, 2001, CLIN RADIOL, V56, P591, DOI 10.1053/crad.2000.0610
   Lee SS, 2004, CANCER-AM CANCER SOC, V100, P783, DOI 10.1002/cncr.20031
   Li ZQ, 2015, INT J CLIN EXP MED, V8, P21802
   NAKAJIMA T, 1988, HUM PATHOL, V19, P1228, DOI 10.1016/S0046-8177(88)80156-4
   Parsi MA, 2015, GASTROINTEST ENDOSC, V81, P231, DOI 10.1016/j.gie.2014.04.040
   Sotiropoulos GC, 2003, SURG TODAY, V33, P781, DOI 10.1007/s00595-003-2595-2
   TAGUCHI J, 1993, ARCH PATHOL LAB MED, V117, P944
   Vassiliou Ioannis, 2006, WORLD J SURG ONCOL, V4, P71, DOI 10.1186/1477-7819-4-71
   Yeh TS, 2006, ANN SURG, V244, P248, DOI 10.1097/01.sla.0000217636.40050.54
   Yeung Yuk Pang, 2003, J HEPATOBILIARY PANCREAT SURG, V10, P390, DOI 10.1007/s00534-002-0837-0
NR 28
TC 3
Z9 3
U1 0
U2 7
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0210-5705
EI 
J9 GASTROENT HEPAT-BARC
JI Gastroenterol. Hepatol.
PD OCT 15
PY 2021
VL 44
IS 8
BP 546
EP 551
DI 10.1016/j.gastrohep.2020.12.012
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA YO2YX
UT WOS:000747812000002
PM 33617929
DA 2026-01-16
ER

PT J
AU Lu, DR
   Xia, YQ
   Chen, F
   Wang, NJ
   He, SQ
   Wang, F
   Zhu, SJ
AF Lu, Dian-Rong
   Xia, Yu-Qing
   Chen, Feng
   Wang, Ning-Jun
   He, Sheng-Qi
   Wang, Fang
   Zhu, Shi-Jie
TI [Effect of electrothermal acupuncture on moderate to severe cancer pain with
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE electrothermal acupuncture; moderate to severe cancer pain; pain remission rate; yin-cold stagnation
AB OBJECTIVE: To observe the effectiveness and safety of electrothermal acupuncture  therapy for patients of moderate to severe cancer pain with yin-cold stagnation.  METHODS: A total of 60 patients of moderate to severe cancer pain with yin-cold  stagnation were randomized into an observation group and a control group, 30  cases in each one. In the control group, opioid painkillers (oxycodone  hydrochloride prolonged-release tablet or morphine sulfate sustained-release  tablet) were taken. On the basis of the control group, electrothermal acupuncture  was applied at Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Hegu (LI 4),  Sanyinjiao (SP 6) in the observation group, 30 min each treatment, once a day for  5 days. Before and after treatment, the scores of pain numerical rating scale  (NRS) and Karnofsky performance scale (KPS) were observed in the two groups. The  pain remission rate, reduction of opioid painkillers and safety were compared.  RESULTS: The variation of NRS scores in the observation group were larger than  the control group 3, 5 days into treatment (P<0.01, P<0.05). The variation of KPS  score in the observation group was larger than the control group after treatment  (P<0.05). The pain remission rate was 100.0% (30/30) in the observation group,  higher than 86.7% (26/30) in the control group (P<0.05). The reduction of opioid  painkillers in the observation group was larger than the control group (P<0.01).  There was no adverse reaction during the treatment in the two groups. CONCLUSION:  On the basis of the conventional western medication for analgesia, electrothermal  acupuncture could relieve pain, reduce the dose of opioid painkillers and improve  the quality of life in patients of moderate to severe cancer pain with yin-cold  stagnation, has a better safety.
C1 Department of Oncology, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Electrothermal Acupuncture, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Acupuncture and Moxibustion, Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Oncology, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Oncology, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Oncology, China Academy of Chinese Medical Sciences, Beijing 100102, China.
   Department of Oncology, China Academy of Chinese Medical Sciences, Beijing 100102, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 1
PY 2021
VL 41
IS 2
BP 121
EP 4
DI 10.13703/j.0255-2930.20190320-0010
PG -117
WC Acupuncture Points; Acupuncture Therapy; Cancer Pain; therapy; Humans; Neoplasms; complications; Oxycodone; Quality of Life; Treatment Outcome
UT PubMed:33788457
PM 33788457
DA 2021-04-01
ER

PT J
AU Wang, JL
   Zhang, QH
   Deng, YW
   Deng, G
   Huang, FH
   Zhou, YD
   Jia, MY
   Yi, HR
AF Wang, Jinlong
   Zhang, Quanhui
   Deng, Yongwen
   Deng, Gen
   Huang, Feihong
   Zhou, Yiduo
   Jia, Mingyan
   Yi, Haoran
TI Efficacy and safety of heat-sensitive moxibustion in the treatment of ulcerative colitis A protocol for a systematic review and meta-analysis
SO MEDICINE
LA English
DT Review
DE heat-sensitive moxibustion; systematic review and meta Analysis; ulcerative colitis
AB Background: Ulcerative colitis (UC) is a chronic nonspecific intestinal inflammatory disease with unclear etiology occurring in the colonic mucosa. Its clinical manifestations are characterized by recurrent abdominal pain, diarrhea, mucous pus, and blood stool. The severity of the disease varies, and itis characterized by a high recurrence rate. Because of its long course of disease, easy to relapse, protracted and difficult to recover, seriously affect the quality of life, increase the economic burden of patients and society, and even the risk of developing cancer, it has become one of the hot issues of general concern in the medical field. Heat-sensitive moxibustion therapy has shown strong advantages in the treatment of UC, and the curative effect is accurate. therefore, this paper will carry out a systematic evaluation and meta analysis of the efficacy and safety of heat-sensitive moxibustion in the treatment of UC. Methods: We will be searching 8 electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, the China National Knowledge Infrastructure, Chinese Science and Technology Periodical Database, Wanfang Database, and Chinese Biomedical Literature Database. We will search above electronic databases from the beginning to December 2020, without any language restriction. Clinical efficacy, including total effective rate or cure rate, clinical symptom integral (abdominal pain, diarrhea, purulent stool), and recurrence rate will be accepted as the primary outcomes. The changes of cytokine Hs-CRP, IL-6, TNF-alpha levels in serum, and improvement of colorectal mucosa will be used as secondary outcomes. RevMan 5.3 software will be used for statistical analysis. The result about the curative effect and safety of heat-sensitive moxibustion for UC will be presented as risk ratio for dichotomous data and mean differences with a 95% confidence interval for continuous data. Results: When this research program is completed, the relevant results can be obtained. Conclusions: The results of this study will provide reliable evidence for the efficacy and safety of heat-sensitive moxibustion in the treatment of UC. INPLASY Registration number: INPLASY20201101034.
C1 [Wang, Jinlong; Deng, Yongwen; Deng, Gen; Huang, Feihong; Zhou, Yiduo; Jia, Mingyan; Yi, Haoran] Jiangxi Univ Tradit Chinese Med, Coll Clin Med, Nanchang, Jiangxi, Peoples R China.
   [Zhang, Quanhui] Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Nanchang 330006, Jiangxi, Peoples R China.
C3 Jiangxi University of Traditional Chinese Medicine; Jiangxi University of Traditional Chinese Medicine
RP Zhang, QH (corresponding author), Jiangxi Univ Tradit Chinese Med, Affiliated Hosp, Nanchang 330006, Jiangxi, Peoples R China.
EM 36791584@qq.com
FU Scientific Research Project of Jiangxi Health and Health Commission [2017A016]
CR Bi Tingting, 2019, CHIN FOLK THER, V27, P105
   Chen Ri-Xin, 2010, ZHEN CI YAN JIU, V35, P311
   Chen Ri-xin, 2008, ZHONGGUO ZHEN JIU, V28, P44
   Guo BJ, 2017, ANN NY ACAD SCI, V1401, P37, DOI 10.1111/nyas.13414
   Lijiu, 2019, ANHUI MED, V23, P860
   Lu Liqun, 2017, SICHUAN TRADIT CHIN, V35, P95
   Lu Shuhong, 2013, JIANGXI TRADIT CHIN, V44, P46
   Lu Shuhong, 2016, BRIGHT CHIN MED, V31, P1604
   Ouyang Q, 2012, J DIGEST DIS, V13, P195, DOI 10.1111/j.1751-2980.2012.00579.x
   Xiang Guo, 2010, CHINESE FOLK THERAPY, V18, P12
   Zhang Juan, 2020, LIAON- ING J TRADIT CHIN MED, V47, P203
   Zhao Qingxi, 2015, J MED C QINGDAO U, V51, P486
   Zhu Yannan, 2019, CLIN RES TRADITIONAL, V11, P146
NR 13
TC 7
Z9 9
U1 1
U2 29
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JAN 29
PY 2021
VL 100
IS 4
BP 
EP 
DI 10.1097/MD.0000000000024078
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA PZ6FF
UT WOS:000612833500050
PM 33530201
DA 2026-01-16
ER

PT J
AU Wong, CHL
   Wong, W
   Lin, WL
   Au, DKY
   Wu, JCY
   Leung, TH
   Wu, IXY
   Chung, VCH
AF Wong, Charlene H L
   Wong, Wendy
   Lin, Wai Ling
   Au, David K Y
   Wu, Justin C Y
   Leung, Ting Hung
   Wu, Irene X Y
   Chung, Vincent C H
TI Prioritizing Chinese medicine clinical research questions in cancer palliative
SO Health expectations : an international journal of public participation in health
LA English
DT Journal Article
DE palliative care; patient participation; research priorities; stakeholder participation; traditional chinese medicine
AB BACKGROUND: Chinese medicine (CM) modalities, including acupuncture and Chinese  herbal medicine (CHM), are popular palliative interventions among patients with  cancer, but further clinical research is required to assess their effectiveness  and safety. OBJECTIVE: To prioritize top ten important CM clinical research  questions from patients with cancer, cancer survivors and caregivers'  perspectives via a face-to-face prioritization workshop in Hong Kong. METHODS: A  list of 25 CM clinical research questions for cancer palliative care, which were  identified from existing systematic reviews (SRs) and overview of SRs, was  presented to 17 participants (patients with cancer [n = 5], cancer survivors  [n = 6] and caregivers [n = 6]). The participants were then invited to establish  consensus on prioritizing top ten research questions. RESULTS: Among the top ten  priorities, five (50%) focused on acupuncture and related therapies, while five  (50%) were on CHM. The three most important research priorities were (i) manual  acupuncture plus opioids for relieving pain; (ii) CHM for improving quality of  life among patients receiving chemotherapy; and (iii) concurrent use of CHM plus  loperamide for reducing stomatitis. CONCLUSION: The top ten participant-endorsed  CM clinical research priorities for cancer palliative care can guide local  researchers on future direction. They can also inform local research funders on  patient-centred allocation of limited funding. Under limited research funding,  the most important co-prioritized research question from professional and patient  perspectives may be addressed first. PATIENT OR PUBLIC CONTRIBUTION: Patients  with cancer, cancer survivors and caregivers participated in conduct of the study  to prioritize CM clinical research questions.
C1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
   Jockey Club School of Public Health and Primary Care, The Chinese University of 
   National Institution of TCM Constitution and Preventive Medicine, Beijing University of Chinese Medicine, Beijing, China.
   Yat Hei Hong Kong Company Limited, Central, Hong Kong.
   Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
   Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
   Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, Hong Kong.
   Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong.
   School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong 
   Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.
   Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong.
   School of Chinese Medicine, The Chinese University of Hong Kong, Shatin, Hong
NR 0
TC 0
SN 1369-762
EI 1369-651
J9 Health Expect
PD JUN 10
PY 2021
VL 24
IS 4
BP 1487
EP 1497
DI 10.1111/hex.13289
PG 10
WC Caregivers; Humans; Medicine, Chinese Traditional; Neoplasms; drug therapy; Palliative Care; Quality of Life
UT PubMed:34107142
PM 34107142
DA 2021-06-10
ER

PT J
AU He, Y
   Zhang, H
   Li, Y
   Long, S
   Xiao, S
   May, BH
   Lin, Zhang A
   Guo, X
   Xue, CC
   Lu, C
AF He, Yihan
   Zhang, Haibo
   Li, Yifang
   Long, Shunqin
   Xiao, Shujing
   May, Brian H
   Lin Zhang, Anthony
   Guo, Xinfeng
   Xue, Charlie Changli
   Lu, Chuanjian
TI Acupuncture combined with opioids for cancer pain: a pilot pragmatic randomized
SO Acupuncture in medicine : journal of the British Medical Acupuncture Society
LA English
DT Journal Article
DE acupuncture; cancer pain; pharmacological analgesics; pragmatic trial
AB OBJECTIVE: Given the existing evidence for the analgesic effect of acupuncture,  the current study aimed to assess whether acupuncture could be feasible and  manageable as an adjunctive therapy for cancer pain in a real-world hospital  setting. METHODS: Thirty patients in an Oncology department with moderate or  severe pain were recruited and randomized to an adjunctive acupuncture group or  control group, who received pharmacotherapy for pain management without  acupuncture. The duration of the treatment course was 1 week with a 2-week  follow-up. In total, four acupuncture sessions were administered, on days 1/2/4/6  of the trial. Pain intensity was measured using a numerical rating scale (NRS)  and the daily opioid dose was recorded. RESULTS: The overall trends favored  acupuncture for both pain intensity and daily opioid consumption. The proportion  of participants experiencing at least a 2-point reduction in the NRS at the end  of the treatment was 93% (n = 14/15) for the acupuncture group and 57% (n = 8/14)  for the control group (risk difference (RD) 36.1%, 95% confidence interval (CI)  [7.4%-65.0%]; relative risk (RR) 1.63, 95% CI [1.02-2.62]; p = 0.04). There were  no serious adverse events and no dropouts during the treatment. CONCLUSION: This  pilot study showed that adding acupuncture to routine analgesia for patients with  cancer pain was feasible and acceptable to patients. The clinical effects of  adding acupuncture as an adjunctive therapy need to be further evaluated.  CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR1800017023 (Chinese Clinical Trial  Registry).
C1 China-Australia International Research Centre for Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital ofGuangzhou University of Chinese Medicine, Guangdong Provincial Academy of ChineseMedical Sciences, Guangzhou, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, GuangdongProvincial Academy of Chinese Medical Sciences, Guangzhou, China.
   Department of Traditional Therapy, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of ChineseMedicine, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou,China.
   Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, GuangdongProvincial Academy of Chinese Medical Sciences, Guangzhou, China.
   Department of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, GuangdongProvincial Academy of Chinese Medical Sciences, Guangzhou, China.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
   China-Australia International Research Centre for Chinese Medicine, School of Health and Biomedical Sciences, RMIT University, Melbourne, VIC, Australia.
   China-Australia International Research Centre for Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital ofGuangzhou University of Chinese Medicine, Guangdong Provincial Academy of ChineseMedical Sciences, Guangzhou, China.
   China-Australia International Research Centre for Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital ofGuangzhou University of Chinese Medicine, Guangdong Provincial Academy of ChineseMedical Sciences, Guangzhou, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   China-Australia International Research Centre for Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital ofGuangzhou University of Chinese Medicine, Guangdong Provincial Academy of ChineseMedical Sciences, Guangzhou, China.
   China-Australia International Research Centre for Chinese Medicine, School of 
   Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China.
NR 0
TC 0
SN 1759-987
EI 
J9 Acupunct Med
PD NOV 11
PY 2021
VL 40
IS 2
BP 133
EP 141
DI 10.1177/09645284211056016
PG 8
WC Acupuncture Therapy; Analgesics, Opioid; therapeutic use; Cancer Pain; drug therapy; Humans; Neoplasms; complications; Pain Management; Pilot Projects
UT PubMed:34755569
PM 34755569
DA 2021-11-11
ER

PT J
AU Ho, EY
   Thompson-Lastad, A
   Lam, R
   Zhang, XY
   Thompson, N
   Chao, MT
AF Ho, Evelyn Y.
   Thompson-Lastad, Ariana
   Lam, Rachele
   Zhang, Xiaoyu
   Thompson, Nicole
   Chao, Maria T.
TI Adaptations to Acupuncture and Pain Counseling Implementation in a Multisite Pragmatic Randomized Clinical Trial
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; pragmatic effectiveness; pain; cancer; implementation; inpatient
ID cancer pain; interventions; management; quality
AB Objectives: As part of a pragmatic effectiveness trial of integrative pain management among inpatients with cancer, the authors sought to understand the clinical context and adaptations to implementation of two study interventions, acupuncture and pain counseling (i.e., pain education and coping skills). Design: The larger study uses a 2 x 2 factorial design with inpatients randomized to: (1) usual care (UC), (2) UC with acupuncture, (3) UC with pain counseling, and (4) UC with acupuncture and pain counseling. The study is being conducted in two hospitals (one academic and one public) and three languages (Cantonese, English, and Spanish). The authors conducted a process evaluation by interviewing study interventionists. Analysis included deductive coding to describe context, intervention, implementation, and inductive thematic coding related to intervention delivery. Results: Interviewees included seven acupuncturists and four pain counselors. Qualitative themes covered adaptations and recognizing site-specific differences that affected implementation. Interventionists adhered closely to protocols and made patient-centered adaptations that were then standardized in broader implementation (e.g., including caregivers in pain counseling sessions; working in culturally nuanced ways with non-English-speaking patients). The public hospital included more patients with recent diagnoses and advanced disease, more ethnically and linguistically diverse patients, less continuity of staffing, and shared patient rooms. At the academic medical center, more patients were familiar with integrative therapies and all were located in single rooms. Providing acupuncture to hospital staff was a key strategy to establish trust, experientially explain the intervention, and create camaraderie and staff buy-in. Conclusions: Providing nonpharmacologic interventions for a pragmatic trial requires adapting to a range of clinical factors. Site-specific factors included greater coordination and resources needed for successful implementation in the public hospital. The authors conclude that adaptation to context and individual patient needs can be done without compromising intervention fidelity and that intervention design should apply principles such as centering at the margins to reduce participation barriers for diverse patient populations.
C1 [Ho, Evelyn Y.] Univ San Francisco, Dept Commun Studies, 2130 Fulton St,KA 313, San Francisco, CA 94117 USA.
   [Ho, Evelyn Y.] Univ Calif San Francisco, Asian Amer Res Ctr Hlth, San Francisco, CA 94143 USA.
   [Thompson-Lastad, Ariana; Lam, Rachele; Zhang, Xiaoyu; Thompson, Nicole; Chao, Maria T.] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA.
   [Thompson-Lastad, Ariana] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Div Gen Internal Med, Dept Family & Community Med, San Francisco, CA 94143 USA.
   [Chao, Maria T.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Div Gen Internal Med, Dept Med, San Francisco, CA 94143 USA.
C3 University of San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco
RP Ho, EY (corresponding author), Univ San Francisco, Dept Commun Studies, 2130 Fulton St,KA 313, San Francisco, CA 94117 USA.
EM eyho@usfca.edu
FU Patient-Centered Outcomes Research Institute Award [CER-1609-36220]; National Institutes of Health National Center for Complementary and Integrative Health [5T32AT003997]; Helen Diller Family Foundation; National Center for Complementary and Integrative Health [T32AT003997] Funding Source: NIH RePORTER
CR Braun V, 2006, QUAL RES PSYCHOL, V3, P77, DOI 10.1191/1478088706QP063OA
   Cotterill S, 2018, BMC MED RES METHODOL, V18, P0, DOI 10.1186/s12874-017-0461-y
   Damschroder LJ, 2009, IMPLEMENT SCI, V4, P0, DOI 10.1186/1748-5908-4-50
   Dedoose, 2018, DED VERS 8 0 35 WEB, V0, P0
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Dusek Jeffery A, 2010, J PATIENT SAF, V6, P48, DOI 10.1097/PTS.0b013e3181d10ad5
   Fisch MJ, 2012, J CLIN ONCOL, V30, P1980, DOI 10.1200/JCO.2011.39.2381
   Ford CL, 2010, SOC SCI MED, V71, P1390, DOI 10.1016/j.socscimed.2010.07.030
   Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574
   Greco MT, 2014, J CLIN ONCOL, V32, P4149, DOI 10.1200/JCO.2014.56.0383
   Griffin KH, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2016-012006
   Harrison JD, 2019, J ALTERN COMPLEM MED, V25, P503, DOI 10.1089/acm.2018.0348
   Hawe P, 2004, BMJ-BRIT MED J, V328, P1561, DOI 10.1136/bmj.328.7455.1561
   Johnson JR, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-486
   Johnson Jill R, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP330, DOI 10.1093/jncimonographs/lgu030
   Kennedy-Martin T, 2015, TRIALS, V16, P0, DOI 10.1186/s13063-015-1023-4
   Loudon K, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h2147
   Moore GF, 2015, BMJ-BRIT MED J, V350, P0, DOI 10.1136/bmj.h1258
   Nate KC, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/394040
   Oh SS, 2015, PLOS MED, V12, P0, DOI 10.1371/journal.pmed.1001918
   Singal AG, 2014, CLIN TRANSL GASTROEN, V5, P0, DOI 10.1038/ctg.2013.13
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Taylor JS, 2003, ACAD MED, V78, P555, DOI 10.1097/00001888-200306000-00003
   Tervalon M, 1998, J HEALTH CARE POOR U, V9, P117
   Waldron EM, 2018, MINDFULNESS, V9, P1671, DOI 10.1007/s12671-018-0920-5
   Zuidgeest MGP, 2017, J CLIN EPIDEMIOL, V88, P7, DOI 10.1016/j.jclinepi.2016.12.023
NR 26
TC 4
Z9 5
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY 1
PY 2021
VL 27
IS 5
BP 398
EP 406
DI 10.1089/acm.2020.0387
EA APR 2021
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA SD2FV
UT WOS:000644199100001
PM 33902333
DA 2026-01-16
ER

PT J
AU Wang, MC
AF Wang, Mei-Chen
TI ACUPUNCTURE FOR CANCER PAIN MANAGEMENT
SO ONCOLOGY NURSING FORUM
LA English
DT Meeting Abstract
C1 [Wang, Mei-Chen] NYU, New York, NY USA.
C3 New York University
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD MAR 15
PY 2021
VL 48
IS 2
BP 89
EP 89
DI 
PG 1
WC Oncology; Nursing
SC Oncology; Nursing
GA QK4IE
UT WOS:000620349200321
DA 2026-01-16
ER

PT J
AU Sung, SH
   Kim, JW
   Han, JE
   Shin, BC
   Park, JK
   Lee, G
AF Sung, Soo-Hyun
   Kim, Ji-Won
   Han, Ji-Eun
   Shin, Byung-Cheul
   Park, Jang-Kyung
   Lee, Gihyun
TI Animal Venom for Medical Usage in Pharmacopuncture in Korean Medicine: Current Status and Clinical Implication
SO TOXINS
LA English
DT Review
DE animal venom; bee venom; snake venom; toad venom; pharmacopuncture
ID bee sting therapy; snake-venom; adhesive capsulitis; shoulder pain; acupuncture; efficacy; physiotherapy; hemocoagulase; coagulation; toxicity
AB Animal venoms, widespread throughout the world, are complex mixtures, the composition of which depends on the venom-producing species. The objective of this study was to contribute to the development of animal venom-based medicines by investigating the use of animal venom pharmacopuncture in Korean medicine (KM) institutions. We surveyed 256 public health centers from 1 through 31 October 2019 as guided by the Ministry of Health and Welfare (MoHW). A questionnaire developed by an expert group was distributed and collected for statistical analysis. The survey identified three types of animal venom-based pharmacopuncture: bee, snake, and toad venoms. The medications are based on a single animal venom ingredient and produced in 11 external herbal dispensaries (EHDs). Each animal venom is processed, refined, and freeze-dried in a cleanroom to produce a powder formulation that is later measured, diluted, filtered, filled, sealed, sterilized, and packaged as pharmacopuncture injections used in KM institutions. Bee venom therapy is effective in treating musculoskeletal pain, snake venom therapy is effective in controlling bleeding during surgery, and toad venom therapy is effective in cancer treatment. The study suggests that bee, snake, and toad venoms could be used in medical institutions and have the potential for drug development.
C1 [Sung, Soo-Hyun; Kim, Ji-Won; Han, Ji-Eun] Natl Dev Inst Korean Med, Dept Policy Dev, Seoul 04554, South Korea.
   [Shin, Byung-Cheul; Park, Jang-Kyung] Pusan Natl Univ, Sch Korean Med, Div Clin Med, Yangsan 50612, South Korea.
   [Lee, Gihyun] Dongshin Univ, Coll Korean Med, Naju 58245, South Korea.
C3 Pusan National University; Dongshin University
RP Lee, G (corresponding author), Dongshin Univ, Coll Korean Med, Naju 58245, South Korea.
EM koyote10010@nikom.or.kr; cactus@nikom.or.kr; jieun2342@nikom.or.kr; drshinbc@pusan.ac.kr; vivat314@pusan.ac.kr; glee@khu.ac.kr
FU Project of National Development Institute of Korean Medicine, Accreditation of External Herbal Dispensaries of Traditional Korean Medicine Clinics - Korean Ministry of Health and Welfare
CR Abd El-Aziz TM, 2019, TOXINS, V11, P0, DOI 10.3390/toxins11100564
   Alqutub AN, 2011, WORLD J HEPATOL, V3, P268, DOI 10.4254/wjh.v3.i10.268
   Amin MR, 2008, J VENOM ANIM TOXINS, V14, P660, DOI 10.1590/S1678-91992008000400009
   Unknown -, 2003, J ORIENT REHAB MED, V0, P0
   Unknown -, 2017, STUDY METHODS PROVE, V0, P0
   Banfi FF, 2016, KOREAN J PARASITOL, V54, P415, DOI 10.3347/kjp.2016.54.4.415
   Boussios S, 2012, ANN GASTROENTEROL, V25, P106
   Byeong-Jun A, 2006, J PHARMACOPUNCT, V9, P167
   Camargo ACM, 2012, TOXICON, V59, P516, DOI 10.1016/j.toxicon.2011.07.013
   Castro HC, 2004, CELL MOL LIFE SCI, V61, P843, DOI 10.1007/s00018-003-3325-z
   Chan YS, 2016, APPL MICROBIOL BIOT, V100, P6165, DOI 10.1007/s00253-016-7610-9
   Chen Na, 2018, BIOPHYS REP, V4, P233, DOI 10.1007/s41048-018-0067-x
   Chen Shi-Yun, 2018, ZHEN CI YAN JIU, V43, P251, DOI 10.13702/j.1000-0607.170506
   Chen Zhe, 2003, ZHONG XI YI JIE HE XUE BAO, V1, P184
   Chippaux JP, 2015, J VENOM ANIM TOXINS, V21, P0, DOI 10.1186/s40409-015-0011-1
   Cho SW, 2005, J. KOREAN MED. REHABIL, V15, P77
   Cho SY, 2018, J ALTERN COMPLEM MED, V24, P25, DOI 10.1089/acm.2016.0250
   Cho SY, 2013, COMPLEMENT THER MED, V21, P155, DOI 10.1016/j.ctim.2013.02.001
   Cho SY, 2012, PARKINSONISM RELAT D, V18, P948, DOI 10.1016/j.parkreldis.2012.04.030
   Conrad VJ, 2019, J ALTERN COMPLEM MED, V25, P845, DOI 10.1089/acm.2019.0121
   de Souza JM, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00145
   Eom JY, 2006, J PHARMACOPUNCT, V9, P139
   GALE AN, 1982, BRIT MED J, V284, P20, DOI 10.1136/bmj.284.6308.20
   GAMBA G, 1979, BLUT, V39, P89, DOI 10.1007/BF01008084
   Gowda R M, 2003, HEART, V89, Pe14, DOI 10.1136/heart.89.4.e14
   Gwaltney-Brant SM, 2017, ZOOTOXINS REPROD DEV, V2nd, P0
   Hakim MA, 2015, TOXINS, V7, P4832, DOI 10.3390/toxins7114832
   Hartmann A, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0158235
   Hayes WK, 2020, METHODS MOL BIOL, V2068, P53, DOI 10.1007/978-1-4939-9845-6_3
   Hoon Kim Ji, 2017, JOURNAL OF KOREAN MEDICINE, V0, P0
   안웅찬, 2016, THE JOURNAL OF HERBAL FORMULA SCIENCE, V0, P0
   HUANG DX, 1992, ACTA CARDIOL, V47, P445
   Huh JE, 2010, CANCER LETT, V292, P98, DOI 10.1016/j.canlet.2009.11.013
   Jang S, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12090558
   Jung JW, 2012, ALLERGY ASTHMA IMMUN, V4, P107, DOI 10.4168/aair.2012.4.2.107
   Kim DH, 2015, POLICY IMPROVEMENT P, V0, P0
   Kim JS, 2001, CEREBROVASC DIS, V11, P251, DOI 10.1159/000047647
   Kim SK, 2014, J PHYS THER SCI, V26, P1419, DOI 10.1589/jpts.26.1419
   Koh PS, 2013, J SHOULDER ELB SURG, V22, P1053, DOI 10.1016/j.jse.2012.10.045
   Korean Pharmacopuncture Institute, 2011, PHARMACOPUNCTUROLOGY, V0, P0
   Kwon YB, 2001, AM J CHINESE MED, V29, P187, DOI 10.1142/S0192415X01000228
   Kwon-Eui H, 2010, J PHARMACOPUNCT, V13, P91, DOI 10.3831/KPI.2010.13.3.091
   이대용, 2006, JOURNAL OF ACUPUNCTURE RESEARCH, V23, P69
   Lee G, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020048
   유상민, 2006, JOURNAL OF ACUPUNCTURE RESEARCH, V23, P39
   Lee KG, 2009, J ETHNOPHARMACOL, V123, P15, DOI 10.1016/j.jep.2009.02.044
   Lee MS, 2008, J PAIN, V9, P289, DOI 10.1016/j.jpain.2007.11.012
   Lee SH, 2003, JOURNAL OF ACUPUNCTURE RESEARCH, V20, P80
   Lim BS, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/369324
   Lim SM, 2015, J INTEGR MED-JIM, V13, P241, DOI 10.1016/S2095-4964(15)60178-9
   Liu M, 1998, J STROKE CEREBROVASC DIS, V7, P63, DOI 10.1016/S1052-3057(98)80023-2
   Mehta S R, 2002, MED J ARMED FORCES INDIA, V58, P247, DOI 10.1016/S0377-1237(02)80140-X
   Meng Z, 2012, BRIT J CANCER, V107, P411, DOI 10.1038/bjc.2012.283
   Mohamed EA, 2016, INT J PHARMTECH RES, V9, P66
   Nitecka-Buchta A, 2014, BIOMED RES INT, V2014, P0, DOI 10.1155/2014/296053
   Park JA, 2011, THE J, V2, P37
   고창남, 2007, JOURNAL OF KOREAN MEDICINE 대한한의학회지, V28, P11
   Park J, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/4683121
   Park YC, 2014, J ALTERN COMPLEM MED, V20, P919, DOI 10.1089/acm.2014.0220
   Qiu MG, 2017, INJURY, V48, P914, DOI 10.1016/j.injury.2016.11.028
   Reisman RE, 2005, CURR OPIN ALLERGY CL, V5, P355, DOI 10.1097/01.all.0000173782.35283.b6
   Ren XH, 2004, J CLIN ACUPUNCT MOXI, V20, P54
   Schmeda-Hirschmann G, 2014, J ETHNOPHARMACOL, V155, P1076, DOI 10.1016/j.jep.2014.06.025
   Seo BK, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110361
   서진우, 2006, JOURNAL OF ACUPUNCTURE RESEARCH, V23, P95
   Shen L, 2020, J PHARMACOPUNCT, V23, P44, DOI 10.3831/KPI.2020.23.008
   Shetty V, 2015, J CRANIO MAXILL SURG, V43, P2000, DOI 10.1016/j.jcms.2015.08.032
   Shin BC, 2012, EUR J INTEGR MED, V4, PE271, DOI 10.1016/j.eujim.2012.02.005
   Song HS, 2005, J PHARMACOPUNCT, V8, P11
   배의종, 2009, KOREAN JOURNAL OF DERMATOLOGY 대한피부과학회지, V47, P350
   Sung SH, 2020, BMC COMPLEMENT MED, V20, P0, DOI 10.1186/s12906-020-03094-0
   Sung SH, 2019, J PHARMACOPUNCT, V22, P75, DOI 10.3831/KPI.2019.22.009
   TAE KIM KYUNG, 2005, JOURNAL OF ACUPUNCTURE RESEARCH, V22, P113
   TAE KIM KYUNG, 2005, JOURNAL OF ACUPUNCTURE RESEARCH, V22, P189
   Utkin Yuri N, 2015, WORLD J BIOL CHEM, V6, P28, DOI 10.4331/wjbc.v6.i2.28
   Vetter RS, 1999, WESTERN J MED, V170, P223
   Wang TT, 2018, PAK J PHARM SCI, V31, P1609
   WARPINSKI JR, 1990, J WILDERNESS MED, V1, P249, DOI 10.1580/0953-9859-1.4.249
   Wesselius T, 2005, NEUROLOGY, V65, P1764, DOI 10.1212/01.wnl.0000184442.02551.4b
   Wu JR, 2020, J TRADIT CHIN MED, V40, P749, DOI 10.19852/j.cnki.jtcm.2020.05.004
   Xu Jing, 2019, ZHONGGUO ZHONG YAO ZA ZHI, V44, P2627, DOI 10.19540/j.cnki.cjcmm.20190304.003
   Yasin MM, 2018, JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE, V8, P159, DOI 10.7324/japs.2018.8124
   Yun Jung Min, 2018, SOCIETY OF PREVENTIVE KOREAN MEDICINE, V0, P0
   Zhang D, 2020, J TRADIT CHIN MED, V40, P167
   Zhang JW, 1995, SHANGHAI J ACUPUNCT, V3, P126
   Zhang S Y, 1994, ZHONGHUA NEI KE ZA ZHI, V33, P244
   Zheng YR, 2022, PLANTA MED, V88, P43, DOI 10.1055/a-1248-2626
NR 88
TC 23
Z9 26
U1 0
U2 26
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2072-6651
J9 TOXINS
JI Toxins
PD FEB 15
PY 2021
VL 13
IS 2
BP 
EP 
DI 10.3390/toxins13020105
PG 14
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA QO6VW
UT WOS:000623280300001
PM 33535603
DA 2026-01-16
ER

PT J
AU Faruqi, F
   Ruddy, KJ
   Blackmon, S
AF Faruqi, Fahad
   Ruddy, Kathryn J.
   Blackmon, Shanda
TI Integrative Approaches to Minimize Peri-operative Symptoms
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Integrative medicine; Acupuncture; Guided imagery; Loving-kindness meditation; Peri-operative symptoms; Post-thoracotomy pain syndrome; PTPS; Complementary medicine; CAM
ID postthoracotomy pain syndrome; pulmonary complications; postoperative pain; thoracoscopic surgery; paravertebral block; analgesia; management; resection; efficacy; requirements
AB Purpose of Review Cancer patients who require surgery often experience peri-operative symptoms, including nausea, anxiety, and pain, which can significantly impair quality of life. Here, we review the evidence for using integrative approaches to manage these peri-operative symptoms. Recent Findings Conventional peri-operative pharmacologic interventions, such as opiates for pain control, can lead to adverse effects such as respiratory depression, prolonged hospital course, and long-term dependence. Integrative medicine, also known as complementary and alternative medicine (CAM), has been explored as way to reduce peri-operative symptoms. Acupuncture, guided imagery, and loving-kindness meditation have all shown potential efficacy in reducing both peri-operative pain and anxiety in retrospective studies and small randomized controlled trials. Summary Integrative medicine techniques, such as acupuncture, are a promising approach to control peri-operative symptoms without the associated adverse effects of more conventional pharmacologic interventions.
C1 [Faruqi, Fahad; Ruddy, Kathryn J.; Blackmon, Shanda] Mayo Clin, Rochester, MN 55905 USA.
C3 Mayo Clinic
RP Faruqi, F (corresponding author), Mayo Clin, Rochester, MN 55905 USA.
EM faruqi.fahad@mayo.edu
CR Attias S, 2016, J CLIN ANESTH, V29, P54, DOI 10.1016/j.jclinane.2015.10.017
   Batchelor TJP, 2019, EUR J CARDIO-THORAC, V55, P91, DOI 10.1093/ejcts/ezy301
   Bialka S, 2018, J THORAC DIS, V10, P0, DOI 10.21037/jtd.2018.07.88
   Brunelli A, 2014, ANN THORAC SURG, V98, P238, DOI 10.1016/j.athoracsur.2014.04.029
   Bucx MJL, 2016, J CLIN ANESTH, V33, P135, DOI 10.1016/j.jclinane.2016.03.025
   Canet J, 2010, ANESTHESIOLOGY, V113, P1338, DOI 10.1097/ALN.0b013e3181fc6e0a
   Carpenter JJ, 2017, J HOLIST NURS, V35, P342, DOI 10.1177/0898010116675462
   Chen JB, 2020, INT J SURG, V73, P57, DOI 10.1016/j.ijsu.2019.10.036
   Fernandez MI, 2005, EUR J CARDIO-THORAC, V27, P671, DOI 10.1016/j.ejcts.2004.12.045
   Fibla JJ, 2011, EUR J CARDIO-THORAC, V40, P907, DOI 10.1016/j.ejcts.2010.12.043
   Gan TJ, 2017, J PAIN RES, V10, P2287, DOI 10.2147/JPR.S144066
   Garland EL, 2020, JAMA INTERN MED, V180, P91, DOI 10.1001/jamainternmed.2019.4917
   Gillis C, 2014, ANESTHESIOLOGY, V121, P937, DOI 10.1097/ALN.0000000000000393
   Granger C, 2017, PREOPERATIVE EXERCIS, V0, P0
   Gustafsson UO, 2019, WORLD J SURG, V43, P659, DOI 10.1007/s00268-018-4844-y
   Hah JM, 2017, ANESTH ANALG, V125, P1733, DOI 10.1213/ANE.0000000000002458
   Hamada K, 2019, LUNG CANCER, V128, P47, DOI 10.1016/j.lungcan.2018.12.013
   Hetmann F, 2017, J PAIN RES, V10, P663, DOI 10.2147/JPR.S126639
   Hill SE, 2006, ANESTHESIOLOGY, V104, P1047, DOI 10.1097/00000542-200605000-00022
   Hirai K, 2019, J THORAC DIS, V11, P3896, DOI 10.21037/jtd.2019.09.07
   Kaplowitz J, 2012, J CARDIOTHOR VASC AN, V26, P312, DOI 10.1053/j.jvca.2011.04.010
   Karmakar Manoj K, 2004, THORAC SURG CLIN, V14, P345, DOI 10.1016/S1547-4127(04)00022-2
   Kaya FN, 2006, J CARDIOTHOR VASC AN, V20, P639, DOI 10.1053/j.jvca.2006.03.022
   Kim JA, 2009, J KOREAN MED SCI, V24, P930, DOI 10.3346/jkms.2009.24.5.930
   Maeda K, 2016, GERIATR GERONTOL INT, V16, P550, DOI 10.1111/ggi.12505
   Mesbah A, 2016, BJA EDUC, V16, P1, DOI 10.1093/bjaceaccp/mkv005
   Metin SK, 2017, ANN THORAC SURG, V103, P1109, DOI 10.1016/j.athoracsur.2016.09.031
   Nelson DB, 2019, J THORAC CARDIOV SUR, V158, P279, DOI 10.1016/j.jtcvs.2019.03.009
   Palmer JB, 2015, J CLIN ONCOL, V33, P3162, DOI 10.1200/JCO.2014.59.6049
   Qiu Robert, 2018, ROM J ANAESTH INTENSIVE CARE, V25, P43, DOI 10.21454/rjaic.7518.251.gab
   Rawal N, 2016, EUR J ANAESTH, V33, P160, DOI 10.1097/EJA.0000000000000366
   Reyad RM, 2020, EUR J PAIN, V24, P159, DOI 10.1002/ejp.1473
   Saito H, 2017, THORAC CANCER, V8, P451, DOI 10.1111/1759-7714.12466
   Schiff E, 2019, COMPLEMENT THER MED, V44, P51, DOI 10.1016/j.ctim.2019.03.003
   Vogt A, 2005, BRIT J ANAESTH, V95, P816, DOI 10.1093/bja/aei250
   Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652
   Williams JB, 2013, AM J CARDIOL, V111, P137, DOI 10.1016/j.amjcard.2012.08.060
   Wren AA, 2019, SUPPORT CARE CANCER, V27, P3583, DOI 10.1007/s00520-019-4657-z
   Wu MS, 2016, PLOS ONE, V11, P0, DOI 10.1371/journal.pone.0150367
   Wunsch H, 2016, JAMA-J AM MED ASSOC, V315, P1654, DOI 10.1001/jama.2016.0130
   Yang CK, 2015, J SURG RES, V198, P441, DOI 10.1016/j.jss.2015.03.028
   Yasin J, 2020, DIAGN INTERV RADIOL, V26, P53, DOI 10.5152/dir.2019.19179
   Yoshioka Masakazu, 2006, ANN THORAC CARDIOVASC SURG, V12, P313
   Zhang RY, 2015, ANN THORAC SURG, V99, P1761, DOI 10.1016/j.athoracsur.2015.01.030
NR 44
TC 1
Z9 3
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUN 15
PY 2021
VL 23
IS 6
BP 
EP 
DI 10.1007/s11912-021-01051-9
PG 6
WC Oncology
SC Oncology
GA RU0EA
UT WOS:000644823900001
PM 33907909
DA 2026-01-16
ER

PT J
AU Zomers, PJW
   Groeneweg, G
   Baart, S
   Huygen, FJP
AF Zomers, Paul J. W.
   Groeneweg, George
   Baart, Sara
   Huygen, Frank J. P.
TI Percutaneous Cervical Cordotomy for the Treatment of Cancer Pain: A Prospective Case Series of 52 Patients with a Long-Term Follow-Up
SO PAIN PRACTICE
LA English
DT Article
DE radiofrequency ablation; percutaneous cervical cordotomy; oncological pain
ID reliability; efficacy; safety; scale
AB Aim The aim of this study is to describe the effects of percutaneous cervical cordotomy (PCC) on pain, opioid consumption, adverse events, and satisfaction in palliative care patients with cancer pain after PCC until end of life. Methods This is a prospective observational case series of 58 PCCs in 52 consecutive patients. Indication for PCC was unilateral cancer pain with a maximum numeric rating scale (NRS) of pain above 5 despite maximal conservative treatment. The PCC was fluoroscopy guided. A radiofrequency lesion was made at 95 degrees C for 20 seconds. The pain location and pain scores, analgesic medication, the cranial and caudal borders of dermatomes hypoesthetic for pin pricks, dysesthesia, urinary retention, Horner's syndrome, muscle strength, Karnofsky performance scale (KPS) score, patient satisfaction, hospital anxiety and distress score (HADS), and RAND 36 score were evaluated at 1 day; 1 and 6 weeks; and 3, 6, 9, 12 18, and 24 months after PCC, or until death if death occurred during the follow-up period. Results Pain relief after PCC was intense (change in median maximum NRS from 9 to 0) and persistent. Median opioid use per day was 240 mg (145 to 565 mg) before PCC and 55 mg (0 to 120 mg) after PCC. The upper and lower borders of dermatomes hypoesthetic for pin pricks were stable over time. The most common side effects were short-term (< 1 week) neck pain (28%), dysesthesia (40%), and mild loss of muscle strength (11%). Approximately 83% of the patients were satisfied or very satisfied with the results of PCC 1 week after the procedure, and this percentage remained high in the long term. There was no significant change in the KPS score, HADS, and RAND 36 score. Conclusion Percutaneous cervical cordotomy is an effective treatment for unilateral cancer pain. The reduction in pain, reduction in opioid consumption, and hypoesthetic area remain stable until death.
C1 [Zomers, Paul J. W.] Bravis Hosp, Pain Dept, Boerhaavelaan 25, NL-4708 AE Roosendaal, Netherlands.
   [Groeneweg, George; Baart, Sara; Huygen, Frank J. P.] Erasmus MC, Ctr Pain Med, Rotterdam, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC
RP Zomers, PJW (corresponding author), Bravis Hosp, Pain Dept, Boerhaavelaan 25, NL-4708 AE Roosendaal, Netherlands.
EM paulzomers@ziggo.nl
CR Bain E, 2013, J PALLIAT MED, V16, P901, DOI 10.1089/jpm.2013.0027
   Bekar A, 2017, TURK NEUROSURG, V27, P133, DOI 10.5137/1019-5149.JTN.14558-15.1
   Bellini M, 2016, ANAESTH INTENSIVE TH, V48, P197, DOI 10.5603/AIT.a2014.0070
   BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160
   COLIER WNJM, 1995, ACTA ANAESTH SCAND, V39, P151, DOI 10.1111/j.1399-6576.1995.tb04350.x
   Collins KL, 2013, NEUROSURGERY, V72, P27, DOI 10.1227/NEU.0b013e31827415e7
   Collins KL, 2012, STEREOT FUNCT NEUROS, V90, P266, DOI 10.1159/000337535
   Crul Ben J P, 2005, J HEADACHE PAIN, V6, P24, DOI 10.1007/s10194-005-0145-6
   EISENBERG E, 1994, J CLIN ONCOL, V12, P2756, DOI 10.1200/JCO.1994.12.12.2756
   Feizerfan A, 2014, BJA EDUC, V14, P23, DOI 10.1093/bjaceaccp/mkt033
   FLORENCE JM, 1992, PHYS THER, V72, P115, DOI 10.1093/ptj/72.2.115
   Fonoff ET, 2016, J NEUROSURG, V124, P389, DOI 10.3171/2014.12.JNS141616
   Fonoff ET, 2010, J NEUROSURG, V113, P524, DOI 10.3171/2010.4.JNS091779
   France BD, 2014, BMJ SUPPORT PALLIAT, V4, P19, DOI 10.1136/bmjspcare-2013-000508
   Hochberg U, 2017, FRONT ONCOL, V7, P0, DOI 10.3389/fonc.2017.00017
   Honey CM, 2019, J NEUROSURG-SPINE, V30, P722, DOI 10.3171/2018.11.SPINE18172
   Honey CR, 2014, J PALLIAT MED, V17, P624, DOI 10.1089/jpm.2013.0664
   ISCHIA S, 1984, J NEUROL NEUROSUR PS, V47, P141, DOI 10.1136/jnnp.47.2.141
   JACK TM, 1983, ANN ROY COLL SURG, V65, P97
   Jackson MB, 1999, THORAX, V54, P238, DOI 10.1136/thx.54.3.238
   Jones B, 2003, J PAIN SYMPTOM MANAG, V25, P179, DOI 10.1016/S0885-3924(02)00689-9
   JONES D, 1995, NEW ZEAL MED J, V108, P492
   Kanpolat Y, 1989, ACTA NEUROCHIR SUPPL (WIEN), V46, P67
   Kanpolat Y, 2013, TURK NEUROSURG, V23, P81, DOI 10.5137/1019-5149.JTN.6980-12.0
   Kanpolat Y, 2009, NEUROSURGERY, V64, PS187, DOI 10.1227/01.NEU.0000335645.67282.03
   Konrad P, 2014, NEUROSURG CLIN N AM, V25, P699, DOI 10.1016/j.nec.2014.07.010
   LAHUERTA J, 1994, J NEUROSURG, V80, P975, DOI 10.3171/jns.1994.80.6.0975
   LAHUERTA J, 1985, ANN ROY COLL SURG, V67, P41
   Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038
   LIPTON S, 1968, BRIT MED J, V2, P210, DOI 10.1136/bmj.2.5599.210
   Meeuse JJ, 2008, PAIN RES MANAG, V13, P506, DOI 10.1155/2008/635197
   NATHAN PW, 1963, J NEUROL NEUROSUR PS, V26, P353, DOI 10.1136/jnnp.26.4.353
   Park SA, 2017, APPL NURS RES, V33, P108, DOI 10.1016/j.apnr.2016.10.002
   Paternostro-Sluga T, 2008, J REHABIL MED, V40, P665, DOI 10.2340/16501977-0235
   Poolman M, 2020, BMJ SUPPORT PALLIAT, V10, P429, DOI 10.1136/bmjspcare-2019-002057
   Price C, 2003, J PAIN SYMPTOM MANAG, V25, P459, DOI 10.1016/S0885-3924(03)00042-3
   Raslan AM, 2011, J NEUROSURG, V114, P155, DOI 10.3171/2010.6.JNS10119
   Raslan AM, 2005, STEREOT FUNCT NEUROS, V83, P159, DOI 10.1159/000088992
   Reddy GD, 2013, J NEUROSURG-PEDIATR, V12, P93, DOI 10.3171/2013.4.PEDS12474
   Romanelli P, 2004, NEUROSURG CLIN N AM, V15, P335, DOI 10.1016/j.nec.2004.02.009
   ROSOMOFF HL, 1969, J NEUROSURG, V31, P41, DOI 10.3171/jns.1969.31.1.0041
   SANDERS M, 1995, J CLIN ONCOL, V13, P1509, DOI 10.1200/JCO.1995.13.6.1509
   Seyidova-Khoshknabi D, 2011, AM J HOSP PALLIAT ME, V28, P119, DOI 10.1177/1049909110381590
   Slavik E, 2005, J BUON, V10, P223
   Sluijter M, 2001, RADIOFREQUENCY 2, V0, P0
   Strauss I, 2017, STEREOT FUNCT NEUROS, V95, P409, DOI 10.1159/000484614
   Strauss KA, 2018, J PEDIATR ORTHOPED, V38, PE610, DOI 10.1097/BPO.0000000000001247
   Vedantam A, 2019, NEUROSURGERY, V84, PE311, DOI 10.1093/neuros/nyy330
   Viswanathan A, 2020, NEUROSURGERY, V87, P394, DOI 10.1093/neuros/nyz527
   Viswanathan A, 2019, ONCOLOGIST, V24, PE590, DOI 10.1634/theoncologist.2018-0570
   Viswanathan A, 2013, NEUROSURG FOCUS, V35, P0, DOI 10.3171/2013.6.FOCUS13237
   Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5
NR 52
TC 5
Z9 5
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1530-7085
EI 1533-2500
J9 PAIN PRACT
JI Pain Pract.
PD JUN 15
PY 2021
VL 21
IS 5
BP 557
EP 567
DI 10.1111/papr.12991
EA JAN 2021
PG 11
WC Anesthesiology; Clinical Neurology
SC Anesthesiology; Neurosciences & Neurology
GA SN8JM
UT WOS:000609940800001
PM 33350042
DA 2026-01-16
ER

PT J
AU Yang, M
   Liou, KT
   Garland, SN
   Bao, T
   Hung, TKW
   Li, SQ
   Li, Y
   Mao, JJ
AF Yang, Mingxiao
   Liou, Kevin T
   Garland, Sheila N
   Bao, Ting
   Hung, Tony K W
   Li, Susan Q
   Li, Yuelin
   Mao, Jun J
TI Acupuncture versus cognitive behavioral therapy for pain among cancer survivors
SO NPJ breast cancer
LA English
DT Journal Article
AB Pain and insomnia often co-occur and impair the quality of life in cancer  survivors. This study evaluated the effect of acupuncture versus cognitive  behavioral therapy for insomnia (CBT-I) on pain severity among cancer survivors  with comorbid pain and insomnia. Using data from the CHOICE trial that compared  acupuncture versus CBT-I for insomnia among cancer survivors, we analyzed the  effect of interventions on pain outcomes in 70 patients with moderate to severe  baseline pain. Interventions were delivered over eight weeks. We assessed average  pain severity (primary outcome) and pain interference at baseline, week 8, and  week 20. We further defined insomnia and pain responders as patients who achieved  clinically meaningful improvement in insomnia and pain outcomes, respectively, at  week 8. We found that compared with baseline, the between-group difference (-1.0,  95% CI -1.8 to -0.2) was statistically significant favoring acupuncture for  reduced pain severity at week 8 (-1.4, 95% CI -2.0 to -0.8) relative to CBT-I  (-0.4, 95% CI-1.0 to 0.2). Responder analysis showed that 1) with acupuncture,  insomnia responders reported significantly greater pain reduction from baseline  to week 4, compared with insomnia non-responders (-1.5, 95% CI -2.7 to -0.3); 2)  with CBT-I, pain responders reported significantly greater insomnia reduction at  week 8, compared with pain non-responders (-4.7, 95% CI -8.7 to -1.0). These  findings suggest that among cancer survivors with comorbid pain and insomnia,  acupuncture led to rapid pain reductions, which contributed to a decrease in  insomnia, whereas CBT-I had a delayed effect on pain, possibly achieved by  insomnia improvement.
C1 Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Psychology and Discipline of Oncology, Memorial University, 232 Elizabeth Avenue, St. John's, NL A1B 3×9, Canada.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Medicine, Division of Solid Tumor Oncology, Head & Neck Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY,10065, USA.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA.
   Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
   Department of Medicine, Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, 1429 First Avenue, New York, NY, 10021, USA. maoj@mskcc.org.
NR 0
TC 0
SN 2374-467
EI 2374-467
J9 NPJ Breast Cancer
PD DEC 2
PY 2021
VL 7
IS 1
BP 148
EP 148
DI 10.1038/s41523-021-00355-0
PG 0
UT PubMed:34848737
PM 34848737
DA 2021-12-02
ER

PT J
AU Gao, YH
   Wang, JY
   Han, YJ
   Liu, JL
AF Gao, Yong-Hui
   Wang, Jun-Ying
   Han, Yan-Jing
   Liu, Jun-Ling
TI [Spinal cord Toll like receptor 4 and its co-stimulatory molecule heat shock
SO Zhen ci yan jiu = Acupuncture research
LA chi
DT Journal Article
DE Acupuncture analgesia; Chronic neuropathic pain; Heat shock protein 90；Microglia; Neuron; Toll-like receptor 4
AB OBJECTIVE: To observe the effect of electroacupuncture (EA) on the expression of  Toll like receptor 4(TLR4)and heat shock protein 90(HSP90) in the spinal cord of  rats with chronic constriction injury (CCI) of sciatic nerve, so as to explore  the mechanism of spinal cord TLR4 and HSP90 in alleviating chronic neuropathic  pain by EA. METHODS: Male Wistar rats were randomized into control, model, EA,  HSP90 inhibitor (inhibitor) and EA+ inhibitor groups (n=10 in each group). The  neuropathic pain model was established by ligature of the right sciatic nerve to  induce CCI. EA (1 mA，2 Hz/15 Hz)was applied at bilateral "Zusanli"(ST36) and  "Yanglingquan"(GB34) for 30 min, once daily for 5 days. Rats of the inhibitor and  EA+inhibitor groups were given a subcutaneous injection of HSP90 inhibitor  geldanamycin (50 μg/kg) at the neck before daily EA. The paw withdrawal latency  (PWL) of the bilateral hind-limbs was detected by using an algesia-detector. The  contents of interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α) in the  lumbar spinal cord (L2-L4) tissue were detected by enzyme-linked immunosorbent  assay. The relative expression levels of HSP90 and TLR4 proteins in the lumbar  spinal cord (L2-L4) were detected using Western blot and immunofluorescence  double labeling, respectively. RESULTS: Following CCI, a strong thermal  hyperalgesia, an apparent up-regulation of expression of HSP90 and TLR4 proteins  and TLR4 in microglia, and increasing levels of IL-1β and TNF-α in the spinal  cord were induced in the model group relevant to the control group  (P<0.01，P<0.05). Five sessions of EA intervention or inhibitor injection  significantly attenuated hyperalgesia, reversed the increase of IL-1β and TNF-α,  and down-regulated the expression of TLR4 in microglia (P<0.05). Compared with  the model group, the expression of HSP90 was further increased (P<0.05), and  those of TLR4 in microglia and neurons were significantly decreased and  increased, respectively in the EA group (P<0.05). Compared with the EA group, the  levels of PWLD,TLR4 and HSP90 expression, and the proportions of neuronal nuclei  antigen（NeuN） and TLR4, and ionized calcium binding adapter molecule （Iba1） and  TLR4 co-expressed cells were significantly decreased in the inhibitor group and  EA+inhibitor group (P<0.05). The proportion of NeuN and TLR4 co-expression cells  in the EA+inhibitor group was significantly higher than that of the inhibitor  group (P<0.05). CONCLUSION: EA stimulation of ST36 and GB34 can alleviate thermal  hyperalgesia in CCI rats, which is closely associated with its effect in  regulating the expression of TLR4 in the spinal cord neurons and microglia. HSP90  in the spinal cord may be a co-stimulatory molecule for EA induced relief of  neuropathic pain by regulating TLR4.
C1 Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700.
   Institute of Acupuncture and Moxibustion, China Academy of Chinese Medical Sciences, Beijing 100700.
NR 0
TC 0
SN 
EI 1000-060
J9 Zhen Ci Yan Jiu
PD SEP 25
PY 2021
VL 46
IS 9
BP 735
EP 41
DI 10.13702/j.1000-0607.201103
PG -694
WC Animals; Electroacupuncture; Heat-Shock Proteins; Male; Neuralgia; genetics; Rats; Rats, Sprague-Dawley; Rats, Wistar; Spinal Cord; Toll-Like Receptor 4; genetics
UT PubMed:34558238
PM 34558238
DA 2021-09-25
ER

PT J
AU Wang, Y
   Zhang, J
   Jin, Y
   Zhang, Q
AF Wang, Yunxia
   Zhang, Jiayuan
   Jin, Yuxia
   Zhang, Qi
TI Auricular Acupressure Therapy for Patients with Cancer with Sleep Disturbance: A
SO Evidence-based complementary and alternative medicine : eCAM
LA English
DT Review
AB AIM: We aim to provide available synthesized evidence of the efficacy and safety  of auricular acupressure for cancer patients with sleep disturbance. METHODS:  Randomized controlled clinical trials (RCTs) were identified from PubMed, EMBASE,  Web of Science, The Cochrane Library, PsycINFO, Chinese Biomedical Database,  China National Knowledge Infrastructure, Chongqing VIP, and Wanfang Data, and the  search date ranged from the inception of the databases to May 2021. Literature  screening and data extraction were independently performed by three researchers.  The Cochrane collaboration's tool for assessing the risk of bias was applied to  evaluate the risk of bias of the RCTs included. The extracted data were analyzed  using Rev-Man 5.4.1 software. RESULTS: Nine trials involving 688 participants met  the inclusion criteria and were included in the qualitative analysis; 6 trials  involving 485 participants were included in the meta-analysis. Synthesized  results showed that auricular acupressure had a significant effect on reducing  the total Pittsburgh Sleep Quality Index (PSQI) score (MD = -3.88, 95% CI (-5.24,  -2.53), P < 0.00001), and the scores of five PSQI components, sleep latency  (MD = -0.53, 95% CI (-0.73, -0.32), P < 0.00001), subjective sleep quality  (MD = -0.79, 95% CI (-1.05, -0.53), P < 0.00001), sleep duration (MD = -0.50, 95%  CI (-0.69, -0.31), P < 0.0001), daytime dysfunction (MD = -0.53, 95% CI (-0.77,  -0.29), P < 0.0001), and sleep disturbances (MD = -0.54, 95% CI (-0.60, -0.49), P  < 0.00001), were also obviously decreased after the intervention of auricular  acupressure. Shenmen and heart were the most commonly selected auricular  acupoints, the main intervention durations ranged from 10 to 42 days, and the  pressing times of auricular acupoints were 1-6 times a day, 1-5 min each time.  One trial reported slight and transient pain caused by auricular acupressure,  while the remaining 8 trials did not report obvious side effects. CONCLUSION:  Auricular acupressure can significantly improve the sleep quality of cancer  patients with sleep disturbance, with no obvious side effects. Rigorously  designed clinical trials are necessary for the further support of the clinical  application.
C1 Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
   Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
NR 0
TC 0
SN 1741-428
EI 1741-427
J9 Evid Based Complement Alternat Med
PD OCT 26
PY 2021
VL 2021
IS 
BP 3996101
EP 3996101
DI 10.1155/2021/3996101
PG 0
UT PubMed:34691214
PM 34691214
DA 2021-10-26
ER

PT J
AU Liu, CT
   Hsieh, TM
   Shih, FY
   Lai, WH
   Hsieh, CH
   Wu, BY
   Chen, YH
AF Liu, Chun-Ting
   Hsieh, Ting-Min
   Shih, Fu-Yuan
   Lai, Wei-Hung
   Hsieh, Ching-Hua
   Wu, Bei-Yu
   Chen, Yung-Hsiang
TI The effects of electroacupuncture and laser acupuncture therapy for patients with
SO Medicine
LA English
DT Journal Article
AB BACKGROUND: Major trauma is the leading cause of death in the young population.  The inflammatory and anti-inflammatory responses are associated with  posttraumatic morbidity and mortality; however, it is not fully clear how to  reestablish the homeostasis in patients with major trauma. METHODS: This study  will be a prospective, randomized, placebo-controlled, partially double-blinded,  three-armed trial. One hundred eighty participants diagnosed with major trauma  will be randomly assigned to an electroacupuncture (EA), a laser acupuncture  (LA), or a sham laser acupuncture group in a 1:1:1 ratio. All participants will  undergo EA, LA, or sham laser acupuncture intervention once a day on 5 acupoints  (LI4, PC6, ST36, SP6, and EX-HN1) for 14 consecutive days after enrollment. The  primary outcome measure will be the length of hospital stay. Secondary outcomes  will be inflammatory mediators, including serum C-reactive protein, interleukin  (IL)-6, tumor necrosis factor-α, IL-1β, and IL-10. Clinical outcomes will be  numeric rating scale scores for pain, sequential organ failure assessment, ICU  length of stay, 30-day mortality, and WHO Disability Assessment Schedule. Data  will be analyzed by chi-square test or t test for pairwise comparisons, as well  as one-way ANOVA followed by post hoc Tukey method between groups. OBJECTIVES:  The aim of this protocol is to investigate the clinical effects of EA and LA on  major trauma. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04970433.  Registered on July 21, 2021.
C1 Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
   Graduate Institute of Integrated Medicine, College of Chinese Medicine, Research 
   Department of Chinese Medicine, Dali Branch, Jen-Ai Hospital, Taichung, Taiwan.
   Division of Trauma Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
   Department of Neurosurgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
   Division of Trauma Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
   Division of Plastic and Reconstructive Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine,Kaohsiung, Taiwan.
   Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
   Graduate Institute of Integrated Medicine, College of Chinese Medicine, Research 
   Fooyin University College of Nursing, Kaohsiung, Taiwan.
   Graduate Institute of Integrated Medicine, College of Chinese Medicine, Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung,Taiwan.
   Department of Psychology, College of Medical and Health Science, Asia University,
NR 0
TC 0
SN 1536-596
EI 0025-797
J9 Medicine (Baltimore)
PD DEC 31
PY 2021
VL 100
IS 52
BP e28367
EP e28367
DI 10.1097/MD.0000000000028367
PG 1
WC Acupuncture Points; Acupuncture Therapy; Adult; Electroacupuncture; Humans; Laser Therapy; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Wounds and Injuries; therapy
UT PubMed:34967368
PM 34967368
DA 2021-12-31
ER

PT J
AU Wong, CHL
   Wong, W
   Lin, WL
   Au, DKY
   Wu, JCY
   Leung, TH
   Wu, IXY
   Chung, VCH
AF Wong, Charlene H. L.
   Wong, Wendy
   Lin, Wai Ling
   Au, David K. Y.
   Wu, Justin C. Y.
   Leung, Ting Hung
   Wu, Irene X. Y.
   Chung, Vincent C. H.
TI Prioritizing Chinese medicine clinical research questions in cancer palliative care from patient and caregiver perspectives
SO HEALTH EXPECTATIONS
LA English
DT Article
DE palliative care; patient participation; research priorities; stakeholder participation; traditional chinese medicine
ID quality-of-life; symptom management; herbal medicine; pain; acupuncture; oncology; family; paper
AB Background Chinese medicine (CM) modalities, including acupuncture and Chinese herbal medicine (CHM), are popular palliative interventions among patients with cancer, but further clinical research is required to assess their effectiveness and safety. Objective To prioritize top ten important CM clinical research questions from patients with cancer, cancer survivors and caregivers' perspectives via a face-to-face prioritization workshop in Hong Kong. Methods A list of 25 CM clinical research questions for cancer palliative care, which were identified from existing systematic reviews (SRs) and overview of SRs, was presented to 17 participants (patients with cancer [n = 5], cancer survivors [n = 6] and caregivers [n = 6]). The participants were then invited to establish consensus on prioritizing top ten research questions. Results Among the top ten priorities, five (50%) focused on acupuncture and related therapies, while five (50%) were on CHM. The three most important research priorities were (i) manual acupuncture plus opioids for relieving pain; (ii) CHM for improving quality of life among patients receiving chemotherapy; and (iii) concurrent use of CHM plus loperamide for reducing stomatitis. Conclusion The top ten participant-endorsed CM clinical research priorities for cancer palliative care can guide local researchers on future direction. They can also inform local research funders on patient-centred allocation of limited funding. Under limited research funding, the most important co-prioritized research question from professional and patient perspectives may be addressed first. Patient or Public Contribution Patients with cancer, cancer survivors and caregivers participated in conduct of the study to prioritize CM clinical research questions.
C1 [Wong, Charlene H. L.; Wu, Justin C. Y.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.
   [Wong, Charlene H. L.; Leung, Ting Hung; Chung, Vincent C. H.] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China.
   [Wong, Wendy] Beijing Univ Chinese Med, Natl Inst TCM Constitut & Prevent Med, Beijing, Peoples R China.
   [Wong, Wendy] Yat Hei Hong Kong Co Ltd, Hong Kong, Peoples R China.
   [Lin, Wai Ling; Au, David K. Y.] Chinese Univ Hong Kong, Hong Kong Inst Integrat Med, Shatin, Hong Kong, Peoples R China.
   [Leung, Ting Hung; Chung, Vincent C. H.] Chinese Univ Hong Kong, Sch Chinese Med, Shatin, Hong Kong, Peoples R China.
   [Wu, Irene X. Y.] Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Changsha, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Beijing University of Chinese Medicine; Chinese University of Hong Kong; Chinese University of Hong Kong; Central South University
RP Wong, W (corresponding author), 15-F Eubank Plaza,9 Chiu Lung St, Hong Kong, Peoples R China.
EM charlene.wong@link.cuhk.edu.hk; wendywong110@gmail.com; wllin@cuhk.edu.hk; davidau@cuhk.edu.hk; justinwu@cuhk.edu.hk; leungthcmph@cuhk.edu.hk; irenexywu@csu.edu.cn; vchung@cuhk.edu.hk
FU Food and Health Bureau, Hong Kong SAR Government [14153141]
CR Adam R, 2015, BRIT J GEN PRACT, V65, PE754, DOI 10.3399/bjgp15X687397
   Aldiss S, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2018-028119
   Unknown -, 2016, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY, V0, P0
   Bhatnagar S, 2015, INDIAN J PALLIAT CAR, V21, P95, DOI 10.4103/0973-1075.150201
   Cao HJ, 2012, PLOS ONE, V7, P0, DOI 10.1371/journal.pone.0031793
   Chalmers I, 2014, LANCET, V383, P156, DOI 10.1016/S0140-6736(13)62229-1
   Chalmers I, 2013, J ROY SOC MED, V106, P482, DOI 10.1177/0141076813493063
   Chamberlain C, 2019, HEALTH POLICY, V123, P706, DOI 10.1016/j.healthpol.2019.05.022
   Chung VCH, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002793
   Chung VCH, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep18111
   del Río MI, 2012, PSYCHO-ONCOLOGY, V21, P913, DOI 10.1002/pon.2099
   Duan Naihua, 2013, SHANGHAI ARCH PSYCHIATRY, V25, P325, DOI 10.3969/j.issn.1002-0829.2013.05.011
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015
   Guise JM, 2013, J CLIN EPIDEMIOL, V66, P666, DOI 10.1016/j.jclinepi.2012.12.010
   Henson LA, 2020, J CLIN ONCOL, V38, P905, DOI 10.1200/JCO.19.00470
   Higginson IJ, 2014, PALLIATIVE MED, V28, P101, DOI 10.1177/0269216313488989
   Hollis C, 2018, LANCET PSYCHIAT, V5, P845, DOI 10.1016/S2215-0366(18)30296-7
   International Agency for Research on Cancer. World Health Organization, 2020, ESTIMATED NUMBER DEA, V0, P0
   Islam KM, 2014, J CANCER EDUC, V29, P796, DOI 10.1007/s13187-014-0657-3
   Jones AP, 2013, BMC MED RES METHODOL, V13, P0, DOI 10.1186/1471-2288-13-50
   Jordan K, 2018, ANN ONCOL, V29, P36, DOI 10.1093/annonc/mdx757
   Lai JN, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/697893
   Lam Yuen-chi, 2009, CHIN MED, V4, P25, DOI 10.1186/1749-8546-4-25
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Li B, 2019, J PALLIAT MED, V22, P1252, DOI 10.1089/jpm.2018.0622
   Liu J, 2015, THORAC CANCER, V6, P561, DOI 10.1111/1759-7714.12270
   Liu Q, 2018, PAIN MANAG NURS, V19, P506, DOI 10.1016/j.pmn.2017.11.006
   Meeker MA, 2011, J FAM NURS, V17, P29, DOI 10.1177/1074840710396091
   Reid J, 2009, INT J NURS STUD, V46, P606, DOI 10.1016/j.ijnurstu.2008.10.012
   Robinson KA, 2011, J CLIN EPIDEMIOL, V64, P1325, DOI 10.1016/j.jclinepi.2011.06.009
   Sakashita A, 2018, J PAIN SYMPTOM MANAG, V55, P379, DOI 10.1016/j.jpainsymman.2017.09.012
   Shippee ND, 2015, HEALTH EXPECT, V18, P1151, DOI 10.1111/hex.12090
   Solheim TS, 2014, ACTA ONCOL, V53, P539, DOI 10.3109/0284186X.2013.823239
   Strömgren AS, 2006, J PAIN SYMPTOM MANAG, V31, P199, DOI 10.1016/j.jpainsymman.2005.07.007
   UpToDate, 2020, CANC PAIN MANAGEMENT, V0, P0
   Wang ZX, 2019, COMPLEMENT THER MED, V43, P165, DOI 10.1016/j.ctim.2019.01.027
   Weeks LC, 2013, CURR ONCOL, V20, PE289, DOI 10.3747/co.20.1378
   WHO, 2012, WORLD MALARIA REPORT 2012, V0, P1
   Wong CHL, 2019, J PAIN SYMPTOM MANAG, V58, P1002, DOI 10.1016/j.jpainsymman.2019.08.002
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Wu XY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002410
   Zeng YC, 2019, CURR ONCOL REP, V21, P0, DOI 10.1007/s11912-019-0786-2
NR 44
TC 7
Z9 9
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1369-6513
EI 1369-7625
J9 HEALTH EXPECT
JI Health Expect.
PD AUG 15
PY 2021
VL 24
IS 4
BP 1487
EP 1497
DI 10.1111/hex.13289
EA JUN 2021
PG 11
WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational Health
GA UB5UX
UT WOS:000659241600001
PM 34107142
DA 2026-01-16
ER

PT J
AU Grant, SJ
   Kwon, K
   Naehrig, D
   Asher, R
   Lacey, J
AF Grant, Suzanne J.
   Kwon, Ki
   Naehrig, Diana
   Asher, Rebecca
   Lacey, Judith
TI Characteristics and Symptom Burden of Patients Accessing Acupuncture Services at a Cancer Hospital
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative oncology; acupuncture; ESAS; patient report outcome measures; cancer; symptom clusters
ID alternative medicine; assessment scale; breast-cancer; complementary; care; management; pain; oncology; fatigue
AB Background: Patients with cancer are often impacted by a significant symptom burden. Cancer hospitals increasingly recognize the value of complementary and integrative therapies to support the management of cancer related symptoms. The aim of this study is to provide a better understanding of the demographic characteristics and symptoms experienced by cancer patients who access acupuncture services in a tertiary hospital in Australia. Methods: A retrospective audit was conducted of patients that presented to the acupuncture service at Chris O'Brien Lifehouse between July 2017 and December 2018. Edmonton Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing (MYCaW) outcome measures were used. The quantitative data was analyzed using descriptive statistics and Principal Component Analysis. Results: A total of 127 inpatients and outpatients (mean age 55, range 19-85) were included with 441 individual surveys completed (264 ESAS, 177 MYCaW). Patients were predominantly female (76.8%) and breast cancer was the most prevalent primary diagnosis (48%). The most prevalent symptoms in the ESAS were sleep problems (88.6%), fatigue (88.3%), lack of wellbeing (88.1%), and memory difficulty (82.6%). Similarly, symptoms with the highest mean scores were numbness, fatigue, sleep problems and hot flushes, whilst neuropathy, and hot flashes were scored as the most severe (score >= 7) by patients. Cluster analysis yielded 3 symptom clusters, 2 included "physical symptoms" (pain, sleep problems, fatigue and numbness/neuropathy), and (nausea, appetite, general well-being), whilst the third included "psychological" symptoms (anxiety, depression, spiritual pain, financial distress). The most frequent concerns expressed by patients (MyCaW) seeking acupuncture were side effects of chemotherapy (24.6%) and pain (20.8%). Conclusion: This audit highlights the most prevalent symptoms, the symptoms with the greatest burden and the types of patients that receive acupuncture services at an Australian tertiary hospital setting. The findings of this audit provide direction for future acupuncture practices and research in hospital settings.
C1 [Grant, Suzanne J.; Kwon, Ki; Lacey, Judith] Western Sydney Univ, NICM Hlth Res Inst, Locked Bag 1797, Penrith, NSW 2751, Australia.
   [Grant, Suzanne J.; Naehrig, Diana; Lacey, Judith] Chris OBrien Comprehens Canc Ctr, Camperdown, NSW, Australia.
   [Naehrig, Diana; Lacey, Judith] Univ Sydney, Sydney, NSW, Australia.
   [Asher, Rebecca] Natl Hlth Med Res Council, Sydney, NSW, Australia.
C3 Western Sydney University; University of Sydney; University of Sydney
RP Grant, SJ (corresponding author), Western Sydney Univ, NICM Hlth Res Inst, Locked Bag 1797, Penrith, NSW 2751, Australia.
EM s.grant@westernsydney.edu.au
CR Amichai T, 2012, EUR J ONCOL NURS, V16, P520, DOI 10.1016/j.ejon.2012.01.004
   Unknown -, 2005, FROM CANCER PATIENT TO CANCER SURVIVOR: LOST IN TRANSITION, V0, P0
   Cotler HB, 2015, MOJ ORTHOPEDICS & RHEUMATOLOGY, V2, P0, DOI 10.15406/mojor.2015.02.00068
   Bell RM, 2010, CLIN J ONCOL NURS, V14, P365, DOI 10.1188/10.CJON.365-370
   Ben-Arye E, 2018, EXPLORE-NY, V14, P289, DOI 10.1016/j.explore.2017.09.012
   Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Cheng KKF, 2005, CLINICAL EFFECTIVENESS IN NURSING, V9, P154
   Cheung WY, 2011, SUPPORT CARE CANCER, V19, P417, DOI 10.1007/s00520-010-0865-2
   Choi TY, 2017, INTEGR CANCER THER, V16, P135, DOI 10.1177/1534735416664172
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Cleeland CS, 2000, CANCER-AM CANCER SOC, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V
   Dodd MJ, 2010, EUR J ONCOL NURS, V14, P101, DOI 10.1016/j.ejon.2009.09.005
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Dos Santos S, 2010, MED ACUPUNCT, V22, P81, DOI 10.1089/acu.2009.0730
   Ezzo JM, 2006, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD002285.pub2
   Fan G, 2007, CURR ONCOL, V14, P173, DOI 10.3747/co.2007.145
   Garcia MK, 2018, INTEGR CANCER THER, V17, P148, DOI 10.1177/1534735416685403
   Garcia MK, 2014, CURR ONCOL REP, V16, P0, DOI 10.1007/s11912-014-0418-9
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Grant SJ, 2019, SUPPORT CARE CANCER, V27, P2069, DOI 10.1007/s00520-018-4460-2
   Greenlee Heather, 2014, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP346, DOI 10.1093/jncimonographs/lgu041
   Health, 2020, DEF INT MED HLTH, V0, P0
   Horneber M, 2012, INTEGR CANCER THER, V11, P187, DOI 10.1177/1534735411423920
   Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437
   Javdan B, 2015, J ACUPUNCT MERIDIAN, V8, P115, DOI 10.1016/j.jams.2015.03.005
   Kremser T, 2008, BREAST, V17, P387, DOI 10.1016/j.breast.2007.12.006
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   McKeon C, 2013, AJACM, V8, P2
   Minasian LM, 2007, J CLIN ONCOL, V25, P5128, DOI 10.1200/JCO.2007.12.6672
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ogawa K, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/928129
   Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI 10.1136/bmjspcare-2011-000022
   Paterson C, 2007, COMPLEMENT THER MED, V15, P38, DOI 10.1016/j.ctim.2006.03.006
   Polley MJ, 2007, SUPPORT CARE CANCER, V15, P963, DOI 10.1007/s00520-007-0283-2
   Polley MJ, 2016, INTEGR CANCER THER, V15, P435, DOI 10.1177/1534735416632060
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Selby D, 2011, J PALLIAT MED, V14, P1309, DOI 10.1089/jpm.2011.0187
   Smith CA, 2018, BMC COMPLEM ALTERN M, V18, P0, DOI 10.1186/s12906-018-2357-8
   Wardley AM, 2020, J CLIN ONCOL, V38, P0
   Witt Claudia M, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP3, DOI 10.1093/jncimonographs/lgx012
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
NR 45
TC 8
Z9 9
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD APR 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/15347354211002253
PG 9
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA RM7ZV
UT WOS:000639878000001
PM 33840252
DA 2026-01-16
ER

PT J
AU Ho, EY
   Agne, RR
   Santana, T
   Thompson, N
   McClendon, G
   Ng, E
   Merrick, S
   Gonzalez, F
   Smith, T
   Drewke, K
   Gutierrez, A
   Floyd, G
   Chao, MT
AF Ho, Evelyn Y
   Agne, Robert R
   Santana, Trilce
   Thompson, Nicole
   McClendon, Genevieve
   Ng, Eliza
   Merrick, Shannette
   Gonzalez, Felicia
   Smith, Tenaya
   Drewke, Kathleen
   Gutierrez, Amalia
   Floyd, Gary
   Chao, Maria T
TI A Communication Perspective on What Patient Advisory Boards Do:
SO Journal of general internal medicine
LA English
DT Journal Article
DE acupuncture; cancer; implementation; inpatient; pain; pragmatic effectiveness
AB Stakeholder advisory boards are recognized as an essential and useful part of  patient-centered research. However, such engagement can involve exchanges of  diverse individual experiences, multiple opinions, and strong feelings in the  face of researchers' limitations, deadlines, and agendas. Yet, little work  examines how these potential tensions occur and are resolved in actual advisory  board meetings. This perspective article describes and employs a communication  framework for analyzing a patient advisory council (PAC) for a comparative  effectiveness study on acupuncture and pain counseling for inpatients with  cancer. The framework, Action-Implicative Discourse Analysis (AIDA), is an  observational method that examines challenges through recorded and transcribed,  naturally occurring interaction. Our analysis focused on two short excerpts from  the first PAC meeting to demonstrate members' navigation of advice-giving and  advice-receiving-one in which advice was ultimately implemented by the study team  and another in which it was deemed unfeasible. Although advice is inherent to the  work of all PACs, it often emerges unannounced as negotiated moments, made up of  seemingly minor conversation moves. As a recurring event, advice can and should  be analyzed and discussed within PACs to improve communication and team dynamics.
C1 Department of Communication Studies, University of San Francisco, 2130 Fulton Street, Communication Studies KA 313, San Francisco, CA, 94117, USA.eyho@usfca.edu.
   Asian American Research Center on Health, University of California, San Francisco 
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA. eyho@usfca.edu.
   School of Communication and Journalism, Auburn University, Auburn, AL, USA.
   Osher Center for Integrative Medicine, UCSF, San Francisco, CA, USA.
   Osher Center for Integrative Medicine, UCSF, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   School of Medicine, University of California Davis, Davis, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services Advisory Board, San Francisco, CA, USA.
   Asian American Research Center on Health, University of California, San Francisco (UCSF), San Francisco, CA, USA.
   Osher Center for Integrative Medicine, UCSF, San Francisco, CA, USA.
   Department of Medicine, Division of General Internal Medicine at San Francisco General Hospital, UCSF, San Francisco, CA, USA.
NR 0
TC 0
SN 1525-149
EI 0884-873
J9 J Gen Intern Med
PD OCT 1
PY 2021
VL 37
IS Suppl 1
BP 99
EP 104
DI 10.1007/s11606-021-07062-3
PG 5
WC Communication; Counseling; Humans; Inpatients; Negotiating
UT PubMed:34591265
PM 34591265
DA 2021-10-01
ER

PT J
AU Wang, YH
   Zhou, MF
   Shen, JM
   Wang, DS
   Xu, N
   Song, YF
   Sun, MZ
   Chen, L
   Pei, LX
   Sun, JH
AF Wang, Yuhang
   Zhou, Mingfei
   Shen, Jianmei
   Wang, Dongsheng
   Xu, Na
   Song, Yafang
   Sun, Mengzhu
   Chen, Lu
   Pei, Lixia
   Sun, Jianhua
TI Effect of electroacupuncture on chemotherapy-induced diarrhea: study protocol for a randomized controlled trial
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Chemotherapy-induced diarrhea (CID); cancer; acupuncture; randomized controlled trial
ID acupuncture; management; pain; prevention; therapy; care
AB Background: Chemotherapy-induced diarrhea (CID) is one of the side effects of chemotherapy. Diarrhea not only affects the overall treatment effectiveness but also reduces patients' quality of life. Severe diarrhea can lead to electrolyte imbalance and even be life-threatening. Although acupuncture has been widely used in clinical practice and its effectiveness for managing functional diarrhea has been recognized, there is no sound evidence of its efficacy in managing CID. Therefore, the aim of the proposed randomized controlled trial is to examine the effectiveness and potential risks of using acupuncture for the management of CID and to describe its protocol herein. Methods: This trial will be conducted in a double-blinded manner and comprise two arms that will be investigated across multiple centers in parallel. The study cohort will comprise 168 outpatients who have CID from six Chinese hospitals. The patients will be randomly and equally divided between an intervention group (electroacupuncture) and a control group (micro-electroacupuncture). In the former, acupuncture will be performed with the conventional method to induce the de qi sensation, and in the latter group, acupuncture will be performed with a sham procedure that does not involve the insertion of needles. The acupoints ST25, SP14, SP6, and ST37 will be applied in the two methods. These procedures will be performed three times a week for four consecutive weeks. The number of days on which CID occurred, the incidence of CID, and fecal characteristics are considered as the primary outcomes, and the Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea subscale score and the World Health Organization Quality of Life assessment are considered as secondary outcomes. The patients will be closely observed for complications and fluctuations in vital signs. Discussion: If the findings from the trial demonstrate the effectiveness and safety of using acupuncture to treat CID, they could serve as evidence for the clinical application of acupuncture as a complementary treatment for cancer patients during chemotherapy.
C1 [Wang, Yuhang; Sun, Mengzhu] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Acupuncture & Rehabil, Nanjing, Peoples R China.
   [Wang, Yuhang; Xu, Na; Song, Yafang; Sun, Mengzhu] Nanjing Univ Chinese Med, Acupuncture & Tuina Acad, Nanjing, Peoples R China.
   [Zhou, Mingfei] Nanjing Xiaohang Hosp, Dept Oncol, Nanjing, Peoples R China.
   [Shen, Jianmei; Wang, Dongsheng] Nanjing Red Cross Hosp, Dept Oncol, Nanjing, Peoples R China.
   [Chen, Lu; Pei, Lixia; Sun, Jianhua] Nanjing Univ Tradit Chinese Med, Affiliated Hosp, Dept Acupuncture & Rehabil, Prov Hosp Tradit Chinese Med, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine
RP Sun, JH (corresponding author), Nanjing Univ Tradit Chinese Med, Affiliated Hosp, Dept Acupuncture & Rehabil, Prov Hosp Tradit Chinese Med, Nanjing, Peoples R China.
EM 377201634@qq.com
FU Leading Talents Project of Jiangsu Provincial Administration of TCM [SLJ0206]; Nanjing University of Chinese Medicine's Jiangsu University Nursing Discipline Construction Funding Project [2019YSHL062]
CR ABIGERGES D, 1995, J CLIN ONCOL, V13, P210, DOI 10.1200/JCO.1995.13.1.210
   Akel T, 2018, ANN NONINVAS ELECTRO, V23, P0, DOI 10.1111/anec.12505
   Andreyev J, 2014, LANCET ONCOL, V15, PE447, DOI 10.1016/S1470-2045(14)70006-3
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bauml J, 2016, INTEGR CANCER THER, V15, P326, DOI 10.1177/1534735415624138
   Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132
   Deng G, 2018, ONCOLOGY-NY, V32, P310
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Gibson RJ, 2006, SUPPORT CARE CANCER, V14, P890, DOI 10.1007/s00520-006-0040-y
   Gibson Rachel J, 2009, CURR OPIN SUPPORT PALLIAT CARE, V3, P31, DOI 10.1097/SPC.0b013e32832531bb
   Haddad NE, 2014, INTEGR CANCER THER, V13, P371, DOI 10.1177/1534735413520181
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P2270, DOI 10.1001/jama.2018.16744
   Hou WZ, 2019, J OBSTET GYNAECOL RE, V45, P2307, DOI 10.1111/jog.14122
   IKUNO N, 1995, J NATL CANCER I, V87, P1876, DOI 10.1093/jnci/87.24.1876
   Kordes M, 2019, ESMO OPEN, V4, P0, DOI 10.1136/esmoopen-2019-000607
   Kornblau S, 2000, J PAIN SYMPTOM MANAG, V19, P118, DOI 10.1016/S0885-3924(99)00149-9
   Kweekel D, 2008, CANCER TREAT REV, V34, P656, DOI 10.1016/j.ctrv.2008.05.002
   Lian QS, 2017, CELL RES, V27, P784, DOI 10.1038/cr.2017.54
   Liu WL, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419848494
   Ma JM, 2019, CA-CANCER J CLIN, V69, P351, DOI 10.3322/caac.21564
   Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Österlund P, 2004, CLIN GASTROENTEROL H, V2, P696, DOI 10.1016/S1542-3565(04)00293-9
   Perez D, 2015, SUPPORT CARE CANCER, V23, P3307, DOI 10.1007/s00520-015-2755-0
   Pérez-Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Shang HX, 2015, WORLD J GASTROENTERO, V21, P4986, DOI 10.3748/wjg.v21.i16.4986
   Sharma R, 2005, LANCET ONCOL, V6, P93, DOI 10.1016/S1470-2045(05)01735-3
   Simcock R, 2013, ANN ONCOL, V24, P776, DOI 10.1093/annonc/mds515
   Sun Bao-Mu, 2010, ZHONG XI YI JIE HE XUE BAO, V8, P641
   Takahashi T, 2006, J GASTROENTEROL, V41, P408, DOI 10.1007/s00535-006-1773-6
   Wang ZQ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3701-0
   Weng ZJ, 2015, PURINERG SIGNAL, V11, P321, DOI 10.1007/s11302-015-9447-6
   Yeung WF, 2014, COMPLEMENT THER MED, V22, P894, DOI 10.1016/j.ctim.2014.08.001
   Zachariah B, 2010, JNCI-J NATL CANCER I, V102, P547, DOI 10.1093/jnci/djq063
   Zheng H, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000003884
   Zhou KH, 2011, J ALTERN COMPLEM MED, V17, P1007, DOI 10.1089/acm.2010.0652
NR 36
TC 2
Z9 2
U1 4
U2 16
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD MAY 15
PY 2021
VL 10
IS 5
BP 2516
EP 2524
DI 10.21037/tcr-20-3400
PG 9
WC Oncology
SC Oncology
GA SL1RG
UT WOS:000656696500050
PM 35116567
DA 2026-01-16
ER

PT J
AU Zhao, YX
   Yu, XC
   Gao, JH
   Yao, MJ
   Zhu, B
AF Zhao, Yu-Xue
   Yu, Xiao-Chun
   Gao, Jun-Hong
   Yao, Ming-Jiang
   Zhu, Bing
TI Acupuncture for Paclitaxel-Induced Peripheral Neuropathy: A Review of Clinical and Basic Studies
SO JOURNAL OF PAIN RESEARCH
LA English
DT Review
DE paclitaxel; peripheral neuropathy; acupuncture
ID bee venom acupuncture; potential vanilloid 1; dorsal-root ganglion; mechanical allodynia; gene-expression; chemotherapy; pain; electroacupuncture; activation; cancer
AB Paclitaxel-induced peripheral neuropathy (PIPN) is a common and intractable side effect of the conventional chemotherapeutic agent paclitaxel. Acupuncture has been reported as an effective alternative therapy in treatment of PIPN in both basic studies and clinical trials. However, there is a lack of comprehensive surveys to summarize the action of acupuncture in management of PIPN. In this review, we briefly demonstrate the basic pathology of PIPN, which includes the activation of ion channels, mitochondrial dysfunction, disruption of axonal transport and also neuro-inflammatory involvement. Meanwhile, we review both the clinical and basic studies as an emphasis to give a general overview of the therapeutic effect of acupuncture against PIPN. Finally, we summarize the current known mechanisms underlying the action of acupuncture against PIPN mainly at peripheral and spinal levels, which include various neurotransmitters, multiple receptors, different types of enzymes and molecules. In conclusion, acupuncture could be considered as a potential alternative therapy in treatment of PIPN, and further clinical and experimental studies are called for in the future.
C1 [Zhao, Yu-Xue; Yu, Xiao-Chun; Gao, Jun-Hong; Zhu, Bing] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, 16 Dong Zhi Men Nei South St, Beijing 100700, Peoples R China.
   [Yao, Ming-Jiang] China Acad Chinese Med Sci, Inst Basic Med Sci, Xiyuan Hosp, Beijing 100091, Peoples R China.
   [Yao, Ming-Jiang] Key Lab Pharmacol Chinese Mat Med, Beijing 100091, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Xiyuan Hospital, CACMS; China Academy of Chinese Medical Sciences
RP Zhao, YX; Zhu, B (corresponding author), China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, 16 Dong Zhi Men Nei South St, Beijing 100700, Peoples R China.
EM claricezhao@live.cn; zhubing@mail.cintcm.ac.cn
FU Beijing Natural Science Foundation [7202141]; Fundamental Research Funds for the Central Public Welfare Research Institutes [201814009, ZZ13-YQ-067]; National Natural Science Foundation of China [81202763, 81674075]
CR Alkislar I, 2021, BIOL PSYCHIAT-COGN N, V6, P479, DOI 10.1016/j.bpsc.2020.11.015
   Andoh T, 2017, PHYTOMEDICINE, V25, P1, DOI 10.1016/j.phymed.2016.12.010
   Areti A, 2014, REDOX BIOL, V2, P289, DOI 10.1016/j.redox.2014.01.006
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Ben-Arye E, 2018, INT J GYNECOL CANCER, V28, P1045, DOI 10.1097/IGC.0000000000001246
   Ben-Horin I, 2017, INTEGR CANCER THER, V16, P258, DOI 10.1177/1534735417690254
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Burgos E, 2012, EUR J PHARMACOL, V682, P62, DOI 10.1016/j.ejphar.2012.02.008
   Chang S, 2019, FRONT NEUROSCI-SWITZ, V13, P0, DOI 10.3389/fnins.2019.00110
   Chen JDZ, 2018, NEUROGASTROENT MOTIL, V30, P0, DOI 10.1111/nmo.13393
   Chen Y, 2011, NEUROSCIENCE, V193, P440, DOI 10.1016/j.neuroscience.2011.06.085
   Chien A, 2021, PM&R, V13, P55, DOI 10.1002/pmrj.12361
   Choi J, 2017, TOXINS, V9, P0, DOI 10.3390/toxins9110351
   Choi JW, 2015, AM J CHINESE MED, V43, P57, DOI 10.1142/S0192415X15500044
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   Donald GK, 2011, ACUPUNCT MED, V29, P230, DOI 10.1136/acupmed.2011.010025
   Ferris Craig F, 2019, NEUROBIOL PAIN, V6, P100034, DOI 10.1016/j.ynpai.2019.100034
   Flatters SJL, 2006, PAIN, V122, P245, DOI 10.1016/j.pain.2006.01.037
   Flatters SJL, 2004, PAIN, V109, P150, DOI 10.1016/j.pain.2004.01.029
   Galley HF, 2017, J PINEAL RES, V63, P0, DOI 10.1111/jpi.12444
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562
   Gornstein E, 2014, NEUROPHARMACOLOGY, V76, P175, DOI 10.1016/j.neuropharm.2013.08.016
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   Grisold W, 2012, NEURO-ONCOLOGY, V14, P45, DOI 10.1093/neuonc/nos203
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hara T, 2013, PAIN, V154, P882, DOI 10.1016/j.pain.2013.02.023
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2014, J CLIN ONCOL, V32, P1941, DOI 10.1200/JCO.2013.54.0914
   Hsieh YL, 2016, ACUPUNCT MED, V34, P398, DOI 10.1136/acupmed-2016-011112
   Hu SY, 2019, CLIN CANCER RES, V25, P6295, DOI 10.1158/1078-0432.CCR-18-2152
   Jeong YJ, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/5367014
   Jia M, 2017, MOL PAIN, V13, P0, DOI 10.1177/1744806917719804
   Kim MJ, 2017, KOREAN J PHYSIOL PHA, V21, P657, DOI 10.4196/kjpp.2017.21.6.657
   Kim W, 2016, TOXINS, V8, P0, DOI 10.3390/toxins8020033
   Lee JH, 2014, BMC COMPLEM ALTERN M, V14, P0, DOI 10.1186/1472-6882-14-471
   Li Y, 2017, PAIN, V158, P417, DOI 10.1097/j.pain.0000000000000774
   Li Y, 2015, J NEUROSCI, V35, P13487, DOI 10.1523/JNEUROSCI.1956-15.2015
   Li Y, 2015, BRAIN BEHAV IMMUN, V49, P255, DOI 10.1016/j.bbi.2015.06.003
   Li Y, 2014, J PAIN, V15, P712, DOI 10.1016/j.jpain.2014.04.001
   Li YY, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20235917
   Liang Jia, 2012, ZHEN CI YAN JIU, V37, P20
   Liang Y, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919847810
   Lin D, 2014, INT J MOL SCI, V15, P3234, DOI 10.3390/ijms15023234
   Liu CC, 2010, MOL PAIN, V6, P0, DOI 10.1186/1744-8069-6-76
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2012, MED ACUPUNCT, V24, P233, DOI 10.1089/acu.2012.0904
   Luo JL, 2018, J NEUROSCI, V38, P474, DOI 10.1523/JNEUROSCI.1816-17.2017
   Luo X, 2019, J NEUROSCI, V39, P6848, DOI 10.1523/JNEUROSCI.3257-18.2019
   Lv QY, 2019, FRONT INTEGR NEUROSC, V13, P0, DOI 10.3389/fnint.2019.00038
   Ma JC, 2018, CANCER-AM CANCER SOC, V124, P2289, DOI 10.1002/cncr.31248
   Masocha W, 2016, PEERJ, V4, P0, DOI 10.7717/peerj.2798
   Masocha W, 2015, GENE EXPRESSION, V16, P145, DOI 10.3727/105221615X14181438356337
   Materazzi S, 2012, PFLUG ARCH EUR J PHY, V463, P561, DOI 10.1007/s00424-011-1071-x
   Melli G, 2008, EXP NEUROL, V214, P276, DOI 10.1016/j.expneurol.2008.08.013
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Molassiotis A, 2019, INTEGR CANCER THER, V18, P0, DOI 10.1177/1534735419836501
   Ochi-ishi R, 2014, MOL PAIN, V10, P0, DOI 10.1186/1744-8069-10-53
   Park SB, 2013, CA-CANCER J CLIN, V63, P419, DOI 10.3322/caac.21204
   Nieto FR, 2008, PAIN, V137, P520, DOI 10.1016/j.pain.2007.10.012
   ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507
   SAHENK Z, 1994, ARCH NEUROL-CHICAGO, V51, P726, DOI 10.1001/archneur.1994.00540190110024
   Salat K, 2015, J ZHEJIANG UNIV-SC B, V16, P167, DOI 10.1631/jzus.B1400189
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Sekiguchi F, 2018, NEUROPHARMACOLOGY, V141, P201, DOI 10.1016/j.neuropharm.2018.08.040
   Shemesh OA, 2010, ACTA NEUROPATHOL, V119, P235, DOI 10.1007/s00401-009-0586-0
   Siau C, 2006, EXP NEUROL, V201, P507, DOI 10.1016/j.expneurol.2006.05.007
   Sisignano M, 2014, NAT REV NEUROL, V10, P694, DOI 10.1038/nrneurol.2014.211
   Son S, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.01108
   Starobova H, 2017, FRONT MOL NEUROSCI, V10, P0, DOI 10.3389/fnmol.2017.00174
   Tao J, 2016, BRAIN RES BULL, V120, P14, DOI 10.1016/j.brainresbull.2015.10.011
   Travis LB, 2014, JNCI-J NATL CANCER I, V106, P0, DOI 10.1093/jnci/dju044
   Ulloa L, 2017, TRENDS MOL MED, V23, P1103, DOI 10.1016/j.molmed.2017.10.006
   Wang YL, 2019, NEUROPEPTIDES, V77, P0, DOI 10.1016/j.npep.2019.101957
   Wu J, 2019, J PAIN, V20, P501, DOI 10.1016/j.jpain.2018.10.007
   Xu H, 2008, J NEUROSCI, V28, P7445, DOI 10.1523/JNEUROSCI.1812-08.2008
   Yadav R, 2015, J NEUROCHEM, V133, P857, DOI 10.1111/jnc.13103
   Yan XS, 2019, GLIA, V67, P482, DOI 10.1002/glia.23557
   Yeo JH, 2016, J PAIN, V17, P298, DOI 10.1016/j.jpain.2015.10.018
   Yoon SY, 2018, J PAIN, V19, P1157, DOI 10.1016/j.jpain.2018.04.015
   Yu ML, 2020, INFLAMMATION, V43, P1233, DOI 10.1007/s10753-020-01203-2
   Zeng QZ, 2019, FRONT IMMUNOL, V10, P0, DOI 10.3389/fimmu.2019.00072
   Zhang HJ, 2014, ANESTHESIOLOGY, V120, P1463, DOI 10.1097/ALN.0000000000000176
   [张虹 Zhang Hong], 2018, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V33, P2103
   Zhang Y, 2018, EUR J PAIN, V22, P679, DOI 10.1002/ejp.1132
   Zhao XM, 2019, PHYSIOL RES, V68, P501, DOI 10.33549/physiolres.934084
   Zhao YX, 2020, J PAIN RES, V13, P239, DOI 10.2147/JPR.S241101
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   Zheng HE, 2011, EXP NEUROL, V232, P154, DOI 10.1016/j.expneurol.2011.08.016
   Zhi WI, 2018, INTEGR CANCER THER, V17, P1079, DOI 10.1177/1534735418788667
NR 90
TC 5
Z9 6
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2021
VL 14
IS 
BP 993
EP 1005
DI 10.2147/JPR.S296150
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA RN4HZ
UT WOS:000640313900001
PM 33883931
DA 2026-01-16
ER

PT J
AU Panicker, L
   Prasun, MA
   Stockmann, C
   Simon, J
AF Panicker, Latha
   Prasun, Marilyn A
   Stockmann, Cherrill
   Simon, Jolene
TI Evaluation of Chronic, Noncancer Pain Management Initiative in a
SO Pain management nursing : official journal of the American Society of Pain
LA English
DT Journal Article
AB BACKGROUND: Chronic pain management is a major challenge for primary care  providers (PCPs). PCPs manage many patients with chronic pain and other  comorbidities including mental health problems like post-traumatic stress  disorder (PTSD) and depression. Chronic pain and opioid problems are a national  crisis, particularly among veterans (U.S. Department of Veterans Affairs, 2019).  There are many veterans with chronic non-cancer pain who are being treated with  opioids. Chronic opioid use has contributed to an epidemic of opioid-related  adverse events (VA, 2017). Opioids not only result in poor pain control, but have  associated risks such as misuse, overdose, and diversion which may be fatal  (Frieden & Houry, 2016). AIMS: The aim of this project was to evaluate chronic  non-cancer pain management of veterans using an advanced practice registered  nurse (APRN)-led multidisciplinary team approach to incorporate non-opioid and  non-pharmacologic modalities to affect self-reported pain and use of prescribed  opioids. METHODS: A retrospective quality improvement (QI) project was conducted  in the multidisciplinary pain (MDP) clinic. The APRN used a biopsychosocial  approach for chronic pain management guided by the Plan, Do, Study, Act (PDSA)  cycle framework. Thirty-four patients who were utilizing opioids for pain  management were included using convenience sampling from the MDP clinic. The APRN  educated and treated patients with non-opioid medications and non-pharmacolog  therapies. A 10-point pain scale and morphine equivalent daily dose (MEDD) were  utilized pre- and post-intervention to evaluate the MDP clinic. RESULTS:  Participants were predominantly male (91.8%), with a mean age of 63.18 ± 15.39  years, and 36.4% of whom were retired. Only 20.6% of the participants reported  the use of opioids for <12 months. Low back pain (93%) was the most common pain  location. The mean baseline MEDD was 41.04 and the post tapered MEDD was 23.05;  this revealed a significant decline in MEDD (p < .0001). A decline was also found  between pre- and post-pain scores (ranges 0-8). There was a significant reported  decline in pain scores with a baseline of 6.11 to post tapering pain of 3.1  (t = 4.99, df = 28, p < .0001). Participants preferred non-opioid medications 94%  and non-pharmacologic therapy 86%, like physical therapy, yoga, and acupuncture.  Fifty-one percent of patients were referred for injections and 46% were referred  to primary care behavior health, which includes pain school, sleep hygiene  classes, and cognitive behavior therapy. CONCLUSIONS: APRNs are in a key position  to assess and treat patients based on current evidence while facilitating opioid  titration. This initiative highlights that safe tapering of opioids is possible  when utilizing a multidisciplinary approach for chronic pain management. Findings  support the use of non-pharmacologic and non-opioid therapy for chronic pain  management which can result in reduced patient-reported pain. Further research is  warranted to examine both pharmacologic (non-opioid) and non-pharmacologic  strategies that promote pain management while tapering opioids.
C1 Illinois State University Mennonite College of Nursing, Normal, Illinois
   Edward Hines Junior VA Hospital, Hines, Illinois. 
   Illinois State University Mennonite College of Nursing, Normal, Illinois.
   Illinois State University Mennonite College of Nursing, Normal, Illinois.
   Edward Hines Junior VA Hospital, Hines, Illinois.
EM atha.panicker@va.gov
NR 0
TC 0
SN 1532-863
EI 
J9 Pain Manag Nurs
PD NOV 11
PY 2021
VL 23
IS 2
BP 122
EP 127
DI 10.1016/j.pmn.2021.09.003
PG 5
WC Aged; Analgesics, Opioid; adverse effects; Chronic Pain; drug therapy; Humans; Male; Middle Aged; Morphine; therapeutic use; Pain Clinics; Pain Management; Retrospective Studies
UT PubMed:34756689
PM 34756689
DA 2021-11-11
ER

PT J
AU Kako, J
   Kajiwara, K
   Kobayashi, M
AF Kako, Jun
   Kajiwara, Kohei
   Kobayashi, Masamitsu
TI Could acupuncture be a treatment option for cancer patients with attitudinal barriers to pharmacological pain management?
SO SUPPORTIVE CARE IN CANCER
LA English
DT Letter
C1 [Kako, Jun] Hiroshima Univ, Div Nursing Sci, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.
   [Kajiwara, Kohei] Japanese Red Cross Kyushu Int Coll Nursing, Munakata, Japan.
   [Kobayashi, Masamitsu] Natl Def Med Coll, Fac Nursing, Tokorozawa, Saitama, Japan.
C3 Hiroshima University; National Defense Medical College - Japan
RP Kako, J (corresponding author), Hiroshima Univ, Div Nursing Sci, Grad Sch Biomed & Hlth Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.
EM jkako-tky@umin.ac.jp
CR Folkman S, 1997, SOC SCI MED, V45, P1207, DOI 10.1016/S0277-9536(97)00040-3
   Liou KT, 2021, SUPPORT CARE CANCER, V29, P427, DOI 10.1007/s00520-020-05504-y
NR 2
TC 0
Z9 0
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JAN 15
PY 2021
VL 29
IS 1
BP 3
EP 3
DI 10.1007/s00520-020-05712-6
EA AUG 2020
PG 1
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA RI9WR
UT WOS:000562347600001
PM 32833095
DA 2026-01-16
ER

PT J
AU Jiang, B
   Zhong, X
   Fang, J
   Zhang, A
   WangD, W
   Liang, Y
   Fang, J
   Chen, F
   Du, J
AF Jiang, Bin
   Zhong, Xuemei
   Fang, Junfan
   Zhang, Aijun
   WangD, Wen
   Liang, Yi
   Fang, Jianqiao
   Chen, Feng
   Du, Junying
TI Electroacupuncture Attenuates Morphine Tolerance in Rats with Bone Cancer Pain by
SO Integrative cancer therapies
LA English
DT Journal Article
DE IGF-1; JNK1/2; LY294002; PI3K/Akt; bone cancer pain; electroacupuncture; morphine tolerance
AB PURPOSE: Morphine is often used for the treatment of moderate and severe cancer  pain, but long-term use can lead to morphine tolerance. Methods for effectively  inhibiting morphine tolerance and the related mechanism of action are of great  significance for the treatment of cancer pain. Previous studies have shown that  electroacupuncture (EA) can inhibit the occurrence of morphine tolerance, but the  mechanism is not yet clear. The aim of the present study was to explore the  signaling pathway by which EA attenuates the development of bone cancer pain  (BCP)-morphine tolerance (MT). MATERIALS AND METHODS: Changes in the paw  withdrawal threshold (PWT) of rats with bone cancer pain-morphine tolerance were  observed in a study of EA combined with intrathecal injection of a PI3K inhibitor  (LY294002) or agonist (insulin-like growth factor-1 [IGF-1]). We also tested the  protein expression of phosphorylated phosphatidylinositol 3-kinase (p-PI3K),  phosphorylated protein kinase B (p-Akt), phosphorylated c-Jun NH(2)-terminal  kinase 1/2 (p-JNK1/2), and β-arrestin2 in the L4-6 spinal dorsal horn of rats.  RESULTS: The protein expression of p-PI3K, p-Akt, p-JNK1/2, and β-arrestin2 was  upregulated in the L4-6 spinal dorsal horn of rats with bone cancer pain and bone  cancer pain-morphine tolerance. EA delayed the occurrence of morphine tolerance  in rats with bone cancer pain and downregulated the protein expression of p-PI3K,  p-Akt, p-JNK1/2, and β-arrestin2 in the L4-6 spinal dorsal horn of rats with bone  cancer pain-morphine tolerance. Intrathecal injection of LY294002 attenuated the  development of morphine tolerance and downregulated the protein expression of  p-Akt, p-JNK1/2, and β-arrestin2 in the spinal dorsal horn of rats with bone  cancer pain-morphine tolerance. In addition, the inhibitory effect of EA on  morphine tolerance was reversed by IGF-1. CONCLUSION: The mechanism underlying  the ability of EA to attenuate morphine tolerance may be associated with  inhibition of the PI3K/Akt/JNK1/2 signaling pathway.
C1 Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical 
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
   The Second Clinical College of Zhejiang University of Traditional Chinese 
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
   Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
   Affiliated Hospital of Jiaxing University, The First Hospital of Jiaxing, Jiaxing, Zhejiang, China.
   Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Key Laboratory of Acupuncture andNeurology of Zhejiang Province, Hangzhou, China.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAR 5
PY 2021
VL 20
IS 
BP 1534735421995237
EP 1534735421995237
DI 10.1177/1534735421995237
PG 1
WC Animals; Cancer Pain; drug therapy; Electroacupuncture; Morphine; pharmacology; Neoplasms; Phosphatidylinositol 3-Kinases; metabolism; Proto-Oncogene Proteins c-akt; metabolism; Rats; Rats, Sprague-Dawley; Signal Transduction; Spinal Cord Dorsal Horn; metabolism
UT PubMed:33660537
PM 33660537
DA 2021-03-05
ER

PT J
AU Xu, M
   Fei, Y
   He, QL
   Fu, J
   Zhu, JJ
   Tao, JC
   Ni, CB
   Xu, CF
   Zhou, QH
   Yao, M
   Ni, HD
AF Xu, Miao
   Fei, Yong
   He, Qiuli
   Fu, Jie
   Zhu, Jianjun
   Tao, Jiachun
   Ni, Chaobo
   Xu, Chengfei
   Zhou, Qinghe
   Yao, Ming
   Ni, Huadong
TI Electroacupuncture Attenuates Cancer-Induced Bone Pain via NF-κB/CXCL12 Signaling in Midbrain Periaqueductal Gray
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE Electroacupuncture; NF-kappa B; CXCL12; PAG; cancer-induced bone pain
ID factor-kappa-b; mechanical allodynia; expression; acupuncture; hypersensitivity; contributes; receptors; model; trpv1; p2x3
AB Electroacupuncture (EA) is effective in various chronic pains. NF-kappa B and CXCL12 modulate the formation of chronic pain. Herein, we hypothesized that EA alleviates cancer-induced bone pain (CIBP) through NF-kappa B/CXCL12 axis in midbrain periaqueductal gray (PAG), which participates in "top-down" pain modulatory circuits. In order to filter the optimum EA frequency for CIBP treatment, 2, 100, or 2/100 Hz EA was set up. In addition, ipsilateral, contralateral, and bilateral EA groups were established to affirm the optimal EA scheme. Bilateral 2/100 Hz EA was considered as the optimal therapeutic scheme and was applied in a subsequent experiment. Western blotting along with immunofluorescence illustrated that CIBP induces a rapid and substantial increase in CXCL12 protein level and NF-kappa B phosphorylation in vlPAG from day 6 to day 12. Anti-CXCL12 neutralizing antibody and pAAV-U6-shRNA(CXCL12)-CMV-EGFP-WPRE in vlPAG remarkably improved the mechanical pain threshold of the hind paw in CIBP model relative to the control. EA inhibited the upregulation of pNF-kappa B and CXCL12 in vlPAG of CIBP. The recombinant CXCL12 and pAAV-CMV-CXCL12-EF1a-EGFP-3Xflag-WPRE reversed the abirritation of EA in the CIBP rat model. NF-kappa B phosphorylation mediated-CXCL12 expression contributed to CIBP allodynia, whereas EA suppressed NF-kappa B phosphorylation in CIBP. According to the above evidence, we conclude that bilateral 2/100 Hz EA is an optimal therapeutic scheme for CIBP. The abirritation mechanism of EA might reduce the expression of CXCL12 by inhibiting the activation of NF-kappa B, which might lead to the restraint of descending facilitation of CIBP.
C1 [Xu, Miao; Fei, Yong; He, Qiuli; Fu, Jie; Zhu, Jianjun; Tao, Jiachun; Ni, Chaobo; Xu, Chengfei; Zhou, Qinghe; Yao, Ming; Ni, Huadong] Jiaxing Univ, Affiliated Hosp, Dept Anesthesiol, Jiaxing 314001, Peoples R China.
   [Xu, Miao; Fei, Yong; He, Qiuli; Fu, Jie; Zhu, Jianjun; Tao, Jiachun; Ni, Chaobo; Xu, Chengfei; Zhou, Qinghe; Yao, Ming; Ni, Huadong] Jiaxing Univ, Affiliated Hosp, Pain Res Ctr, Jiaxing 314001, Peoples R China.
C3 Jiaxing University; Jiaxing University
RP Ni, HD (corresponding author), Jiaxing Univ, Affiliated Hosp, Dept Anesthesiol, Jiaxing 314001, Peoples R China.; Ni, HD (corresponding author), Jiaxing Univ, Affiliated Hosp, Pain Res Ctr, Jiaxing 314001, Peoples R China.
EM huadongni@126.com
FU National Science Foundation for Young Scientists of China [81901124]; Natural Science Foundation of Zhejiang Province [LQ19H090007, Y20H090134]; Medical and Health General Research Program of Zhejiang Province [2020RC122, 2021RC130]; Jiaxing City Science and Technology Project [2021AY30023]; Key Medical Subjects Established by Zhejiang Province and Jiaxing City Jointly Pain Medicine [2019-ssttyx]; Construction Project of Key Laboratory of Nerve and Pain Medicine in Jiaxing City; Key Laboratory of Precision Diagnosis and Treatment of Intractable Pain of Zhejiang Provincial
CR Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038
   Bonavia R, 2003, TOXICOL LETT, V139, P181, DOI 10.1016/S0378-4274(02)00432-0
   Borghi SM, 2021, FRONT IMMUNOL, V11, P0, DOI 10.3389/fimmu.2020.539086
   Borghi SM, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-019-1496-2
   Caraceni A, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11040510
   Chai WX, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/2598975
   CHIENG B, 1994, BRIT J PHARMACOL, V113, P121, DOI 10.1111/j.1476-5381.1994.tb16183.x
   Coulombe MA, 2016, HUM BRAIN MAPP, V37, P1514, DOI 10.1002/hbm.23117
   Da Silva JT, 2021, AGING CELL, V20, P0, DOI 10.1111/acel.13292
   de Novellis V, 2012, EUR J PHARMACOL, V676, P41, DOI 10.1016/j.ejphar.2011.11.034
   Donaldson LF, 2017, J PHYSIOL-LONDON, V595, P4139, DOI 10.1113/JP273361
   Du Junying, 2015, ZHONGGUO ZHEN JIU, V35, P161
   Fang JQ, 2018, LIFE SCI, V200, P69, DOI 10.1016/j.lfs.2018.03.028
   Galeotti N, 2013, PSYCHOPHARMACOLOGY, V227, P149, DOI 10.1007/s00213-012-2950-3
   Garg B, 2018, GASTROENTEROLOGY, V155, P880, DOI 10.1053/j.gastro.2018.05.051
   Gebhart GF, 2004, NEUROSCI BIOBEHAV R, V27, P729, DOI 10.1016/j.neubiorev.2003.11.008
   Gough Nancy R, 2017, SCI SIGNAL, V10, P0, DOI 10.1126/scisignal.aam7233
   Guo W, 2006, J NEUROSCI, V26, P126, DOI 10.1523/JNEUROSCI.3686-05.2006
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hu J, 2009, MOL PAIN, V5, P0, DOI 10.1186/1744-8069-5-71
   Hu QM, 2020, J PAIN, V21, P1060, DOI 10.1016/j.jpain.2020.01.007
   Huang SJ, 2018, J NEUROINFLAMM, V15, P0, DOI 10.1186/s12974-017-1021-4
   Jayaraj ND, 2018, J CLIN INVEST, V128, P2205, DOI 10.1172/JCI92117
   Jia LL, 2020, OXID MED CELL LONGEV, V2020, P0, DOI 10.1155/2020/9187406
   Khalid S, 2018, FRONT PHARMACOL, V9, P0, DOI 10.3389/fphar.2018.00140
   Li H, 2020, NEUROIMAGE, V221, P0, DOI 10.1016/j.neuroimage.2020.117186
   Li Y, 2015, BRAIN BEHAV IMMUN, V49, P255, DOI 10.1016/j.bbi.2015.06.003
   Liao HY, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-16031-y
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Lin YW, 2020, BRAIN BEHAV IMMUN, V89, P604, DOI 10.1016/j.bbi.2020.06.033
   Liu ZY, 2019, CNS NEUROSCI THER, V25, P922, DOI 10.1111/cns.13128
   Luo M, 2020, NAT SCI SLEEP, V12, P583, DOI 10.2147/NSS.S261043
   Luo X, 2016, REV NEUROSCIENCE, V27, P83, DOI 10.1515/revneuro-2015-0016
   Mai CL, 2021, THERANOSTICS, V11, P1059, DOI 10.7150/thno.44364
   Meng XZ, 2011, BRAIN RES, V1414, P58, DOI 10.1016/j.brainres.2011.08.004
   Moon HJ, 2014, J PHYSIOL SCI, V64, P151, DOI 10.1007/s12576-013-0297-0
   Ni HD, 2020, FRONT PHARMACOL, V11, P0, DOI 10.3389/fphar.2020.00436
   Ni HD, 2019, J NEUROINFLAMM, V16, P0, DOI 10.1186/s12974-018-1391-2
   Oliva V, 2021, NEUROIMAGE, V226, P0, DOI 10.1016/j.neuroimage.2020.117548
   Ramakrishnan R, 2020, CELL REP, V31, P0, DOI 10.1016/j.celrep.2020.107684
   Santini D, 2020, ESMO OPEN, V5, P0, DOI 10.1136/esmoopen-2019-000652
   Shen W, 2014, J NEUROINFLAMM, V11, P0, DOI 10.1186/1742-2094-11-75
   Shi L, 2013, CNS NEUROSCI THER, V19, P83, DOI 10.1111/cns.12035
   Theodoraki MN, 2018, CANCER RES, V78, P4292, DOI 10.1158/0008-5472.CAN-17-3985
   Wan J, 2017, FRONT NEUROSCI-SWITZ, V11, P0, DOI 10.3389/fnins.2017.00644
   Wan L, 2020, PHARMACOL RES, V159, P0, DOI 10.1016/j.phrs.2020.104923
   Wang YG, 2018, MOL PAIN, V14, P0, DOI 10.1177/1744806918788681
   Xu AP, 2020, J ALZHEIMERS DIS, V77, P387, DOI 10.3233/JAD-200242
   Xu J, 2014, J NEUROINFLAMM, V11, P0, DOI 10.1186/1742-2094-11-38
   Xu M, 2019, MOL PAIN, V15, P0, DOI 10.1177/1744806919886498
   Xu T, 2017, PAIN, V158, P637, DOI 10.1097/j.pain.0000000000000805
   Xue M, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21186524
   Yang F, 2015, J NEUROINFLAMM, V12, P0, DOI 10.1186/s12974-015-0441-2
   Zhang RX, 2008, EUR J PAIN, V12, P870, DOI 10.1016/j.ejpain.2007.12.006
   Zhang RX, 2007, ANESTH ANALG, V105, P1482, DOI 10.1213/01.ane.0000284705.34629.c5
   Zhou L, 2018, NEUROPHARMACOLOGY, V135, P34, DOI 10.1016/j.neuropharm.2018.03.004
   Zhou YL, 2015, PAIN, V156, P1892, DOI 10.1097/j.pain.0000000000000248
   ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4
NR 59
TC 31
Z9 37
U1 2
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
EI 
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD SEP 15
PY 2021
VL 12
IS 18
BP 3323
EP 3334
DI 10.1021/acschemneuro.1c00224
EA AUG 2021
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology
GA US2RK
UT WOS:000697282400005
PM 34460214
DA 2026-01-16
ER

PT J
AU Znidarsic, J
   Kirksey, KN
   Dombrowski, SM
   Tang, A
   Lopez, R
   Blonsky, H
   Todorov, I
   Schneeberger, D
   Doyle, J
   Libertini, L
   Jamie, S
   Segall, T
   Bang, A
   Barringer, K
   Judi, B
   Ehrman, JP
   Roizen, MF
   Golubić, M
AF Znidarsic, Josie
   Kirksey, Kellie N
   Dombrowski, Stephen M
   Tang, Anne
   Lopez, Rocio
   Blonsky, Heather
   Todorov, Irina
   Schneeberger, Dana
   Doyle, Jonathan
   Libertini, Linda
   Jamie, Starkey
   Segall, Tracy
   Bang, Andrew
   Barringer, Kathy
   Judi, Bar
   Ehrman, Jane Pernotto
   Roizen, Michael F
   Golubić, Mladen
TI "Living Well with Chronic Pain": Integrative Pain Management via Shared Medical
SO Pain medicine (Malden, Mass.)
LA English
DT Journal Article
DE Chronic Pain; Opioids; Pain Management
AB OBJECTIVE: To evaluate the effectiveness of a multidisciplinary,  nonpharmacological, integrative approach that uses shared medical appointments to  improve health-related quality of life and reduce opioid medication use in  patients with chronic pain. DESIGN: This is a retrospective, pre-post review of  "Living Well with Chronic Pain" shared medical appointments (August 2016 through  May 2018). SETTING: The appointments included eight 3-hour-long visits held once  per week at an outpatient wellness facility. SUBJECTS: Patients with chronic,  non-cancer-related pain. METHODS: Patients received evaluation and evidence-based  therapies from a team of integrative and lifestyle medicine professionals, as  well as education about nonpharmacological therapeutic approaches, the etiology  of pain, and the relationship of pain to lifestyle factors. Experiential elements  focused on the relaxation techniques of meditation, yoga, breathing, and  hypnotherapy, while patients also received acupuncture, acupressure, massage,  cognitive behavioral therapy, and chiropractic education. Patients self-reported  data via the Patient-Reported Outcomes Measurement Information System (PROMIS-57)  standardized questionnaire. Use of opioid medications was evaluated in morphine  milligram equivalents. RESULTS: A total of 178 participants completed the  PROMIS-57 questionnaire at the first and the last visits. Statistically  significant improvements in all domains (Physical Functioning, Anxiety,  Depression, Fatigue, Social Roles, Pain Interference, and Sleep Disturbance) were  observed (P < 0.001) between the pre-intervention (visit 1) and post-intervention  (visit 8) scores. Average opioid use decreased nonsignificantly over the 8-week  intervention, but the lower rate of opioid use was not sustained at 6 and  12 months' follow-up. CONCLUSIONS: Patients suffering from chronic pain who  participated in a multidisciplinary, nonpharmacological treatment approach  delivered via shared medical appointments experienced reduced pain and improved  measures of physical, mental, and social health without increased use of opioid  pain medications.
NR 0
TC 0
SN 1526-463
EI 1526-237
J9 Pain Med
PD FEB 6
PY 2021
VL 22
IS 1
BP 181
EP 190
DI 10.1093/pm/pnaa418
PG 9
WC Chronic Pain; therapy; Humans; Pain Management; Quality of Life; Retrospective Studies; Shared Medical Appointments
UT PubMed:33543263
PM 33543263
DA 2021-02-06
ER

PT J
AU Shao, JK
   Liu, Q
   Pei, W
   Wang, Y
   Yang, NN
   Qi, LY
   Huang, J
   Yang, JW
   Liu, CZ
AF Shao, Jia-Kai
   Liu, Qian
   Pei, Wei
   Wang, Yu
   Yang, Na-Na
   Qi, Ling-Yu
   Huang, Jin
   Yang, Jing-Wen
   Liu, Cun-Zhi
TI Electroacupuncture for postoperative ileus after laparoscopic surgery on
SO Trials
LA English
DT Journal Article
DE Electroacupuncture; Postoperative ileus; Randomized controlled trial; Single acupoint
AB BACKGROUND: Postoperative ileus (POI) occurs in almost all patients after  abdominal laparoscopic surgery, resulting in complications and increasing the  length of hospitalization. Electroacupuncture has been used as an alternative  therapy for gastrointestinal dysfunction, but its efficacy for POI is  inconclusive. The study is designed to determine whether electroacupuncture can  accelerate recovery from POI. METHODS/DESIGN: This study is a three-arm,  randomized controlled trial. A total of 105 patients will be randomized into a  group receiving electroacupuncture at Tianshu (ST25), a group receiving  electroacupuncture at Zusanli (ST36), or a control group in a 1:1:1 ratio.  Patients in the electroacupuncture groups will receive electroacupuncture  treatment for 4 days from the first day after surgery. The primary outcome  consists of the time to first flatus and the time to first defecation. Secondary  outcomes include the time to first tolerance of liquid and semiliquid food; the  length of the hospital stay; postoperative pain, nausea, and vomiting; abdominal  distension; the time to first get out of bed; and postoperative complications.  The outcomes will be assessed by the patients themselves every day during  hospitalization. Surgeons, nurses, assessors, and statisticians will be blinded  to the group assignments. Patients in the two electroacupuncture groups, but not  in the control group, will be blinded to the group assignments. The  acupuncturists will not be blinded. DISCUSSION: The aim of this trial is to  provide a nonpharmacological therapy for POI and may provide evidence of the  effect of electroacupuncture at ST25 or ST36 on POI. TRIAL REGISTRATION: Chinese  Clinical Trial Registry ChiCTR1900027466 . Registered on 14 November 2019.
C1 International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
   Department of Colorectal Surgery, Chinese Academy of Medical Sciences Cancer Institute and Hospital, Beijing, China.
   Department of Colorectal Surgery, Chinese Academy of Medical Sciences Cancer Institute and Hospital, Beijing, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.yangjw0626@126.com.
   International Acupuncture and Moxibustion Innovation Institute, School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, No.11, Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
NR 0
TC 0
SN 1745-621
EI 
J9 Trials
PD SEP 11
PY 2021
VL 22
IS 1
BP 610
EP 610
DI 10.1186/s13063-021-05564-3
PG 0
WC Colorectal Neoplasms; Electroacupuncture; adverse effects; Humans; Ileus; diagnosis; Laparoscopy; adverse effects; Postoperative Complications; etiology; Randomized Controlled Trials as Topic
UT PubMed:34503565
PM 34503565
DA 2021-09-11
ER

PT J
AU Lu, Z
   Wang, Q
   Sun, X
   Zhang, W
   Min, S
   Zhang, J
   Zhao, W
   Jiang, J
   Wang, Y
   Zhu, Y
   Zheng, L
   Wang, Y
   Guo, Y
   Zhang, L
   Wang, L
   Lei, C
   Liu, T
   Yang, X
   Zhang, J
   Li, C
   Zhang, N
   Dong, H
   Xiong, L
AF Lu, Zhihong
   Wang, Qiang
   Sun, Xude
   Zhang, Wei
   Min, Su
   Zhang, Jiaqiang
   Zhao, Weixian
   Jiang, Jianfeng
   Wang, Yonghui
   Zhu, Yaomin
   Zheng, Lanlan
   Wang, Ying
   Guo, Yuanyuan
   Zhang, Liyuan
   Wang, Lini
   Lei, Chong
   Liu, Tingting
   Yang, Xue
   Zhang, Junbao
   Li, Chen
   Zhang, Nian
   Dong, Hailong
   Xiong, Lize
TI Transcutaneous electrical acupoint stimulation before surgery reduces chronic
SO Journal of clinical anesthesia
LA English
DT Journal Article
DE Acupoint stimulation; Chronic pain; Combined acupoints; Mastectomy; Postoperative pain
AB STUDY OBJECTIVE: Despite multiple interventions, the incidence of chronic pain  after mastectomy could be as high as 50% after surgery. This study aimed to  determine the efficacy of transcutaneous electrical acupoint stimulation (TEAS)  before anesthesia induction in reducing chronic pain and to compare the effect of  combined acupoint TEAS with that of single acupoint TEAS. DESIGN: A multicenter  randomized clinical trial. SETTING: The study was conducted at six medical  centers in China from May 2016 to April 2018. Final follow-up was on October 26,  2018. PARTICIPANTS: Eligible patients were women scheduled for radical mastectomy  under general anesthesia. INTERVENTIONS: Patients were randomly and equally  grouped into sham control (n = 188), single acupoint (PC6, n = 198), or combined  acupoints (PC6 and CV17, n = 190) TEAS groups using a centralized  computer-generated randomization system. TEAS was applied for 30 min before  anesthesia induction. The sham-operated control group received electrode  attachment but without stimulation. Anesthesiologists, surgeons, and outcome  assessors were blinded to the interventions. MEASURES: The primary endpoint was  the incidence of chronic pain 6 months after surgery. Incidences were compared  among the groups using the unadjusted χ(2) test. RESULTS: Of the 576 randomized  patients, 568 completed the trial. In the intention-to-treat analysis,  post-mastectomy pain at 6 months was reported in 42 of 190 patients (22.1%) in  the combined acupoints group, 65 of 188 patients (34.6%) in the sham-operated  group (P = 0.007; relative risk [RR], 95% confidence interval [CI]: 0.68,  0.52-0.89), and 72 of 198 patients (36.4%) in the single acupoint group  (P = 0.002; RR, 95% CI: 0.72, 0.55-0.93). Remifentanil consumption during surgery  and postoperative nausea and vomiting at 24 h after surgery were lower in the  combined acupoint group than that in the sham-operated group. CONCLUSION: TEAS at  combined acupoints before surgery was associated with reduced chronic pain  6 months after surgery. TRIAL REGISTRATION: Clinicaltrials.gov identifier:  NCT02741726. Registered on April 13, 2016.
C1 Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China. 
   Department of Anesthesiology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
   Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
   Department of Anesthesiology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China.
   Department of Anesthesiology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
   Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.
   Department of Anesthesiology, Second Affiliated Hospital of Guangdong University of Traditional Chinese Medicine, Guangzhou, Guangdong 510120, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
   Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
   Department of Anesthesiology, First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan 450052, China.
   Department of Anesthesiology, First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
   Department of Anesthesiology and Perioperative Medicine, People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Medical Statistics, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
   Department of Anesthesiology and Perioperative Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China
   Department ofAnesthesiology and Perioperative Medicine, Translational Research Institute ofBrain and Brain-Like Intelligence， Shanghai Fourth People's Hospital Affiliatedto Tongji University School of Medicine, Shanghai 200434, China. Electronicaddress: lizexiong@tongji.edu.cn.
EM eerlu23@163.com
NR 0
TC 0
SN 1873-452
EI 
J9 J Clin Anesth
PD JUL 17
PY 2021
VL 74
IS 
BP 110453
EP 110453
DI 10.1016/j.jclinane.2021.110453
PG 0
WC Acupuncture Points; Anesthesia, General; adverse effects; Breast Neoplasms; surgery; Chronic Pain; epidemiology; Female; Humans; Mastectomy; adverse effects
UT PubMed:34271271
PM 34271271
DA 2021-07-17
ER

PT J
AU Weisfeld, CC
   Turner, JA
   Dunleavy, K
   Ko, A
   Bowen, JI
   Roelk, B
   Eissa, R
   Benfield, E
   Robertson, K
AF Weisfeld, Carol C.
   Turner, Jill A.
   Dunleavy, Kim
   Ko, Arthur
   Bowen, Jennifer I.
   Roelk, Brandi
   Eissa, Reem
   Benfield, Erica
   Robertson, Kristen
TI Dealing with Anxious Patients: A Systematic Review of the Literature on Nonpharmaceutical Interventions to Reduce Anxiety in Patients Undergoing Medical or Dental Procedures
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Review
DE patient anxiety; music; patient education; massage; distraction; hypnosis
ID music; depression; surgery; pain
AB Objectives: State (situational) anxiety can create suboptimal outcomes for patients across a variety of health care specializations. While anxiolytic medications reduce anxiety, problematic side effects can compromise outcomes. These challenges have spurred searches for nonpharmaceutical approaches to alleviate patient anxiety. This systematic literature review, largely following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, aimed to determine patterns and effectiveness of interventions across medical health care specialty areas, including dentistry. Methods: A systematic review was conducted, using PubMed, CINAHL, and PsycINFO databases, with search terms related to anxiety, specific interventions, and medical or dental procedures. Hand searching for additional citations was performed on the bibliographies of dissertations, meta-analyses, and systematic reviews that met article inclusion criteria. The search process yielded 48,324 articles and 257 dissertations published in English between 1974 and 2018. Each abstract was evaluated for inclusion by two reviewers, yielding 718 articles that were read and evaluated for outcomes, risk of bias, pretest and post-test, controls and quality, using a Critical Appraisal Skills Programme instrument. Of these, 408 articles, describing 501 experimental trials, were accepted for inclusion in this analysis. Results: A total of 50,343 patients were included in these experiments, with an overall success rate of 71% for reducing patient anxiety. Results are summarized by health care specialty area: surgery, oncology, cardiology, obstetrics/gynecology, dentistry, and pain/trauma, and the following diagnostic testing and intervention areas: imaging, colonoscopy, mechanical ventilation, and other. The largest number of experiments (114) was in the surgery category. The types of interventions included music, education, relaxation, cognitive behavioral therapy (CBT), massage, distraction, hypnosis, acupuncture/acupressure, social support, aromatherapy, nature sounds, natural visual stimuli, special garment, and other. The largest numbers of experiments were done with music (143) and education (130). Discussion: The following interventions were most successful, reducing anxiety in over 70% of experiments: music, CBT, relaxation, massage, acupuncture/acupressure, hypnosis, and natural sounds. Confidence in results is limited by publication bias, small sample sizes, and the lack of placebo controls. Directions for future research are discussed.
C1 [Weisfeld, Carol C.; Roelk, Brandi; Eissa, Reem; Benfield, Erica] Univ Detroit Mercy, Dept Psychol, 4001 West McNichols Rd, Detroit, MI 48219 USA.
   [Turner, Jill A.; Bowen, Jennifer I.] Univ Detroit Mercy, Lib IDS, Detroit, MI 48221 USA.
   [Dunleavy, Kim] Univ Florida, Dept Phys Therapy, Gainesville, FL USA.
   [Ko, Arthur] Univ Detroit Mercy, Coll Hlth Profess, McAuley Sch Nursing, Detroit, MI 48221 USA.
   [Robertson, Kristen] Walk Line Recovery Therapy, Orthoped Phys Therapy Program, Southfield, MI USA.
C3 University of Detroit Mercy; University of Detroit Mercy; State University System of Florida; University of Florida; University of Detroit Mercy
RP Weisfeld, CC (corresponding author), Univ Detroit Mercy, Dept Psychol, 4001 West McNichols Rd, Detroit, MI 48219 USA.
EM weisfecc@udmercy.edu
CR Bailey Laila, 2010, AORN J, V92, P445, DOI 10.1016/j.aorn.2010.04.017
   Bell SK, 2019, J CONTIN EDUC HEALTH, V39, P201, DOI 10.1097/CEH.0000000000000259
   Benedetti F, 2011, PATIENT EDUC COUNS, V84, P413, DOI 10.1016/j.pec.2011.04.034
   Bringman H, 2009, ACTA ANAESTH SCAND, V53, P759, DOI 10.1111/j.1399-6576.2009.01969.x
   CHAPMAN CR, 1977, J PSYCHOSOM RES, V21, P7, DOI 10.1016/0022-3999(77)90020-4
   Chaturvedi SK, 1996, PSYCHO-ONCOL, V5, P343, DOI 10.1002/(SICI)1099-1611(199612)5:4<343::AID-PON232>3.3.CO;2-E
   Chernyak Y, 2020, J CLIN PSYCHOL MED S, V27, P305, DOI 10.1007/s10880-019-09691-7
   Critical Appraisal Skills Programme, 2015, CASP RAND CONTR TRIA, V0, P0
   Daitch C, 2014, EUR J PERS CENT HEAL, V2, P303
   Dallam SJ, 2010, THESIS U KANSAS LAWR, V0, P0
   ENGEL GL, 1981, J MED PHILOS, V6, P101, DOI 10.1093/jmp/6.2.101
   Eshed I, 2007, J MAGN RESON IMAGING, V26, P401, DOI 10.1002/jmri.21012
   Gallagher R, 2010, EUR J CARDIOVASC NUR, V9, P38, DOI 10.1016/j.ejcnurse.2009.09.001
   Grey SJ, 2000, MAGN RESON IMAGING, V18, P351, DOI 10.1016/S0730-725X(00)00112-0
   Hedgpeth, 2012, THESIS W U HLTH SCI, V0, P0
   Heikkilä J, 1998, J ADV NURS, V28, P1225, DOI 10.1046/j.1365-2648.1998.00852.x
   Lushene, 1983, MANUAL STATE TRAIT A, V0, P0
   Moher D, 2009, BMJ-BRIT MED J, V339, P0, DOI 10.1136/bmj.b2535
   Shahid M, 2019, INT DENT J, V69, P369, DOI 10.1111/idj.12483
   SHAW DW, 1974, J COUNS PSYCHOL, V21, P415, DOI 10.1037/h0037102
   Song MZ, 2018, J ADV NURS, V74, P1016, DOI 10.1111/jan.13509
   Tolunay T, 2018, INJURY, V49, P593, DOI 10.1016/j.injury.2018.02.008
   Tsay SL, 2005, J ADV NURS, V52, P142, DOI 10.1111/j.1365-2648.2005.03576.x
   Tugwell JR, 2018, RADIOGRAPHY, V24, P122, DOI 10.1016/j.radi.2017.10.001
   Weiland TJ, 2011, MED J AUSTRALIA, V195, P694, DOI 10.5694/mja10.10662
   Williams JB, 2013, AM J CARDIOL, V111, P137, DOI 10.1016/j.amjcard.2012.08.060
   Yinger OS, 2015, J MUSIC THER, V52, P1, DOI 10.1093/jmt/thv004
NR 27
TC 14
Z9 20
U1 2
U2 38
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP 1
PY 2021
VL 27
IS 9
BP 717
EP 726
DI 10.1089/acm.2020.0504
EA JUN 2021
PG 10
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA UP8ZQ
UT WOS:000657060400001
PM 34076531
DA 2026-01-16
ER

PT J
AU Yang, MX
   Liou, KT
   Garland, SN
   Bao, T
   Hung, TKW
   Li, SSQ
   Li, YL
   Mao, JJ
AF Yang, Mingxiao
   Liou, Kevin T.
   Garland, Sheila N.
   Bao, Ting
   Hung, Tony K. W.
   Li, Susan Q.
   Li, Yuelin
   Mao, Jun J.
TI Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial
SO NPJ BREAST CANCER
LA English
DT Article
ID severity index; sleep disturbance; adults; validation; management; medication; symptoms
AB Pain and insomnia often co-occur and impair the quality of life in cancer survivors. This study evaluated the effect of acupuncture versus cognitive behavioral therapy for insomnia (CBT-I) on pain severity among cancer survivors with comorbid pain and insomnia. Using data from the CHOICE trial that compared acupuncture versus CBT-I for insomnia among cancer survivors, we analyzed the effect of interventions on pain outcomes in 70 patients with moderate to severe baseline pain. Interventions were delivered over eight weeks. We assessed average pain severity (primary outcome) and pain interference at baseline, week 8, and week 20. We further defined insomnia and pain responders as patients who achieved clinically meaningful improvement in insomnia and pain outcomes, respectively, at week 8. We found that compared with baseline, the between-group difference (-1.0, 95% CI -1.8 to -0.2) was statistically significant favoring acupuncture for reduced pain severity at week 8 (-1.4, 95% CI -2.0 to -0.8) relative to CBT-I (-0.4, 95% CI-1.0 to 0.2). Responder analysis showed that 1) with acupuncture, insomnia responders reported significantly greater pain reduction from baseline to week 4, compared with insomnia non-responders (-1.5, 95% CI -2.7 to -0.3); 2) with CBT-I, pain responders reported significantly greater insomnia reduction at week 8, compared with pain non-responders (-4.7, 95% CI -8.7 to -1.0). These findings suggest that among cancer survivors with comorbid pain and insomnia, acupuncture led to rapid pain reductions, which contributed to a decrease in insomnia, whereas CBT-I had a delayed effect on pain, possibly achieved by insomnia improvement.
C1 [Yang, Mingxiao; Liou, Kevin T.; Bao, Ting; Li, Susan Q.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
   [Garland, Sheila N.] Mem Univ, Dept Psychol & Discipline Oncol, 232 Elizabeth Ave, St John, NF A1B 3X9, Canada.
   [Hung, Tony K. W.] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol Head & Neck Oncol Serv, 1275 York Ave, New York, NY 10065 USA.
   [Li, Yuelin] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 1275 York Ave, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial University Newfoundland; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Integrat Med Serv, 1429 First Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU Patient-Centered Outcomes Research Institute (PCORI) award [CER-1403-14292]; National Institutes of Health/National Cancer Institute Cancer Center [P30 CA008748]; Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center; National Cancer Institute [P30CA008748] Funding Source: NIH RePORTER
CR Unknown -, 1980, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, V3rd, P0, DOI 10.1176/APPI.BOOKS.9780890425596
   Babiloni AH, 2020, J NEURAL TRANSM, V127, P647, DOI 10.1007/s00702-019-02067-z
   Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4
   Campbell CM, 2015, ARTHRIT CARE RES, V67, P1387, DOI 10.1002/acr.22609
   Cheatle MD, 2016, SLEEP MED CLIN, V11, P531, DOI 10.1016/j.jsmc.2016.08.004
   Chim K, 2013, BMC CANCER, V13, P0, DOI 10.1186/1471-2407-13-401
   Cleeland CS, 1994, ANNALS ACADEMY OF MEDICINE SINGAPORE, V23, P129
   Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407
   Desai K, 2013, SUPPORT CARE CANCER, V21, P43, DOI 10.1007/s00520-012-1490-z
   Edinger JD, 2015, ARCH INTERN MED, V165, P2535
   Farrar JT, 2020, PAIN, V88, P294
   Finan PH, 2014, SLEEP MED CLIN, V9, P261, DOI 10.1016/j.jsmc.2014.02.007
   Fu C, 2017, SLEEP, V40, P0, DOI 10.1093/sleep/zsx153
   Garland SN, 2019, JNCI-J NATL CANCER I, V111, P1323, DOI 10.1093/jnci/djz050
   Garland SN, 2016, CONTEMP CLIN TRIALS, V47, P349, DOI 10.1016/j.cct.2016.02.010
   Haack M, 2020, NEUROPSYCHOPHARMACOL, V45, P205, DOI 10.1038/s41386-019-0439-z
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Howell D, 2014, ANN ONCOL, V25, P791, DOI 10.1093/annonc/mdt506
   Inotai A, 2021, CANCER TREAT REV, V100, P0, DOI 10.1016/j.ctrv.2021.102264
   Jungquist CR, 2010, SLEEP MED, V11, P302, DOI 10.1016/j.sleep.2009.05.018
   Koffel E, 2019, PAIN, V160, P529, DOI 10.1097/j.pain.0000000000001423
   Kwak A, 2020, BREAST CANCER RES TR, V181, P269, DOI 10.1007/s10549-020-05635-0
   LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876
   Liu FS, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5381028
   Loh KP, 2018, J GERIATR ONCOL, V9, P464, DOI 10.1016/j.jgo.2018.02.006
   Ma Y, 2021, SLEEP MED REV, V55, P0, DOI 10.1016/j.smrv.2020.101376
   Mandelblatt JS, 2020, CANCER-AM CANCER SOC, V126, P1183, DOI 10.1002/cncr.32663
   Mazor M, 2019, CANCER-AM CANCER SOC, V125, P4509, DOI 10.1002/cncr.32477
   McCrae CS, 2019, SLEEP, V42, P0, DOI 10.1093/sleep/zsy234
   McCurry SM, 2021, JAMA INTERN MED, V181, P530, DOI 10.1001/jamainternmed.2020.9049
   Morin CM, 2014, SLEEP MED, V15, P701, DOI 10.1016/j.sleep.2014.02.004
   Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601
   Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682
   Pachman DR, 2012, J CLIN ONCOL, V30, P3687, DOI 10.1200/JCO.2012.41.7238
   Qaseem A, 2016, ANN INTERN MED, V165, P125, DOI 10.7326/M15-2175
   Salwen JK, 2017, SLEEP, V40, P0, DOI 10.1093/sleep/zsw064
   Savard J, 2021, J CLIN ONCOL, V19, P908
   Savard J, 2011, J CLIN ONCOL, V29, P3580, DOI 10.1200/JCO.2010.33.2247
   Savard MH, 2005, PSYCHO-ONCOLOGY, V14, P429, DOI 10.1002/pon.860
   Sela Rami A, 2005, PALLIAT SUPPORT CARE, V3, P23
   Shaffer KM, 2020, J BEHAV MED, V43, P503, DOI 10.1007/s10865-019-00065-w
   Theobald Dale E, 2004, CLIN CORNERSTONE, V6 Suppl 1D, PS15, DOI 10.1016/S1098-3597(05)80003-1
   Toivonen KI, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13010107
   van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340
   Yin X, 2017, SLEEP MED, V37, P193, DOI 10.1016/j.sleep.2017.02.012
   Yusufov M, 2011, BREAST CANCER RES TR, V185, P62
   Zia FZ, 2017, JNCI MONOGR, V52, P0
NR 48
TC 22
Z9 24
U1 0
U2 23
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 
EI 2374-4677
J9 NPJ BREAST CANCER
JI npj Breast Cancer
PD NOV 30
PY 2021
VL 7
IS 1
BP 
EP 
DI 10.1038/s41523-021-00355-0
PG 7
WC Oncology
SC Oncology
GA XF6RL
UT WOS:000724196900001
PM 34848737
DA 2026-01-16
ER

PT J
AU Sedhom, R
   Gupta, A
   Wang, L
   Paller, C
   Bao, T
AF Sedhom, Ramy
   Gupta, Arjun
   Wang, Lin
   Paller, Channing
   Bao, Ting
TI Payer Coverage of Integrative Medicine Interventions for Symptom Control in Patients With Cancer
SO JCO ONCOLOGY PRACTICE
LA English
DT Editorial Material
ID randomized controlled-trial; breast-cancer; alternative medicine; acupuncture; pain; oncology; complementary; management; survivors; exercise
C1 [Sedhom, Ramy] Penn Med, Div Hematol & Oncol, Philadelphia, PA USA.
   [Gupta, Arjun; Paller, Channing] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Wang, Lin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Wang, Lin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA.
   [Bao, Ting] Mem Sloan Kettering Canc, Dept Med, Integrat Med & Breast Med Serv, New York, NY USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Memorial Sloan Kettering Cancer Center
RP Sedhom, R (corresponding author), Penn Med Princeton Hlth, 5 Plainsboro Rd,Suite 500, Plainsboro, NJ 08536 USA.
EM ramy.sedhom@pennmedicine.upenn.edu
FU individual Conquer Cancer ASCO Young Investigator Awards
CR Bao T, 2018, ACUPUNCT MED, V36, P80, DOI 10.1136/acupmed-2017-011435
   Brauer JA, 2010, J ALTERN COMPLEM MED, V16, P183, DOI 10.1089/acm.2009.0354
   Courneya KS, 2007, CANCER EPIDEM BIOMAR, V16, P2572, DOI 10.1158/1055-9965.EPI-07-0413
   Courneya KS, 2009, J CLIN ONCOL, V27, P4605, DOI 10.1200/JCO.2008.20.0634
   Dy SM, 2020, INTERVENTIONS BREATH, V0, P0
   Fan AY, 2018, J INTEGR MED-JIM, V16, P1, DOI 10.1016/j.joim.2017.12.003
   Fritts Matthew, 2009, EXPLORE (NY), V5, P228, DOI 10.1016/j.explore.2009.05.013
   Garcia MK, 2013, J CLIN ONCOL, V31, P952, DOI 10.1200/JCO.2012.43.5818
   Gewandter JS, 2020, SUPPORT CARE CANCER, V28, P2553, DOI 10.1007/s00520-019-05063-x
   Greenlee H, 2019, J ONCOL PRACT, V15, P17, DOI 10.1200/JOP.18.00755
   Gupta A, 2021, JAMA ONCOL, V7, P290, DOI 10.1001/jamaoncol.2020.5184
   Gupta A, 2020, JCO ONCOL PRACT, V16, P733, DOI 10.1200/OP.20.00113
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2021, J CLIN ONCOL, V39, P0
   Heyward J, 2018, JAMA NETW OPEN, V1, P0, DOI 10.1001/jamanetworkopen.2018.3044
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Kuo YF, 2016, AM J MED, V129, P0, DOI 10.1016/j.amjmed.2015.10.002
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Mao JJ, 2018, J CLIN ONCOL, V36, P0, DOI 10.1200/JCO.2018.36.15_suppl.10001
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   McGivney WT, 2010, J NATL COMPR CANC NE, V8, P625, DOI 10.6004/jnccn.2010.0048
   Meng ZQ, 2012, EUR J CANCER, V48, P1692, DOI 10.1016/j.ejca.2011.12.030
   Naeim A, 2008, J CLIN ONCOL, V26, P3903, DOI 10.1200/JCO.2007.15.9533
   Nahin Richard L, 2016, NCHS DATA BRIEF, V0, P1
   Paice JA, 2016, J CLIN ONCOL, V34, P3325, DOI 10.1200/JCO.2016.68.5206
   Polite BN, 2019, JAMA-J AM MED ASSOC, V321, P1663, DOI 10.1001/jama.2019.4266
   Saper Robert, 2016, GLOB ADV HEALTH MED, V5, P5, DOI 10.7453/gahmj.2015.133
   Sedhom R, 2020, JCO ONCOL PRACT, V16, P537, DOI 10.1200/OP.20.00137
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Witt CM, 2009, AM J EPIDEMIOL, V169, P562, DOI 10.1093/aje/kwn370
   Yun Hyeongjun, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP29, DOI 10.1093/jncimonographs/lgx004
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 33
TC 10
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2688-1527
EI 2688-1535
J9 JCO ONCOL PRACT
JI JCO Oncol. Pract.
PD OCT 15
PY 2021
VL 17
IS 10
BP 587
EP +
DI 10.1200/OP.21.00361
PG 5
WC Oncology
SC Oncology
GA WI1AW
UT WOS:000708099700001
PM 34310190
DA 2026-01-16
ER

PT J
AU Soylu, D
   Kartin, PT
AF Soylu, Dilek
   Kartin, Pinar Tekinsoy
TI The effect on gastrointestinal system functions, pain and anxiety of acupressure applied following laparoscopic cholecystectomy operation: A randomised, placebo-controlled study
SO COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE
LA English
DT Article
DE Laporascopic cholecystectomy; Acupressure; Gastrointestinal system functions; Anxiety; Pain; Nursing
ID postoperative ileus; gastric-cancer; acupuncture; stimulation; gastrectomy; depression; surgery; nausea
AB The aim of this randomised, placebo-controlled, 3-way blinded study was to determine the effect on GIS symptoms, pain and anxiety of acupressure applied for a total of 12 min, as 3 min at each of the ST25, CV12, TH6, and HT7 acupuncture points, at 0, 4 and 8 h after laparoscopic cholecystectomy operation. The research data were collected using a patient data collection form, the Numeric Pain Intensity Scale and the State-Trait Anxiety Inventory. The patients were evaluated in respect of the time to first flatus and defecation, pain and the State-Trait Anxiety points at 0, 4, and 8 h postoperatively. The application of acupressure was determined to have signficantly reduced acute postoperative pain and shortened the time to defecation (p < 0.05). The application of acupressure can be recommended in the nursing interventions following laparoscopic cholecystectomy to reduce acute pain and shorten the time to defecation.
C1 [Soylu, Dilek] Erciyes Univ, Inst Hlth Sci, Surg Nursing, Kayseri, Turkey.
   [Kartin, Pinar Tekinsoy] Erciyes Univ, Fac Hlth Sci, Nursing Dept, Kayseri, Turkey.
C3 Erciyes University; Erciyes University
RP Soylu, D (corresponding author), Kahramanmaras Sutcu Imam Univ, Hlth Practice & Res Hosp, Kahramanmaras, Turkey.
EM dsoylu@ksu.edu.tr; ptekinsoy@erciyes.edu.tr
CR Abadi F, 2017, J ACUPUNCT MERIDIAN, V10, P114, DOI 10.1016/j.jams.2016.11.008
   Addolorato G, 2008, INT J CLIN PRACT, V62, P1063, DOI 10.1111/j.1742-1241.2008.01763.x
   Adib-Hajbaghery Mohsen, 2013, J CARING SCI, V2, P115, DOI 10.5681/jcs.2013.014
   Adib-Hajbaghery M, 2013, J RES MED SCI, V18, P482
   Agarwal A, 2005, ANAESTHESIA, V60, P978, DOI 10.1111/j.1365-2044.2005.04332.x
   Ahmed MT, 2010, TURK FIZ TIP REHAB D, V56, P170, DOI 10.4274/tftr.56.170
   Arı M, 2016, TURKISH JOURNAL OF COLORECTAL DISEASE, V26, P39, DOI 10.4274/tjcd.72677
   Bakan M, 2015, REV BRAS ANESTESIOL, V65, P191, DOI 10.1016/j.bjane.2014.05.001
   Boogaerts JG, 2000, ACTA ANAESTH SCAND, V44, P470, DOI 10.1034/j.1399-6576.2000.440420.x
   CALDWELL CB, 1987, J SURG RES, V43, P14, DOI 10.1016/0022-4804(87)90041-2
   Çatal O, 2019, HASEKI TIP BUL, V57, P191, DOI 10.4274/haseki.galenos.2018.4749
   Chae HD, 2016, J ALTERN COMPLEM MED, V22, P465, DOI 10.1089/acm.2015.0161
   Chang LH, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/528452
   Chen LL, 2003, AM J CHINESE MED, V31, P781, DOI 10.1142/S0192415X03001466
   Chen YQ, 2015, INT J CLIN EXP MED, V8, P5972
   Chou HL, 2013, ONCOL NURS FORUM, V40, P61
   Dalamagka M, 2015, ACUPUNCT MED, V33, P360, DOI 10.1136/acupmed-2014-010689
   Dogan N, 2016, SPATULA, V6, P1
   Eti-Aslan F, 2002, C.U. HEMSIRELIK YUKSEKOKULU DERG, V6, P113, DOI 10.22233/9781910443231.9
   Gurusamy KS, 2010, GASTROENTEROL CLIN N, V39, P229, DOI 10.1016/j.gtc.2010.02.004
   Hmwe NTT, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-020-04286-2
   Hsiung WT, 2015, COMPLEMENT THER MED, V23, P339, DOI 10.1016/j.ctim.2015.03.010
   Iqbal KM, 2009, ORION MED J, V32, P623
   Jung SY, 2017, J GASTRIC CANCER, V17, P11
   Kao ML, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/1892161
   Kehlet H, 2008, NAT CLIN PRACT GASTR, V5, P552, DOI 10.1038/ncpgasthep1230
   Kurt S, 2011, EUR J ONCOL NURS, V15, P137, DOI 10.1016/j.ejon.2010.07.004
   Lee C, 2017, J NEUROGASTROENTEROL, V23, P349
   Liang C, 2016, BMC PLANT BIOL, V16, P0, DOI 10.1186/s12870-016-0726-3
   Liu MY, 2017, CHIN MED-UK, V12, P0, DOI 10.1186/s13020-016-0122-9
   Luckey A, 2003, ARCH SURG-CHICAGO, V138, P206, DOI 10.1001/archsurg.138.2.206
   Moradi Z, 2014, NURS MIDWIFERY STUD, V3, P0, DOI 10.17795/nmsjournal19948
   Movahedi M, 2017, IRAN J NURS MIDWIFE, V22, P108
   Noll E, 2017, TRIALS, V18, P0, DOI 10.1186/s13063-017-1839-1
   Sahin SY, 2018, INT J NURS STUD, V87, P40, DOI 10.1016/j.ijnurstu.2018.07.011
   Sakanoue Y, 1993, SURG ENDOSC, V8, P759
   Scott MJ, 2015, ACTA ANAESTH SCAND, V59, P1212, DOI 10.1111/aas.12601
   Tan YH, 2016, TRIALS, V17, P0, DOI 10.1186/s13063-016-1404-3
   Topcu SY, 2016, COMPLEMENT THER CLIN, V23, P21, DOI 10.1016/j.ctcp.2016.02.001
   Wang M, 2015, COMPLEMENT THER MED, V23, P469, DOI 10.1016/j.ctim.2015.03.013
   Wong WK, 2015, CHIN MED-UK, V10, P0, DOI 10.1186/s13020-015-0064-7
   Wu X, 2018, EVID-BASED COMPL ALT, V2018, P0, DOI 10.1155/2018/6438458
   Yang Y, 2017, SCI REP-UK, V7, P0, DOI 10.1038/srep37826
   Yazici K, 2003, KLIN PSIKIYATRI, V6, P95
   Yeh Mei-Ling, 2010, ACTA ANAESTHESIOL TAIWAN, V48, P80, DOI 10.1016/S1875-4597(10)60018-5
   Yin JY, 2010, AUTON NEUROSCI-BASIC, V157, P31, DOI 10.1016/j.autneu.2010.03.007
   Zhang GL, 2015, J BIOL REG HOMEOS AG, V29, P187
NR 47
TC 19
Z9 21
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-3881
EI 1873-6947
J9 COMPLEMENT THER CLIN
JI Complement. Ther. Clin. Pract.
PD MAY 15
PY 2021
VL 43
IS 
BP 
EP 
DI 10.1016/j.ctcp.2021.101304
EA FEB 2021
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA RY1WM
UT WOS:000647709400001
PM 33540298
DA 2026-01-16
ER

PT J
AU Chen, YB
   Leng, J
   Lin, BJ
   Xu, MH
AF Chen, Ya-Bei
   Leng, Jing
   Lin, Bo-Jie
   Xu, Ming-Hui
TI [Thunder-fire moxibustion combined with mifepristone for ovarian chocolate cyst
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE dysmenorrhea; mifepristone; ovarian chocolate cyst; randomized controlled trial (RCT); thunder-fire moxibustion
AB OBJECTIVE: To observe the clinical efficacy of thunder-fire moxibustion combined  with mifepristone for ovarian chocolate cyst dysmenorrhea with kidney deficiency  and blood stasis. METHODS: Seventy patients were randomly divided into an  observation group and a control group, 35 cases in each group. The patients in  the the control group were treated with oral administration of mifepristone, 10  mg each time, once a day; based on the treatment of the control group, the  patients in the observation group were treated with thunder-fire moxibustion at  Guanyuan (CV 4), Zigong (EX-CA 1), Xuehai (SP 10), once every other day. Both the  groups were treated for 3 months. The Cox menstrual symptom scale (CMSS) score,  the maximum cross-sectional area of ectopic cyst, and the serum levels of  transforming growth factor-β1 (TGF-β1) and interleukin-17 (IL-17) were observed  before and after treatment in the two groups. The clinical efficacy was  evaluated. RESULTS: Compared before treatment, the severity scores and duration  scores of CMSS as well as the serum levels of TGF-β1 were reduced after treatment  in the two groups (P<0.05), and the serum level of IL-17 in the observation group  was reduced (P<0.05); the reducing of the severity score and duration score of  CMSS as well as the serum levels of TGF-β1 and IL-17 in the observation group  were more significant than those in the control group (P<0.05). After treatment,  the maximum cross-sectional area of ectopic cyst in the two groups was decreased  (P<0.05), and the reducing in the observation group was more significant than  that in the control group (P<0.05). The total effective rate was 94.3% (33/35) in  the observation group, which was higher than 71.4% (25/35) in the control group  (P<0.05). CONCLUSION: Thunder-fire moxibustion combined with mifepristone could  significantly improve dysmenorrhea symptoms, shorten dysmenorrhea time and  promote atrophy of ovarian heterotopic cyst in patients with ovarian chocolate  cyst dysmenorrhea of kidney deficiency and blood stasis, and the mechanism may be  related to the reduction of serum levels of TGF-β1 and IL-17.
C1 College of Acupuncture-Moxibustion and Tuina, Guangxi University of CM, Nanning 530001, China
   Nanning Huidong Outpatient Department, Nanning 530200, GuangxiZhuang Autonomous Region.
   College of Acupuncture-Moxibustion and Tuina, Guangxi University of CM, Nanning 530001, China.
   Department of Plastic and Cosmetic Surgery, First Affiliated Hospital of Guangxi Medical University.
   College of Acupuncture-Moxibustion and Tuina, Guangxi University of CM, Nanning 530001, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD APR 1
PY 2021
VL 41
IS 2
BP 161
EP 4
DI 10.13703/j.0255-2930.20191011-0002
PG -157
WC Acupuncture Points; Chocolate; Cysts; Dysmenorrhea; drug therapy; Female; Humans; Kidney; Mifepristone; Moxibustion
UT PubMed:33788463
PM 33788463
DA 2021-04-01
ER

PT J
AU Dai, L
   Liu, Y
   Ji, G
   Xu, Y
AF Dai, Liang
   Liu, Yang
   Ji, Guang
   Xu, Yangxian
TI Acupuncture and Derived Therapies for Pain in Palliative Cancer Management:
SO Journal of palliative medicine
LA English
DT Journal Article
DE acupuncture; cancer pain; systematic review
AB Background: Acupuncture is a classical complementary therapy, but benefits in  palliative cancer pain are still unclear due to lack of consistent evidence.  Objectives: To comprehensively evaluate the effectiveness of acupuncture and  derived therapies (such as electroacupuncture, laser acupuncture, and  transcutaneous electrical nerve stimulation) for analgesia in palliative cancer  care based on both single-arm and controlled trials. Design: Eight databases were  searched from inception to August 31, 2020. Both single-arm trials and controlled  trials were included. The primary outcome was the change in pain intensity, as  evaluated by the numeric rating scale (NRS) and the visual analog scale.  Subjects: Adults with cancer. Results: Forty-one controlled studies with 2685  participants and 18 single-arm studies with 1084 participants were included. For  controlled trials, meta-analysis indicated that acupuncture and derived therapies  in addition led to greater reductions in the NRS score than conventional  analgesics alone (weighted mean difference [WMD]: 1.33 [0.85-1.82], p < 0.001).  For single-arm trials, meta-analysis showed that both the immediate effect (WMD:  1.57 [1.43-1.71], p < 0.001) and long-term longitudinal effect (WMD: 1.81  [1.25-2.37], p < 0.001) of acupuncture on analgesia were positive, as evaluated  by the NRS, respectively. The benefits of acupuncture and derived therapies were  also seen in quality of life and the global improvement rate. LI4 (Hegu) was the  most frequently used acupoint. Conclusions: This systematic review supported the  application of acupuncture and derived therapies for managing pain during  palliative cancer care from two dimensions. Further studies could explore the  effect of acupuncture on other predominant symptoms in palliative cancer  patients.
C1 Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Department of Gastrointestinal Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
   Department of Gastrointestinal Surgery, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
NR 0
TC 0
SN 1557-774
EI 
J9 J Palliat Med
PD MAR 12
PY 2021
VL 24
IS 7
BP 1078
EP 1099
DI 10.1089/jpm.2020.0405
PG 21
WC Acupuncture Therapy; Adult; Complementary Therapies; Humans; Neoplasms; complications; Pain; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic
UT PubMed:33691493
PM 33691493
DA 2021-03-12
ER

PT J
AU Liu, XM
   Wang, GX
   Xue, MX
AF Liu, Xiao-Meng
   Wang, Guo-Xin
   Xue, Ming-Xin
TI [Professor SHAO Ming-xi's experience in differentiation and treatment of
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE SHAO Ming-xi; acupuncture-moxibustion; arthralgia; breast cancer; famous doctor's experience; tuina
AB Professor SHAO Ming-xi 's experience in treatment of arthralgia in breast cancer  is summarized. Professor SHAO believes that the dysfunction of liver, spleen and  kidney is the primary and the invasion of the exogenous wind, cold and damp is  the secondary in arthralgia in breast cancer. Emphasized on syndrome/pattern  differentiation, this disorder is identified as 4 patterns, i.e. liver qi  stagnation, blockage by phlegm and stasis, qi and blood deficiency and  obstruction by wind, cold and damp. Acupuncture-moxibustion is applied to Hegu  (LI 4), Taichong (LR 3) and Waiguan (TE 5). The supplementary acupoints are  selected on the base of syndrome/pattern differentiation. Tuina is combined with  acupuncture-moxibustion and the reinforcing and reducing techniques are used  appropriately. Shaoyang meridian is specially considered, due to which, Waiguan  (TE 5) and Zhongzhu (TE 3) of triple energizer meridian of hand-shaoyang and  Yanglingquan (GB 34) and Zulinqi (GB 41) of gallbladder meridian of foot-shaoyang  are combined. Additionally, it stresses the combination of the local and distal  acupoints and the coordination of various therapies of TCM to achieve the better  effect.
C1 First Clinical Medical School of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   First Clinical Medical School of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
   First Clinical Medical School of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu Province, China.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD MAY 19
PY 2021
VL 41
IS 5
BP 541
EP 4
DI 10.13703/j.0255-2930.20200326-k0003
PG -537
WC Acupuncture; Acupuncture Points; Acupuncture Therapy; Arthralgia; Breast Neoplasms; therapy; Humans; Moxibustion
UT PubMed:34002570
PM 34002570
DA 2021-05-19
ER

PT J
AU Dymackova, R
   Selingerova, I
   Kazda, T
   Slavik, M
   Halamkova, J
   Svajdova, M
   Slampa, P
   Slama, O
AF Dymackova, Radana
   Selingerova, Iveta
   Kazda, Tomas
   Slavik, Marek
   Halamkova, Jana
   Svajdova, Michaela
   Slampa, Pavel
   Slama, Ondrej
TI Effect of Acupuncture in Pain Management of Head and Neck Cancer Radiotherapy: Prospective Randomized Unicentric Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE acupuncture; head and neck cancer; radiotherapy; toxicity; pain
AB This prospective randomized open-label trial aimed to evaluate the role of acupuncture in the treatment of pain related to curative and adjuvant (chemo)radiotherapy of head and neck cancer. Patients in two arms (30 patients in each arm) underwent standard oncology therapy and standard supportive care with or without acupuncture. The stratification factors were the type of treatment and chemotherapy indication. The toxicity assessed was represented by pain rated on a 10-point pain scale and analgesic use. Average pain (AP) and the worst pain during the day (WP) were significantly lower in the acupuncture arm during radiotherapy (AP median 0.16 vs. 1.36, p < 0.001; WP median 0.90 vs. 1.96, p < 0.001) and three months after radiotherapy (AP median 0.07 vs. 0.50, p < 0.001; WP median 0.30 vs. 0.83, p = 0.002). The analgesic consumption between arms was statistically significantly different. A median of the proportion of days when the patients used analgesics was 8% and 32.5% during radiotherapy (p = 0.047) and 0% and 20.8% during three months after radiotherapy (p = 0.006) for the acupuncture and control arm, respectively. Results point out lower analgesic consumption and milder pain in acupuncture arm. Acupuncture consequently offers another alternative to standard treatment leading to a reduction in the toxicity of oncological treatment.
C1 [Dymackova, Radana; Slavik, Marek; Svajdova, Michaela] Masaryk Univ, Dept Radiat Oncol, Fac Med, Brno 62500, Czech Republic.
   [Dymackova, Radana; Kazda, Tomas; Slavik, Marek; Slampa, Pavel] Masaryk Mem Canc Inst, Dept Radiat Oncol, Brno 65653, Czech Republic.
   [Selingerova, Iveta; Kazda, Tomas] Masaryk Mem Canc Inst, Res Ctr Appl Mol Oncol RECAMO, Brno 65653, Czech Republic.
   [Halamkova, Jana] Masaryk Univ, Dept Comprehens Canc Care, Fac Med, Brno 62500, Czech Republic.
   [Halamkova, Jana; Slama, Ondrej] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno 65653, Czech Republic.
   [Svajdova, Michaela] Cent Mil Hosp, Clin Radiat & Clin Oncol, Teaching Hosp, Ruzomberok 03401, Slovakia.
C3 Masaryk University; Masaryk Memorial Cancer Institute; Masaryk Memorial Cancer Institute; Masaryk University; Masaryk Memorial Cancer Institute
RP Selingerova, I (corresponding author), Masaryk Mem Canc Inst, Res Ctr Appl Mol Oncol RECAMO, Brno 65653, Czech Republic.
EM radana.dymackova@mou.cz; iveta.selingerova@mou.cz; tomas.kazda@mou.cz; slavik@mou.cz; jana.halamkova@mou.cz; svajdovam@uvn.sk; slampa@mou.cz; oslama@mou.cz
FU Ministry of Health of the Czech Republic MH CZ-DRO (MMCI) [00209805]
CR Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   Unknown -, 2020, NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY: PROSTATE CANCER VERSION 2, V0, P0
   Unknown -, 2020, R LANG ENV STAT COMP, V0, P0
   Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266
   Chen Zhong-jie, 2008, ZHONGGUO ZHEN JIU, V28, P251
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646
   Deng G, 2020, MED ACUPUNCT, V32, P394, DOI 10.1089/acu.2020.1494
   Dillon M, 1999, PALLIATIVE MED, V13, P253, DOI 10.1191/026921699667999073
   Dymackova R, 2014, KLIN ONKOL, V27, P291
   Dymackova R, 2020, BIOMED PAP, V164, P454, DOI 10.5507/bp.2020.021
   Garcia MK, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.16910
   Gregoire V, 2010, ANN ONCOL, V21, Pv184, DOI 10.1093/annonc/mdq185
   Kasymjanova G, 2013, CURR ONCOL, V20, P152, DOI 10.3747/co.20.1312
   Lian WL, 2014, CHIN J INTEGR MED, V20, P136, DOI 10.1007/s11655-013-1439-1
   Lu WD, 2016, ONCOLOGIST, V21, P1522, DOI 10.1634/theoncologist.2015-0538
   Miller KR, 2019, AM J HOSP PALLIAT ME, V36, P326, DOI 10.1177/1049909118804464
   Pfister DG, 2010, J CLIN ONCOL, V28, P2565, DOI 10.1200/JCO.2009.26.9860
   Qiao DP, 2008, J PRACT ONCOL, V22, P446
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
NR 20
TC 3
Z9 7
U1 0
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR 15
PY 2021
VL 10
IS 5
BP 
EP 
DI 10.3390/jcm10051111
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA QV9FY
UT WOS:000628269300001
PM 33799949
DA 2026-01-16
ER

PT J
AU Luh, C
   Eckstrom, E
AF Luh, Colin
   Eckstrom, Elizabeth
TI Perceptions That Influence Acupuncture Use in Hospice Settings: Results of a State-Wide Survey Study
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE acupuncture; hospice; barriers
ID radiation-induced xerostomia; palliative care; controlled-trial; cancer; chemotherapy; pain; efficacy; safety; management; children
AB Background: Acupuncture is an effective and low-risk therapy for a wide spectrum of medical conditions. In the hospice setting, where comfort is the top priority, acupuncture could play a vital role in reducing symptom burden at the end of life. Objective: This state-wide survey study explored perceived barriers to acupuncture use in the hospice setting from acupuncturist and hospice staff perspectives. Specific barriers addressed included insurance coverage/funding for acupuncture, lack of knowledge of acupuncture as a therapeutic modality, and perceived insufficient evidence base for acupuncture. Materials and Methods: Acupuncturists and hospice staff in Oregon were recruited by e-mail and/or telephone to complete their survey. Results: Among acupuncturists, a response rate of 50% was obtained. The response rate of hospice staff could not be obtained. There were a total of 270 providers and hospice staff (102 acupuncturists, 16 hospice doctors, 14 hospice directors, 93 hospice nurses, 30 hospice social workers, and 15 hospice chaplains). The majority of acupuncturists (76% and 89%, respectively) and hospice staff (59% and 82%, respectively) strongly agreed or somewhat agreed that insurance coverage/funding for acupuncture and lack of knowledge of acupuncture as a therapeutic modality are important barriers. With respect to the perceived evidence base for acupuncture, the majority of acupuncturists (91%) and hospice staff (69%) strongly agreed or somewhat agreed that acupuncture can help provide a higher quality of life for hospice patients, although knowledge of specific conditions amenable to acupuncture among acupuncturists and hospice staff varied. Conclusions: From the acupuncturist and hospice staff perspectives, insurance coverage/funding for acupuncture, lack of knowledge of acupuncture as a therapeutic modality, and perceived insufficient evidence base for acupuncture are primary barriers to the use of acupuncture in hospice care. Increased awareness/education about acupuncture in the hospice setting, as well as improved funding structures, is critical.
C1 [Luh, Colin] OHSU Sch Med, Portland, OR 97209 USA.
   [Eckstrom, Elizabeth] OHSU Div Gen Internal Med & Geriatr, Portland, OR USA.
C3 Oregon Health & Science University
RP Luh, C (corresponding author), OHSU Sch Med, Portland, OR 97209 USA.
EM colinluh@hotmail.com
FU Cambia Health Foundation; OHSU School of Medicine
CR Adams D, 2011, PEDIATRICS, V128, PE1575, DOI 10.1542/peds.2011-1091
   Alimi D, 2003, J CLIN ONCOL, V21, P4120, DOI 10.1200/JCO.2003.09.011
   AUNG S, 1994, ACUPUNCT MED, V12, P37
   Birch S, 2004, J ALTERN COMPLEM MED, V10, P468, DOI 10.1089/1075553041323894
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Chen L, 2010, PAIN MED, V11, P530, DOI 10.1111/j.1526-4637.2010.00815.x
   Dang W, 1998, J TRADIT CHIN MED, V18, P31
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Demmer Craig, 2004, J PALLIAT MED, V7, P510, DOI 10.1089/1096621041838335
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   Ezzo J, 2005, J CLIN ONCOL, V23, P7188, DOI 10.1200/JCO.2005.06.028
   Filshie J, 2001, ACUPUNCT MED, V19, P117
   Filshie J, 1996, PALLIATIVE MED, V10, P145, DOI 10.1177/026921639601000209
   FILSHIE J, 1990, ACUPUNCT MED, V8, P38
   Braga FDF, 2011, BRAZ ORAL RES, V25, P180
   Gadsby JG, 1997, COMPLEMENTARY THER MED, V5, P13, DOI 10.1016/S0965-2299(97)80084-2
   Jindal V, 2008, J PEDIAT HEMATOL ONC, V30, P431, DOI 10.1097/MPH.0b013e318165b2cc
   JOBST K, 1986, LANCET, V2, P1416, DOI 10.1016/S0140-6736(86)92732-7
   Johnstone PAS, 2002, CANCER, V94, P1151, DOI 10.1002/cncr.10348
   Korak LE, 2008, AM J HOSP PALLIAT ME, V25, P463, DOI 10.1177/1049909108322292
   Lau CHY, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002901
   Lee A, 2009, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD003281.pub3
   Lee H, 2005, EUR J PAIN, V9, P437, DOI 10.1016/j.ejpain.2004.10.004
   Leng G, 1999, PALLIATIVE MED, V13, P163, DOI 10.1191/026921699676243035
   Leng G, 2013, ACUPUNCT MED, V31, P16, DOI 10.1136/acupmed-2012-010230
   Lu WD, 2008, HEMATOL ONCOL CLIN N, V22, P631, DOI 10.1016/j.hoc.2008.04.005
   Lytle CD, 1993, OVERVIEW ACUPUNCTURE, V0, P0
   MANN F, 1973, LANCET, V2, P57
   Mansky PJ, 2006, CANCER J, V12, P425, DOI 10.1097/00130404-200609000-00011
   Meidell L, 2009, INT J PALLIAT NURS, V15, P12, DOI 10.12968/ijpn.2009.15.1.37947
   Molassiotis A, 2007, COMPLEMENT THER MED, V15, P228, DOI 10.1016/j.ctim.2006.09.009
   Rydholm M, 1999, J PALLIATIVE CARE, V15, P20, DOI 10.1177/082585979901500404
   Shafto K, 2018, CHILDREN-BASEL, V5, P0, DOI 10.3390/children5060075
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Simcock R, 2009, ACUPUNCT MED, V27, P109, DOI 10.1136/aim.2009.000935
   Standish LJ, 2008, AM J HOSP PALLIAT ME, V25, P298, DOI 10.1177/1049909108315916
   Suzuki M, 2012, ARCH INTERN MED, V172, P878, DOI 10.1001/archinternmed.2012.1233
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Vickers A, 2002, QUAL SAF HEALTH CARE, V11, P92, DOI 10.1136/qhc.11.1.92
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vickers AJ, 1996, J ROY SOC MED, V89, P303, DOI 10.1177/014107689608900602
   WEN HL, 1977, MOD MED ASIA, V13, P12
   Wright Leonard D, 2005, AM J HOSP PALLIAT CARE, V22, P49, DOI 10.1177/104990910502200111
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Yang CS, 2015, PEDIATR RES, V78, P112, DOI 10.1038/pr.2015.91
   Yang J, 1990, ACUPUNCT MED, V7, P2
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 47
TC 2
Z9 2
U1 0
U2 4
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD SEP 1
PY 2021
VL 27
IS 9
BP 760
EP 770
DI 10.1089/acm.2021.0028
EA JUN 2021
PG 11
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA UP8ZQ
UT WOS:000661610300001
PM 34129378
DA 2026-01-16
ER

PT J
AU Chen, H
   So, TH
   Cho, WC
   Qin, Z
   Ma, CH
   Li, SG
   Yang, Z
   Jiang, F
   Wu, J
   Zhang, ZJ
   Kong, FM
   Lao, L
AF Chen, Haiyong
   So, Tsz Him
   Cho, William Chi-Shing
   Qin, Zongshi
   Ma, Chun Ho
   Li, Shi Guang
   Yang, Zhenjiang
   Jiang, Fei
   Wu, Junmei
   Zhang, Zhang Jin
   Kong, Feng Ming
   Lao, Lixing
TI The Adjunctive Effect of Acupuncture for Advanced Cancer Patients in a
SO Integrative cancer therapies
LA English
DT Journal Article
DE acupuncture; cancer related symptoms; palliative care; quality of life; randomized controlled trial
AB BACKGROUND: Cancer is the second leading cause of death before the age of 70.  Improved cancer survival has put increasing demands on cancer care. Palliative  care is the specialized multi-disciplinary care providing relief from the pain,  symptoms, and stress of serious illness. The study aims to evaluate the  adjunctive effect of acupuncture for advanced cancer patients in a collaborative  model of palliative care. METHODS/DESIGN: This is a single-blinded, randomized,  sham-controlled trial. One hundred twenty advanced cancer patients undergoing  palliative care will be randomized in a ratio of 2:1:1 to manual acupuncture plus  standard care group (ASC), sham acupuncture plus standard care group (SSC), and  standard care group (SC). Patients in ASC and SSC will receive 9 sessions of  acupuncture or sham acupuncture for 3 weeks, and will be followed up for  2 months. The primary measure is the change from baseline score of the Edmonton  Symptom Assessment System at 3 weeks. The secondary measures include the Brief  Fatigue Inventory, Hospital Anxiety and Depression Scale, Insomnia Severity  Index, Numeric Rating Scale, and European Organization for Research and Treatment  of Cancer Quality of Life 15 items Questionnaire for Palliative Care. DISCUSSION:  The finding of this trial will provide high-quality evidence on the adjunctive  effect of acupuncture to standard care on advanced cancer patients undergoing  palliative care. TRIAL REGISTRATION: Clinicaltrials.gov, NCT04398875  (https://www.clinicaltrials.gov/ct2/show/NCT04398875), Registered on 21 May 2020.
C1 The University of Hong Kong, Hong Kong, China.
   The University of Hong Kong, Hong Kong, China.
   Queen Elizabeth Hospital, Hong Kong, China.
   The University of Hong Kong, Hong Kong, China.
   The University of Hong Kong Clinical Centre for Teaching and Research in Chinese Medicine (Aberdeen), Hong Kong, China.
   Shen Zhen Hospital of Traditional Chinese Medicine, Shenzhen, China.
   Shen Zhen Hospital of Traditional Chinese Medicine, Shenzhen, China.
   University of California, San Francisco, CA, USA.
   The University of Hong Kong, Hong Kong, China.
   The University of Hong Kong, Hong Kong, China.
   Queen Elizabeth Hospital, Hong Kong, China.
   The University of Hong Kong, Hong Kong, China.
   Virginia University of Integrative Medicine, Fairfax, VA, USA.
NR 0
TC 0
SN 1552-695
EI 1534-735
J9 Integr Cancer Ther
PD MAY 8
PY 2021
VL 20
IS 
BP 15347354211012749
EP 15347354211012749
DI 10.1177/15347354211012749
PG 1
WC Acupuncture Therapy; Humans; Neoplasms; therapy; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome
UT PubMed:33957783
PM 33957783
DA 2021-05-08
ER

PT J
AU Jiang, B
   Zhong, XM
   Fang, JF
   Zhang, AJ
   Wang, W
   Liang, Y
   Fang, JQ
   Chen, F
   Du, JY
AF Jiang, Bin
   Zhong, Xuemei
   Fang, Junfan
   Zhang, Aijun
   Wang, Wen
   Liang, Yi
   Fang, Jianqiao
   Chen, Feng
   Du, Junying
TI Electroacupuncture Attenuates Morphine Tolerance in Rats with Bone Cancer Pain by Inhibiting PI3K/Akt/JNK1/2 Signaling Pathway in the Spinal Dorsal Horn
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE electroacupuncture; bone cancer pain; morphine tolerance; LY294002; IGF-1; PI3K; Akt; JNK1; 2
ID beta-arrestin 2; protein-kinase b/akt; analgesic tolerance; activation; contributes; acupuncture; involvement; model; mechanism; trpv1
AB Purpose: Morphine is often used for the treatment of moderate and severe cancer pain, but long-term use can lead to morphine tolerance. Methods for effectively inhibiting morphine tolerance and the related mechanism of action are of great significance for the treatment of cancer pain. Previous studies have shown that electroacupuncture (EA) can inhibit the occurrence of morphine tolerance, but the mechanism is not yet clear. The aim of the present study was to explore the signaling pathway by which EA attenuates the development of bone cancer pain (BCP)-morphine tolerance (MT). Materials and methods: Changes in the paw withdrawal threshold (PWT) of rats with bone cancer pain-morphine tolerance were observed in a study of EA combined with intrathecal injection of a PI3K inhibitor (LY294002) or agonist (insulin-like growth factor-1 [IGF-1]). We also tested the protein expression of phosphorylated phosphatidylinositol 3-kinase (p-PI3K), phosphorylated protein kinase B (p-Akt), phosphorylated c-Jun NH2-terminal kinase 1/2 (p-JNK1/2), and beta-arrestin2 in the L4-6 spinal dorsal horn of rats. Results: The protein expression of p-PI3K, p-Akt, p-JNK1/2, and beta-arrestin2 was upregulated in the L4-6 spinal dorsal horn of rats with bone cancer pain and bone cancer pain-morphine tolerance. EA delayed the occurrence of morphine tolerance in rats with bone cancer pain and downregulated the protein expression of p-PI3K, p-Akt, p-JNK1/2, and beta-arrestin2 in the L4-6 spinal dorsal horn of rats with bone cancer pain-morphine tolerance. Intrathecal injection of LY294002 attenuated the development of morphine tolerance and downregulated the protein expression of p-Akt, p-JNK1/2, and beta-arrestin2 in the spinal dorsal horn of rats with bone cancer pain-morphine tolerance. In addition, the inhibitory effect of EA on morphine tolerance was reversed by IGF-1. Conclusion: The mechanism underlying the ability of EA to attenuate morphine tolerance may be associated with inhibition of the PI3K/Akt/JNK1/2 signaling pathway.
C1 [Jiang, Bin; Zhang, Aijun; Chen, Feng] Jiaxing Univ, First Hosp Jiaxing, Affiliated Hosp, 1882 South Zhonghuan Rd, Jiaxing 314001, Zhejiang, Peoples R China.
   [Jiang, Bin; Zhong, Xuemei; Fang, Junfan; Wang, Wen; Liang, Yi; Fang, Jianqiao; Du, Junying] Zhejiang Chinese Med Univ, Dept Neurobiol & Acupuncture Res, Third Clin Med Coll, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhong, Xuemei] Zhejiang Univ Tradit Chinese Med, Second Clin Coll, Hangzhou, Zhejiang, Peoples R China.
C3 Jiaxing University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Chen, F (corresponding author), Jiaxing Univ, First Hosp Jiaxing, Affiliated Hosp, 1882 South Zhonghuan Rd, Jiaxing 314001, Zhejiang, Peoples R China.; Du, JY (corresponding author), Zhejiang Chinese Med Univ, Dept Neurobiol & Acupuncture Res, Third Clin Med Coll, Key Lab Acupuncture & Neurol Zhejiang Prov, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
EM cfly149@126.com; dujunying0706@163.com
FU Zhejiang Provincial Natural Science Fund of China [LY16H270017]; Jiaxing Key Discipline of Chinese and Western Medicine-Acupuncture (Derived) [2019XK-B01]
CR Bian JH, 2016, SAUDI PHARM J, V24, P354, DOI 10.1016/j.jsps.2016.04.017
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Bu HL, 2015, INT J NEUROSCI, V125, P56, DOI 10.3109/00207454.2014.896913
   Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008
   Chen Y, 2009, MOL NEUROBIOL, V40, P101, DOI 10.1007/s12035-009-8074-z
   Cheng YC, 2019, INT J MOL MED, V43, P791, DOI 10.3892/ijmm.2018.4030
   Dai WL, 2018, EXP MOL MED, V50, P0, DOI 10.1038/s12276-018-0175-1
   Ding X, 2018, NEUROSCIENCE, V385, P102, DOI 10.1016/j.neuroscience.2018.06.013
   Ducourneau VRR, 2014, PAIN, V155, P275, DOI 10.1016/j.pain.2013.10.008
   Eidson LN, 2013, J PAIN, V14, P393, DOI 10.1016/j.jpain.2012.12.010
   Fan AY, 2017, J INTEGR MED-JIM, V15, P411, DOI 10.1016/S2095-4964(17)60378-9
   Fu Taofang, 2017, ZHONGGUO ZHEN JIU, V37, P513, DOI 10.13703/j.0255-2930.2017.05.017
   Günther T, 2018, BRIT J PHARMACOL, V175, P2857, DOI 10.1111/bph.13809
   Hai-Tao Liu, 2007, SHENGLI XUEBAO, V59, P651
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han Y, 2012, NEUROSCI BULL, V28, P165, DOI 10.1007/s12264-012-1211-0
   Haninec P, 2003, ANN ANAT, V185, P233, DOI 10.1016/S0940-9602(03)80030-4
   Huang MN, 2011, TIANJIN MED J, V39, P542
   Jin WY, 2010, ACS CHEM NEUROSCI, V1, P122, DOI 10.1021/cn900005d
   Kim HN, 2012, BRAIN RES BULL, V87, P199, DOI 10.1016/j.brainresbull.2011.11.010
   Li YL, 2015, INFLAMMATION, V38, P134, DOI 10.1007/s10753-014-0015-y
   Li YT, 2009, INT J MOL SCI, V10, P954, DOI 10.3390/ijms10030954
   Li Z, 2020, BRIT J PHARMACOL, V177, P5046, DOI 10.1111/bph.15169
   [梁宜 Liang Yi], 2018, 中华中医药杂志 CHINA JOURNAL OF TRADITIONAL CHINESE MEDICINE AND PHARMACY, V33, P4877
   Marcus DJ, 2015, MOL PAIN, V11, P0, DOI 10.1186/s12990-015-0031-4
   Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7
   Mei HX, 2017, BIOSCIENCE REP, V37, P0, DOI 10.1042/BSR20160517
   Mittal N, 2012, NEUROPSYCHOPHARMACOL, V37, P1953, DOI 10.1038/npp.2012.42
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Qing Peng, 2016, ZHEN CI YAN JIU, V41, P314
   Shi HX, 2016, IUBMB LIFE, V68, P735, DOI 10.1002/iub.1531
   Shi Ren-Yi, 2019, ZHEN CI YAN JIU, V44, P161, DOI 10.13702/j.1000-0607.180635
   Sima L, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/8028474
   Sun RQ, 2006, PAIN, V120, P86, DOI 10.1016/j.pain.2005.10.017
   Tian Y, 2015, BRAIN BEHAV IMMUN, V50, P63, DOI 10.1016/j.bbi.2015.06.016
   Wang J, 2017, ONCOTARGET, V8, P28203, DOI 10.18632/oncotarget.15997
   Wang JW, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep24660
   Xiang Rong, 2013, ZHONGGUO SHENGWU HUAXUE YU FENZI SHENGWU XUEBAO, V29, P122
   Xu JT, 2007, EXP NEUROL, V206, P269, DOI 10.1016/j.expneurol.2007.05.029
   Xu JT, 2014, J CLIN INVEST, V124, P592, DOI 10.1172/JCI70236
   Yan Y, 2019, NEUROSCI LETT, V701, P100, DOI 10.1016/j.neulet.2019.02.024
   Yang CH, 2011, BRIT J ANAESTH, V107, P774, DOI 10.1093/bja/aer291
   Yudin Y, 2019, BRIT J PHARMACOL, V176, P3110, DOI 10.1111/bph.14702
   Zhang HH, 2018, ACUPUNCT MED, V36, P96, DOI 10.1136/acupmed-2016-011335
   Zhang Y, 2018, MEDICINE, V97, P0, DOI 10.1097/MD.0000000000011627
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
   [郑宇欣 ZHENG Yuxin], 2009, 中国现代医学杂志 CHINA JOURNAL OF MODERN MEDICINE, V19, P1315
NR 47
TC 21
Z9 22
U1 2
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD MAR 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/1534735421995237
PG 13
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA QT4PJ
UT WOS:000626570500001
PM 33660537
DA 2026-01-16
ER

PT J
AU Li, SS
   Huang, J
   Guo, Y
   Wang, JQ
   Lu, SS
   Wang, B
   Gong, YA
   Qin, SR
   Zhao, SH
   Wang, SJ
   Liu, YY
   Fang, YX
   Guo, YM
   Xu, ZF
   Ulloa, L
AF Li, Shanshan
   Huang, Jin
   Guo, Yi
   Wang, Jiaqi
   Lu, Shanshan
   Wang, Bin
   Gong, Yinan
   Qin, Siru
   Zhao, Suhong
   Wang, Shenjun
   Liu, Yangyang
   Fang, Yuxin
   Guo, Yongming
   Xu, Zhifang
   Ulloa, Luis
TI PAC1 Receptor Mediates Electroacupuncture-Induced Neuro and Immune Protection During Cisplatin Chemotherapy
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE neuromodulation; chemotherapy; immunosuppression; hematopoiesis; neurotoxic; electroacupuncture
ID cyclase-activating polypeptide; hematopoietic stem; adenylate-cyclase; cell-proliferation; peripheral neuropathy; induced neutropenia; vagal modulation; lung-cancer; growth; insights
AB Platinum-based chemotherapy is an effective treatment used in multiple tumor treatments, but produces severe side effects including neurotoxicity, anemia, and immunosuppression, which limits its anti-tumor efficacy and increases the risk of infections. Electroacupuncture (EA) is often used to ameliorate these side effects, but its mechanism is unknown. Here, we report that EA on ST36 and SP6 prevents cisplatin-induced neurotoxicity and immunosuppression. EA induces neuroprotection, prevents pain-related neurotoxicity, preserves bone marrow (BM) hematopoiesis, and peripheral levels of leukocytes. EA activates sympathetic BM terminals to release pituitary adenylate cyclase activating polypeptide (PACAP). PACAP-receptor PAC1-antagonists abrogate the effects of EA, whereas PAC1-agonists mimic EA, prevent neurotoxicity, immunosuppression, and preserve BM hematopoiesis during cisplatin chemotherapy. Our results indicate that PAC1-agonists may provide therapeutic advantages during chemotherapy to treat patients with advanced neurotoxicity or neuropathies limiting EA efficacy.
C1 [Li, Shanshan; Huang, Jin; Guo, Yi; Wang, Jiaqi; Lu, Shanshan; Gong, Yinan; Qin, Siru; Zhao, Suhong; Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Guo, Yongming; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin, Peoples R China.
   [Guo, Yi] Tianjin Univ Tradit Chinese Med, Sch Tradit Chinese Med, Tianjin, Peoples R China.
   [Guo, Yi; Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Guo, Yongming; Xu, Zhifang] Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China.
   [Wang, Bin] Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Canc Inst & Hosp, Tianjin, Peoples R China.
   [Wang, Shenjun; Liu, Yangyang; Fang, Yuxin; Guo, Yongming; Xu, Zhifang] Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, Tianjin, Peoples R China.
   [Ulloa, Luis] Duke Univ, Ctr Perioperat Organ Protect, Dept Anesthesiol, Durham, NC 27708 USA.
C3 Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Tianjin Medical University; Tianjin University of Traditional Chinese Medicine; Duke University
RP Xu, ZF (corresponding author), Tianjin Univ Tradit Chinese Med, Res Ctr Expt Acupuncture Sci, Tianjin, Peoples R China.; Xu, ZF (corresponding author), Natl Clin Res Ctr Chinese Med Acupuncture & Moxib, Tianjin, Peoples R China.; Xu, ZF (corresponding author), Tianjin Univ Tradit Chinese Med, Sch Acupuncture & Moxibust & Tuina, Tianjin, Peoples R China.; Ulloa, L (corresponding author), Duke Univ, Ctr Perioperat Organ Protect, Dept Anesthesiol, Durham, NC 27708 USA.
EM xuzf1209@tjutcm.edu.cn; Luis.Ulloa@Duke.edu
FU National Natural Science Foundation of China [81704146, 82030125, 82074534]; Research Project of Tianjin Municipal Health Commission on Traditional Chinese Medicine and Integrative Medicine [2019140]; Graduate Research Innovation Project of Tianjin University of Traditional Chinese Medicine [YJSKC-20201009, YJSKC20201029]; NIH [R01-GM114180]
CR Aloe L, 2000, AUTON NEUROSCI-BASIC, V86, P84, DOI 10.1016/S1566-0702(00)00247-2
   ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003
   Armstrong DK, 2019, J NATL COMPR CANC NE, V17, P896, DOI 10.6004/jnccn.2019.0039
   Bassi GS, 2020, NEUROSCI BIOBEHAV R, V112, P363, DOI 10.1016/j.neubiorev.2020.02.011
   Beerman I, 2017, EXP HEMATOL, V50, P22, DOI 10.1016/j.exphem.2017.01.008
   Bhola NE, 2008, FRONT BIOSCI-LANDMRK, V13, P1857, DOI 10.2741/2805
   Bik W, 2006, J NEUROIMMUNOL, V177, P76, DOI 10.1016/j.jneuroim.2006.04.013
   Broome CS, 2000, ANN NY ACAD SCI, V917, P424
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323
   Cavaletti G, 2010, NAT REV NEUROL, V6, P657, DOI 10.1038/nrneurol.2010.160
   Challen GA, 2009, CYTOM PART A, V75A, P14, DOI 10.1002/cyto.a.20674
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chitteti BR, 2015, J IMMUNOL METHODS, V425, P108, DOI 10.1016/j.jim.2015.07.001
   Choi JS, 2017, SCI ADV, V3, P0, DOI 10.1126/sciadv.1600455
   Crawford J, 2004, CANCER-AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882
   da Silva MD, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq036
   Ettinger DS, 2018, J NATL COMPR CANC NE, V16, P807, DOI 10.6004/jnccn.2018.0062
   Fan CM, 2016, J BONE MINER METAB, V34, P277, DOI 10.1007/s00774-015-0679-x
   Goetz MP, 2019, J NATL COMPR CANC NE, V17, P119, DOI 10.6004/jnccn.2019.0009
   Han XY, 2017, BMC CANCER, V17, P0, DOI 10.1186/s12885-016-3037-z
   Hesketh PJ, 2008, NEW ENGL J MED, V358, P2482, DOI 10.1056/NEJMra0706547
   Huston A, 2007, EXPERT OPIN INV DRUG, V16, P1831, DOI 10.1517/13543784.16.11.1831
   Iravani S, 2020, PAIN RES MANAG, V2020, P0, DOI 10.1155/2020/2504674
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n
   Jiang X, 2019, INT J MED SCI, V16, P1642, DOI 10.7150/ijms.38521
   Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762
   Joseph B, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-018-36298-z
   Kanashiro A, 2020, PHARMACOL RES, V151, P0, DOI 10.1016/j.phrs.2019.104580
   Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kramer AC, 2017, STEM CELL REP, V9, P770, DOI 10.1016/j.stemcr.2017.07.021
   Li DX, 2020, TOXINS, V12, P0, DOI 10.3390/toxins12120775
   Lin CH, 2015, STEM CELLS, V33, P1153, DOI 10.1002/stem.1915
   Liu SB, 2020, NEURON, V108, P436, DOI 10.1016/j.neuron.2020.07.015
   Lu WD, 2020, ONCOLOGIST, V25, P310, DOI 10.1634/theoncologist.2019-0489
   Lu WD, 2009, J ALTERN COMPLEM MED, V15, P745, DOI 10.1089/acm.2008.0589
   Lucas D, 2013, NAT MED, V19, P695, DOI 10.1038/nm.3155
   Manecka DL, 2016, PITUITARY ADENYLATE, V11, P0
   Matsumoto M, 2016, J MOL NEUROSCI, V59, P270, DOI 10.1007/s12031-016-0731-x
   Melnikov SV, 2016, NUCLEIC ACIDS RES, V44, P4978, DOI 10.1093/nar/gkw246
   Méndez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685
   Méndez-Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mercer A, 2004, J NEUROSCI RES, V76, P205, DOI 10.1002/jnr.20038
   MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9
   NAITO S, 1986, CANCER RES, V46, P4109
   Nian JY, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2015-010787
   Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103
   Organization W H, 2003, ACUPUNCTURE: REVIEW AND ANALYSIS OF REPORTS ON CONTROLLED CLINICAL TRIALS, V0, PPS163, DOI 10.1016/S1353-8020(11)70706-4
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Ozdian T, 2017, J PROTEOMICS, V162, P73, DOI 10.1016/j.jprot.2017.05.005
   Pan H, 2019, J DIABETES, V11, P928, DOI 10.1111/1753-0407.12916
   Passegué E, 2005, J EXP MED, V202, P1599, DOI 10.1084/jem.20050967
   Probst K, 2018, STEM CELLS, V36, P1752, DOI 10.1002/stem.2892
   Qi LY, 2019, CHEM RES TOXICOL, V32, P1469, DOI 10.1021/acs.chemrestox.9b00204
   Razzaghdoust A, 2020, SUPPORT CARE CANCER, V28, P155, DOI 10.1007/s00520-019-04780-7
   Ringer C, 2013, NEUROBIOL DIS, V54, P32, DOI 10.1016/j.nbd.2013.02.010
   Shapiro GI, 2021, BRIT J CANCER, V125, P520, DOI 10.1038/s41416-021-01406-w
   Shen CH, 2017, BIOL RES NURS, V19, P145, DOI 10.1177/1099800416683801
   Skoetz N, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007107.pub3
   Spiegel A, 2007, NAT IMMUNOL, V8, P1123, DOI 10.1038/ni1509
   Staff NP, 2019, J PERIPHER NERV SYST, V24, PS26, DOI 10.1111/jns.12335
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stankevicius V, 2017, ONCOL LETT, V13, P4190, DOI 10.3892/ol.2017.5877
   Szanto Z, 2012, J MOL NEUROSCI, V48, P667, DOI 10.1007/s12031-012-9815-4
   Tamas A, 2016, J MOL NEUROSCI, V59, P177, DOI 10.1007/s12031-015-0652-0
   Taylor SJ, 2017, SCI TRANSL MED, V9, P0, DOI 10.1126/scitranslmed.aam8060
   Tixier F, 2017, HEMATOL ONCOL, V35, P584, DOI 10.1002/hon.2328
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479
   Tsumuraya T, 2015, J NEUROINFLAMM, V12, P0, DOI 10.1186/s12974-015-0252-5
   Ulloa L, 2017, TRENDS MOL MED, V23, P1103, DOI 10.1016/j.molmed.2017.10.006
   Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370
   Vizoso-Vázquez A, 2018, SCI REP-UK, V8, P0, DOI 10.1038/s41598-018-21439-1
   Wang Q, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/368103
   Wang WJ, 2021, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.618215
   Wang ZX, 2019, INT J BIOL SCI, V15, P2676, DOI 10.7150/ijbs.35630
   WEINSTEIN R, 1989, BLOOD, V73, P111
   Winkler J, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-020-18794-x
   Xu XL, 2016, SCI CHINA LIFE SCI, V59, P656, DOI 10.1007/s11427-016-0018-0
   Xu ZF, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep22373
   Yamashina T, 2014, CANCER RES, V74, P2698, DOI 10.1158/0008-5472.CAN-13-2169
   Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053
   Yin LM, 2019, TRENDS BIOCHEM SCI, V44, P885, DOI 10.1016/j.tibs.2019.05.004
   Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723
   Zhang Y, 2019, BIOMED PHARMACOTHER, V118, P0, DOI 10.1016/j.biopha.2019.109291
   Zhang Y, 2019, J ETHNOPHARMACOL, V238, P0, DOI 10.1016/j.jep.2019.111869
   Zhang YZ, 2021, FRONT ONCOL, V11, P0, DOI 10.3389/fonc.2021.646315
   Zheng QW, 2017, TUMOR BIOL, V39, P0, DOI 10.1177/1010428317692232
NR 88
TC 10
Z9 12
U1 3
U2 42
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
EI 
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 6
PY 2021
VL 12
IS 
BP 
EP 
DI 10.3389/fimmu.2021.714244
PG 16
WC Immunology
SC Immunology
GA UT9RN
UT WOS:000698445100001
PM 34552585
DA 2026-01-16
ER

PT J
AU Xin, Y
   Dai, YY
   Zhang, XW
   Yang, HX
   Hou, AL
   Yang, K
   Li, ZY
   Li, B
   Liu, H
AF Xin, Yu
   Dai, Yan-Yan
   Zhang, Xiu-Wen
   Yang, Hao-Xin
   Hou, Ai-Lin
   Yang, Kai
   Li, Ze-Yu
   Li, Bo
   Liu, Hui
TI A brief discussion on evidence-based clinical research of traditional Chinese medicine
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Traditional Chinese medicine (TCM); evidence-based medicine (EBM); efficacy evaluation; clinical research
ID breast-cancer; acupuncture; women; pain
AB Background: The evaluation of clinical efficacy of traditional Chinese medicine (TCM) is the focus of the development of Chinese medicine, but at present there is no internationally recognized clinical efficacy evaluation system, which prevents TCM going abroad. Evidence-based medicine (EBM) research methods have achieved good results in the evaluation of TCM, but there are still some problems. How to use EBM methods in accordance with China's national conditions and develop evidence-based TCM that meets its own characteristics is the key to the current discussion. Methods: Search websites such as PubMed, China National Knowledge Infrastructure, Wanfang Data and VIP by computer, and search papers related to evidence-based clinical research of TCM. Results: A total of 15 high quality representative research papers published in internationally renowned journals were selected for example, including 4 randomized controlled trials (RCTs) related to Chinese medicine, 9 RCTs related to acupuncture, and 2 observational studies on the safety of TCM. Conclusions: EBM method is suitable for clinical research of TCM. There are differences between "disease" and "syndromes" in the use of TCM. Based on the further standardization of syndromes and classification of TCM, modern clinical research methods can be reasonably applied. However, the quality of clinical research related to TCM is not high, and there is a lack of research related to the safety of it, which should be paid attention to and improved in future research.
C1 [Xin, Yu; Li, Ze-Yu; Li, Bo] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China.
   [Xin, Yu; Dai, Yan-Yan; Zhang, Xiu-Wen; Yang, Hao-Xin; Hou, Ai-Lin; Yang, Kai] Beijing Univ Tradit Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China.
   [Li, Bo] Beijing Inst Tradit Chinese Med, Beijing 100010, Peoples R China.
   [Liu, Hui] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Beijing, Peoples R China.
C3 Capital Medical University; Beijing University of Chinese Medicine; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College
RP Li, B (corresponding author), Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China.; Xin, Y (corresponding author), Beijing Univ Tradit Chinese Med, Dongzhimen Hosp, Beijing 100700, Peoples R China.; Li, B (corresponding author), Beijing Inst Tradit Chinese Med, Beijing 100010, Peoples R China.; Liu, H (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Beijing, Peoples R China.
EM 2941172785@qq.com; libo@bjzhongyi.com; liuhui@pumc.edu.cn
FU National Natural Science Foundation of China (NSFC) [81774146]; Chinese Academy of Engineering [2018-ZD-09-09]
CR Bensoussan A, 1998, JAMA-J AM MED ASSOC, V280, P1585, DOI 10.1001/jama.280.18.1585
   Brinkhaus B, 2013, ANN INTERN MED, V158, P225, DOI 10.7326/0003-4819-158-4-201302190-00002
   Chen K, 2019, CHIN J INTEG TRAD WE, V39, P1159
   Enblom A, 2012, ANN ONCOL, V23, P1353, DOI 10.1093/annonc/mdr402
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hinman RS, 2014, JAMA-J AM MED ASSOC, V312, P1313, DOI 10.1001/jama.2014.12660
   Li B, 2019, ANN TRANSL MED, V7, P0, DOI 10.21037/atm.2019.01.62
   Li J, 2011, CHINA MED HERALD, V8, P113
   Liu H, 2011, GUIDING J TCM, V17, P15
   刘建平, 2007, 中医杂志 JOURNAL OF TRADITIONAL CHINESE MEDICINE, V48, P26
   Liu J, 2006, EVIDENCE BASED CHINE, V0, P5
   Liu ZS, 2017, JAMA-J AM MED ASSOC, V317, P2493, DOI 10.1001/jama.2017.7220
   Molassiotis A, 2012, J CLIN ONCOL, V30, P4470, DOI 10.1200/JCO.2012.41.6222
   Ren B, 2019, HLTH NEWSM 0709, V0, P0
   Song YL, 2019, CRIT CARE MED, V47, PE735, DOI 10.1097/CCM.0000000000003842
   Wang C, 2011, ANN INTERN MED, V155, P217, DOI 10.7326/0003-4819-155-4-201108160-00005
   Wang Jia-bo, 2016, YAOXUE XUEBAO, V51, P1681, DOI 10.16438/j.0513-4870.2016-0812
   Wang X, 2018, CHINESE J EVIDENCE B, V10, P379
   Wu XK, 2017, JAMA-J AM MED ASSOC, V317, P2502, DOI 10.1001/jama.2017.7217
   Zhang Jun-Hua, 2018, ZHONGGUO ZHONG YAO ZA ZHI, V43, P1, DOI 10.19540/j.cnki.cjcmm.20171127.001
   [张俊华 Zhang Junhua], 2019, 中国循证医学杂志 CHINESE JOURNAL OF EVIDENCE-BASED MEDICINE, V19, P515
   Zhang M, 2019, SCI REP-UK, V9, P0, DOI 10.1038/s41598-019-41118-z
   Zhao L, 2019, JAMA INTERN MED, V179, P1388, DOI 10.1001/jamainternmed.2019.2407
   Zhao L, 2017, JAMA INTERN MED, V177, P508, DOI 10.1001/jamainternmed.2016.9378
   Zheng R, 2019, ANN TRANSL MED, V7, P0, DOI 10.21037/atm.2018.09.26
NR 25
TC 7
Z9 7
U1 1
U2 29
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD DEC 15
PY 2021
VL 10
IS 12
BP 12937
EP 12944
DI 10.21037/apm-20-697
PG 8
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA YZ0VV
UT WOS:000755202200092
PM 32819138
DA 2026-01-16
ER

PT J
AU Yang, W
   Zhang, YK
   Yang, GY
   Geng, YH
   Chen, D
   Wang, J
   Ye, Y
   Wang, HC
   Xia, DJ
   Hu, FL
   Jiang, J
   Xu, XF
AF Yang, Wei
   Zhang, Yeke
   Yang, Gaoyi
   Geng, Yanhua
   Chen, Da
   Wang, Jun
   Ye, Yang
   Wang, Huaichong
   Xia, Dajing
   Hu, Fuliang
   Jiang, Jing
   Xu, Xiaofeng
TI Anti-PD-1 Immunotherapy and Bee Venom for Relapsed and Refractory Liposarcoma: A Case Report
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE bee venom; PD-1 inhibitor; STING pathway; immunotherapy; apitherapy; liposarcoma; innate immunity; complementary medicine
ID melittin; blockade; cells
AB Cancer immunotherapies, including immune checkpoint inhibitors, elicit long-term clinical responses but many cancer patients do not respond. Intensive efforts are therefore underway to identify additional immune pathways that may be modulated to enhance the efficacy of existing immunotherapies. Bee venom strongly stimulates the immune system, and is used as a complementary therapy to treat cancer pain in patients with advanced tumors in China. Bee venom contains several allergenic protease inhibitors and peptides. It triggers hypersensitivity reactions; that is, it is an immune system agonist. The generation of a spontaneous T cell response against tumor-associated antigens requires innate immune activation; this drives type I interferon production. We report a patient with a relapsed and refractory liposarcoma who had undergone several operations, chemotherapies, and radiotherapies. The tumor was large. The patient had attained the maximum radiation exposure dose. The tumor was resistant to chemotherapy and was infiltrating the pericardium, lungs, and diaphragm. The patient was a poor candidate for resection. He thus received apitherapy (a combination of bee venom and acupuncture) to control pain; then apatinib (an anti-angiogenic drug) was given to inhibit tumor growth but was terminated early because the patient could not tolerate the side effects. Subsequently, a programmed death 1 inhibitor was combined with apitherapy. Bee venom served as an innate immune system agonist promoting immune cell priming and recruitment in the tumor microenvironment. The patient was finally able to undergo radical liposarcoma resection, and no evidence of recurrence was found at re-examination 16 months after surgery.
C1 [Yang, Wei; Zhang, Yeke; Jiang, Jing; Xu, Xiaofeng] Hangzhou Red Cross Hosp, Dept Oncol, Hangzhou, Peoples R China.
   [Yang, Gaoyi] Hangzhou Red Cross Hosp, Dept Med Imaging, Hangzhou, Peoples R China.
   [Geng, Yanhua] Hangzhou Red Cross Hosp, Dept Pathol, Hangzhou, Peoples R China.
   [Chen, Da] Hangzhou Red Cross Hosp, Dept Thorac Surg, Hangzhou, Peoples R China.
   [Wang, Jun; Ye, Yang] Hangzhou Red Cross Hosp, Dept Tradit Chinese Med, Hangzhou, Peoples R China.
   [Wang, Huaichong] Hangzhou Red Cross Hosp, Dept Pharm, Hangzhou, Peoples R China.
   [Xia, Dajing] Zhejiang Univ, Sch Med, Sch Publ Hlth, Dept Toxicol, Hangzhou, Peoples R China.
   [Hu, Fuliang] Zhejiang Univ, Coll Anim Sci, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Xu, XF (corresponding author), Hangzhou Red Cross Hosp, Dept Oncol, Hangzhou, Peoples R China.
EM zjszxyjhyy1941@126.com
FU Hangzhou Municipal Health and Family Planning Commission [0020190125, 0020190293, ZD20200004]
CR Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8
   Borojeni SK, 2020, J PHARMACOPUNCT, V23, P212, DOI 10.3831/KPI.2020.23.4.212
   Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8
   Caramalho I, 2015, ALLERGY, V70, P1340, DOI 10.1111/all.12691
   Cherniack EP, 2018, TOXICON, V154, P74, DOI 10.1016/j.toxicon.2018.09.013
   Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255
   Corrales L, 2017, CELL RES, V27, P96, DOI 10.1038/cr.2016.149
   Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031
   Crunkhorn S, 2020, NAT REV DRUG DISCOV, V19, P669, DOI 10.1038/d41573-020-00148-3
   Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019
   Duffy C, 2020, NPJ PRECIS ONCOL, V4, P0, DOI 10.1038/s41698-020-00129-0
   Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006
   Gajewski TF, 2020, SCIENCE, V369, P921, DOI 10.1126/science.abc6622
   Gajski G, 2016, TOXICON, V110, P56, DOI 10.1016/j.toxicon.2015.12.005
   Gajski G, 2012, ENVIRON MOL MUTAGEN, V53, P469, DOI 10.1002/em.21708
   Gauci ML, 2019, CLIN CANCER RES, V25, P946, DOI 10.1158/1078-0432.CCR-18-0793
   Guo BC, 2016, SCI REP-UK, V6, P0, DOI 10.1038/srep36107
   Haslam A, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.2535
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8
   Hingorani SR, 2018, J CLIN ONCOL, V36, P359, DOI 10.1200/JCO.2017.74.9564
   Ip SW, 2012, INT J UROL, V19, P61, DOI 10.1111/j.1442-2042.2011.02876.x
   Jung GB, 2018, BIOMED OPT EXPRESS, V9, P5703, DOI 10.1364/BOE.9.005703
   Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116
   Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133
   Keung EZ, 2018, BMC CANCER, V18, P0, DOI 10.1186/s12885-018-4829-0
   Kohno M, 2014, CHEM BIOL, V21, P1522, DOI 10.1016/j.chembiol.2014.09.008
   Konopleva M, 2020, LEUKEMIA, V34, P2858, DOI 10.1038/s41375-020-0949-z
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Liang LJ, 2019, CANCER IMMUNOL IMMUN, V68, P1467, DOI 10.1007/s00262-019-02375-z
   Liu MJ, 2016, J TRANSL MED, V14, P0, DOI 10.1186/s12967-016-0910-0
   Livingston JA, 2017, SCI REP-UK, V7, P0, DOI 10.1038/s41598-017-12132-w
   Luo L, 2018, BIOCONJUGATE CHEM, V29, P2936, DOI 10.1021/acs.bioconjchem.8b00352
   Lyu C, 2019, CURR PROTEIN PEPT SC, V20, P240, DOI 10.2174/1389203719666180612084615
   Marill J, 2019, RADIOTHER ONCOL, V141, P262, DOI 10.1016/j.radonc.2019.07.029
   Martín-Sánchez F, 2017, CELL DEATH DIS, V8, P0, DOI 10.1038/cddis.2017.390
   Medina PJ, 2016, PHARMACOTHERAPY, V36, P317, DOI 10.1002/phar.1714
   Moreno M, 2015, TOXINS, V7, P1126, DOI 10.3390/toxins7041126
   Nakashima A, 2020, INT IMMUNOL, V32, P371, DOI 10.1093/intimm/dxaa005
   Pan BS, 2020, SCIENCE, V369, P935, DOI 10.1126/science.aba6098
   Park HS, 2016, JAMA OPHTHALMOL, V134, P0, DOI 10.1001/jamaophthalmol.2016.1024
   Peng H, 2016, ONCOTARGET, V7, P17220, DOI 10.18632/oncotarget.7948
   Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8
   Salama Mohamed A, 2020, J COMPLEMENT INTEGR MED, V18, P75, DOI 10.1515/jcim-2019-0182
   Shao GC, 2015, ONCOL LETT, V9, P2729, DOI 10.3892/ol.2015.3125
   Shaw P, 2019, CANCERS, V11, P0, DOI 10.3390/cancers11081109
   Shu YF, 2019, INT J CLIN EXP MED, V12, P9468
   Su MM, 2016, ONCOL REP, V35, P1179, DOI 10.3892/or.2015.4448
   Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1
   Tipgomut Chartsiam, 2018, ASIAN PAC J CANCER PREV, V19, P3427, DOI 10.31557/apjcp.2018.19.12.3427
   Vazquez-Revuelta P, 2018, J INVEST ALLERG CLIN, V28, P45, DOI 10.18176/jiaci.0202
   Voronov E, 2017, CURR PHARM DESIGN, V23, P4893, DOI 10.2174/1381612823666170613080919
   Wehbe R, 2019, MOLECULES, V24, P0, DOI 10.3390/molecules24162997
   Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017
   Yu X, 2020, NAT COMMUN, V11, P0, DOI 10.1038/s41467-020-14906-9
   Yu X, 2019, NAT COMMUN, V10, P0, DOI 10.1038/s41467-019-08538-x
   Zhao S, 2019, CANCER IMMUNOL RES, V7, P630, DOI 10.1158/2326-6066.CIR-17-0640
NR 57
TC 5
Z9 6
U1 2
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 29
PY 2021
VL 11
IS 
BP 
EP 
DI 10.3389/fonc.2021.668992
PG 9
WC Oncology
SC Oncology
GA SB1YU
UT WOS:000649798200001
PM 33996596
DA 2026-01-16
ER

PT J
AU Chen, HY
   So, TH
   Cho, WCS
   Qin, ZS
   Ma, CH
   Li, SG
   Yang, ZJ
   Jiang, F
   Wu, JM
   Zhang, ZJ
   Kong, FM
   Lao, LX
AF Chen, Haiyong
   So, Tsz Him
   Cho, William Chi-Shing
   Qin, Zongshi
   Ma, Chun Ho
   Li, Shi Guang
   Yang, Zhenjiang
   Jiang, Fei
   Wu, Junmei
   Zhang, Zhang Jin
   Kong, Feng Ming
   Lao, Lixing
TI The Adjunctive Effect of Acupuncture for Advanced Cancer Patients in a Collaborative Model of Palliative Care: Study Protocol for a 3-Arm Randomized Trial
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE acupuncture; cancer related symptoms; palliative care; quality of life; randomized controlled trial
ID symptoms; insomnia; validation; fatigue; version; trends; scale; pain
AB Background: Cancer is the second leading cause of death before the age of 70. Improved cancer survival has put increasing demands on cancer care. Palliative care is the specialized multi-disciplinary care providing relief from the pain, symptoms, and stress of serious illness. The study aims to evaluate the adjunctive effect of acupuncture for advanced cancer patients in a collaborative model of palliative care. Methods/Design: This is a single-blinded, randomized, sham-controlled trial. One hundred twenty advanced cancer patients undergoing palliative care will be randomized in a ratio of 2: 1:1 to manual acupuncture plus standard care group (ASC), sham acupuncture plus standard care group (SSC), and standard care group (SC). Patients in ASC and SSC will receive 9 sessions of acupuncture or sham acupuncture for 3 weeks, and will be followed up for 2 months. The primary measure is the change from baseline score of the Edmonton Symptom Assessment System at 3 weeks. The secondary measures include the Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Insomnia Severity Index, Numeric Rating Scale, and European Organization for Research and Treatment of Cancer Quality of Life 15 items Questionnaire for Palliative Care. Discussion: The finding of this trial will provide high-quality evidence on the adjunctive effect of acupuncture to standard care on advanced cancer patients undergoing palliative care.
C1 [Chen, Haiyong; So, Tsz Him; Qin, Zongshi; Wu, Junmei; Zhang, Zhang Jin; Lao, Lixing] Univ Hong Kong, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong, Peoples R China.
   [Cho, William Chi-Shing; Kong, Feng Ming] Queen Elizabeth Hosp, Hong Kong, Peoples R China.
   [Ma, Chun Ho] Univ Hong Kong, Clin Ctr Teaching & Res Chinese Med Aberdeen, Hong Kong, Peoples R China.
   [Li, Shi Guang; Yang, Zhenjiang] Shen Zhen Hosp Tradit Chinese Med, Shenzhen, Peoples R China.
   [Jiang, Fei] Univ Calif San Francisco, San Francisco, CA USA.
   [Lao, Lixing] Virginia Univ Integrat Med, Fairfax, VA USA.
C3 University of Hong Kong; Queen Elizabeth Hospital - Hong Kong; University of Hong Kong; University of California System; University of California San Francisco
RP Chen, HY (corresponding author), Univ Hong Kong, Sch Chinese Med, Pokfulam, 10 Sassoon Rd, Hong Kong, Peoples R China.
EM haiyong@hku.hk
FU Health and Medical Research Fund (HMRF), Food and Health Bureau, Hong Kong SAR Government [17181831]
CR Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3
   Unknown -, 2017, STRATEGIC SERVICE FRAMEWORK FOR REHABILITATION SERVICES, V0, P0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Brierley J, 2017, TNM CLASSIFICATION M, V0, P0
   Bruera E, 2012, ONCOLOGIST, V17, P267, DOI 10.1634/theoncologist.2011-0219
   Chen HY, 2007, J ALTERN COMPLEM MED, V13, P669, DOI 10.1089/acm.2006.6400
   Chen HY, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-362
   Chen HY, 2019, AM J CHINESE MED, V47, P1, DOI 10.1142/S0192415X19500010
   Cheng CS, 2017, SUPPORT CARE CANCER, V25, P3807, DOI 10.1007/s00520-017-3812-7
   Chung KF, 2011, SLEEP MED, V12, P463, DOI 10.1016/j.sleep.2010.09.019
   Dean-Clower E, 2010, INTEGR CANCER THER, V9, P158, DOI 10.1177/1534735409360666
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Hashim D, 2016, ANN ONCOL, V27, P926, DOI 10.1093/annonc/mdw027
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Khan SA, 2014, NAT REV CLIN ONCOL, V11, P100, DOI 10.1038/nrclinonc.2013.217
   Kramer S, 2017, J ACUPUNCT MERIDIAN, V10, P294, DOI 10.1016/j.jams.2017.04.004
   Leung CM, 1999, ACTA PSYCHIAT SCAND, V100, P456, DOI 10.1111/j.1600-0447.1999.tb10897.x
   Lopez G, 2018, J CANCER, V9, P3613, DOI 10.7150/jca.26527
   Lund Irene, 2006, ACUPUNCT MED, V24, P13
   Lundeberg T, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep049
   MacPherson H, 2014, PLOS ONE, V9, P0, DOI 10.1371/journal.pone.0093739
   Noone AM HN, 2017, SEER CANC STAT REV 1, V0, P0
   Quaresma M, 2015, LANCET, V385, P1206, DOI 10.1016/S0140-6736(14)61396-9
   Quirico PE, 2007, TEACHING ATLAS OF ACUPUNCTURE: CHANNELS AND POINTS, V1, P0
   Romeo MJ, 2015, EXPLORE-NY, V11, P357, DOI 10.1016/j.explore.2015.06.001
   Schroeder K, 2018, ASIA-PAC J ONCOL NUR, V5, P4, DOI 10.4103/apjon.apjon_43_17
   Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8
   Swami M, 2018, ONCOLOGY-NY, V32, P180
   Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678
   Towler P, 2013, SUPPORT CARE CANCER, V21, P2913, DOI 10.1007/s00520-013-1882-8
   Vas J, 2006, PAIN, V126, P245, DOI 10.1016/j.pain.2006.07.002
   Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P322, DOI 10.1016/j.jpainsymman.2003.09.008
   Wu XY, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep16776
   Xie CC, 2013, EVID BASED COMPLEMENT ALTERNAT MED, V2013, P0
   Yeung WF, 2018, J SLEEP RES, V27, P220, DOI 10.1111/jsr.12597
   Zhang L, 2016, PALLIATIVE MED, V30, P401, DOI 10.1177/0269216315593671
   Zia Farah Z, 2017, JOURNAL OF THE NATIONAL CANCER INSTITUTE MONOGRAPHS, V0, PP68, DOI 10.1093/jncimonographs/lgx005
NR 37
TC 2
Z9 3
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JUN 15
PY 2021
VL 20
IS 
BP 
EP 
DI 10.1177/15347354211012749
PG 10
WC Oncology; Integrative & Complementary Medicine
SC Oncology; Integrative & Complementary Medicine
GA VN9HT
UT WOS:001255333400001
PM 33957783
DA 2026-01-16
ER

PT J
AU Faruqi, F
   Ruddy, KJ
   Blackmon, S
AF Faruqi, Fahad
   Ruddy, Kathryn J
   Blackmon, Shanda
TI Integrative Approaches to Minimize Peri-operative Symptoms.
SO Current oncology reports
LA English
DT Review
DE Acupuncture; CAM; Complementary medicine; Guided imagery; Integrative medicine; Loving-kindness meditation; PTPS; Peri-operative symptoms; Post-thoracotomy pain syndrome
AB PURPOSE OF REVIEW: Cancer patients who require surgery often experience  peri-operative symptoms, including nausea, anxiety, and pain, which can  significantly impair quality of life. Here, we review the evidence for using  integrative approaches to manage these peri-operative symptoms. RECENT FINDINGS:  Conventional peri-operative pharmacologic interventions, such as opiates for pain  control, can lead to adverse effects such as respiratory depression, prolonged  hospital course, and long-term dependence. Integrative medicine, also known as  complementary and alternative medicine (CAM), has been explored as way to reduce  peri-operative symptoms. Acupuncture, guided imagery, and loving-kindness  meditation have all shown potential efficacy in reducing both peri-operative pain  and anxiety in retrospective studies and small randomized controlled trials.  Integrative medicine techniques, such as acupuncture, are a promising approach to  control peri-operative symptoms without the associated adverse effects of more  conventional pharmacologic interventions.
C1 Mayo Clinic, Rochester, MN, USA. faruqi.fahad@mayo.edu.
   Mayo Clinic, Rochester, MN, USA.
   Mayo Clinic, Rochester, MN, USA.
NR 0
TC 0
SN 1534-626
EI 
J9 Curr Oncol Rep
PD APR 29
PY 2021
VL 23
IS 6
BP 73
EP 73
DI 10.1007/s11912-021-01051-9
PG 0
WC Anxiety; therapy; Enhanced Recovery After Surgery; Humans; Integrative Medicine; methods; Nausea; therapy; Neoplasms; surgery; Pain Management; methods; Perioperative Care
UT PubMed:33907909
PM 33907909
DA 2021-04-29
ER

PT J
AU Kannan, P
   Lam, HY
   Ma, TK
   Lo, CN
   Mui, TY
   Tang, WY
AF Kannan, Priya
   Lam, Hiu Ying
   Ma, Tsz Kiu
   Lo, Chiu Ngai
   Mui, Ting Yan
   Tang, Wing Yan
TI Efficacy of physical therapy interventions on quality of life and upper quadrant
SO Quality of life research : an international journal of quality of life aspects of
LA English
DT Journal Article
DE Acupuncture; Decongestive therapy; Exercise; Post-mastectomy pain syndrome; Quality of Life
AB PURPOSE: To determine the efficacy of physical therapy interventions on quality  of life (QoL) and pain severity in post-mastectomy pain syndrome (PMPS). METHODS:  Multiple databases were searched from database inception to October 2020.  Searches were limited to human studies published in either English or Chinese in  peer-reviewed journals with full text available for randomized controlled trials  conducted on females. Trials comparing the effectiveness of physical therapy  interventions against control conditions on QoL and pain were included. RESULTS:  Eighteen trials were included in the review. The pooled analysis of the four  exercise trials revealed a significant effect of the intervention on general  [standardized mean difference [SMD]: 0.87 (95%CI: 0.36, 1.37); p = 0.001],  physical [SMD: 0.34 (95%CI: 0.01, 0.66); p = 0.044], and mental health components  [SMD: 0.27 (95%CI: 0.03, 0.51); p = 0.027] of QoL compared with the control  condition. Meta-analyses of six exercise trials, two myofascial release trials,  and two acupuncture trials revealed a significant improvement in pain severity in  the treatment group than in the control group. However, meta-analyses of two  studies revealed a non-significant effect of compression therapy compared to  control on pain severity. CONCLUSION: Our meta-analyses found that exercise is  beneficial for improving the QoL and pain severity of women with PMPS. Future  studies are needed to determine the optimal parameters for exercise interventions  designed to improve QoL and pain severity in women with PMPS. The effect of  acupuncture, myofascial release, and compression therapy remains inconclusive,  and future research is required to validate the effect of these interventions on  PMPS.
C1 Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong. priya.kannan@polyu.edu.hk.
   Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
   Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
   Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
   Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
   Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong.
NR 0
TC 0
SN 1573-264
EI 0962-934
J9 Qual Life Res
PD JUN 30
PY 2021
VL 31
IS 4
BP 951
EP 973
DI 10.1007/s11136-021-02926-x
PG 22
WC Breast Neoplasms; Chronic Pain; Female; Humans; Mastectomy; adverse effects; Pain Measurement; Physical Therapy Modalities; Quality of Life; psychology
UT PubMed:34185226
PM 34185226
DA 2021-06-30
ER

PT J
AU Li, H
   Wang, B
   Chen, C
AF Li, Hanjing
   Wang, Biao
   Chen, Chuanyuan
TI Acupuncture around the greater tuberosity of the femur combined with acupuncture
SO American journal of translational research
LA English
DT Journal Article
DE Greater tuberosity of the femur; Xuehai acupoint; intertrochanteric fracture; pain
AB OBJECTIVE: To determine the efficacy of acupuncture around the greater tuberosity  of the femur (AGTF) combined with acupuncture at Xuehai acupoint for  postoperative pain in elderly patients with intertrochanteric fracture. METHODS:  A total of 97 elderly patients with intertrochanteric fracture treated by  proximal femoral nail antirotation (PFNA) were enrolled and randomly assigned  into an observation group (Obs group, n=48) and a control group (Con group,  n=49). The Obs group was treated by aspirin and AGTF combined with acupuncture at  Xuehai acupoint for analgesia, while the Con group was treated by aspirin alone  for analgesia. Both groups were treated for 7 consecutive days. The two groups  were compared in pain degree (visual analog scale (VAS) score) after operation  and hip joint function (Harris score), daily living ability (modified Barthel  index (MBI) score), bone metabolism-related indexes, and inflammatory factors  before and after treatment. RESULTS: At 1-7 d after operation, both groups had  gradually lower VAS scores, and at 5 and 7 d after operation, the Obs group had a  lower VAS score than the Con group (both P<0.05). Additionally, at 2 months after  operation, both groups had higher Harris scores and MBI scores, and the scores of  the Obs group were both higher than those of the Con group (both P<0.05). At 7 d  after operation, both groups showed a decrease in serum beta collagen degradation  products (β-CTx) and an increase in procollagen type I amino-terminal propeptide  (PINP) (both P<0.05), but the differences between the two groups in β-CTx and  PINP were insignificant (P>0.05). Moreover, at 7 d after operation, both groups  showed a decrease in C-reactive protein (CRP) and tumor necrosis factor-α  (TNF-α), and the two levels in the Obs group were lower than those in the Con  group (both P<0.05). CONCLUSION: For elderly patients with intertrochanteric  fracture, AGTF combined with acupuncture at the Xuehai acupoint can more  effectively relieve their postoperative pain and postoperative inflammation and  more strongly promote their postoperative recovery of hip joint function.
C1 Department of Traditional Chinese Medicine, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.
   Department of Orthopedics, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.
   Department of Orthopedics, Fuzhou Second Hospital Affiliated to Xiamen University Fuzhou, Fujian Province, China.
NR 0
TC 0
SN 1943-814
EI 1943-814
J9 Am J Transl Res
PD AUG 12
PY 2021
VL 13
IS 7
BP 8372
EP 8378
DI 
PG 6
UT PubMed:34377330
PM 34377330
DA 2021-08-12
ER

PT J
AU Kutcher, AM
   LeBaron, VT
AF Kutcher, Anna M
   LeBaron, Virginia T
TI Evaluating Acupuncture for the Treatment of Chemotherapy-induced Peripheral
SO Western journal of nursing research
LA English
DT Review
DE acupuncture; cancer; chemotherapy-induced peripheral neuropathy; electro-acupuncture; integrative oncology; integrative review
AB The purpose of this integrative review of the literature is to synthesize the  current evidence and identify gaps in knowledge regarding the effectiveness of  acupuncture to treat chemotherapy-induced peripheral neuropathy (CIPN). PubMed,  CINAHL, Web of Science, and Cochrane Review databases were searched using  inclusion criteria: keywords acupuncture, cancer, and peripheral neuropathy,  published in English, between 2009 and 2019. Sixteen articles met the inclusion  criteria. The literature indicates that acupuncture is generally well tolerated  by patients with cancer, and a majority of patients with CIPN reported decreased  pain and increased quality of life after receiving acupuncture treatment. A  comprehensive understanding of the ability of acupuncture to treat CIPN is  limited by variability of acupuncture techniques and inconsistency in measures of  evaluation.
C1 University of Virginia School of Nursing, Charlottesville, VA, USA.
   University of Virginia School of Nursing, Charlottesville, VA, USA.
NR 0
TC 0
SN 1552-845
EI 
J9 West J Nurs Res
PD FEB 10
PY 2021
VL 44
IS 2
BP 169
EP 179
DI 10.1177/0193945921992538
PG 10
WC Acupuncture Therapy; methods; Antineoplastic Agents; adverse effects; Humans; Neoplasms; drug therapy; Peripheral Nervous System Diseases; chemically induced; Quality of Life
UT PubMed:33559535
PM 33559535
DA 2021-02-10
ER

PT J
AU Xu, GX
   Lei, HZ
   Zhou, YF
   Huang, LY
   Tian, H
   Zhou, Z
   Zhao, L
   Liang, FR
AF Xu, Guixing
   Lei, Hanzhou
   Zhou, Yuanfang
   Huang, Liuyang
   Tian, Hao
   Zhou, Zhuo
   Zhao, Ling
   Liang, Fanrong
TI Acupuncture for Quality of Life of Patients with Defecation Dysfunction after Sphincter Preserving Surgery for Rectal Cancer: A Systematic Review
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID low anterior resection; postoperative ileus; electroacupuncture; input; trial; bias
AB Purpose. To evaluate the effectiveness and safety of acupuncture for quality of life of patients with defecation dysfunction (DD) after sphincter preserving surgery for rectal cancer. Methods. We searched nine online databases from inception to July 1, 2021, and did not restrict the type of language. Then, studies were independently selected by two research team members with screening criteria and risk bias assessment, and the data were extracted. The primary outcome was Quality of Life Questionnaire-Core 29 (QLQ-CR29). The data were then synthesized using the RevMan V. 5.2 by random-effects model. Also, we used the standardized mean differences with 95% credible interval (CI) to describe the outcome of the analysis. Results. A total of 6 randomized controlled trials (RCTs) (with 439 patients) were included in the systematic review, and data from 2 RCTs (with 200 patients) were used in the meta-analysis. Five studies (83%) were judged to have a medium risk of bias, and one was at high risk of bias. For synthesis, data from two medium-risk studies found that acupuncture or electropuncture may improve the QLQ-CR29 with urination (mean difference, -0.39 points; 95% CI, -0.46 to -0.32; I-2. 34%), abdominal pain (mean difference, -0.71 points; 95%CI, -0.89 to -0.54; I-2. 9%), stool (mean difference, -0.49 points; 95% CI, -0.77 to -0.20; I-2. 57%), defecation (mean difference, -0.59 points; 95% CI, -0.85 to -0.33; I-2. 51%), sexual function (mean difference, 0.93 points; 95% CI, 0.48 to 1.38; I-2. 90%), and self-feelings (mean difference, 1.04 points; 95% CI, 0.36 to 1.73; I-2. 94%). Conclusion. Findings in this study indicate that acupuncture or electropuncture may be effective and safe for DD, but the quality of included studies was very low. So, more large-scale, multicenter, long-term, and high-quality original research is still expected in the future.
C1 [Xu, Guixing; Lei, Hanzhou; Zhou, Yuanfang; Huang, Liuyang; Tian, Hao; Zhou, Zhuo; Zhao, Ling; Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine
RP Zhao, L; Liang, FR (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM zhaoling@cdutcm.edu.cn; acuresearch@126.com
FU National Natural Science Foundation of China [81590950]; Key Research and Development Program of Science and Technology Department of Sichuan Province [20ZDYF1199]
CR Unknown -, 2011, THE COCHRANE COLLABORATIONS TOOL FOR ASSESSING RISK OF BIAS IN RANDOMISED TRIALS, V0, P0
   Cancer UK, 2012, CANCERSTATS CANC STA, V0, P0
   CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204
   Chapman SJ, 2017, DIS COLON RECTUM, V60, P240, DOI 10.1097/DCR.0000000000000649
   Cooke HJ, 2000, ANN NY ACAD SCI, V915, P77
   Deng G, 2013, ANN SURG ONCOL, V20, P1164, DOI 10.1245/s10434-012-2759-7
   Dennett ER, 1999, DIS COLON RECTUM, V42, P804, DOI 10.1007/BF02236940
   Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2
   Fujii S, 2014, SURG ENDOSC, V28, P466, DOI 10.1007/s00464-013-3223-x
   Gershon MD, 2002, FASEB J, V16, P0
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hou L, 2017, ZHONGHUA YI XUE ZA ZHI, V97, P3492, DOI 10.3760/cma.j.issn.0376-2491.2017.44.012
   Juul T, 2014, DIS COLON RECTUM, V57, P585, DOI 10.1097/DCR.0000000000000116
   Juul T, 2014, ANN SURG, V259, P728, DOI 10.1097/SLA.0b013e31828fac0b
   Liu F, 2015, BIOFEEDBACK ACUPUNCT, V0, P0
   Lundgren O, 2000, GUT, V47, P33
   Meng ZQ, 2010, WORLD J GASTROENTERO, V16, P104, DOI 10.3748/wjg.v16.i1.104
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202
   Pildal J, 2005, BMJ-BRIT MED J, V330, P1049, DOI 10.1136/bmj.38414.422650.8F
   Powley TL, 2000, GUT, V47, P30
   Schulz KF, 2010, BMJ-BRIT MED J, V340, P0, DOI 10.1136/bmj.c869
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456
   SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Vader, 1998, BMJ, V317, P1258
   Wang Y, 2019, J CLIN ACUPUNCT MOXIBUST, V35, P26, DOI 10.3969/J.ISSN.1005-0779.2019.04.008
   WILLIAMSON MER, 1994, DIS COLON RECTUM, V37, P1228, DOI 10.1007/BF02257786
   Xia H, 2019, ZHEJIANG J INTEGRATE, V54, P291
   Xia Y, 2018, CHINA MODERN DOCTOR, V56, P146
   Xiao Y, 2017, STUDY BIOFEEDBACK AC, V0, P0
   Xu GX, 2020, BMJ OPEN, V10, P0, DOI 10.1136/bmjopen-2019-034152
   Xu Y, 2013, DEV OWING ACUPUNCTUR, V0, P0
   Yu S, 2011, MODERN J INTEGRATED, V20, P0
   [赵加应 Zhao Jiaying], 2020, 中国康复理论与实践 CHINESE JOURNAL OF REHABILITATION THEORY AND PRACTICE, V26, P715
   Zhao JY, 2018, ACUPUNCTURE ELECTRO, V43, P103, DOI 10.3727/036012918X15353852193131
NR 37
TC 4
Z9 6
U1 0
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD DEC 15
PY 2021
VL 2021
IS 
BP 
EP 
DI 10.1155/2021/7858252
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 5E7PT
UT WOS:000865816000004
PM 34956383
DA 2026-01-16
ER

PT J
AU Mattia, C
   Luongo, L
   Innamorato, M
   Melis, L
   Sofia, M
   Zappi, L
   Puntillo, F
AF Mattia, Consalvo
   Luongo, Livio
   Innamorato, Massimo
   Melis, Luca
   Sofia, Michele
   Zappi, Lucia
   Puntillo, Filomena
TI An Italian Expert Consensus on the Use of Opioids for the Management of Chronic Non-Oncological Pain in Clinical Practice: Focus on Buprenorphine
SO JOURNAL OF PAIN RESEARCH
LA English
DT Article
DE pain; chronic; non-oncological; strong opioids; buprenorphine; Delphi survey
ID chronic noncancer pain; transdermal buprenorphine; analgesics; mechanism; therapy
AB Purpose: The aim of the present work was to evaluate the knowledge and prescriptive habits of clinicians involved in the management of chronic non cancer pain (CNCP), with a special focus on the use of opioids. Methods: A Delphi method was used. A Board of specialists elaborated and discussed a series of statements, based on available literature and personal clinical expertise, about particularly controversial topics on pain pathophysiology and treatment. A Panel of experts in the field of pain management, selected by the Board, was invited to vote the proposed statements, indicating the level of agreement on a 5-point Likert scale (1: strongly disagree; 2: disagree; 3: partially agree; 4: agree; 5: strongly agree). The threshold for consensus was set at minimum 66.6% of the number of respondents with a level of agreement >= 4 (Agree or Strongly agree). Results: The Board included 5 pain therapists, 1 pharmacologist and 1 methodology expert and drew up a total of 36 statements (for a total of 40 requested answers)". A total of 100 clinicians were included in the Expert Panel. Respondents were 89 (89%). Consensus was achieved for 32 out of 40 answers. Most of the lack of consensus was recorded for statements regarding opioids use, and resulted from a low level of agreement (3 on the Likert scale), suggesting a neutral position deriving from a lack of knowledge rather than a strong contrary opinion. Conclusion: Most of the proposed items reached consensus, suggesting a generally homogeneous approach to CNCP management. However, the lack of consensus recorded for several items regarding opioid use confirms the need to fill important gaps in the knowledge of available agents. A clear explanation of the peculiar pharmacological properties of drugs associated with potential clinical advantages (such as buprenorphine) will help optimize pain treatment in both primary care and hospital settings and improving pain control in CNCP patients.
C1 [Mattia, Consalvo] Sapienza Univ Rome, Fac Pharm & Med, Dept Med & Surg Sci & Biotechnol, Rome, Italy.
   [Mattia, Consalvo] ICOT Polo Pontino, Anesthesia Intens Care & Pain Unit, Latina, Italy.
   [Luongo, Livio] Univ Campania L Vanvitelli, Dept Expt Med, Div Pharmacol, Naples, Italy.
   [Luongo, Livio] NEUROMED, Pozzilli, Italy.
   [Innamorato, Massimo] AUSL Romagna, SM Croci Hosp Ravenna, Pain Therapy Unit, Ravenna, Italy.
   [Melis, Luca] Poliste, Cagliari, Italy.
   [Sofia, Michele] ASST Rodhense, Dept Palliat Care & Pain Therapy, Garbagnate Milanese, Italy.
   [Zappi, Lucia] San Martino Polyclin Hosp, Emergency & Acceptance Dept, UOC Antalg Therapy, Genoa, Italy.
   [Puntillo, Filomena] Aldo Moro Univ Bari, Dept Interdisciplinary Med, I-70124 Bari, Italy.
   [Puntillo, Filomena] Policlin Hosp Bari, Anesthesia Intens Care & Pain Unit, I-70124 Bari, Italy.
C3 Sapienza University Rome; Universita della Campania Vanvitelli; IRCCS Neuromed; AUSL della Romagna
RP Mattia, C (corresponding author), Univ Sapienza, Dept Med & Surg Sci, Corso Repubbl 79, I-04100 Latina, Italy.
EM consalvo.mattia@uniroma1.it
FU Camilla Ciani, Poliste Srl; Sandoz SpA
CR Aloisi Anna Maria, 2009, PSYCHONEUROENDOCRINOLOGY, V34 Suppl 1, PS162, DOI 10.1016/j.psyneuen.2009.05.013
   Anekar AA, 2020, STATPEARLS, V0, P0
   Bawor M, 2015, DRUG ALCOHOL DEPEN, V149, P1, DOI 10.1016/j.drugalcdep.2015.01.038
   Behzadi M, 2018, MED PRIN PRACT, V27, P401, DOI 10.1159/000492616
   Bindu S, 2020, BIOCHEM PHARMACOL, V180, P0, DOI 10.1016/j.bcp.2020.114147
   Bliesener N, 2005, J CLIN ENDOCR METAB, V90, P203, DOI 10.1210/jc.2004-0929
   Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086
   Caraceni A, 2012, LANCET ONCOL, V13, PE58, DOI 10.1016/S1470-2045(12)70040-2
   Chen L, 2013, J PAIN, V14, P384, DOI 10.1016/j.jpain.2012.12.012
   Coluzzi F, 2018, J ENDOCRINOL INVEST, V41, P1377, DOI 10.1007/s40618-018-0964-3
   Costa T, 2018, ACTA REUMATOL PORT, V43, P172
   Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223
   Cuomo A, 2019, J PAIN RES, V12, P711, DOI 10.2147/JPR.S178910
   Davis MP, 2018, DRUGS, V78, P1211, DOI 10.1007/s40265-018-0953-z
   Davis MP, 2016, CURR ONCOL REP, V18, P0, DOI 10.1007/s11912-016-0558-1
   Demartini L, 2019, NEUROMODULATION, V22, P327, DOI 10.1111/ner.12867
   Ding Z, 2009, BRIT J PHARMACOL, V157, P831, DOI 10.1111/j.1476-5381.2009.00209.x
   Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464
   Fishman MA, 2018, CURR PAIN HEADACHE R, V22, P0, DOI 10.1007/s11916-018-0732-2
   Fornasari D, 2020, PHARMADVANCES, V02, P0, DOI 10.36118/pharmadvances.01.2020.08
   Fu K, 2018, RHEUMATOLOGY, V57, P43, DOI 10.1093/rheumatology/kex419
   Glanz JM, 2019, JAMA NETW OPEN, V2, P0, DOI 10.1001/jamanetworkopen.2019.2613
   Guillou-Landreat M, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18042097
   Harris SC, 2017, POSTGRAD MED, V129, P69, DOI 10.1080/00325481.2017.1270156
   Heijmans L, 2020, POSTGRAD MED, V132, P17, DOI 10.1080/00325481.2020.1769393
   Higgins C, 2018, BRIT J ANAESTH, V120, P1335, DOI 10.1016/j.bja.2018.03.009
   Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135
   Hylands-White N, 2017, RHEUMATOL INT, V37, P29, DOI 10.1007/s00296-016-3481-8
   Infantino R, 2021, BIOMOLECULES, V11, P0, DOI 10.3390/biom11060816
   Ingrasciotta Y, 2019, PLOS ONE, V14, P0, DOI 10.1371/journal.pone.0222836
   Isagulyan E, 2020, KOREAN J PAIN, V33, P99, DOI 10.3344/kjp.2020.33.2.99
   Jacobsen JHW, 2014, INT REV NEUROBIOL, V118, P129, DOI 10.1016/B978-0-12-801284-0.00006-3
   Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005
   JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376
   Lamprecht A, 2018, EUR J ENDOCRINOL, V179, P353, DOI 10.1530/EJE-18-0530
   Likar Rudolf, 2006, THER CLIN RISK MANAG, V2, P115
   Lippe PM, 2010, PAIN MED, V11, P1447, DOI 10.1111/j.1526-4637.2010.00961.x
   Malfait AM, 2013, NAT REV RHEUMATOL, V9, P654, DOI 10.1038/nrrheum.2013.138
   Manchikanti L, 2017, PAIN PHYSICIAN, V20, PS3, DOI 10.36076/ppj.2017.s92
   Mills S, 2016, CURR PSYCHIAT REP, V18, P0, DOI 10.1007/s11920-015-0659-9
   Mills SEE, 2019, BRIT J ANAESTH, V123, PE273, DOI 10.1016/j.bja.2019.03.023
   Özcan Ç, 2019, PAIN PRACT, V19, P821, DOI 10.1111/papr.12812
   Pacifico S, 2020, J MED CHEM, V63, P10782, DOI 10.1021/acs.jmedchem.9b02057
   Pedersen L, 2014, ACTA ANAESTH SCAND, V58, P390, DOI 10.1111/aas.12279
   Pedersen MF, 2020, NEUROPHARMACOLOGY, V166, P0, DOI 10.1016/j.neuropharrn.2019.107718
   Pergolizzi JV, 2019, J PAIN RES, V12, P3299, DOI 10.2147/JPR.S231948
   Pergolizzi JV, 2018, EXPERT REV NEUROTHER, V18, P359, DOI 10.1080/14737175.2018.1462701
   Pergolizzi Joseph V Jr, 2015, ACTA ANAESTHESIOL TAIWAN, V53, P71, DOI 10.1016/j.aat.2015.06.001
   Simpson RW, 2016, DIABETES CARE, V39, P1493, DOI 10.2337/dc16-0123
   Staunton CA, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0378-z
   Stein M, 2020, ADDICTION, V115, P82, DOI 10.1111/add.14737
   Treede RD, 2019, PAIN, V160, P19, DOI 10.1097/j.pain.0000000000001384
   van Hecke O, 2013, BRIT J ANAESTH, V111, P13, DOI 10.1093/bja/aet123
   Varrassi G, 2020, J PAIN RES, V13, P979, DOI 10.2147/JPR.S243222
   Webster LR, 2020, ADV THER, V37, P4685, DOI 10.1007/s12325-020-01481-0
   Yang J, 2020, J PAIN RES, V13, P411, DOI 10.2147/JPR.S244173
   Zamarripa CA, 2018, DRUG ALCOHOL DEPEN, V192, P158, DOI 10.1016/j.drugalcdep.2018.08.002
NR 57
TC 3
Z9 3
U1 1
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-7090
EI 
J9 J PAIN RES
JI J. Pain Res.
PD JUN 15
PY 2021
VL 14
IS 
BP 3193
EP 3206
DI 10.2147/JPR.S314206
PG 14
WC Clinical Neurology
SC Neurosciences & Neurology
GA WK5AQ
UT WOS:000709738500011
PM 34675646
DA 2026-01-16
ER

PT J
AU Pérez, C
   Martin-Delgado, J
   Vinuesa, M
   Ibor, PJ
   Guilabert, M
   Gomez, J
   Beato, C
   Sánchez-Jiménez, J
   Velázquez, I
   Calvo-Espinos, C
   Cánovas, ML
   Yáñez, JA
   Rodríguez, M
   Baquero, JL
   Gallach, E
   Folch, E
   Tuca, A
   Santiña, M
   Mira, JJ
AF Perez, Concepcion
   Martin-Delgado, Jimmy
   Vinuesa, Mercedes
   Ibor, Pedro J.
   Guilabert, Mercedes
   Gomez, Jose
   Beato, Carmen
   Sanchez-Jimenez, Juana
   Velazquez, Ignacio
   Calvo-Espinos, Claudio
   Canovas, Maria L.
   Yanez, Jose A.
   Rodriguez, Mireia
   Baquero, Jose L.
   Gallach, Elisa
   Folch, Emma
   Tuca, Albert
   Santina, Manel
   Mira, Jose J.
TI Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study
SO JOURNAL OF PERSONALIZED MEDICINE
LA English
DT Article
DE pain; cancer; quality of care; accreditation; patient-centered care; patient-safety
ID cancer pain; management; prevalence; patient
AB Up to 50% of cancer patients and up to 90% of those in terminal stages experience pain associated with disease progression, poor quality of life, and social impact on caregivers. This study aimed to establish standards for the accreditation of oncological pain management in healthcare organizations. A mixed methods approach was used. First, a pragmatic literature review was conducted. Second, consensus between professionals and patients was reached using the Nominal Group and Delphi technique in a step that involved anesthesiologists, oncologists, family physicians, nurses, psychologists, patient representatives, and caregivers. Third, eight hospitals participated in a pilot assessment of the level of fulfillment of each standard. A total of 37 standards were extracted. The Nominal Group produced additional standards, of which 60 were included in Questionnaire 0 that was used in the Delphi Technique. Two Delphi voting rounds were performed to reach a high level of consensus, and involved 64 and 62 participants with response rates of 90% and 87%, respectively. Finally, 39 standards for the management of cancer pain were agreed upon. In the self-evaluation, the average range of compliance was between 56.4% and 100%. The consensus standards of the ACDON Project might improve the monitoring of cancer pain management. These standards satisfied the demands of professionals and patients and could be used for the accreditation of approaches in cancer pain management.
C1 [Perez, Concepcion; Vinuesa, Mercedes] La Princesa Univ Hosp, Qual Dept, Pain Unit, Madrid 28006, Spain.
   [Martin-Delgado, Jimmy; Mira, Jose J.] Fdn Promot Hlth & Biomed Res, Atenea Res Grp, Sant Joan dAlacant 03550, Spain.
   [Ibor, Pedro J.] Spanish Soc Primary Care Phys, Pain Res Grp, Valencia 28009, Spain.
   [Guilabert, Mercedes; Mira, Jose J.] Miguel Hernandez Univ, Hlth Psychol Dept, Elche 03202, Spain.
   [Gomez, Jose] Le Fe Hosp, Oncol Dept, Valencia 46026, Spain.
   [Beato, Carmen] Virgen Rocio Univ Hosp, Oncol Dept, Seville 41013, Spain.
   [Sanchez-Jimenez, Juana] Daroca Hlth Ctr, Family Med Dept, Madrid 28017, Spain.
   [Velazquez, Ignacio] Guadix High Resolut Hosp, Pain Unit, Guadix 18500, Spain.
   [Calvo-Espinos, Claudio] Rioja Salud Fdn, Palliat Care Dept, La Rioja 26006, Spain.
   [Canovas, Maria L.; Rodriguez, Mireia] Ourense Hosp Complex, Anesthesiol Dept, Orense 32005, Spain.
   [Yanez, Jose A.] Carlos Haya Hosp, Nursery Dept, Malaga 29010, Spain.
   [Rodriguez, Mireia] Terrassa Hlth Consortium, Nursery Dept, Terrassa 08227, Spain.
   [Baquero, Jose L.] Spanish Forum Patients, Sci Coordinat, Madrid 28018, Spain.
   [Gallach, Elisa] La Fe Hosp, Psychol Dept, Valencia 46026, Spain.
   [Folch, Emma] Francoli Sociosanitary Hosp, Nursery Dept, Tarragona 43005, Spain.
   [Tuca, Albert] Barcelona Clin Hosp, Oncol Dept, Barcelona 08036, Spain.
   [Santina, Manel] Spanish Soc Qual Care, Oviedo 33003, Spain.
   [Mira, Jose J.] Alicante St Joan Hlth Dist, Alicante 03013, Spain.
C3 Universidad Miguel Hernandez de Elche; Virgen del Rocio University Hospital; Complexo Hospitalario Universitario de Ourense, Verin e O Barco de Valdeorras; Hospital Regional Universitario de Malaga
RP Guilabert, M (corresponding author), Miguel Hernandez Univ, Hlth Psychol Dept, Elche 03202, Spain.
EM concha.phte@gmail.com; jimmy.martind@umh.es; mvinuesa@salud.madrid.org; iborvidal@gmail.com; mguilabert@umh.es; jgcodina@outlook.es; cbeato@hotmail.com; jsanjin@semg.es; ignavel50@hotmail.com; clacales75@yahoo.es; maria.de.la.luz.canovas.martinez@sergas.es; jays56@yahoo.es; manel45545@gmail.com; jlbaquero@forodepacientes.org; gallach.eli@gmail.com; efolch.gipss@gencat.cat; atuca@clinic.cat; msantina@clinic.cat; jose.mira@umh.es
FU Ferrer International
CR American Society of Clinical Oncology, 2018, QOPI STAND MAN CERT, V0, P0
   Unknown -, 1986, CANC PAIN REL, V0, P0
   Babchuk WA, 2019, FAM MED COMMUNITY HE, V7, P0, DOI 10.1136/fmch-2018-000040
   Bennett MI, 2019, EUR J PAIN, V23, P660, DOI 10.1002/ejp.1346
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Cherny N, 2010, ANN ONCOL, V21, P362, DOI 10.1093/annonc/mdp318
   Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056
   Everdingen MHJVDBV, 2007, PAIN, V132, P312, DOI 10.1016/j.pain.2007.08.022
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Ferri, 2018, GUIA ABORDAJE INTERD, V0, P0
   Fiset VJ, 2019, INT J EVID-BASED HEA, V17, P92, DOI 10.1097/XEB.0000000000000160
   Gaertner J, 2017, BMJ-BRIT MED J, V358, P0, DOI 10.1136/bmj.j2925
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   Haun MW, 2017, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD011129.pub2
   Hui D, 2018, ESMO OPEN, V3, P0, DOI 10.1136/esmoopen-2018-000372
   Janjan N, 2014, J NATL COMPR CANC NE, V12, P1243, DOI 10.6004/jnccn.2014.0122
   Mira JJ, 2014, HEALTH EXPECT, V17, P826, DOI 10.1111/j.1369-7625.2012.00809.x
   Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840
   Shahi PK, 2007, AN MED INTERN, V24, P554
   Law E, 2019, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD009660.pub4
   Lema MJ, 2010, ONCOLOGIST, V15, P3, DOI 10.1634/theoncologist.2009-S505
   Mira J J, 2004, ATEN PRIMARIA, V34, P161, DOI 10.1157/13065823
   Paley CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.pub3
   Reis-Pina P, 2017, J PAIN RES, V10, P2097, DOI 10.2147/JPR.S139715
   Scarborough BM, 2018, CA-CANCER J CLIN, V68, P182, DOI 10.3322/caac.21453
   Smith TJ, 2015, MAYO CLIN PROC, V90, P1428, DOI 10.1016/j.mayocp.2015.08.009
   Weiner BJ, 2011, MED CARE RES REV, V68, P3, DOI 10.1177/1077558710372810
NR 27
TC 3
Z9 3
U1 0
U2 7
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND
SN 
EI 2075-4426
J9 J PERS MED
JI J. Pers. Med.
PD FEB 15
PY 2021
VL 11
IS 2
BP 
EP 
DI 10.3390/jpm11020102
PG 11
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA QN8OG
UT WOS:000622710900001
PM 33562456
DA 2026-01-16
ER

PT J
AU He, YH
   Xu, NG
   Zhang, HB
   Xue, CL
   Kang, FQ
   Wang, Q
   Li, JY
   Ge, L
   Guo, XF
AF He, Yi-Han
   Xu, Neng-Gui
   Zhang, Hai-Bo
   Xue, Chang-Li
   Kang, Fu-Qin
   Wang, Qi
   Li, Jie-Yun
   Ge, Long
   Guo, Xin-Feng
TI [Acupoint selection for cancer pain: based on current evidence and Delphi
SO Zhongguo zhen jiu = Chinese acupuncture & moxibustion
LA chi
DT Journal Article
DE Delphi method; acupoint selection; acupuncture; cancer pain; literature research
AB Based on literature research and Delphi expert consensus method, the important  acupoints for cancer pain was summarized to provide evidence basis for the  formulation of Clinical Practice Guide of Acupuncture in the Treatment of Cancer  Pain. Through systematic search of Chinese and English databases, 28 clinical  studies regarding acupuncture for cancer pain were included. The acupoint  selection methods and high-frequency acupoints were summarized and analyzed.  Based on this, a Delphi questionnaire was designed and two rounds of  questionnaire survey on 30 experts in acupuncture and tumor related fields in  China and abroad were conducted. As a result, it was suggested that the  individualized acupoint selection should be adopted for acupuncture treatment of  cancer pain, with Zusanli (ST 36), Hegu (LI 4), Taichong (LR 3), Sanyinjiao (SP  6), Yanglingquan (GB 34) and ashi points as the main acupoints. Combined with  clinical research evidence and expert consensus, the important acupoints for  cancer pain were identified. However, clinical acupoint selection still needed  further research and refinement.
C1 Second Affiliated Hospital of Guangzhou University of CM/Guangdong Hospital of TCM, Guangzhou 510120, China
   Second Clinical Medical College of GuangzhouUniversity of CM, Guangzhou 510120, Guangdong Province
   Royal Melbourne Instituteof Technology University, Melbourne 3083, Australia.
   South China Research Center for Acupuncture and Moxibustion, Guangzhou University of CM.
   Second Affiliated Hospital of Guangzhou University of CM/Guangdong Hospital of TCM, Guangzhou 510120, China
   Second Clinical Medical College of GuangzhouUniversity of CM, Guangzhou 510120, Guangdong Province.
   Second Affiliated Hospital of Guangzhou University of CM/Guangdong Hospital of TCM, Guangzhou 510120, China
   Second Clinical Medical College of GuangzhouUniversity of CM, Guangzhou 510120, Guangdong Province
   Royal Melbourne Instituteof Technology University, Melbourne 3083, Australia.
   Second Clinical Medical College of Guangzhou University of CM, Guangzhou 510120, Guangdong Province.
   Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University.
   Evidence-Based Medicine Research Center, School of Basic Medical Sciences, Lanzhou University.
   Key Laboratory of Evidence-Based Medicine and Clinical Transformation of Gansu Province.
   Second Affiliated Hospital of Guangzhou University of CM/Guangdong Hospital of TCM, Guangzhou 510120, China
   Second Clinical Medical College of GuangzhouUniversity of CM, Guangzhou 510120, Guangdong Province.
NR 0
TC 0
SN 
EI 0255-293
J9 Zhongguo Zhen Jiu
PD OCT 11
PY 2021
VL 41
IS 10
BP 1161
EP 5
DI 10.13703/j.0255-2930.20200831-k0002
PG -1156
WC Acupuncture Points; Acupuncture Therapy; Cancer Pain; therapy; Humans; Meridians; Neoplasms; complications; Publications
UT PubMed:34628751
PM 34628751
DA 2021-10-11
ER

PT J
AU Han, CH
   Liu, YJ
   Fan, HF
   Li, DH
   Guo, N
AF Han, Changhui
   Liu, Yingjuan
   Fan, Huanfang
   Li, Dehui
   Guo, Na
TI Acupuncture Relieves Opioid-Induced Constipation in Clinical Cancer Therapy-A Meta-Analysis and Systematic Review
SO CLINICAL EPIDEMIOLOGY
LA English
DT Review
DE acupuncture; opioid-induced constipation; cancer; pain; meta-analysis
ID patient assessment; management; pain; reliability; validity
AB Cancer pain is a common problem in clinical cancer therapy. Opioid analgesia is one of the most effective drugs for pain relief with satisfying performance besides the side effect of opioid-induced constipation (OIC). Acupuncture, as a Chinese traditional noninvasive intervention, has been applied to clinical cancer pain management and functional constipation therapy. However, only a few studies have adopted this treatment for OIC patients. Due to limited numbers of investigated subjects and variability of application methods, including treatment apparatus, acupoints, durations, and sessions, the interpretation of acupuncture's therapy effects from single-site randomized clinical trials (RCT) is limited. Therefore, we conducted a meta-analysis by collecting published data from Pubmed, Embase, Cochrane library, and Web of Science. Five RCTs focusing on the application of acupuncture with or without medication in OIC patients were included. An overall remission rate of 86.8% in the acupuncture-treated group was achieved, higher than the control group (78.9%; RR, 1.10, 95% CI [1.03, 1.18]). The symptom scores, reporting on defecation frequency, defecation straining, abdominal pain, defection time, and stool property, in acupuncture groups were lower than control groups with a standardized mean difference (SMD) of -2.21 [-4.15, -0.27]. The quality of life (QOL) for patients in the acupuncture treated group increased compared to the control group with reduced PAC-QOL scores (SMD, -1.02 [-1.78, -0.26]). Referring to the effects from pure acupuncture treatment (SMD, -0.43 [-0.83, -0.03]), the co-intervention of acupuncture and drugs (SMD, -1.77 [-2.51, -1.02]) improved the life quality of patients more remarkably (P < 0.05). Overall, our data confirmed the therapeutic effects of acupuncture in the treatment of OIC. The co-intervention of acupuncture with drugs improves the outcomes of OIC patients better than a single strategy. Combined therapy with both medicine and acupuncture has insightful potential for future clinical cancer patient management on constipation problems.
C1 [Han, Changhui; Fan, Huanfang; Li, Dehui; Guo, Na] Hebei Univ Tradit Chinese Med, Affiliated Hosp, Prov Hosp Tradit Chinese Med, Shijiazhuang, Hebei, Peoples R China.
   [Liu, Yingjuan] Univ Manchester, Inst Cardiovasc Sci, Manchester, Lancs, England.
C3 University of Manchester
RP Liu, YJ (corresponding author), Univ Manchester, 46 Grafton St, Manchester M13 9PT, Lancs, England.
EM liuyingjuan2008@gmail.com
FU Scientific Research Project of Hebei Administration of Traditional Chinese Medicine [2019030]
CR Unknown -, 2009, BMJ-BRIT MED J, V6, Pe1000097, DOI 10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1371/JOURNAL.PMED.1000097
   Australian New Zealand Clinical Trials Registry, 2009, REGISTRATION NUMBER, V0, P0
   Bell TJ, 2009, PAIN MED, V10, P35, DOI 10.1111/j.1526-4637.2008.00495.x
   Bharucha AE, 2016, MAYO CLIN PROC, V91, P1118, DOI 10.1016/j.mayocp.2016.06.003
   Cai H, 2019, J INT MED RES, V47, P6337, DOI 10.1177/0300060519874539
   Ceniceros S, 1998, SOUTH MED J, V91, P1121, DOI 10.1097/00007611-199812000-00005
   Chen YJ, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/5281039
   Chiu HY, 2017, EUR J CANCER CARE, V26, P0, DOI 10.1111/ecc.12457
   Daniali M, 2020, EXPERT REV GASTROENT, V14, P721, DOI 10.1080/17474124.2020.1781617
   Ernst G, 2003, COMPLEMENT THER MED, V11, P93, DOI 10.1016/S0965-2299(03)00004-9
   Fallon M, 2018, ANN ONCOL, V29, P166, DOI 10.1093/annonc/mdy152
   Gatti A, 2012, CLIN DRUG INVEST, V32, P293, DOI 10.2165/11598000-000000000-00000
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, P0, DOI 10.1136/bmj.d5928
   Hu CQ, 2016, EVID-BASED COMPL ALT, V2016, P0, DOI 10.1155/2016/1720239
   Hwang TY, 2019, EVID-BASED COMPL ALT, V2019, P0, DOI 10.1155/2019/3612587
   Lee BH, 2020, J ACUPUNCT MERIDIAN, V13, P71, DOI 10.1016/j.jams.2020.03.012
   Itoh Kazunori, 2009, COMPLEMENT THER CLIN PRACT, V15, P22, DOI 10.1016/j.ctcp.2008.09.003
   Jiang YL, 2010, CHINESE JOURNAL OF TRADITIONAL MEDICAL SCIENCE AND TECHNOLOGY, V17, P544, DOI 10.3969/j.issn.1005-7072.2010.06.059
   Liu Louis Wing Cheong, 2011, CAN J GASTROENTEROL, V25 Suppl B, P0
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Marquis P, 2005, SCAND J GASTROENTERO, V40, P540, DOI 10.1080/00365520510012208
   McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X
   MOR V, 1984, CANCER-AM CANCER SOC, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W
   Murad MH, 2019, BMJ-BRIT MED J, V364, P0, DOI 10.1136/bmj.k4817
   Neefjes ECW, 2019, BMC PALLIAT CARE, V18, P0, DOI 10.1186/s12904-019-0416-7
   Nikjooy A, 2018, IRAN J MED SCI, V43, P261
   Péus D, 2013, BMC MED INFORM DECIS, V13, P0, DOI 10.1186/1472-6947-13-72
   Portalatin Meredith, 2012, CLIN COLON RECTAL SURG, V25, P12, DOI 10.1055/s-0032-1301754
   Prichard David, 2016, BR J NURS, V25, PS4, DOI 10.12968/bjon.2016.25.10.s4
   Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628
   Shi YZ, 2019, TRIALS, V20, P0, DOI 10.1186/s13063-019-3433-1
   Song N, 2020, WORLD J ACUPUNCT-MOX, V30, P13, DOI 10.1016/j.wjam.2020.01.002
   Tao B, 2016, J TRADIT CHIN MED, V36, P578, DOI 10.1016/S0254-6272(16)30076-0
   Wang L, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/6137450
   Wang PM, 2019, SUPPORT CARE CANCER, V27, P3473, DOI 10.1007/s00520-019-4655-1
   Wang Y, 2019, THER ADV GASTROENTER, V12, P0, DOI 10.1177/1756284819881859
   Zhang Feng-Li, 2009, ZHONGGUO ZHONG XI YI JIE HE ZA ZHI, V29, P922
   Zhang T, 2013, AM J CHINESE MED, V41, P717, DOI 10.1142/S0192415X13500493
   Zhu HD, 2018, INTEGR CANCER THER, V17, P437, DOI 10.1177/1534735417734910
NR 40
TC 12
Z9 14
U1 3
U2 28
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1349
EI 
J9 CLIN EPIDEMIOL
JI Clin. Epidemiol.
PD JUN 15
PY 2021
VL 13
IS 
BP 907
EP 919
DI 10.2147/CLEP.S324193
PG 13
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA WE0ZY
UT WOS:000705359100002
PM 34629905
DA 2026-01-16
ER

PT J
AU Jazebi, N
   Evans, C
   Kadaru, HS
   Kompella, D
   Raji, M
   Fang, F
   Pappolla, M
   Tang, SJ
   Chung, JM
   Hammock, B
   Fang, X
AF Jazebi, Noushin
   Evans, Chad
   Kadaru, Hima S
   Kompella, Divya
   Raji, Mukaila
   Fang, Felix
   Pappolla, Miguel
   Tang, Shao-Jun
   Chung, Jin Mo
   Hammock, Bruce
   Fang, Xiang
TI HIV-related Neuropathy: Pathophysiology, Treatment and Challenges.
SO Journal of neurology and experimental neuroscience
LA English
DT Journal Article
DE HIV; neuropathy; pain; pathophysiology; treatment
AB HIV-sensory neuropathy (HIV-SN) is a debilitating complication in HIV patients  with or without anti-retroviral treatment (ART). Common symptoms of HIV-SN  include pain, decreased sensation, paresthesias, and dysesthesias in a symmetric  stocking-glove distribution. While HIV-1 protein such as gp120 is implicated in  HIV-SN (e.g. impaired large-diameter fiber), ART itself was recently shown to  contribute to HIV-SN in HIV patients and impair thin fiber. Multiple host  mechanisms may play roles during the pathogenesis of HIV-SN, including  neuron-glia interactions in the spinal dorsal horn (SDH), inflammation,  mitochondrial dysfunction and endoplasmic reticulum stress. Concurrent  infections, such as tuberculosis, also carry a higher likelihood of HIV-SN as  well as environmental or genetic predisposition. Pro-inflammatory cytokines such  as IL-1, IL2 receptor-alpha, and tumor necrosis factor (TNF) along with abnormal  lactate levels have been identified as potential players within the complex  pathophysiology of this condition. In this paper, we review the pathophysiology  of HIV neuropathy, focusing on the various treatment options available or under  investigation. Although several treatment options are available e.g., the  capsaicin patch and spinal cord stimulation, symptomatic control of HIV-SN are  often challenging. Alternative approaches such as self-hypnosis, resistance  exercise, cannabinoids, and acupuncture have all shown promising results, but  need further investigation.
C1 Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Medicine, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neuroscience & Cell Biology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neuroscience & Cell Biology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Neuroscience & Cell Biology, University of Texas Medical Branch, Galveston, TX 77555.
   Department of Entomology and Nematology & Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA.
   Department of Neurology, University of Texas Medical Branch, Galveston, TX 77555.
NR 0
TC 0
SN 2469-407
EI 2469-407
J9 J Neurol Exp Neurosci
PD JAN 1
PY 2021
VL 7
IS 1
BP 15
EP 24
DI 10.17756/jnen.2021-082
PG 9
UT PubMed:35252633
PM 35252633
DA 2021-01-01
ER

PT J
AU Oberoi, DV
   Longo, CJ
   Reed, EN
   Landmann, J
   Piedalue, KAL
   Carlson, LE
AF Oberoi, Devesh V.
   Longo, Christopher J.
   Reed, Erica Nicole
   Landmann, Jessa
   Piedalue, Katherine-Ann Laura
   Carlson, Linda E.
TI Cost-Utility of Group Versus Individual Acupuncture for Cancer-Related Pain Using Quality-Adjusted Life Years in a Noninferiority Trial
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
DE oncology; acupuncture; group acupuncture; cost&#8211; utility analysis; quality of life; out-of-pocket costs for cancer care
AB Introduction: Individual acupuncture (AP) is the gold standard method of AP delivery for cancer-related pain; however, costs can be prohibitive. Group AP allows four to six patients to be treated in a single session. This study sought to examine the cost-utility of group AP compared with individual AP from a patient perspective. Materials and Methods: Effectiveness and cost data from a noninferiority randomized trial of group versus individual AP for cancer-related pain were used. In the trial, 74 patients were randomly assigned to individual or group AP treatments twice per week for 6 weeks. The EuroQol five-dimension five level questionnaire (EQ-5D-5L) was used to assess health-related quality of life, and the EQ-5D Utility Index was used as a composite measure constituted of five domains (mobility, self-care, usual activities, anxiety-depression, and pain-discomfort). Linear mixed models were used to compare the change in EQ-5D-5L states pre-post intervention between the two arms. A cost-utility analysis was performed in terms of the incremental costs per additional quality-adjusted life year (QALY) gained. Results: Group AP participants experienced more significant relief in the pain-discomfort subscale of the EQ-5D-5L measure compared with individual AP participants (group x time, F = 6.18; p = 0.02). The effect size on pain-discomfort for group AP (d = 0.80) was higher than that of individual AP (d = 0.34). There were no significant differences between the two study arms for other subscales of the EQ-5D-5L over time. QALYs at 6 weeks were slightly higher for group AP (0.020) compared with individual AP (0.007) leading to an incremental QALY gained by the group arm of 0.013, but this difference was not statistically significant (p = 0.07). The cost of delivering AP treatment for the group arm over 6 weeks ($201.25) was nearly half of the individual arm ($400). Conclusions: Group AP was superior to individual AP in cancer patients. These findings have implications for the use of group AP in low-resource settings and in health care systems where AP for cancer patients is not covered by public health insurance. ClinicalTrials.gov (NCT03641222). Registered July 10, 2018-Retrospectively registered, https://clinicaltrials.gov/ct2/show/study/NCT03641222
C1 [Oberoi, Devesh V.; Reed, Erica Nicole; Piedalue, Katherine-Ann Laura; Carlson, Linda E.] Univ Calgary, Cumming Sch Med, Div Psychosocial Oncol, Dept Oncol, Calgary, AB, Canada.
   [Oberoi, Devesh V.; Piedalue, Katherine-Ann Laura; Carlson, Linda E.] Holy Cross Ctr Phase I, Dept Psychosocial Oncol, Canc Control Alberta, 2202 2nd St SW, Calgary, AB T2S 3C1, Canada.
   [Longo, Christopher J.] McMaster Univ, DeGroote Sch Business, Hamilton, ON, Canada.
   [Landmann, Jessa] Vive Integrat Hlth Grp, Calgary, AB, Canada.
C3 University of Calgary; McMaster University
RP Carlson, LE (corresponding author), Holy Cross Ctr Phase I, Dept Psychosocial Oncol, Canc Control Alberta, 2202 2nd St SW, Calgary, AB T2S 3C1, Canada.
EM lcarlso@ucalgary.ca
FU Enbridge Research Chair in Psychosocial Oncology - Canadian Cancer Society Alberta/NWT Division; Alberta Cancer Foundation
CR Anderson KO, 2002, CANCER, V94, P2295, DOI 10.1002/cncr.10414
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Blom M, 1996, ORAL ONCOL, V32B, P182
   Chao MT, 2012, J ALTERN COMPLEM MED, V18, P561, DOI 10.1089/acm.2011.0128
   Choi TY, 2012, SUPPORT CARE CANCER, V20, P1147, DOI 10.1007/s00520-012-1432-9
   Chuang E, 2018, J ALTERN COMPLEM MED, V24, P336, DOI 10.1089/acm.2017.0262
   CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902
   Craig BM, 2010, PAIN MED, V11, P240, DOI 10.1111/j.1526-4637.2009.00762.x
   Cui Y, 2004, BREAST CANCER RES TR, V85, P263, DOI 10.1023/B:BREA.0000025422.26148.8d
   Deng G, 2005, CA-CANCER J CLIN, V55, P109, DOI 10.3322/canjclin.55.2.109
   DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508
   Feelemyer JP, 2014, DRUG ALCOHOL DEPEN, V134, P251, DOI 10.1016/j.drugalcdep.2013.10.011
   Fisch MJ, 2012, J CLIN ONCOL, V30, P1980, DOI 10.1200/JCO.2011.39.2381
   Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482
   Green CR, 2011, CANCER-AM CANCER SOC, V117, P1994, DOI 10.1002/cncr.25761
   Green CR, 2003, J PAIN, V4, P29, DOI 10.1054/jpai.2003.5
   Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Herbert MS, 2017, J PAIN, V18, P200, DOI 10.1016/j.jpain.2016.10.014
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Johnstone PAS, 2001, INT J RADIAT ONCOL, V50, P353, DOI 10.1016/S0360-3016(00)01530-3
   Julious SA, 2004, STAT MED, V23, P1921, DOI 10.1002/sim.1783
   Lafferty WE, 2004, CANCER-AM CANCER SOC, V100, P1522, DOI 10.1002/cncr.20105
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   McKee MD, 2020, J GEN INTERN MED, V35, P1227, DOI 10.1007/s11606-019-05583-6
   Morris KT, 2000, AM J SURG, V179, P407, DOI 10.1016/S0002-9610(00)00358-5
   PALEY CA, 2015, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD007753.PUB3
   Ramsey S, 2013, HEALTH AFFAIR, V32, P1143, DOI 10.1377/hlthaff.2012.1263
   Reed EN, 2020, EVID-BASED COMPL ALT, V2020, P0, DOI 10.1155/2020/7209548
   Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9
   Running A, 2012, CURR PAIN HEADACHE R, V16, P325, DOI 10.1007/s11916-012-0275-x
   Sculpher MJ, 2006, HEALTH ECON, V15, P677, DOI 10.1002/hec.1093
   Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Tippens KM, 2013, BMC COMPLEM ALTERN M, V13, P0, DOI 10.1186/1472-6882-13-293
   Vickers AJ, 2004, J CLIN ONCOL, V22, P1731, DOI 10.1200/JCO.2004.04.102
   Vinjamury SP, 2013, CHIN MED-UK, V8, P0, DOI 10.1186/1749-8546-8-15
   Winkelmayer WC, 2003, CONTEMP CARDIOL, V0, P329
   Wong RKW, 2003, INT J RADIAT ONCOL, V57, P472, DOI 10.1016/S0360-3016(03)00572-8
   Zhang Y, 2007, EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, V2012, P8, DOI 10.1155/2012/710750
NR 40
TC 5
Z9 8
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1075-5535
EI 1557-7708
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD MAY 1
PY 2021
VL 27
IS 5
BP 390
EP 397
DI 10.1089/acm.2020.0386
EA APR 2021
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA SD2FV
UT WOS:000644564100001
PM 33904784
DA 2026-01-16
ER

PT J
AU Zhou, X
   Cao, SG
   Tan, XJ
   Liu, XD
   Li, ZQ
   Kong, LX
   Tian, YL
   Liu, D
   Shen, S
   Sun, YQ
   Jiang, HT
   Zhou, YB
AF Zhou, Xin
   Cao, Shou-Gen
   Tan, Xiao-Jie
   Liu, Xiao-Dong
   Li, Ze-Qun
   Kong, Ling-Xin
   Tian, Yu-Long
   Liu, Dan
   Shen, Shuai
   Sun, Yu-Qi
   Jiang, Hai-Tao
   Zhou, Yan-Bing
TI Effects of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Postoperative Recovery in Patients with Gastric Cancer: A Randomized Controlled Trial
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE stomach neoplasms; acupuncture therapy; enhanced recovery after surgery; pain management; gastrointestinal function
ID induced nausea; electroacupuncture; acupuncture; analgesia; surgery; pain; mechanisms; release
AB Purpose: Transcutaneous electrical acupoint stimulation (TEAS) is an innovative choice for postoperative pain management. However, the safety and effectiveness of this traditional Chinese medicine (TCM) therapy for patients who underwent gastrectomy is largely unknown. So, the purpose of this study is to evaluate the safety and effectiveness of TEAS for patients who underwent gastrectomy. Patients and Methods: We recruited 96 patients with gastric cancer from May 2019 to November 2019; 82 patients were enrolled, and 81 patients completed. Patients were randomly assigned to TEAS group (TG) received TEAS on postoperative day (POD) 1-3 or control group (CG) at a 1:1 ratio. The primary outcomes were pain score and consumption of analgesics. The secondary were the time of first postoperative flatus and defecation, frequency of postoperative nausea, vomiting, distention, diarrhea, comfort of semi-fluid diet, Clavien-Dindo grade (C-D grade) and length of postoperative day. We performed hematological analysis to explore the possible mechanisms. Results: Overall, 81 patients were enrolled included in the analysis. Compared with CG, pain scores in TG were lower on POD 1-5 (average: 2.55 +/- 0.21 vs 3.10 +/- 0.42, P<0.001), and the use rate of opioids was lower (43.9 vs 75.0, P=0.004); time of first postoperative flatus (55.63 +/- 16.74 vs 72.60 +/- 20.92, P<0.001) and defecation (72.20 +/- 16.24 vs 95.78 +/- 17.75, P<0.001) were shorter; the frequency of nausea were fewer (1.88 +/- 1.09 vs 2.58 +/- 0.77, P=0.029) and patients were more comfortable with semi-fluid diet (7.63 +/- 0.63 vs 6.93 +/- 0.69, P<0.001); among the hematologic results, beta-endorphin (beta-End), interleukin-2 (IL-2), motilin (MTL) on POD 3, POD 5 were lower, 5-hydroxytryptamine (5-HT), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) were higher. And no adverse event was reported. Conclusion: TEAS can relieve postoperative pain and promote the recovery of gastrointestinal function. Consequently, it can be an adjunctive therapy to enhance postoperative recovery for patients after gastrectomy.
C1 [Zhou, Xin; Cao, Shou-Gen; Tan, Xiao-Jie; Liu, Xiao-Dong; Li, Ze-Qun; Tian, Yu-Long; Liu, Dan; Shen, Shuai; Sun, Yu-Qi; Jiang, Hai-Tao; Zhou, Yan-Bing] Qingdao Univ, Dept Gastrointestinal Surg, Affiliated Hosp, 16 Jiangsu Rd, Qingdao, Shandong, Peoples R China.
   [Kong, Ling-Xin] Qingdao Univ, Dept Rehabil, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University
RP Zhou, YB (corresponding author), Qingdao Univ, Dept Gastrointestinal Surg, Affiliated Hosp, 16 Jiangsu Rd, Qingdao, Shandong, Peoples R China.
EM zhouyanbing999@aliyun.com
CR Aarts MA, 2018, ANN SURG, V267, P992, DOI 10.1097/SLA.0000000000002632
   Alazawi W, 2016, ANN SURG, V264, P73, DOI 10.1097/SLA.0000000000001691
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Cabioglu MT, 2008, AM J CHINESE MED, V36, P25, DOI 10.1142/S0192415X08005552
   Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9
   Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3
   Groppetti D, 2011, BRIT J ANAESTH, V107, P612, DOI 10.1093/bja/aer199
   Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019
   Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1
   Hughes MJ, 2014, JAMA SURG, V149, P1224, DOI 10.1001/jamasurg.2014.210
   Janicki PK, 2014, EXP BRAIN RES, V232, P2613, DOI 10.1007/s00221-014-3968-z
   Johnson MI, 2019, BMJ OPEN, V9, P0, DOI 10.1136/bmjopen-2019-029999
   Kehlet H, 1997, BRIT J ANAESTH, V78, P606, DOI 10.1093/bja/78.5.606
   Kehlet H, 2018, PAIN, V159, PS11, DOI 10.1097/j.pain.0000000000001243
   Kim HH, 2014, J CLIN ONCOL, V32, P627, DOI 10.1200/JCO.2013.48.8551
   Lee S, 2013, CHIN J INTEGR MED, V19, P277, DOI 10.1007/s11655-013-1425-7
   Lin JG, 2008, AM J CHINESE MED, V36, P635, DOI 10.1142/S0192415X08006107
   Ng SSM, 2013, GASTROENTEROLOGY, V144, P307, DOI 10.1053/j.gastro.2012.10.050
   Patil S, 2016, CURR PAIN HEADACHE R, V20, P0, DOI 10.1007/s11916-016-0552-1
   Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908
   STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506
   Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9
   Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6
   Wang H, 2014, BRIT J ANAESTH, V112, P1075, DOI 10.1093/bja/aeu001
   Wang Y, 2005, EXP NEUROL, V192, P156, DOI 10.1016/j.expneurol.2004.11.003
   Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898
   Wu CL, 2011, LANCET, V377, P2215, DOI 10.1016/S0140-6736(11)60245-6
   Yu XD, 2020, TRIALS, V21, P0, DOI 10.1186/s13063-019-3892-4
   Zhang B, 2018, AM J GASTROENTEROL, V113, P1026, DOI 10.1038/s41395-018-0156-y
   Zhang Q, 2014, ANAESTHESIA, V69, P832, DOI 10.1111/anae.12639
   Zhang RX, 2014, ANESTHESIOLOGY, V120, P482, DOI 10.1097/ALN.0000000000000101
   Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004
NR 32
TC 40
Z9 46
U1 6
U2 48
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
EI 
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PD JUN 15
PY 2021
VL 13
IS 
BP 1449
EP 1458
DI 10.2147/CMAR.S292325
PG 10
WC Oncology
SC Oncology
GA QI8ZD
UT WOS:000619274800001
PM 33603487
DA 2026-01-16
ER

PT J
AU Larbi, OM
   Jiang, C
   McLane, B
   Wang, GM
   Daunov, K
   Hobson, SM
   Daly, B
   Mazanec, SR
   Feyes, D
   Rodgers-Melnick, S
   Li, M
   Momotaz, H
   Lee, RT
AF Larbi, Olivia M.
   Jiang, Cherry
   McLane, Bethanny
   Wang, Gi-Ming
   Daunov, Katherine
   Hobson, Sean M.
   Daly, Barbara
   Mazanec, Susan R.
   Feyes, Denise
   Rodgers-Melnick, Samuel
   Li, Ming
   Momotaz, Hasina
   Lee, Richard T.
TI Interest and Willingness to Pay for Integrative Therapies of Patients With Cancer and Caregivers
SO JCO ONCOLOGY PRACTICE
LA English
DT Article; Proceedings Paper
ID alternative medicine; financial toxicity; complementary; pain
AB PURPOSE Complementary and integrative medicine (CIM) services are more prevalent in cancer centers but continue to be underutilized by patients. This study examines perspectives from patients and caregivers about these services being offered at a comprehensive cancer center. METHODS Patients and caregivers were surveyed about their familiarity, interest, and experience with five CIM therapies: acupuncture, massage, meditation, music therapy, and yoga. Respondents were also asked about their interest when recommended by their medical team and when offered in a clinical trial as well as their willingness to pay for these services. Respondents were also asked about perceived barriers to accessing these services. Chi-squared tests were performed to explore associations between past experience, interest levels, and willingness to pay. RESULTS A total of 576 surveys were obtained (464 patients and 112 caregivers). Most respondents identified as White or Caucasian (65.6%), female (57.2%), had been a patient for < 3 years (74.2%), had some college education (73.8%), and made > $40,000 in US dollars as their annual household income (69.1%). Respondents were most familiar with therapeutic massage (34.2%) and least familiar with acupuncture (20.0%). The average interest in these services increased from 53.3% to 64.1% when recommended by a medical professional. Respondents were most willing to pay $1-60 for therapeutic massage (62.3%) and least willing to pay for meditation (43.7%). The main barriers to accessing CIM services were cost (56.0%) and lack of knowledge (52.1%). CONCLUSION Overall, a significant proportion of patients and caregivers were unfamiliar with these five integrative therapies. Increasing education, decreasing cost, and a recommendation by medical professionals would improve CIM usage. (C) 2021 by American Society of Clinical Oncology
C1 [Larbi, Olivia M.; Jiang, Cherry; Wang, Gi-Ming; Daly, Barbara; Mazanec, Susan R.; Li, Ming; Momotaz, Hasina] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [McLane, Bethanny; Daunov, Katherine; Hobson, Sean M.; Rodgers-Melnick, Samuel; Lee, Richard T.] Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA.
   [Feyes, Denise; Lee, Richard T.] Case Western Reserve Univ, Comprehens Canc Ctr, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University System of Ohio; Case Western Reserve University
RP Lee, RT (corresponding author), Univ Hosp Seidman Canc Ctr, Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.; Lee, RT (corresponding author), Univ Hosp Seidman Canc Ctr, Support & Integrat Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA.; Lee, RT (corresponding author), Case Western Reserve Univ, Sch Med, Integrat Oncol, 11100 Euclid Ave, Cleveland, OH 44106 USA.
EM Richard.T.Lee@case.edu
FU University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,; Helen Moss Foundation-Schoff Family Professorship in Integrative Oncology
CR Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548
   Carrera PM, 2018, CA-CANCER J CLIN, V68, P153, DOI 10.3322/caac.21443
   Chou R, 2017, ANN INTERN MED, V166, P493, DOI 10.7326/M16-2459
   Dusek JA, 2018, J ALTERN COMPLEM MED, V24, P557, DOI 10.1089/acm.2017.0203
   Horrigan B, 2012, GLOBAL ADV HLTH MED, V1, P18, DOI 10.7453/gahmj.2012.1.3.006
   Liou KT, 2019, PAIN MED, V20, P2060, DOI 10.1093/pm/pnz087
   Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721
   Mao JJ, 2011, J CANCER SURVIV, V5, P8, DOI 10.1007/s11764-010-0153-7
   Montross-Thomas LP, 2017, J ALTERN COMPLEM MED, V23, P259, DOI 10.1089/acm.2016.0288
   Sherman Karen J, 2004, BMC COMPLEMENT ALTERN MED, V4, P9, DOI 10.1186/1472-6882-4-9
   Swarm RA, 2019, J NATL COMPR CANC NE, V17, P977, DOI 10.6004/jnccn.2019.0038
   Zafar SY, 2013, ONCOLOGIST, V18, P381, DOI 10.1634/theoncologist.2012-0279
NR 12
TC 14
Z9 14
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2688-1527
EI 2688-1535
J9 JCO ONCOL PRACT
JI JCO Oncol. Pract.
PD NOV 15
PY 2021
VL 17
IS 11
BP 672
EP +
DI 10.1200/OP.20.00471
PG 10
WC Oncology
SC Oncology
GA ZC1JK
UT WOS:000757284900006
PM 33492981
DA 2026-01-16
ER

PT J
AU Bao, T
   Baser, R
   Chen, C
   Weitzman, M
   Zhang, YL
   Seluzicki, C
   Li, QS
   Piulson, L
   Zhi, WI
AF Bao, Ting
   Baser, Raymond
   Chen, Connie
   Weitzman, Matthew
   Zhang, Yi Lily
   Seluzicki, Christina
   Li, Qing Susan
   Piulson, Lauren
   Zhi, W Iris
TI Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced
SO The oncologist
LA English
DT Journal Article
DE Acupuncture; Anxiety; Cancer; Insomnia; Neuropathy; Quality of life
AB BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) is a common,  debilitating adverse effect of neurotoxic chemotherapy that significantly worsens  the quality of life of cancer survivors. MATERIALS AND METHODS: Survivors of  solid tumors with persistent moderate-to-severe CIPN defined as numbness,  tingling, or pain rated ≥4 on an 11-point numeric rating scale (NRS) were  randomized in a 1:1:1 ratio to 8 weeks of real acupuncture (RA) versus sham  acupuncture (SA) versus usual care (UC). We previously reported the primary  endpoint (NRS); here we report the following health-related quality of life  endpoints: Functional Assessment of Cancer Therapy/Gynecologic Oncology  Group-Neurotoxicity (FACT/GOG-Ntx), Hospital Anxiety and Depression Scale (HADS),  Insomnia Severity Index (ISI), and Brief Fatigue Inventory (BFI). For each  endpoint, the mean changes from baseline and 95% confidence intervals were  estimated within each arm and compared between arms using linear mixed models.  RESULTS: We enrolled 75 survivors of solid tumors with moderate-to-severe CIPN  into the study. Compared with baseline, at week 8, FACT/GOG-Ntx, HADS anxiety,  and ISI scores significantly improved in RA and SA, but not in UC. Compared with  UC, at week 8, FACT/GOG-Ntx scores significantly increased in RA and SA arms  indicating improved CIPN-related symptoms and quality of life (p = .001 and  p = .01). There was no statistically significant difference between RA and SA.  There was no difference in HADS depression or BFI among RA, SA, and UC at weeks 8  and 12. CONCLUSION: Acupuncture may improve CIPN-related symptoms and quality of  life in cancer survivors with persistent CIPN. Further large sample size studies  are needed to delineate placebo effects. IMPLICATIONS FOR PRACTICE: The authors  conducted a randomized sham acupuncture- and usual care-controlled clinical trial  to evaluate the impact of acupuncture on health-related quality of life outcomes  in patients with solid tumors with chemotherapy-induced peripheral neuropathy  (CIPN). Statistically significant improvements in quality of life, anxiety,  insomnia, and fatigue were achieved with 8 weeks of real acupuncture when  compared with baseline, without statistically significant differences between  real and sham acupuncture. These findings suggest that acupuncture may be  effective for improving CIPN-related symptoms and quality of life and reducing  anxiety and insomnia in cancer survivors with persistent CIPN, with further study  needed to delineate placebo effects.
C1 Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Epidemiology and Biostatics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Department of Medicine, New York University Winthrop Hospital, Mineola, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Integrative Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
   Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Commack, New York, USA.
NR 0
TC 0
SN 1549-490
EI 1083-715
J9 Oncologist
PD AUG 15
PY 2021
VL 26
IS 11
BP e2070
EP e2078
DI 10.1002/onco.13933
PG 1
WC Acupuncture Therapy; Antineoplastic Agents; adverse effects; Cancer Survivors; Female; Humans; Neoplasms; drug therapy; Peripheral Nervous System Diseases; chemically induced; Quality of Life
UT PubMed:34390283
PM 34390283
DA 2021-08-15
ER

PT J
AU Zeng, JC
   Zhang, RL
   Wei, XJ
   Lin, GH
AF Zeng, Jing-Chun
   Zhang, Rui-Lin
   Wei, Xiao-Jing
   Lin, Guo-Hua
TI Acupuncture for improving a case of widespread herpes zoster after non-Hodgkin's
SO Explore (New York, N.Y.)
LA English
DT Journal Article
DE Acupuncture; Alternative therapy; Chemotherapy; Herpes zoster; Non-Hodgkin's lymphoma; Varicella Zoster Virus
AB BACKGROUND: Herpes zoster presents as clustered blisters on one side of the body,  accompanied by nerve pain. This is caused by reactivation of the varicella zoster  virus, and it occurs primarily in people with weakened immunity. Tumor and  chemotherapy drugs can impair the patient's immune function, induce herpes zoster  and prolong the course of disease.In these patients, skin changes can last for  months and blisters can recur and cause serious complications such as  postherpetic neuralgia.Acupuncture is a common alternative therapy for herpes  zoster in East Asia. CASE PRESENTATION: We report a case of an elderly male  patient with widespread herpes zoster in the trunk after non-Hodgkin's lymphoma  chemotherapy. The patient had received conventional treatment with valaciclovir  and mecobalamin within 24 hours of symptom onset. Because neither the clustered  blisters nor the nerve pain were improved a week later, acupuncture and related  techniques were applied. These included electro-acupuncture, surrounding  acupuncture, fire acupuncture, and cupping. The patient recovered 20 days after  the herpes zoster attack, and there were no adverse reactions during the  treatment process. CONCLUSIONS: This case suggests that acupuncture and related  techniques are effective interventions for this condition.This case report is  innovative because it shows that acupuncture as an adjuvant treatment can improve  the skin lesions in patients with HZ after tumour chemotherapy, relieve pain, and  shorten the course of HZ.
C1 First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China. 
   First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
   Guangzhou University of Chinese Medicine, Guangzhou, China.
   First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
EM tcmlin-801@163.com
NR 0
TC 0
SN 1878-754
EI 
J9 Explore (NY)
PD AUG 22
PY 2021
VL 18
IS 5
BP 608
EP 611
DI 10.1016/j.explore.2021.08.003
PG 3
WC Acupuncture Therapy; Aged; Blister; Herpes Zoster; Herpesvirus 3, Human; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Neuralgia
UT PubMed:34417113
PM 34417113
DA 2021-08-22
ER

PT J
AU Han, QQ
   Fu, Y
   Le, JM
   Ma, YJ
   Wei, XD
   Ji, HL
   Jiang, H
   Gao, Y
   Wu, H
AF Han, Qiu-Qin
   Fu, Yi
   Le, Jia-Mei
   Ma, Yu-Jie
   Wei, Xin-Dong
   Ji, Hou-Lin
   Jiang, Haochen
   Gao, Yueqiu
   Wu, Hailong
TI The Therapeutic Effects of Acupuncture and Electroacupuncture on Cancer-related
SO Journal of Cancer
LA English
DT Review
DE acupuncture; cancer; chemotherapy; electroacupuncture; pain; surgery
AB In addition to cancer-related death, malignant progression also leads to a series  of symptoms and side-effects, which would detrimentally affect cancer patients'  the quality of life, adversely influence their adherence to treatments, and,  therefore, negatively affect their long-term survival. Acupuncture and  electroacupuncture (EA), as two classic treatment methods in traditional Chinese  medicine, have been widely employed to cure various diseases. Recently, the  clinical application of acupuncture and EA in cancer patients has received great  attention. In this review, we summarized the clinical application of acupuncture  and EA in alleviating the cancer symptoms, reducing the cancer treatment-related  side-effects, and relieving the cancer pain. The symptoms and side-effects  discussed in this review include fatigue, insomnia, chemotherapy-associated  dyspepsia syndrome (CADS), pain, xerostomia, and anxiety and depression. The  underlying mechanisms of the therapeutic effects of acupuncture and EA might be  related to the regulation of the mitochondrial function, coordination of the  activity of the nervous system, adjustment of the production of  neurotransmitters, and alleviation of the immune responses. In conclusion,  acupuncture and EA have been proved to be beneficial for cancer patients. More  research, however, is required to clarify the potential mechanisms behind  acupuncture and EA for widespread adoption in clinical application.
C1 Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
   Institute of Clinical Immunology, Department of Liver Diseases, Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of TraditionalChinese Medicine, Shanghai 200021, China.
   Laboratory of Cellular Immunity, Shuguang Hospital Affiliated to Shanghai 
   Institute of Clinical Immunology, Department of Liver Diseases, Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of TraditionalChinese Medicine, Shanghai 200021, China.
   Laboratory of Cellular Immunity, Shuguang Hospital Affiliated to Shanghai 
   Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China.
   Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine & 
   Collaborative Innovation Center for Biomedicine, Shanghai University of Medicine & Health Sciences, Shanghai 201318, China.
NR 0
TC 0
SN 1837-966
EI 1837-966
J9 J Cancer
PD NOV 4
PY 2021
VL 12
IS 23
BP 7003
EP 7009
DI 10.7150/jca.55803
PG 6
UT PubMed:34729102
PM 34729102
DA 2021-11-04
ER

PT J
AU Youn, I
   Cheong, MJ
   Kim, J
   Kim, SI
   Kim, HK
   Kwon, M
   Seo, J
   Nam, D
   Leem, J
AF Youn, Inae
   Cheong, Moon Joo
   Kim, Jinwon
   Kim, Soo Im
   Kim, Hye Kyung
   Kwon, Miri
   Seo, Joohee
   Nam, Dongwoo
   Leem, Jungtae
TI Understanding the experiences and perception of people living with HIV on integrative traditional East Asian medicine management in Korea: an interview protocol for qualitative research
SO BMJ OPEN
LA English
DT Article
ID alternative medicine; immune reconstitution; hiv/aids; complementary; acupuncture; pain; information; survival; cancer; aids
AB Introduction Patients with HIV/AIDS have been able to experience the average life expectancy of the general population due to medical advancements. However, they face physical, emotional and social difficulties that worsen their quality of life. The pharmacological approach is often the first choice to address these issues, but it involves some limitations. Integrative traditional East Asian medicine (ITEAM) can compensate for the limitations of drugs and can be applied to treat physiological and psychiatric problems. In Korea, ITEAM interventions are easily accessible under the government insurance. However, the experiences, perceptions and barriers to the use of ITEAM in patients with HIV/AIDS are less studied. Therefore, we will interview them to explore their experiences and examine the strengths, limitations, barriers and improvements in the use of ITEAM. Methods and analysis This is a qualitative study using a phenomenological framework. We will conduct one-to-one interviews with 3-10 patients with HIV/AIDS who have been treated with ITEAM from March 2021 to January 2022. We will present semistructured open-ended questions and analyse them using experiential phenomenological research methods. The results will be reported in accordance with the Consolidated Criteria for Reporting Qualitative Studies. Ethics and dissemination This research was approved by the Institutional Review Board of the National Medical Center (IRB number, NMC-2101-008). The results of this study will be disseminated through journal articles, newspapers and conference proceedings.
C1 [Youn, Inae; Kwon, Miri] Kyung Hee Univ, Clin Korean Med, Seoul, South Korea.
   [Youn, Inae] Natl Med Ctr, Dept Acupuncture & Moxibust, Seoul, South Korea.
   [Cheong, Moon Joo] Wankwang Univ, Jangheung Integrat Med Hosp, Rare Dis Integrated Treatment Res Ctr, Jeonju, South Korea.
   [Kim, Jinwon] Natl Med Ctr, Dept Internal Korean Med, Seoul, South Korea.
   [Kim, Soo Im] Dankook Univ, Dept Counseling, Gyeonggi, South Korea.
   [Kim, Hye Kyung] Psychol Counseling Off, LG Elect Gasan Res & Dev Campus, Seoul, South Korea.
   [Seo, Joohee] Natl Med Ctr, Dept Korean Neuropsychiatry, Seoul, South Korea.
   [Nam, Dongwoo] Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, Seoul, South Korea.
   [Leem, Jungtae] Wonkwang Univ, Res Ctr Tradit Korean Med, Jeollabuk, South Korea.
C3 Kyung Hee University; National Medical Center - Korea; National Medical Center - Korea; Dankook University; National Medical Center - Korea; Kyung Hee University; Wonkwang University
RP Nam, D (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Acupuncture & Moxibust, Seoul, South Korea.; Leem, J (corresponding author), Wonkwang Univ, Res Ctr Tradit Korean Med, Jeollabuk, South Korea.
EM hanisanam@daum.net; julcho@naver.com
FU National Medical Center, Republic of Korea [NMC2020-PR-007]
CR Amorim D, 2018, COMPLEMENT THER CLIN, V31, P31, DOI 10.1016/j.ctcp.2018.01.008
   Anastasi Joyce K, 2010, EJOM, V6, P40
   Anastasi JK, 2013, J ASSOC NURSE AIDS C, V24, P268, DOI 10.1016/j.jana.2012.09.006
   Arias-Colmenero T, 2020, INT J ENV RES PUB HE, V17, P0, DOI 10.3390/ijerph17020639
   Barbier F, 2020, INTENS CARE MED, V46, P329, DOI 10.1007/s00134-020-05945-3
   Brandt CP, 2016, AIDS CARE, V28, P432, DOI 10.1080/09540121.2015.1100704
   Chang BH, 2011, ACUPUNCT MED, V29, P180, DOI 10.1136/acupmed-2011-010026
   Cho HY, 2017, APPL CLIN INFORM, V8, P348, DOI 10.4338/ACI-2016-10-R-0175
   Cooper V, 2017, HEALTH QUAL LIFE OUT, V15, P0, DOI 10.1186/s12955-017-0778-6
   Deng G, 2019, CANCER J, V25, P343, DOI 10.1097/PPO.0000000000000399
   Drewes Jochen, 2013, J INT ASSOC PROVID AIDS CARE, V12, P18, DOI 10.1177/1545109712456429
   DUKES S, 1984, J RELIG HEALTH, V23, P197, DOI 10.1007/BF00990785
   Ezeamama AE, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000002525
   Finkelstein JL, 2015, J INT AIDS SOC, V18, P0, DOI 10.7448/IAS.18.1.19033
   Gallo RC, 2003, NEW ENGL J MED, V349, P2283, DOI 10.1056/NEJMp038194
   Gardner AT, 2016, MEDICINE, V95, P0, DOI 10.1097/MD.0000000000005021
   Garner BK, 2018, MED ACUPUNCT, V30, P262, DOI 10.1089/acu.2018.1294
   Halpin SN, 2018, AIDS BEHAV, V22, P848, DOI 10.1007/s10461-017-1866-7
   Harris TG, 2018, AIDS, V32, P1563, DOI 10.1097/QAD.0000000000001870
   Jin YT, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/282819
   Leem J, 2021, INTEGR MED RES, V10, P0, DOI 10.1016/j.imr.2020.100430
   Li MX, 2020, COMPLEMENT THER MED, V50, P0, DOI 10.1016/j.ctim.2019.102202
   Lim B, 2013, INTEGR MED RES, V2, P81, DOI 10.1016/j.imr.2013.06.004
   Liu ZB, 2015, INFECT DIS POVERTY, V4, P0, DOI 10.1186/s40249-015-0093-6
   Liu ZB, 2015, J TRADIT CHIN MED, V35, P473, DOI 10.1016/S0254-6272(15)30127-8
   Lorenc A, 2013, AIDS PATIENT CARE ST, V27, P503, DOI 10.1089/apc.2013.0175
   Milan FB, 2008, AIDS PATIENT CARE ST, V22, P811, DOI 10.1089/apc.2007.0159
   Namuleme RK, 2015, HEALTH INFO LIBR J, V32, P61, DOI 10.1111/hir.12090
   Navarrete-Dechent C, 2015, REV CHIL INFECTOL, V32, PS57, DOI 10.4067/s0716-10182015000100005
   Nguyen AL, 2017, MEDICINE, V96, P0, DOI 10.1097/MD.0000000000008495
   Ofotokun I, 2011, DISCOV MED, V11, P385
   Palinkas LA, 2015, ADM POLICY MENT HLTH, V42, P533, DOI 10.1007/s10488-013-0528-y
   Rueda S, 2016, BMJ OPEN, V6, P0, DOI 10.1136/bmjopen-2016-011453
   Sadler GR, 2010, NURS HEALTH SCI, V12, P369, DOI 10.1111/j.1442-2018.2010.00541.x
   Shiflett SC, 2011, EXPLORE-NY, V7, P148, DOI 10.1016/j.explore.2011.02.004
   Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007
   Suphanchaimat R, 2014, HIV AIDS-RES PALLIAT, V6, P19, DOI 10.2147/HIV.S56277
   Swanson B, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/908538
   Takemura Y, 2005, TOHOKU J EXP MED, V206, P151, DOI 10.1620/tjem.206.151
   Tenny S, 2022, STATPEARLS, V0, P0
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Torres RA, 2014, LAB INVEST, V94, P120, DOI 10.1038/labinvest.2013.142
   van Manen M, 1990, THEORY INTOPRACTICE, V29, P152, DOI 10.1080/00405849009543448
   Vickers AJ, 2018, J PAIN, V19, P455, DOI 10.1016/j.jpain.2017.11.005
   Vreeman RC, 2019, J INT ASSOC PRO AIDS, V18, P0, DOI 10.1177/2325958219880570
   Wang J, 2013, CHIN J INTEGR MED, V19, P340, DOI 10.1007/s11655-013-1449-z
   Wang J, 2010, CHIN J INTEGR MED, V16, P557, DOI 10.1007/s11655-010-0573-2
   Wang XY, 2018, J AM MED INFORM ASSN, V25, P931, DOI 10.1093/jamia/ocy012
   Wu XL, 2015, SCI REP-UK, V5, P0, DOI 10.1038/srep11728
   Yang J, 2003, QUAL RES, V4, P87
   Yoo M, 2020, SCI REP-UK, V10, P0, DOI 10.1038/s41598-020-66314-0
   Zhao HL, 2014, AM J CHINESE MED, V42, P261, DOI 10.1142/S0192415X14500177
   Zhu QS, 2020, MEDICINE, V99, P0, DOI 10.1097/MD.0000000000023638
NR 53
TC 0
Z9 2
U1 0
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
EI 
J9 BMJ OPEN
JI BMJ Open
PD DEC 15
PY 2021
VL 11
IS 12
BP 
EP 
DI 10.1136/bmjopen-2021-051880
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA XN5WT
UT WOS:000729575800016
PM 34887276
DA 2026-01-16
ER

PT J
AU Weisfeld, CC
   Turner, JA
   Dunleavy, K
   Ko, A
   Bowen, JI
   Roelk, B
   Eissa, R
   Benfield, E
   Robertson, K
AF Weisfeld, Carol Cronin
   Turner, Jill A
   Dunleavy, Kim
   Ko, Arthur
   Bowen, Jennifer I
   Roelk, Brandi
   Eissa, Reem
   Benfield, Erica
   Robertson, Kristen
TI Dealing with Anxious Patients: A Systematic Review of the Literature on
SO Journal of alternative and complementary medicine (New York, N.Y.)
LA English
DT Journal Article
DE distraction; hypnosis; massage; music; patient anxiety; patient education
AB Objectives: State (situational) anxiety can create suboptimal outcomes for  patients across a variety of health care specializations. While anxiolytic  medications reduce anxiety, problematic side effects can compromise outcomes.  These challenges have spurred searches for nonpharmaceutical approaches to  alleviate patient anxiety. This systematic literature review, largely following  Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines,  aimed to determine patterns and effectiveness of interventions across medical  health care specialty areas, including dentistry. Methods: A systematic review  was conducted, using PubMed, CINAHL, and PsycINFO databases, with search terms  related to anxiety, specific interventions, and medical or dental procedures.  Hand searching for additional citations was performed on the bibliographies of  dissertations, meta-analyses, and systematic reviews that met article inclusion  criteria. The search process yielded 48,324 articles and 257 dissertations  published in English between 1974 and 2018. Each abstract was evaluated for  inclusion by two reviewers, yielding 718 articles that were read and evaluated  for outcomes, risk of bias, pretest and post-test, controls and quality, using a  Critical Appraisal Skills Programme instrument. Of these, 408 articles,  describing 501 experimental trials, were accepted for inclusion in this analysis.  Results: A total of 50,343 patients were included in these experiments, with an  overall success rate of 71% for reducing patient anxiety. Results are summarized  by health care specialty area: surgery, oncology, cardiology,  obstetrics/gynecology, dentistry, and pain/trauma, and the following diagnostic  testing and intervention areas: imaging, colonoscopy, mechanical ventilation, and  other. The largest number of experiments (114) was in the surgery category. The  types of interventions included music, education, relaxation, cognitive  behavioral therapy (CBT), massage, distraction, hypnosis,  acupuncture/acupressure, social support, aromatherapy, nature sounds, natural  visual stimuli, special garment, and other. The largest numbers of experiments  were done with music (143) and education (130). Discussion: The following  interventions were most successful, reducing anxiety in over 70% of experiments:  music, CBT, relaxation, massage, acupuncture/acupressure, hypnosis, and natural  sounds. Confidence in results is limited by publication bias, small sample sizes,  and the lack of placebo controls. Directions for future research are discussed.
C1 Department of Psychology, University of Detroit Mercy, Detroit, MI, USA.
   Libraries/IDS, University of Detroit Mercy, Detroit, MI, USA.
   Department of Physical Therapy, University of Florida, Gainesville, FL, USA.
   McAuley School of Nursing, College of Health Professions, University of Detroit Mercy, Detroit, MI, USA.
   Libraries/IDS, University of Detroit Mercy, Detroit, MI, USA.
   Department of Psychology, University of Detroit Mercy, Detroit, MI, USA.
   Department of Psychology, University of Detroit Mercy, Detroit, MI, USA.
   Department of Psychology, University of Detroit Mercy, Detroit, MI, USA.
   Orthopedic Physical Therapy Program, Walk the Line Recovery Therapy, Southfield, MI, USA.
NR 0
TC 0
SN 1557-770
EI 
J9 J Altern Complement Med
PD JUN 3
PY 2021
VL 27
IS 9
BP 717
EP 726
DI 10.1089/acm.2020.0504
PG 9
WC Anxiety; prevention & control; Anxiety Disorders; Aromatherapy; Dentistry; Female; Humans; Hypnosis; Pregnancy
UT PubMed:34076531
PM 34076531
DA 2021-06-03
ER

PT J
AU Jung, MS
   Lee, JS
   Sohn, EH
   Cha, K
   Dlamini, NS
   Kim, M
AF Jung, Mi Sook
   Lee, Jin Sun
   Sohn, Eun Hee
   Cha, Kyeongin
   Dlamini, Nondumiso Satiso
   Kim, Mijung
TI Efficacy and safety of auricular acupressure for chemotherapy-induced peripheral neuropathy among patients with breast cancer: a study protocol for a randomized controlled trial
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Peripheral neuropathy; ear; acupressure; clinical trial protocol; randomized controlled trial (RCT)
ID quality-of-life; general fact-g; functional assessment; acupuncture; reliability; validity; pain; neurotoxicity; questionnaire; paclitaxel
AB Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a frequently-reported distress symptom in breast carcinoma patients under chemotherapy. Although previous studies emphasized lack of ideal neuroprotective or therapeutic agents for CIPN, there are no strongly recommended treatments. Nevertheless, auricular acupressure (AA) is a novel remedy for controlling symptoms in many healthcare settings. However, therapeutic effects of AA among patients with CIPN have not yet been elucidated fully. Therefore, we designed a trial to examine the effectiveness and safety of AA in breast cancer patients. Methods: This randomized, double-blind, sham-controlled trial will assess 120 breast cancer survivors. After enrollment, the participants will be stratified depending on administration of medications prescribed for CIPN treatment, and then assigned randomly to the experimental or control groups in an allocation ratio of 1:1. For experimental groups, AA will be applied on four points, namely, shemen, liver, spleen, and finger/ toe, while for the control groups, sham AA will be exerted on other four points that are remote from the treatment points and unrelated to neuropathic symptoms. All participants will undergo the same acupressure procedure, for two minutes each time, thrice daily for 3 weeks, and CIPN symptoms and health-related quality of life will be assessed by a blinded research assistant and a physician before, during, immediately after, and 4 weeks after AA. Occurrence, type, and severity of safety issues will be routinely monitored to confirm the non-toxic nature of AA. Repeated measures analysis of variance will be used to examine the changing pattern of CIPN symptoms and based on sensitivity analysis. Discussion: It is expected that the rationale and design of this protocol will offer knowledge regarding a standardized process to guide current and future studies and accumulates clinical experiences in applying non-pharmacological intervention. The present trial is the first to examine the therapeutic effects of AA in breast cancer patients with CIPN. The findings of the study may provide convincing evidence regarding the effectiveness of CIPN symptoms.
C1 [Jung, Mi Sook; Cha, Kyeongin; Dlamini, Nondumiso Satiso; Kim, Mijung] Chungnam Natl Univ, Coll Nursing, 266 Munhwa Ro, Daejeon 35015, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Dept Surg, Daejeon, South Korea.
   [Lee, Jin Sun] Chungnam Natl Univ, Coll Med, Res Inst Med Sci, Daejeon, South Korea.
   [Sohn, Eun Hee] Chungnam Natl Univ Hosp, Dept Neurol, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University; Chungnam National University; Chungnam National University; Chungnam National University Hospital
RP Kim, M (corresponding author), Chungnam Natl Univ, Coll Nursing, 266 Munhwa Ro, Daejeon 35015, South Korea.
EM cipnmj@gmail.com
FU National Research Foundation of Korea - Korea government [2017RA2B4004328]; Brain Korea 21 Plus project of the National Research Foundation of Korea Grant
CR Alimi D, 2002, MED ACUPUNCT, V13, P18
   Unknown -, 2014, AURICULOTHERAPY MANUAL: CHINESE AND WESTERN SYSTEMS OF EAR ACUPUNCTURE, V0, P0
   Argyriou AA, 2008, CRIT REV ONCOL HEMAT, V66, P218, DOI 10.1016/j.critrevonc.2008.01.008
   Bao T, 2018, EUR J CANCER, V101, P12, DOI 10.1016/j.ejca.2018.06.008
   Bao T, 2016, BREAST CANCER RES TR, V159, P327, DOI 10.1007/s10549-016-3939-0
   Bao T, 2014, INTEGR CANCER THER, V13, P396, DOI 10.1177/1534735414534729
   Bhatnagar B, 2014, SPRINGERPLUS, V3, P0, DOI 10.1186/2193-1801-3-366
   Bhide A, 2018, ACTA OBSTET GYN SCAN, V97, P380, DOI 10.1111/aogs.13309
   Carlson K, 2011, CLIN BREAST CANCER, V11, P73, DOI 10.1016/j.clbc.2011.03.006
   Cavaletti G, 2013, ANN ONCOL, V24, P454, DOI 10.1093/annonc/mds329
   Cavaletti G, 2003, NEUROLOGY, V61, P1297, DOI 10.1212/01.WNL.0000092015.03923.19
   Cavaletti G, 2007, J PERIPHER NERV SYST, V12, P210, DOI 10.1111/j.1529-8027.2007.00141.x
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Colvin LA, 2019, PAIN, V160, PS1, DOI 10.1097/j.pain.0000000000001540
   Eckhoff L, 2015, EUR J CANCER, V51, P292, DOI 10.1016/j.ejca.2014.11.024
   Eghbali M, 2016, COMPLEMENT THER CLIN, V24, P189, DOI 10.1016/j.ctcp.2016.06.006
   Fradkin M, 2019, CURR MED CHEM, V26, P4698, DOI 10.2174/0929867326666190107163756
   Freund CL, 2004, J LAW MED ETHICS, V32, P106, DOI 10.1111/j.1748-720X.2004.tb00454.x
   Garcia MK, 2014, J HEMATOL ONCOL, V7, P0, DOI 10.1186/1756-8722-7-41
   Gornstein E, 2014, NEUROPHARMACOLOGY, V76, P175, DOI 10.1016/j.neuropharm.2013.08.016
   Greenlee H, 2016, BREAST CANCER RES TR, V156, P453, DOI 10.1007/s10549-016-3759-2
   He W, 2012, EVID-BASED COMPL ALT, V2012, P0, DOI 10.1155/2012/786839
   Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063
   Hershman DL, 2016, J CLIN ONCOL, V34, P3014, DOI 10.1200/JCO.2015.66.2346
   Hou PW, 2015, EVID-BASED COMPL ALT, V2015, P0, DOI 10.1155/2015/495684
   Huang CF, 2019, MEDICINE, V98, P0, DOI 10.1097/MD.0000000000016144
   Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892
   Kieffer JM, 2017, QUAL LIFE RES, V26, P2999, DOI 10.1007/s11136-017-1626-1
   Kim HY, 2014, J KOREAN ACAD NURS, V44, P735, DOI 10.4040/jkan.2014.44.6.735
   Kim M, 2020, J KOREAN ACAD FUNDAM, V27, P323
   Kim M, 2019, CANC NURS, V0, P0
   King HC, 2015, MIL MED, V180, P582, DOI 10.7205/MILMED-D-14-00451
   Kober A, 2003, ANESTHESIOLOGY, V98, P1328, DOI 10.1097/00000542-200306000-00005
   Li K, 2019, CURR ONCOL, V26, PE147, DOI 10.3747/co.26.4261
   Lu WD, 2013, CURR PAIN HEADACHE R, V17, P0, DOI 10.1007/s11916-013-0321-3
   Nogier R, 2014, MED ACUPUNCT, V26, P76, DOI 10.1089/acu.2014.1035
   Oh PJ, 2018, J KOREAN ACAD NURS, V48, P123, DOI 10.4040/jkan.2018.48.2.123
   Paice JA, 1997, CANCER NURS, V20, P88, DOI 10.1097/00002820-199704000-00002
   Postma TJ, 2005, EUR J CANCER, V41, P1135, DOI 10.1016/j.ejca.2005.02.012
   Romoli M, 2014, NEUROL SCI, V35, PS189, DOI 10.1007/s10072-014-1768-7
   Samuels N, 2020, CURR ONCOL REP, V22, P0, DOI 10.1007/s11912-020-0891-2
   Schroeder S, 2012, ACUPUNCT MED, V30, P4, DOI 10.1136/acupmed-2011-010034
   Seretny M, 2014, PAIN, V155, P2461, DOI 10.1016/j.pain.2014.09.020
   Shin J, 2018, WESTERN J NURS RES, V40, P67, DOI 10.1177/0193945916680362
   Sparano JA, 2015, J CLIN ONCOL, V33, P2353, DOI 10.1200/JCO.2015.60.9271
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Stubblefield MD, 2009, J NATL COMPR CANC NE, V7, PS1, DOI 10.6004/jnccn.2009.0078
   Sun Li-hong, 2015, ZHEN CI YAN JIU, V40, P70
   Victorson D, 2008, QUAL LIFE RES, V17, P1137, DOI 10.1007/s11136-008-9398-2
   Weaver M T, 1985, NURSE PRACT, V10, P38
   WinsteadFry P, 1997, CANCER, V79, P2446, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2446::AID-CNCR23>3.0.CO;2-Q
   Xu SF, 2013, EVID-BASED COMPL ALT, V2013, P0, DOI 10.1155/2013/581203
   Yang Jin-Liang, 2014, ZHONGGUO ZHEN JIU, V34, P1165
   Yang LH, 2017, EVID-BASED COMPL ALT, V2017, P0, DOI 10.1155/2017/6383649
   Yeh Chao Hsing, 2020, GLOB ADV HEALTH MED, V9, P2164956120906092, DOI 10.1177/2164956120906092
   Yeh CH, 2019, PAIN MANAG NURS, V20, P623, DOI 10.1016/j.pmn.2019.04.004
   Yeh CH, 2019, PAIN MANAG NURS, V20, P614, DOI 10.1016/j.pmn.2019.04.005
   Yeh CH, 2016, CANCER NURS, V39, P402, DOI 10.1097/NCC.0000000000000303
   Zajaczkowska R, 2019, INT J MOL SCI, V20, P0, DOI 10.3390/ijms20061451
   Zanville NR, 2016, SUPPORT CARE CANCER, V24, P4779, DOI 10.1007/s00520-016-3329-5
   Zhong Baoliang, 2009, J THORAC DIS, V1, P51
   Zhong Q, 2019, CHIN J INTEGR MED, V25, P225, DOI 10.1007/s11655-019-3063-1
NR 64
TC 3
Z9 4
U1 5
U2 31
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG 00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD JAN 15
PY 2021
VL 10
IS 1
BP 721
EP +
DI 10.21037/apm-20-1469
PG 13
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA QC0UM
UT WOS:000614549600077
PM 33440985
DA 2026-01-16
ER

PT J
AU Zhu, XY
   Li, Z
   Chen, C
   Feng, RL
   Cheng, BR
   Liu, RY
   Wang, RT
   Xu, L
   Wang, Y
   Tao, X
   Zhao, P
AF Zhu, Xue-Ying
   Li, Zhong
   Chen, Cong
   Feng, Ru-Li
   Cheng, Bai-Ru
   Liu, Ruo-Yi
   Wang, Rui-Ting
   Xu, Li
   Wang, Yue
   Tao, Xin
   Zhao, Peng
TI Physical Therapies for Psychosomatic Symptoms and Quality of Life Induced by Aromatase Inhibitors in Breast Cancer Patients: A Systematic Review and Meta-Analysis
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE physical therapies; acupuncture; exercise; breast cancer; aromatase inhibitors; pain; quality of life
ID randomized controlled-trial; clinical-practice guideline; musculoskeletal symptoms; induced arthralgia; double-blind; dual-center; exercise; women; acupuncture; pain
AB Objective: To evaluate the effects of Physical Therapies (PTs) on improvement in psychosomatic symptoms and quality of life (QOL) in breast cancer patients. Data Sources: Seven databases (MEDLINE, EMBASE, Cochrane CENTRAL, China National Knowledge Infrastructure, Wangfang, VIP, and China Biology Medicine disc databases) were systematically searched from the database inception through May 18, 2021. Study Selection: Randomized controlled trials (RCTs) which compared acupuncture or exercise with a sham control or usual care for the treatment of aromatase inhibitors (AIs)-related psychosomatic symptoms and QOL. Data Extraction and Synthesis: Data were screened and extracted independently using predesigned forms. The quality of RCTs was assessed with the Cochrane Handbook for Systematic Reviews of Interventions. The effect size was calculated via random-effects modeling. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. Main Outcomes and Measures: The score of pain was measured with BPI scale and Western Ontario and the McMaster Universities Index (WOMAC) scale. Emotional state was measured with Pittsburgh Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS-A), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). The QOL score was measured by self-reported measurements, including the Functional Assessment of Cancer Therapy-General (FACT-G) scale and 36-Item Short Form Survey (SF-36) scale. Results: Eleven RCTs (with 830 patients) were included in the systematic review, and data from 10 RCTs (with 798 patients) were used in the meta-analysis. Results showed acupuncture significantly reduced worst pain scores (P < 0.00001, I (2) = 83.5%) [SMD = -0.81, 95% CI (-1.51, -0.11)], but the effect of exercise therapies was not significant in overall change in worst pain scores (P =0.006, I (2) = 72.3%) [SMD = -0.30, 95% CI (-0.76, 0.16)]. Both acupuncture and exercise resulted in little to no difference in overall change in HADS-A subscale (P = 0.026 < 0.05, I (2) = 79.8%) [WMD = -0.21, 95% CI (-3.44, 3.03)], PSQI subscale (P = 0.488, I (2) = 0%) [WMD = 0.98, 95% CI (-0.57, 2.53)], and FACIT-Fatigue subscale (P = 0.022 < 0.05, I (2) = 81.0%) [WMD = 1.6, 95% CI (-5.75, 8.94)]. Exercise (compared with usual care) was associated with improving overall change in health-related QOL (subscales of SF-36 tool) (P = 0, I (2) = 72.1%) [WMD = 7.97, 95% CI (5.68, 10.25)] and cancer-specific QOL (subscales of FACT-G tool) (P = 0.304, I (2) = 16%) [WMD = 1.16, 95% CI (0.34, 1.97)]. Conclusions and Relevance: This systematic review and meta-analysis suggested that based on moderate-level evidence, acupuncture was associated with significant reductions in pain intensity, and exercise might improve QOL in breast cancer patients treated with AIs. However, in psychosomatic symptoms such as anxiety, sleep disturbance, and fatigue, acupuncture and exercise training did not result in significant improvements.
C1 [Zhu, Xue-Ying; Li, Zhong] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Oncol, Beijing, Peoples R China.
   [Chen, Cong; Feng, Ru-Li; Cheng, Bai-Ru; Wang, Rui-Ting; Zhao, Peng] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Cardiol, Beijing, Peoples R China.
   [Liu, Ruo-Yi] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Encephalopathy, Beijing, Peoples R China.
   [Xu, Li] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Gynecol, Beijing, Peoples R China.
   [Wang, Yue] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China.
   [Tao, Xin] Capital Med Univ, Sch Med Humanities, Beijing, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Capital Medical University
RP Zhao, P (corresponding author), Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Cardiol, Beijing, Peoples R China.
EM kyushuzhaopeng@hotmail.com
FU 2020 Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Science and Technology Innovation Special Fund [DZMKJCX-2020-027]
CR Baglia ML, 2019, CANCER-AM CANCER SOC, V125, P2262, DOI 10.1002/cncr.32051
   Baker MK, 2018, INTEGR CANCER THER, V17, P968, DOI 10.1177/1534735418781489
   Bao T, 2014, CANCER-AM CANCER SOC, V120, P381, DOI 10.1002/cncr.28352
   Bao T, 2013, BREAST CANCER RES TR, V138, P167, DOI 10.1007/s10549-013-2427-z
   BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511
   Beckwée D, 2017, SUPPORT CARE CANCER, V25, P1673, DOI 10.1007/s00520-017-3613-z
   Boing L, 2020, MATURITAS, V141, P71, DOI 10.1016/j.maturitas.2020.06.022
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21609
   Brown JC, 2014, BREAST J, V20, P22, DOI 10.1111/tbj.12202
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Campbell KL, 2019, MED SCI SPORT EXER, V51, P2375, DOI 10.1249/MSS.0000000000002116
   CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126, DOI 10.1016/j.jclinepi.2013.11.007
   Chavooshi B, 2017, PSYCHOSOMATICS, V58, P506, DOI 10.1016/j.psym.2017.01.003
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chien TJ, 2015, J ALTERN COMPLEM MED, V21, P251, DOI 10.1089/acm.2014.0083
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006
   Crew KD, 2010, J CLIN ONCOL, V28, P1154, DOI 10.1200/JCO.2009.23.4708
   Faller H, 2013, J CLIN ONCOL, V31, P782, DOI 10.1200/JCO.2011.40.8922
   Fields J, 2016, J PAIN SYMPTOM MANAG, V52, P548, DOI 10.1016/j.jpainsymman.2016.03.010
   Foldi J, 2021, CURR TREAT OPTION ON, V22, P0, DOI 10.1007/s11864-021-00879-4
   Gentry AL, 2018, CONTEMP CLIN TRIALS, V67, P109, DOI 10.1016/j.cct.2018.02.012
   Gradishar W, 2016, J NATL COMPR CANC NE, V14, P641, DOI 10.6004/jnccn.2016.0181
   He YH, 2020, JAMA ONCOL, V6, P271, DOI 10.1001/jamaoncol.2019.5233
   Hershman DL, 2018, JAMA-J AM MED ASSOC, V320, P167, DOI 10.1001/jama.2018.8907
   Hershman DL, 2015, ADV EXP MED BIOL, V862, P89, DOI 10.1007/978-3-319-16366-6_7
   Hershman DL, 2011, BREAST CANCER RES TR, V126, P529, DOI 10.1007/s10549-010-1132-4
   Invernizzi M, 2022, ANTI-CANCER AGENT ME, V22, P801, DOI 10.2174/1871520621666210609095602
   Invernizzi M, 2020, FRONT ONCOL, V10, P0, DOI 10.3389/fonc.2020.556718
   Irwin ML, 2015, J CLIN ONCOL, V33, P1104, DOI 10.1200/JCO.2014.57.1547
   Kemp-Casey A, 2017, ASIA-PAC J CLIN ONCO, V13, PE161, DOI 10.1111/ajco.12600
   Khosravi N, 2019, BRAIN BEHAV IMMUN, V81, P92, DOI 10.1016/j.bbi.2019.08.187
   Koual M, 2020, ENVIRON HEALTH-GLOB, V19, P0, DOI 10.1186/s12940-020-00670-2
   Liberati Alessandro, 2009, PLOS MED, V6, Pe1000100, DOI 10.1371/journal.pmed.1000100
   Liu XM, 2021, INTEGR CANCER THER, V20, P0, DOI 10.1177/1534735420980811
   Lu GL, 2020, SUPPORT CARE CANCER, V28, P1587, DOI 10.1007/s00520-019-05186-1
   Mandelblatt JS, 2013, SEMIN ONCOL, V40, P709, DOI 10.1053/j.seminoncol.2013.09.006
   Mao JJ, 2014, CANCER-AM CANCER SOC, V120, P3744, DOI 10.1002/cncr.28917
   Mao JJ, 2014, EUR J CANCER, V50, P267, DOI 10.1016/j.ejca.2013.09.022
   Mehnert A, 2014, J CLIN ONCOL, V32, P3540, DOI 10.1200/JCO.2014.56.0086
   Meneses-Echávez JF, 2016, CANCER EPIDEM BIOMAR, V25, P1009, DOI 10.1158/1055-9965.EPI-15-1061
   Miglietta F, 2021, CANCER TREAT REV, V98, P0, DOI 10.1016/j.ctrv.2021.102222
   Möller UO, 2019, BMC CANCER, V19, P0, DOI 10.1186/s12885-019-5648-7
   Nadji M, 2005, AM J CLIN PATHOL, V123, P21, DOI 10.1309/4WV79N2GHJ3X1841
   Nahm Nicole, 2018, ASIA PAC J CLIN ONCOL, V14, P374, DOI 10.1111/ajco.12845
   Newton RU, 2019, MED J AUSTRALIA, V210, P0, DOI 10.5694/mja2.12043
   Nyrop KA, 2017, ONCOLOGIST, V22, P1238, DOI 10.1634/theoncologist.2017-0174
   Oh B, 2013, ACUPUNCT MED, V31, P264, DOI 10.1136/acupmed-2012-010309
   Paulo TRS, 2019, HEALTH QUAL LIFE OUT, V17, P0, DOI 10.1186/s12955-019-1090-4
   Ramírez-Vélez R, 2021, CANCERS, V13, P0, DOI 10.3390/cancers13020264
   Roberts K, 2017, CRIT REV ONCOL HEMAT, V111, P66, DOI 10.1016/j.critrevonc.2017.01.010
   Roberts KE, 2020, COCHRANE DB SYST REV, V0, P0, DOI DOI 10.1002/14651858.CD012988.pub2
   Saanijoki T, 2018, NEUROPSYCHOPHARMACOL, V43, P246, DOI 10.1038/npp.2017.148
   Schmidt T, 2017, J CANCER RES THER, V13, P392, DOI 10.4103/0973-1482.150356
   Stout NL, 2017, PM&R, V9, PS347, DOI 10.1016/j.pmrj.2017.07.074
   Swieboda P, 2013, ANN AGR ENV MED, V0, P2
   Tenti S, 2020, INT J MOL SCI, V21, P0, DOI 10.3390/ijms21165625
   Weis JB, 2020, SUPPORT CARE CANCER, V28, P3033, DOI 10.1007/s00520-019-05076-6
   Xiao LJ, 2017, ADV EXP MED BIOL, V1010, P247, DOI 10.1007/978-981-10-5562-1_12
   Zhang XY, 2019, SUPPORT CARE CANCER, V27, P9, DOI 10.1007/s00520-018-4363-2
   Zidkova R, 2021, INT J ENV RES PUB HE, V18, P0, DOI 10.3390/ijerph18073570
NR 60
TC 15
Z9 17
U1 1
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
EI 
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 12
PY 2021
VL 11
IS 
BP 
EP 
DI 10.3389/fonc.2021.745280
PG 16
WC Oncology
SC Oncology
GA XH6XB
UT WOS:000725574000001
PM 34868943
DA 2026-01-16
ER

